Cumberland Pharmaceuticals Inc.
As filed with the Securities and Exchange Commission on
May 1, 2007
Registration
No.
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM S-1
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF
1933
Cumberland Pharmaceuticals
Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
Tennessee
|
|
2834
|
|
62-1765329
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(Primary Standard Industrial
Classification Code Number)
|
|
(I.R.S. Employer
Identification No.)
|
2525 West End Avenue,
Suite 950
Nashville, Tennessee
37203
(615) 255-0068
(Address, including zip code,
and telephone number, including
area code, of registrants
principal executive offices)
A.J. Kazimi
Chairman and CEO
2525 West End Avenue,
Suite 950
Nashville, Tennessee
37203
(615) 255-0068
(Name, address, including zip
code, and telephone number, including area code, of agent for
service)
Copies to:
|
|
|
Martin S.
Brown, Esq.
Virginia Boulet, Esq.
Adams and Reese LLP
424 Church Street, Suite 2800
Nashville, Tennessee 37219
(615) 259-1450
|
|
Donald J. Murray, Esq.
Dewey Ballantine LLP
1301 Avenue of the Americas
New York, New York 10019-6092
(212) 259-8000
|
Approximate date of commencement of proposed offering to the
public: As soon as practicable after this
registration statement becomes effective.
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act of 1933 check the
following box: o
If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act,
please check the following box and list the Securities Act
registration statement number of the earlier effective
registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering. o
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Proposed Maximum
|
|
|
|
Title of Each Class of
|
|
|
Aggregate Offering
|
|
|
Amount of
|
Securities to be Registered
|
|
|
Price(1)
|
|
|
Registration Fee
|
Common Stock, no par value per share
|
|
|
$115,000,000
|
|
|
$3,531
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Estimated solely for purpose of
calculating the registration fee pursuant to Rule 457(o)
under the Securities Act.
|
The registrant hereby amends this registration statement on
such date or dates as may be necessary to delay its effective
date until the registrant shall file a further amendment which
specifically states that this registration statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until the registration
statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.
The
information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange
Commission is effective. This preliminary prospectus is not an
offer to sell these securities and it is not soliciting an offer
to buy these securities in any state where the offer or sale is
not permitted.
|
|
|
|
PRELIMINARY
PROSPECTUS
|
SUBJECT
TO COMPLETION
|
,
2007
|
Shares
Common
Stock
This is the initial public offering of our common stock. No
public market currently exists for our common stock. We are
offering all of
the shares
of our common stock offered by this prospectus.
We have applied to have our common stock included for quotation
on The Nasdaq Global Market under the symbol CPIX.
Investing in our common stock involves a high degree of risk.
Before buying any shares, you should carefully read the
discussion of material risks of investing in our common stock in
Risk factors beginning on page 6 of this
prospectus.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
|
|
|
|
|
|
|
|
|
|
|
Per
share
|
|
|
Total
|
|
|
|
Public offering price
|
|
$
|
|
|
|
$
|
|
|
|
|
Underwriting discounts and
commissions
|
|
$
|
|
|
|
$
|
|
|
|
|
Proceeds, before expenses, to us
|
|
$
|
|
|
|
$
|
|
|
|
|
The underwriters may also purchase up to an
additional shares
of our common stock at the public offering price, less the
underwriting discounts and commissions payable by us, to cover
over-allotments, if any, within 30 days from the date of
this prospectus. If the underwriters exercise this option in
full, the total underwriting discounts and commissions will be
$ and our total proceeds, before
expenses, will be $ .
The underwriters are offering the common stock as set forth
under Underwriting. Delivery of the shares will be
made on or
about ,
2007.
UBS
Investment Bank
Inside front cover of prospectus to feature two product photos:
[Artwork to be submitted]
You should rely only on the information contained in this
prospectus. We have not, and the underwriters have not,
authorized anyone to provide you with additional information or
information different from that contained in this prospectus. We
are offering to sell, and seeking offers to buy, shares of our
common stock only in jurisdictions where offers and sales are
permitted. The information contained in this prospectus is
accurate only as of the date of this prospectus, regardless of
the time of delivery of this prospectus or of any sale of shares
of our common stock.
TABLE OF
CONTENTS
Through and
including ,
2007 (the 25th day after the date of this prospectus),
federal securities laws may require all dealers that effect
transactions in our common stock, whether or not participating
in this offering, to deliver a prospectus. This is in addition
to the dealers obligation to deliver a prospectus when
acting as underwriters and with respect to their unsold
allotments or subscriptions.
Amelior®,
Acetadote®
and the Cumberland Pharmaceuticals logo are trademarks or
service marks of Cumberland Pharmaceuticals Inc. All other
trademarks or service marks appearing in this prospectus are the
property of their respective holders.
.1
Prospectus summary
This summary highlights select contents of this prospectus,
and may not contain all of the information that you should
consider before investing in our common stock. This summary
should be read together with the more detailed information found
elsewhere in this prospectus, including Risk factors
and our consolidated financial statements and related notes
beginning on
page F-1.
References in this prospectus to Cumberland,
we, us and our refer to
Cumberland Pharmaceuticals Inc. and our consolidated
subsidiaries, unless the context indicates otherwise.
OUR
COMPANY
We are a profitable and growing specialty pharmaceutical company
focused on the acquisition, development and commercialization of
branded prescription products. Our primary target markets are
hospital acute care and gastroenterology, which are
characterized by relatively concentrated physician prescriber
bases. Unlike many emerging pharmaceutical and biotechnology
companies, we have established a product development and
commercial operating infrastructure that is scalable to
accommodate our expected growth. Our management team consists of
pharmaceutical industry veterans experienced in business
development, clinical and regulatory affairs, and sales and
marketing.
Since our inception in 1999, we have successfully funded the
acquisition and development of our product portfolio with
limited external investment, while maintaining profitable
operations over the past three years. Our portfolio consists of
two products approved by the U.S. Food and Drug Administration,
or FDA, one late-stage development product candidate nearing
completion of Phase III clinical trials and several
early-stage development projects. We were directly responsible
for the clinical development and regulatory approval of
Acetadote, one of our marketed products, and are currently
completing development of Amelior, our lead product candidate.
We promote Acetadote and our other FDA-approved product,
Kristalose, through dedicated hospital and gastroenterology
sales forces, which together are comprised of 42 sales
representatives and managers. We believe that our target markets
are highly concentrated, and consequently can be penetrated
effectively by small, dedicated sales forces without large-scale
promotional activity. For the years 2004, 2005 and 2006, our net
revenue was $12.0 million, $10.7 million and
$17.8 million, respectively, and our net income was
$558,000, $2.0 million and $4.4 million, respectively.
OUR
PRODUCTS
Our key products and product candidates include:
|
|
|
|
|
|
|
Product
|
|
Indication
|
|
Delivery
|
|
Status
|
|
|
Amelior®
|
|
Pain and Fever
|
|
Injectable
|
|
Phase III
|
Acetadote®
|
|
Acetaminophen Poisoning
|
|
Injectable
|
|
Marketed
|
Kristalose®
|
|
Chronic and Acute Constipation
|
|
Oral Solution
|
|
Marketed
|
|
|
Amelior, our lead pipeline candidate, is an intravenous
formulation of ibuprofen that we expect will be the first
injectable product approved in the U.S. for the treatment
of both pain and fever. Amelior is currently in Phase III
clinical trials. We expect to complete clinical development by
early 2008 and are preparing to submit our new drug application,
or NDA, to the FDA for review. Amelior is designed to provide
physicians with a safe, effective treatment alternative for
patients who are unable to take oral medication for pain relief
and fever reduction. If approved, we plan to market Amelior in
the U.S. through our hospital sales force and in
international markets through alliances with marketing partners.
We believe Amelior currently represents our most significant
product opportunity.
According to IMS Health, the U.S. market for injectable
analgesics, or pain relievers, exceeded $302 million, or
491 million units, in 2006. This market consists primarily
of the non-steroidal anti-inflammatory drug ketorolac and
generic opioids. Despite having a poor safety profile, usage of
1
ketorolac has grown from approximately 38 million units in
2003, or 7% of the market, to approximately 43 million
units in 2006, or 9% of the market, according to IMS Health.
Injectable opioids such as morphine and meperidine accounted for
approximately 447 million units sold in 2006. While opioids
are widely used for acute pain management, they are associated
with a variety of side effects including sedation, nausea,
vomiting, headache, cognitive impairment and respiratory
depression. Based on the results of clinical studies to date, we
believe Amelior represents a potentially safer alternative to
ketorolac, the only non-opioid injectable pain relief drug
available in the U.S. Further, we believe Amelior is a safe and
effective treatment for hospitalized patients with fever who are
unable to take oral medication. There is currently no approved
injectable treatment for fever in the U.S.
Acetadote is the only intravenous formulation of
N-acetylcysteine, or NAC, approved in the U.S. for the
treatment of acetaminophen poisoning. Though safe at recommended
doses, acetaminophen can cause liver damage with excessive use.
Acetaminophen overdose is the most common cause of acute liver
failure in adults in the U.S. According to the American
Association of Poison Control Centers Toxic Exposure
Surveillance System, acetaminophen was the leading cause of
poisonings presenting to emergency departments in the
U.S. in 2005, with approximately 77,000 cases treated.
NAC is accepted worldwide as the standard of care for treating
acetaminophen overdose. Until our 2004 launch of Acetadote, the
only FDA-approved form of NAC available in the U.S. was an
oral preparation. Medical literature suggests that, for a number
of patients, IV treatment is the only reasonable route of
administration due to nausea and vomiting associated with the
administration of oral NAC for acetaminophen overdose. Sales of
Acetadote have increased consistently since we launched the
product in June 2004, with wholesaler sales to hospitals growing
43% from $9 million in 2005 to $13 million in 2006. We
believe that we can continue to expand market share, and that
our Acetadote sales and marketing platform should help
facilitate the anticipated launch of Amelior.
Kristalose, a prescription laxative product, is a
crystalline form of lactulose designed to enhance patient
acceptance and compliance. Based on data from IMS Health, the
U.S. prescription laxative market has grown rapidly over
the past few years, increasing from approximately
$206 million in 2003 to $389 million in 2006,
representing a compound annual growth rate of 24%. Wholesaler
sales of Kristalose to pharmacies were $10.5 million in
2006. During that year, we acquired exclusive
U.S. commercialization rights to Kristalose, subsequently
assembling a dedicated field sales force and re-launching the
product in October 2006 under the Cumberland brand. We believe
that we can increase market share for Kristalose given its many
positive, competitive attributes including better taste,
consistency, ease of use and cost relative to competing products.
Early-stage product candidates. Our
early-stage product candidates are being developed by Cumberland
Emerging Technologies, Inc., or CET, our 86%-owned subsidiary.
CET collaborates with leading research institutions to identify
and advance the development of promising pre-clinical product
candidates within our target segments. Current CET projects
include an improved treatment for fluid buildup in the lungs of
cancer patients and an anti-infective for treating fungal
infections in immuno-compromised patients.
OUR COMPETITIVE
STRENGTHS
We believe our key competitive strengths include the following:
|
|
Ø
|
A significant late-stage product opportunity in Amelior;
|
|
Ø
|
Strong growth potential of our existing marketed products,
Acetadote and Kristalose;
|
|
Ø
|
Our focus on underserved niche markets, including hospital acute
care and gastroenterology;
|
|
Ø
|
A profitable business with a history of fiscal discipline; and
|
|
Ø
|
Extensive management expertise in business development, clinical
and regulatory affairs, and sales and marketing.
|
2
OUR
STRATEGY
Our objective is to develop, acquire and commercialize branded
pharmaceutical products for specialty physician market segments.
Our strategy to achieve this objective includes the following
key elements:
|
|
Ø
|
Successfully develop and commercialize Amelior, our lead product
candidate in Phase III clinical trials;
|
|
Ø
|
Maximize sales of our marketed products, Acetadote and
Kristalose;
|
|
Ø
|
Expand our dedicated hospital and gastroenterology sales forces;
|
|
Ø
|
Expand our product portfolio by acquiring rights to additional
marketed products and late-stage product candidates; and
|
|
Ø
|
Develop a pipeline of early-stage products through CET, our
majority-owned subsidiary.
|
RISKS AFFECTING
US
Our business is subject to numerous risks that could prevent us
from successfully implementing our business strategy. These and
other risks are discussed further in the section entitled
Risk factors immediately following this prospectus
summary, and include the following:
|
|
Ø
|
Our Amelior product candidate has not been approved for sale and
may never be successfully commercialized;
|
|
Ø
|
We currently market two products, Acetadote and Kristalose. An
adverse development regarding either of these products could
have a material and adverse impact on us;
|
|
Ø
|
If any manufacturer we rely upon fails to produce our products
and product candidates in the amounts we require on a timely
basis, or fails to comply with stringent regulations applicable
to pharmaceutical drug manufacturers, we may face delays in the
commercialization of Amelior, or may be unable to meet demand
for the product supplied by the manufacturer and may lose
potential revenues;
|
|
Ø
|
We are dependent on a variety of other third parties. If these
third parties fail to perform as we expect, our operations could
be disrupted and our financial results could suffer; and
|
|
Ø
|
If we are unable to maintain and build an effective sales and
marketing infrastructure, we will not be able to successfully
commercialize and grow our products and product candidates.
|
CORPORATE
INFORMATION
We were incorporated in Tennessee in 1999. Our principal
executive offices are located at 2525 West End Avenue,
Suite 950, Nashville, Tennessee 37203, and our telephone
number is
(615) 255-0068.
Our website address is www.cumberlandpharma.com. The information
on, or accessible through, our website is not part of this
prospectus.
3
The offering
|
|
|
Common stock we are offering |
|
shares |
|
Common stock to be outstanding after this offering |
|
shares |
|
Use of proceeds |
|
We estimate that the net proceeds from this offering will be
approximately $ million, or
approximately $ million if
the underwriters exercise their over-allotment option in full,
assuming an initial public offering price of
$ per share. We expect to use
the net proceeds from this offering primarily for potential
acquisitions, product development and expansion, and general
corporate purposes. We may use a portion of the net proceeds to
acquire the rights to one or more marketed, FDA-approved
products or one or more product candidates in late-stage
development. We may use a portion of the net proceeds to expand
our operations in order to prepare for the launch of one or more
new products. We may also repay outstanding borrowings under our
credit facilities. |
|
Proposed Nasdaq Global Market Symbol |
|
CPIX |
The number of shares of common stock to be outstanding after
this offering is based
on shares
outstanding as
of
and excludes:
|
|
Ø
|
shares
of common stock issuable upon exercise of options issued under
our 1999 Stock Option Plan and options issued in connection with
debt financings in 2001 and 2003, at a weighted average exercise
price of $ per share;
|
|
Ø
|
shares
of common stock issuable upon exercise of outstanding warrants
at a weighted average exercise price of
$ and
$ per share;
|
|
Ø
|
shares
of common stock issuable upon conversion of outstanding
preferred stock; and
|
|
Ø
|
shares
of common stock reserved for future issuance under our current
stock option plans.
|
Unless otherwise indicated, all information in this prospectus
assumes the underwriters do not exercise their option to
purchase up
to shares
of our common stock to cover over-allotments.
4
Summary consolidated
financial data
The tables below summarize our financial data as of the dates
and for the periods indicated. You should read the following
information together with the more detailed information
contained in Selected consolidated financial data,
Managements discussion and analysis of financial
condition and results of operations and our consolidated
financial statements and the accompanying notes included
elsewhere in this prospectus.
Pro forma data below gives effect to the conversion
of
shares of our preferred stock
into
shares of common stock. Pro forma as adjusted data below gives
effect to the sale
of
shares of common stock that we are offering at an assumed
initial public offering price of $
per share, after deducting underwriting discounts and
commissions and estimated offering expenses to be paid by us.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended
December 31,
|
|
Statement of
operations data:
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
|
(in thousands,
except per share data)
|
|
|
Net revenues
|
|
$
|
12,032
|
|
|
$
|
10,690
|
|
|
$
|
17,815
|
|
Operating income
|
|
|
1,569
|
|
|
|
750
|
|
|
|
2,224
|
|
Net income before income taxes
|
|
|
558
|
|
|
|
770
|
|
|
|
1,708
|
|
Net income
|
|
|
558
|
|
|
|
1,954
|
|
|
|
4,404
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per sharebasic
|
|
$
|
0.12
|
|
|
$
|
0.41
|
|
|
$
|
0.90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per sharediluted
|
|
$
|
0.07
|
|
|
$
|
0.24
|
|
|
$
|
0.55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
outstandingbasic
|
|
|
4,541
|
|
|
|
4,748
|
|
|
|
4,899
|
|
Weighted average shares
outstandingdiluted
|
|
|
7,741
|
|
|
|
8,045
|
|
|
|
8,016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
December 31, 2006
|
|
|
|
|
|
|
|
|
|
Pro Forma
|
|
Balance sheet
data:
|
|
Actual
|
|
|
Pro
Forma
|
|
|
as
Adjusted
|
|
|
|
|
|
(in
thousands)
|
|
|
Cash and cash equivalents
|
|
$
|
6,255
|
|
|
$
|
|
|
|
$
|
|
|
Working capital
|
|
|
3,945
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
26,481
|
|
|
|
|
|
|
|
|
|
Total long-term debt and other
long-term obligations
|
|
|
10,543
|
|
|
|
|
|
|
|
|
|
Preferred stock
|
|
|
2,743
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
11,126
|
|
|
|
|
|
|
|
|
|
5
Risk factors
Investing in our common stock involves a high degree of risk.
You should carefully consider the following risks, together with
all of the information included in this prospectus, before
investing in our common stock. In addition to the risks outlined
below, there may be other unforeseen risks which may not or
cannot be identified at this time. If any of these risks were to
occur, our business, financial condition and results of
operations could be materially and adversely affected. In that
case, the trading price of our common stock could decline, and
you might lose all or part of your investment.
RISKS RELATED TO
OUR BUSINESS
Our Amelior
product candidate has not been approved for sale and may never
be successfully commercialized.
We anticipate that a substantial portion of our future growth
will come from sales of our Amelior product candidate. However,
Amelior has neither been approved nor marketed by the U.S. Food
and Drug Administration, or FDA, and it is still subject to
risks associated with its clinical development.
Amelior is undergoing Phase III clinical trials to test its
efficacy and safety. Delays in the completion of these clinical
trials, which can result from unforeseen issues, FDA
interventions, problems with enrolling patients and other
reasons, could significantly delay commercial launch and affect
our product development costs. Moreover, results from these
clinical studies may not be as favorable as the results we
obtained in prior, completed studies.
If the results of our clinical trials are favorable, we intend
to submit to the FDA an application for marketing approval for
Amelior. The FDA may decline to accept our application. If the
FDA declines our application, it may require that we conduct
additional studies and submit additional data prior to
resubmitting the application. If the FDA accepts and reviews the
application, it may still require that we conduct additional
studies or submit other data. Conducting studies and collecting,
analyzing and submitting necessary data can be time-consuming
and expensive. The FDA may not act on our application during the
timeframe that we expect. Moreover, the FDA might not approve
our application, in which event we would not be able to sell
Amelior in the U.S., or it might approve Amelior for only
limited uses, in which event the market for this product could
be significantly reduced, adversely affecting our commercial
opportunity. In addition, new government regulations could
prevent or delay regulatory approval of Amelior.
Amelior, which is injectable ibuprofen, is a non-steroidal
anti-inflammatory drug, or NSAID. The widespread use of NSAIDs
has meant that the adverse effects of these relatively safe
drugs have become increasingly prevalent. The two main adverse
drug reactions associated with NSAIDs relate to the
gastrointestinal tract and the kidneys. Recent studies suggest
there may also be a risk of cardiovascular adverse effects
associated with NSAIDs. While we are currently studying the
safety of Amelior in our clinical trials, the FDA may require
additional safety data be collected prior to or after any
approval of the product.
Even if Amelior is successfully developed and approved by the
FDA, it may never gain significant acceptance in the marketplace
and therefore never generate substantial revenue or profits for
us. Physicians may determine that existing drugs are adequate to
address patients needs. For example, oral non-narcotic
pain and fever reducers, as well as narcotic IV pain
relievers, are widely available and commonly prescribed. If
physicians determine that Amelior is safe and effective, it will
still compete, on a
patient-by-patient
and
physician-by-physician
basis, with other therapeutic alternatives. Additionally, we are
aware of other companies developing products that would address
the same market that we are targeting for Amelior. The extent to
which Amelior will be reimbursed by the U.S. government or third-
6
Risk
factors
party payors is also currently unknown, and reimbursement levels
of Amelior compared to those of other competitive drugs will
also affect the level of market acceptance.
As a result of the foregoing and other factors, we do not know
the extent to which Amelior will contribute to our future growth.
We currently
market two products, Acetadote and Kristalose. An adverse
development regarding either of these products could have a
material and adverse impact on us.
We currently market and sell two products, Acetadote and
Kristalose. Changes impacting either product in areas such as
competition, government regulation, intellectual property,
reimbursement and manufacturing would profoundly affect us.
Similarly, a product contamination or other safety issue in
either of our product markets, whether or not directly involving
our products, could negatively impact us.
If any
manufacturer we rely upon fails to produce our products and
product candidates in the amounts we require on a timely basis,
or fails to comply with stringent regulations applicable to
pharmaceutical drug manufacturers, we may face delays in the
commercialization of Amelior, or may be unable to meet demand
for the product supplied by the manufacturer and may lose
potential revenues.
We do not manufacture any of our products or product candidates,
and we do not currently plan to develop any capacity to do so.
Our dependence upon third parties for the manufacture of
products could adversely affect our profit margins or our
ability to develop and deliver products on a timely and
competitive basis. If for any reason we are unable to obtain or
retain third-party manufacturers on commercially acceptable
terms, we may not be able to sell our products as planned.
Furthermore, if we encounter delays or difficulties with
contract manufacturers in producing our products, the
distribution, marketing and subsequent sales of these products
could be adversely affected. In either event, we may choose to
or need to seek an alternative source of supply for, or abandon,
a product line or sell a product line on unsatisfactory terms.
Our agreement with Bioniche Teoranta, or Bioniche, for the
exclusive manufacture and supply of Acetadote requires that we
obtain Acetadote only from Bioniche, even if we could obtain
Acetadote from another supplier on terms more favorable than the
terms of our agreement with Bioniche.
We have minimum purchase obligations under our Acetadote supply
agreement with Bioniche and our Kristalose supply agreement with
Inalco S.p.A. and Inalco Biochemicals, Inc., or collectively
Inalco. If our purchase obligations exceed demand for these
products, we may be forced to either breach our contract with
that manufacturer or purchase a supply of the product that we
may be unable to sell. Our contract with Bioniche extends until
2011, and our contract with Inalco extends until 2021.
On February 2, 2007, Mayne Pharma Pty. Ltd., our exclusive
manufacturer of Amelior, was acquired by Hospira, Inc. If
Hospira encounters integration problems or if we have
disagreements with Hospira, with whom we have not collaborated
in the past, our supply of Amelior could be interrupted.
Amelior is manufactured at a single facility in Australia.
Acetadote is manufactured at a single facility in Ireland and
the active pharmaceutical ingredient for Kristalose is
manufactured at a single facility in Italy. If any one of these
facilities is damaged or destroyed, or if local conditions
result in a work stoppage, we could suffer a delay or suspension
of clinical trials, in the case of Amelior, or an inability to
meet demand in the case of our marketed products. Kristalose is
manufactured through a complex process involving trade secrets
of the manufacturer. Accordingly, it would be particularly
difficult to find a new manufacturer of Kristalose on an
expedited basis.
7
Risk
factors
In addition, all manufacturers of our products and product
candidates must comply with current good manufacturing
practices, referred to as cGMP, enforced by the FDA through its
facilities inspection program. These requirements include
quality control, quality assurance and the maintenance of
records and documentation. Manufacturers of our product
candidates may be unable to comply with cGMP requirements and
with other FDA, state and foreign regulatory requirements. We
have no control over our manufacturers compliance with
these regulations and standards. If our third-party
manufacturers do not comply with these requirements, we could be
subject to:
|
|
Ø
|
fines and civil penalties;
|
|
Ø
|
suspension of production or distribution;
|
|
Ø
|
suspension or delay in product approval;
|
|
Ø
|
product seizure or recall; and
|
|
Ø
|
withdrawal of product approval.
|
We are dependent
on a variety of other third parties. If these third parties fail
to perform as we expect, our operations could be disrupted and
our financial results could suffer.
We have a relatively small internal infrastructure. We rely on a
variety of third parties, other than our third-party
manufacturers, to help us operate our business. Other third
parties on which we rely include:
|
|
Ø
|
Cardinal Health Specialty Pharmaceutical Services, a logistics
and fulfillment company and business unit of Cardinal, which
warehouses and ships both Kristalose and Acetadote;
|
|
Ø
|
Advogent Group, Inc., a spin-off of Cardinal, which provides a
field sales force that is the primary selling team for
Kristalose; and
|
|
Ø
|
Vanderbilt University and the Tennessee Technology Development
Corporation, co-owners with us of Cumberland Emerging
Technologies, Inc., or CET, and the universities that
collaborate with us in connection with CETs research and
development programs.
|
If these third parties do not continue to provide services to
us, or collaborate with us, we might not be able to obtain
others who can serve these functions. This could disrupt our
business operations, delay completion of clinical trials,
regulatory approval and market launch of Amelior or any future
product candidate, increase our operating expenses and otherwise
adversely affect our operating results.
If we are unable
to maintain and build an effective sales and marketing
infrastructure, we will not be able to commercialize and grow
our products and product candidates successfully.
Historically, we have relied on Cardinal, to provide sales
representatives to promote our products. Recently, we exercised
an option under our agreement with Cardinal to convert the
hospital sales force for our products to Cumberland employees.
This conversion was completed in January 2007. Our ability to
maintain and increase our revenues and profitability,
particularly in the near term, will depend on our ability to
address any issues or inefficiencies that arise from
transitioning this sales force from Cardinal employees to our
employees.
As we grow, we may not be able to secure sales personnel or
organizations that are adequate in number or expertise to
successfully market and sell our products. This risk would be
accentuated if we acquire products in areas outside of acute
care/emergency medicine and gastroenterology, since our sales
forces specialize in these areas. If we are unable to expand our
sales and marketing capability or any other capabilities
necessary to commercialize our products and product candidates,
we will need to contract
8
Risk
factors
with third parties to market and sell our products. If we are
unable to establish and maintain adequate sales and marketing
capabilities:
|
|
Ø
|
we may not be able to increase our product revenue;
|
|
Ø
|
we may generate increased expenses; and
|
|
Ø
|
we may not continue to be profitable.
|
Competitive
pressures could reduce our revenues and profits.
The pharmaceutical industry is intensely competitive. Our
strategy is to target differentiated products in specialized
markets. However, this strategy does not relieve us from
competitive pressures, and can entail distinct competitive
risks. For example, a new entrant into a smaller market could
have a disproportionately large impact on others in the market.
In addition, certain of our competitors do not aggressively
promote their products in our markets. A relatively modest
increase in promotional activity in our markets could result in
large shifts in market share, adversely affecting us.
Kristalose competes in the U.S. with several other prescription
laxative products, two of which are marketed by large,
international pharmaceutical companies. Acetadote competes
domestically with several orally administered prescription
products for treating acetaminophen overdose. We are aware of
products under development, including an intravenous
acetaminophen product, which could compete with Amelior. We have
limited patent protection against direct competition.
We compete with numerous pharmaceutical, specialty
pharmaceutical and biotechnology companies. Our competitors may
sell or develop drugs that are more effective and useful and
less costly than ours, and they may be more successful in
manufacturing and marketing their products. Many of our
competitors have significantly greater financial and marketing
resources than we do. Additional competitors may enter our
markets.
The pharmaceutical industry is characterized by constant and
significant investment in new product development, which can
result in rapid technological change. The introduction of new
products could substantially reduce our market share or render
our products obsolete. The selling prices of pharmaceutical
products tend to decline as competition increases, through new
product introduction or otherwise, which could reduce our
revenues and profitability.
Governmental and private health care payors have recently
emphasized substitution of branded pharmaceuticals with less
expensive generic equivalents. An increase in the sales of
generic pharmaceutical products could result in a decrease in
our revenues. While there are no generic equivalents competing
with Amelior, Acetadote or Kristalose at this time, in the
future we could face generic competition.
Our future growth
depends on our ability to identify and acquire rights to
products. If we do not successfully identify and acquire rights
to products and successfully integrate them into our operations,
our growth opportunities would be limited.
We acquired rights to Amelior, Acetadote and Kristalose. Our
business strategy is to continue to acquire rights to
FDA-approved products as well as pharmaceutical product
candidates in the late stages of development. We do not plan to
conduct basic research or early-stage product development,
except to the extent of our investment in CET. We have limited
resources to acquire third-party products, businesses and
technologies and integrate them into our current infrastructure.
Many acquisition opportunities involve competition among several
potential purchasers including large multi-national
pharmaceutical companies and other competitors that have access
to greater financial resources than we do.
9
Risk
factors
With future acquisitions, we may face financial and operational
risks and uncertainties, including:
|
|
Ø
|
not realizing the expected economic return or other benefits
from an acquisition;
|
|
Ø
|
incurring higher than expected acquisition and integration costs;
|
|
Ø
|
assuming or otherwise being exposed to unknown liabilities;
|
|
Ø
|
developing or integrating new products that could disrupt our
business and divert our managements time and attention;
|
|
Ø
|
not being able to preserve key suppliers or distributors of any
acquired products;
|
|
Ø
|
incurring substantial debt or issue dilutive securities to pay
for acquisitions; and
|
|
Ø
|
acquiring products that could substantially increase our
amortization expenses.
|
We are not precluded from engaging in a large acquisition in the
future, including an acquisition that entails the investment of
substantially all of the proceeds from this offering. While
large acquisitions potentially present large opportunities, they
also could magnify the risks identified above.
We may not be able to engage in future product acquisitions, and
those we do complete may not be beneficial to us in the long
term.
Continued
consolidation of distributor networks in the pharmaceutical
industry as well as increases in retailer concentration may
limit our ability to profitably sell our products.
We sell most of our products to large pharmaceutical
wholesalers, who in turn sell to, thereby supplying, hospitals
and retail pharmacies. The distribution network for
pharmaceutical products has become increasingly consolidated in
recent years. Today, three large wholesalers control most of the
market. Further consolidation among, or any financial
difficulties of, pharmaceutical wholesalers or retailers could
result in the combination or elimination of warehouses, which
could cause product returns to us. In addition, further
consolidation or financial difficulties could also cause our
customers to reduce the amounts of our products that they
purchase, which would materially and adversely affect our
business, financial condition and results of operations.
If governmental
or third-party payors do not provide adequate reimbursement for
our products, our revenue and prospects for continued
profitability will be limited.
Our financial success depends, in part, on the availability of
adequate reimbursement from third-party healthcare payors. Such
third-party payors include governmental health programs such as
Medicare and Medicaid, managed care providers and private health
insurers. Third-party payors are increasingly challenging the
pricing of medical products and services, while governments
continue to propose and pass legislation designed to reduce the
cost of healthcare. Adoption of such legislation could further
limit reimbursement for pharmaceuticals. For example, in
December 2003, Congress enacted a limited prescription drug
benefit for Medicare beneficiaries in the Medicare Prescription
Drug, Improvement, and Modernization Act of 2003. Under this
program, drug prices for certain prescription drugs are
negotiated by drug plans, with the goal to lower costs for
Medicare beneficiaries. Future cost control initiatives could
decrease the price that we would receive for any products, which
would limit our revenue and profitability. In addition,
legislation and regulations affecting the pricing of
pharmaceuticals might change.
Reimbursement practices of third-party payors might preclude us
from achieving market acceptance for our products or maintaining
price levels sufficient to realize an appropriate return on our
investment in product acquisition and development. If we cannot
obtain adequate reimbursement levels, our business, financial
condition and results of operations would be materially and
adversely affected.
10
Risk
factors
Formulary
practices of third-party payors could adversely affect our
competitive position.
Many managed health care organizations are now controlling the
pharmaceutical products listed on their formulary lists. The
benefit of having products listed on these formulary lists
creates competition among pharmaceutical companies which, in
turn, has created a trend of downward pricing pressure in our
industry. In addition, many managed care organizations are
pursuing various ways to reduce pharmaceutical costs and are
considering formulary contracts primarily with those
pharmaceutical companies that can offer a full line of products
for a given therapy sector or disease state. Our products might
not be included on the formulary lists of managed care
organizations, and downward pricing pressure in our industry
generally could negatively impact our operations.
Our CET joint
initiative may not result in our gaining access to commercially
viable products.
Our CET joint initiative with Vanderbilt University and
Tennessee Technology Development Corporation is designed to help
us investigate, in a cost-effective manner, early-stage products
and technologies. However, we may never gain access to
commercially viable products from CET for a variety of reasons,
including:
|
|
Ø
|
CET investigates early-stage products, which have the greatest
risk of failure prior to FDA approval and commercialization;
|
|
Ø
|
In some programs, we do not have pre-set rights to product
candidates developed by CET. We would need to agree with CET and
its collaborators on the terms of any product license to, or
acquisition by, us;
|
|
Ø
|
We rely principally on government grants to fund CETs
research and development programs. If these grants were no
longer available, we or our co-owners might be unable or
unwilling to fund CET operations at current levels or at
all;
|
|
Ø
|
We may become involved in disputes with our co-owners regarding
CET policy or operations, such as how best to deploy CET assets
or which product opportunities to pursue. Disagreement could
disrupt or halt product development; and
|
|
Ø
|
CET may disagree with one of the various universities with which
CET is collaborating on research. A disagreement could disrupt
or halt product development.
|
The size of our
organization and our activities are growing, and we may
experience difficulties in managing growth.
As of April 30, 2007, we had 33 full-time employees.
We may need to continue to expand our managerial, operational,
financial and other resources in order to increase our marketing
efforts with regard to our currently marketed products, continue
our business development and product development activities and
commercialize our product candidates. We have experienced, and
may continue to experience, rapid growth in the scope of our
operations in connection with the commercial launch of new
products. Our financial performance will depend, in part, on our
ability to manage any such growth effectively. Our management,
personnel, systems and facilities currently in place may not be
adequate to support this future growth.
We depend on our
key personnel, the loss of whom would adversely affect our
operations. If we fail to attract and retain the talent required
for our business, our business will be materially
harmed.
We are a relatively small company, and we depend to a great
extent on principal members of our management and scientific
staff. If we lose the services of any key personnel, in
particular, A.J. Kazimi,
11
Risk
factors
our Chief Executive Officer, it could have a material adverse
effect on our business prospects. We currently have a key man
life insurance policy covering the life of Mr. Kazimi. We
have entered into agreements with each of our employees that
contain restrictive covenants relating to non-competition and
non-solicitation of our customers and suppliers for one year
after termination of employment. Nevertheless, each of our
officers and key employees may terminate his or her employment
at any time without notice and without cause or good reason, and
so as a practical matter these agreements do not guarantee the
continued service of these employees. Our success depends on our
ability to attract and retain highly qualified scientific,
technical and managerial personnel and research partners.
Competition among pharmaceutical companies for qualified
employees is intense, and we may not be able to retain existing
personnel or attract and retain qualified staff in the future.
If we experience difficulties in hiring and retaining personnel
in key positions, we could suffer from delays in product
development, loss of customers and sales and diversion of
management resources, which could adversely affect operating
results.
We face potential
product liability exposure, and if successful claims are brought
against us, we may incur substantial liability for a product or
product candidate and may have to limit its
commercialization.
We face an inherent risk of product liability lawsuits related
to the testing of our product candidates and the commercial sale
of our products. An individual may bring a liability claim
against us if one of our product candidates or products causes,
or appears to have caused, an injury. If we cannot successfully
defend ourselves against the product liability claim, we may
incur substantial liabilities. Liability claims may result in:
|
|
Ø
|
decreased demand for our products;
|
|
Ø
|
injury to our reputation;
|
|
Ø
|
withdrawal of clinical trial participants;
|
|
Ø
|
significant litigation costs;
|
|
Ø
|
substantial monetary awards to or costly settlement with
patients;
|
|
Ø
|
product recalls;
|
|
Ø
|
loss of revenue; and
|
|
Ø
|
the inability to commercialize our product candidates.
|
We are highly dependent upon medical and patient perceptions of
us and the safety and quality of our products. We could be
adversely affected if we or our products are subject to negative
publicity. We could also be adversely affected if any of our
products or any similar products sold by other companies prove
to be, or are asserted to be, harmful to patients. Also, because
of our dependence upon medical and patient perceptions, any
adverse publicity associated with illness or other adverse
effects resulting from the use or misuse of our products or any
similar products sold by other companies could have a material
adverse impact on our results of operations.
We have product liability insurance that covers our clinical
trials and the marketing and sale of our products up to a
$10 million annual aggregate limit, subject to specified
deductibles. Our current or future insurance coverage may prove
insufficient to cover any liability claims brought against us.
Because of the increasing costs of insurance coverage, we may
not be able to maintain insurance coverage at a reasonable cost
or obtain insurance coverage that will be adequate to satisfy
any liability that may arise.
12
Risk
factors
We have never
paid dividends on our capital stock, and we do not anticipate
paying any cash dividends in the foreseeable future.
We have never paid cash dividends on our capital stock. We do
not anticipate paying cash dividends to our shareholders in the
foreseeable future. The availability of funds for distributions
to shareholders will depend substantially on our earnings. Even
if we become able to pay dividends in the future, we expect that
we would retain such earnings to enhance capital
and/or
reduce long-term debt.
RISKS RELATING TO
GOVERNMENT REGULATION
We are subject to
stringent government regulation. All of our products face
regulatory challenges.
Virtually all aspects of our business activities are regulated
by government agencies. The manufacturing, processing,
formulation, packaging, labeling, distribution, promotion and
sampling, and advertising of our products, and disposal of waste
products arising from such activities, are subject to
governmental regulation. These activities are regulated by one
or more of the FDA, the Federal Trade Commission, or the FTC,
the Consumer Product Safety Commission, the U.S. Department
of Agriculture and the U.S. Environmental Protection
Agency, or the EPA, as well as by comparable agencies in foreign
countries. These activities are also regulated by various
agencies of the states and localities in which our products are
sold. For more information, see BusinessGovernment
Regulation.
Like all pharmaceutical manufacturers, we are subject to
regulation by the FDA under the authority of the Federal Food,
Drug and Cosmetic Act, or the FDC Act. All new drugs
must be the subject of an FDA-approved new drug application, or
NDA, before they may be marketed in the U.S. The FDA has the
authority to withdraw existing NDA approvals and to review the
regulatory status of products marketed under the enforcement
policy. The FDA may require an approved NDA for any drug product
marketed under the enforcement policy if new information reveals
questions about the drugs safety and effectiveness. All
drugs must be manufactured in conformity with cGMP, and drug
products subject to an approved NDA must be manufactured,
processed, packaged, held and labeled in accordance with
information contained in the NDA. Since we rely on third parties
to manufacture our products, cGMP requirements directly affect
our third party manufacturers and indirectly affect us. The
manufacturing facilities of our third-party manufacturers are
continually subject to inspection by such governmental agencies,
and manufacturing operations could be interrupted or halted in
any such facilities if such inspections prove unsatisfactory.
Our third-party manufacturers are subject to periodic inspection
by the FDA to assure such compliance.
Pharmaceutical products must be distributed, sampled and
promoted in accordance with FDA requirements. The FDA also
regulates the advertising of prescription drugs. The FDA has the
authority to request post-approval commitments that can be
time-consuming and expensive to comply with.
Under the FDC Act, the federal government has extensive
enforcement powers over the activities of pharmaceutical
manufacturers to ensure compliance with FDA regulations. Those
powers include, but are not limited to, the authority to
initiate court action to seize unapproved or non-complying
products, to enjoin non-complying activities, to halt
manufacturing operations that are not in compliance with cGMP,
and to seek civil monetary and criminal penalties. The
initiation of any of these enforcement activities, including the
restriction or prohibition on sales of our products, could
materially adversely affect our business, financial condition
and results of operations.
Any change in the FDAs enforcement policy could have a
material adverse effect on our business, financial condition and
results of operations.
13
Risk
factors
We cannot determine what effect changes in regulations or
statutes or legal interpretation, when and if promulgated or
enacted, may have on our business in the future. Such changes
could, among other things, require:
|
|
Ø
|
changes to manufacturing methods;
|
|
Ø
|
expanded or different labeling;
|
|
Ø
|
recall, replacement or discontinuance of certain products;
|
|
Ø
|
additional record keeping; and
|
|
Ø
|
expanded documentation of the properties of certain products and
scientific substantiation.
|
Such changes, or new legislation, could have a material adverse
effect on our business, financial condition and results of
operations.
RISKS RELATING TO
INTELLECTUAL PROPERTY
Our strategy to
secure and extend marketing exclusivity or patent rights may
provide only limited protection from competition.
We seek to secure and extend marketing exclusivity for our
products through a variety of means, including FDA exclusivity
and patent rights. Acetadote has been designated as an
orphan drug and is indicated to prevent or lessen
hepatic (liver) injury when administered intravenously within
eight to ten hours after ingesting quantities of acetaminophen
that are potentially toxic to the liver. As such, Acetadote is
protected until 2011 against competition from another drug using
the same active ingredient to treat the same indication. Orphan
drug marketing exclusivity does not, however, protect a drug
from competition by a different drug marketed for the same
indications.
We do not have composition of matter or
use patents for our marketed products. We do have a
U.S. patent, No. 6,727,286, and some related
international patents, which are directed to ibuprofen solution
formulations, methods of making the same, and methods of using
the same, and which are related to our formulation and
manufacture of Amelior. We have applied for additional U.S. and
international patent protection for our invention related to
ibuprofen solution formulations, methods of making the same, and
methods of using the same, but those applications may not result
in issued patents. Additionally, the active ingredient in
Amelioribuprofenis in the public domain, and if a
competitor were to develop a sufficiently distinct formulation,
it could develop and seek FDA approval for an ibuprofen product
that competes with Amelior. Following successful completion of
our clinical studies, we also plan to seek three-year marketing
exclusivity for Amelior.
Inalco manufactures Kristalose and owns two U.S. patents,
Nos. 5,003,061 and 5,480,491, related to the manufacture of
Kristalose. These patents are not directed to the composition or
use of Kristalose and do not prevent a competitor from
developing a formulation and developing and seeking FDA approval
for a product that competes with Kristalose.
While we consider patent protection when evaluating product
acquisition opportunities, any products we acquire in the future
may not have significant patent protection. Neither the
U.S. Patent and Trademark Office nor the courts have a
consistent policy regarding the breadth of claims allowed or the
degree of protection afforded under many pharmaceutical patents.
Patent applications in the U.S. and many foreign jurisdictions
are typically not published until 18 months following their
priority filing date, and in some cases not at all. In addition,
publication of discoveries in scientific literature often lags
significantly behind actual discoveries. Therefore, neither we
nor our licensors can be certain that we or they were the first
to make the inventions claimed in our issued patents or pending
patent applications, or that we or they were the first to file
for protection of the inventions set forth in these
14
Risk
factors
patent applications. In addition, changes in either patent laws
or in interpretations of patent laws in the U.S. and other
countries may diminish the value of our intellectual property or
narrow the scope of our patent protection. Furthermore, our
competitors may independently develop similar technologies or
duplicate technology developed by us in a manner that does not
infringe our patents or other intellectual property. As a result
of these factors, our patent rights may not provide any
commercially valuable protection from competing products.
If we are unable
to protect the confidentiality of our proprietary information
and know-how, the value of our technology and products could be
adversely affected.
In addition to patents, we rely upon trade secrets, unpatented
proprietary know-how and continuing technological innovation
where we do not believe patent protection is appropriate or
attainable. For example, the manufacturing process for
Kristalose involves substantial trade secrets and proprietary
know-how. We have entered into confidentiality agreements with
certain key employees and consultants pursuant to which such
employees and consultants must assign to us any inventions
relating to our business if made by them while they are our
employees, as well as certain confidentiality agreements
relating to the acquisition of rights to products.
Confidentiality agreements can be breached, though, and we might
not have adequate remedies for any breach. Also, others could
acquire or independently develop similar technology.
We depend on our
licensors for the maintenance and enforcement of our
intellectual property and have limited, if any, control over the
amount or timing of resources that our licensors devote on our
behalf.
When we license products, we often depend on our licensors to
protect the proprietary rights covering those products. We have
limited, if any, control over the amount or timing of resources
that our licensors devote on our behalf or the priority they
place on maintaining patent or other rights and prosecuting
patent applications to our advantage. While any such licensor is
expected to be under contractual obligations to us to diligently
prosecute its patent applications and allow us the opportunity
to consult, review and comment on patent office communications,
we cannot be sure that it will perform as required. If a
licensor does not perform and if we do not assume the
maintenance of the licensed patents in sufficient time to make
required payments or filings with the appropriate governmental
agencies, we risk losing the benefit of all or some of those
patent rights.
If the use of our
technology conflicts with the intellectual property rights of
third parties, we may incur substantial liabilities, and we may
be unable to commercialize products based on this technology in
a profitable manner or at all.
Third parties, including our competitors, could have or acquire
patent rights that they could enforce against us. In addition,
we may be subject to claims from others that we are
misappropriating their trade secrets or confidential proprietary
information. If our products conflict with the intellectual
property rights of others, they could bring legal action against
us or our licensors, licensees, manufacturers, customers or
collaborators. If we were found to be infringing a patent or
other intellectual property rights held by a third party, we
could be forced to seek a license to use the patented or
otherwise protected technology. We might not be able to obtain
such a license on terms acceptable to us or at all. If an
infringement or misappropriation legal action were to be brought
against us or our licensors, we would incur substantial costs in
defending the action. If such a dispute were to be resolved
against us, we could be subject to significant damages, and the
manufacturing or sale of one or more of our products could be
enjoined.
15
Risk
factors
We may be
involved in lawsuits to protect or enforce our patents or the
patents of our collaborators or licensors, which could be
expensive and time consuming.
Competitors may infringe our patents or the patents of our
collaborators or licensors. To counter infringement or
unauthorized use, we may be required to file infringement
claims, which can be expensive and time-consuming. In addition,
in an infringement proceeding, a court may decide that a patent
of ours is not valid or is unenforceable, or may refuse to stop
the other party from using the technology at issue on the
grounds that our patents do not cover the technology in
question. An adverse result in any litigation or defense
proceeding could put one or more of our patents at risk of being
invalidated or interpreted narrowly and could put our patent
applications at risk of not issuing.
Interference proceedings brought by the U.S. Patent and
Trademark Office may be necessary to determine the priority of
inventions with respect to our patent applications or those of
our collaborators or licensors. Litigation or interference
proceedings may fail and, even if successful, may result in
substantial costs and distract our management. We may not be
able, alone or with our collaborators and licensors, to prevent
misappropriation of our proprietary rights, particularly in
countries where the laws may not protect such rights as fully as
in the U.S.
Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation,
some of our confidential information could be disclosed during
this type of litigation. In addition, there could be public
announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could have a
substantial adverse effect on the price of our common stock.
If we breach any
of the agreements under which we license rights to our products
and product candidates from others, we could lose the ability to
continue commercialization of our products and development and
commercialization of our product candidates.
We have exclusive licenses for the marketing and sale of certain
products and may acquire additional licenses. Such licenses may
terminate prior to expiration if we breach our obligations under
the license agreement related to these pharmaceutical products.
For example, the licenses may terminate if we fail to meet
specified quality control standards, including cGMP with respect
to the products, or commit a material breach of other terms and
conditions of the licenses. Such early termination could have a
material adverse effect on our business, financial condition and
results of operations.
Our agreement with Inalco appoints us as the exclusive marketer,
seller and distributor of Kristalose in the U.S. Either we or
Inalco may terminate this agreement upon the breach of any
material provision of the agreement if the breach is not cured
within 45 days following written notice. If our agreement
with Inalco were terminated, we would lose our right to continue
commercialization of Kristalose in the U.S.
Under an agreement between us and Vanderbilt University, we have
received certain clinical data to support our planned NDA
submission for Amelior. Either we or Vanderbilt may terminate
this agreement upon the breach of any material provision of the
agreement if the breach is not cured within 45 days
following written notice. If our agreement with Vanderbilt were
terminated, we would lose our right to use the data to support
our planned NDA submission, and this loss may hinder our ability
to commercialize Amelior in accordance with our plans.
16
Risk
factors
RISKS RELATED TO
OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS
We have
identified material weaknesses and a significant deficiency in
our internal controls that, if not properly corrected, could
result in material misstatements in our financial
statements.
In connection with our fiscal year 2006 financial statement
audit, we identified three material weaknesses, and an
additional significant deficiency (not rising to the level of a
material weakness), in our internal controls. A significant
deficiency is a control deficiency, or a combination of control
deficiencies, that adversely affects our ability to initiate,
authorize, record, process, or report external financial data
reliably in accordance with U.S. generally accepted accounting
principles such that there is more than a remote likelihood that
a misstatement of our annual or interim financial statements
that is more that inconsequential will not be prevented or
detected by our employees. A material weakness is a significant
deficiency, or combination of significant deficiencies, that
results in more than a remote likelihood that a material
misstatement of our annual or interim financial statement will
not be presented or detected by our employees. We have
undertaken a remediation plan designed to correct these issues.
We summarize below the nature of the material weaknesses
referenced above as well as the related remediation steps that
we are implementing or plan to implement:
|
|
Ø
|
Non-Routine Transactions. We did not maintain
adequate policies and procedures related to our financial
reporting in order to account for significant, non-routine
transactions in accordance with U.S. generally accepted
accounting principles. To remedy this material weakness, we are
implementing a new policy requiring management to review
quarterly the accounting treatment for all transactions and
contracts entered into.
|
|
Ø
|
Financial Statement Review Process. We lack
adequate personnel resources possessing sufficient expertise in
U.S. generally accepted accounting principles to effectively
perform a review of the annual financial statements. To remedy
this material weakness, we intend to establish a new internal
position that will be primarily responsible for SEC and other
external reporting requirements. This position will report to
the Vice President of Finance and Accounting.
|
|
Ø
|
Taxes. We do not have an adequate number of
personnel with appropriate qualifications and training in
accounting for income taxes to perform a sufficient review of
the income tax provision. To remedy this material weakness, we
are implementing new procedures that, among other things,
require us to further review the work of our external tax
provider and to increase communication and information-sharing
between our external tax provider and us.
|
The significant deficiency relates to our policies and
procedures for the review of our master listing of stock options
granted. To remedy this significant deficiency, we are reviewing
each transaction on our master listing against the relevant
source documents and implementing new policies requiring
quarterly review of the master listing by departments including
our finance and accounting departments.
If we are not able to timely remedy the material weaknesses and
significant deficiency described above, we may be unable to
provide to our shareholders the required financial information
in a timely and reliable manner, and we may misreport financial
information, either of which could subject us to stockholder
litigation and regulatory enforcement actions. This could
materially and adversely impact our financial condition and the
market value of our securities.
17
Risk
factors
Our operating
results are likely to fluctuate from period to period.
We are a relatively new company seeking to capture significant
growth. While our revenues and operating income have increased
over time, we anticipate that there may be fluctuations in our
future operating results. Potential causes of future
fluctuations in our operating results may include:
|
|
Ø
|
new product launches, which could increase revenues but also
increase sales and marketing expenses;
|
|
Ø
|
acquisition activity and other one-time charges (such as for
inventory expiration);
|
|
Ø
|
increases in research and development expenses resulting from
the acquisition of a product candidate that requires significant
additional development;
|
|
Ø
|
changes in the competitive, regulatory or reimbursement
environment, which could drive down revenues or drive up sales
and marketing or compliance costs; and
|
|
Ø
|
unexpected product liability or intellectual property claims and
lawsuits.
|
See also Managements discussion and analysis of
financial condition and results of operations
Liquidity and capital resources. Fluctuation in operating
results, particularly if not anticipated by investors and other
members of the financial community, could add to volatility in
our stock price.
Our focus on
acquisitions as a growth strategy has created a large amount of
intangible assets whose amortization could negatively affect our
results of operations.
Our total assets include intangible assets related to our
acquisitions. The value of these intangible assets represents
the excess of the acquisition purchase price over the fair value
of the separate assets we acquired. As of December 31,
2006, intangible assets relating to product and data
acquisitions represented approximately 37.1% of our total
assets. We may never realize the value of these assets.
Generally accepted accounting principles require that we
evaluate on a regular basis whether events and circumstances
have occurred that indicate that all or a portion of the
carrying amount of the asset may no longer be recoverable, in
which case we would write down the value of the asset and take a
corresponding charge to earnings. Any determination requiring
the write-off of a significant portion of unamortized intangible
assets would adversely affect our results of operations.
We may need
additional funding and may be unable to raise capital when
needed, which could force us to delay, reduce or eliminate our
product development or commercialization and marketing
efforts.
We may need to raise additional funds in order to meet the
capital requirements of running our business and acquiring and
developing new pharmaceutical products. If we require additional
funding, we may seek to sell common stock or other equity or
equity-linked securities, which could result in dilution to
purchasers of common stock in this offering. We may also seek to
raise capital through a debt financing, which would result in
ongoing debt-service payments and increased interest expense.
Any financings would also likely involve operational and
financial restrictions being imposed on us. We might also seek
to sell assets or rights in one or more commercial products or
product development programs. Additional capital might not be
available to us when we need it on acceptable terms or at all.
If we are unable to raise additional capital when needed, we
could be forced to scale back our operations to conserve cash.
18
Risk
factors
We have a
relatively short history of profitability and may not be able to
sustain or increase our net income levels.
We were incorporated in 1999 and incurred operating losses until
2004. We recorded our first year of profitability in 2004 and
have increased profitability in each of 2005 and 2006. As of
December 31, 2006, however, we still had an accumulated
deficit of ($7.4) million, representing the amount by which
our historical losses have exceeded our historical profits. We
may not be able to maintain or improve our current levels of
revenue or net income. In such event, investors are likely to
lose confidence in our ability to grow, and our stock price
would suffer.
RISKS RELATED TO
THIS OFFERING AND AN INVESTMENT IN OUR STOCK
As a new
investor, you will experience immediate and substantial dilution
in the net tangible book value of your shares.
The initial public offering price of our common stock in this
offering is considerably more than the net tangible book value
per share of our outstanding common stock. Investors purchasing
shares of common stock in this offering will pay a price that
substantially exceeds the value of our tangible assets after
subtracting liabilities. As a result, investors in this offering
will:
|
|
Ø
|
incur immediate dilution of
$ per share, based on an
assumed initial public offering price of
$ per share;
|
|
Ø
|
contribute % of the total amount
invested to date to fund our company based on an assumed initial
offering price to the public of
$ per share;
|
|
Ø
|
but will own only % of the shares
of common stock outstanding after the offering.
|
We may conduct substantial additional equity offerings or issue
equity as consideration in an acquisition or otherwise. These
future equity issuances, together with the exercise of
outstanding options or warrants, could result in future dilution
to investors.
The market price
of our common stock may fluctuate substantially.
The initial public offering price for the shares of our common
stock sold in this offering has been determined by negotiation
between the representatives of the underwriters and us. This
price may not reflect the market price of our common stock
following this offering. The price of our common stock may
decline. In addition, the market price of our common stock is
likely to be highly volatile and may fluctuate substantially.
The realization of any of the risks described in these
Risk factors could have a dramatic and material
adverse impact on the market price of our common stock. In
addition, securities class action litigation has often been
instituted against companies whose securities have experienced
periods of volatility in market price. Any such securities
litigation brought against us could result in substantial costs
and a diversion of managements attention and resources,
which could negatively impact our business, operating results
and financial condition.
We will incur
increased costs as a result of operating as a public company,
and our management will be required to devote additional time to
new compliance initiatives.
We will incur increased costs as a result of operating as a
public company, and our management will be required to devote
additional time to new compliance initiatives. As a public
company, we will incur legal, accounting and other expenses that
we did not incur as a private company. In addition, the
Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well
as rules subsequently implemented by
19
Risk
factors
the SEC and Nasdaq, have imposed various new requirements on
public companies, including requiring establishment and
maintenance of effective disclosure and financial controls and
changes in corporate governance practices. These rules and
regulations will increase our legal and financial compliance
costs and will render some activities more time-consuming and
costly.
The Sarbanes-Oxley Act will require, among other things, that we
maintain effective internal controls for financial reporting and
disclosure controls and procedures. In particular, we must
perform system and process evaluation and testing of our
internal controls over financial reporting to allow management
and our independent registered public accounting firm to report
on the effectiveness of our internal controls over financial
reporting, beginning with our Annual Report on Form 10-K
for the fiscal year ending December 31, 2008, as required
by Section 404 of the Sarbanes-Oxley Act. Our testing, or
the subsequent testing by our independent registered public
accounting firm, may reveal deficiencies in our internal
controls over financial reporting that are deemed to be material
weaknesses. As described in a previous risk factor, we have
identified certain deficiencies in the past. Our compliance with
Section 404 will require that we incur substantial
accounting expense and expend significant management efforts.
Moreover, if we are not able to comply with the requirements of
Section 404 in a timely manner, or if we or our independent
registered public accounting firm identifies deficiencies in our
internal controls over financial reporting that are deemed to be
material weaknesses, the market price of our stock could decline
and we could be subject to sanctions or investigations by
Nasdaq, the SEC or other regulatory authorities, which would
require additional financial and management resources.
There may not be
a viable public market for our common stock.
Prior to this offering, there has been no public market for our
common stock, and a regular trading market might not develop or
continue after this offering. Moreover, the market price of our
common stock might decline below the initial public offering
price.
We will have
broad discretion in how we use the proceeds of this offering,
and we may not use these proceeds effectively, which could
affect our results of operations and cause our stock price to
decline.
We will have broad discretion over the use of proceeds from this
offering. We expect that the net proceeds from this offering
will be used to fund clinical trials for Amelior and other
research, marketing and development activities, and to fund
working capital, capital expenditures and other general
corporate purposes. We may also use a portion of the net
proceeds to acquire products. We have no present agreements with
respect to any such product acquisitions. We will have
considerable discretion in the application of the net proceeds,
and you will not have the opportunity, as part of your
investment decision, to assess whether the proceeds are being
used appropriately. The net proceeds may be used for purposes
that do not increase our operating results or market value.
Until the net proceeds are used, they may be placed in
investments that do not produce significant income or that lose
value.
Future sales of
our common stock may depress our stock price.
Sales of a substantial number of shares of our common stock in
the public market after this offering or the perception that
these sales may occur could cause the market price of our common
stock to decline. In addition, the sale of these shares in the
public market could impair our ability to raise capital through
the sale of additional common or preferred stock. After this
offering, we will
have shares
of common stock outstanding. Of these shares, all shares sold in
the offering, other than shares, if any, purchased by our
affiliates, will be freely tradable.
20
Risk
factors
Some provisions
of our second amended and restated charter, bylaws and Tennessee
law may inhibit potential acquisition bids that you may consider
favorable.
Our corporate documents contain provisions that may enable our
board of directors to resist a change in control of our company
even if a change in control were to be considered favorable by
you and other shareholders. These provisions include:
|
|
Ø
|
the authorization of undesignated preferred stock, the terms of
which may be established and shares of which may be issued
without shareholder approval;
|
|
Ø
|
advance notice procedures required for shareholders to nominate
candidates for election as directors or to bring matters before
an annual meeting of shareholders;
|
|
Ø
|
limitations on persons authorized to call a special meeting of
shareholders;
|
|
Ø
|
a staggered board of directors;
|
|
Ø
|
a requirement that vacancies in directorships are to be filled
by a majority of the directors then in office and the number of
directors is to be fixed by the board of directors; and
|
|
Ø
|
no cumulative voting.
|
These and other provisions contained in our second amended and
restated charter and bylaws could delay or discourage
transactions involving an actual or potential change in control
of us or our management, including transactions in which our
shareholders might otherwise receive a premium for their shares
over then current prices, and may limit the ability of
shareholders to remove our current management or approve
transactions that our shareholders may deem to be in their best
interests and, therefore, could adversely affect the price of
our common stock.
In addition, we are subject to control share acquisitions
provisions and affiliated transaction provision of the Tennessee
Business Corporation Act, the applications of which may have the
effect of delaying or preventing a merger, takeover or other
change of control of us and therefore could discourage attempts
to acquire our company. For more information, see
Description of capital stockAnti-takeover effects of
Tennessee law and provisions of our charter and bylaws.
21
Special note
regarding forward-looking statements
Statements in this prospectus that are not historical factual
statements are forward-looking statements.
Forward-looking statements include, among other things,
statements regarding our intent, belief or expectations, and can
be identified by the use of terminology such as may,
will, expect, believe,
intend, plan, estimate,
should, seek, anticipate and
other comparable terms or the negative thereof. In addition, we,
through our senior management, from time to time make
forward-looking oral and written public statements concerning
our expected future operations and other developments. While
forward-looking statements reflect our good-faith beliefs and
best judgment based upon current information, they are not
guarantees of future performance and are subject to known and
unknown risks and uncertainties, including those mentioned in
Risk factors, Managements discussion and
analysis of financial condition and results of operations
and elsewhere in this prospectus. Actual results may differ
materially from the expectations contained in the
forward-looking statements as a result of various factors. Such
factors include, without limitation:
|
|
Ø
|
legislative, regulatory or other changes in the healthcare
industry at the local, state or federal level which increase the
costs of, or otherwise affect our operations;
|
|
Ø
|
changes in reimbursement available to us by government or
private payers, including changes in Medicare and Medicaid
payment levels and availability of third-party insurance
coverage;
|
|
Ø
|
competition; and
|
|
Ø
|
changes in national or regional economic conditions, including
changes in interest rates and availability and cost of capital
to us.
|
22
Use of proceeds
We estimate that the net proceeds to us from the sale of
the shares
of common stock offered hereby will be approximately
$ million, assuming an
initial public offering price of $
and after deducting underwriting discounts and commissions and
estimated offering expenses. If the underwriters exercise their
over-allotment option in full, we estimate that our net proceeds
will be approximately
$ million. Each $1.00
increase (decrease) in the assumed initial public offering price
of $ per share would increase
(decrease) the net proceeds to us from this offering by
approximately $ million,
assuming that the number of shares offered by us, as set forth
on the cover page of this prospectus, remains the same.
Depending on market conditions at the time of pricing of this
offering and other considerations, we may sell fewer or more
shares than the number set forth on the cover page of this
prospectus.
The principal purposes of this offering are to obtain additional
capital and to create a public market for our common stock. We
expect to use the net proceeds from this offering primarily for
potential acquisitions, product development and expansion and
general corporate purposes. We may use a portion of the net
proceeds to acquire the rights to one or more marketed,
FDA-approved products or one or more product candidates. We may
also use a portion of the net proceeds to expand our operations
in order to prepare for the launch of one or more new products,
including expanding our sales forces. We may also use a portion
of the net proceeds of this offering to repay all or a portion
of our outstanding borrowings under our credit facility. Amounts
loaned under our credit facility bear interest at BBA LIBOR
Daily Floating Rate plus 2.50% per annum, and the facility
expires in April 2008 with respect to the revolving line of
credit and in April 2009 with respect to the term loan.
The amounts we actually expend for the above-specified purposes
may vary depending on a number of factors, including changes in
our business strategy, the amount of our future revenues and
expenses and our future cash flow. If our future revenues or
cash flow are less than we currently anticipate, we may need to
support our ongoing business operations with net proceeds from
this offering that we would otherwise use to support
acquisitions and other methods of growth.
Until we use the net proceeds from this offering for the above
purposes, we intend to invest the funds in short-term,
investment-grade, interest-bearing securities as directed by our
investment policy. Our goals with respect to the investment of
these net proceeds are capital preservation and liquidity so
that such funds are readily available.
Dividend policy
We have not declared or paid any dividends on our common stock
and do not anticipate paying cash dividends on our common stock
for the foreseeable future. We currently intend to retain any
future earnings for use in the operation of our business and to
fund future growth. The payment of any dividends by us on our
common or preferred stock is limited by our loan agreement with
Bank of America. Any future decision to declare and pay
dividends will be at the sole discretion of our board of
directors.
23
Capitalization
The following table sets forth our capitalization as of
December 31, 2006:
|
|
Ø
|
on an actual basis;
|
|
Ø
|
on a pro forma basis to give effect to the conversion of all of
our outstanding preferred stock
into shares of
common stock; and
|
|
Ø
|
on a pro forma as adjusted basis to give further effect to the
sale
of shares
of common stock that we are offering at an assumed initial
public offering price of
$ per share, after deducting
underwriting discounts and commissions and estimated offering
expenses to be paid by us.
|
You should read the following table in conjunction with our
consolidated financial statements and related notes and
Managements discussion and analysis of financial
condition and results of operations appearing elsewhere in
this prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
December 31, 2006
|
|
|
|
|
|
|
|
|
|
Pro Forma
|
|
|
|
Actual
|
|
|
Pro
Forma
|
|
|
as
Adjusted
|
|
|
|
|
|
(in
thousands)
|
|
|
Cash and cash
equivalents(1)
|
|
$
|
6,255
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt and long-term
obligations
|
|
|
6,657
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, no par value;
3,000,000 shares authorized, 855,495 shares issued and
outstanding, actual;
and shares
authorized, no shares issued or outstanding, pro forma and pro
forma as
adjusted(2)
|
|
|
2,743
|
|
|
|
|
|
|
|
|
|
Common Stock, no par value;
10,000,000 shares authorized; 4,922,075 shares issued
and outstanding,
actual; shares
authorized, shares
issued and outstanding, pro forma;
and shares
authorized, shares
issued and outstanding on a pro forma as adjusted
basis(3)
|
|
|
15,743
|
|
|
|
|
|
|
|
|
|
Additional paid-in
capital(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated deficit
|
|
|
(7,360
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders
equity(1)
|
|
|
11,126
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
capitalization(1)
|
|
$
|
17,783
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Each $1.00 increase or decrease in
the assumed initial public offering price of
$ per share would increase or
decrease, as applicable, the amount of cash and cash
equivalents, additional paid-in capital, total
shareholders equity and total capitalization by
approximately $ million,
assuming the number of shares offered by us, as set forth on the
cover of this prospectus, remains the same and after deducting
the estimated underwriting discounts and commissions payable by
us.
|
|
(2)
|
|
Upon the completion of this
offering, the outstanding shares of preferred stock will convert
into an aggregate
of shares
of common stock.
|
|
(3)
|
|
Excludes:
|
|
|
|
|
Ø
|
shares
of common stock issuable upon exercise of outstanding options at
a weighted average exercise price of
$ per share;
|
|
|
Ø
|
shares
of common stock reserved for future issuance under our 2007
Long-Term Incentive Compensation Plan and our 2007
Directors Plan; and
|
|
|
Ø
|
shares
of common stock issuable upon the exercise of outstanding
warrants at a weighted average exercise price of
$ per share.
|
24
Dilution
Our net tangible book as of December 31, 2006 was
$1.3 million, or $ per share.
Net tangible book value per share represents the amount of our
total tangible assets less total liabilities, divided by the
total number of shares of common stock outstanding. Our pro
forma net tangible book value as of December 31, 2006 was
$
million, or
$
per share of common stock. Pro forma net tangible book value per
share gives effect to the conversion of all of our preferred
stock
into shares
of our common stock, which will occur upon completion of this
offering.
After giving further effect to the sale by us
of shares
of common stock in this offering at an assumed initial public
offering price of
$ per
share, after taking into account the automatic conversion of our
preferred stock upon completion of this offering, and after
deducting underwriting discounts and commissions and estimated
offering expenses payable by us, our pro forma as adjusted net
tangible book value as of December 31, 2006 would have been
approximately
$ million,
or approximately
$ per
share. This amount represents an immediate increase in pro forma
net tangible book value of
$ per
share to our existing shareholders and an immediate dilution in
pro forma net tangible book value of approximately
$ per
share to new investors purchasing shares of common stock in this
offering. We determine dilution by subtracting the pro forma as
adjusted net tangible book value per share after this offering
from the amount of cash that a new investor paid for a share of
common stock.
The following table illustrates this dilution on a per share
basis:
|
|
|
|
|
|
|
|
|
Assumed initial public offering
price per share
|
|
|
|
|
|
$
|
|
|
Net tangible book value per share
as of December 31, 2006
|
|
$
|
|
|
|
|
|
|
Effect on net tangible book value
per share on conversion of preferred stock into common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma net tangible book value
per share as of December 31, 2006
|
|
|
|
|
|
|
|
|
Increase per share attributable to
this offering
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma as adjusted net tangible
book value per share after this offering
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilution per share to new investors
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
A $1.00 increase (decrease) in the assumed initial public
offering price of
$ per
share would increase (decrease) our pro forma as adjusted net
tangible book value as of December 31, 2006 by
approximately
$ million,
the pro forma as adjusted net tangible book value per share
after this offering by
$
and the dilution in pro forma as adjusted net tangible book
value to new investors in this offering by
$ per
share, assuming the number of shares offered by us, as set forth
on the cover page of this prospectus, remains the same and after
deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us.
25
Dilution
The following table summarizes, as of December 31, 2006,
the differences between the number of shares purchased from us,
the total consideration paid to us and the average price per
share that existing shareholders and new investors paid. The
table gives effect to the conversion of all of our outstanding
preferred stock
into shares of
common stock, which will occur upon completion of this offering.
The calculation below is based on an assumed initial public
offering price of
$ per
share and before deducting underwriting discounts and
commissions and estimated offering expenses that we must pay.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Total
Shares
|
|
|
Total
Consideration
|
|
|
Price
|
|
|
Number
|
|
%
|
|
|
Number
|
|
%
|
|
|
per
Share
|
|
|
Existing shareholders
|
|
|
|
|
|
|
%
|
|
|
|
|
|
|
%
|
|
$
|
|
New investors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
100.0
|
%
|
|
|
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A $1.00 increase (decrease) in the assumed initial public
offering price of
$ per
share would increase (decrease) total consideration paid to us
by investors participating in this offering by approximately
$ million,
assuming the number of shares offered by us, as set forth on the
cover page of this prospectus, remains the same and after
deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us.
The discussion and tables above assume no exercise of the
underwriters over-allotment option. If the
underwriters over-allotment option is exercised in full,
the number of shares of common stock held by existing
shareholders will be further reduced
to ,
or % of the total number of shares of common stock to
be outstanding after this offering, and the number of shares of
common stock held by investors participating in this offering
will be further increased
to ,
or % of the total number of shares of common stock to
be outstanding after this offering.
In addition, the above discussion and table assume no exercise
of stock options after December 31, 2006. As of
December 31, 2006, we had outstanding options to purchase a
total
of shares
of common stock at a weighted average exercise price of
$ per
share and we had
reserved shares
of common stock issuable upon the exercise of outstanding
warrants at a weighted average exercise price of
$ per share. If all such
options and warrants had been exercised as of December 31,
2006, pro forma as adjusted net tangible book value per share
would have been $ per share,
and dilution to new investors would have been
$ per
share.
26
Selected
consolidated financial data
The following consolidated statement of operations data for the
years ended December 31, 2004, 2005 and 2006 and
consolidated balance sheet data as of December 31, 2005 and
2006 have been derived from our audited consolidated financial
statements and related notes, which are included elsewhere in
this prospectus. The consolidated statements of operations data
for the years ended December 31, 2002 and 2003 and the
consolidated balance sheet data as of December 31, 2002,
2003 and 2004 have been derived from our audited consolidated
financial statements that do not appear in this prospectus. The
following selected consolidated financial data should be read in
conjunction with, and is qualified by reference to, our
consolidated financial statements and related notes, which were
examined and reported upon by KPMG LLP, and
Managements discussion and analysis of financial
condition and results of operations appearing elsewhere in
this prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended
December 31,
|
|
Statement of
operations
data(1):
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
|
(in thousands,
except per share data)
|
|
|
Net revenues
|
|
$
|
2,086
|
|
|
$
|
2,943
|
|
|
$
|
12,032
|
|
|
$
|
10,690
|
|
|
$
|
17,815
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold
|
|
|
|
|
|
|
|
|
|
|
816
|
|
|
|
533
|
|
|
|
2,399
|
|
Selling and marketing
|
|
|
2,100
|
|
|
|
2,726
|
|
|
|
6,802
|
|
|
|
5,647
|
|
|
|
7,349
|
|
Research and development
|
|
|
934
|
|
|
|
1,658
|
|
|
|
746
|
|
|
|
1,158
|
|
|
|
2,233
|
|
General and administrative
|
|
|
2,279
|
|
|
|
2,265
|
|
|
|
2,358
|
|
|
|
2,588
|
|
|
|
2,999
|
|
Amortization of product license
rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
515
|
|
Other
|
|
|
|
|
|
|
5
|
|
|
|
6
|
|
|
|
13
|
|
|
|
96
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
5,313
|
|
|
|
6,654
|
|
|
|
10,729
|
|
|
|
9,940
|
|
|
|
15,592
|
|
Gain on insurance recovery
|
|
|
|
|
|
|
|
|
|
|
266
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
(3,227
|
)
|
|
|
(3,710
|
)
|
|
|
1,569
|
|
|
|
750
|
|
|
|
2,224
|
|
Interest income
|
|
|
3
|
|
|
|
8
|
|
|
|
1
|
|
|
|
89
|
|
|
|
209
|
|
Interest expense
|
|
|
73
|
|
|
|
765
|
|
|
|
1,012
|
|
|
|
63
|
|
|
|
722
|
|
Other expense (income)
|
|
|
(9
|
)
|
|
|
2
|
|
|
|
|
|
|
|
6
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income before minority interest
and income taxes
|
|
|
(3,289
|
)
|
|
|
(4,469
|
)
|
|
|
558
|
|
|
|
770
|
|
|
|
1,708
|
|
Minority interest in net loss of
consolidated subsidiary
|
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax benefit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,184
|
|
|
|
2,697
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
(3,282
|
)
|
|
$
|
(4,469
|
)
|
|
$
|
558
|
|
|
$
|
1,954
|
|
|
$
|
4,404
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per
sharebasic
|
|
$
|
(0.80
|
)
|
|
$
|
(1.05
|
)
|
|
$
|
0.12
|
|
|
$
|
0.41
|
|
|
$
|
0.90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per
sharediluted
|
|
$
|
(0.80
|
)
|
|
$
|
(1.05
|
)
|
|
$
|
0.07
|
|
|
$
|
0.24
|
|
|
$
|
0.55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
outstandingbasic
|
|
|
4,116
|
|
|
|
4,261
|
|
|
|
4,541
|
|
|
|
4,748
|
|
|
|
4,899
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
outstandingdiluted
|
|
|
4,116
|
|
|
|
4,261
|
|
|
|
7,741
|
|
|
|
8,045
|
|
|
|
8,016
|
|
|
|
|
(1)
|
|
The sum of the individual amounts
may not agree due to rounding.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
December 31,
|
|
Balance sheet
data:
|
|
2002
|
|
|
2003
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
|
(in
thousands)
|
|
|
Cash and cash equivalents
|
|
$
|
1,790
|
|
|
$
|
771
|
|
|
$
|
516
|
|
|
$
|
5,536
|
|
|
$
|
6,255
|
|
Working capital
|
|
|
(485
|
)
|
|
|
(3,110
|
)
|
|
|
262
|
|
|
|
5,640
|
|
|
|
3,945
|
|
Total assets
|
|
|
1,946
|
|
|
|
2,083
|
|
|
|
4,507
|
|
|
|
10,173
|
|
|
|
26,481
|
|
Total long-term debt and other
long-term obligations
|
|
|
2,358
|
|
|
|
3,108
|
|
|
|
2,436
|
|
|
|
2,398
|
|
|
|
10,543
|
|
Preferred stock
|
|
|
2,743
|
|
|
|
2,743
|
|
|
|
2,743
|
|
|
|
2,743
|
|
|
|
2,743
|
|
Total shareholders equity
(deficit)
|
|
|
(1,762
|
)
|
|
|
(3,433
|
)
|
|
|
(22
|
)
|
|
|
6,234
|
|
|
|
11,126
|
|
27
Managements
discussion and analysis of financial condition and results of
operations
The following discussion and analysis of our financial
position and results of operations should be read together with
our audited consolidated financial statements and related notes
appearing elsewhere in this prospectus. This discussion and
analysis may contain forward-looking statements that involve
risks and uncertainties. You should review the Risk
factors section of this prospectus for a discussion of
important factors that could cause actual results to differ
materially from the results described in or implied by the
forward-looking statements described in the following discussion
and analysis.
OVERVIEW
We are a specialty pharmaceutical company focused on the
acquisition, development and commercialization of branded,
prescription products. We are building our product portfolio
primarily by acquiring rights to FDA-approved and late-stage
development products and marketing them to specialty physician
segments. Our primary target markets are hospital acute care and
gastroenterology. Our current portfolio consists of two marketed
products and one late-stage development product nearing
completion of Phase III clinical trials.
We pursued the development of Acetadote for the treatment of
acetaminophen poisoning and acquired rights to clinical data to
support its approval. Approval of the product was obtained in
January 2004 and we began to market Acetadote in the second
quarter of 2004 and launched the product with a dedicated
hospital sales force. In March 2006, we received approval from
the FDA for the use of Acetadote in pediatric patients.
We gained access to marketed gastroenterology products by
negotiating co-promotion agreements with the original developers
of these products. These agreements allowed us to enter the
gastroenterology market with minimal up-front costs and limited
ongoing operating risk. In 2005, we made a strategic decision to
de-emphasize our reliance on co-promotion agreements as a
primary growth driver. In April 2006, we acquired exclusive
commercial rights in the U.S. to Kristalose, a
gastroenterology product we had previously co-promoted under an
arrangement with Bertek Pharmaceuticals Inc., a subsidiary of
Mylan Laboratories Inc. In October 2006, we re-launched
Kristalose under the Cumberland brand with a dedicated field
sales force targeting gastroenterologists and other high
prescribers of laxative products.
Our research and development expenses have grown consistently
because of our program to develop Amelior. We expect research
and development expenses to increase in 2007 as we continue our
clinical work related to Amelior. We plan to complete the
Amelior clinical work in early 2008.
We have funded our operations with private equity capital of
approximately $14 million during the past six years. We
have supplemented this equity funding by re-investing our
profits and utilizing our credit facilities in order to support
our operations.
Prior to 2007, our sales forces were contracted to us by a third
party. In January 2007, we brought the hospital sales force
in-house via our
newly-formed,
wholly-owned
subsidiary, Cumberland Pharma Sales Corp. We continue to
outsource the dedicated gastroenterology sales force. All
expenses associated with the sales forces are included in
selling and marketing expense.
In 2000, we formed CET with Vanderbilt University and Tennessee
Technology Development Corporation to identify early-stage drug
development activities. CET partners with universities and other
research organizations to advance promising, early-stage product
candidates through the development process and on to
commercialization.
28
Managements
discussion and analysis of financial condition and results of
operations
Our operating results have fluctuated in the past and are likely
to fluctuate in the future. These fluctuations can result from
competitive factors, new product acquisitions or introduction,
the nature, scope and result of our research and development
programs, pursuit of our growth strategy and other factors. As a
result of these fluctuations, our historical financial results
are not necessarily indicative of future results.
We were incorporated in 1999 and have been headquartered in
Nashville, Tennessee since inception.
CRITICAL
ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND
ESTIMATES
Accounting
Estimates and Judgments
The preparation of the consolidated financial statements in
conformity with U.S. generally accepted accounting principles
requires management to make estimates, judgments and assumptions
that affect the reported amounts of assets and liabilities and
disclosure of contingent liabilities at the date of the
financial statements and the reported amounts of revenues and
expenses during the period. We base our estimates on past
experience and on other factors we deem reasonable given the
circumstances. Past results help form the basis of our judgments
about the carrying value of assets and liabilities that are not
determined from other sources. Actual results could differ from
those estimates. These estimates, judgments and assumptions are
most critical with respect to our accounting for revenue
recognition, provision for income taxes, stock-based
compensation, research and development accounting, and
intangible assets.
Revenue
Recognition
Our revenue is derived primarily from the product sales of
Acetadote and Kristalose. Revenue is recognized when persuasive
evidence of an arrangement exists, delivery has occurred, the
fee is fixed and determinable and collectibility is probable.
Delivery is considered to have occurred upon either shipment or
arrival at destination on shipping terms. When these conditions
are satisfied, we recognize gross revenue, which is the price we
charge generally to our wholesalers for a particular product. We
record allowances for estimated chargebacks, discounts and
damaged goods, and accruals for rebates and fees for services.
Allowances and accruals are established by management as its
best estimate at the time of sale based on each products
historical experience adjusted to reflect known changes in the
factors that impact such reserves. Allowances for chargebacks
and discounts, and accruals for rebates and returns are
established based on the contractual terms with customers;
analysis of historical levels of discounts, returns, chargebacks
and rebates; communications with customers and purchased
information about the rate of prescriptions being written and
the levels of inventory remaining in the distribution channel,
if known, as well as expectations about the market for each
product and anticipated introduction of competitive products.
The allowances for chargebacks and accruals for rebates and
returns are established by product, and are the most significant
estimates used in the recognition of our revenue from product
sales. If the actual amount of cash discounts taken,
chargebacks, rebates and expired product returns differ from the
amounts estimated by management, material differences may result
from the amount of our revenue recognized from product sales.
From January 2006 through part of April 2006, we recorded
contract sales revenue which was based on co-promotion
agreements primarily with Bertek Pharmaceuticals Inc., for the
sales of Kristalose. Co-promotion fees were calculated based on
a percent of gross sales or similar calculation. Contract sales
revenue is included in net revenues.
29
Managements
discussion and analysis of financial condition and results of
operations
Other income, which is included in net revenues, includes rental
and grant income. Rental income and grant income were three
percent of net revenues in 2006.
Income
Taxes
We provide for deferred taxes using the asset and liability
approach. Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to
operating loss and tax credit carry-forwards and differences
between the financial statement carrying amounts of existing
assets and liabilities and their respective tax bases. Our
principal differences are related to the timing of deductibility
of certain items such as depreciation, amortization and expense
for options issued to non-employees. Deferred tax assets and
liabilities are measured using managements estimate of tax
rates expected to apply to taxable income in the years in which
management believes those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in
the period that includes the enactment date.
In assessing the realizability of deferred tax assets,
management considers whether it is more likely than not that
some portion or all of the deferred tax assets will not be
realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income during
the periods in which those temporary differences become
deductible. Management considers the scheduled reversal of
deferred tax liabilities, projected future taxable income, and
tax planning strategies in making this assessment. In order to
fully utilize the deferred tax asset of $4.0 million as of
December 31, 2006, we will need to generate future taxable
income of approximately $11.8 million prior to the
expiration of the net operating loss carry-forwards in 2025.
Stock-Based
Compensation
Prior to January 1, 2006 we applied the intrinsic-value-based
method of accounting prescribed by Accounting Principles Board
(APB) Opinion No. 25, Accounting for Stock issued to
Employees, and related interpretations including
FIN No. 44, Accounting for Certain Transactions
involving Stock Compensation an interpretation of APB Opinion
No. 25, to account for our stock options issued under
the 1999 Stock Option Plan. Under this method, compensation
expense is recorded on the date of grant only if the current
market price of the underlying stock exceeded the exercise
price. Statement of Financial Accounting Standards, or
SFAS, No. 123, Accounting for Stock-Based
Compensation and Financial Accounting Standards Boards, or
FASB No. 148, Accounting for Stock-Based
CompensationTransition and Disclosure, an amendment of
FASB Statement No. 123, established accounting and
disclosure requirements using a fair-value-based method of
accounting for stock-based employee compensation plans. As
permitted by then-existing accounting standards, we elected to
continue to apply the intrinsic-value-based method of accounting
described above, and adopted only the disclosure requirements of
SFAS No. 123, as amended.
Effective January 1, 2006, we adopted SFAS,
No. 123(R), Share-Based Payment, which revises
SFAS No. 123, Accounting for Stock-Based
Compensation and supersedes Accounting Principles Board, or
APB, Opinion No. 25, Accounting for Stock Issued to
Employees. SFAS 123(R) requires that share-based
payment transactions with employees be recognized in the
financial statements based on their fair value and recognized as
compensation expense over the vesting period. We adopted
SFAS 123(R) effective January 1, 2006, prospectively
for new equity awards issued subsequent to December 31,
2005.
30
Managements
discussion and analysis of financial condition and results of
operations
Information on employee and non-employee stock options granted
in 2006 is summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
Weighted
|
|
Average
|
|
Weighted
Average
|
|
|
Stock Options
|
|
Average
|
|
Intrinsic
Value
|
|
Fair Value of
|
Grants made
during quarter ended
|
|
Granted
|
|
Exercise
Price
|
|
per
Share
|
|
Option (per
Share)
|
|
|
March 31, 2006
|
|
|
12,000
|
|
|
$18.00
|
|
|
$4.00
|
|
|
$8.36
|
June 30, 2006
|
|
|
24,300
|
|
|
$18.74
|
|
|
$3.26
|
|
|
$9.90
|
September 30, 2006
|
|
|
9,075
|
|
|
$18.00
|
|
|
$4.00
|
|
|
$11.16
|
December 31, 2006
|
|
|
2,600
|
|
|
$18.00
|
|
|
$4.00
|
|
|
$11.01
|
Under SFAS No. 123(R), we calculate the fair value of
stock option grants using the Black-Scholes option-pricing
model. The assumptions used in the Black-Scholes model ranged
from two months to ten years for the expected term, 37%-63% for
the expected volatility, 4.34% to 5.08% for the risk free rate
and zero percent for dividend yield for the year ended
December 31, 2006. Future option expense could be impacted
by changes in our model assumptions.
For employee stock option grants, the weighted average expected
option terms for 2006 represent the application of the
simplified method as defined in SEC Staff Accounting Bulletin
(or SAB), No. 107 issued in March of 2005. The simplified
method defines the expected life as the average of the
contractual term of the options and the weighted average vesting
period for the option. For non-employee stock option grants, the
expected option terms for 2006 represent the contractual term.
Estimated volatility for 2006 was determined in accordance of
SAB No. 107 and was determined by reviewing historical
volatility of similar public companies.
As of December 31, 2006, we had approximately $322,000 of
unrecognized share-based compensation expense related to
unvested option awards. Additionally, as of December 31,
2006, we had outstanding vested options to purchase
3,899,088 shares of our common stock and unvested options
to purchase 105,890 shares of our common stock.
Furthermore, as of December 31, 2006, we had outstanding
34,479 warrants to purchase shares of our common stock.
Research and
Development
We account for research and development costs and accrue
expenses, based on estimates of work performed, patient
enrollment or fixed-fee-for-services. As work is performed
and/or
invoices are received, we adjust our estimates and accruals. To
date, our accruals have been within our estimates. Total
research and development costs are a function of studies being
conducted and will increase or decrease depending on the level
of activity in any particular year.
Intangible
Assets
Intangible assets include license agreements, product rights and
other identifiable intangible assets. We assess the impairment
of identifiable intangible assets whenever events or changes in
circumstances indicate that the carrying value may not be
recoverable. In determining the recoverability of our intangible
assets, we must make assumptions regarding estimated future cash
flows and other factors. If the estimated undiscounted future
cash flows do not exceed the carrying value of the intangible
assets, we must determine the fair value of the intangible
assets. If the fair value of the intangible assets is less than
the carrying value, an impairment loss will be recognized in an
amount equal to the difference.
31
Managements
discussion and analysis of financial condition and results of
operations
RESULTS OF
OPERATIONS
The following table sets forth, for the periods indicated,
certain items from our statement of operations expressed as a
percentage of net revenues, as well as the
period-to-period
change in these items.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended
|
|
|
|
|
|
|
December 31,
|
|
|
%
Change
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
2004-2005
|
|
|
2005-2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
(11.2
|
%)
|
|
|
66.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold
|
|
|
6.8
|
|
|
|
5.0
|
|
|
|
13.5
|
|
|
|
(34.7
|
)
|
|
|
349.9
|
|
Selling and marketing
|
|
|
56.5
|
|
|
|
52.8
|
|
|
|
41.2
|
|
|
|
(17.0
|
)
|
|
|
30.1
|
|
Research and development
|
|
|
6.2
|
|
|
|
10.8
|
|
|
|
12.5
|
|
|
|
55.2
|
|
|
|
92.9
|
|
General and administrative
|
|
|
19.6
|
|
|
|
24.2
|
|
|
|
16.8
|
|
|
|
9.7
|
|
|
|
15.9
|
|
Amortization of product license
rights
|
|
|
|
|
|
|
|
|
|
|
2.9
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
0.1
|
|
|
|
0.1
|
|
|
|
0.5
|
|
|
|
117.4
|
|
|
|
614.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
89.2
|
|
|
|
93.0
|
|
|
|
87.5
|
|
|
|
(7.4
|
)
|
|
|
56.9
|
|
Gain on insurance recovery
|
|
|
2.2
|
|
|
|
0.0
|
|
|
|
0.0
|
|
|
|
(100.0
|
)
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
13.0
|
|
|
|
7.0
|
|
|
|
12.5
|
|
|
|
(52.2
|
)
|
|
|
196.5
|
|
Interest income
|
|
|
0.0
|
|
|
|
0.8
|
|
|
|
1.2
|
|
|
|
|
(1)
|
|
|
133.8
|
|
Interest expense
|
|
|
8.4
|
|
|
|
0.6
|
|
|
|
4.1
|
|
|
|
(93.8
|
)
|
|
|
|
(1)
|
Other expense
|
|
|
0.0
|
|
|
|
0.1
|
|
|
|
0.0
|
|
|
|
|
|
|
|
(50.3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income before income taxes
|
|
|
4.6
|
|
|
|
7.2
|
|
|
|
9.6
|
|
|
|
38.0
|
|
|
|
121.7
|
|
Income tax benefit
|
|
|
0.0
|
|
|
|
11.1
|
|
|
|
15.1
|
|
|
|
|
|
|
|
127.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income(2)
|
|
|
4.6
|
|
|
|
18.3
|
|
|
|
24.7
|
|
|
|
250.1
|
|
|
|
125.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Not meaningful.
|
|
(2)
|
|
The sum of the individual amounts
do not agree to the total due to rounding.
|
Description of
operating accounts
Net revenues consist of net product revenue, revenue from
co-promotion agreements and other revenue. Net product revenue
consists primarily of gross revenue less discounts and
allowances, such as cash discounts, rebates, chargebacks and
returns. Revenue from co-promotion agreements includes product
promotion fees. Other income includes rental and grant income.
Cost of products sold consists primarily of the cost of
each unit of product sold. Cost of products sold also includes
expense for slow moving or expired product.
Selling and marketing expense consists primarily of
expense relating to the promotion, distribution and sale of
products, including salaries and related costs.
Research and development expense consists primarily of
clinical trial expenses, salary and wages and related costs of
materials and supplies, and certain activities of third-party
providers participating in our clinical studies.
General and administrative expense includes finance and
accounting expenses, executive expenses, office expenses and
business development expenses, including salaries and related
costs.
32
Managements
discussion and analysis of financial condition and results of
operations
Amortization of product license rights resulted from our
acquisition of the exclusive U.S. commercialization rights to
Kristalose.
Interest income consists primarily of interest income
earned on cash deposits.
Interest expense consists primarily of interest incurred
on debt and other long-term obligations.
Income tax benefit consists primarily of the realization
of our deferred tax assets less taxes incurred on income.
Year ended
December 31, 2006 compared to year ended December 31,
2005
Net revenues. Net revenues in 2006 totaled
$17.8 million, representing an increase of
$7.1 million, or 66.7%, over net revenues in 2005 of
$10.7 million. This increase was primarily due to
additional product revenue from sales of Kristalose, as well as
continued growth of Acetadote. In April 2006, we entered into an
agreement to acquire the exclusive U.S. commercial rights
to Kristalose and began recording revenue based on shipments of
the product. Prior to April 2006, we co-promoted Kristalose and
recorded a co-promotion fee based on a percentage of the
products sales. In 2005, revenue was reduced by
$2.0 million for promotional costs owed to a wholesaler.
Additionally, unlike prior years, in 2006, we did not offer any
special purchasing opportunities to our customers prior to
product price increases.
Cost of products sold. Cost of products sold
in 2006 totaled $2.4 million, representing an increase of
$1.9 million, or 349.9%, over cost of products sold in 2005
of $533,000. Cost of products sold as a percentage of net
revenues was 13.5% and 5.0% in 2006 and 2005, respectively. The
majority of the increase was due to recording the cost of
products sold associated with Kristalose beginning in April
2006. Prior to that date, we recorded no Kristalose cost of
products sold because of the co-promotion arrangement referred
to above. Acetadote cost of products sold, as a percentage of
Acetadote net revenue, was not materially different between 2006
and 2005.
Selling and marketing. Selling and marketing
expense in 2006 totaled $7.3 million, representing an
increase of $1.7 million, or 30.1%, over selling and marketing
expense in 2005 of $5.6 million. Selling and marketing
expense as a percentage of net revenues was 41.2% and 52.8% in
2006 and 2005, respectively. The increase was primarily due to
the launch of our new dedicated gastroenterology field sales
force as well as other sales and marketing costs associated with
the re-launch of Kristalose. We anticipate selling and marketing
expense will grow, as we expand both sales forces as well as our
product lines.
Research and development. Research and
development expense in 2006 totaled $2.2 million,
representing an increase of $1.1 million, or 92.9%, over
research and development expense in 2005 of $1.2 million.
Research and development expense as a percentage of net revenues
was 12.5% and 10.8% in 2006 and 2005, respectively. This
increase was primarily due to increased clinical studies
activities associated with the development of Amelior. Research
and development expense is expected to continue to grow in 2007,
as we work to complete our final studies of Amelior prior to
submission for approval to the FDA.
General and administrative. General and
administrative expense in 2006 totaled $3.0 million,
representing an increase of $412,000, or 15.9%, over general and
administrative expense in 2005 of $2.6 million. General and
administrative expense as a percentage of net revenues was 16.8%
and 24.2% in 2006 and 2005, respectively. The dollar increase in
general and administrative expense was primarily due to an
increase in salaries and related expenses from 2005, as a result
of the addition of personnel to support our growth. We expect
general and administrative expense to increase in future
33
Managements
discussion and analysis of financial condition and results of
operations
periods as we continue to add staff, expand our infrastructure
and support the requirements of a public company.
Amortization of product license
rights. Amortization of product license rights
totaled $515,000 in 2006. This expense is a result of
amortization associated with our acquisition of the exclusive
U.S. commercialization rights to Kristalose. We expect to incur
annual amortization expense relating to these product license
rights through March 2021.
Interest income. Interest income in 2006
totaled $209,000 compared to interest income in 2005 of $89,000.
The majority of the increase in interest income was due to
larger cash balances in 2006.
Interest expense. Interest expense in 2006
totaled $722,000 compared to interest expense in 2005 of
$63,000. The majority of the increase in interest expense was
due to interest expense associated with debt incurred to finance
the acquisition of Kristalose. In 2005, we had minimal debt and
thus, minimal interest expense.
Income tax benefit. Net income tax benefit in
2006 totaled $2.7 million compared to net income tax
benefit in 2005 of $1.2 million. The increase was due to
full recording of our deferred tax asset after determining that
it was more likely than not that we would realize the benefits
of the deferred tax asset.
Year ended
December 31, 2005 compared to year ended December 31,
2004
Net revenues. Net revenues in 2005 totaled
$10.7 million, representing a decrease of $1.3 million, or
11.2%, over net revenues in 2004 of $12.0 million. This
decrease was primarily due to promotional costs owed to a
wholesaler. This was partially off-set by a full year of sales
of Acetadote in 2005, versus nine months in 2004. In 2005, two
products accounted for all product sales, and there were two
additional products for which we received a portion of product
revenue based on promotion agreements. In 2004 and 2005, we
provided our key customers the opportunity to purchase
additional product prior to implementing a price increase.
Certain customers took advantage of this opportunity and
purchased additional product. The last year we offered such an
incentive to our customers was 2005.
Cost of products sold. Cost of products sold
in 2005 totaled $533,000, representing a decrease of $283,000,
or 34.7%, over cost of products sold in 2004 of $816,000. Cost
of products sold as a percentage of net revenues was 5.0% and
6.8% in 2005 and 2004, respectively. The majority of the
decrease was due to a change in the product mix, which in 2004
included a higher ratio of gastroenterology products as compared
to 2005. Gastroenterology products tend to have a higher
manufacturing cost per unit than our other products.
Selling and marketing. Selling and marketing
expense in 2005 totaled $5.6 million representing a
decrease of $1.2 million, or 17.0%, over selling and marketing
expense in 2004 of $6.8 million. Selling and marketing
expense as a percentage of net revenues was 52.8% and 56.5% in
2005 and 2004, respectively. The decrease was due to lower
royalty costs, a reduction in marketing costs relative to 2004
when we launched Acetadote, reduced distribution costs and
reduced sales force expenses.
Research and development. Research and
development expense in 2005 totaled $1.2 million,
representing an increase of $412,000 or 55.2%, over research and
development expense in 2004 of $746,000. Research and
development expense as a percentage of net revenues was 10.8%
and 6.2% in 2005 and 2004, respectively. This increase was
primarily due to increased expenses relating to clinical studies
associated with the development of Amelior.
General and administrative. General and
administrative expense in 2005 totaled $2.6 million,
representing an increase of $230,000, or 9.7%, over general and
administrative expense in 2004 of
34
Managements
discussion and analysis of financial condition and results of
operations
$2.4 million. General and administrative expense as a
percentage of net revenues was 24.2% and 19.6% in 2005 and 2004,
respectively. This increase was primarily due to increased stock
option expense for consulting services as well as increased
salaries and related expenses.
Interest income. Interest income in 2005
totaled $89,000 compared to interest income in 2004 of $1,000.
The majority of the increase in interest income in 2005 resulted
from higher levels of cash and cash equivalents.
Interest expense. Interest expense in 2005
totaled $63,000 compared to interest expense in 2004 of
$1.0 million. The majority of the decrease in interest
expense in 2005 resulted from lower levels of outstanding debt
as 2004 had significant interest expense associated with
convertible debt which was converted to equity in 2004.
Income tax benefit. Net income tax benefit in
2005 totaled $1.2 million. We had no income tax benefit in
2004. The existence of the income tax benefit was due to
initial, partial recording of our deferred tax asset after
determining that it was more likely than not that we would
realize at least a portion of benefits of the deferred tax asset.
LIQUIDITY AND
CAPITAL RESOURCES
As of December 31, 2006, cash and cash equivalents was
$6.3 million, working capital was $3.9 million and our
current ratio (current assets to current liabilities) was 1.5 to
1. Management expects funds for our operating and capital
requirements will be provided by continuing revenue and existing
cash balances, as well as from collaborative agreements and
other financing arrangements. As of December 31, 2006, we
also had the ability to make additional draws of up to
$3 million on our line of credit and will have substantial
proceeds from this offering.
The following table summarizes our net increase (decrease) in
cash and cash equivalents for the years ended December 31,
2004, 2005 and 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended
December 31,
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
|
(in
thousands)
|
|
|
Net cash provided by (used in):
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities
|
|
$
|
(1,439
|
)
|
|
$
|
2,416
|
|
|
$
|
2,163
|
|
Investing activities
|
|
|
(51
|
)
|
|
|
(318
|
)
|
|
|
(6,553
|
)
|
Financing activities
|
|
|
1,236
|
|
|
|
2,922
|
|
|
|
5,109
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash
and cash equivalents
|
|
$
|
(255
|
)(1)
|
|
$
|
5,020
|
|
|
$
|
719
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The sum of the individual amounts
do not agree to the total due to rounding.
|
Net cash provided by operating activities was $2.2 million
for the year ended December 31, 2006. During this time, net
income of $4.4 million was partially offset by net changes
in assets and liabilities of $713,000 and adjustments to
reconcile net income to net cash for depreciation, amortization,
stock-based compensation, and deferred tax benefit.
Net cash used in investing activities was $6.6 million for
the year ended December 31, 2006. This use of cash was
primarily due to a payment of $6.5 million for the
acquisition of exclusive U.S. rights to Kristalose.
35
Managements
discussion and analysis of financial condition and results of
operations
Net cash provided by financing activities was $5.1 million
for the year ended December 31, 2006, including
$5.5 million of proceeds from the issuance of long-term
debt to fund the acquisition of rights to Kristalose.
In April 2006, we entered into an agreement with Inalco to
acquire exclusive U.S. commercial rights for Kristalose. In
order to complete this transaction, we obtained funding from
Bank of America in the form of a three-year term loan for
$5.5 million and a new two-year revolving line of credit
agreement, both with an interest rate of LIBOR plus 2.5% (7.83%
as of December 31, 2006). The borrowings are collateralized
by a first lien against all of our assets. We are paying off the
term loan in quarterly installments, with the final payment due
in 2009. This agreement contains various covenants, all of which
we were in compliance with as of December 31, 2006. In
addition to the three-year term loan, we deferred
$4.5 million of the purchase price, with $1.5 million
due in 2007 and $3.0 million due in 2009.
In conjunction with this line of credit agreement and term loan
agreement, we issued to the lender warrants to purchase up to
1,979 shares of common stock at $18.00 per share. The
warrants expire in April 2016. The estimated fair value of such
warrants of $25,680, as determined using the Black-Scholes
model, has been recorded in the accompanying financial
statements as permanent equity in accordance with Emerging
Issues Task Force, or EITF,
No. 00-19,
Accounting for Derivative Financial Instruments Indexed to,
and Potentially Settled in, a Companys Own Stock.
In conjunction with the Kristalose agreement with Inalco, we are
obligated to purchase a minimum amount of Kristalose inventory
each year. We expect our normal inventory purchasing to be above
the required minimum amount.
As part of our agreement with Bioniche, our supplier of
Acetadote, we are obligated to purchase a minimum amount of
Acetadote inventory each year beginning in 2007, through 2011.
We expect that our normal inventory purchasing to be above the
required minimum amount.
In the second quarter of 2005, we received approximately
$2.0 million from various investors in exchange for
convertible promissory notes with a maturity date six months
from the date of issuance. The notes bore interest at a fixed
annual rate of 3.5%. In the fourth quarter of 2005, and pursuant
to the terms of the notes, the principal value plus all elected
accrued interest was converted into shares of our common stock.
In April 2005, we conducted a private placement of our common
stock in which we issued 100,000 shares of common stock for
total gross proceeds of $1.8 million, with net proceeds of
$1.7 million. The purpose of this offering was to provide
funding to advance product agreements, to complete product
development and for general corporate purposes.
In May 2004, we issued 43,000 shares of our common stock to
S.C.O.U.T. Healthcare Fund, L.P., or S.C.O.U.T., for cash
consideration of $516,000.
On October 21, 2003, we amended our $1.0 million,
one-year revolving line of credit. Under the terms of the
amended agreement, we had borrowing capacity up to the lesser of
$3.5 million or 80% of our eligible receivables, plus 50%
of our eligible inventory. The agreement was extended to March
2006. The agreement contained various provisions and covenants
with which we were in compliance at December 31, 2005.
On September 5, 2003, we received $1.0 million from
S.C.O.U.T. in the form of a convertible promissory note with a
maturity date of September 5, 2004. The note bore interest
at a fixed annual rate of 10%. Pursuant to the terms of the
note, on its maturity date the principal value of the note plus
all accrued interest automatically converted into
91,667 shares of our common stock.
36
Managements
discussion and analysis of financial condition and results of
operations
During 2000, we signed an agreement with a third party to cover
a variety of development efforts related to a specific
pharmaceutical drug, including preparation of submissions to the
FDA. Under the terms of the agreement, we deferred a portion of
each bill from the third party. One-third of the deferred amount
accrued interest at an annual rate of 12.5% and was due after
eighteen months. The remaining two-thirds will be due upon
specific milestone events. Upon meeting the first milestone, an
amount equal to one-third of the original deferred amount, or
approximately $205,000, will become due and payable. Upon
completion of the final milestone event, an amount equal to five
times one-third of the original deferred amount, or
approximately $1 million, will become due and payable to
the third party. Since the application of these factors is
contingent upon specific events which may or may not occur in
the future and which have not occurred as of December 31,
2006, the expense for these factors has not been recorded.
The following table sets forth a summary of our contractual cash
obligations as of December 31, 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by
Year
|
|
Contractual
obligations
|
|
2007
|
|
|
2008
|
|
|
2009
|
|
|
2010
|
|
|
2011+
|
|
|
|
|
|
(in
thousands)
|
|
|
Amounts reflected in the
balance sheet:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line of credit
|
|
$
|
|
|
|
$
|
826
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Term loan
|
|
|
1,833
|
|
|
|
1,833
|
|
|
|
917
|
|
|
|
|
|
|
|
|
|
Other contractual obligations
|
|
|
2,078
|
|
|
|
411
|
|
|
|
3,000
|
|
|
|
|
|
|
|
|
|
Other cash obligations not
reflected in the balance sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
375
|
|
|
|
487
|
|
|
|
492
|
|
|
|
460
|
|
|
|
47
|
|
Purchase
obligations(1)
|
|
|
2,084
|
|
|
|
2,384
|
|
|
|
2,684
|
|
|
|
2,984
|
|
|
|
809
|
|
|
|
|
(1)
|
|
Represents minimum purchase
obligations under Kristalose and Acetadote manufacturing
agreements.
|
OFF-BALANCE SHEET
ARRANGEMENTS
During 2004, 2005 and 2006, we did not engage in any off-balance
sheet arrangements.
RECENT ACCOUNTING
PRONOUNCEMENTS
In September 2005, the EITF issued EITF Issue
No. 04-13,
Accounting for Purchases and Sales of Inventory with the Same
Counterparty. EITF
No. 04-13
provides guidance as to when purchases and sales of inventory
with the same counterparty should be accounted for as a single
exchange transaction. EITF
No. 04-13
also provides guidance as to when a non-monetary exchange of
inventory should be accounted for at fair value. EITF
No. 04-13
will be applied to new arrangements entered into, and
modifications or renewals to existing arrangements occurring
after January 1, 2007. The application of EITF
No. 04-13
is not expected to have a significant impact on our financial
statements.
In September 2006, the FASB issued FASB Statement No. 157,
Fair Value Measurement, or Statement 157.
SFAS 157 defines fair value, establishes a framework for
the measurement of fair value, and enhances disclosures about
fair value measurements. The Statement does not require any new
fair value measures. The Statement is effective for fair value
measures already required or permitted by other standards for
fiscal years beginning after November 15, 2007. We are
required to adopt Statement 157 beginning on
January 1, 2008. Statement 157 is required to be
applied prospectively, except for certain financial instruments.
Any transition adjustment will be recognized as an adjustment to
opening retained earnings in the year of adoption. We are
currently evaluating the impact of adopting Statement 157
on our results of operations and financial position.
37
Managements
discussion and analysis of financial condition and results of
operations
In July 2006, the FASB issued FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes, an
interpretation of FASB Statement 109 (FIN 48).
FIN 48 clarifies the accounting for uncertainty in income
taxes recognized in an enterprises financial statements
and prescribes a threshold of more-likely-than-not for
recognition of tax benefits of uncertain tax positions taken or
expected to be taken in a tax return. FIN 48 also provides
related guidance on measurement, de-recognition, classification,
interest and penalties, and disclosure. The provisions of
FIN 48 are effective for us as of January 1, 2007,
with any cumulative effect of the change in accounting principle
recorded as an adjustment to opening retained earnings. We are
in the process of assessing the impact of adopting FIN 48
on our results of operations and financial position.
RECENTLY ADOPTED
ACCOUNTING STANDARDS
In March 2005, the FASB issued Statement No. 123R (which
replaces Statement No. 123 issued in 1995), Share-Based
Payments, which addresses accounting for transactions in
which an entity exchanges its equity instruments for goods or
services, with a primary focus on transactions in which an
entity obtains employee services in share-based payment
transactions. This Statement is a revision of Statement
No. 123 and supersedes APB Opinion No. 25,
Accounting for Stock Issued to Employees, and its related
implementation guidance. For nonpublic companies, this Statement
requires measurement of the cost of employee services received
in exchange for stock compensation based on the grant-date fair
value of the employee stock options. Incremental compensation
costs arising from subsequent modifications of awards after the
grant date must be recognized. This Statement was effective for
us as of January 1, 2006.
QUANTITATIVE AND
QUALITATIVE DISCLOSURE OF MARKET RISKS
Our exposure to market risk is related to interest rates on our
cash on deposit in highly liquid money market accounts. The main
objective of our cash investment activities is to preserve
principal while maximizing interest income through low risk
investments. Derivative instruments are not included in our
investment portfolio. Our investment policy focuses on principal
preservation and liquidity.
While we operate primarily in the U.S., we do have foreign
currency exposure considerations. Acetadote is manufactured by a
supplier that denominates supply prices in Canadian dollars.
Additionally, much of our research and development is performed
abroad. Foreign currency transactions in U.S. dollars totaled
approximately $1.4 million in 2006.
38
Business
OVERVIEW
We are a profitable and growing specialty pharmaceutical company
focused on the acquisition, development and commercialization of
branded prescription products. Our primary target markets are
hospital acute care and gastroenterology, which are
characterized by relatively concentrated physician prescriber
bases. Unlike many emerging pharmaceutical and biotechnology
companies, we have established a product development and
commercial operating infrastructure that is scalable to
accommodate our expected growth. Our management team consists of
pharmaceutical industry veterans with significant experience in
business development, clinical and regulatory affairs, and sales
and marketing.
Since our inception in 1999, we have successfully funded the
acquisition and development of our product portfolio with
limited external investment and maintained profitable operations
over the past three years. Our portfolio consists of two
products approved by the U.S. Food and Drug Administration, or
FDA, one late-stage development product candidate nearing
completion of Phase III clinical trials and several
early-stage development projects. We were directly responsible
for the clinical development and regulatory approval of
Acetadote, one of our marketed products, and are currently
completing development of Amelior, our lead product candidate.
We promote Acetadote and our other FDA-approved product,
Kristalose, through dedicated hospital and gastroenterology
sales forces, which are comprised of 42 sales representatives
and managers.
Our key products and product candidates include:
|
|
|
|
|
|
|
Product
|
|
Indication
|
|
Delivery
|
|
Status
|
|
|
Amelior®
|
|
Pain and Fever
|
|
Injectable
|
|
Phase III
|
Acetadote®
|
|
Acetaminophen Poisoning
|
|
Injectable
|
|
Marketed
|
Kristalose®
|
|
Chronic and Acute Constipation
|
|
Oral Solution
|
|
Marketed
|
|
|
Amelior, our lead pipeline candidate, is an intravenous
formulation of ibuprofen that we expect will be the first
injectable product approved in the U.S. for the treatment
of both pain and fever. Amelior is currently in Phase III
clinical trials. We expect to complete clinical development by
early 2008 and are preparing to submit our new drug application,
or NDA, to the FDA for review. Amelior is designed to provide
physicians with a safe, effective treatment alternative for
patients who are unable to take oral medication for pain relief
or fever reduction. If approved, we plan to market Amelior in
the U.S. through our hospital sales force and in
international markets through alliances with marketing partners.
We believe Amelior currently represents our most significant
product opportunity.
Injectable analgesics, or pain relievers, currently available in
the U.S. include opioids, such as morphine and meperdine,
and ketorolac, a non-steroidal anti-inflammatory drug, or NSAID.
While opioids accounted for over 91% of market volume, with
approximately 447 million units sold in 2006, they are
known to cause undesirable side effects including nausea,
vomiting and cognitive impairment. Ketorolac is the only
non-opioid injectable analgesic approved for sale in the U.S.
and has also been known to cause unwanted side effects. Despite
strong safety warnings from the FDA, use of ketorolac in the
U.S. has grown from approximately 38 million units
sold in 2003 (7% of the market) to approximately 43 million
units sold in 2006 (9% of the market) according to IMS Health
Inc., or IMS Health. Based on the results of clinical studies to
date, we believe Amelior represents a potentially safer
alternative therapy to ketorolac. Further, we believe Amelior is
a safe and effective treatment for hospitalized patients with
fever who are unable to take oral medication. There is currently
no approved injectable treatment for fever in the U.S.
39
Business
Acetadote is an intravenous formulation of
N-acetylcysteine, or NAC, indicated for the treatment of
acetaminophen poisoning. According to the American Association
of Poison Control Centers Toxic Exposure Surveillance
System, acetaminophen was the leading cause of poisonings
presenting to emergency departments in the U.S., with
approximately 77,000 cases treated in 2005. In January 2004,
Acetadote received FDA approval as an orphan drug, a designation
which provides for seven years of marketing exclusivity from
date of approval. Since its launch in June 2004, we have
consistently grown product sales for Acetadote, with wholesaler
sales to hospitals growing 43% to $13 million in 2006. We
believe that we can continue to expand market share, and that
our Acetadote sales and marketing platform should help
facilitate the commercial launch of Amelior.
Kristalose, a prescription laxative product, is a
crystalline form of lactulose designed to enhance patient
acceptance and compliance. Based on data from IMS Health, the
market for prescription laxatives in the U.S. grew from
approximately $206 million in 2003 to $389 million in
2006, driven largely by new product introductions and increased
promotional activity by our competitors. Wholesaler sales of
Kristalose to pharmacies were $10.5 million in 2006. We
acquired exclusive U.S. commercialization rights to
Kristalose during that year, assembled a new dedicated field
sales force and re-launched the product in October 2006 under
the Cumberland brand. We believe that Kristalose has competitive
advantages over competing prescription laxatives, and that the
potential for growth of this product is significant.
Early-stage product candidates. Our
early-stage product candidates are being developed through
Cumberland Emerging Technologies, Inc., or CET, our 86%-owned
subsidiary. CET collaborates with leading research institutions
to identify and pursue promising pre-clinical programs within
our target market segments. We have negotiated rights to develop
and commercialize these product candidates. Current CET projects
include an improved treatment for fluid buildup in the lungs of
cancer patients and an anti-infective for treating fungal
infections in immuno-compromised patients. In conjunction with
these research institutions, we have obtained grant funding to
support the development of these programs.
OUR COMPETITIVE
STRENGTHS
Significant
late-stage product opportunity in Amelior
We believe Amelior currently represents our most significant
product opportunity based on the large potential markets for
intravenous treatment of pain and fever, as well as clinical
results for the product to date. We have conducted several
clinical trials to support this product and expect to complete
Phase III clinical studies by early 2008. Based on our
clinical results to date, we believe Amelior represents a
potentially safer alternative to ketorolac, which is the only
injectable non-opioid analgesic currently on the
U.S. market, with approximately 43 million units sold
in 2006. We have retained exclusive commercialization rights for
Amelior in the U.S. and plan to market the product through our
existing hospital sales force.
Strong growth
potential of our existing marketed products, Acetadote and
Kristalose
We believe that there is significant opportunity to increase
sales of our two currently approved products, Acetadote and
Kristalose. Since its launch in June 2004, we have consistently
grown product sales for Acetadote. During 2006, hospital
purchases of Acetadote from wholesalers grew 43% to
$13 million. Kristalose competes in the high growth
U.S. prescription laxatives market which, based on data
from IMS Health, grew from approximately $206 million in
2003 to $389 million in 2006, or a compound annual growth
rate of approximately 24%. After acquiring exclusive U.S. rights
to Kristalose in April 2006, we assembled an experienced,
dedicated sales force and designed a new marketing
40
Business
program, re-launching the product in October 2006. We believe
both Kristalose and Acetadote have favorable competitive
profiles, and that we can increase market share for each.
Focus on
underserved niche markets
We focus our efforts on specialty physician segments where we
believe we can leverage our industry expertise and sales
capability to deliver products that address unmet medical needs.
Currently, our primary target markets are hospital acute care
and gastroenterology. We consider these markets attractive
because of their relatively concentrated prescriber bases, which
allow us to reach target prescribers with a small number of
sales representatives. Moreover, we believe these markets are
less prone to competition from larger pharmaceutical companies
than other pharmaceutical sectors.
Profitable
business with a history of fiscal discipline
We have been profitable since 2004, during which time we have
generated sufficient cash flows to fund our development and
marketing programs without the need for significant external
financing. As an emerging pharmaceutical company with limited
resources, we have historically focused on product opportunities
with relatively low acquisition, development, and
commercialization costs. Further, we believe that our
third-party manufacturing and distribution relationships allow
us to outsource these functions efficiently while directing most
of our resources to our core competencies of business
development, clinical and regulatory affairs, and sales and
marketing.
Integrated
specialty pharmaceutical company with extensive management
expertise
Our executives have significant pharmaceutical industry
experience in business development, clinical and regulatory
affairs, and sales and marketing. This team is augmented by our
Pharmaceutical and Medical Advisory Boards, which consist of
highly experienced healthcare professionals.
|
|
Ø
|
Our business development team is led by our CEO and our Director
of Business Development and is comprised of a multi-disciplinary
group of executives. This team sources product opportunities
independently as well as through our international network of
pharmaceutical and medical industry insiders. Their efforts have
resulted in acquisition, license, co-promotion and strategic
alliance agreements, and have provided us with rights to our
current portfolio. This group is also responsible for acquiring
rights to early-stage product candidates through CET.
|
|
Ø
|
Our clinical, regulatory affairs and product development team is
led by three professionals with substantial experience advancing
late-stage clinical candidates successfully through the FDA
approval process. This team was directly responsible for
obtaining FDA approval for Acetadote and is responsible for our
development of Amelior. We have established internal
capabilities to develop proprietary product formulations, design
and manage our clinical trials, prepare all regulatory
submissions and manage our medical call center.
|
|
Ø
|
Our sales and marketing team is managed by five executives who
have broad experience marketing branded pharmaceuticals. They
manage the dedicated hospital and gastroenterology sales forces
that promote our products and that together are comprised of 42
sales representatives and managers. Our executives also direct
our national marketing campaigns and manage relationships with
key accounts.
|
41
Business
OUR
STRATEGY
Our objective is to develop, acquire and commercialize branded
pharmaceutical products for specialty physician market segments.
Specifically, we plan to:
Successfully
develop and commercialize Amelior, our Phase III product
candidate
Amelior is in late-stage Phase III clinical development for
the treatment of pain and fever. We have gathered positive data
regarding the safety and efficacy of this product, and we expect
to complete clinical trials in early 2008. We believe that there
is significant market potential for Amelior in both pain and
fever. We intend to penetrate the U.S. hospital market with
our existing hospital sales force and to commercialize the
product internationally through alliances with marketing
partners.
Maximize sales of
our marketed products
Over the past three years, we have employed an effective
marketing campaign resulting in consistent sales growth for our
product Acetadote. We intend to expand our hospital sales force
in anticipation of a potential launch of Amelior. We believe we
can leverage this expanded sales force to increase Acetadote
sales. We are also supporting several studies to explore other
potential indications for Acetadote. In October 2006, we
re-launched Kristalose under the Cumberland brand with a new
marketing program and dedicated sales force, which we expect to
expand significantly over time. This marketing program is
designed to enhance brand awareness through increased
promotional activity and highlights Kristaloses many
positive, competitive attributes. In addition to our sales
efforts, we may also pursue co-promotion arrangements with third
parties to support growth of our products.
Expand sales
force operations
We intend to continue building our sales and marketing
infrastructure in order to drive prescription volume and product
sales. We currently utilize two distinct sales teams:
|
|
Ø
|
We promote Acetadote, and plan to promote Amelior,
through our dedicated hospital sales team consisting of 16
representatives and managers covering approximately 1,400 major
U.S. medical centers. We expect to significantly increase
this sales force in order to fully capitalize on the market
potential of Acetadote and Amelior.
|
|
Ø
|
We promote Kristalose through a dedicated field sales force
of 26 sales representatives and managers to approximately 6,400
gastroenterologists and other high prescribers of laxatives. We
believe that we can increase the market for Kristalose
significantly by investing in our marketing program and
significantly expanding this sales force.
|
Expand our
product portfolio by acquiring rights to additional products and
late-stage product candidates
We intend to build a portfolio of complementary, niche products
largely through product acquisitions. We focus on
under-promoted, FDA-approved drugs with existing brand
recognition as well as late-stage development products which
address unmet medical needs, a strategy which we believe helps
minimize our exposure to the significant risk, cost and time
associated with drug discovery and research. We plan to continue
to target products that are competitively differentiated, have
valuable trademarks or other intellectual property, and allow us
to leverage our existing infrastructure. We also plan to explore
opportunities to seek approval for new uses of existing
pharmaceutical products.
42
Business
Develop a
pipeline of early-stage products through CET
In order to build our product pipeline, we are supplementing our
acquisition and late-stage development activities with the
early-stage drug development activities of CET, our
majority-owned subsidiary. CET partners with universities and
other research organizations to cost-effectively develop
promising, early-stage product candidates. Current pre-clinical
projects nearing clinical-stage development include:
|
|
Ø
|
a treatment for fluid buildup in the lungs of cancer patients,
in collaboration with Vanderbilt University, and
|
|
Ø
|
a highly purified anti-infective for treating fungal infections
in immuno-compromised patients, in collaboration with the
University of Mississippi.
|
INDUSTRY
The hospital
market
According to IMS Health, U.S. hospitals accounted for
approximately $31 billion, or 11%, of
U.S. pharmaceutical sales in 2006. IMS Health also reports
that in 2006, marketing and promotional efforts focused on
hospital-use drugs represented only about $662 million, or
3%, of approximately $21 billion total pharmaceutical
industry spending on promotional activity. The majority of
promotional spending is directed towards large outpatient
markets promoting drugs intended for chronic use rather than
short-term use in the hospital setting. We believe the lack of
promotional emphasis on the hospital marketplace indicates that
the hospital market is underserved. We also believe that the
hospital market is highly concentrated, with a small number of
large institutions responsible for a majority of pharmaceutical
spending, and consequently that it can be penetrated effectively
without large-scale promotional activity by a small, dedicated
sales force.
Market for
injectable analgesics
Therapeutic agents used to treat pain are collectively known as
analgesics. Physicians prescribe injectable analgesics for
hospitalized patients who have high levels of acute pain,
require rapid pain relief or cannot take oral analgesics.
According to IMS Health, the U.S. market for injectable
analgesics exceeded $302 million, or 491 million
units, in 2006. This market is comprised principally of generic
opioids and the NSAID ketorolac. Injectable opioids such as
morphine, meperidine, hydromorphone and fentanyl accounted for
approximately 447 million units sold in 2006. While opioids
are widely used for acute pain management, they are associated
with a variety of unwanted side effects including sedation,
nausea, vomiting, constipation, headache, cognitive impairment
and respiratory depression. Respiratory depression, if not
monitored closely, can be deadly. Opioid-related side effects
can warrant dosing limitations, which may reduce overall
effectiveness of pain relief. Side effects from opioids can
cause a need for further medication or treatment, and can
increase lengths of stay in post-anesthesia care units as well
as overall hospital stay, which can lead to increased costs for
hospitals and patients.
Despite having a poor safety profile, usage of ketorolac, the
only non-opioid injectable analgesic available in the U.S., has
grown from approximately 38 million units in 2003, or 7% of
the market, to approximately 43 million units in 2006,
representing 9% of the market, according to IMS Health. The FDA
specifically warns that ketorolac should not be used in various
patient populations that are at-risk for bleeding, as a
prophylactic analgesic prior to major surgery or for
intraoperative administration when stoppage of bleeding is
critical.
43
Business
Fever
Significant fever is generally defined as a temperature of
greater than 102 degrees Fahrenheit. High fevers can cause
hallucinations, confusion, convulsions and death. Hospitalized
patients are subject to increased risk for developing fever,
especially from exposure to infectious agents. Patients with
endotracheal intubation, sedation, reduced gastric motility,
nausea or recent surgery are frequently unable to ingest,
digest, absorb, or tolerate oral products to reduce fever.
Treatment for these patients ranges from rectal delivery of
medication to physical cooling measures such as tepid baths, ice
packs and cooling blankets. In the U.S., there is currently no
FDA-approved intravenous medication for the treatment of fever.
Acetaminophen
poisoning
Acetaminophen is one of the most widely used drugs for oral
treatment of pain and fever in the U.S. and can be found in many
common
over-the-counter,
or OTC products and prescription narcotics. Though safe at
recommended doses, the drug can cause liver damage with
excessive use. According to the American Association of Poison
Control Centers Toxic Exposure Surveillance System,
acetaminophen poisoning is the leading cause of toxic drug
ingestions in the U.S. In 2005, approximately 77,000 people
were treated and 333 people died due to acetaminophen
poisoning in the U.S.
In a study published in 2005 that examined acute liver failure,
researchers concluded that acetaminophen poisoning was
responsible for acute liver failure in over half the patients
examined in 2003, up from 28% in 1998. While an estimated 48% of
cases were due to the accidental use of acetaminophen over
several days, causing chronic liver failure, an estimated 44% of
the cases were intentional overdoses, causing acute liver
failure.
According to the FDA, four grams of acetaminophen is the daily
maximum dosage recommended for adults. Ingesting eight grams of
acetaminophen in a single day causes a significant number of
people, whose livers have been previously stressed by a virus,
medication or alcohol, to experience more serious complications.
When used in conjunction with opiates, acetaminophen can be
effective in relieving pain after surgery or injury; however,
some patients who take acetaminophen/opiate combination drugs on
a chronic basis eventually require increasing amounts to achieve
the same level of pain relief, which can also lead to liver
failure.
Market for the
treatment of Acetaminophen overdose
NAC is widely accepted as the standard of care for acetaminophen
overdose. Throughout Europe and much of the rest of the world,
NAC has been available in an injectable formulation for over
25 years. Until the 2004 approval of Acetadote, however,
the only FDA-approved form of NAC available in the U.S. was
an oral preparation. Prior to the approval of Acetadote, many
U.S. hospitals prepared an off-label, IV form of NAC from
the oral solution to treat patients suffering from acetaminophen
poisoning. For a number of these patients, an IV product is
the only reasonable route of administration due to nausea and
vomiting associated with the administration of oral NAC for the
overdose. Moreover, IV treatment requires fewer doses and a
shorter treatment protocol, reducing treatment from three days
to one day.
Acetaminophen poisoning treatment is typically initiated in the
emergency department and continued in the intensive care unit.
NAC is marketed to emergency physicians and nurses, critical
care physicians, clinical and medical toxicologists and poison
control centers. According to The Medical Letter on Drugs and
Therapeutics, NAC is virtually 100% effective in preventing
severe liver damage, renal failure and death if administered
within eight to ten hours of the overdose.
44
Business
The
gastrointestinal market
According to the National Institute of Diabetes, Digestive and
Kidney Diseases, gastrointestinal diseases result in
approximately 50 million physician visits and
14 million hospitalizations annually. Many of these
physician visits are to one of the only 11,700
gastroenterologists in the U.S.
There are over 40 common, well-defined gastrointestinal
conditions recognized in the U.S., including constipation,
chronic liver disease and cirrhosis, gastroesophageal reflux
disease, infectious diarrhea, irritable bowel syndrome, lactose
intolerance, pancreatitis and peptic ulcers. Because the market
for gastrointestinal diseases is broad in patient scope, yet
relatively narrow in physician base, we believe that it is an
attractive specialty focus which can provide a wide variety of
product opportunities but can be penetrated with a modest sales
force.
Market for
treatment of constipation
Constipation is a common condition in the U.S., affecting
approximately 20% of the population each year. While many
occurrences are non-recurring, a significant number are chronic
in nature and require some treatment to control or resolve.
Constipation treatments are sold in both the OTC, and
prescription segments. We believe that the prescription laxative
market in which Kristalose competes has historically consisted
of a few highly promoted brands including
MiraLax®
(polyethylene glycol 3350), which is now being sold as an OTC
product, Amitiza and
Zelnorm®,
which is used for multiple indications including constipation,
as well as several generic forms of liquid lactulose and
polyethylene glycol 3350. Zelnorm was removed from the market in
March 2007 due to adverse safety findings, and is pending
further FDA review. According to data from IMS Health, this
market grew from approximately $206 million in 2003 to
$389 million in 2006, a compound annual growth rate of
approximately 24%. This increase in sales resulted primarily
from new product introductions and increased promotion of
branded products.
PRODUCTS
Our key products and product candidates include:
|
|
|
|
|
|
|
Product
|
|
Indication
|
|
Delivery
|
|
Status
|
|
|
Amelior®
|
|
Pain and Fever
|
|
Injectable
|
|
Phase III
|
Acetadote®
|
|
Acetaminophen Poisoning
|
|
Injectable
|
|
Marketed
|
Kristalose®
|
|
Chronic and Acute Constipation
|
|
Oral Solution
|
|
Marketed
|
|
|
Amelior
Amelior is an intravenous formulation of ibuprofen. We expect
Amelior will be the first injectable non-opioid product
available in the U.S. for the treatment of pain and fever.
The product is currently in Phase III clinical trials, and
we are preparing for our NDA submission to the FDA for
regulatory approval. If approved, we believe Amelior will
provide physicians with a safe, effective treatment alternative
for acute care patients requiring an intravenous product for
pain relief or fever reduction. We have retained the
U.S. marketing rights for Amelior and, if approved, plan to
market it in the U.S. through our hospital sales force. We
plan to commercialize the product outside of the
U.S. through alliances with international marketing
partners.
Ibuprofen, an NSAID, is a widely-used product now taken orally
for pain relief and fever reduction, but is currently
unavailable in an injectable formulation for this use. In May
1999, we acquired from Vanderbilt University an exclusive,
worldwide license to data on the use of intravenous ibuprofen.
45
Business
Published in the New England Journal of Medicine in March
1997, this data indicated that intravenous ibuprofen was
effective in reducing high fever in critically ill patients who
were largely unable to receive oral medication. Following
discussion with and recommendation by the FDA, we implemented a
development program for Amelior designed to obtain approval for
a dual indication for the productreduction of pain and
treatment of fever.
We expect Amelior will be administered primarily to hospitalized
patients who are unable to receive analgesics or antipyretics
orally. We believe Amelior represents our most significant
product opportunity to date.
Development
history
We have actively managed the development of Amelior by
implementing the following steps:
|
|
Ø
|
We obtained exclusive rights to an investigator IND which
contains supportive safety and efficacy data in which
hospitalized adult patients with sepsis received intravenous
ibuprofen.
|
|
Ø
|
We developed a patented formulation for Amelior as well as a
proprietary manufacturing process.
|
|
Ø
|
We completed a clinical study to establish the pharmacokinetic
equivalence of oral and intravenous ibuprofen in February 2001,
a study to establish safe administration of the optimized
dilution of Ameliors IV preparation in March 2002, and a
study to demonstrate that the product is effective in reducing
fever in hospitalized adult malaria patients in July 2002.
|
|
Ø
|
We completed a dose-ranging study to determine the optimum dose
to treat fever in hospitalized adult patients in August 2005.
|
|
Ø
|
We completed enrollment for a dose-ranging study to determine
the products effectiveness in controlling pain in
post-surgical adult patients in October 2006.
|
|
Ø
|
In January 2007, we initiated a pivotal study to demonstrate the
products effectiveness in controlling pain in
post-surgical adult patients. In April 2007, a subsequent study
was initiated to support the products use in additional
surgical populations.
|
|
Ø
|
Over four years of stability studies for Amelior have been
successfully completed.
|
|
Ø
|
A study to obtain data to support pediatric use is ongoing.
|
|
Ø
|
An integrated safety database is being built, combining both
published experience with data from these new studies.
|
We intend to complete clinical development of Amelior by early
2008.
Commercialization
strategy
We intend to expand our existing U.S. hospital sales force
to promote Amelior to physicians, nurses and pharmacy
directors, principally in the hospital setting. We believe that
we can achieve our commercial goals by utilizing our experienced
sales organization, and supporting them with an internal
marketing infrastructure that targets high-use institutions. We
have an international strategic alliance with Mayne Pharma Pty.
Ltd., which will manufacture commercial supplies of Amelior. We
intend to partner with third-parties to reach markets outside
the U.S. or to expand our reach to physician groups outside
the hospital where applicable.
Acetadote
Acetadote is N-acetylcysteine, or NAC, for the intravenous
treatment of acetaminophen overdose. Until we obtained FDA
approval for Acetadote in 2004, the only FDA-approved form of
NAC available in
46
Business
the U.S. was an oral preparation. Medical literature
suggested that many hospitals prepared an off-label, IV form of
NAC from the oral solution for easier administration and
accuracy in dosing. Given this market dynamic, we concluded that
a medical need existed for an FDA-approved, injectable
formulation of NAC for the U.S. market.
We actively managed the development and regulatory approval of
Acetadote by implementing the following steps:
|
|
Ø
|
We held initial discussions with the FDA to design a development
plan.
|
|
Ø
|
Acetadote was granted orphan drug status in October 2001, which
provides for seven years of marketing exclusivity from date of
marketing approval.
|
|
Ø
|
We submitted our NDA in July 2002.
|
|
Ø
|
We submitted a complete response to FDA initial review questions
in July 2003.
|
|
Ø
|
We received FDA marketing approval for Acetadote in January 2004
for the treatment of acetaminophen overdose.
|
|
Ø
|
Acetadote was launched in June 2004.
|
|
Ø
|
Early in 2006, the FDA-approved revised labeling for the
product, which included an expanded indication for dosing in
pediatric patients.
|
In connection with the FDAs approval of Acetadote, we
committed to certain post-marketing activities for the product.
Our first phase IV commitment (pediatric) was completed and
accepted by the FDA in December 2004. Our second phase IV
commitment (clinical) was completed and accepted by the FDA in
August 2006. We anticipate completing our third and final
phase IV commitment (manufacturing) for Acetadote in 2007.
We are also supporting a number of studies to explore other
potential indications for the product.
We believe Acetadote has clinical and financial benefits
relative to oral NAC, including ease of administration,
minimizing nausea and vomiting associated with oral NAC,
accurate dosage control, shorter treatment protocol and
reduction in overall cost of acetaminophen overdose management.
Acetadote makes NAC administration easier to tolerate for
patients and easier to administer for medical providers. We
believe Acetadote also offers a significant cost benefit to both
patient and hospital by reducing the treatment regimen, usually
from three days to one day.
Acetadote is manufactured for us by Bioniche Teoranta at its
FDA-approved manufacturing facility in Ireland.
Kristalose
Kristalose is a prescription laxative administered orally for
the treatment of constipation. In patients with a history of
chronic constipation, lactulose therapy increases the number of
bowel movements per day and the number of days on which they
occur. Lactulose is a product with a long history of use as a
laxative, and as a treatment for hepatic encephalopathy, which
is a deterioration of the liver resulting in a
build-up of
ammonia. Kristalose is an innovative, dry powder crystalline
formulation of lactulose which is designed to enhance patient
compliance and acceptance.
We co-promoted Kristalose from 2002 until April 2006 under an
agreement with Bertek Pharmaceuticals, Inc., the branded
division of Mylan Laboratories, Inc. Following Mylans
discontinuance of Bertek operations in 2006, we acquired
exclusive U.S. commercialization rights to Kristalose. We
re-launched Kristalose under the Cumberland brand in October
2006 with a dedicated, contract sales force of 26 sales
representatives and managers. We direct our sales efforts to
physicians
47
Business
who are the most prolific writers of prescription laxatives.
These physicians include gastroenterologists, pediatricians,
internists and colon and rectal surgeons.
We believe Kristalose offers competitive advantages over other
laxative products. Packaged in single dose packets, Kristalose
is very portable, is reconstituted in as little as four ounces
of water, is clear, virtually tasteless, does not change the
viscosity of the water and contains almost no calories, all of
which we believe cause Kristalose to compare favorably to liquid
lactulose products. Compared to polyethylene glycol 3350
products, we believe Kristalose has a fast onset of action and a
better pregnancy category rating. Compared with
Zelnorm®
and
Amitiza®,
Kristalose has fewer potential side effects or contraindications
and is less expensive.
Kristalose is manufactured for us by Inalco S.p.A. at an
FDA-approved facility in Italy.
Early-stage
product candidates
Our early-stage product candidates are being developed by CET,
which collaborates with leading research institutions to
identify and pursue promising pre-clinical programs. Two of the
more advanced CET development programs are:
|
|
Ø
|
In collaboration with Vanderbilt University, we are currently
developing a new treatment for fluid buildup in the lungs of
cancer patients. The product candidate is a protein therapeutic
being designed to treat pleural effusion, a
condition which occurs when cancer spreads to the surface of the
lung and chest cavity, causing fluid to accumulate and patients
to suffer shortness of breath and chest pain. An estimated
100,000 patients are affected by this condition each year.
Currently, the substances used in treating this cause pain and
have only a
60-90%
success rate. Vanderbilt University researchers believe they
have found a method of treating this condition which may involve
less pain, a higher success rate and faster healing time,
resulting in significantly shorter hospital stays.
|
|
Ø
|
In collaboration with the University of Mississippi, we are
developing a highly purified, injectable anti-infective used to
treat fungal infections in immuno-compromised patients. This
product candidates active ingredient is currently
FDA-approved in a different formulation, and while it is the
therapeutic of choice for infectious disease specialists in
treating such fungal infections, it can produce serious side
effects related to renal toxicity, often resulting in dosage
limitations or discontinued use. University of Mississippi
researchers have developed what they believe is a purer and
safer form of the anti-infective.
|
BUSINESS
DEVELOPMENT
Since inception, we have had an active business development
program focused on acquiring rights to marketed products and
product candidates that fit our strategy and target markets. We
source our business development leads both through our senior
executives and our international network of pharmaceutical and
medical industry insiders. These opportunities are reviewed and
considered on a regular basis by a multi-disciplinary team of
our managers against a list of selection criteria. We have
historically focused on product opportunities with relatively
low acquisition, development and commercialization costs,
employing a variety of deal structures.
We intend to continue to build a portfolio of complementary,
niche products largely through product acquisitions. Our primary
targets are under-promoted, FDA-approved drugs with existing
brand recognition and late-stage development products that
address unmet medical needs in the hospital acute care and
gastroenterology markets. We also plan to explore opportunities
to acquire rights to and seek approval for new uses of
pharmaceutical products. We believe that by focusing mainly on
approved or
48
Business
late-stage products, we can minimize the significant risk, cost
and time associated with drug development. We have completed
three material acquisitions including:
|
|
Ø
|
exclusive, worldwide rights from Vanderbilt University to data
for intravenous ibuprofen to support our FDA submission for
Amelior;
|
|
Ø
|
exclusive, worldwide rights to clinical data supporting the
safety and efficacy of Acetadote, which served as a key
component of our FDA submission and approval; and
|
|
Ø
|
exclusive U.S. commercial rights to Kristalose.
|
Our business development team is also responsible for
identifying appropriate CET product candidates and negotiating
with our university partners to secure rights to these
candidates. Through CET, we are collaborating with a growing
list of research institutions including:
|
|
Ø
|
Vanderbilt University;
|
|
Ø
|
University of Mississippi, School of Pharmacy; and
|
|
Ø
|
University of Tennessee Research Foundation.
|
Since 2004, these collaborations secured nearly $1 million
in National Institutes of Health grant funding for the
development of promising new products and several additional
proposals have been submitted or are awaiting review.
CLINICAL AND
REGULATORY AFFAIRS
We have established in-house capabilities for the management of
our clinical, professional and regulatory affairs. Our team
develops and manages our clinical trials, prepares regulatory
submissions, manages ongoing product-related regulatory
responsibilities and manages our medical information call
center. They were responsible for devising the regulatory and
clinical strategy and obtaining FDA approval for Acetadote and
are responsible for ongoing development of Amelior.
Clinical
development
Our in-house clinical development personnel are responsible for:
|
|
Ø
|
creating clinical development strategies;
|
|
Ø
|
designing and monitoring our clinical trials;
|
|
Ø
|
creating case report forms and other study-related documents;
|
|
Ø
|
overseeing clinical work contracted to third parties; and
|
|
Ø
|
overseeing CET grant funding proposals.
|
Regulatory and
quality affairs
Our internal regulatory and quality affairs team is responsible
for:
|
|
Ø
|
preparing and submitting NDAs and fulfilling post-approval
marketing commitments;
|
|
Ø
|
maintaining investigational and marketing applications through
the submission of appropriate reports;
|
|
Ø
|
submitting supplemental applications for additional label
indications, product line extensions and manufacturing
improvements;
|
|
Ø
|
evaluating regulatory risk profiles for product acquisition
candidates, including compliance with manufacturing, labeling,
distribution and marketing regulations;
|
49
Business
|
|
Ø
|
monitoring applicable third-party service providers for quality
and compliance with current Good Manufacturing Practices, Good
Laboratory Practices, and Good Clinical Practices, and
performing periodic audits of such vendors; and
|
|
Ø
|
maintaining systems for document control, product and process
change control, customer complaint handling, product stability
studies and annual drug product reviews.
|
Professional and
medical affairs
Our clinical and regulatory team provides in-house, medical
information support for our marketed products. This includes
interacting directly with healthcare professionals to address
any product or medical inquiries through our medical information
call center. Our call center was previously operated by the
Rocky Mountain Poison and Drug Center, or RMPDC. In 2006, we
expanded our clinical and regulatory capabilities and brought
our call center in-house in an effort to ensure the highest
level of quality and service. The RMPDC continues to supplement
our efforts by providing
after-hours
support for our call center and assisting us with our adverse
event collection/reporting and global pharmacovigilance
activities. In addition to coordinating the call center, our
clinical/regulatory group generates medical information letters,
provides informational memos to our sales forces and assists
with ongoing training for the sales forces.
SALES AND
MARKETING
Our sales and marketing team has broad industry experience in
selling branded pharmaceuticals. They manage the dedicated
hospital and gastroenterology sales forces, which are comprised
of 42 sales representatives and managers, direct our national
marketing campaigns and maintain key national account
relationships. We promote our products to hospitals and
office-based physicians across the U.S. and plan to
commercialize our products internationally through marketing
alliances.
In January 2007, we converted our hospital sales force, which
had previously been contracted to us by Cardinal Health Inc., or
Cardinal, to Cumberland employees through our newly-formed,
wholly-owned subsidiary, Cumberland Pharma Sales Corp. The
hospital sales team is comprised of 16 sales representatives and
managers, covering approximately 1,400 major medical centers
across the U.S. The gastroenterology-focused team, formed
in September 2006 with our re-launch of Kristalose, is a field
sales force comprised of 26 representatives and managers and
covering approximately 6,400 high prescribers of laxatives. This
gastroenterology sales force is contracted to us by Advogent
Group, Inc., or Advogent. Under our agreement, we pay Advogent a
monthly fee, a portion of which is used to compensate the sales
force. We also reimburse Advogent for bonuses and expense
reimbursement paid to the sales force. This agreement terminates
in August 2008. We have the option, with Advogents
consent, to extend the contract for one additional year. We also
have the option to bring this sales force in-house. We expect to
expand both sales forces significantly over the next several
years.
Our sales and marketing executives conduct ongoing market
analyses to evaluate marketing campaigns and promotional
programs. The evaluations include development of product
profiles, testing of the profiles against the needs of the
market, determining what additional product information or
development work is needed to effectively market the products
and preparing financial forecasts. We utilize professional
branding and packaging as well as promotional items to support
our products, including direct mail, sales brochures, journal
advertising, educational and reminder leave-behinds, patient
educational pieces and product sampling. We also attend regular
trade shows to promote broad awareness of our products.
50
Business
Our National Accounts group is responsible for key large buyers
and related marketing programs. This group supports sales and
marketing efforts by maintaining relationships with our
wholesaler customers as well as with third-party payors such as
Group Purchasing Organizations, Pharmacy Benefit Managers,
Hospital Buying Groups, state and federal government purchasers
and influencers and health insurance companies.
International
Sales and Marketing
Consistent with our strategy to outsource non-core functions, we
have licensed to third parties the right to distribute Amelior
outside the U.S. We have granted Alveda Pharmaceuticals
Inc., or Alveda, an exclusive license to distribute Amelior in
Canada subject to receipt of regulatory approval. Alveda is
obligated to make payments to us upon Ameliors achieving
specified regulatory milestones in Canada and to pay us a
royalty based on Canadian sales of Amelior. This license
terminates five years after regulatory approval is obtained in
Canada for the later of the fever or pain indications. We have
granted Mayne Pharma (SEA) Pte Limited an exclusive license to
market and distribute Amelior in Southeast Asia subject to the
receipt of regulatory approval. Mayne Pharma (SEA) Pte Limited
is obligated to make payments to us upon Ameliors
achieving specified regulatory milestones in Southeast Asia as
well royalty payments. The initial term of the agreement expires
on the fifth anniversary of Amelior obtaining regulatory
approval in Southeast Asia.
MANUFACTURING AND
DISTRIBUTION
We outsource certain non-core, capital-intensive functions,
including manufacturing and distribution. Our executives have
years of experience in these areas and manage these third-party
relationships with a focus on quality assurance.
Manufacturing
Our key manufacturing relationships include:
|
|
Ø
|
In July 2000, we established an international manufacturing
alliance with Australia-based Mayne Pharma Pty. Ltd., or Mayne.
Mayne sources active pharmaceutical ingredients, or APIs, and
manufactures Amelior exclusively for us under an agreement that
expires on the fifth anniversary of FDA approval of Amelior,
subject to early termination upon 45 days prior notice in
the event of uncured material breach by us or Mayne. The
agreement will automatically renew for successive three-year
terms unless Mayne or we provide at least 12 months prior
written notice of non-renewal. Under the agreement, we pay Mayne
a transfer price per unit of Amelior supplied. In addition, we
reimburse Mayne for
agreed-upon
development, regulatory and inspection and audit costs. We have
also granted Mayne a right of first negotiation with respect to
the manufacture of all future pharmaceutical products we intend
to sell and the distribution of these products in Australia, New
Zealand, Canada and mutually agreed Southeast Asian and Latin
American countries.
|
|
Ø
|
Bioniche Teoranta, or Bioniche, sources APIs and manufactures
Acetadote exclusively for us for sale in the U.S. at its
FDA-approved manufacturing facility in Ireland. Our relationship
with Bioniche began in January 2002. Bioniche manufactures and
packages Acetadote for us, and we purchase Acetadote exclusively
from Bioniche, pursuant to an agreement expiring in January
2011. This agreement is subject to early termination upon prior
written notice in the event of an uncured material default by us
or Bioniche. We have an option to renew the agreement for a
five-year term upon expiration. Under the agreement, we pay
Bioniche a transfer price per unit of Acetadote supplied, which
transfer price is subject to annual adjustment, and a royalty
based on our net sales of the product. In addition, we are
required to purchase minimum quantities of Acetadote.
|
51
Business
|
|
Ø |
Inalco S.p.A. and Inalco Biochemicals, Inc., or collectively
Inalco, from which we licensed exclusive
U.S. commercialization rights to Kristalose in April 2006,
source APIs and provide us with a manufacturing supply for the
product under an agreement that expires in 2021. The agreement
renews automatically for successive three-year terms unless we
or Inalco provide written notice of intent not to renew at least
12 months prior to expiration of a term. Either we or
Inalco may terminate this agreement upon at least 45 days
prior written notice in the event of uncured material breach.
Under the agreement, we are required to pay Inalco a transfer
price per unit of Kristalose supplied and a royalty based on our
net sales of Kristalose. In addition, we are required to
purchase minimum quantities of Kristalose.
|
Distribution
Like many other pharmaceutical companies, we employ an outside
contractor to facilitate our distribution efforts. Since August
2002, Specialty Pharmaceutical Services, or SPS, (formerly CORD
Logistics, Inc.) has exclusively handled all aspects of our
product logistics efforts, including warehousing, shipping,
customer billing and collections. A division of Cardinal, SPS is
located just outside of Nashville, Tennessee, and has a
well-established infrastructure. We maintain ownership of
finished products until their sale to our customers.
INTELLECTUAL
PROPERTY
We seek to protect our products from competition through a
combination of patents, trademarks, trade secrets, FDA
exclusivity and contractual restrictions on disclosure.
Proprietary rights, including patents, are an important element
of our business. We seek to protect our proprietary information
by requiring our employees, consultants, contractors and other
advisors to execute agreements providing for protection of our
confidential information on commencement of their employment or
engagement, through which we seek to protect our intellectual
property. We also require confidentiality agreements from
entities that receive our confidential data or materials.
Amelior
We are the owner of U.S. Patent No. 6,727,286, which
is directed to ibuprofen solution formulations, methods of
making the same, and methods of using the same, and which
expires in 2021. This U.S. patent is associated with our
completed international application
No. PCT/US01/42894.
We have filed for international patent protection in association
with this PCT application in various countries, some of which
have been allowed and some of which remain pending.
We have applied for additional protection for our invention
related to ibuprofen solution formulations, methods of making
the same and methods of using the same through
U.S. application
No. 10/739,050
and international application
No. PCT/US04/39770,
both of which remain pending.
We have an exclusive, worldwide license to clinical data for
intravenous ibuprofen from Vanderbilt University, in
consideration for royalty and other payment obligations that are
conditioned upon approval by the FDA of Amelior.
If Amelior is approved by the FDA, we intend to seek three years
marketing exclusivity from the FDA based on the clinical studies
we have sponsored to pursue approval of the product.
Acetadote
Acetadote was approved by the FDA in January 2004 as an orphan
drug for the intravenous treatment of acetaminophen overdose. As
an orphan drug, Acetadote is entitled to seven years of
marketing
52
Business
exclusivity for the treatment of this approved indication. We
have applied for patent protection for a new formulation of
Acetadote through U.S. patent application
No. 11/209,804,
as well as through international application
No. PCT/US06/20691,
both of which are directed to acetylcysteine compositions,
methods of making the same and methods of using the same. In
addition, we have an exclusive, worldwide license to NAC
clinical data from Newcastle Master Misercordiae Hospital in
Australia. We have no expected outstanding payment obligations
pursuant to this contract.
Kristalose
We are the exclusive licensee of two U.S. patents owned by
Inalco relating to Kristalose. The first, U.S. Patent
No. 5,003,061, is directed to a method for preparing
high-purity crystalline lactulose. The second, U.S. Patent
No. 5,480,491, is directed to a process for preparation of
crystalline lactulose. Our license rights include an exclusive
license to use related Inalco know-how and the Kristalose
trademark to manufacture, market and distribute Kristalose in
the U.S. Under our agreement with Inalco, Inalco is solely
responsible for prosecuting and maintaining both the patents and
know-how that we license from them. Our license expires in 2021
and is subject to earlier termination for material breach. Our
payment obligations under this agreement are described under
Manufacturing and Distribution
Manufacturing.
COMPETITION
The pharmaceutical industry is characterized by intense
competition and rapid innovation. Our continued success in
developing and commercializing pharmaceutical products will
depend, in part, upon our ability to compete against existing
and future products in our target markets. Competitive factors
directly affecting our markets include but are not limited to:
|
|
Ø
|
product attributes such as efficacy, safety,
ease-of-use
and cost-effectiveness;
|
|
Ø
|
brand awareness and recognition driven by sales and marketing
and distribution capabilities;
|
|
Ø
|
intellectual property and other exclusivity rights;
|
|
Ø
|
availability of resources to build and maintain developmental
and commercial capabilities;
|
|
Ø
|
successful business development activities;
|
|
Ø
|
extent of third-party reimbursements; and
|
|
Ø
|
establishment of advantageous collaborations to conduct
development, manufacturing or commercialization efforts.
|
A number of our competitors possess research and development and
sales and marketing capabilities as well as financial resources
greater than ours. These competitors, in addition to emerging
companies and academic research institutions, may be developing,
or in the future could develop, new technologies that could
compete with our current and future products or render our
products obsolete.
Amelior
We are developing Amelior for the treatment of pain and fever,
primarily in a hospital setting. A variety of products already
address the acute pain market.
|
|
Ø
|
Morphine, the most commonly used product for the treatment of
acute, post-operative pain, is manufactured and distributed by
several generic pharmaceutical companies.
|
|
Ø
|
Depodur®
is an extended release injectable formulation of morphine that
is marketed by SkyePharma PLC.
|
53
Business
|
|
Ø
|
Other generic injectable opioids, including fentanyl, meperidine
and hydromorphone.
|
|
Ø
|
Ketorolac (brand name
Toradol®),
an injectable NSAID, is also manufactured and distributed by
several generic pharmaceutical companies.
|
We are aware of other product candidates in development to treat
acute pain including injectable NSAIDs, novel opioids, new
formulations of existing therapies and extended release
anesthetics. We believe the companies developing injectable,
non-narcotic analgesics for the treatment of post-surgical pain
are the primary potential competitors to Amelior. Cadence
Pharmaceuticals Inc. is developing an injectable formulation of
acetaminophen for the treatment of pain and fever, and Javelin
Pharmaceuticals Inc. is developing an injectable form of an
NSAID, diclofenac.
In addition to the injectable analgesic products above, many
companies are developing analgesics for specific indications
such as migraine and neuropathic pain, oral extended-release
forms of existing narcotic and non-narcotic products, and
products with new methods of delivery such as transdermal.
We are not aware of any approved injectable products indicated
for the treatment of fever in the U.S. There are, however,
numerous drugs available to physicians to reduce fevers in
hospital settings via oral administration to the patient,
including acetaminophen, ibuprofen and aspirin. These drugs are
manufactured by numerous pharmaceutical companies.
Acetadote
Acetadote is our injectable formulation of NAC for the treatment
of acetaminophen overdose. NAC is accepted worldwide as the
standard of care for acetaminophen overdose. Despite the
availability of injectable NAC outside the United States,
Acetadote, to our knowledge, is the only injectable NAC product
approved in the U.S. to treat acetaminophen overdose. Our
competitors in the acetaminophen overdose market are those
companies selling orally administered NAC including, but not
limited to, Geneva Pharmaceuticals, Inc., Bedford Laboratories
division of Ben Venue Laboratories, Inc., Roxane Laboratories,
Inc. and Hospira Inc.
Kristalose
Kristalose is a dry powder crystalline prescription formulation
of lactulose indicated for the treatment of constipation. The
U.S. constipation therapy market includes various
prescription and OTC products. The prescription products which
we believe are our primary competitors are
Amitiza®
and liquid lactuloses:
|
|
Ø
|
Amitiza is indicated for the treatment of chronic idiopathic
constipation in adults and is marketed by Sucampo
Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited;
and
|
|
Ø
|
Liquid lactulose products are marketed by a number of
pharmaceutical companies.
|
In addition, Kristalose competed with the prescription product
Zelnorm®
until it was pulled from the market in March 2007 due to adverse
safety findings. Indicated for treatment of chronic idiopathic
constipation in persons under aged 65 and produced by Novartis
Pharma AG, Zelnorm is under further review by the FDA.
There are several hundred OTC products used to treat
constipation marketed by numerous pharmaceutical and consumer
health companies.
MiraLax®
(polyethylene glycol 3350), previously a prescription product,
is indicated for the treatment of constipation and is
manufactured and marketed by Braintree Laboratories, Inc. and
other generic pharmaceutical firms. Under an agreement with
Braintree, Schering-Plough introduced MiraLax as an OTC product
in February 2007.
54
Business
EMPLOYEES
As of April 30, 2007, we had 33 full-time employees,
which included 16 hospital sales representatives and managers.
We also have a dedicated gastroenterology field sales force
under contract that is comprised of 26 dedicated sales
representatives and managers. We believe that employing
experienced, independent contractors and consultants is a
cost-efficient and effective way to accomplish our goals. A
number of additional individuals have provided or are currently
providing services to us pursuant to agreements between the
individuals or their employers and us. None of our employees are
represented by a collective bargaining unit. We believe that we
have positive relationships with our employees.
FACILITIES
We currently lease approximately 6,300 square feet of
office space in Nashville, Tennessee for our headquarters under
an agreement expiring in December 2010. We have an option to
renew this lease for a five-year term upon expiration. We also
have entered into an occupancy agreement for approximately
9,000 square feet of additional office space adjoining our
headquarters. This occupancy agreement will be replaced by a
sublease for the same space, effective June 1, 2007. The
sublease expires in October 2010. We believe that these
facilities are adequate to meet our current needs for office
space. We currently do not plan to purchase or lease facilities
for manufacturing, packaging or warehousing, as such services
are provided to us by third-party contract groups.
Under an agreement expiring in May 2011, CET leases
approximately 6,900 square feet of office and wet
laboratory space in Nashville, Tennessee. CET uses this space to
operate the CET Life Sciences Center for product development
work to be carried out in collaboration with universities,
research institutions and entrepreneurs. CET has an option to
lease up to 20,000 square feet at the Life Sciences Center
should it need additional space. The CET Life Sciences Center
provides laboratory and office space, equipment and
infrastructure to early-stage life sciences companies and
university spin-outs.
GOVERNMENT
REGULATION
Pharmaceutical companies are subject to extensive regulation by
national, state, and local agencies in countries in which they
do business. The manufacture, distribution, marketing and sale
of pharmaceutical products is subject to government regulation
in the U.S. and various foreign countries. Additionally, in the
U.S., we must follow rules and regulations established by the
FDA requiring the presentation of data indicating that our
products are safe and efficacious and are manufactured in
accordance with cGMP regulations. If we do not comply with
applicable requirements, we may be fined, the government may
refuse to approve our marketing applications or allow us to
manufacture or market our products and we may be criminally
prosecuted.
We and our manufacturers and clinical research organizations may
also be subject to regulations under other federal, state and
local laws, including the Occupational Safety and Health Act,
the Resource Conservation and Recovery Act, the Clean Air Act
and import, export and customs regulations as well as the laws
and regulations of other countries.
FDA Approval
Process
The steps required to be taken before a new prescription drug
may be marketed in the U.S. include:
|
|
Ø
|
completion of pre-clinical laboratory and animal testing;
|
|
Ø
|
the submission to the FDA of an investigational new drug
application, or IND, which must be evaluated and found
acceptable by the FDA before human clinical trials may commence;
|
55
Business
|
|
Ø
|
performance of adequate and well-controlled human clinical
trials to establish the safety and efficacy of the proposed drug
for its intended use; and
|
|
Ø
|
submission and approval of a NDA.
|
The sponsor of the drug typically conducts human clinical trials
in three sequential phases, but the phases may overlap. In
Phase I clinical trials, the product is tested in a small
number of patients or healthy volunteers, primarily for safety
at one or more dosages. In Phase II clinical trials, in
addition to safety, the sponsor evaluates the efficacy of the
product on targeted indications, and identifies possible adverse
effects and safety risks in a patient population. Phase III
clinical trials typically involve testing for safety and
clinical efficacy in an expanded population at
geographically-dispersed test sites.
The FDA requires that clinical trials be conducted in accordance
with the FDAs good clinical practices (GCP) requirements.
The FDA may order the partial, temporary or permanent
discontinuation of a clinical trial at any time or impose other
sanctions if it believes that the clinical trial is not being
conducted in accordance with FDA requirements or presents an
unacceptable risk to the clinical trial patients. The
institutional review board (IRB), or ethics committee (outside
of the U.S.), of each clinical site generally must approve the
clinical trial design and patient informed consent and may also
require the clinical trial at that site to be halted, either
temporarily or permanently, for failure to comply with the
IRBs requirements, or may impose other conditions.
The results of the pre-clinical and clinical trials, together
with, among other things, detailed information on the
manufacture and composition of the product and proposed
labeling, are submitted to the FDA in the form of an NDA for
marketing approval. The FDA reviews all NDAs submitted before it
accepts them for filing and may request additional information
rather than accepting an NDA for filing. Once the submission is
accepted for filing, the FDA begins an in-depth review of the
NDA. Under the policies agreed to by the FDA under the
Prescription Drug User Fee Act, or PDUFA, the FDA has ten months
in which to complete its initial review of a standard NDA and
respond to the applicant. The review process and the PDUFA goal
date may be extended by three months if the FDA requests or the
NDA sponsor otherwise provides additional information or
clarification regarding information already provided in the
submission within the last three months of the PDUFA goal date.
If the FDAs evaluations of the NDA and the clinical and
manufacturing procedures and facilities are favorable, the FDA
may issue an approval letter. The FDA may also issue an
approvable letter setting forth further conditions that must be
met in order to secure final approval of the NDA. If and when
those conditions have been met to the FDAs satisfaction,
the FDA will issue an approval letter. An approval letter
authorizes commercial marketing of the drug for certain
indications. According to the FDA, the median total approval
time for NDAs approved during calendar year 2004 was
approximately 13 months for standard applications. If the
FDAs evaluations of the NDA submission and the clinical
and manufacturing procedures and facilities are not favorable,
it may refuse to approve the NDA and issue a not-approvable
letter.
The time and cost of completing these steps and obtaining FDA
approval can vary dramatically depending on the drug. However,
to complete these steps for a novel drug can take many years and
cost millions of dollars.
Section 505(b)(2)
New Drug Applications
As an alternate path for FDA approval of new indications or new
formulations of previously-approved products, a company may file
a Section 505(b)(2) NDA, instead of a
stand-alone or full NDA.
Section 505(b)(2) of the FDC Act was enacted as part of the
Drug Price Competition and Patent Term Restoration Act of 1984,
otherwise known as the Hatch-Waxman Amendments.
Section 505(b)(2) permits the submission of an NDA where at
least some of the information required for approval comes
56
Business
from studies not conducted by or for the applicant and for which
the applicant has not obtained a right of reference. Some
examples of products that may be allowed to follow a 505(b)(2)
path to approval are drugs which have a new dosage form,
strength, route of administration, formulation or indication.
We successfully secured FDA approval of a 505(b)(2) NDA for
Acetadote in January 2004. We also plan to pursue marketing
approval for Amelior pursuant to the 505(b)(2) pathway.
Upon approval of a full or 505(b)(2) NDA, a drug may
be marketed only for the FDA-approved indications in the
approved dosage forms. Further clinical trials are necessary to
gain approval for the use of the product for any additional
indications or dosage forms. The FDA may also require
post-market reporting and may require surveillance programs to
monitor the side effects of the drug, which may result in
withdrawal of approval after marketing begins.
Special Protocol
Assessment Process
The special protocol assessment, or SPA, process generally
involves FDA evaluation of a proposed Phase III clinical
trial protocol and a commitment from the FDA that the design and
analysis of the trial are adequate to support approval of an
NDA, if the trial is performed according to the SPA and meets
its endpoints. The FDAs guidance on the SPA process
indicates that SPAs are designed to evaluate individual clinical
trial protocols primarily in response to specific questions
posed by the sponsors. In practice, the sponsor of a product
candidate may request an SPA for proposed Phase III trial
objectives, designs, clinical endpoints and analyses. A request
for an SPA is submitted in the form of a separate amendment to
an IND, and the FDAs evaluation generally will be
completed within a
45-day
review period under applicable PDUFA goals, provided that the
trials have been the subject of discussion at an
end-of-Phase II
and pre-Phase III meeting with the FDA, or in other limited
cases.
On June 14, 2004, we submitted a request for SPA of our
Amelior Phase III clinical study. During a meeting with the
FDA on September 29, 2004, the FDA confirmed that the
efficacy data from our study of post-operative pain with a
positive outcome will be considered sufficient to support a
505(b)(2) application for the pain indication. Final
determinations by the FDA with respect to a product candidate,
including as to the scope of its labeling, are made
after a complete review of the applicable NDA and are based on
the entire data in the application. Moreover, notwithstanding
any SPA, FDA approval of an NDA is subject to future public
health concerns unrecognized at the time of protocol assessment.
Orphan Drug
Designation
The Orphan Drug Act of 1983, or Orphan Drug Act, encourages
manufacturers to seek approval of products intended to treat
rare diseases and conditions with a prevalence of
fewer than 200,000 patients in the U.S. or for which there
is no reasonable expectation of recovering the development costs
for the product. For products that receive orphan drug
designation by the FDA, the Orphan Drug Act provides tax credits
for clinical research, FDA assistance with protocol design,
eligibility for FDA grants to fund clinical studies, waiver of
the FDA application fee, and a period of seven years of
marketing exclusivity for the product following FDA marketing
approval. Acetadote received Orphan Drug designation in October
2001 and was approved by the FDA for the intravenous treatment
of moderate to severe acetaminophen overdose in January 2004. As
an orphan drug, Acetadote is entitled to marketing exclusivity
until January 2011 for the treatment of this approved
indication. This exclusivity would not prevent a product with a
different formulation from competing with Acetadote, however.
57
Business
The Hatch-Waxman
Act
The Hatch-Waxman Act provides three years of marketing
exclusivity for the approval of new and supplemental NDAs,
including Section 505(b)(2) NDAs, for, among other things,
new indications, dosages or strengths of an existing drug, if
new clinical investigations that were conducted or sponsored by
the applicant are essential to the approval of the application.
It is under this provision that we expect to receive three years
marketing exclusivity for Amelior.
Other regulatory
requirements
Regulations continue to apply to pharmaceutical products after
FDA approval occurs. Post-marketing safety surveillance is
required in order to continue to market an approved product. The
FDA also may, in its discretion, require post-marketing testing
and surveillance to monitor the effects of approved products or
place conditions on any approvals that could restrict the
commercial applications of these products.
If we seek to make certain changes to an FDA-approved product,
such as promoting or labeling a product for a new indication,
making certain manufacturing changes or product enhancements or
adding labeling claims, we will need FDA review and approval
before the change can be implemented. While physicians may use
products for indications that have not been approved by the FDA,
we may not label or promote the product for an indication that
has not been approved. Securing FDA approval for new indications
or product enhancements and, in some cases, for manufacturing
and labeling claims, is generally a time-consuming and expensive
process that may require us to conduct clinical trials under the
FDAs IND regulations. Even if such studies are conducted,
the FDA may not approve any change in a timely fashion, or at
all. In addition, adverse experiences associated with use of the
products must be reported to the FDA, and FDA rules govern how
we can label, advertise or otherwise commercialize our products.
In addition to FDA restrictions on marketing of pharmaceutical
products, several other types of state and federal laws have
been applied to restrict certain marketing practices in the
pharmaceutical industry in recent years. These laws include
anti-kickback statutes and false claims statutes. The federal
health care program anti-kickback statute prohibits, among other
things, knowingly and willfully offering, paying, soliciting or
receiving remuneration to induce or in return for purchasing,
leasing, ordering or arranging for the purchase, lease or order
of any health care item or service reimbursable under Medicare,
Medicaid or other federally financed health care programs. This
statute has been interpreted to apply to arrangements between
pharmaceutical manufacturers on the one hand and prescribers,
purchasers and formulary managers on the other. Violations of
the anti-kickback statute are punishable by imprisonment,
criminal fines, civil monetary penalties and exclusion from
participation in federal health care programs.
Federal false claims laws prohibit any person from knowingly
presenting, or causing to be presented, a false claim for
payment to the federal government, or knowingly making, or
causing to be made, a false statement to have a false claim
paid. Recently, several pharmaceutical and other health care
companies have been prosecuted under these laws for allegedly
inflating drug prices they report to pricing services, which in
turn were used by the government to set Medicare and Medicaid
reimbursement rates, and for allegedly providing free product to
customers with the expectation that the customers would bill
federal programs for the product.
Outside of the U.S., our ability to market our products will
also depend on receiving marketing authorizations from the
appropriate regulatory authorities. The foreign regulatory
approval process includes all of the risks associated with the
FDA approval process described above. The requirements
58
Business
governing the conduct of clinical trials and marketing
authorization vary widely from country to country.
LEGAL
PROCEEDINGS
Except as described below, we are not a party to litigation or
other legal proceedings.
During the second quarter of 2006, our Chief Executive, a Vice
President of ours, and we were named as co-defendants in
Parniani v. Cardinal Health, Inc. et al., Case
No. 0:06-cv-02514-PJS-JJG
in the U.S. District Court in the District of Minnesota for
unspecified damages based on workers compensation and
related claims. A former employee of a third-party service
provider to us filed the complaint. The service provider, which
is also named as a co-defendant, has agreed to assume control of
our defense at its cost pursuant to a contract between it and
us. The service provider is seeking dismissal of the lawsuit
against us, our Chief Executive, and our Vice President, among
other co-defendants. Based upon the information available to us
to date, we believe that all asserted claims against us and the
individual defendants are without merit. However, if any of the
claims are deemed meritorious by judicial determination, we
expect to be indemnified by the service provider so that
resolution of this matter is not expected to have a material
adverse effect on our future financial results or financial
condition.
59
Management
OFFICERS AND
DIRECTORS
The following table sets forth the names and ages of our
directors, executive officers and key managers as of
April 30, 2007:
|
|
|
|
|
|
|
Name
|
|
Age
|
|
|
Position
|
|
|
A.J. Kazimi
|
|
|
49
|
|
|
Chairman and Chief Executive
Officer
|
Martin E.
Cearnal(1),(2)
|
|
|
62
|
|
|
Director
|
Dr. Robert G. Edwards
|
|
|
79
|
|
|
Director
|
Dr. Lawrence W.
Greer(1),(2)
|
|
|
62
|
|
|
Director
|
Thomas R.
Lawrence(1),(2)
|
|
|
67
|
|
|
Director
|
Jean W. Marstiller
|
|
|
57
|
|
|
Senior Vice President and
Corporate Secretary
|
Dr. Gordon R. Bernard
|
|
|
55
|
|
|
Senior Vice President and Medical
Director
|
Leo Pavliv
|
|
|
46
|
|
|
Vice President, Operations
|
J. William Hix
|
|
|
59
|
|
|
Vice President, Sales &
Marketing
|
David L. Lowrance
|
|
|
39
|
|
|
Vice President and Chief Financial
Officer
|
James L. Herman
|
|
|
52
|
|
|
Senior Director, National Accounts
and Corporate Compliance Officer
|
Elizabeth C. Gerken
|
|
|
38
|
|
|
Director, Business Development
|
Bruce J. Kent
|
|
|
44
|
|
|
Senior Manager, District Sales
|
Amy D. Rock
|
|
|
36
|
|
|
Senior Manager, Regulatory Affairs
|
|
|
|
(1)
|
|
Member of Audit Committee
|
|
(2)
|
|
Member of Compensation Committee
|
A.J. Kazimi, Chairman and Chief Executive
Officer. Mr. Kazimi founded our company in
1999 and has served as our Chief Executive Officer and Chairman
of our Board of Directors since inception. His career includes
20 years in the biopharmaceutical industry. Prior to
joining our company, he spent eleven years from 1987 to 1998
helping to build Therapeutic Antibodies Inc., a
biopharmaceutical company, where as President and Chief
Operating Officer he made key contributions to the
companys growth from its
start-up
phase through its initial public offering and product launches.
Mr. Kazimi oversaw operations in three countries and was
personally involved with the companys product development
strategies, licensing and distribution agreements, and the
raising of more than $100 million through equity and debt
financings. From
1984-1987,
Mr. Kazimi worked at Brown-Forman Corporation, rising
through a series of management positions and helping to launch
several new products. Mr. Kazimi currently serves on the
board of directors for Aegis Sciences Corporation, a federally
certified forensic toxicology laboratory; the Tennessee
Biotechnology Association; and Aetos Technologies Inc., a
technology development company associated with Auburn
University. He also serves as Chairman and Chief Executive
Officer of Cumberland Emerging Technologies, Inc., or CET. He
holds a B.S. from the University of Notre Dame and an M.B.A.
from the Vanderbilt Owen Graduate School of Management.
Martin E. Cearnal, Director. Mr. Cearnal
has served as a member of our board of directors since 2004. He
is the former President and Chief Executive Officer of
Physicians World, which became the largest provider of
continuing medical education during his tenure from 1985 to
2000. Physicians World was acquired by Thomson Healthcare in
2000. Mr. Cearnal served as President of Thomson Physicians
World from 2000 to 2003, and Executive Vice President-Chief
Strategy Officer for Thomson Medical Education from 2003 through
2005. Since 2006, he has been Executive Vice President-Chief
Strategy Officer for Jobson Medical Information.
Mr. Cearnal has 40 years experience in the Healthcare
industry
60
Management
and has been involved with the launches of such noteworthy
pharmaceutical products as
Lipitor®,
Actos®,
Intron-A®,
Straterra®,
Botox®
and
Humira®.
Mr. Cearnal spent 17 years at Revlon Healthcare in a
variety of domestic and international pharmaceutical marketing
roles culminating in his position as Vice President, Marketing
for the International Operations. He serves the industry through
leadership and participation in several organizations, including
the Healthcare Marketing & Communications Council and
the Alliance for Continuing Medical Education. Mr. Cearnal
also serves as a member of our Audit Committee and our
Compensation Committee. He has a BS degree from Southeast
Missouri State University.
Dr. Robert G. Edwards,
Director. Dr. Edwards has served as a member
of our board of directors since 1999. From 1991 to 1999, he was
Chairman and Managing Director of the Australasian subsidiary of
Therapeutic Antibodies Inc., overseeing operations in Australia,
New Zealand and Southeast Asia. Dr. Edwards also served as
Deputy Director of the Institute for Medical &
Veterinary Science in South Australia, President of the Royal
College of Pathologists of Australasia, and member of the
Australian National Health & Medical Research Council.
He currently serves as a director for CET, and is chairman of
the CET Scientific Advisory Board. Dr. Edwards holds a
Primary Degree from London University, Master of Human
Physiology from London University and an M.D. from the
University of Adelaide.
Dr. Lawrence W. Greer,
Director. Dr. Greer has served as a member
of our board of directors since 1999. Since 2002, he has been
Senior Managing Partner of Greer Capital Advisors of Birmingham,
Alabama. Dr. Greer serves as investment advisor to two
private equity funds and general partner for two additional
private equity funds, including the S.C.O.U.T. Healthcare Fund
from which we have received equity financing. Dr. Greer and
his firm are established leaders in private healthcare
investments in the mid-south. Previously, he served as Vice
President-Investments of Dunn Investment Company, where he was
responsible for management of a marketable securities portfolio
plus personal management of a portfolio of 15 private equity
investments. He is the former Chairman of Southern BioSystems
which was acquired by DURECT Corporation in 2001. Dr. Greer
has also worked as an independent consultant in healthcare
administration and finance. Dr. Greer serves as the
chairman of the Audit Committee of our board of directors, as a
member of our Compensation Committee, and is an Audit Committee
financial expert. He also served as the chairman of the Audit
Committee for the Southtrust (Bank) Funds Board of Trustees for
several years. Dr. Greer holds a B.S. from Tulane
University, D.D.S. from Emory University and an M.B.A. from
Emory University.
Thomas R. Lawrence,
Director. Mr. Lawrence has served as a
member of our board of directors since 1999. Since 2003 he has
been Chairman and Chief Executive Officer of Aetos Technologies
Inc., a corporation formed in 2003 by Auburn University to
market technological breakthroughs by its faculty. From 1998 to
2003, Mr. Lawrence advised business clients on matters of
marketing and corporate governance through his firm Capital
Consultants. He previously served as Co-Founder and Managing
Partner of Delta Capital Partners in Memphis from 1989 to 1998.
The partnership made investments in ten early-stage companies
which, by 1998, were valued at more than $30 million. Prior
to the formation of Delta, Mr. Lawrence founded several
companies in the areas of commercial leasing and venture capital
financing. He also worked for most of the 1980s as an
Institutional Sales Representative and Commercial Leasing
Specialist with the Investment Banking Group of Union Planters
Bank in Memphis, where he was responsible for the structure and
sale of over $1 billion in securities. Mr. Lawrence
serves as the chairman of our Compensation Committee, as a
member of our Audit Committee and as a director for CET. He
holds a B.S. from Mississippi State University.
Jean W. Marstiller, Senior Vice President and Corporate
Secretary. Ms. Marstiller joined our Company
in 1999. She oversees our administrative operations, human
resources, site services and information systems, and became our
Corporate Secretary in 2007. She has 17 years
biopharmaceutical industry
61
Management
experience and was formerly Director of Administrative
Operations at Therapeutic Antibodies Inc., where she worked from
1989 until 1998. In that capacity, she oversaw administrative
services, information systems, and human resources.
Ms. Marstiller was employed by Brown-Forman Corporation
from 1982 until 1987, where she held management level positions
in the areas of finance and operations. She holds a B.E. from
Vanderbilt University and attended the Vanderbilt Owen Graduate
School of Management.
Dr. Gordon R. Bernard, Senior Vice President and Medical
Director. Dr. Bernard has served as our
medical director since 1999. Dr. Bernard is the Assistant
Vice-Chancellor for Research at Vanderbilt University, and also
the Melinda Owen Bass Professor of Medicine and former Chief of
the Division of Allergy, Pulmonary and Critical Care Medicine at
Vanderbilt. In addition, he is the Medical Director of the
Vanderbilt Institutional Review Board and Chairman of
Vanderbilts Pharmacy and Therapeutics Committee, which is
responsible for approving the Vanderbilt Medical Center
Formulary of approved drugs and therapeutics. Dr. Bernard
also chairs the National Institutes of Health, Acute Respiratory
Distress Syndrome Clinical Trials Network. He holds a B.S. from
the University of Southwestern Louisiana and an M.D. from
Louisiana State University.
Leo Pavliv, Vice President, Operations. Mr.
Pavliv has served as our Vice President, Operations since 2003,
and is responsible for Cumberlands overall drug
development, including manufacturing and quality operations. He
has 23 years of experience developing pharmaceutical and
biological products. From 1997 to 2003 he worked at Cato
Research, a contract research organization, most recently as
Vice President of Pharmaceutical Development where he oversaw
development of a wide variety of products throughout the
development cycle. Prior to 1997, he held various scientific and
management positions at both large pharmaceutical and smaller
biopharmaceutical firms including Parke-Davis from 1984 to 1986,
Agouron Pharmaceuticals from 1992 to 1997, ProCyte from 1989 to
1992, and Interferon Sciences from 1986 to 1989. He is a
registered pharmacist (R.Ph.) and is regulatory affairs
certified (RAC). Mr. Pavliv holds a B.S., Pharmacy, and an
M.B.A. from Rutgers University.
J. William Hix, Vice President, Sales and
Marketing. Mr. Hix is responsible for all
our sales and marketing efforts. He joined us in 2004 to form
and manage our national sales force promoting our acute care
product line to hospitals, poison control centers and
physicians. He was also instrumental in the design and
implementation of our field sales force which is responsible for
promoting our products in the gastroenterology market.
Mr. Hix brings significant industry experience to our
company having spent 30 years at Novartis/CIBA-GEIGY
Pharmaceutical Corporation from 1974 to 2004. There, his
responsibilities ranged from field sales, sales management,
sales operations, planning and promotion to marketing support
and operations. He holds a B.S. from the University of Memphis
and an M.B.A. from Our Lady of the Lake University.
David L. Lowrance, Vice President and Chief Financial
Officer. Mr. Lowrance is responsible for
overseeing all our accounting and financial activities,
including financial reporting and planning. He has been with us
since 2003 and has 17 years of accounting and financial
experience in both international business and manufacturing.
From 1994 to 2003, he spent eight years with two global
conglomerates, including four years as Senior Vice President for
Icore International, a division of Smiths Group, PLC. Prior to
that, Mr. Lowrance worked as a senior accountant for
Ernst & Young, LLP from 1990 to 1994. He is a Certified
Public Accountant, or CPA, and holds a B.B.A. from the
University of Georgia.
James L. Herman, Senior Director, National Accounts and
Corporate Compliance Officer. Mr. Herman
handles all national accounts sales, including wholesalers and
retail chain buying offices, managed care home offices and
federal government accounts. He is also charged with overseeing
our corporate compliance efforts. He has been with us since 2003
and has 17 years pharmaceutical industry experience. From
1998 to 2003, he was with Solvay Pharmaceuticals and served as
Director of
62
Management
Managed Care as well as Director of Trade Affairs and Customer
Service. From 1990 to 1998, Mr. Herman was with Schwarz
Pharma, where he held national sales leadership positions in
National Accounts and Managed Care. He holds a B.S. from Indiana
University and an M.B.A. from Cardinal Stritch University.
Elizabeth C. Gerken, Director, Business
Development. Ms. Gerken has served as our
head of business development since 2001. She coordinates all
business development activities and is actively engaged in the
identification of product opportunities, the process of due
diligence and the negotiation of deal terms for our agreements.
Ms. Gerken has 15 years pharmaceutical industry
experience. She worked at Eli Lilly and Company from 1992 to
2000 with management roles in strategic planning, brand
management, sales management, and business development. She
holds a B.E. from Vanderbilt University and an M.B.A. from the
Vanderbilt Owen Graduate School of Management.
Bruce J. Kent, Senior Manager, District
Sales. Mr. Kent joined us in July 2006 to
form and launch our field sales force. He is responsible for
managing that group of sales representatives which promotes our
gastroenterology product line. Mr. Kent has 19 years
of pharmaceutical industry experience. Beginning his career with
CIBA Pharmaceuticals in 1988, he spent 15 years with the
company now known as Novartis Pharmaceuticals, where he held
positions of increasing responsibility in sales, sales
management, managed healthcare, business analysis, and
ebusiness. Prior to joining our company, Mr. Kent
was the Executive Director of Sales for Rx Sample Solutions and
the head of the Northeast Regional Office from 2004 to 2006. He
holds a B.S. from the Pennsylvania State University.
Amy Dix Rock, Ph.D., Senior Manager, Regulatory
Affairs. Dr. Rock joined our company in 2001
and built our Regulatory Affairs Department and infrastructure.
In addition to managing all interactions between our company and
the FDA, Dr. Rock oversees the preparation of pre-approval
and post-approval regulatory submissions. Her additional
responsibilities include involvement in protocol development and
clinical trials management, overseeing our medical call center
and supporting our corporate compliance initiatives. She holds a
B.A. from Washington University, a PhD in Immunology from the
University of Kentucky, and an M.B.A. from the Vanderbilt Owen
Graduate School of Management.
ADVISORY
BOARDS
In order to augment the efforts of our management and directors,
we have established two key advisory boards to support our
management and directors.
Pharmaceutical
Advisory Board
Our Board of Pharmaceutical Advisors is comprised of eight
individuals who have spent their careers in the pharmaceutical
industry. This group includes former senior executives from a
number of the major pharmaceutical firms including
Warner-Lambert Co. and its Parke-Davis division, Pfizer, Inc.,
Bristol-Myers Squibb Company, and CIBA Geigy Corp. These
individuals each advise members of our companys management
on a wide variety of issues based on their expertise. These
industry advisors are helping to build our company by actively
contributing to many areas of our business such as strategy,
business development, human resources, marketing, international
activities, accounting and logistics.
Medical Advisory
Board
We have also established a Board of Medical Advisors to support
our product development efforts. This board includes six
physicians with representatives from the U.S. and international
medical communities who are leaders in the fields of emergency,
critical care and infectious disease medicine as well as
toxicology and cardiology. These individuals meet as a group
with our management to help us identify
63
Management
unmet medical needs and underserved patient populations in our
target areas. They also help us identify and evaluate relevant
product opportunities.
BOARD
COMPOSITION
Our board of directors currently consists of five directors who
are divided into three classes serving staggered three-year
terms. Dr. Robert G. Edwards is a Class I
director who will serve until our 2008 annual meeting of
shareholders. Dr. Lawrence W. Greer and Thomas R.
Lawrence are Class II directors who will serve until our
2009 annual meeting. A.J. Kazimi and Martin E. Cearnal
are Class III directors who will serve until our 2010
annual meeting. Upon expiration of the term of a class of
directors, directors in that class will be eligible to be
elected for a new three-year term at the annual meeting of
shareholders in the year in which their term expires. Any
additional directorships resulting from an increase in the
number of directors will be distributed among the three classes
so that, as nearly as possible, each class will consist of
one-third of the directors. This classification of directors
could have the effect of increasing the length of time necessary
to change the composition of a majority of our board of
directors. In general, at least two annual meetings of
shareholders will be necessary for shareholders to effect a
change in a majority of the members of our board of directors.
DIRECTOR
INDEPENDENCE
In December 2006 and in February 2007, our board of directors
undertook reviews of the independence of the directors and
considered whether any director had a material relationship with
us that could compromise his ability to exercise independent
judgment in carrying out his responsibilities. As a result of
this review, our board of directors determined that
Dr. Lawrence W. Greer and Martin E. Cearnal are
independent as defined under applicable National
Association of Securities Dealers Automated Quotation System, or
NASDAQ, rules and SEC rules and regulations. We expect that a
majority of our board will be independent within a year
following this offering as required by the Sarbanes-Oxley Act of
2002, SEC rules and regulations and NASDAQ rules.
BOARD
COMMITTEES
The standing committees of our board consist of an audit
committee and a compensation committee. Both committees will
have three members following this offering, two of whom will be
independent. We expect that all directors on our audit and
compensation committees will be independent within a year
following this offering.
Audit
committee
The members of our audit committee are Dr. Lawrence W.
Greer, Martin E. Cearnal and Thomas R. Lawrence. The Chair of
the audit committee is Dr. Greer, who has been
affirmatively determined by our board of directors to be
independent in accordance with applicable rules. In addition,
the board of directors has determined that Dr. Greer is an
audit committee financial expert, as such term is
described in Item 407 of
Regulation S-K.
The primary function of the audit committee is to assist our
board of directors in fulfilling its oversight responsibilities
by reviewing the financial reports and certain financial
information provided by us to any governmental body or the
public, reviewing our systems of internal controls regarding
finance, accounting, legal compliance and ethics that we have
established and overseeing our auditing, accounting and
financial reporting processes generally. Consistent with this
function, we expect the audit committee to encourage continuous
improvement of, and to foster adherence to, our policies,
procedures and practices at all levels, to be responsible for
managing the relationship with our
64
Management
independent registered public accountants, and to provide a
forum for discussion with the independent registered public
accountants and our board.
Some of the audit committees responsibilities include:
|
|
Ø
|
appointing, determining the compensation for and overseeing our
relationship with our independent registered public accountants;
|
|
Ø
|
overseeing, reviewing and evaluating our financial statements,
the audits of our financial statements, our accounting and
financial reporting processes, the integrity of our financial
statements, our disclosure controls and procedures and our
internal audit functions;
|
|
Ø
|
reviewing and approving the services provided by our independent
registered public accountants, including the scope and results
of their audits and pre-approving permissible non-audit services
to be performed by them;
|
|
Ø
|
resolving disagreements between management and our independent
registered public accountants;
|
|
Ø
|
overseeing our compliance with legal and regulatory requirements
and compliance with ethical standards adopted by us;
|
|
Ø
|
establishing and maintaining whistleblower procedures; and
|
|
Ø
|
evaluating periodically our Standards of Business Conduct and
Ethics, Code of Ethics for Senior Financial Officers and
Procedures for Complaints and Concerns Regarding Accounting,
Internal Accounting Controls and Auditing Matters.
|
Compensation
committee
The members of our compensation committee are Dr. Lawrence
W. Greer, Martin E. Cearnal, and Thomas R. Lawrence. The Chair
of the compensation committee is Thomas R. Lawrence. The
responsibilities of the compensation committee include:
|
|
Ø
|
reviewing and recommending to the board of directors the
compensation and benefits of all of our executive officers and
directors;
|
|
Ø
|
evaluating the performance of the principal executive officer;
|
|
Ø
|
administering our equity incentive plans;
|
|
Ø
|
establishing and reviewing general policies relating to
compensation and benefits of our employees;
|
|
Ø
|
reviewing and evaluating the compensation discussion and
analysis prepared by management; and
|
|
Ø
|
preparing an executive compensation report for publication in
our annual proxy statement.
|
COMPENSATION
COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
Thomas R. Lawrence, the Chair of our compensation committee, is
the Chairman of Aetos Technologies, Inc., a corporation formed
in 2003 by Auburn University to market technological
breakthroughs by its faculty. Mr. Kazimi, our Chairman and
Chief Executive Officer, serves on the board of directors of
Aetos Technologies. Other than this relationship, none of our
executive officers serves as a member of the board of directors
or compensation committee of any other entity that has one or
more executive officers who serve on our board of directors or
compensation committee.
CODES OF CONDUCT
AND CORPORATE GOVERNANCE
We are currently in the process of developing a Corporate
Compliance Program. Within this program, we plan to maintain
internal processes and review procedures that ensure our
business activities are
65
Management
conducted in compliance with applicable federal and state laws,
statutes, regulations or program requirements, including
guidance documents drafted specifically by governing entities
for the healthcare and pharmaceutical industries, consistent
with advancing, preserving and protecting public health.
To help ensure compliance, we plan to conduct regular, periodic
compliance audits by internal and external auditors and
compliance staff, who have expertise in federal and state
healthcare laws and regulations.
Our codes of conduct consist of a Standards of Business Conduct
and Ethics, a Code of Ethics for Senior Financial Officers, an
Insider Information, Trading or Dealing and Stock Tipping Policy
and Procedures for Complaints and Concerns Regarding Accounting,
Internal Accounting Controls, and Auditing Matters. As part of
our corporate compliance program, in 2006 we established a
compliance hotline to enable employees, directors and other
representatives to report compliance violations, including
violations of our codes of conduct.
Standards of
Business Conduct and Ethics
Our board of directors has adopted a Standards of Business
Conduct and Ethics which establish the standards of ethical
conduct applicable to all of our directors, officers, employees,
key advisors, consultants and contract organizations. The code
of ethics addresses, among other things, compliance with laws
and regulations, business practices, conflicts of interest,
employment policies and reporting procedures. Suspected
violations of this code may be reported on a confidential,
anonymous basis through the compliance hotline. The audit
committee oversees this process, tracks the complaints and
resolutions and reports the significant results to the full
board of directors. The code is distributed to all employees and
directors. All employees and directors must sign, date and
return a certification stating that they received, understand
and will comply with the code.
Code of Ethics
for Senior Financial Officers
In 2006, we adopted a Code of Ethics for Senior Financial
Officers. The code is designed to deter wrongdoing and to
promote honest and ethical conduct, full and accurate disclosure
in periodic reports, and compliance with laws and regulations by
our senior management who has financial responsibility. We
expect that any suspected violations of this code will be
reported to the audit committee. Any waiver of this code may
only be authorized by our audit committee and will be disclosed
as required by applicable law.
Insider
Information, Trading or Dealing and Stock Tipping
Policy
We are committed to fair trading for publicly traded securities
and have established standards of conduct for directors,
employees and others who obtain material or price-sensitive,
non-public information through their work with us. The policy is
distributed to all employees. Non-compliance with the policy may
be submitted on a confidential, anonymous basis through the
compliance hotline.
Procedures for
Complaints and Concerns Regarding Accounting, Internal
Accounting Controls, and Auditing Matters
In 2006, we established Procedures for Complaints and Concerns
Regarding Accounting, Internal Accounting Controls and Auditing
Matters to encourage any person who has a reasonable basis for a
complaint or concern regarding our financial statement
disclosures, accounting matters, internal accounting controls or
auditing matters to promptly submit a complaint or concern.
Complaints may be submitted on a confidential, anonymous basis
through the compliance hotline. The audit committee oversees
this process, immediately reviews the complaints and oversees
all necessary investigations. The audit committee tracks the
complaints and resolutions and reports the significant results
to the full board of directors.
66
Compensation
COMPENSATION
DISCUSSION AND ANALYSIS
We provide what we believe is a competitive total compensation
package to our executive management team through a combination
of base salary, long-term equity incentive compensation plan and
broad-based benefits programs.
We place significant emphasis on performance-based incentive
compensation programs. This Compensation Discussion and Analysis
explains our compensation philosophy, policies and practices
with respect to our chief executive officer, chief financial
officer, and the other three most highly-compensated executive
officers or the named executive officers.
The objectives of
our executive compensation program
Our compensation committee is responsible for establishing and
administering the policies governing the compensation for our
executive officers. Our executive officers are appointed by our
board of directors.
Our executive compensation programs are designed to achieve the
following objectives:
|
|
Ø
|
attract and retain talented and experienced executives;
|
|
Ø
|
motivate and reward executives whose knowledge, skills and
performance are critical to our success;
|
|
Ø
|
align the interests of our executive officers and shareholders
by motivating executive officers to increase shareholder value
and rewarding executive officers when shareholder value
increases;
|
|
Ø
|
provide a competitive compensation package in which total
compensation is primarily determined by company and individual
results and the creation of shareholder value;
|
|
Ø
|
ensure fairness among the executive management team by
recognizing the contributions each executive makes to our
success; and
|
|
Ø
|
compensate our executives to manage our business to meet our
long-range objectives.
|
The compensation committee meets outside the presence of all of
our executive officers, including the named executive officers,
to consider appropriate compensation for our CEO. For all other
named executive officers, the committee meets outside the
presence of all executive officers except our CEO.
Mr. Kazimi annually reviews each other named executive
officers performance with the committee and makes
recommendations to the compensation committee with respect to
the appropriate base salary and the grants of long-term equity
incentive awards for all executive officers. Based in part on
these recommendations from our CEO, the compensation committee
approves the annual compensation package of our executive
officers other than our CEO. The compensation committee also
annually analyzes Mr. Kazimis performance and
determines his base salary and grants of long-term equity
incentive awards based on its assessment of his performance.
When making decisions on setting base salary and initial grants
of long-term equity incentive awards for new executive officers,
the compensation committee considers the importance of the
position to us, the past salary history of the executive officer
and the contributions to be made by the executive officer to us.
We use the following principles to guide our decisions regarding
executive compensation:
|
|
Ø
|
provide compensation opportunities targeted at market median
levels;
|
|
Ø
|
require performance goals to be achieved or common stock price
to increase in order for the majority of the target pay levels
to be earned;
|
|
Ø
|
offer a comprehensive benefits package to all full-time
employees; and
|
67
Compensation
|
|
Ø |
provide fair and equitable compensation.
|
Our executive
compensation programs
Overall, our executive compensation programs are designed to be
consistent with the objectives and principles set forth above.
The basic elements of our executive compensation programs are
base salary, long-term equity incentive plan awards, retirement
savings opportunities and health and welfare benefits. Each of
these elements is summarized below.
Base
salary
Annually we review salary ranges and individual salaries for our
executive officers. We establish the base salary for each
executive officer based on consideration of median pay levels in
the market and internal factors, such as the individuals
performance and experience, and the pay of others on the
executive team.
The base salaries paid to our named executive officers are set
forth below in the Summary Compensation Table. For the fiscal
year ended December 31, 2006, base cash compensation to our
named executive officers was approximately $1,079,090, with our
CEO receiving approximately $293,130 of that amount. We believe
that the base salary paid to our executive officers during 2006
achieves our executive compensation objectives, compares
favorably to market pay levels and is within our target of
providing a base salary at the market median.
In 2007, adjustments to our executive officers total
compensation were made based on an analysis of current market
pay levels of peer companies and in published surveys. In
addition to the market pay levels, factors taken into account in
making any changes for 2007 included the contributions made by
the executive officer, the performance of the executive officer,
the role and responsibilities of the executive officer and the
relationship of the executive officers base pay to the
base salary of our other executives.
Long-term equity
incentive compensation
We award long-term equity incentive grants to executive
officers, including the named executive officers, as part of our
total compensation package. These awards are consistent with our
pay for performance principles and align the interests of the
executive officers to the interests of our shareholders. The
compensation committee reviews and recommends to the board of
directors the amount of each award to be granted to each named
executive officer and the board of directors approves each
award. Long-term equity incentive awards to our executives were
made pursuant to our 1999 Stock Option Plan, or the 1999 Plan,
until April 2007, and thereafter, pursuant to our Long-Term
Incentive Compensation Plan.
1999
Stock Option Plan
Our 1999 Plan provides for the grant of incentive stock options
and nonqualified stock options. Grants can be made under the
1999 Plan to any of our employees, directors and consultants.
The 1999 Plan is administered by a committee designated by our
board of directors. The committee, in its sole discretion,
granted options under the 1999 Plan to certain persons rendering
services to us. Except as otherwise determined by the committee
and stated in the applicable option agreement, the exercise
price per share of each option granted under the 1999 Plan will
be the fair market value per share, as defined in the 1999 Plan.
In general, the fair market value per share is determined by our
board of directors.
68
Compensation
An option may generally be exercised until the tenth anniversary
of the date that we granted the option. Option holders who
exercise their options may pay for their shares in cash, check
or such other consideration as is deemed acceptable by us.
As
of ,
there were outstanding options to purchase a total
of shares
of common stock pursuant to the 1999 Plan. The exercise price
per share under such options ranges from $ to
$ .
Under the 1999 Plan, all executive officers were granted
incentive option agreements for common stock at exercise prices
equal to fair market value at time of issuance, except
Mr. Kazimis, whose exercise price is 110% of fair
market value at time of issuance. Each option agreement has a
term of ten years, except for Mr. Kazimis option
agreements, which have five-year terms. All agreements have
defined vesting schedules.
Long-Term
Incentive Compensation Plan
The purposes of the Long-Term Incentive Compensation Plan are:
|
|
Ø
|
to encourage our employees and consultants to acquire stock and
other equity-based interests; and
|
|
Ø
|
to replace the 1999 Plan without impairing the vesting or
exercise of any option granted thereunder.
|
The Long-Term Incentive Compensation Plan authorizes the
issuance of each of the following incentives:
|
|
Ø
|
incentive stock options (options that meet Internal Revenue
Service requirements for special tax treatment);
|
|
Ø
|
non-statutory stock options (all stock options other than
Incentive Stock Options);
|
|
Ø
|
stock appreciation rights (right to receive any excess in fair
market values of shares over a specified exercise price);
|
|
Ø
|
restricted stock (shares subject to transfer and forfeiture
limitations); and
|
|
Ø
|
performance shares (contingent awards comprised of stock
and/or cash
and paid only if specified performance goals are met).
|
The compensation committee administers the Long-Term Incentive
Compensation Plan. The compensation committee is authorized to
select participants, determine the type and number of awards to
be granted, determine and later amend, subject to certain
limitations, the terms of any award, interpret and specify the
rules and regulations relating to the Long-Term Incentive
Compensation Plan and make all other necessary determinations.
Employees and consultants other than non-employee directors are
eligible to participate. We may cancel unvested or unpaid
incentives for terminated employees and consultants to the
extent permitted by law.
Upon the occurrence of a change of control event, as defined in
the Long-Term Incentive Compensation Plan, all outstanding
options will automatically become exercisable in full, and
restrictions and conditions for other issued incentives will
generally be deemed terminated or satisfied. In addition, our
board of directors may amend or terminate the Long-Term
Incentive Compensation Plan, subject to shareholder approval, to
comply with tax or regulatory requirements.
Retirement
savings opportunity
Effective January 1, 2006, we established a 401(k) plan
covering all employees meeting certain minimum service and age
requirements. The plan allows all qualifying employees to
contribute the
69
Compensation
maximum tax-deferred contribution allowed by the Internal
Revenue Code. The non-Highly Compensated Employees, or non-HCEs,
do not have a minimum or maximum percentage limit that they can
defer. The HCEs, however, are limited to what they can defer
based on prior years testing. Hardship distributions are
permitted under well-defined circumstances. We do not currently
match employee contributions nor provide profit sharing at this
time; however, the plan is designed so that matching or profit
sharing can be arranged at any time.
Health and
welfare benefits
All full-time employees, including our named executive officers,
may participate in our health and welfare benefits programs,
including medical, dental and vision care coverage, disability
insurance and life insurance.
Employment
agreements, severance benefits and change in control
provisions
We have entered into employment agreements in 2007 with A.J.
Kazimi, our Chairman and CEO; Jean W. Marstiller, our Senior
Vice President, Administrative Services and Corporate Secretary;
Leo Pavliv, our Vice President, Operations; J. William Hix, our
Vice President, Sales and Marketing; and David L. Lowrance, our
Vice President and CFO. The following is a summary of the
material provisions of those employment agreements.
The employment agreements provide for an annual base salary of
$303,390 for Mr. Kazimi, $170,000 for Ms. Marstiller,
$211,000 for Mr. Pavliv, $180,000 for Mr. Hix, and
$158,400 for Mr. Lowrance. In addition, the employment
agreements provide that the individuals may be eligible for any
bonus program which has been approved by our board of directors.
Any such bonus is discretionary and will be subject to the terms
of the bonus program, the terms of which may be modified from
year-to-year
in the sole discretion of our board of directors. During the
period of employment under these agreements, each of our
executives will be entitled to additional benefits, including
eligibility to participate in any company-wide employee benefits
programs approved by our board of directors and reimbursement of
reasonable expenses.
Each executives employment is at-will and may be
terminated by us at any time, with or without notice and with or
without cause. Similarly, each executive may terminate his or
her employment with us at any time, with or without notice. The
employment agreements do not provide for any severance payments
in the event the employment is terminated for cause nor any
severance benefits in the event the employment is terminated as
a result of his or her death or permanent disability.
The employment agreements also include non-competition,
non-solicitation and nondisclosure covenants on the part of the
executives. During the term of each executives employment
with us and for one year after the executive ceases to be
employed by us, the employment agreements provide that he or she
may not compete with our business in any manner, unless the
executive discloses all facts to our board of directors and
receives a release allowing him or her to engage in a specific
activity. Pursuant to the employment agreements, the executives
also agree for a period of one year after the executive ceases
to be employed by us, he or she will not solicit business
related to the development or sales of pharmaceuticals products
from any entity, organization or person which is contracted with
us, which has been doing business with us, or a firm which the
executive knew we were going to solicit business from at the
time the executive ceased to be employed. Also, the executives
may not solicit our employees. The employment agreements also
impose obligations regarding confidential information and state
that any discoveries or improvements that are conceived,
developed or otherwise made by the executives, or with others,
are deemed our sole property. The employment agreements do not
contain any termination or change in control provisions.
70
Compensation
SUMMARY
COMPENSATION TABLE
The following table sets forth information, for the fiscal year
ended December 31, 2006, regarding the aggregate
compensation we paid to our named executive officers:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonqualified
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
Option
|
|
Compensation
|
|
All Other
|
|
|
Name and
|
|
|
|
Salary
|
|
Bonus
|
|
Awards
|
|
Awards
|
|
Earnings
|
|
Compensation
|
|
Total
|
Principal
Position
|
|
Year
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
|
A.J. Kazimi
|
|
|
2006
|
|
|
293,130
|
|
|
96,255
|
|
|
|
|
|
20,825
|
|
|
|
|
|
|
|
|
410,210
|
Chairman and CEO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James D. Aderhold
|
|
|
2006
|
|
|
194,000
|
|
|
40,000
|
|
|
|
|
|
17,940
|
|
|
|
|
|
|
|
|
251,940
|
former
V.P., Sales &
Marketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leo Pavliv
|
|
|
2006
|
|
|
192,500
|
|
|
42,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
234,500
|
V.P., Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
J. William Hix
|
|
|
2006
|
|
|
137,800
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
162,800
|
V.P., Sales & Marketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jean W. Marstiller
|
|
|
2006
|
|
|
135,160
|
|
|
40,000
|
|
|
|
|
|
15,180
|
|
|
|
|
|
|
|
|
190,340
|
Senior V.P. and Corporate Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David L. Lowrance
|
|
|
2006
|
|
|
126,500
|
|
|
28,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
155,000
|
V.P. and CFO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GRANTS OF
PLAN-BASED AWARDS TABLE
The following table sets forth information regarding grants of
compensatory awards we paid to our named executive officers
during the fiscal year ended December 31, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
All Other
|
|
|
|
|
|
|
|
|
Stock
|
|
Option
|
|
|
|
|
|
|
|
|
Awards:
|
|
Awards:
|
|
|
|
|
|
|
|
|
Number of
|
|
Number of
|
|
Exercise or
|
|
Grant Date
|
|
|
|
|
Shares of
|
|
Securities
|
|
Base Price
|
|
Fair Value
|
|
|
|
|
Stock or
|
|
Underlying
|
|
of Option
|
|
of Stock
|
|
|
|
|
Units
|
|
Options
|
|
Awards
|
|
and Option
|
Name
|
|
Grant
Date
|
|
(#)
|
|
(#)
|
|
($/Sh)
|
|
Awards
|
|
|
A.J. Kazimi
|
|
|
6/30/06
|
|
|
|
|
|
10,000
|
|
|
19.80
|
|
|
8.33
|
James D. Aderhold
|
|
|
6/30/06
|
|
|
|
|
|
6,500
|
|
|
18.00
|
|
|
11.04
|
Leo Pavliv
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
J. William Hix
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jean W. Marstiller
|
|
|
6/30/06
|
|
|
|
|
|
5,500
|
|
|
18.00
|
|
|
11.04
|
David L. Lowrance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Our executive compensation policies and practices, pursuant to
which the compensation set forth in the Summary Compensation
Table and the Grants of Plan-Based Awards Table was paid or
awarded, are described above under, Compensation
Discussion and Analysis. A summary of certain material
terms of our compensation plans and arrangements is set forth
above under Compensation Discussion and
AnalysisEmployment Agreements, Severance Benefits and
Change in Control Provisions.
71
Compensation
OUTSTANDING
EQUITY AWARDS TABLE
The following table sets forth information regarding unvested
stock and unexercised option awards held by our named executive
officers as of December 31, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
Market or
|
|
|
Option
Awards
|
|
|
|
|
|
Awards:
|
|
Payout
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
Number of
|
|
Value of
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
Market
|
|
Unearned
|
|
Unearned
|
|
|
|
|
|
|
Plan
|
|
|
|
|
|
Number
|
|
Value of
|
|
Shares,
|
|
Shares,
|
|
|
|
|
|
|
Awards:
|
|
|
|
|
|
of Shares
|
|
Shares or
|
|
Units or
|
|
Units or
|
|
|
Number of
|
|
Number of
|
|
Number of
|
|
|
|
|
|
or Units
|
|
Units of
|
|
Other
|
|
Other
|
|
|
Securities
|
|
Securities
|
|
Securities
|
|
|
|
|
|
of Stock
|
|
Stock
|
|
Rights
|
|
Rights
|
|
|
Underlying
|
|
Underlying
|
|
Underlying
|
|
|
|
|
|
That
|
|
That
|
|
That
|
|
That
|
|
|
Unexercised
|
|
Unexercised
|
|
Unexercised
|
|
Option
|
|
Option
|
|
Have
|
|
Have
|
|
Have
|
|
Have
|
|
|
Options(#)
|
|
Options(#)
|
|
Unearned
|
|
Exercise
|
|
Expiration
|
|
Not
|
|
Not
|
|
Not
|
|
Not
|
Name
|
|
Exercisable
|
|
Unexercisable
|
|
Options(#)
|
|
Price($)
|
|
Date
|
|
Vested(#)
|
|
Vested($)
|
|
Vested(#)
|
|
Vested($)
|
|
A.J.
Kazimi(1)
|
|
|
292,500
|
|
|
|
|
|
|
|
|
0.22
|
|
|
01/23/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,048,545
|
|
|
|
|
|
|
|
|
1.10
|
|
|
09/15/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,465
|
|
|
|
|
|
|
|
|
3.25
|
|
|
12/18/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,154
|
|
|
|
|
|
|
|
|
3.58
|
|
|
01/04/07
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000
|
|
|
|
|
|
|
|
|
7.70
|
|
|
01/31/08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,700
|
|
|
|
|
|
|
|
|
13.20
|
|
|
04/01/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,900
|
|
|
10,600
|
|
|
|
|
|
13.20
|
|
|
01/15/10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500
|
|
|
7,500
|
|
|
|
|
|
19.80
|
|
|
06/30/11
|
|
|
|
|
|
|
|
|
|
|
|
|
James D.
Aderhold(2)
|
|
|
5,000
|
|
|
|
|
|
|
|
|
1.00
|
|
|
12/27/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
186,300
|
|
|
|
|
|
|
|
|
3.25
|
|
|
01/08/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,505
|
|
|
|
|
|
|
|
|
3.25
|
|
|
12/18/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,650
|
|
|
|
|
|
|
|
|
3.25
|
|
|
01/04/12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,400
|
|
|
|
|
|
|
|
|
7.00
|
|
|
01/31/13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
525
|
|
|
|
|
|
|
|
|
12.00
|
|
|
04/01/14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,000
|
|
|
4,000
|
|
|
|
|
|
12.00
|
|
|
01/15/15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,625
|
|
|
4,875
|
|
|
|
|
|
18.00
|
|
|
06/30/16
|
|
|
|
|
|
|
|
|
|
|
|
|
Leo
Pavliv(3)
|
|
|
2,500
|
|
|
|
|
|
|
|
|
1.00
|
|
|
12/27/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,000
|
|
|
|
|
|
|
|
|
1.85
|
|
|
05/15/10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,500
|
|
|
|
|
|
|
|
|
3.25
|
|
|
09/30/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
|
|
|
|
|
|
|
|
7.00
|
|
|
04/14/13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
|
|
|
12.00
|
|
|
01/15/15
|
|
|
|
|
|
|
|
|
|
|
|
|
J. William
Hix(4)
|
|
|
29,000
|
|
|
|
|
|
|
|
|
12.00
|
|
|
05/03/14
|
|
|
|
|
|
|
|
|
|
|
|
|
Jean W.
Marstiller(5)
|
|
|
72,840
|
|
|
|
|
|
|
|
|
0.20
|
|
|
01/23/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
140,000
|
|
|
|
|
|
|
|
|
1.00
|
|
|
09/15/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,615
|
|
|
|
|
|
|
|
|
3.25
|
|
|
01/04/12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200
|
|
|
|
|
|
|
|
|
7.00
|
|
|
01/31/13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
|
|
|
|
|
|
|
|
12.00
|
|
|
04/01/14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,500
|
|
|
3,000
|
|
|
|
|
|
12.00
|
|
|
01/15/15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,375
|
|
|
4,125
|
|
|
|
|
|
18.00
|
|
|
06/30/16
|
|
|
|
|
|
|
|
|
|
|
|
|
David L.
Lowrance(6)
|
|
|
45,000
|
|
|
|
|
|
|
|
|
7.00
|
|
|
01/30/13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000
|
|
|
|
|
|
|
|
|
12.00
|
|
|
04/01/14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,500
|
|
|
|
|
|
12.00
|
|
|
01/15/15
|
|
|
|
|
|
|
|
|
|
|
|
|
72
Compensation
|
|
|
(1)
|
|
A.J. Kazimi:
292,500 Options granted on January 23, 1999; vested
immediately.
2,048,545 Option granted on September 15, 1999; vested 20%
equally each December 31 over 5 year period
1999-2003.
3,465 Options granted on December 18, 2001; vested
immediately.
6,154 Options granted on January 4, 2002; vested
immediately.
3,000 Options granted on January 31, 2003; vested
December 31, 2003.
1,700 Options granted on April 1, 2004; vested
immediately.
26,500 Options granted on January 15, 2005; 5,300 options
or 20% vested immediately; 20% more vested each
December 31, 2005 and 2006; the remaining options will vest
equally each December 31, 2007 and 2008.
10,000 Options granted on June 30, 2006; 25% vested on
December 31, 2006; the remainder of options vest 25%
equally each December 31, 2007, 2008, 2009.
|
|
(2)
|
|
James D. Aderhold:
5,000 Options granted on December 27, 1999; vested on
December 31, 2000.
186,300 Options granted on January 8, 2001; 36,300 vested
immediately; 50,000 options vested each December 31, 2001,
2002, 2003.
4,505 Options granted on December 18, 2001; vested
immediately.
9,650 Options granted on January 4, 2002; vested
immediately.
1,400 Options granted on January 31, 2003; vested
immediately.
525 Options granted on April 1, 2004; vested
immediately.
10,000 Options granted on January 15, 2005; 2,000 options
vested immediately; 2,000 options vested each December 31,
2005 and 2006; 2,000 options will vest each December 31,
2007 and 2008.
6,500 Options granted on June 30, 2006; 25% or 1,625
options vested on December 31, 2006. The remaining options
vest 1,625 each December 31, 2007, 2008 and 2009.
|
|
(3)
|
|
Leo Pavliv:
2,500 Options granted on December 27, 1999; vested
immediately.
9,000 Options granted on May 15, 2000; vested
immediately.
1,500 Options granted on September 30, 2001; vested
immediately.
80,000 Options granted on April 14, 2003; 25% vested each
December 31 over the 4 year period
2003-2006.
20,000 Options granted on January 15, 2005; all options
will vest on December 31, 2009.
|
|
(4)
|
|
J. William Hix:
29,000 Options granted on May 3, 2004; 5,000 vested
immediately; 8,000 options vested each December 31 2004,
2005, 2006.
|
|
(5)
|
|
Jean W. Marstiller:
72,840 Options granted on January 23, 1999; vested
immediately.
140,000 Options granted on September 15, 1999; 25,000
vested immediately; 23,000 vested each December 31,
1999-2003.
4,615 Options granted on January 4, 2002; vested
immediately.
200 Options granted on January 31, 2003; vested
immediately.
5,000 Options granted on April 1, 2004; vested
immediately.
7,500 Options granted on January 15, 2005; 1,500 vested
immediately; 1,500 vested each December 31, 2005 and 2006;
1,500 will vest each December 31, 2007 and 2008.
5,500 Options granted on June 30, 2006; 1,375 vested
December 31, 2006; 1,375 will vest each December 31,
2007, 2008, 2009.
|
|
(6)
|
|
David L. Lowrance:
45,000 Options granted on January 30, 2003; 5,000 vested
immediately; 10,000 options vested each December 31,
2003-2006.
2,000 Options granted on April 1, 2004; vested
immediately.
12,500 Options granted on January 15, 2005; all options
will vest on December 31, 2009.
|
73
Compensation
OPTION EXERCISES
AND STOCK VESTED
The following table sets forth information regarding the
exercise and vesting of stock and option awards held by our
named executive officers during the fiscal year ended
December 31, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option
Awards
|
|
Stock
Awards
|
|
|
Number of
|
|
|
|
Number of
|
|
|
|
|
Shares
Acquired
|
|
Value Realized
|
|
Shares
Acquired
|
|
Value Realized
|
Name
|
|
on
Exercise(#)
|
|
on
Exercise($)
|
|
on
Vesting(#)
|
|
on
Vesting($)
|
|
|
A.J. Kazimi
|
|
|
6,154
|
|
|
113,357
|
|
|
|
|
|
|
James D. Aderhold
|
|
|
5,000
|
|
|
105,000
|
|
|
|
|
|
|
Leo Pavliv
|
|
|
|
|
|
|
|
|
|
|
|
|
J. William Hix
|
|
|
|
|
|
|
|
|
|
|
|
|
Jean W. Marstiller
|
|
|
7,830
|
|
|
139,374
|
|
|
|
|
|
|
David L. Lowrance
|
|
|
|
|
|
|
|
|
|
|
|
|
PENSION BENEFITS
TABLE
We do not have any plan that provides for payments or other
benefits at, following, or in connection with retirement.
NONQUALIFIED
DEFERRED COMPENSATION TABLE
We do not have any plan that provides for the deferral of
compensation on a basis that is not tax qualified.
DIRECTOR
COMPENSATION TABLE
The following table sets forth information regarding the
aggregate compensation we paid to the members of our board of
directors during the fiscal year ended December 31, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
|
|
|
|
Fees
|
|
|
|
|
|
|
|
Value and
|
|
|
|
|
|
|
Earned
|
|
|
|
|
|
Non-Equity
|
|
Nonqualified
|
|
|
|
|
|
|
or Paid
|
|
Stock
|
|
Option
|
|
Incentive Plan
|
|
Deferred
|
|
All Other
|
|
|
|
|
in Cash
|
|
Awards
|
|
Awards
|
|
Compensation
|
|
Compensation
|
|
Compensation
|
|
Total
|
Name
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
Earnings
|
|
($)
|
|
($)
|
|
|
Martin E.
Cearnal(1)
|
|
|
2,500
|
|
|
24,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,500
|
Dr. Robert G.
Edwards(2)
|
|
|
26,500
|
|
|
24,000
|
|
|
|
|
|
|
|
|
|
|
|
128,420
|
|
|
178,920
|
Dr. Lawrence W.
Greer(3)
|
|
|
26,500
|
|
|
69,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95,500
|
Thomas R.
Lawrence(4)
|
|
|
26,500
|
|
|
54,000
|
|
|
|
|
|
|
|
|
|
|
|
16,500
|
|
|
97,000
|
|
|
|
(1)
|
|
For service as a director in 2006,
Mr. Cearnal received fees equal to $26,500, paid as
follows: $2,500 cash, and shares of our common stock valued at
$24,000. These amounts exclude options to purchase
2,000 shares of our common stock that vested in 2006.
|
|
(2)
|
|
For service as a director in 2006,
Dr. Edwards received fees equal to $50,500, paid as
follows: $26,500 cash, and shares of our common stock valued at
$24,000. For consulting services provided in 2006 Dr. Edwards
received other compensation of $128,420, paid as follows:
$20,420 cash, and shares of our common stock valued at $108,000.
|
|
(3)
|
|
For service as a director in 2006,
Dr. Greer received fees equal to $50,500, paid as follows:
$26,500 cash, and shares of our common stock valued at $24,000.
In addition, for service as chairman of the Audit Committee of
the board of directors, Dr. Greer received a fee equal to
$45,000 paid in shares of our common stock valued at $45,000.
|
|
|
|
(4)
|
|
For service as a director in 2006,
Mr. Lawrence received fees equal to $50,500, paid as
follows: $26,500 cash, and shares of our common stock valued at
$24,000. In addition, for service as chairman of the
Compensation Committee of the board of directors,
Mr. Lawrence received a fee of $30,000 cash. For consulting
services provided in 2006, Mr. Lawrence received other
compensation of $16,500, paid entirely in cash.
|
74
Compensation
Director
compensation
Compensation to each outside director for service on the board
of directors including board committee responsibilities for 2007
will consist of a total fee in the amount of $75,500. All fees
will be paid in a combination of cash and equity, as we and each
director shall agree. Cash fees will include $2,500 paid in the
first quarter of 2007 and the remainder accrued and paid on
either a monthly or quarterly basis. Directors will not receive
separate compensation for attendance at board meetings, board
committee meetings or other company related activities. In
addition, outside directors will be reimbursed for all
reasonable and necessary business expenses incurred in the
performance of their service on the board of directors.
As part of their director compensation for 2007, Martin E.
Cearnal and Dr. Lawrence W. Greer have elected to take
equity. Martin E. Cearnal will be granted 3,318 shares of
common stock and Dr. Lawrence W. Greer will be granted
2,200 shares of common stock.
Long-term equity incentive awards to our directors were made
pursuant to the 1999 Plan until April 2007, and
thereafter, pursuant to the 2007 Directors Compensation
Plan, or the Directors Plan.
The purposes of the Directors Plan are:
|
|
Ø
|
to strengthen our ability to attract, motivate, and retain
qualified independent directors; and
|
|
Ø
|
to replace the 1999 Plan without impairing the vesting or
exercise of any option granted to any director thereunder.
|
The Directors Plan authorizes the issuance to non-employee
directors of each of the following types of awards:
|
|
Ø
|
options (all options to be issued under the Directors Plan
will not meet IRS requirements for special tax treatment and
therefore are non-qualified options);
|
|
Ø
|
restricted stock grants (shares subject to various restrictions
and conditions as determined by our compensation committee); and
|
|
Ø
|
stock grants (award of shares or our common stock with full and
unrestricted ownership rights).
|
The compensation committee of our board of directors will
administer the Directors Plan, if it is adopted. In the
event of a change of control of our company (as defined in the
Directors Plan), all outstanding options would
automatically become exercisable in full, and restrictions and
conditions for other issued awards shall generally be deemed
terminated or satisfied. Our board of directors may amend or
terminate the Directors Plan, subject to shareholder
approval if necessary, to comply with tax or regulatory
requirements.
INDEMNIFICATION
OF DIRECTORS AND EXECUTIVE OFFICERS AND LIMITATION OF
LIABILITY
Our charter and bylaws provide for indemnification of our
directors to the fullest extent permitted by the Tennessee
Business Corporation Act, as amended from time to time. Our
directors shall not be liable to us or our shareholders for
monetary damages for breach of their fiduciary duty of care. The
Tennessee Business Corporation Act provides that a Tennessee
corporation may indemnify its directors and officers against
expenses, judgments, fines and amounts paid in settlement
actually and reasonably incurred by them in connection with any
proceeding, whether criminal or civil, administrative or
investigative if, in connection with the matter in issue, the
individuals conduct was in good faith, and the individual
reasonably believed: in the case of conduct in the
individuals official capacity with the corporation, that
the individuals conduct was in its best interest; and in
all other cases, that the individuals behavior was at
least not opposed to its best interest; and in the case of a
criminal
75
Compensation
proceeding, the individual had no reason to believe the
individuals conduct was unlawful. In addition, we have
entered into indemnification agreements with our directors.
These provisions and agreements may have the practical effect in
certain cases of eliminating the ability of our shareholders to
collect monetary damages from directors. We believe that these
contractual agreements and the provisions in our charter and
bylaws are necessary to attract and retain qualified persons as
directors.
DIRECTORS AND
OFFICERS INSURANCE
We maintain a directors and officers insurance
policy that provides coverage to our directors and officers
relating to certain potential liabilities. The directors
and officers insurance policy, provided by The Hartford
with a coverage amount of up to $3,000,000, covers
wrongful act or securities claims.
76
Certain
relationships and related party transactions
Other than compensation agreements and other arrangements which
are described in Compensation and the transactions
described below, since January 1, 2004, there has not been,
and there is not currently proposed, any transaction or series
of similar transactions to which we were or will be a party in
which the amount involved exceeded or will exceed $120,000 and
in which any related party, including any director, executive
officer, holder of five percent or more of any class of our
capital stock or any member of their immediate families had or
will have a direct or indirect material interest.
All of the transactions set forth below were approved by a
majority of the board of directors, including a majority of any
independent and disinterested members of the board of directors.
We believe that all of the transactions set forth below had
terms no less favorable to us than we could have obtained from
unaffiliated third parties. In connection with this offering, we
have adopted a written policy which requires all future
transactions between us and any related persons (as defined in
Item 404 of
Regulation S-K)
be approved in advance by our audit committee.
In September 2003, we borrowed $1,000,000 from S.C.O.U.T. in the
form of a convertible promissory note with a maturity date of
September 2004. The President and majority shareholder of the
general partner of S.C.O.U.T., Dr. Lawrence W. Greer,
serves on our board of directors. Pursuant to the terms of the
note, on its maturity date, S.C.O.U.T. converted the principal
value of the note plus all interest accrued at a fixed rate of
ten percent per annum into 91,667 shares of our common
stock at a price of $12.00 per share.
In April 2004, S.C.O.U.T. purchased 43,000 shares of our
common stock at a price of $12.00 per share and a five-year
warrant to purchase 20,000 of our common stock at an exercise
price of $12.00 per share.
Board members were granted a total of 12,409, 23,120 and
15,600 shares of common stock in 2006, 2005 and 2004,
respectively, for services rendered as directors and
consultants. The amounts recorded for such services were
$249,000, $277,000, and $187,000 in 2006, 2005 and 2004,
respectively. Additionally, two board members received a total
of 11,000 options with an exercise price of $18.00 per
share in 2005 and 16,780 options with an exercise price of
$12.00 per share in 2004. No options were issued to board
members in 2006.
In connection with this offering, we have adopted a written
policy, the Policy and Procedures with Respect to Related Person
Transactions. Our board of directors has determined that our
audit committee is best suited to review and approve all future
related person transactions. The Policy and Procedures with
Respect to Related Person Transactions covers a transaction,
arrangement, or relationship in which we or any of our
subsidiaries is or will be a participant and the amount involved
exceeds $120,000 per year, and in which any related person
has or will have a direct or indirect interest. The Policy and
Procedures with Respect to Related Person Transactions defines a
related person as:
|
|
Ø
|
any person who is, or at any time since the beginning of our
last fiscal year was, a director or executive officer of ours or
a nominee to become a director of ours;
|
|
Ø
|
any person who is known to be the beneficial owner of more than
5% of any class of our voting securities;
|
|
Ø
|
any immediate family member of any of the foregoing
persons; and
|
|
Ø
|
any firm, corporation or other entity in which any of the
foregoing persons is employed or is a partner or principal or in
a similar position or in which such person has a 5% or greater
beneficial ownership interest.
|
No member of our audit committee shall review or approve a
related person transaction in which he or an immediate family
member of his is the related person. The audit committee shall
approve only those related person transactions that are in, or
are not inconsistent with, the best interests of us and our
shareholders.
77
Principal
shareholders
The following table sets forth information known to us with
respect to beneficial ownership of shares of our common stock as
of February 28, 2007 by (i) each of our directors,
(ii) each of our named executive officers; (iii) all
of our directors and executive officers as a group; and
(iv) each person or group of affiliated persons known to us
to be the beneficial owner of 5% or more of our outstanding
common stock.
Beneficial ownership and percentage ownership are determined in
accordance with the rules of the SEC. This information does not
necessarily indicate beneficial ownership for any other purpose.
In computing the number of shares beneficially owned by a person
and the percentage ownership of that person, shares of common
stock underlying options or warrants held by that person that
are currently exercisable or will become exercisable within
60 days of February 28, 2007 are deemed outstanding
and are included in the number of shares beneficially owned,
while the shares are not deemed outstanding for purposes of
computing percentage ownership of any other person. To our
knowledge, except as indicated in the footnotes to this table
and subject to community property laws where applicable, the
persons named in the table have sole voting and investment power
with respect to all shares of our common stock shown as
beneficially owned by them.
As of February 28, 2007, there were 228 holders of
record of our common stock and 42 holders of record of preferred
stock, which will automatically be converted into common stock
at the completion of this offering. For purposes of calculating
amounts beneficially owned by a shareholder before the offering,
the number of shares deemed issued and outstanding was
4,938,845 shares of common stock as of February 28,
2007. The percentage of beneficial ownership after this offering
is based
on shares
of common stock. For purposes of calculating the percentage
beneficially owned after the offering, the number of shares
deemed outstanding includes all shares deemed to be outstanding
before the offering, all shares into which our outstanding
shares of preferred stock will be converted as a result of the
offering and all shares being sold in the offering.
Unless otherwise indicated, the address for each person listed
is c/o Cumberland Pharmaceuticals Inc., 2525 West End
Ave., Suite 950, Nashville, Tennessee 37203.
78
Principal
shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Percentage of
Shares
|
|
|
|
Shares
|
|
|
Beneficially
Owned
|
|
|
|
Beneficially
|
|
|
Before
|
|
|
After
|
|
Executive
officers and directors
|
|
Owned
|
|
|
Offering
|
|
|
Offering
|
|
|
|
|
A.J.
Kazimi(1)
|
|
|
3,647,317
|
|
|
|
49.92
|
%
|
|
|
|
|
Thomas R.
Lawrence(2)
|
|
|
122,288
|
|
|
|
2.47
|
%
|
|
|
|
|
Robert G.
Edwards(3)
|
|
|
220,473
|
|
|
|
4.37
|
%
|
|
|
|
|
Lawrence W.
Greer(4)
|
|
|
408,090
|
|
|
|
8.15
|
%
|
|
|
|
|
Martin E.
Cearnal(5)
|
|
|
61,801
|
|
|
|
1.25
|
%
|
|
|
|
|
James D. Aderhold,
Jr.(6)
|
|
|
223,809
|
|
|
|
4.34
|
%
|
|
|
|
|
Leo
Pavliv(7)
|
|
|
93,000
|
|
|
|
1.85
|
%
|
|
|
|
|
Jean W.
Marstiller(8)
|
|
|
317,273
|
|
|
|
6.14
|
%
|
|
|
|
|
Gordon R.
Bernard(9)
|
|
|
56,592
|
|
|
|
1.15
|
%
|
|
|
|
|
David L.
Lowrance(10)
|
|
|
47,000
|
|
|
|
*
|
|
|
|
|
|
J. William
Hix(11)
|
|
|
29,000
|
|
|
|
*
|
|
|
|
|
|
Directors and executive officers
as a group (11 persons)
|
|
|
4,878,459
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5%
Shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
Douglas J.
Marchant(12)
|
|
|
350,000
|
|
|
|
7.09
|
%
|
|
|
|
|
Mr. and Mrs. J. Kenneth
Hazen(13)(14)
|
|
|
300,000
|
|
|
|
6.07
|
%
|
|
|
|
|
S.C.O.U.T. Healthcare Fund,
L.P.(15)(16)
|
|
|
348,184
|
|
|
|
7.05
|
%
|
|
|
|
|
|
|
|
*
|
|
Less than 1.0% of the outstanding
common stock.
|
|
|
|
(1)
|
|
Includes 2,367,610 shares that
Mr. Kazimi has the right to acquire upon the exercise of
outstanding stock options.
|
|
(2)
|
|
Includes 19,233 shares
Mr. Lawrence has the right to acquire upon exercise of
outstanding stock options.
|
|
(3)
|
|
Includes 107,904 shares
Dr. Edwards has the right to acquire upon exercise of
outstanding stock options.
|
|
(4)
|
|
Includes
(i) 306,624 shares owned of record by S.C.O.U.T., a
limited partnership with respect to which Dr. Greer is the
President and majority Shareholder of the general partner,
(ii) 21,560 shares S.C.O.U.T. has the right to acquire
upon exercise of outstanding stock options,
(iii) 20,000 shares S.C.O.U.T. has the right to
acquire immediately from us pursuant to a warrant, and
(iv) 26,000 shares Dr. Greer has the right to
acquire immediately upon exercise of outstanding stock options.
|
|
(5)
|
|
Includes
(i) 11,700 shares Mr. Cearnal has the right to
acquire upon exercise of outstanding stock options and
(ii) 7,700 shares Mr. Cearnal will receive upon
conversion of his preferred stock.
|
|
(6)
|
|
Includes 215,005 shares
Mr. Aderhold has the right to acquire upon exercise of
outstanding stock options.
|
|
(7)
|
|
Includes 93,000 shares
Mr. Pavliv has the right to acquire upon exercise of
outstanding stock options.
|
|
(8)
|
|
Includes 228,530 shares
Ms. Marstiller has the right to acquire upon exercise of
outstanding stock options.
|
|
(9)
|
|
Includes 2,308 shares
Dr. Bernard has the right to acquire upon exercise of
outstanding stock options.
|
|
(10)
|
|
Includes 47,000 shares
Mr. Lowrance has the right to acquire upon exercise of
outstanding stock options.
|
|
(11)
|
|
Includes 29,000 shares
Mr. Hix has the right to acquire upon exercise of
outstanding stock options.
|
|
(12)
|
|
The address for Mr. Marchant
is 60 Germantown Court, Suite 220, Cordova, Tennessee,
38018.
|
|
(13)
|
|
The address for Mr. and
Mrs. J. Kenneth Hazen is 260 St. Andrews Fairway, Memphis,
Tennessee, 38111.
|
|
(14)
|
|
The number of shares reflected
above as beneficially held by Mr. and Mrs. J. Kenneth
Hazen are held jointly.
|
|
(15)
|
|
Includes
(i) 21,560 shares S.C.O.U.T. has the right to acquire
upon exercise of outstanding stock options, and
(ii) 20,000 shares S.C.O.U.T. has the right to acquire
immediately from us pursuant to a warrant.
|
|
(16)
|
|
The address for S.C.O.U.T. is 2200
Woodcrest Place, Suite 309, Birmingham, Alabama, 35209.
|
79
Description of
capital stock
GENERAL
Our authorized capital stock consists of one hundred million
shares of common stock, no par value, three million shares of
Series A preferred stock, no par value, and twenty million
shares of undesignated preferred stock, no par value.
COMMON
STOCK
As
of , shares
of common stock were issued and outstanding (which does not
include shares of
common stock issuable upon exercise of outstanding stock options
issued pursuant to our 1999 Plan or other options or warrants to
purchase common stock, and which does not
include shares of
common stock issuable upon conversion of all outstanding shares
of our preferred stock). We plan to issue additional stock
options to our directors, employees and consultants, and we may
issue shares of common stock to sellers of rights to certain
pharmaceutical products. Giving effect to the sale
of shares
offered hereby and the conversion of all outstanding shares of
our preferred stock, there would
be shares
of common stock outstanding following this offering.
The holders of shares of common stock are entitled to one vote
per share on any matter that comes before the shareholders.
Cumulative voting is not authorized. Holders of shares of common
stock do not have preemptive rights to purchase securities that
we may subsequently issue. Subject to preferences that may be
applicable to any outstanding preferred stock, the holders of
common stock are entitled to receive such dividends as may be
declared by our board of directors out of funds legally
available for payment as dividends. However, we do not
anticipate paying any dividends in the foreseeable future to
holders of our common stock. In the event of a liquidation,
dissolution, or winding up of our affairs, the holders of
outstanding shares will be entitled to share pro rata according
to their respective interests in our assets and funds remaining
after payment of all of our debts and other liabilities and the
liquidation preference of any outstanding preferred stock. All
of the shares of common stock currently outstanding are fully
paid and nonassessable.
PREFERRED
STOCK
Our board of directors is authorized, without approval of our
shareholders, to provide for the issuance of shares of preferred
stock in one or more series, to establish the number of shares
in each series, and to fix the designations, powers,
preferences, and rights of each such series and the
qualifications, limitations, or restrictions. Among the specific
matters that may be determined by our board are:
|
|
Ø
|
the designation of each series;
|
|
Ø
|
the number of shares of each series;
|
|
Ø
|
the rights in respect of dividends, if any;
|
|
Ø
|
whether dividends, if any, shall be cumulative or non-cumulative;
|
|
Ø
|
the terms of redemption, repurchase obligation or sinking fund,
if any;
|
|
Ø
|
the rights in the event of any voluntary or involuntary
liquidation, dissolution or winding up of our affairs;
|
|
Ø
|
rights and terms of conversion, if any;
|
|
Ø
|
restrictions on the creation of indebtedness, if any;
|
|
Ø
|
restrictions on the issuance of additional preferred stock or
other capital stock, if any;
|
80
Description of
capital stock
|
|
Ø
|
restrictions on the payment of dividends on shares ranking
junior to the preferred stock; and
|
|
Ø
|
voting rights, if any.
|
Upon completion of this offering, no shares of preferred stock
will be outstanding and we have no current plans to issue
preferred stock. The issuance of shares of preferred stock, or
the issuance of rights to purchase preferred stock, could be
used to discourage an unsolicited acquisition proposal. For
example, a business combination could be impeded by the issuance
of a series of preferred stock containing class voting rights
that would enable the holder or holders of such series to block
any such transaction. Alternatively, a business combination
could be facilitated by the issuance of a series of preferred
stock having sufficient voting rights to provide a required
percentage vote of our shareholders. In addition, under some
circumstances, the issuance of preferred stock could adversely
affect the voting power and other rights of the holders of
common stock. Although prior to issuing any series of preferred
stock our board is required to make a determination as to
whether the issuance is in the best interests of our
shareholders, our board could act in a manner that would
discourage an acquisition attempt or other transaction that
some, or a majority, of our shareholders might believe to be in
their best interests or in which our shareholders might receive
a premium for their stock over prevailing market prices of such
stock. Our board of directors does not at present intend to seek
shareholder approval prior to any issuance of currently
authorized preferred stock, unless otherwise required by law or
applicable stock exchange requirements.
OUTSTANDING
OPTIONS AND WARRANTS
As
of ,
in addition to outstanding options to
acquire shares of
common stock issued pursuant to our 1999 Plan, we have issued
options to
purchase shares
of our common stock in connection with two debt financing rounds
in 2001 and 2003. These options have ten-year terms with
exercise prices of $ and
$ per share, respectively.
Total options outstanding as
of
have an average exercise price of
$ per share. We have also
issued warrants to purchase 32,500 shares of our common
stock at a price of $12.00 per share to Bank of America and
to S.C.O.U.T., a consulting and investment company in which
Dr. Lawrence W. Greer, one of our directors, is a
principal, and warrants to purchase 1,979 shares of our
common stock at a price of $18.00 per share to Bank of
America.
ANTI-TAKEOVER
EFFECTS OF TENNESSEE LAW AND PROVISIONS OF OUR CHARTER AND
BYLAWS
The Tennessee Business Combination Act, the Tennessee Investor
Protection Act, the Tennessee Greenmail Act and the Tennessee
Control Share Acquisition Act provide certain anti-takeover
protections for Tennessee corporations.
The Tennessee
Business Combination Act
The Tennessee Business Combination Act, or TBCA, governs all
Tennessee corporations. It imposes a five-year standstill on
transactions such as mergers, share exchanges, sales of assets,
liquidations and other interested party transactions between
Tennessee corporations and interested shareholders
and their associates or affiliates, unless the business
combination is approved by the board of directors before the
interested shareholder goes above the 10% ownership threshold.
Thereafter, the transaction either requires a two-thirds vote of
the shareholders other than the interested shareholder or
satisfaction of certain fair price standards.
The TBCA also provides for additional exculpatory protection for
the board of directors in resisting mergers, exchanges and
tender offers if a Tennessee corporations charter
specifically opts-in to such
81
Description of
capital stock
provisions. A Tennessee corporations charter may
specifically authorize the members of a board of directors, in
the exercise of their judgment, to give due consideration to
factors other than price and to consider whether a merger,
exchange, tender offer or significant disposition of assets
would adversely affect the corporations employees,
customers, suppliers, the communities in which the corporation
operates, or any other relevant factor in the exercise of their
fiduciary duty to the shareholders.
Our charter expressly opts-in and provides for exculpation of
the board of directors to the full extent permitted under the
TBCA. The opt-in will have the effect of protecting us from
unwanted takeover bids, because the board of directors is
permitted by the charter to take into account all relevant
factors in performing its duly authorized duties and acting in
good faith and in our best interests.
The Tennessee
Investor Protection Act
The Tennessee Investor Protection Act, or TIPA, generally
requires the registration, or an exemption from registration,
before a person can make a tender offer for shares of a
Tennessee corporation which, if successful, will result in the
offeror beneficially owning more than 10% of any class of
shares. Registration requires the filing with the Tennessee
Commissioner of Commerce and Insurance of a registration
statement, a copy of which must be sent to the target company,
and the public disclosure of the material terms of the proposed
offer. Additional requirements are imposed under that act if the
offeror beneficially owns 5% or more of any class of equity
securities of the target company, any of which was purchased
within one year prior to the proposed takeover offer. TIPA also
prohibits fraudulent and deceptive practices in connection with
takeover offers, and provides remedies for violations.
TIPA does not apply to an offer involving a vote by holders of
equity securities of the offeree company, pursuant to its
charter, on a share exchange, consolidation or sale of corporate
assets in consideration of the issuance of securities of another
corporation, or on a sale of its securities in exchange for cash
or securities of another corporation. Also exempt from TIPA are
tender offers which are open on substantially equal terms to all
shareholders, are recommended by the board of directors of the
target company, and include full disclosure of all terms.
The Tennessee
Greenmail Act
The Tennessee Greenmail act, or TGA, prohibits us from
purchasing or agreeing to purchase any of our securities, at a
price higher than fair market value, from a holder of 3% or more
of any class of its securities who has beneficially owned the
securities for less than two years. We can, however, make this
purchase if the majority of the outstanding shares of each class
of voting stock issued by us approves the purchase or if we make
an offer of at least equal value per share to all holders of
shares of the same class of securities as those held by the
prospective seller.
The Tennessee
Control Share Acquisition Act
Sections 48-103-301
through
48-103-312
of the Tennessee Control Share Acquisition Act, or TCSA, limit
the voting rights of shares owned by a person above certain
percentage thresholds, unless the non-interested shareholders of
the corporation approve the acquisition above the designated
threshold. However, the TCSA only applies to corporations whose
charter or bylaws contain an express declaration that control
share acquisitions are to be governed by the TCSA. In addition,
the charter or bylaws must specifically provide for the
redemption of control shares or appraisal rights for dissenting
shareholders in a control share transaction.
Our charter makes all of the express declarations necessary to
avail us of the full protection under the TCSA. The provisions
described above will have the general effect of discouraging, or
rendering more
82
Description of
capital stock
difficult, unfriendly takeover or acquisition attempts.
Consequently, such provisions would be beneficial to current
management in an unfriendly takeover attempt but could have an
adverse effect on shareholders who might wish to participate in
such a transaction. However, management believes that such
provisions are advantageous to shareholders in that they will
permit management and the shareholders to carefully consider and
understand a proposed acquisition and may require a higher level
of shareholder participation in the decision.
Pursuant to
Section 48-103-308
of the TCSA, we, at our option, may redeem from an acquiring
person all, but not less than all, control shares acquired in a
control share acquisition, at any time during the period ending
60 days after the last acquisition of control shares by
that person, for the fair value of those shares, if (1) no
control acquisition statement has been filed, or (2) a
control acquisition statement has been filed and the shares are
not accorded voting rights by the shareholders of this
corporation pursuant to
Section 48-103-307.
For these purposes, fair value shall be determined as of the
effective date of the vote of the shareholders denying voting
rights to the acquiring person, if a control acquisition
statement is filed, or if no control acquisition statement is
filed, as of the date of the last acquisition of control shares
by the acquiring person in a control share acquisition.
Pursuant to
Section 48-103-309
of the TCSA, if control shares acquired in a control share
acquisition are accorded voting rights and the acquiring person
has acquired control shares that confer upon that person a
majority or more of all voting power entitled to vote generally
with respect to the election of directors, all this
corporations shareholders of record, other than the
acquiring person, who have not voted in favor of granting those
voting rights to the acquiring person shall be entitled to an
appraisal of the fair market value of their shares in accordance
with Chapter 23 of the Tennessee Business Corporation Act.
Our corporate documents contain provisions that may enable our
board of directors to resist a change in control of our company
even if a change in control were to be considered favorable by
you and other shareholders. These provisions include:
|
|
Ø
|
the authorization of undesignated preferred stock, the terms of
which may be established and shares of which may be issued
without shareholder approval;
|
|
Ø
|
advance notice procedures required for shareholders to nominate
candidates for election as directors or to bring matters before
an annual meeting of shareholders;
|
|
Ø
|
limitations on persons authorized to call a special meeting of
shareholders;
|
|
Ø
|
a staggered board of directors;
|
|
Ø
|
a requirement that vacancies in directorships are to be filled
by a majority of the directors then in office and the number of
directors is to be fixed by the board of directors; and
|
|
Ø
|
no cumulative voting.
|
These and other provisions contained in our second amended and
restated charter and bylaws could delay or discourage
transactions involving an actual or potential change in control
of us or our management, including transactions in which our
shareholders might otherwise receive a premium for their shares
over then current prices, and may limit the ability of
shareholders to remove our current management or approve
transactions that our shareholders may deem to be in their best
interests and, therefore, could adversely affect the price of
our common stock.
83
Description of
capital stock
TRANSFER AGENT
AND REGISTRAR
The transfer agent and registrar for our common stock is Mellon
Investor Services.
NASDAQ GLOBAL
MARKET LISTING
We have applied for our common stock to be quoted on The Nasdaq
Global Market under the trading symbol CPIX.
84
Shares eligible for
future sale
Immediately prior to this offering, there was no public market
for our common stock. Future sales of substantial amounts of
common stock in the public market, or the perception that such
sales may occur, could adversely affect the market price of our
common stock and could impair our ability to raise capital in
the future through the sale of our securities. Although we have
applied to have our common stock approved for quotation on The
Nasdaq Global Market, we cannot assure you that there will be an
active public market for our common stock.
Upon completion of this offering, we will have outstanding an
aggregate
of shares
of common stock, assuming the issuance
of shares
of common stock offered in our initial public offering,
conversion of our outstanding shares of preferred stock and no
exercise of options after December 31, 2006. Of these
shares, the shares sold in this offering will be freely tradable
without restriction or further registration under the Securities
Act, except for any shares purchased by our
affiliates, as that term is defined in Rule 144
under the Securities Act, whose sales would be subject to
certain limitations and restrictions described below. See
Lock-Up
Agreements. Persons who may be deemed affiliates generally
include individuals or entities that control, are controlled by
or are under common control with us and may include our
officers, directors and significant shareholders.
The remaining shares of
common stock held by existing shareholders were issued and sold
by us in reliance on exemptions from the registration
requirements of the Securities Act. Of these shares,
shares
will be subject to
lock-up
agreements described below on the effective date of this
offering. Upon expiration of the
lock-up
agreements 180 days after the effective date of this
offering, shares will become eligible for sale, subject in most
cases to the limitations of Rule 144. In addition, holders
of stock options could exercise such options and sell certain of
the shares issued upon exercise as described below. See
Lock-Up
Agreements.
|
|
|
|
|
Days after date
of
|
|
Shares
eligible
|
|
|
this
prospectus
|
|
for
sale
|
|
Comment
|
|
|
Upon effectiveness
|
|
|
|
Shares sold in the offering
|
Upon effectiveness
|
|
|
|
Freely tradable shares saleable
under Rule 144(k) that are not subject to the
lock-up
|
90 Days
|
|
|
|
Shares saleable under
Rules 144 and 701 that are not subject to a
lock-up
|
180 Days
|
|
|
|
Lock-up
released; shares saleable under Rules 144 and 701
|
Thereafter
|
|
|
|
Restricted securities held for one
year or less
|
EMPLOYEE BENEFIT
PLANS
As of December 31, 2006, there were a total
of shares
of common stock subject to outstanding options under our 1999
Option Plan,
approximately of
which were vested and exercisable.
Immediately after the completion of this offering, we intend to
file registration statements on
Form S-8
under the Securities Act to register all of the shares of common
stock issued or reserved for future issuance under the 1999
Option Plan and the 2007 Long-Term Incentive Compensation Plan.
On the date which is 180 days after the effective date of
this offering, a total of
approximately shares of
common stock subject to outstanding options will be vested and
exercisable. After the effective dates of the registration
statements on
Form S-8,
shares purchased under the 1999 Option Plan and the 2007
Long-Term Incentive Compensation Plan generally would be
available for resale in the public market.
85
Shares eligible
for future sale
LOCK-UP
AGREEMENTS
We, all of our directors and executive officers and their
affiliates, and holders
of shares
of our outstanding stock have agreed that, without the prior
written consent of UBS Securities LLC, we and they will not
directly or indirectly, sell, offer, contract or grant any
option to sell (including without limitation any short sale),
pledge, transfer, establish an open put equivalent
position or liquidate or decrease a call equivalent
position or otherwise dispose of or transfer (or enter
into any transaction which is designed to, or might reasonably
be expected to, result in the disposition of), including the
filing (or participation in the filing) of a registration
statement with the SEC in respect of, any shares of common
stock, options or warrants to acquire shares of common stock, or
securities exchangeable or exercisable for or convertible into
shares of common stock currently or hereafter owned either of
record or beneficially by such persons (except for the
S-8 filings
referred to in the previous paragraph), or publicly announce an
intention to do any of the foregoing, for a period commencing on
the date hereof and continuing through the close of trading on
the date 180 days after the date of this prospectus, other
than permitted transfers described below. In addition, we and
they agree that, without the prior written consent of UBS
Securities LLC, we and they will not, during such period, make
any demand for or exercise any right with respect to, the
registration of any shares of common stock or any security
convertible into or exercisable or exchangeable for common stock.
The 180-day
restricted period described in the preceding two paragraphs will
be extended if:
|
|
Ø
|
during the last 17 days of the
180-day
restricted period we issue an earnings release or announce
material news or a material event relating to us occurs; or
|
|
Ø
|
prior to the expiration of the
180-day
restricted period, we announce that we will release earnings
results during the
16-day
period beginning on the last day of the
180-day
period,
|
in which case the restrictions described in the preceding two
paragraphs will continue to apply until the expiration of the
18-day
period beginning on the issuance of the earnings release, the
announcement of material news or the occurrence of a material
event.
UBS Securities LLC, in its sole discretion, may release the
common stock and other securities subject to the
lock-up
agreements described above in whole or in part at any time with
or without notice. When determining whether or not to release
common stock and other securities from
lock-up
agreements, UBS Securities LLC will consider, among other
factors, the holders reasons for requesting the release,
the number of shares of common stock and other securities for
which the release is being requested and market conditions at
the time.
RULE 144
In general, under Rule 144 as currently in effect,
beginning 90 days after the date of this prospectus, a
person who has beneficially owned shares of our common stock for
at least one year, including an affiliate, would be entitled to
sell in brokers transactions or to market
makers, within any three-month period, a number of shares that
does not exceed the greater of:
|
|
Ø
|
1% of the number of shares of our common stock then outstanding,
which will equal
approximately shares
immediately after this offering; or
|
|
Ø
|
the average weekly trading volume in our common stock on The
Nasdaq Global Market during the four calendar weeks preceding
the filing of a notice on Form 144 with respect to such
sale.
|
Sales under Rule 144 are generally subject to the
availability of current public information about us.
86
Shares eligible
for future sale
RULE 144(K)
Under Rule 144(k), a person who is not deemed to have been
an affiliate of ours at any time during the three months
preceding a sale, and who has beneficially owned the shares
proposed to be sold for at least two years, is entitled to sell
such shares without having to comply with the manner of sale,
public information, volume limitation or notice filing
provisions of Rule 144. Therefore, unless otherwise
restricted, 144(k) shares may be sold immediately
upon the completion of this offering.
RULE 701
In general, under Rule 701, any of our employees,
directors, officers, consultants or advisors who purchases
shares from us in connection with a compensatory stock or option
plan or other written agreement before the effective date of
this offering is entitled to sell such shares 90 days after
the effective date of this offering in reliance on
Rule 144, without having to comply with the holding period
and notice filing requirements of Rule 144 and, in the case
of non-affiliates, without having to comply with the public
information, volume limitation or notice filing provisions of
Rule 144.
The SEC has indicated that Rule 701 will apply to typical
stock options granted by an issuer before it becomes subject to
the reporting requirements of the Securities Exchange Act of
1934, as amended, along with the shares acquired upon exercise
of such options, including exercises after the date of this
prospectus.
87
Material
U.S. federal income and estate tax consequences to
non-U.S. holders
GENERAL
The following is a general summary of the material
U.S. federal income and estate tax consequences of the
ownership and disposition of our common stock that may be
relevant to a
non-U.S. holder
(as defined below). The summary is based on provisions of the
Internal Revenue Code of 1986, as amended, U.S. Treasury
regulations promulgated thereunder, rulings and pronouncements
of the Internal Revenue Service, or IRS, and judicial decisions,
all as in effect on the date of this prospectus and all of which
are subject to change (possibly on a retroactive basis) or to
differing interpretations. We have not sought, and will not
seek, any ruling from the IRS with respect to the tax
consequences discussed in this prospectus, and there can be no
assurance that the IRS will not take a position contrary to the
tax discussion below or that any such position would not be
sustained.
This summary is limited to
non-U.S. holders
that purchase our common stock issued pursuant to this offering
and that hold our common stock as a capital asset, which
generally is property held for investment. This summary also
does not address the tax considerations arising under the laws
of any foreign, state or local jurisdiction, or under
U.S. federal estate or gift tax laws except as specifically
described below. In addition, this summary does not address tax
considerations that may be applicable to a
non-U.S. holder
in light of its particular circumstances or to
non-U.S. holders
that may be subject to special tax rules, including, without
limitation:
|
|
Ø
|
banks, insurance companies or other financial institutions;
|
|
Ø
|
partnerships or other pass through entities;
|
|
Ø
|
U.S. expatriates;
|
|
Ø
|
tax-exempt organizations;
|
|
Ø
|
tax-qualified retirement plans;
|
|
Ø
|
dealers in securities or currencies;
|
|
Ø
|
traders in securities that elect to use a
mark-to-market
method of accounting for their securities holdings; or
|
|
Ø
|
persons that will hold common stock as a position in a hedging
transaction, straddle or conversion
transaction for tax purposes.
|
For purposes of this summary, the term
non-U.S. holder
means a beneficial owner of our common stock that is not, for
U.S. federal income tax purposes:
|
|
Ø
|
an individual citizen or resident of the U.S.;
|
|
Ø
|
a corporation, or other entity treated as a corporation for
U.S. federal income tax purposes, that is created or
organized under the laws of the United States or any political
subdivision of the United States;
|
|
Ø
|
an estate whose income, regardless of its source, is includible
in gross income for U.S. federal income tax purposes;
|
|
Ø
|
a trust (1) if a U.S. court is able to exercise
primary supervision over the administration of the trust and one
or more U.S. persons have the authority to control all
substantial decisions regarding the trust, or (2) that has
in effect a valid election to be treated as a U.S. person;
or
|
|
Ø
|
a partnership, or other entity treated as a partnership for
U.S. federal income tax purposes.
|
88
Material
U.S. federal income and estate tax consequences to
non-U.S. holders
If a partnership or other entity classified as such for
U.S. federal income tax purposes holds shares of our common
stock, the tax treatment of a partner or owner will generally
depend on the status of the partner or owner and the activities
of the partnership or other entity. It is advised that
partnerships (and other entities classified as such for
U.S. federal income tax purposes) owning shares of our
common stock, and holders of interests in such entities, consult
their tax advisors.
Any
non-U.S. holder
of our common stock should consult their tax advisor regarding
the tax consequences of purchasing, holding, and disposing of
these shares of stock.
DIVIDENDS
As previously discussed, we do not anticipate paying dividends
on our common stock in the foreseeable future. If we pay
dividends on our common stock, however, those payments will
constitute dividends for U.S. federal income tax purposes
to the extent paid from our current or accumulated earnings and
profits, as determined under U.S. federal income tax
principles. To the extent those payments exceed our current and
accumulated earnings and profits, the payments will constitute a
return of capital and first reduce the
non-U.S. holders
adjusted tax basis, but not below zero, and then will be treated
as gain from the sale of stock, as described below under the
heading Gain on Disposition of Common Stock. Any
amount treated as a dividend paid to a
non-U.S. holder
will ordinarily be subject to a 30% U.S. federal
withholding tax, or a lower rate if an applicable income tax
treaty so provides. A
non-U.S. holder
will be required to satisfy certain certification and disclosure
requirements in order to claim a reduced rate of withholding
pursuant to an applicable income tax treaty.
Dividends that are effectively connected with a
non-U.S. holders
conduct of trade or business within the United States (and,
where an applicable tax treaty so requires, are attributable to
a permanent establishment or fixed base in the U.S.) will not be
subject to U.S. federal withholding tax, provided certain
certification and disclosure requirements are met, but instead
generally will be taxed in the same manner as if the
non-U.S. holder
were a U.S. person. Additionally,
non-U.S. holders
that are corporations receiving such dividends may be subject to
an additional branch profits tax at a rate of 30%, or at a lower
rate if provided by an applicable income tax treaty.
Non-U.S. holders
are encouraged to consult their tax advisors regarding any claim
to benefits under an applicable income tax treaty and the method
of claiming the benefits of the treaty. A refund or credit for
any
non-U.S. holder
that is subject to a reduced U.S. federal withholding
income tax rate may be obtained by timely filing a claim for a
refund with the IRS.
GAIN ON
DISPOSITION OF COMMON STOCK
A
non-U.S. holder
of our common stock generally will not be taxed on gain
recognized upon disposition unless:
|
|
Ø
|
the
non-U.S. holder
is present in the U.S. for 183 days or more during the
taxable year of the disposition and has met certain other
requirements.
|
|
Ø
|
the income or gain is effectively connected with the
non-U.S. holders
conduct of trade or business within the U.S. and, if an
applicable income tax treaty so requires, is attributable to a
permanent establishment or fixed base of the
non-U.S. holder
in the U.S.; or
|
|
Ø
|
we are or have been a United States real property holding
corporation for U.S. federal income tax purposes at
any time within the shorter of the five-year period preceding
such disposition or your holding period for our common stock,
and certain other requirements are met. We believe that we are
not, and that we will not become, a United States real property
holding corporation.
|
89
Material
U.S. federal income and estate tax consequences to
non-U.S. holders
If you are an individual described in the first bullet point
immediately above you will be subject to a flat 30% tax on the
amount by which gain resulting from the disposition of our
common stock and any other
U.S.-source
capital gains realized in the same taxable year exceed the
U.S.-source
capital losses recognized in that taxable year, unless an
applicable income tax treaty provides for an exemption or lower
rate. If you are an individual described in the second bullet
point immediately above you will be subject to tax on the net
gain derived from the sale under regular graduated
U.S. federal income tax rates. If you are a corporation
described in the second bullet point immediately above, you will
be subject to tax on the net gain generally in the same manner
as if you were a U.S. corporation for U.S. federal
income tax purposes, and may also be subject to the branch
profits tax equal to 30%, or such lower rate as may be specified
by an applicable income tax treaty, on your effectively
connected earnings and profits.
U.S. FEDERAL
ESTATE TAX
Common stock owned or treated as owned by a
non-U.S. holder
who is an individual will be included in that
non-U.S. holders
gross estate for U.S. federal estate tax purposes unless an
applicable estate tax or other treaty provides otherwise and
such
non-U.S. holder
therefore may be subject to U.S. federal estate tax.
U.S. INFORMATION
REPORTING AND BACKUP WITHHOLDING
We must report to you and to the Internal Revenue Service on an
annual basis the amount of dividends paid to you and any related
taxes withheld from those dividends. Copies of the information
returns reporting dividends and the related tax withheld may
also be made available to the tax authorities in the country in
which you reside under the provisions of an applicable income
tax treaty.
Backup withholding generally will not apply to payments of
dividends made by us or our paying agents, in their capacities
as such, to a
non-U.S. holder
of our common stock if the holder has provided the required
certification that it is not a U.S. person or certain other
requirements are met.
In general, backup withholding and information reporting will
not apply to proceeds from the disposition of our common stock
paid to a
non-U.S. holder
if the holder has provided the required certification that it is
a
non-U.S. holder.
Backup withholding is not an additional tax. Any amounts
withheld may be refunded or credited against the holders
U.S. federal income tax liability, if any, provided that
the required information is furnished to the IRS in a timely
manner.
Non-U.S. holders
should consult their tax advisors regarding the application of
the information reporting and backup withholding rules to them.
Prospective
non-U.S. holders
of our common stock should consult their tax advisors with
respect to the particular tax consequences to them of owning and
disposing of our common stock, including the consequences under
the laws of any state, local or foreign jurisdiction or under
any applicable tax treaty.
90
Underwriting
We are offering the shares of our common stock described in this
prospectus through the underwriters named below. UBS Securities
LLC, Jefferies & Company, Inc., Wachovia Capital
Markets, LLC and Morgan Joseph & Co. Inc. are the
representatives of the underwriters. UBS Securities LLC is the
sole book-running manager of this offering. We have entered into
an underwriting agreement with the representatives. Subject to
the terms and conditions of the underwriting agreement, each of
the underwriters has severally agreed to purchase the number of
shares of common stock listed next to its name in the following
table.
|
|
|
|
|
|
|
Number of
|
|
Underwriters
|
|
Shares
|
|
|
|
|
UBS Securities LLC
|
|
|
|
|
Jefferies & Company,
Inc.
|
|
|
|
|
Wachovia Capital Markets,
LLC
|
|
|
|
|
Morgan Joseph & Co.
Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
The underwriting agreement provides that the underwriters must
buy all of the shares if they buy any of them. However, the
underwriters are not required to take or pay for the shares
covered by the underwriters over-allotment option
described below.
Our common stock is offered subject to a number of conditions,
including:
|
|
Ø
|
receipt and acceptance of our common stock by the underwriters,
and
|
|
Ø
|
the underwriters right to reject orders in whole or in
part.
|
We have been advised by the representatives that the
underwriters intend to make a market in our common stock, but
that they are not obligated to do so and may discontinue making
a market at any time without notice.
In connection with this offering, certain of the underwriters or
securities dealers may distribute prospectuses electronically.
OVER-ALLOTMENT
OPTION
We have granted the underwriters an option to buy up to an
aggregate of additional shares of our common stock. The
underwriters may exercise this option solely for the purpose of
covering over-allotments, if any, made in connection with this
offering. The underwriters have 30 days from the date of
this prospectus to exercise this option. If the underwriters
exercise this option, they will each purchase additional shares
approximately in proportion to the amounts specified in the
table above.
COMMISSIONS AND
DISCOUNTS
Shares sold by the underwriters to the public will initially be
offered at the initial offering price set forth on the cover of
this prospectus. Any shares sold by the underwriters to
securities dealers may be sold at a discount of up to
$ per share from the initial
public offering price. Any of these securities dealers may
resell any shares purchased from the underwriters to other
brokers or dealers at a discount of up to
$ per share from the initial
public offering price. If all the shares are not sold at the
initial public offering price, the representatives may change
the offering price and the other selling terms. Upon execution
of the underwriting agreement, the underwriters will be
obligated to purchase the shares at
91
Underwriting
the prices and upon the terms stated therein and, as a result,
will thereafter bear any risk associated with changing the
offering price to the public or other selling terms. The
representatives of the underwriters have informed us that they
do not expect to sell more than an aggregate
of shares
of common stock to accounts over which such representatives
exercise discretionary authority.
The following table shows the per share and total underwriting
discounts and commissions we will pay to the underwriters
assuming both no exercise and full exercise of the
underwriters option to purchase up to an additional shares.
|
|
|
|
|
|
|
|
|
|
|
No
exercise
|
|
|
Full
exercise
|
|
|
|
|
Per share
|
|
$
|
|
|
|
$
|
|
|
Total
|
|
$
|
|
|
|
$
|
|
|
We estimate that the total expenses of this offering payable by
us, not including the underwriting discounts and commissions,
will be approximately
$ million.
NO SALES OF
SIMILAR SECURITIES
We, our executive officers and directors and shareholders owning
substantially all of our stock have entered into
lock-up
agreements with the underwriters. Under these agreements,
subject to certain exceptions, we and each of these persons may
not, without the prior written approval of UBS Securities LLC,
offer, sell, contract to sell or otherwise dispose of, directly
or indirectly, or hedge our common stock or securities
convertible into or exchangeable or exercisable for our common
stock. These restrictions will be in effect for a period of
180 days after the date of this prospectus. At any time and
without public notice, UBS Securities LLC may, in its sole
discretion, release some or all of the securities from these
lock-up
agreements.
INDEMNIFICATION
We have agreed to indemnify the underwriters against certain
liabilities, including certain liabilities under the Securities
Act. If we are unable to provide this indemnification, we have
agreed to contribute to payments the underwriters may be
required to make in respect of those liabilities.
NASDAQ GLOBAL
MARKET QUOTATION
We have applied to have our common stock approved for quotation
on The Nasdaq Global Market under the trading symbol
CPIX.
PRICE
STABILIZATION, SHORT POSITIONS
In connection with this offering, the underwriters may engage in
activities that stabilize, maintain or otherwise affect the
price of our common stock, including:
|
|
Ø
|
stabilizing transactions;
|
|
Ø
|
short sales;
|
|
Ø
|
purchases to cover positions created by short sales;
|
|
Ø
|
imposition of penalty bids; and
|
|
Ø
|
syndicate covering transactions.
|
Stabilizing transactions consist of bids or purchases made for
the purpose of preventing or retarding a decline in the market
price of our common stock while this offering is in progress.
These transactions
92
Underwriting
may also include making short sales of our common stock, which
involve the sale by the underwriters of a greater number of
shares of common stock than they are required to purchase in
this offering, and purchasing shares of common stock on the open
market to cover positions created by short sales. Short sales
may be covered short sales, which are short
positions in an amount not greater than the underwriters
over-allotment option referred to above, or may be naked
short sales, which are short positions in excess of that
amount.
The underwriters may close out any covered short position by
either exercising their over-allotment option, in whole or in
part, or by purchasing shares in the open market. In making this
determination, the underwriters will consider, among other
things, the price of shares available for purchase in the open
market as compared to the price at which they may purchase
shares through the over-allotment option.
Naked short sales are in excess of the over-allotment option.
The underwriters must close out any naked short position by
purchasing shares in the open market. A naked short position is
more likely to be created if the underwriters are concerned that
there may be downward pressure on the price of the common stock
in the open market that could adversely affect investors who
purchased in this offering.
The underwriters also may impose a penalty bid. This occurs when
a particular underwriter repays to the underwriters a portion of
the underwriting discount received by it because the
representatives have repurchased shares sold by or for the
account of that underwriter in stabilizing or short covering
transactions.
As a result of these activities, the price of our common stock
may be higher that the price that otherwise might exist in the
open market. If these activities are commenced, they may be
discontinued by the underwriters at any time. The underwriters
may carry out these transactions on The Nasdaq Global Market, in
the
over-the-counter
market or otherwise.
DETERMINATION OF
OFFERING PRICE
Prior to this offering, there was no public market for our
common stock. The initial public offering price will be
determined by negotiation by us and the representatives of the
underwriters. The principal factors to be considered in
determining the initial public offering price include:
|
|
Ø
|
the information set forth in this prospectus and otherwise
available to representatives;
|
|
Ø
|
our history and prospects, and the history of and prospects for
the industry in which we compete;
|
|
Ø
|
our past and present financial performance and an assessment of
our management;
|
|
Ø
|
our prospects for future earnings and the present state of our
development;
|
|
Ø
|
the general condition of the securities markets at the time of
this offering;
|
|
Ø
|
the recent market prices of, and demand for, publicly traded
common stock of generally comparable companies; and
|
|
Ø
|
other factors deemed relevant by the underwriters and us.
|
AFFILIATIONS
Certain of the underwriters and their affiliates may from time
to time provide certain commercial banking, financial advisory,
investment banking and other services for us for which they were
and will be entitled to receive separate fees. The underwriters
and their affiliates may from time to time in the future engage
in transactions with us and perform services for us in the
ordinary course of their business.
93
Notice to investors
EUROPEAN ECONOMIC
AREA
In relation to each Member State of the European Economic Area,
or EEA, which has implemented the Prospectus Directive (each, a
Relevant Member State), with effect from and including the date
on which the Prospectus Directive is implemented in that
Relevant Member State, or the Relevant Implementation Date, our
common stock will not be offered to the public in that Relevant
Member State prior to the publication of a prospectus in
relation to our common stock that has been approved by the
competent authority in that Relevant Member State or, where
appropriate, approved in another Relevant Member State and
notified to the competent authority in that Relevant Member
State, all in accordance with the Prospectus Directive, except
that, with effect from and including the Relevant Implementation
Date, our common stock may be offered to the public in that
Relevant Member State at any time:
|
|
Ø
|
to legal entities which are authorized or regulated to operate
in the financial markets or, if not so authorized or regulated,
whose corporate purpose is solely to invest in securities;
|
|
Ø
|
to any legal entity which has two or more of (1) an average
of at least 250 employees during the last financial year;
(2) a total balance sheet of more than 43,000,000 and
(3) an annual net turnover of more than 50,000,000,
as shown in its last annual or consolidated accounts; or
|
|
Ø
|
in any other circumstances which do not require the publication
by us of a prospectus pursuant to Article 3 of the
Prospectus Directive.
|
As used above, the expression offered to the public
in relation to any of our common stock in any Relevant Member
State means the communication in any form and by any means of
sufficient information on the terms of the offer and our common
stock to be offered so as to enable an investor to decide to
purchase or subscribe for our common stock, as the same may be
varied in that Member State by any measure implementing the
Prospectus Directive in that Member State and the expression
Prospectus Directive means Directive
2003/71/ EC
and includes any relevant implementing measure in each Relevant
Member State.
The EEA selling restriction is in addition to any other selling
restrictions set out below.
UNITED
KINGDOM
Our common stock may not be offered or sold and will not be
offered or sold to any persons in the United Kingdom other than
to persons whose ordinary activities involve them in acquiring,
holding, managing or disposing of investments (as principal or
as agent) for the purposes of their businesses and in compliance
with all applicable provisions of the Financial Services and
Markets Act 2000, or the FSMA, with respect to anything done in
relation to our common stock in, from or otherwise involving the
United Kingdom. In addition, each underwriter has only
communicated or caused to be communicated and will only
communicate or cause to be communicated any invitation or
inducement to engage in investment activity (within the meaning
of Section 21 of the FSMA) received by it in connection
with the issue or sale of our common stock in circumstances in
which Section 21(1) of the FSMA does not apply to us.
Without limitation to the other restrictions referred to herein,
this prospectus is directed only at (1) persons outside the
United Kingdom, (2) persons having professional experience
in matters relating to investments who fall within the
definition of investment professionals in
Article 19(5) of the Financial Services and Markets Act
2000 (Financial Promotion) Order 2005; or (3) high net
worth bodies corporate, unincorporated associations and
partnerships and trustees of high value trusts as described in
Article 49(2) of the Financial Services and Markets Act
2000 (Financial Promotion) Order 2005. Without limitation to the
other restrictions referred to herein, investment or investment
activity to which this prospectus relates is available only to,
and will be engaged in only with, such persons, and persons
within the United Kingdom who receive this
94
Notice to
investors
communication (other than persons who fall within (2) or
(3) above) should not rely or act upon this communication.
FRANCE
No prospectus (including any amendment, supplement or
replacement thereto) has been prepared in connection with the
offering of our common stock that has been approved by the
Autorité des marchés financiers or by the competent
authority of another State that is a contracting party to the
Agreement on the European Economic Area and notified to the
Autorité des marchés financiers; no common stock has
been offered or sold and will be offered or sold, directly or
indirectly, to the public in France except to permitted
investors, consisting of persons licensed to provide the
investment service of portfolio management for the account of
third parties, qualified investors (investisseurs
qualifiés) acting for their own account
and/or
corporate investors meeting one of the four criteria provided in
Article 1 of Decree N7
2004-1019 of
September 28, 2004 and belonging to a limited circle of
investors (cercle restreint dinvestisseurs) acting for
their own account, with qualified investors and
limited circle of investors having the meaning
ascribed to them in Article L.
411-2 of the
French Code Monétaire et Financier and applicable
regulations thereunder; none of this prospectus or any other
materials related to the offer or information contained therein
relating to our common stock has been released, issued or
distributed to the public in France except to Permitted
Investors; and the direct or indirect resale to the public in
France of any common stock acquired by any Permitted Investors
may be made only as provided by articles L.
412-1 and L.
621-8 of the
French Code Monétaire et Financier and applicable
regulations thereunder.
ITALY
The offering of shares of our common stock has not been cleared
by the Italian Securities Exchange Commission (Commissione
Nazionale per le Società e la Borsa, or the CONSOB)
pursuant to Italian securities legislation and, accordingly,
shares of our common stock may not and will not be offered, sold
or delivered, nor may or will copies of this prospectus or any
other documents relating to shares of our common stock or the
offering be distributed in Italy other than to professional
investors (operatori qualificati), as defined in
Article 31, paragraph 2 of CONSOB
Regulation No. 11522 of July 1, 1998, as amended,
or Regulation No. 11522.
Any offer, sale or delivery of shares of our common stock or
distribution of copies of this prospectus or any other document
relating to shares of our common stock or the offering in Italy
may and will be effected in accordance with all Italian
securities, tax, exchange control and other applicable laws and
regulations, and, in particular, will be: (i) made by an
investment firm, bank or financial intermediary permitted to
conduct such activities in Italy in accordance with the
Legislative Decree No. 385 of September 1, 1993, as
amended, or the Italian Banking Law, Legislative Decree
No. 58 of February 24, 1998, as amended,
Regulation No. 11522, and any other applicable laws
and regulations; (ii) in compliance with Article 129
of the Italian Banking Law and the implementing guidelines of
the Bank of Italy; and (iii) in compliance with any other
applicable notification requirement or limitation which may be
imposed by CONSOB or the Bank of Italy.
Any investor purchasing shares of our common stock in the
offering is solely responsible for ensuring that any offer or
resale of shares of common stock it purchased in the offering
occurs in compliance with applicable laws and regulations.
This prospectus and the information contained herein are
intended only for the use of its recipient and are not to be
distributed to any third party resident or located in Italy for
any reason. No person
95
Notice to
investors
resident or located in Italy other than the original recipients
of this document may rely on it or its content.
In addition to the above (which shall continue to apply to the
extent not inconsistent with the implementing measures of the
Prospective Directive in Italy), after the implementation of the
Prospectus Directive in Italy, the restrictions, warranties and
representations set out under the heading European
Economic Area above shall apply to Italy.
GERMANY
Shares of our common stock may not be offered or sold or
publicly promoted or advertised by any underwriter in the
Federal Republic of Germany other than in compliance with the
provisions of the German Securities Prospectus Act
(WertpapierprospektgestzWpPG) of June 22, 2005, as
amended, or of any other laws applicable in the Federal Republic
of Germany governing the issue, offering and sale of securities.
SPAIN
Neither the common stock nor this prospectus have been approved
or registered in the administrative registries of the Spanish
National Securities Exchange Commission (Comisión Nacional
del Mercado de Valores). Accordingly, our common stock may not
be offered in Spain except in circumstances which do not
constitute a public offer of securities in Spain within the
meaning of articles 30bis of the Spanish Securities Markets
Law of 28 July 1988 (Ley
24/1988, de
28 de Julio, del Mercado de Valores), as amended and
restated, and supplemental rules enacted thereunder.
SWEDEN
This is not a prospectus under, and has not been prepared in
accordance with the prospectus requirements provided for in, the
Swedish Financial Instruments Trading Act [lagen (1991:980) om
handel med finasiella instrument] nor any other Swedish
enactment. Neither the Swedish Financial Supervisory Authority
nor any other Swedish public body has examined, approved, or
registered this document.
SWITZERLAND
The common stock may not and will not be publicly offered,
distributed or re-distributed on a professional basis in or from
Switzerland and neither this prospectus nor any other
solicitation for investments in our common stock may be
communicated or distributed in Switzerland in any way that could
constitute a public offering within the meaning of
Articles 1156 or 652a of the Swiss Code of Obligations or
of Article 2 of the Federal Act on Investment Funds of
March 18, 1994. This prospectus may not be copied,
reproduced, distributed or passed on to others without the
underwriters prior written consent. This prospectus is not
a prospectus within the meaning of Articles 1156 and 652a
of the Swiss Code of Obligations or a listing prospectus
according to article 32 of the Listing Rules of the Swiss
Exchange and may not comply with the information standards
required thereunder. We will not apply for a listing of our
common stock on any Swiss stock exchange or other Swiss
regulated market and this prospectus may not comply with the
information required under the relevant listing rules. The
common stock offered hereby has not and will not be registered
with the Swiss Federal Banking Commission and has not and will
not be authorized under the Federal Act on Investment Funds of
March 18, 1994. The investor protection afforded to
acquirers of investment fund certificates by the Federal Act on
Investment Funds of March 18, 1994 does not extend to
acquirers of our common stock.
96
Notice to
investors
Legal matters
The validity of the shares of common stock issued in this
offering will be passed upon for us by the law firm of Adams and
Reese LLP, Nashville, Tennessee. Dewey Ballantine LLP, New York,
New York is counsel to the underwriters in connection with this
offering.
Experts
The consolidated financial statements and schedule of the
Company as of December 31, 2006 and 2005, and for each of
the years in the three-year period ended December 31, 2006,
have been included herein and in the registration statement in
reliance upon the report of KPMG LLP, independent
registered public accounting firm, appearing elsewhere herein,
and upon the authority of said firm as experts in accounting and
auditing. The audit report covering the December 31, 2006
financial statements refer to a change in accounting for
stock-based compensation.
Where you can find
additional information
We filed a registration statement on
Form S-1
with the Commission with respect to the registration of the
common stock offered for sale with this prospectus. This
prospectus, which constitutes part of the registration
statement, does not contain all of the information set forth in
the registration statement and the exhibits to the registration
statement. For further information about us, the common stock we
are offering by this prospectus and related matters, you should
review the registration statement, including the exhibits filed
as a part of the registration statement. Statements contained in
this prospectus about the contents of any contract or any other
document that is filed as an exhibit to the registration
statement are not necessarily complete, and we refer you to the
full text of the contract or other document filed as an exhibit
to the registration statement. A copy of the registration
statement and the exhibits that were filed with the registration
statement may be inspected without charge at the public
reference facilities maintained by the Securities and Exchange
Commission Headquarters Office, 100 F Street, N.E.,
Washington, D.C. 20549, and copies of all or any part of
the registration statement may be obtained from the SEC upon
payment of the prescribed fee. Information on the operation of
the public reference facilities may be obtained by calling the
SEC at
1-800-SEC-0330.
The SEC maintains a world wide web site that contains reports,
proxy and information statements and other information regarding
registrants that file electronically with the SEC. The address
of the site is http://www.sec.gov.
Upon completion of this offering, we will become subject to the
information and periodic reporting requirements of the Exchange
Act, and, in accordance with such requirements, will file
periodic reports, proxy statements and other information with
the SEC. These periodic reports, proxy statements and other
information will be available for inspection and copying at the
regional offices, public reference facilities and web site of
the SEC referred to above.
97
Report of
Independent Registered Public Accounting Firm
The Board of Directors
Cumberland Pharmaceuticals Inc.:
We have audited the accompanying consolidated balance sheets of
Cumberland Pharmaceuticals Inc. and subsidiaries (the Company)
as of December 31, 2005 and 2006, and the related
consolidated statements of income, shareholders equity
(deficit) and comprehensive income, and cash flows for each of
the years in the three-year period ended December 31, 2006.
In connection with our audits of the consolidated financial
statements, we have also audited the financial statement
Schedule IIValuation and Qualifying Accounts for each
of the years in the three-year period ended December 31,
2006. These consolidated financial statements and financial
statement schedule are the responsibility of the Companys
management. Our responsibility is to express an opinion on these
consolidated financial statements and financial statement
schedule based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial
position of Cumberland Pharmaceuticals Inc. and subsidiaries as
of December 31, 2005 and 2006, and the results of their
operations and their cash flows for each of the years in the
three-year period ended December 31, 2006, in conformity
with U.S. generally accepted accounting principles. Also,
in our opinion, the related financial statement schedule, when
considered in relation to the consolidated financial statements
taken as a whole, present fairly, in all material respects, the
information set forth herein.
As discussed in notes 2 and 9 to the consolidated financial
statements, effective January 1, 2006, the Company adopted
the fair value method of accounting for stock-based compensation
as required by Statement of Financial Accounting Standards
No. 123(R), Share-Based Payments.
April 23, 2007
F-2
Cumberland
Pharmaceuticals Inc. and Subsidiaries
Consolidated balance
sheets
December 31,
2005 and 2006
|
|
|
|
|
|
|
|
|
|
|
2005
|
|
|
2006
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
5,535,985
|
|
|
|
6,255,398
|
|
Accounts receivable, net of
allowances
|
|
|
2,414,813
|
|
|
|
5,120,462
|
|
Inventories
|
|
|
546,382
|
|
|
|
671,098
|
|
Prepaid assets
|
|
|
60,040
|
|
|
|
142,569
|
|
Deferred tax assets
|
|
|
12,492
|
|
|
|
405,443
|
|
Other current assets
|
|
|
21,185
|
|
|
|
48,352
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
8,590,897
|
|
|
|
12,643,322
|
|
Property and equipment, net
|
|
|
373,944
|
|
|
|
365,774
|
|
Intangible assets, net
|
|
|
36,975
|
|
|
|
9,834,270
|
|
Deferred tax assets
|
|
|
1,171,508
|
|
|
|
3,611,861
|
|
Other assets
|
|
|
|
|
|
|
25,897
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
10,173,324
|
|
|
|
26,481,124
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
SHAREHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Current portion of long-term debt
|
|
$
|
281,209
|
|
|
|
1,833,332
|
|
Current portion of other long-term
obligations
|
|
|
1,127,455
|
|
|
|
2,052,501
|
|
Accounts payable
|
|
|
990,123
|
|
|
|
3,372,936
|
|
Accrued interest
|
|
|
2,205
|
|
|
|
101,913
|
|
Other accrued liabilities
|
|
|
549,723
|
|
|
|
1,337,472
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
2,950,715
|
|
|
|
8,698,154
|
|
Long-term debt, excluding current
portion
|
|
|
|
|
|
|
3,575,951
|
|
Other long-term obligations,
excluding current portion
|
|
|
988,961
|
|
|
|
3,081,359
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
3,939,676
|
|
|
|
15,355,464
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (see
notes)
|
|
|
|
|
|
|
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
Preferred stockno par value.
Authorized 3,000,000 shares; $2,780,359 or $3.25 per
share liquidation preference; issued and outstanding
855,495 shares at both December 31, 2005 and 2006
|
|
|
2,742,994
|
|
|
|
2,742,994
|
|
Common stockno par value.
Authorized 10,000,000 shares; issued and outstanding
4,890,149 and 4,922,075 shares at December 31, 2005
and 2006, respectively
|
|
|
15,255,029
|
|
|
|
15,742,590
|
|
Accumulated deficit
|
|
|
(11,764,375
|
)
|
|
|
(7,359,924
|
)
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
6,233,648
|
|
|
|
11,125,660
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and
shareholders equity
|
|
$
|
10,173,324
|
|
|
|
26,481,124
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-3
CUMBERLAND
PHARMACEUTICALS INC. AND SUBSIDIARIES
Consolidated
Statements of Income
Years ended
December 31, 2004, 2005, and 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net product revenue
|
|
$
|
8,869,358
|
|
|
|
8,224,670
|
|
|
|
16,980,898
|
|
Revenue from co-promotion
agreements
|
|
|
2,874,544
|
|
|
|
1,812,242
|
|
|
|
286,624
|
|
Other revenue
|
|
|
288,308
|
|
|
|
652,752
|
|
|
|
547,958
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues
|
|
|
12,032,210
|
|
|
|
10,689,664
|
|
|
|
17,815,480
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold
|
|
|
816,345
|
|
|
|
533,263
|
|
|
|
2,399,133
|
|
Selling and marketing
|
|
|
6,802,482
|
|
|
|
5,647,254
|
|
|
|
7,348,540
|
|
Research and development
|
|
|
745,932
|
|
|
|
1,157,881
|
|
|
|
2,232,984
|
|
General and administrative
|
|
|
2,357,968
|
|
|
|
2,587,861
|
|
|
|
2,999,347
|
|
Amortization of product license
rights
|
|
|
|
|
|
|
|
|
|
|
515,181
|
|
Other
|
|
|
6,205
|
|
|
|
13,489
|
|
|
|
96,433
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
10,728,932
|
|
|
|
9,939,748
|
|
|
|
15,591,618
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on insurance recovery
|
|
|
265,588
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
1,568,866
|
|
|
|
749,916
|
|
|
|
2,223,862
|
|
Interest income
|
|
|
969
|
|
|
|
89,239
|
|
|
|
208,677
|
|
Interest expense
|
|
|
1,011,631
|
|
|
|
63,204
|
|
|
|
721,804
|
|
Other expense
|
|
|
|
|
|
|
5,632
|
|
|
|
2,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income before income taxes
|
|
|
558,204
|
|
|
|
770,319
|
|
|
|
1,707,935
|
|
Income tax benefit
|
|
|
|
|
|
|
1,184,000
|
|
|
|
2,696,516
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
558,204
|
|
|
|
1,954,319
|
|
|
|
4,404,451
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per sharebasic
|
|
$
|
0.12
|
|
|
|
0.41
|
|
|
|
0.90
|
|
Net income per sharediluted
|
|
|
0.07
|
|
|
|
0.24
|
|
|
|
0.55
|
|
Weighted average shares
outstandingbasic
|
|
|
4,541,076
|
|
|
|
4,747,866
|
|
|
|
4,898,595
|
|
Weighted average shares
outstandingdiluted
|
|
|
7,741,140
|
|
|
|
8,045,045
|
|
|
|
8,016,426
|
|
See accompanying notes to consolidated financial statements.
F-4
Cumberland
Pharmaceuticals Inc. and Subsidiaries
Consolidated
statements of shareholders equity (deficit) and
comprehensive income
Years ended
December 31, 2004, 2005, and 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
Preferred
stock
|
|
|
Common
stock
|
|
|
Accumulated
|
|
|
shareholders
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
deficit
|
|
|
equity
(deficit)
|
|
|
|
|
Balance, December 31,
2003
|
|
|
855,495
|
|
|
$
|
2,742,994
|
|
|
|
4,444,852
|
|
|
$
|
8,101,251
|
|
|
$
|
(14,276,898
|
)
|
|
$
|
(3,432,653
|
)
|
Issuance of common stock, net of
proceeds allocated to common stock warrants issued with the
common stock
|
|
|
|
|
|
|
|
|
|
|
43,000
|
|
|
|
373,850
|
|
|
|
|
|
|
|
373,850
|
|
Issuance of common stock warrants
in consideration with issuance of common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
142,150
|
|
|
|
|
|
|
|
142,150
|
|
Issuance of common stock upon
conversion of note payable
|
|
|
|
|
|
|
|
|
|
|
111,489
|
|
|
|
1,337,868
|
|
|
|
|
|
|
|
1,337,868
|
|
Issuance of common stock for
services received
|
|
|
|
|
|
|
|
|
|
|
25,267
|
|
|
|
303,204
|
|
|
|
|
|
|
|
303,204
|
|
Stock options granted for services
received
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43,928
|
|
|
|
|
|
|
|
43,928
|
|
Exercise of options and related tax
benefit, net of mature shares redeemed for the exercise price
|
|
|
|
|
|
|
|
|
|
|
18,799
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options granted to note holders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
454,453
|
|
|
|
|
|
|
|
454,453
|
|
Issuance of common stock options
upon extension of notes payable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
151,074
|
|
|
|
|
|
|
|
151,074
|
|
Change in fair value of embedded
conversion feature
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45,534
|
|
|
|
|
|
|
|
45,534
|
|
Net and comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
558,204
|
|
|
|
558,204
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31,
2004
|
|
|
855,495
|
|
|
|
2,742,994
|
|
|
|
4,643,407
|
|
|
|
10,953,312
|
|
|
|
(13,718,694
|
)
|
|
|
(22,388
|
)
|
Issuance of common stock
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
|
1,789,364
|
|
|
|
|
|
|
|
1,789,364
|
|
Offering costs settled with stock
options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(51,806
|
)
|
|
|
|
|
|
|
(51,806
|
)
|
Issuance of common stock upon
conversion of note payable
|
|
|
|
|
|
|
|
|
|
|
112,916
|
|
|
|
2,032,488
|
|
|
|
|
|
|
|
2,032,488
|
|
Issuance of common stock for
services received
|
|
|
|
|
|
|
|
|
|
|
25,001
|
|
|
|
300,012
|
|
|
|
|
|
|
|
300,012
|
|
Stock options granted for services
received
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
226,709
|
|
|
|
|
|
|
|
226,709
|
|
Exercise of options and related tax
benefit, net of mature shares redeemed for the exercise price
|
|
|
|
|
|
|
|
|
|
|
8,825
|
|
|
|
4,950
|
|
|
|
|
|
|
|
4,950
|
|
Net and comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,954,319
|
|
|
|
1,954,319
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31,
2005
|
|
|
855,495
|
|
|
|
2,742,994
|
|
|
|
4,890,149
|
|
|
|
15,255,029
|
|
|
|
(11,764,375
|
)
|
|
|
6,233,648
|
|
Issuance of common stock for
services received
|
|
|
|
|
|
|
|
|
|
|
13,759
|
|
|
|
273,298
|
|
|
|
|
|
|
|
273,298
|
|
Stock options granted for services
received
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,751
|
|
|
|
|
|
|
|
37,751
|
|
Exercise of options and related tax
benefit, net of mature shares redeemed for the exercise price
|
|
|
|
|
|
|
|
|
|
|
18,167
|
|
|
|
46,747
|
|
|
|
|
|
|
|
46,747
|
|
Stock-based
compensationemployee stock options grants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
104,085
|
|
|
|
|
|
|
|
104,085
|
|
Issuance of common stock warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,680
|
|
|
|
|
|
|
|
25,680
|
|
Net and comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,404,451
|
|
|
|
4,404,451
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31,
2006
|
|
|
855,495
|
|
|
$
|
2,742,994
|
|
|
|
4,922,075
|
|
|
$
|
15,742,590
|
|
|
$
|
(7,359,924
|
)
|
|
$
|
11,125,660
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-5
Cumberland
Pharmaceuticals Inc. and Subsidiaries
Consolidated
statements of cash flows
Years ended
December 31, 2004, 2005, and 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Cash flows from operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
558,204
|
|
|
|
1,954,319
|
|
|
|
4,404,451
|
|
Adjustments to reconcile net income
to net cash (used in) provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
expense
|
|
|
44,006
|
|
|
|
53,537
|
|
|
|
587,742
|
|
Deferred tax benefit
|
|
|
|
|
|
|
(1,184,000
|
)
|
|
|
(2,833,304
|
)
|
Non-employee stock grant expense
|
|
|
303,204
|
|
|
|
300,012
|
|
|
|
273,298
|
|
Non-employee stock option grant
expense
|
|
|
43,928
|
|
|
|
174,903
|
|
|
|
37,751
|
|
Stock-based
compensation employee stock options
|
|
|
|
|
|
|
|
|
|
|
104,085
|
|
Excess tax benefit derived from
exercise of stock options
|
|
|
|
|
|
|
|
|
|
|
(37,747
|
)
|
Non-cash interest expense
|
|
|
785,433
|
|
|
|
|
|
|
|
339,593
|
|
Net changes in assets and
liabilities affecting operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(2,789,172
|
)
|
|
|
584,603
|
|
|
|
(2,705,649
|
)
|
Inventory
|
|
|
(6,905
|
)
|
|
|
254,492
|
|
|
|
(124,716
|
)
|
Prepaid and other current assets
|
|
|
(10,275
|
)
|
|
|
(36,743
|
)
|
|
|
(71,844
|
)
|
Accounts payable, accrued interest,
and other accrued liabilities
|
|
|
501,699
|
|
|
|
(518,922
|
)
|
|
|
3,308,017
|
|
Deferred revenue
|
|
|
(699,718
|
)
|
|
|
|
|
|
|
|
|
Other long-term obligations
|
|
|
(169,784
|
)
|
|
|
833,806
|
|
|
|
(1,118,422
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in)
operating activities
|
|
|
(1,439,380
|
)
|
|
|
2,416,007
|
|
|
|
2,163,255
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of intangible
assets-license
|
|
|
|
|
|
|
|
|
|
|
(6,479,658
|
)
|
Additions to property and equipment
|
|
|
(50,271
|
)
|
|
|
(301,908
|
)
|
|
|
(59,714
|
)
|
Additions to trademarks and patents
|
|
|
(839
|
)
|
|
|
(16,591
|
)
|
|
|
(13,558
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing
activities
|
|
|
(51,110
|
)
|
|
|
(318,499
|
)
|
|
|
(6,552,930
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of note
payable
|
|
|
|
|
|
|
|
|
|
|
5,500,000
|
|
Costs of financing for long-term
debt and credit facility
|
|
|
|
|
|
|
|
|
|
|
(65,733
|
)
|
Principal payments on notes payable
|
|
|
(278,000
|
)
|
|
|
|
|
|
|
(916,668
|
)
|
Net borrowings (repayments) on line
of credit
|
|
|
997,577
|
|
|
|
(871,839
|
)
|
|
|
544,742
|
|
Proceeds from issuance of
convertible note
|
|
|
|
|
|
|
1,999,998
|
|
|
|
|
|
Proceeds from exercise of stock
options
|
|
|
|
|
|
|
4,950
|
|
|
|
9,000
|
|
Excess tax benefit from stock
compensation
|
|
|
|
|
|
|
|
|
|
|
37,747
|
|
Proceeds from issuance of stock and
warrants
|
|
|
516,000
|
|
|
|
1,789,364
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing
activities
|
|
|
1,235,577
|
|
|
|
2,922,473
|
|
|
|
5,109,088
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and
cash equivalents
|
|
|
(254,913
|
)
|
|
|
5,019,981
|
|
|
|
719,413
|
|
Cash and cash equivalents,
beginning of year
|
|
|
770,917
|
|
|
|
516,004
|
|
|
|
5,535,985
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of
year
|
|
$
|
516,004
|
|
|
|
5,535,985
|
|
|
|
6,255,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash
flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid during the year for:
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
$
|
123,482
|
|
|
|
63,809
|
|
|
|
377,202
|
|
Income taxes
|
|
|
|
|
|
|
18,000
|
|
|
|
55,659
|
|
Non-cash investing and financing
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Liability for license acquired
(note 6)
|
|
|
|
|
|
|
|
|
|
|
4,500,000
|
|
Deferred financing costs
(note 5)
|
|
|
|
|
|
|
|
|
|
|
25,680
|
|
Settlement of notes payable
including accrued interest with issuance of common stock
(notes 5)
|
|
|
1,337,868
|
|
|
|
2,032,488
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-6
CUMBERLAND
PHARMACEUTICALS INC. AND SUBSIDIARIES
Notes to
consolidated financial statements
(1) ORGANIZATION
AND BASIS OF PRESENTATION
Cumberland Pharmaceuticals Inc. and its subsidiaries (the
Company or Cumberland) is a specialty pharmaceutical company,
which was incorporated in Tennessee on January 6, 1999. Its
mission is to provide high quality products to address
underserved medical needs. Cumberland is focused on acquiring
rights to, developing, and commercializing branded prescription
products for the acute care and gastroenterology markets.
The Companys corporate operations and product acquisitions
have been funded by a combination of equity and debt financings.
The Company focuses its resources on maximizing the commercial
potential of its products, as well as developing new product
candidates, and has outsourced manufacturing and distribution to
carefully selected entities with the appropriate expertise and
infrastructure to support these activities.
In order to create access to a pipeline of early-stage product
candidates, the Company formed a subsidiary, Cumberland Emerging
Technologies (CET), which assists universities and other
research organizations to help bring biomedical projects from
the laboratory to the marketplace. The Companys ownership
in CET is 86%. The remaining interest is owned by Vanderbilt
University and the Tennessee Technology Development Corporation.
During 2002, CETs losses reduced its equity to a deficit
position. Accordingly, the Company reduced minority interest to
zero and has recorded 100% of the losses associated with the
joint venture since that time in accordance with Accounting
Research Bulletin No. 51, Consolidated Financial
Statements. These losses amounted to
approximately $92,000, $22,000, and $172,000 at
December 31, 2004, 2005, and 2006, respectively. The
Company will recover the cumulative loss of $445,000 before any
income is allocated to the minority interest holders.
In December 2006, the Company created a new, wholly-owned
subsidiary, Cumberland Pharma Sales Corp., that includes the
Companys newly acquired hospital sales force who promote
the Companys products,
Acetadote®
and
Kristalose®.
These consolidated financial statements are stated in
U.S. dollars and are prepared under U.S. generally accepted
accounting principles. The accompanying consolidated financial
statements include the accounts of the Company and its majority
owned subsidiaries. All significant inter-company balances and
transfers have been eliminated.
(2) SIGNIFICANT
ACCOUNTING POLICIES
(a) Cash
and Cash Equivalents
For the purpose of the consolidated statements of cash flows,
cash and cash equivalents include highly liquid investments with
original maturities of three months or less when purchased.
(b) Accounts
Receivable
Trade accounts receivable are recorded at the invoiced amount
and do not bear interest. The Company records allowances for
uncollectible amounts, cash discounts, chargebacks, and credits
to be taken by customers for product damaged in shipment based
on historical experience. The Company reviews its customer
balances on an individual account basis for collectibility. As
of December 31, 2005 and 2006, the allowance for
uncollectible amounts, cash discounts, chargebacks, and credits
for damaged product was $184,334 and $298,913, respectively.
Cash discounts are reductions to invoiced amounts offered to
customers for payment within a specified period of time from the
date of the invoice. The majority of the Companys products
are distributed
F-7
Notes to
consolidated financial statements
through independent pharmaceutical wholesalers. In conjunction
with recognizing a sale to a wholesaler, Net Product
revenue and Accounts Receivables take into
account the sale of the product at the wholesale acquisition
cost and an accrual to reflect the difference between the
wholesale acquisition cost and the estimated average end-user
contract price. This accrual is calculated on a product specific
basis and is based on the estimated number of outstanding units
sold to wholesalers that will ultimately be sold under end-user
contracts. When the wholesaler sells the product to the end user
at the agreed upon end-user contract price, the wholesaler
charges the Company (chargeback) for the difference
between the wholesale acquisition price and the end-user
contract price and that chargeback is offset against the initial
accrual balance.
The Companys estimate of the allowance for damaged product
is based upon historical experience of claims made for damaged
product. The Company recognizes revenue for its product when the
shipment is received by the customer. At this time, the Company
records a reduction in revenue for the estimate of product
damaged in shipment as the damaged product may not always be
discovered upon receipt of the product by the customer.
Accrued balances for discounts, chargebacks, and credits for
damaged product are recorded as a reduction to Accounts
Receivable. The majority of the 2006 allowance relates to
anticipated chargebacks.
(c) Inventories
The Company utilizes third parties to manufacturer and package
finished goods for sale, takes title to the finished goods at
the time of shipment from the manufacturer, and warehouses such
goods until distribution and sale. The Companys inventory
was comprised completely of finished goods at December 31,
2005 and 2006. Inventories are stated at the lower of cost or
market. Cost is determined using the
first-in,
first-out method (FIFO).
In 2004, the Company recorded the net impact of an insurance
recovery of $265,588 related to the settlement of an insurance
claim for $73,815 of damaged inventory. The cost of the
inventory included in cost of products sold has been offset by a
portion of the insurance proceeds.
(d) Prepaid
Assets
Prepaid assets consist of the prepaid premium for
directors and officers insurance, product liability
insurance, prepaid consulting services, etc. The Company
expenses or amortizes all prepaid amounts as used or over the
period of benefit on a straight-line basis, as applicable.
(e) Property
and Equipment
Property and equipment, including leasehold improvements, are
stated at cost. Depreciation is provided using the straight-line
method over the estimated useful lives of the assets, ranging
from three to 15 years. Leasehold improvements are
amortized over the shorter of the initial lease term plus its
renewal options, if renewal is reasonably assured, or the
remaining useful life of the related asset. Upon retirement or
disposal of assets, the asset and accumulated depreciation
accounts are adjusted accordingly and any gain or loss is
reflected in operations. Repairs and maintenance costs are
expensed as incurred. Improvements that extend an assets
useful life are capitalized.
The Companys intangible assets consist of costs incurred
related to licenses, trademarks, and patents.
F-8
Notes to
consolidated financial statements
In 2006, the Company acquired the exclusive
U.S. commercialization rights (licenses) to
Kristalose®.
The cost of acquiring the licenses of products that are approved
for commercial use are capitalized and are amortized ratably
over the estimated life of the products. At the time of
acquisition, the product life is estimated based upon the term
of the license agreement, patent life or market exclusivity of
the products and our assessment of future sales and
profitability of the product. We assess this estimate regularly
during the amortization period and adjust the asset value or
useful life when appropriate. The total purchase price, which
includes the cost of the U.S. commercialization rights and
other related costs of obtaining these licenses, is being
amortized on a straight-line basis over 15 years, which is
managements estimate of the assets useful life.
Trademarks are amortized on a straight-line basis over
10 years, which is managements estimate of the
assets useful life.
Patents consist of outside legal costs associated with obtaining
patents for products that have already been approved for
marketing by the Food and Drug Administration (FDA). Upon
issuance of a patent, the finite useful economic life of the
patent (or family of patents) is determined, and the patent is
amortized over such useful life. If it becomes probable that a
patent will not be issued, related costs associated with the
patent application will be expensed at that time. All costs
associated with obtaining patents for products that have not
been approved for marketing by the FDA are expensed as incurred.
When the Company acquires license agreements, product rights,
and other identifiable intangible assets, it records the
aggregate purchase price as an intangible asset. The Company
allocates the purchase price to the fair value of the various
intangible assets in order to amortize their cost as an expense
in the consolidated statements of income, over the estimated
useful life of the related asset.
In accordance with Statement of Financial Accounting Standards
(SFAS) No. 144, Accounting for the Impairment or
Disposal of Long-Lived Assets, long-lived assets, such as
property, plant, and equipment, and purchased intangible assets
subject to amortization, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If circumstances
require a long-lived asset be tested for possible impairment,
the Company first compares undiscounted cash flows expected to
be generated by an asset to the carrying value of the asset. If
the carrying value of the long-lived asset is not recoverable on
an undiscounted cash flow basis, an impairment is recognized to
the extent that the carrying value exceeds its fair value. Fair
value is determined through various valuation techniques
including discounted cash flow models, quoted market values and
third-party independent appraisals, as considered necessary.
Assets to be disposed of would be separately presented in the
balance sheet and reported at the lower of the carrying amount
or fair value less costs to sell, and no longer depreciated. The
assets and liabilities of a disposed group classified as held
for sale would be presented separately in the appropriate asset
and liability sections of the balance sheet. The Company
recorded no impairment charges during the three-year period
ended December 31, 2006.
The Company recognizes revenue in accordance with the Security
and Exchange Commissions (SEC) Staff Accounting
Bulletin No. 101, Revenue Recognition in Financial
Statements as amended by Staff Accounting
Bulletin No. 104 (together, SAB 101), and
SFAS No. 48, Revenue Recognition When Right of
Return Exists (SFAS 48). Revenue is realized or
realizable and earned when all of the following criteria are
met: (1) persuasive evidence of an arrangement exists;
(2) delivery has occurred or services have been rendered;
(3) the sellers price to the buyer is fixed and
determinable; and (4) collectibility is
F-9
Notes to
consolidated financial statements
reasonably assured. SFAS 48 states that revenue from
sales transactions where the buyer has the right to return the
product shall be recognized at the time of sale only if
(1) the sellers price to the buyer is substantially
fixed or determinable at the date of sale, (2) the buyer
has paid the seller, or the buyer is obligated to pay the seller
and the obligation is not contingent on resale of the product,
(3) the buyers obligation to the seller would not be
changed in the event of theft or physical destruction or damage
of the product, (4) the buyer acquiring the product for
resale has economic substance apart from that provided by the
seller, (5) the seller does not have significant
obligations for future performance to directly bring about
resale of the product by the buyer, and (6) the amount of
future returns can be reasonably estimated.
The Companys net product revenue reflects reduction of
gross product revenue at the time of initial sales recognition
for estimated allowances for chargebacks, discounts, and damaged
goods and accruals of rebates, product returns, and
administrative fees for product promotion and fee for services.
Allowances of $184,334 and $298,913 as of December 31, 2005
and 2006, respectively, for chargebacks, discounts and
allowances for product damaged in shipment reduce accounts
receivable, and accrued balances of $83,056 and $742,678 as of
December 31, 2005 and 2006, respectively, for rebates,
product returns, and administrative fees increase other accrued
expenses.
As discussed in 2(b) above, the allowances for chargebacks,
discounts, and damaged goods are determined on a
product-by-product
basis, and are established by management as the Companys
best estimate at the time of sale based on each products
historical experience adjusted to reflect known changes in the
factors that impact such allowances. These are established based
on the contractual terms with direct and indirect customers and
analysis of historical levels of chargebacks, discounts, and
credits claimed for damaged product.
Other organizations, such as managed care providers, pharmacy
benefit management companies, and government agencies, may
receive rebates from the Company based on negotiated contracts
to carry our product or reimbursements for filled prescriptions.
These entities represent indirect customers of the Company. In
addition, the Company may provide rebates to the end user. In
conjunction with recognizing a sale to a wholesaler, sales
revenues are reduced and accrued expenses are increased by our
estimates of the rebates that will be owed.
Consistent with industry practice, the Company maintains a
return policy that allows customers to return product within a
specified period prior to and subsequent to the expiration date.
The Companys estimate of the provision for returns of
expired product is based upon historical experience with actual
returns.
The Company has also entered into agreements with key
wholesalers, resulting in product promotion and fee service
costs. In accordance with Emerging Issues Task Force (EITF)
No. 01-9,
Accounting for Consideration Given by a Vendor (Including a
Reseller of the Vendors Products) (EITF
01-9), these
administrative costs have been netted against product revenues.
For the first quarter of 2006 and the years ended
December 31, 2004 and 2005, the Company had two products
for which it received a co-promotion fee under the related
co-promotion agreements. The Company recognized the promotional
fees as revenue from co-promotion agreements during the period
in which the sales of the respective product occurred.
Other revenue is primarily comprised of revenue generated by CET
through consulting services, development funding, either from
private sector investment or through federal Small Business
(SBIR/STTR) grant programs, and lease income generated by
CETs Life Sciences Center, a research center that provides
scientists with access to flexible lab space and other resources
to develop their products. The Company has received two grants
for medical research and a grant related to the product
Acetadote®.
F-10
Notes to
consolidated financial statements
Revenue related to grants is recognized when all conditions
related to such grants have been met. Grant revenue totaled
approximately $50,000, $253,000, and $375,000 for the years
ended December 31, 2004, 2005, and 2006, respectively.
The Company provides for deferred taxes using the asset and
liability approach. Under this method, deferred tax assets and
liabilities are recognized for future tax consequences
attributable to operating loss and tax credit carryforwards, as
well as differences between the carrying amounts of existing
assets and liabilities and their respective tax bases. The
Companys principal differences are related to timing of
deductibility of certain items, such as depreciation,
amortization, and expense for options issued to nonemployees.
Deferred tax assets and liabilities are measured using enacted
tax rates, which are expected to apply to taxable income in the
years such temporary differences are expected to be recovered or
settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period of
enactment.
Prior to January 1, 2006, the Company applied the
intrinsic-value-based method of accounting prescribed by
Accounting Principles Board (APB) Opinion No. 25,
Accounting for Stock Issued to Employees, and related
interpretations and provided the required pro-forma disclosures
of SFAS No. 123, Accounting for Stock-Based
Compensation (SFAS 123) and
SFAS No. 148, Accounting for Stock-Based
CompensationTransition and Disclosure-an Amendment of FASB
Statement No. 123. Under this method, compensation
expense is recorded only if the current market price of the
underlying stock exceeded the exercise price on the date of
grant. All options granted by the Company had an exercise price
equal to or greater than the market price of the underlying
stock on the date of grant.
Effective January 1, 2006, the Company adopted the
requirements of SFAS No. 123 (revised), Share-Based
Payment (SFAS 123R), utilizing the prospective method
of adoption. Under this approach, SFAS 123R applies to new
awards and the modification, repurchase, or cancellation of
outstanding awards beginning on January 1, 2006. Under the
prospective method of adoption, compensation cost recognized in
2006 includes only share-based compensation cost for all
share-based payments granted subsequent to January 1, 2006.
The cost is based on the grant-date fair value estimated in
accordance with the provisions of SFAS 123R and is
recognized as expense over the employees requisite service
period. The Company calculates the fair value of employee
options using the Black-Scholes option pricing model. No
compensation cost for share-based payments granted prior to, but
not yet vested as of January 1, 2006 has been recognized.
Because the Company used the minimum value method for purposes
of estimating fair value under SFAS No. 123 prior to
January 1, 2006, no pro forma disclosures (as required by
SFAS 123 related to 2004 and 2005) are permitted under
SFAS 123R.
|
|
(k)
|
Research and
Development
|
Research and development costs are expensed in the period
incurred. Research and development costs are comprised mainly of
clinical trial expenses, salary and wages, and other related
costs such as materials and supplies. Development expense
includes activities performed by third-party providers
participating in the Companys clinical studies. The
Company accounts for these costs based on estimates of work
performed, patient enrollment, or fixed fee for services.
F-11
Notes to
consolidated financial statements
Advertising costs, including samples and print materials, are
expensed as incurred and amounted to $777,010, $479,361, and
$738,647 in 2004, 2005, and 2006, respectively.
The Company expenses distribution costs as incurred.
Distribution costs included in sales and marketing expenses
amounted to $610,424, $365,331, and $436,115 in 2004, 2005, and
2006, respectively.
The Company accounts for net income per share in accordance with
Statement of Financial Accounting Standards No. 128,
Earnings per Share. Basic net income per share is
calculated by dividing net income by the weighted average number
of shares outstanding. Except where the result would be
antidilutive to income from continuing operations, diluted
earnings per share is calculated by assuming the conversion of
convertible instruments and the elimination of related interest
expense, and the exercise of stock options, as well as their
related income tax benefits.
The following table reconciles the numerator and the denominator
used to calculate diluted net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended
December 31
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
558,204
|
|
|
|
1,954,319
|
|
|
|
4,404,451
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
outstandingbasic
|
|
|
4,541,076
|
|
|
|
4,747,866
|
|
|
|
4,898,595
|
|
Preferred stock shares
|
|
|
855,495
|
|
|
|
855,495
|
|
|
|
855,495
|
|
Dilutive effect of stock options
and warrants
|
|
|
2,344,569
|
|
|
|
2,441,684
|
|
|
|
2,262,336
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
outstandingdiluted
|
|
|
7,741,140
|
|
|
|
8,045,045
|
|
|
|
8,016,426
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The number of outstanding stock options that are excluded from
the above calculation, as their impact would be anti-dilutive,
was 18,038 for the year ended December 31, 2006. There were
no anti-dilutive outstanding options as of December 31,
2004 and 2005. The convertible promissory notes were excluded
from the diluted computation in 2004, as they were anti-dilutive.
Total comprehensive income was comprised solely of net income
for all periods presented.
The preparation of the consolidated financial statements in
conformity with U.S. generally accepted accounting
principles requires management of the Company to make estimates
and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent liabilities at the date
of the financial statements and the reported amounts of revenues
and expenses during the period. Significant items subject to
estimates and assumptions include those related to chargebacks,
rebates, discounts, credits for damaged product, and returns,
the valuation and determination of useful lives of
F-12
Notes to
consolidated financial statements
intangible assets and the rate such assets are amortized, and
the realization of deferred tax assets. Actual results could
differ from those estimates.
|
|
(q)
|
Recently Issued
Accounting Standards
|
In September 2005, the Emerging Issues Task Force issued EITF
No. 04-13,
Accounting for Purchases and Sales of Inventory with the Same
Counterparty (EITF
01-14). EITF
04-13
provides guidance as to when purchases and sales of inventory
with the same counterparty should be accounted for as a single
exchange transaction. EITF
04-13 also
provides guidance as to when a nonmonetary exchange of inventory
should be accounted for at fair value. EITF
04-13 will
be applied to new arrangements entered into, and modifications
or renewals to existing arrangements occurring after
January 1, 2007. The application of EITF
04-13 is not
expected to have a material impact on the Companys
consolidated financial statements.
In July 2006, the Financial Accounting Standards Board (FASB)
issued FIN No. 48, Accounting for Uncertainty in
Income Taxes-an interpretation of FASB Statement 109
(FIN 48). FIN 48 clarifies the accounting for
uncertainty in income taxes recognized in an enterprises
financial statements and prescribes a threshold of
more-likely-than-not for recognition of tax benefits of
uncertain tax positions taken or expected to be taken in a tax
return. FIN 48 also provides related guidance on
measurement, derecognition, classification, interest and
penalties, and disclosure. The provisions of FIN 48 will be
effective for the Company on January 1, 2007, with any
cumulative effect of the change in accounting principle recorded
as an adjustment to opening retained earnings. The Company is in
the process of assessing the impact of adopting FIN 48 on
its results of operations and financial position.
In September 2006, the FASB issued SFAS No. 157,
Fair Value Measurement (SFAS 157). SFAS 157
defines fair value, establishes a framework for the measurement
of fair value, and enhances disclosures about fair value
measurements. The Statement does not require any new fair value
measures. The Statement is effective for fair value measures
already required or permitted by other standards for fiscal
years beginning after November 15, 2007. The Company is
required to adopt SFAS 157 beginning on January 1,
2008. SFAS 157 is required to be applied prospectively,
except for certain financial instruments. Any transition
adjustment will be recognized as an adjustment to opening
retained earnings in the year of adoption. The Company is
currently evaluating the impact of adopting SFAS 157 on its
results of operations and financial position.
(3) PROPERTY
AND EQUIPMENT
Property and equipment consist of the following at
December 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Range of
|
|
|
|
|
|
|
|
|
|
useful
lives
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Computer hardware and software
|
|
|
3-5 years
|
|
|
$
|
97,862
|
|
|
|
119,143
|
|
Office equipment
|
|
|
3-15 years
|
|
|
|
23,521
|
|
|
|
24,167
|
|
Furniture and fixtures
|
|
|
5-10 years
|
|
|
|
119,328
|
|
|
|
140,866
|
|
Leasehold improvements
|
|
|
15 years
|
|
|
|
273,016
|
|
|
|
289,265
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
513,727
|
|
|
|
573,441
|
|
Less accumulated depreciation and
amortization
|
|
|
|
|
|
|
(139,783
|
)
|
|
|
(207,667
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
373,944
|
|
|
|
365,774
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-13
Notes to
consolidated financial statements
Depreciation and amortization expense during 2004, 2005, and
2006 was $39,216, $48,862, and $67,884, respectively, and is
included in the consolidated statements of income in general and
administrative expense.
(4) INTANGIBLE
ASSETS
Intangible assets consist of the following at December 31:
|
|
|
|
|
|
|
|
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Trademarks
|
|
$
|
46,986
|
|
|
|
46,986
|
|
Less accumulated amortization
|
|
|
(26,323
|
)
|
|
|
(31,000
|
)
|
|
|
|
|
|
|
|
|
|
Total trademarks
|
|
|
20,663
|
|
|
|
15,986
|
|
License
|
|
|
|
|
|
|
10,303,595
|
|
Less accumulated amortization
|
|
|
|
|
|
|
(515,181
|
)
|
|
|
|
|
|
|
|
|
|
Total license
|
|
|
|
|
|
|
9,788,414
|
|
Patents
|
|
|
16,312
|
|
|
|
29,870
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
36,975
|
|
|
|
9,834,270
|
|
|
|
|
|
|
|
|
|
|
Amortization expense, excluding amortization of product license
rights of $515,181 in 2006, for fiscal years 2004, 2005, and
2006 was $4,790, $4,675, and $4,677, respectively, and is
reflected in general and administrative expenses on the
accompanying consolidated statements of income. Amortization
expense, including the amortization of product licenses, is
expected to be approximately $690,000 in each of the years 2007
through 2011.
In April 2006, the Company completed a transaction to acquire
exclusive U.S. commercial rights (product licenses) for
Kristalose®
for fair value of $10,303,595. This amount includes cash paid on
the effective date of the agreement of $6,500,000, installment
payments discounted using an interest rate of 7.33% of
$1,397,560 and $2,426,377 due April 7, 2007 and
April 7, 2009, respectively, and acquisition costs of
$13,775, and is net of the fair value of services received by
the Company in 2006 of $34,117 under a transition agreement. The
fair value of these services was included in selling and
marketing expenses.
(5) LONG-TERM
DEBT
A summary of long-term debt is as follows at December 31:
|
|
|
|
|
|
|
|
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Revolving line of credit
|
|
$
|
281,209
|
|
|
|
825,951
|
|
Term note payable
|
|
|
|
|
|
|
4,583,332
|
|
|
|
|
|
|
|
|
|
|
|
|
|
281,209
|
|
|
|
5,409,283
|
|
Less current portion
|
|
|
281,209
|
|
|
|
1,833,332
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
|
3,575,951
|
|
|
|
|
|
|
|
|
|
|
In August and September 2003, the Company issued nine unsecured
promissory notes (the notes) with a combined face value of
$500,000 to several investors with original maturity dates of
130 days. One of the notes in the amount of $100,000 was
issued to a member of the Companys Board of Directors, and
the transaction is considered to be a related party transaction.
These notes bore interest at the
F-14
Notes to
consolidated financial statements
contractual rate of 12% per annum for the first
30 days and 15% per annum thereafter. In addition to
the contractual interest rate, if the Company had not paid all
amounts due under the notes, the Company agreed to grant stock
options at the rate of 770 shares of common stock per
$50,000 face value of the notes on each of (i) the
30 day after the issuance of the notes and (ii) on a
continuing basis, each successive
30-day
period thereafter, or portion thereof, as the notes remained
outstanding. The holders of the notes had, at their option,
until the maturity date of the notes, the right to convert all
or a portion of unpaid principal and interest into shares of the
Companys common stock at an exercise price of one share
per $12. In accordance with the terms of the note agreements,
the Company also agreed to issue stock options upon the issuance
of the notes to purchase shares of the Companys common
stock at an exercise price of $12 per share and at the rate
of 1,540 shares of common stock per $50,000 face value of
the notes.
The aggregate fair value of the stock options granted upon the
issuance of the notes was $153,538. In accordance with
Accounting Principles Board Opinion No. 14, Accounting
for Convertible Debt and Debt Issued with Stock Purchase
Warrants, the portion of the proceeds of the notes which is
allocable to the options was recorded as paid-in capital. The
allocation of value between the notes and the options of
$346,462 and $153,538, respectively, was based on the fair value
of the stock options at time of issuance, since the instruments
qualified for equity classification under EITF
No. 00-19,
Accounting for Derivative Instruments Indexed to, and
Potentially Settled in, a Companys Own
Stock. The discount on the instruments created by
an allocation of value to the options resulted in an effective
conversion price less than the fair market value of the
Companys common stock on the day the debt was issued
(commitment date). In accordance with EITF
No. 98-5,
Accounting for Convertible Securities with Beneficial
Conversion Features or Contingently Adjustable Conversion
Ratios, and EITF
No. 00-27,
Application of Issue
No. 98-5
to Certain Convertible Instruments, this difference was the
per share beneficial conversion feature and resulted in an
additional discount on the notes of $153,538. The total of the
discounts on the notes of $307,076 was accreted back to the
notes redemption value based on the effective-interest method
over the term of the notes. The Company amended the note
agreements in January 2004 to extend the maturity date an
additional 130 days. The modification was not considered to
be substantial under EITF
No. 96-19,
Debtors Accounting for a Modification or Exchange of Debt
Instruments
(EITF 96-19),
and was accounted for as a modification of the original debt. In
accordance with
EITF 96-19,
since the modification of the terms did not result in a debt
extinguishment, the change in the fair value of the embedded
conversion feature at the modification date (difference between
the fair value of the embedded conversion option immediately
before and after the modifications) of $45,534 should be
accounted for as an additional debt discount resulting in an
effect on the subsequent recognition of interest expense for the
associated debt. The amendments provided for an additional 1,540
stock options per $50,000 face value of the notes upon extension
of the notes. The fair value of the stock options, $151,074, was
recognized as additional interest expense over the extension
period. The modified notes had a 15% contractual interest rate
and contained similar provisions for granting 770 stock options
per $50,000 face value of the notes of each
30-day
anniversary of the notes being outstanding in the event of
nonpayment on the
agreed-upon
due dates. The following is a summary of the settlement of the
notes in May 2004.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued
|
|
|
|
|
|
|
Principal
|
|
|
interest
|
|
|
Total
|
|
|
|
|
Settled in 19,822 shares of
common stock
|
|
$
|
222,000
|
|
|
|
15,864
|
|
|
|
237,864
|
|
Settled in cash
|
|
|
278,000
|
|
|
|
37,053
|
|
|
|
315,053
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
500,000
|
|
|
|
52,917
|
|
|
|
552,917
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-15
Notes to
consolidated financial statements
During 2004, interest expense of $1,011,631 included $710,794
recorded by the Company as a result of the notes, which included
interest based on the contractual interest rate of the notes of
$29,167, the accretion of the discounts on the notes of $227,174
resulting from the fair value of the options granted when the
notes were issued and modified and the beneficial conversion
feature, and the fair value of the options issued at each thirty
day anniversary of $454,453.
At December 31, 2003, the Companys revolving line of
credit provided that the Company could borrow the lesser of
$3.5 million or 80% of eligible accounts receivable, plus
50% of eligible inventory. The interest rate on the line was
LIBOR, plus 4% and 2.5% at December 31, 2003 and 2004,
respectively (5.13% and 4.92% as of December 31, 2003 and
2004, respectively). In 2004, the remaining unamortized discount
related to the value of stock warrants to purchase
12,500 shares of common stock at an exercise price of
$12 per share that were issued when the Company modified
this line of credit in 2003 was $103,806 and was included in
interest expense. The warrants, which were outstanding and
exercisable as of December 31, 2006 and expire October
2013, were valued utilizing the Black-Scholes model, with a
expected term of 10 years, 0% dividend yield, expected
volatility of 79%, and a risk-free interest rate of 4.26%.
In April 2006, the Company completed a transaction with Inalco
Biochemicals, Inc. and Inalco S.p.A. (collectively Inalco) to
acquire exclusive U.S. commercial rights for
Kristalose®.
In order to complete this transaction, funding was obtained from
Bank of America in the form of a three-year term loan for
$5,500,000 and a new two-year revolving line of credit
agreement, both with an interest rate of LIBOR plus 2.5% (7.83%
as of December 31, 2006). The term loan is being paid off
in quarterly installments of $458,334, with final payment due in
2009. The Company can borrow under the revolving line of credit
through April 2008 the lesser of $4.0 million or 80% of
eligible accounts receivable, plus 50% of eligible inventory.
The Company must pay an annual commitment fee of
1/2
of 1% on the unused portion of the commitment. The credit
agreement provides that borrowings are collateralized by a first
priority lien on all of the Companys assets, except for
the Companys equity interest in Cumberland Emerging
Technologies, Inc. The credit agreement contains an adverse
subjective acceleration clause and also requires that the
Company maintain a lockbox. However, cash received in the
lockbox is not required to be applied against amounts borrowed
under the line of credit. This credit agreement contains various
covenants and the Company was in compliance with all covenants
at December 31, 2006. As of December 31, 2005 and
2006, the Company has borrowed $281,209 and $825,951,
respectively, under its revolving line of credit and had
additional credit available under the revolving line of credit
of approximately $2,982,000 at December 31, 2006. In
conjunction with these agreements, the Company issued warrants
to purchase up to 1,979 share of common stock at an
exercise price of $18 per share, which expire in April 2016 and
are outstanding and exercisable as of December 31, 2006.
The estimated fair value of these warrants of $25,680, as
determined using the Black-Scholes model utilizing a expected
term of 10 years, risk-free interest rate of 4.89%,
volatility of 60%, and 0% dividend yield, has been recorded in
the accompanying consolidated financial statements as equity and
deferred financing costs.
On September 4, 2003, the Company borrowed $1,000,000 from
S.C.O.U.T. Healthcare Fund, L.P. (S.C.O.U.T.) in the form of an
uncollateralized convertible promissory note with a maturity
date of September 3, 2004. This transaction is a related
party transaction as the general partner of S.C.O.U.T. serves on
the Board of Directors of the Company. The note bore interest at
a fixed annual rate of 10%. Pursuant to the terms of the note,
on its maturity date, the principal value of the note plus any
accrued interest totaling $1,100,004 automatically converted
into 91,667 shares of common stock of the Company. Total
interest expense under this note in 2004 was $67,670.
In the second quarter of 2005, the Company received
approximately $2,000,000 from various individuals and companies
in exchange for uncollateralized convertible promissory notes
with maturity
F-16
Notes to
consolidated financial statements
dates six months from the date of issuance. The notes bore
interest at a fixed annual rate of 3.5%. In the fourth quarter
of 2005, and pursuant to the terms of the note, the principal
value of the note of $2,000,000, plus all accrued interest of
$32,488, converted into 112,916 shares of the
Companys common stock. Accrued interest of $2,205 was paid
in cash at the request of the noteholder.
Future maturities of debt at December 31, 2006, by year and
in the aggregate, were as follow:
|
|
|
|
|
2007
|
|
$
|
1,833,332
|
|
2008
|
|
|
2,659,281
|
|
2009
|
|
|
916,670
|
|
|
|
|
|
|
Total debt payments
|
|
$
|
5,409,283
|
|
|
|
|
|
|
Interest expense associated with the Companys long-term
debt and other long-term obligations consist of the following
components for the years ended December 31.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Noncash interest expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of deferred financing
costsrevolving line of credit
|
|
$
|
|
|
|
|
|
|
|
|
14,433
|
|
Amortization of deferred financing
coststerm note payable
|
|
|
103,806
|
|
|
|
|
|
|
|
13,231
|
|
Options grant
expenseunsecured promissory notes
|
|
|
454,453
|
|
|
|
|
|
|
|
|
|
Accretion of
discountunsecured promissory notes
|
|
|
227,174
|
|
|
|
|
|
|
|
|
|
Accretion of
discountdeferred purchase price
|
|
|
|
|
|
|
|
|
|
|
210,220
|
|
Accretion of discountproduct
promotion costs
|
|
|
|
|
|
|
|
|
|
|
101,709
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785,433
|
|
|
|
|
|
|
|
339,593
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual interest expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
Revolving line of credit and term
note payable
|
|
|
75,841
|
|
|
|
57,967
|
|
|
|
351,875
|
|
Uncollateralized convertible
promissory notes
|
|
|
67,670
|
|
|
|
34,693
|
|
|
|
|
|
Unsecured promissory notes
|
|
|
29,167
|
|
|
|
|
|
|
|
|
|
Other long-term obligations
|
|
|
53,520
|
|
|
|
(29,456
|
)
|
|
|
30,336
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
226,198
|
|
|
|
63,204
|
|
|
|
382,211
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$
|
1,011,631
|
|
|
|
63,204
|
|
|
|
721,804
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6) OTHER
LONG-TERM OBLIGATIONS
Other long-term obligations consist of the following components
at December 31:
|
|
|
|
|
|
|
|
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Deferred purchase price, net of
discount of $465,843
|
|
$
|
|
|
|
|
4,034,157
|
|
Third-party development costs
|
|
|
410,846
|
|
|
|
410,846
|
|
Third-party sales force costs
|
|
|
329,169
|
|
|
|
|
|
Product promotional costs
|
|
|
1,376,401
|
|
|
|
578,111
|
|
Other
|
|
|
|
|
|
|
110,746
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,116,416
|
|
|
|
5,133,860
|
|
Less current portion
|
|
|
1,127,455
|
|
|
|
2,052,501
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
988,961
|
|
|
|
3,081,359
|
|
|
|
|
|
|
|
|
|
|
F-17
Notes to
consolidated financial statements
In April 2006, the Company entered into an agreement with Inalco
Biochemicals, Inc. and Inalco S.p.A. (collectively Inalco) to
acquire exclusive U.S. commercialization rights (the
rights) for
Kristalose®.
In order to complete this transaction, funding was obtained from
Bank of America in the form of a term loan and a new revolving
line of credit. Additionally, in accordance with the terms of
the agreement, the Company has deferred a portion of this
purchase price. The following is a summary of amounts deferred
under the agreement as of December 31, 2006:
|
|
|
|
|
First installment paid upon the
effective date of the agreement
|
|
$
|
6,500,000
|
|
Second installment of $1,500,000
due on April 7, 2007, net of $25,610 discount using an
effective interest rate of 7.33%, as of December 31, 2006
|
|
|
1,474,390
|
|
Third installment of $3,000,000
due on April 7, 2009, net of $440,233 discount using an
effective interest rate of 7.33%, as of December 31, 2006
|
|
|
2,559,767
|
|
|
|
|
|
|
|
|
|
10,534,157
|
|
Less amounts previously paid
|
|
|
6,500,000
|
|
|
|
|
|
|
Deferred purchase price, net of
unaccreted discount
|
|
$
|
4,034,157
|
|
|
|
|
|
|
During 2000, the Company signed an agreement with a third party
to cover a variety of development efforts related to a specific
pharmaceutical drug, including preparation of submissions to the
FDA. In accordance with the agreement, the Company was billed,
and the Company expensed, approximately $1,010,000 during the
fiscal years 2001 through 2003. As of December 31, 2006,
the Company has paid approximately $600,000 of this balance and
has accrued approximately $410,000 as a long-term obligation.
The balance of approximately $410,000 is due in the following
timeframe (a) approximately $205,000 due no later than
submission of an application to the FDA, and
(b) approximately $205,000 due no later than FDA approval.
If neither the submission of the FDA application nor FDA
approval occurs due to the Company terminating the project, the
$410,000 will become due and payable and will accrue interest at
12.5% until paid.
The agreement also calls for contingent payments upon certain
milestones. Upon meeting the first milestone, New Drug
Application (NDA) submission for the pharmaceutical drug and FDA
acceptance of the submission for review, a contingent payment of
approximately $205,000 will become due and payable. Upon meeting
the second milestone, FDA approval, a contingent payment of
approximately $1,005,000 will become due and payable as follows:
approximately $800,000 immediately and approximately $205,000 in
twelve monthly installments starting on the date the milestone
is met. Since the payments are contingent on specific events
which may or may not occur in the future, and which have not
occurred or are deemed probable of occurring as of
December 31, 2006, the contingent liability for these
amounts of approximately $1,200,000 has not been recorded.
In connection with the aforementioned agreement, the Company
granted 50,000 stock options with contingent vesting clauses to
purchase the Companys common stock at an exercise price of
$3.25. Vesting for 20,000 of these options was contingent upon
an NDA submission for the product candidate and FDA acceptance
of the submission for review on or before a target date of
July 30, 2003. If the NDA submission were to occur three
months after the target date, 12,000 options would vest. If the
submission for the product occurred between three and six months
after this target, 5,000 options would vest. None of the 20,000
options vested since the milestone was not met within six months
subsequent to the target date. The third party will have the
ability to vest in 30,000 options if FDA approval occurs within
13 months after the NDA is accepted for review. If approval
occurs within 14 and 15 months after acceptance for review,
the third party will vest in 15,000 options. If approval occurs
between 15 and 18 months after acceptance, the third party
will vest in 7,500 options. No options will vest after
18 months. As of December 31, 2006, the NDA submission
for the product candidate has not been submitted to the FDA for
review. Because vesting for these options is contingent
F-18
Notes to
consolidated financial statements
on events, which may or may not occur in the future, and which
have not occurred as of December 31, 2006, the expense for
these options has not been accounted for in the accompanying
consolidated financial statements.
The Company outsources certain sales force activities through an
agreement with a third party. Under the terms of the original
two-year agreement, the third party would bill the Company for
services performed regardless of whether or not the services led
to the generation and collection of co-promotion fees. However,
the agreement provided for deferral of payment for certain
amounts during the initial 12 months of the program, which
ended in November 2002. Beginning in the 13th month
(December 2002), the cumulative deferred amounts became due no
later than the 24th month of the program (November 2003),
payable in monthly installments of principal and interest.
However, the Company amended the agreement in April 2003 to
extend the due date of such deferred amounts to January 31,
2004. In February 2004, the Company amended the agreement to
extend the due date of such deferred amounts to June 30,
2004, at which time the full amount deferred was due. In 2005,
the Company agreed to make equal monthly payments to pay off the
balance owed. The amounts due under this agreement at
December 31, 2005 and 2006 were $329,169 and $0,
respectively. Total fees billed by the third party under this
and similar agreements, including various amendments, and
expensed by the Company totaled approximately $2,960,000,
$3,082,000, and $3,393,000 in 2004, 2005, and 2006, respectively.
In 2005, the Company entered into an agreement with a key
wholesaler for settlement of amounts owed under a contract in
the amount of $2,100,000 to be paid in installments over
28 months. The Company recorded this liability based on its
net present value of the payments of $1,976,000 using an
interest rate of 10%. At December 31, 2005 and 2006, the
Company had recorded liabilities of approximately $1,376,000 and
$578,000, respectively, related to this arrangement. In 2006,
interest expense includes accretion of the discount of $101,709
related to this liability.
As stated above in note 5, interest expense associated with
the Companys other long-term obligations in 2004, 2005,
and 2006 was $53,520, $(29,456), and $30,336, respectively. In
2005, amounts owed to a vendor were forgiven and the accrued
interest balance was reduced by that amount.
(7) Income
Taxes
Income tax benefit includes the following components:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
|
|
|
|
|
|
|
|
(121,359
|
)
|
State
|
|
|
|
|
|
|
|
|
|
|
(15,429
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(136,788
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
|
|
|
|
|
1,146,580
|
|
|
|
2,861,859
|
|
State
|
|
|
|
|
|
|
37,420
|
|
|
|
(28,555
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,184,000
|
|
|
|
2,833,304
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
|
1,184,000
|
|
|
|
2,696,516
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-19
Notes to
consolidated financial statements
The Companys effective income tax rate for 2004, 2005, and
2006 reconciles with the federal statutory tax rate as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Federal tax expense at statutory
rate
|
|
|
(34
|
)%
|
|
|
(34
|
)%
|
|
|
(34
|
)%
|
State income tax expense (net of
federal income tax benefit)
|
|
|
(3
|
)
|
|
|
(3
|
)
|
|
|
(2
|
)
|
Permanent differences
|
|
|
(51
|
)
|
|
|
1
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
Change in deferred tax asset
valuation allowance
|
|
|
88
|
|
|
|
192
|
|
|
|
194
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income tax benefit
|
|
|
|
%
|
|
|
154
|
%
|
|
|
158
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Components of the net deferred tax assets are as follows at
December 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Net operating loss and tax credits
|
|
$
|
4,096,939
|
|
|
|
3,520,054
|
|
|
|
2,834,870
|
|
Depreciation and amortization
|
|
|
(15,000
|
)
|
|
|
(9,914
|
)
|
|
|
71,412
|
|
Allowance for accounts receivable
|
|
|
76,000
|
|
|
|
97,032
|
|
|
|
30,841
|
|
Inventory write-off
|
|
|
|
|
|
|
73,271
|
|
|
|
175,961
|
|
Deferred charges
|
|
|
179,900
|
|
|
|
358,302
|
|
|
|
399,010
|
|
Investment income
|
|
|
|
|
|
|
(10,448
|
)
|
|
|
(10,448
|
)
|
Employee stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
37,747
|
|
Expense for options and stock
grants to nonemployees
|
|
|
488,126
|
|
|
|
505,489
|
|
|
|
517,523
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
|
4,825,965
|
|
|
|
4,533,786
|
|
|
|
4,056,916
|
|
Less deferred tax asset valuation
allowance
|
|
|
(4,825,965
|
)
|
|
|
(3,349,786
|
)
|
|
|
(39,612
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
|
|
|
|
1,184,000
|
|
|
|
4,017,304
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In assessing the realizability of deferred tax assets,
management considers whether it is more likely than not that
some portion or all of the deferred tax assets will not be
realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income during
the periods in which those temporary differences become
deductible. Management considers the scheduled reversal of
deferred tax liabilities, projected future taxable income, and
tax planning strategies in making this assessment. In order to
fully realize the deferred tax asset, the Company will need to
generate future taxable income of approximately $11,816,000
prior to the expiration of the net operating loss carryforwards
in 2025. Taxable income for the years ended December 31,
2004, 2005, and 2006 was $1,616,571, $1,969,198, and $2,139,954,
respectively. In the fiscal years 2004, 2005, and 2006, the
valuation allowance was reduced by $490,198, $1,476,179, and
$3,310,174, respectively, resulting in corresponding credits to
deferred income tax expense. Based upon the level of taxable
income over the last three years and projections for future
taxable income over the periods in which the deferred tax assets
are deductible, management believes it is more likely than not
that the Company will realize the benefits of these deductible
differences, net of the existing valuation allowances, at
December 31, 2006. The valuation allowance at
December 31, 2006 represents the deferred tax assets
associated with CET that the Company believes are not more
likely than not will be utilized. The amount of the deferred tax
asset considered realizable, however, could be reduced in the
near term if estimates of future taxable income during the
carryforward period are reduced.
The Company has federal net operating loss carryforwards of
approximately $6,255,000 at December 31, 2006 that expire
between 2022 and 2025. The Company also has state net operating
losses of approximately $9,615,000 that expire between 2016 and
2025. The Company has federal credit carryforwards of
approximately $323,000 that expire starting in 2021.
F-20
Notes to
consolidated financial statements
(8) SHAREHOLDERS
EQUITY
Preferred stock shareholders are entitled to vote with the
holders of common stock, as each preferred share is entitled to
the number of votes the holder would be entitled to if converted
to shares of common stock immediately prior to the vote. They
are also entitled to receive dividends on an equal basis with
holders of common stock on an if-converted equivalent.
Preferred stock shareholders are entitled to receive a
$3.25 per share liquidation preference in the event of the
dissolution, liquidation, or winding up of the Company. If
assets are insufficient to permit full payment, preferred
holders are entitled to ratable distribution of the available
assets. Preferred shares are convertible, at the option of the
holder, at any time after issuance, at the rate of one share of
common stock for each share of preferred stock. The preferred
stock will automatically be converted into common stock in the
event of an underwritten public offering of the Companys
common stock or in the event of a consolidation, merger, or sale
of substantially all of the assets of the Company. In addition,
preferred shareholders are entitled to adjustment of the ratio
of conversion of Series A Preferred Stock into common stock
to reduce dilution in the event that the Company issued
additional equity securities at a purchase price of less than
$3.25 per share.
|
|
(b)
|
Common Stock and
Warrants
|
In April 2004, the Company issued 43,000 shares of common
stock to a related party at a purchase price of $12 per
share for total proceeds of $516,000. Simultaneously with the
issuance of the shares of stock, the Company issued a stock
purchase warrant with a fair value of $196,200 to purchase
20,000 shares of common stock at an exercise price of
$12 per share at any time within seven years of issuance.
The warrants, all of which are outstanding as of
December 31, 2006, were valued using the Black-Scholes
model using the following assumptions: 0% dividend yield, 77%
volatility, and 3.90% risk-free interest rate. The shares of
stock and the stock warrants were recorded at their relative
fair value of $142,150 and $373,850, respectively.
In March 2005, the Company initiated a private placement
offering of its common stock. The purpose of this offering was
for working capital and for other general corporate purposes,
including, but not limited to, the acquisition and development
of pharmaceutical products. The offering was a private, limited
offering by the Company in reliance upon exemptions from the
federal registration provisions of the Securities Act of 1933,
as amended, promulgated by the SEC under Regulation D. This
offering was completed in 2005, and the Company issued
100,000 shares of common stock at $18 per share, for
total net proceeds of $1,789,364 (gross proceeds of
$1,800,000 net of cash offering costs of $10,636). The
Company issued 3,500 stock options with a fair value of $51,806
to a non-employee as compensation for consulting services
associated with the private placement. The fair value of these
options has been recorded as additional offering costs and as
stock options granted for services received.
In 2004 and 2005, the Company issued 111,489 and
112,916 shares of common stock, respectively, upon
conversion of certain promissory notes into shares of the
Companys common stock. See note 5 for a more in-depth
discussion of these transactions.
During 2004, 2005, and 2006, the Company issued 25,267, 25,001,
and 13,759 shares of common stock, respectively, valued at
$303,204, $300,012, and $273,298, respectively, to executives,
related parties, and advisors as compensation for services, and
is included in general and administrative expenses in the
consolidated statements of income. Included in these amounts are
shares of common stock granted to board members of 15,600,
23,120, and 12,409 in 2004, 2005, and 2006, respectively, for
consulting services rendered. The expense associated with these
grants to board members was
F-21
Notes to
consolidated financial statements
$187,200, $277,400, and $248,998 in 2004, 2005, and 2006,
respectively. In addition, the Company issued 18,799, 8,825, and
18,167 net shares of common stock to key executives and an
advisor, who exercised options in 2004, 2005, and 2006,
respectively.
As disclosed in notes 5 and 8(b), at December 31,
2006, the Company had outstanding warrants to acquire
34,479 shares of its common stock. See notes 5 and
8(b) for further information.
(9) STOCK
OPTIONS
The Company has adopted the Cumberland Pharmaceuticals Inc. 1999
Stock Option Plan (the Plan) that includes both incentive stock
options and nonqualified stock options to be granted to
employees, officers, consultants, directors, and affiliates of
the Company. The Company has reserved 4,050,000 shares of
no par value common stock for issuance under this Plan.
Incentive stock options must be granted with an exercise price
not less than the fair market value of the common stock on the
grant date. The options granted to shareholders owning more than
10% of the common stock on the grant date must be granted with
an exercise price not less than 110% of the fair market value of
the common stock on the grant date.
The options are exercisable on the date(s) established by each
grant; however, options granted to officers or directors are not
exercisable until at least six months after grant date. The
maximum exercise life of an option is ten years from grant date
and is five years for stock options issued to 10% shareholders.
Vesting is determined on a
grant-by-grant
basis, in accordance with the terms of the Plan and the related
grant agreements.
Options granted in connection with financing arrangements
discussed in note 5 were separately approved by the board of
directors and do not reduce the amount of options available for
issuance under the Plan.
Stock option activity for the three-year period ended
December 31, 2006 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
average
|
|
|
|
Number of
|
|
|
exercise price
|
|
|
|
shares
|
|
|
per
share
|
|
|
|
|
Options outstanding,
December 31, 2003
|
|
|
3,901,133
|
|
|
$
|
1.89
|
|
Options granted
|
|
|
170,625
|
|
|
|
12.01
|
|
Options exercised
|
|
|
(19,150
|
)
|
|
|
0.22
|
|
Options expired
|
|
|
(20,000
|
)
|
|
|
3.25
|
|
|
|
|
|
|
|
|
|
|
Options outstanding,
December 31, 2004
|
|
|
4,032,608
|
|
|
|
2.34
|
|
Options granted
|
|
|
131,350
|
|
|
|
12.98
|
|
Options exercised
|
|
|
(9,555
|
)
|
|
|
1.89
|
|
|
|
|
|
|
|
|
|
|
Options outstanding,
December 31, 2005
|
|
|
4,154,403
|
|
|
|
2.68
|
|
Options granted
|
|
|
47,975
|
|
|
|
18.38
|
|
Options exercised
|
|
|
(19,484
|
)
|
|
|
1.93
|
|
Options expired
|
|
|
(4,500
|
)
|
|
|
18.00
|
|
Options forfeited
|
|
|
(173,416
|
)
|
|
|
5.26
|
|
|
|
|
|
|
|
|
|
|
Options outstanding,
December 31, 2006
|
|
|
4,004,978
|
|
|
|
2.74
|
|
|
|
|
|
|
|
|
|
|
F-22
Notes to
consolidated financial statements
Of the options outstanding in 2004, 2005, and 2006, 2,361,518,
2,388,018, and 2,391,864, respectively, were options issued to
one key executive.
The following table summarizes information concerning currently
outstanding and exercisable options:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
outstanding
|
|
|
Remaining
|
|
|
average
|
|
|
|
|
|
|
Range of
|
|
and expected
|
|
|
contractual
|
|
|
exercise
|
|
|
Options
|
|
Year
|
|
Exercise
Prices
|
|
to vest
|
|
|
life
|
|
|
price
|
|
|
exercisable
|
|
|
|
|
1999
|
|
$0.20-0.22
|
|
|
422,840
|
|
|
|
2.06 years
|
|
|
$
|
0.21
|
|
|
|
422,840
|
|
1999
|
|
1.00-1.10
|
|
|
2,355,379
|
|
|
|
2.70 years
|
|
|
|
1.09
|
|
|
|
2,355,379
|
|
2000
|
|
1.85
|
|
|
94,200
|
|
|
|
3.55 years
|
|
|
|
1.85
|
|
|
|
94,200
|
|
2001
|
|
3.25
|
|
|
401,078
|
|
|
|
4.22 years
|
|
|
|
3.25
|
|
|
|
401,078
|
|
2002
|
|
3.25-3.58
|
|
|
162,108
|
|
|
|
5.03 years
|
|
|
|
3.26
|
|
|
|
162,108
|
|
2002
|
|
6.25
|
|
|
6,775
|
|
|
|
5.48 years
|
|
|
|
6.25
|
|
|
|
6,775
|
|
2003
|
|
6.25-12.00
|
|
|
227,923
|
|
|
|
6.32 years
|
|
|
|
8.21
|
|
|
|
227,923
|
|
2004
|
|
12.00-13.20
|
|
|
160,625
|
|
|
|
7.36 years
|
|
|
|
12.01
|
|
|
|
160,625
|
|
2005
|
|
12.00-18.00
|
|
|
131,075
|
|
|
|
7.15 years
|
|
|
|
12.97
|
|
|
|
58,110
|
|
2006
|
|
18.00-19.80
|
|
|
42,975
|
|
|
|
7.48 years
|
|
|
|
18.42
|
|
|
|
10,050
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,004,978
|
|
|
|
|
|
|
|
|
|
|
|
3,899,088
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The fair value of employee options granted during 2006 were
estimated using the Black-Scholes option pricing model and the
following assumptions:
|
|
|
|
|
Dividend yield
|
|
|
0%
|
|
Expected term (years)
|
|
|
3-7
|
|
Expected volatility (range)
|
|
|
47%-54%
|
|
Risk-free interest rate (range)
|
|
|
4.68%-5.08%
|
|
The Company determined the expected life of share options based
on the simplified method allowed by SEC Staff Accounting
Bulletin No. 107. Under this approach,
the expected term is presumed to be the average between the
weighted average vesting period and the contractual term. The
expected volatility over the term of the respective option was
based on the volatility of similar entities. In evaluating
similarity, the Company considered factors such as industry,
stage of life cycle, size, and financial leverage. The risk-free
rate is based on a zero-coupon U.S. Treasury bond with a
term substantially equal to the corresponding options
expected term. The Company has never declared or paid any cash
dividends and does not presently plan to pay cash dividends in
the foreseeable future. The Company has reviewed historical
termination behavior and does not anticipate any further
forfeitures on options granted during 2006.
The fair value of non-employee options was estimated using the
Black-Scholes option pricing model and the following assumptions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Dividend yield
|
|
|
0%
|
|
|
|
0%
|
|
|
|
0%
|
|
Expected term (years)
|
|
|
10
|
|
|
|
10
|
|
|
|
.17-10
|
|
Expected volatility (range)
|
|
|
77%
|
|
|
|
77%
|
|
|
|
37%-63%
|
|
Risk-free interest rate (range)
|
|
|
3.90%
|
|
|
|
4.13%-4.39%
|
|
|
|
4.34%-4.42%
|
|
F-23
Notes to
consolidated financial statements
The Company determined the above assumptions utilizing the same
methodology as noted above for employees, except for the
expected term, which was calculated to be the contractual terms
of the options in accordance with SFAS 123R.
As previously discussed in item (j) of note 2, there
was no expense recorded in 2006 and there will be no expense in
future years associated with unvested employee stock option
awards outstanding as of January 1, 2006 due to the Company
utilizing the prospective method upon adoption of SFAS 123R.
The weighted average grant date fair value of share options
granted during the year ended December 31, 2004, 2005, and
2006 was approximately $12.00, $12.73, and $18.00, respectively.
The Company received cash from the exercise of stock options of
$4,950 and $9,000 during 2005 and 2006, respectively. Upon
exercise, the Company issues new shares of stock. During the
years ended December 31, 2004, 2005, and 2006, the
aggregate intrinsic value of options exercised under the Plan
was $225,587, $153,899, and $357,730, respectively, determined
as of the date of option exercise.
During the year ended December 31, 2006, the Company
recognized $141,836 of compensation expense related to stock
options and recognized a corresponding tax benefit of $37,747.
This amount consists of non-employee stock option expense of
$37,751 and employee stock option expense of $104,085. Such
expense is presented as a component of general and
administrative expenses. At December 31, 2006, there was
approximately $321,535 of unrecognized compensation cost related
to share-based payments granted in 2006, which is expected to be
recognized over a period of four years. This amount consists of
non-employee unrecognized compensation cost of $55,077 and
employee unrecognized compensation cost of $266,458.
The Company issued a total of 18,780, 23,800, and 12,000 stock
options to non-employees for services rendered by these
individuals in 2004, 2005, and 2006 as compensation for
assisting the Companys management and supporting
operations. The amount of compensation expense recorded for such
services was $43,928, $226,709, and $37,751, in 2004, 2005, and
2006, respectively. Such expense is presented as a component of
general and administrative expenses. Included in these amounts
are options to purchase 16,780 shares of common stock at an
exercise price of $12.00 in 2004 and options to purchase
11,000 shares of common stock at an exercise price of
$18.00 in 2005 and that were granted to two board members.
(10) LEASES
The Company is obligated under long-term real estate leases for
office space expiring at various times through December 2011.
The Company also subleases a portion of the space under these
leases. Rent expense is recognized over the expected term of the
lease, including renewal option periods, on a straight-line
basis. Rent expense for 2004, 2005, and 2006 was $139,587,
$151,479, and $286,037, respectively, and sublease income was
$45,035, $49,131, and $71,173, respectively. Future minimum
lease payments under non-cancelable operating leases (with
initial or remaining lease terms in excess of one year) are:
|
|
|
|
|
Year ending December 31:
|
|
|
|
|
2007
|
|
$
|
375,461
|
|
2008
|
|
|
487,015
|
|
2009
|
|
|
492,278
|
|
2010
|
|
|
460,490
|
|
2011
|
|
|
46,711
|
|
|
|
|
|
|
Total minimum lease payments
|
|
$
|
1,861,955
|
|
|
|
|
|
|
F-24
Notes to
consolidated financial statements
Minimum lease payments have not been reduced by minimum sublease
rentals of $49,880 and $7,860 in 2007 and 2008, respectively,
under non-cancelable subleases.
During December of 2006, the Company signed a lease agreement
for additional office space at its West End location. The lease
agreement begins June 1, 2007 and ends on October 31,
2010. The additional cost of this agreement is approximately
$223,000 per year and has been included in the table above.
(11) MANUFACTURING
AND SUPPLY AGREEMENTS
The Company utilizes one supplier to manufacture each of its
products and product candidates. Although there are a limited
number of manufacturers of pharmaceutical products, management
believes that they could utilize other suppliers to manufacture
their prescription products on comparable terms. A change in
suppliers, any problems with such manufacturing operations or
capacity, or contract disputes with the suppliers, however,
could cause a delay in manufacturing and a possible loss of
sales, which would affect operating results adversely.
The Companys manufacturing and supply agreements with the
manufacturers of its products contain minimum purchase
obligations. For 2007, these obligations require the Company to
purchase approximately $2.1 million of product,
$2.4 million during 2008, $2.7 million during 2009,
$3.0 million during 2010, and $800,000 during 2011.
Beginning in April 2011 and continuing through the life of the
agreement, one of the manufacturing and supply agreements
requires minimum purchases of not less than 65% of the average
purchases in each of the three immediately preceding annual
periods.
The Companys purchases under these agreements are
reflected in the cost of products sold in the accompanying
consolidated statements of income.
(12) CONTINGENCIES
The Company is currently party to one legal proceeding brought
about by an employee of a third-party contract sales
organization that does business with the Company. The lawsuit
asserts a multitude of claims arising out of the contract sales
organizations decision to separate employment after the
employee claimed to have suffered a workers compensation
injury. The Company filed a Motion to Dismiss all of the claims
against the Company and its representatives. The oral arguments
were heard on the motion in November 2006. In December 2006, the
Magistrate Judge recommended the Companys Motion to
Dismiss be granted on all claims.
(13) EMPLOYMENT
AGREEMENTS
Effective January 1, 2006, the Company entered into
employment agreements with its full-time and part-time
employees. Each employment agreement provides for a salary basis
for services performed, a potential annual bonus, and, if
applicable, a grant of incentive options to purchase the
Companys common shares pursuant to an option agreement.
Two of the employment agreements address expense reimbursements
for relevant and applicable licenses and continuing education.
Employment agreements are amended each successive one-year
period, unless terminated.
(14) MARKET
CONCENTRATIONS
The Company currently focuses on acquiring, developing, and
commercializing branded prescription products for the acute care
and gastroenterology markets. The Companys principal
financial instruments subject to potential concentration of
credit risk are accounts receivable, which are unsecured, and
cash equivalents. The Companys cash equivalents consist
primarily of money market
F-25
Notes to
consolidated financial statements
funds. Certain bank deposits may at times be in excess of the
Federal Deposit Insurance Corporation (FDIC) insurance limits.
The Companys primary customers are wholesale
pharmaceutical distributors in the U.S. Total revenues from
customers representing 10% or more of total revenues for the
respective years are summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004
|
|
|
2005
|
|
|
2006
|
|
|
|
|
Customer 1
|
|
|
34
|
%
|
|
|
34
|
%
|
|
|
22
|
%
|
Customer 2
|
|
|
13
|
|
|
|
33
|
|
|
|
20
|
|
Customer 3
|
|
|
27
|
|
|
|
13
|
|
|
|
25
|
|
Additionally, 92% and 67% of the Companys accounts
receivable balances were due from these three customers at
December 31, 2005 and 2006, respectively.
(15) EMPLOYEE
BENEFIT PLAN
The Company sponsors an employee benefit plan that was
established January 1, 2006, the Cumberland Pharmaceuticals
401(k) Plan (the Plan) under section 401(k) of the Internal
Revenue Code of 1986, as amended, for the benefit of all
employees over the age of 21, having been employed by the
Company for at least six months. The Plan provides that
participants may contribute up to the maximum amount of their
compensation as set forth by the Internal Revenue Service each
year. Employee contributions are invested in various investment
funds based upon elections made by the employee. There were no
contributions made by the Company to the Plan in 2006.
(16) SUBSEQUENT
EVENTS
Beginning January 1, 2007, the Companys newly formed
subsidiary, Cumberland Pharma Sales Corp., began full operations
for the purpose of employing the newly acquired hospital sales
force, which promotes the Companys products,
Acetadote®
and
Kristalose®
in the acute care market. Previously, this sales force was
contracted through a third-party contract sales organization. In
October 2006, the Company notified the contract sales
organization that it was exercising its right to convert the
sales force to the Companys employees and would,
therefore, not renew the contract sales agreement which expired
on December 31, 2006.
In January 2007, the Companys board of directors approved
the Long-Term Incentive Compensation Plan, which was
subsequently approved by the shareholders in April 2007. The
purposes of the Long-Term Incentive Compensation Plan are to
encourage the Companys employees and consultants to
acquire stock and other equity-based interests and is intended
to replace the Cumberland Pharmaceuticals Inc. 1999 Stock Option
Plan without impairing the vesting or exercise of any option
granted thereunder.
F-26
Cumberland
Pharmaceuticals Inc. and Subsidiaries
Schedule IIvaluation
and qualifying accounts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Column
B
|
|
|
Column
C
|
|
|
|
|
|
Column
E
|
|
|
|
Balance at
|
|
|
Charged to
|
|
|
Charged to
|
|
|
Column
D
|
|
|
Balance
|
|
Column
A
|
|
beginning
|
|
|
costs and
|
|
|
other accounts
|
|
|
Deductions
|
|
|
at end
|
|
Description
|
|
of
period
|
|
|
expenses
|
|
|
describe
|
|
|
describe(1)
|
|
|
of
period
|
|
|
|
|
Allowance for uncollectible
amounts, cash discounts, chargebacks, and credits issued for
damaged products:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the period ended:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2004
|
|
$
|
|
|
|
$
|
1,134,053
|
|
|
$
|
|
|
|
$
|
(944,094
|
)
|
|
$
|
189,959
|
|
December 31, 2005
|
|
|
189,959
|
|
|
|
616,908
|
|
|
|
|
|
|
|
(622,533
|
)
|
|
|
184,334
|
|
December 31, 2006
|
|
|
184,334
|
|
|
|
1,449,564
|
|
|
|
|
|
|
|
(1,334,985
|
)
|
|
|
298,913
|
|
Valuation allowance for deferred
tax assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the period ended:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2004
|
|
$
|
5,316,163
|
|
|
$
|
(490,198
|
)
|
|
$
|
|
|
|
$
|
|
|
|
$
|
4,825,965
|
|
December 31, 2005
|
|
|
4,825,965
|
|
|
|
(1,476,179
|
)(2)
|
|
|
|
|
|
|
|
|
|
|
3,349,786
|
|
December 31, 2006
|
|
|
3,349,786
|
|
|
|
(3,310,174
|
)(3)
|
|
|
|
|
|
|
|
|
|
|
39,612
|
|
|
|
|
(1) |
|
Write-off of uncollectible accounts, net of recoveries,
discounts, chargebacks, and credits taken by customers. |
|
(2) |
|
Includes a $1,184,000 reduction in the valuation allowance
reflecting the Companys belief that the future recognition
of this amount of deferred tax assets is more likely than not.
Remaining decrease is due to the utilization of deferred tax
assets. |
|
(3) |
|
Includes a $2,833,303 reduction in the valuation allowance
reflecting the Companys belief that the future recognition
of this amount of deferred tax assets is more likely than not.
Remaining decrease is due to the utilization of deferred tax
assets. |
F-27
Part II
Information not
required in prospectus
|
|
ITEM 13.
|
OTHER EXPENSES OF
ISSUANCE AND DISTRIBUTION.
|
The expenses relating to the registration of the shares of
common stock being offered hereby, other than underwriting
discounts and commissions, will be borne by us. Such expenses
are estimated to be as follows:
|
|
|
|
|
Item
|
|
Amount
|
|
|
|
|
SEC registration fee
|
|
$
|
|
|
NASD filing fee
|
|
$
|
|
|
NASDAQ listing fee
|
|
$
|
|
|
Printing expenses
|
|
$
|
|
|
Legal fees and expenses
|
|
$
|
|
|
Accounting fees and expenses
|
|
$
|
|
|
Transfer agent and registrar
expenses
|
|
$
|
|
|
Total
|
|
$
|
|
|
|
|
ITEM 14.
|
INDEMNIFICATION
OF DIRECTORS AND OFFICERS.
|
Our charter and bylaws provide for indemnification of our
directors to the fullest extent permitted by the Tennessee
Business Corporation Act, as amended from time to time. Our
directors shall not be liable to the corporation or its
shareholders for monetary damages for breach of fiduciary duty
as a director. The Tennessee Business Corporation Act provides
that a Tennessee corporation may indemnify its directors and
officers against expenses, judgments, fines and amounts paid in
settlement actually and reasonably incurred by them in
connection with any proceeding, whether criminal or civil,
administrative or investigative if, in connection with the
matter in issue, the individuals conduct was in good
faith, and the individual reasonably believed: in the case of
conduct in the individuals official capacity with the
corporation, that the individuals conduct was in its best
interest; and in all other cases, that the individuals
behavior was at least not opposed to its best interest; and in
the case of a criminal proceeding, the individual had no reason
to believe the individuals conduct was unlawful. In
addition, we have entered into indemnification agreements with
our directors. These provisions and agreements may have the
practical effect in certain cases of eliminating the ability of
our shareholders to collect monetary damages from directors. We
believe that these contractual agreements and the provisions in
our charter and bylaws are necessary to attract and retain
qualified persons as directors.
|
|
ITEM 15.
|
RECENT SALES OF
UNREGISTERED SECURITIES.
|
In September 2003, we borrowed $500,000 from nine existing and
accredited shareholders pursuant to uncollateralized secured
notes payable with original maturity dates of 130 days.
These notes bore interest at 12% for the first 30 days and
15% thereafter. The holders of the notes had, at their option,
until the maturity date of the notes payable, the right to
convert all or a portion of the unpaid principal and interest
into shares of our common stock at a rate of $12.00 per share.
We also issued to these lenders options to purchase shares of
our common stock, at an exercise price of $12.00 per share,
and at the rate of 1,540 shares of common stock per $50,000
face value of the notes. If we had not prepaid all amounts due
and owing under the notes, we agreed to grant additional options
at the rate of 770 shares of common stock per $50,000 face
value on each of (i) the 30th day after the date of
the notes and (ii) on a continuing basis, each successive
30-day
period thereafter, or portion thereof, as the notes remained
outstanding. At December 31, 2003, the notes payable had
not been prepaid, so we granted options to acquire an additional
30,800 shares. We amended the notes agreements in
January 2004 to extend the maturity date 130 days. The
amendments granted an additional option to
II-1
Part II
purchase 1,540 shares per $50,000 face value upon extension
of the notes and contained similar provisions for granting
options in the event of nonpayment on the
agreed-upon
due dates. Based on the extension of the maturity date, to
purchase a total of 61,600 shares were earned by the
holders of the notes in 2004. We repaid these notes or settled
these notes in shares in May 2004. The issuance of these
securities was exempt from registration under the Securities Act
in reliance on Section 4(2) of the Securities Act.
In September 2003, we borrowed $1,000,000 from S.C.O.U.T.
Healthcare Fund, L.P., or S.C.O.U.T., in the form of a
convertible promissory note with a maturity date of September
2004. The President and majority shareholder of the general
partner of S.C.O.U.T., Dr. Lawrence W. Greer, serves on our
board of directors. Pursuant to the terms of the note, on its
maturity date, S.C.O.U.T. converted the principal value of the
note plus all interest accrued at a fixed rate of ten percent
per annum into 91,667 shares of our common stock at a price
of $12.00 per share.
On April 15, 2004, we issued 43,000 common shares at
$12.00 per share, for an aggregate consideration of
$516,000 and a five-year warrant to purchase 20,000 common
shares at $12.00 per share to S.C.O.U.T., which represented
to us that it was an accredited investor. This issuance was
exempt from registration under the Securities Act in reliance on
Section 4(2) of the Securities Act.
By an offering memorandum dated April 1, 2005, we offered
100,000 shares of our common stock at a purchase price of
$18.00 per share. Thirty investors subscribed for
100,000 shares in the aggregate, for an aggregate
consideration of $1,800,000. This issuance was exempt from
registration under the Securities Act in reliance on
Section 4(2) of the Securities Act.
By an offering memorandum dated May 5, 2005, we received
approximately $2,000,000 from approximately 41 investors in
exchange for uncollateralized convertible promissory notes with
a maturity date six months from the date of issuance. Upon
maturity, the principal and accrued interest payable on the
notes converted into 112,916 shares of common stock at a
rate of $18.00 per share. This issuance was exempt from
registration under the Securities Act in reliance on
Section 4(2) of the Securities Act.
Since January 1, 2004, we have granted options to purchase
287,610 shares of our common stock under the
1999 Option Plan to our employees, directors and
consultants at exercise prices ranging from $12.00 to
$22.00 per share. Of these, an aggregate of 775 shares
of our common stock were issued upon the exercise of stock
options.
Since January 1, 2004, we also issued an aggregate of
75,645 shares of common stock as compensation for services
pursuant to contracts. Restricted-stock legends were affixed to
the securities issued in these transactions. Our board of
directors determined that the fair value of the services
received equaled the value of the stock granted with values
ranging from $12.00 to $22.00 per share. The issuances of
common stock in connection with awards of restricted stock were
exempt either pursuant to Rule 701 or pursuant to
Section 4(2) of the Securities Act as transactions by an
issuer not involving a public offering.
|
|
ITEM 16.
|
EXHIBITS AND
FINANCIAL STATEMENT SCHEDULES.
|
(a)
|
|
|
No.
|
|
Description
|
|
|
1.1*
|
|
Form of Underwriting Agreement.
|
3.1
|
|
Second Amended and Restated
Charter of Cumberland Pharmaceuticals Inc.
|
3.2
|
|
Amended and Restated Bylaws of
Cumberland Pharmaceuticals Inc.
|
II-2
Part II
|
|
|
No.
|
|
Description
|
|
|
4.1*
|
|
Specimen Common Stock Certificate
of Cumberland Pharmaceuticals Inc.
|
4.2
|
|
Warrant to Purchase Common Stock
of Cumberland Pharmaceuticals Inc., issued to Bank of America,
N.A. on October 21, 2003.
|
4.3*
|
|
Stock Purchase Warrant, issued to
S.C.O.U.T. Healthcare Fund L.P. on April 15, 2004.
|
4.4
|
|
Warrant to Purchase Common Stock
of Cumberland Pharmaceuticals Inc., issued to Bank of America,
N.A. on April 6, 2006.
|
4.5#
|
|
Form of Option Agreement under
1999 Stock Option Plan of Cumberland Pharmaceuticals Inc.
|
4.6*#
|
|
Form of Option Agreement under
2007 Long-Term Incentive Compensation Plan of Cumberland
Pharmaceuticals Inc.
|
4.7*#
|
|
Form of Agreement under
2007 Directors Compensation Plan of Cumberland
Pharmaceuticals Inc.
|
5.1*
|
|
Opinion of Adams and Reese LLP.
|
10.1
|
|
Manufacturing and Supply Agreement
for N-Acetylcysteine, dated January 15, 2002, by and
between Bioniche Life Sciences, Inc. and Cumberland
Pharmaceuticals Inc.
|
10.2
|
|
Novation Agreement, dated
January 27, 2006, by and among Bioniche Life Sciences,
Inc., Bioniche Pharma Group Ltd., and Cumberland Pharmaceuticals
Inc.
|
10.3
|
|
First Amendment to Manufacturing
and Supply Agreement for N-Acetylcysteine, dated
November 16, 2006, by and between Bioniche Teoranta and
Cumberland Pharmaceuticals Inc.
|
10.4
|
|
Cardinal Health Contract Sales and
Services for Cumberland Pharmaceuticals Inc. Dedicated Sales
Force Agreement, dated May 16, 2006, by and between
Cardinal Health PTS, LLC and Cumberland Pharmaceuticals Inc.
|
10.5
|
|
First Amendment to Contract Sales
and Service Agreement, dated July 19, 2006, by and between
Cardinal Health PTS, LLC and Cumberland Pharmaceuticals Inc.
|
10.6
|
|
Consent to Assignment by Cardinal
Health PTS, LLC to PG Holding Corporation of all of their
rights, title, interests and obligations under that certain
Cardinal Health Contract Sales and Services for Cumberland
Pharmaceuticals Inc. Dedicated Sales Force Agreement, dated
May 16, 2006, by and between Cardinal Health PTS, LLC and
Cumberland Pharmaceuticals Inc., as amended by that certain
First Amendment to Contract Sales and Service Agreement, dated
July 19, 2006, by and between Cardinal Health PTS, LLC and
Cumberland Pharmaceuticals Inc.
|
10.7
|
|
Distribution Services Agreement,
dated August 3, 2000, by and between CORD Logistics, Inc.
and Cumberland Pharmaceuticals Inc.
|
10.8
|
|
Strategic Alliance Agreement,
dated July 21, 2000, by and between F.H.
Faulding & Co. Limited and Cumberland Pharmaceuticals
Inc.
|
10.9
|
|
Kristalose Agreement, dated
April 7, 2006, by and among Inalco Biochemicals, Inc.,
Inalco S.p.A., and Cumberland Pharmaceuticals Inc.
|
10.10
|
|
License Agreement, dated
May 28, 1999, by and between Vanderbilt University and
Cumberland Pharmaceuticals Inc.
|
10.11#
|
|
Employment Agreement effective as
of January 1, 2007 by and between A.J. Kazimi and
Cumberland Pharmaceuticals Inc.
|
II-3
Part II
|
|
|
No.
|
|
Description
|
|
|
10.12#
|
|
Employment Agreement effective as
of January 1, 2007 by and between Jean W. Marstiller and
Cumberland Pharmaceuticals Inc.
|
10.13#
|
|
Employment Agreement effective as
of January 1, 2007 by and between Leo Pavliv and Cumberland
Pharmaceuticals Inc.
|
10.14#
|
|
Employment Agreement effective as
of January 1, 2007 by and between J. William Hix and
Cumberland Pharmaceuticals Inc.
|
10.15#
|
|
Employment Agreement effective as
of January 1, 2007 by and between David L. Lowrance and
Cumberland Pharmaceuticals Inc.
|
10.16*
|
|
Second Amended and Restated Loan
Agreement by and between Cumberland Pharmaceuticals Inc. and
Bank of America, N.A., dated April 6, 2006.
|
10.17#
|
|
1999 Stock Option Plan of
Cumberland Pharmaceuticals Inc.
|
10.18*#
|
|
2007 Long-Term Incentive
Compensation Plan of Cumberland Pharmaceuticals Inc.
|
10.19*#
|
|
2007 Directors
Compensation Plan of Cumberland Pharmaceuticals Inc.
|
10.20
|
|
Form of Indemnification Agreement
between Cumberland Pharmaceuticals Inc. and all members of its
Board of Directors.
|
10.21
|
|
Lease Agreement, dated
September 10, 2005, by and between Nashville Hines
Development, LLC and Cumberland Pharmaceuticals Inc.
|
10.22*
|
|
Sublease Agreement, dated
December 14, 2006, by and between Robert W.
Baird & Co. Incorporated and Cumberland Pharmaceuticals
Inc.
|
10.23
|
|
Amended and Restated Lease
Agreement, dated November 11, 2004, by and between The
Gateway to Nashville LLC and Cumberland Emerging Technologies,
Inc.
|
10.24
|
|
First Amendment to Amended and
Restated Lease Agreement, dated August 23, 2005, by and
between The Gateway to Nashville LLC and Cumberland Emerging
Technologies, Inc.
|
21
|
|
Subsidiaries of Cumberland
Pharmaceuticals Inc.
|
23.1
|
|
Consent of KPMG LLP.
|
23.2*
|
|
Consent of Adams and Reese, LLP
(contained in Exhibit 5).
|
24
|
|
Powers of Attorney (contained on
the signature page hereto).
|
|
|
*
|
To be filed by amendment.
|
|
#
|
Indicates a management contract or compensatory plan.
|
|
|
Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the Registration
Statement and submitted separately to the Securities and
Exchange Commission.
|
|
|
(b) |
See Schedule IIValuation and qualifying accounts
included in our audited financial statements included elsewhere
in this registration statement.
|
All other schedules have been omitted because they are not
applicable.
II-4
Part II
The undersigned registrant hereby undertakes to provide to the
underwriters at the closing specified in the underwriting
agreement certificates in such denominations and registered in
such names as required by the underwriters to permit prompt
delivery to each purchaser.
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers,
and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as
expressed in the Securities Act of 1933 and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer,
or controlling person of the registrant in the successful
defense of any action, suit, or proceeding) is asserted by such
director, officer, or controlling person in connection with the
securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Securities Act of 1933
and will be governed by the final adjudication of such issue.
The undersigned registrant hereby undertakes that:
1) For purposes of determining any liability under
the Securities Act of 1933, the information omitted from the
form of prospectus filed as part of this Registration Statement
in reliance upon Rule 430A and contained in a form of
prospectus filed by the Registrant pursuant to
Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of this Registration Statement as
of the time it was declared effective.
2) For the purpose of determining any liability under
the Securities Act of 1933, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new
Registration Statement relating to the securities offered
therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
II-5
Signatures
Pursuant to the requirements of the Securities Act of 1933, the
registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly
authorized in the City of Nashville, State of Tennessee, on the
1st day of May, 2007.
CUMBERLAND PHARMACEUTICALS INC.
A.J. Kazimi
Chairman and CEO
(Principal Executive Officer)
Signatures and Power
of Attorney
Each person whose signature appears below constitutes and
appoints A. J. Kazimi and David L. Lowrance, and each of them
individually, his or her true and lawful
attorneys-in-fact
and agents, with full power of substitution and resubstitution,
for him or her and in his or her name, place and stead, in any
and all capacities, to sign any and all amendments (including
post effective amendments) to this registration statement and
any additional registration statements to be filed pursuant to
Rule 462(b) under the Securities Act of 1933, and to file
the same, with all exhibits thereto and other documents in
connection therewith, with the SEC, granting unto said
attorneys-in-fact
and agents, and each of them, full power and authority to do and
perform each and every act and thing requisite and necessary to
be done in connection therewith, as fully to all intents and
purposes as he or she might or could do in person, hereby
ratifying and confirming all that said
attorneys-in-fact
and agents or any of them, or their or his or her substitute or
substitutes, may lawfully do or cause to be done by virtue
hereof.
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons
in the capacities and on the dates indicated.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
/s/ a.j.
kazimi
A.J.
Kazimi
|
|
Chairman and CEO (Principal
Executive Officer)
|
|
May 1, 2007
|
/s/ david
l. lowrance
David
L. Lowrance
|
|
Vice President and CFO (Principal
Financial and Accounting Officer)
|
|
May 1, 2007
|
/s/ robert
g. edwards
Robert
G. Edwards
|
|
Director
|
|
May 1, 2007
|
/s/ thomas
r. lawrence
Thomas
R. Lawrence
|
|
Director
|
|
May 1, 2007
|
/s/ lawrence
w. greer
Lawrence
W. Greer
|
|
Director
|
|
May 1, 2007
|
/s/ martin
e. cearnal
Martin
E. Cearnal
|
|
Director
|
|
May 1, 2007
|
S-1
Exhibit Index
|
|
|
No.
|
|
Description
|
|
|
1.1*
|
|
Form of Underwriting Agreement.
|
3.1
|
|
Second Amended and Restated
Charter of Cumberland Pharmaceuticals Inc.
|
3.2
|
|
Amended and Restated Bylaws of
Cumberland Pharmaceuticals Inc.
|
4.1*
|
|
Specimen Common Stock Certificate
of Cumberland Pharmaceuticals Inc.
|
4.2
|
|
Warrant to Purchase Common Stock
of Cumberland Pharmaceuticals Inc., issued to Bank of America,
N.A. on October 21, 2003.
|
4.3*
|
|
Stock Purchase Warrant, issued to
S.C.O.U.T. Healthcare Fund L.P. on April 15, 2004.
|
4.4
|
|
Warrant to Purchase Common Stock
of Cumberland Pharmaceuticals Inc., issued to Bank of America,
N.A. on April 6, 2006.
|
4.5#
|
|
Form of Option Agreement under
1999 Stock Option Plan of Cumberland Pharmaceuticals Inc.
|
4.6*#
|
|
Form of Option Agreement under
2007 Long-Term Incentive Compensation Plan of Cumberland
Pharmaceuticals Inc.
|
4.7*#
|
|
Form of Agreement under
2007 Directors Compensation Plan of Cumberland
Pharmaceuticals Inc.
|
5.1*
|
|
Opinion of Adams and Reese LLP.
|
10.1
|
|
Manufacturing and Supply Agreement
for N-Acetylcysteine, dated January 15, 2002, by and
between Bioniche Life Sciences, Inc. and Cumberland
Pharmaceuticals Inc.
|
10.2
|
|
Novation Agreement, dated
January 27, 2006, by and among Bioniche Life Sciences,
Inc., Bioniche Pharma Group Ltd., and Cumberland Pharmaceuticals
Inc.
|
10.3
|
|
First Amendment to Manufacturing
and Supply Agreement for N-Acetylcysteine, dated
November 16, 2006, by and between Bioniche Teoranta and
Cumberland Pharmaceuticals Inc.
|
10.4
|
|
Cardinal Health Contract Sales and
Services for Cumberland Pharmaceuticals Inc. Dedicated Sales
Force Agreement, dated May 16, 2006, by and between
Cardinal Health PTS, LLC and Cumberland Pharmaceuticals Inc.
|
10.5
|
|
First Amendment to Contract Sales
and Service Agreement, dated July 19, 2006, by and between
Cardinal Health PTS, LLC and Cumberland Pharmaceuticals Inc.
|
10.6
|
|
Consent to Assignment by Cardinal
Health PTS, LLC to PG Holding Corporation of all of their
rights, title, interests and obligations under that certain
Cardinal Health Contract Sales and Services for Cumberland
Pharmaceuticals Inc. Dedicated Sales Force Agreement, dated
May 16, 2006, by and between Cardinal Health PTS, LLC and
Cumberland Pharmaceuticals Inc., as amended by that certain
First Amendment to Contract Sales and Service Agreement, dated
July 19, 2006, by and between Cardinal Health PTS, LLC and
Cumberland Pharmaceuticals Inc.
|
10.7
|
|
Distribution Services Agreement,
dated August 3, 2000, by and between CORD Logistics, Inc.
and Cumberland Pharmaceuticals Inc.
|
10.8
|
|
Strategic Alliance Agreement,
dated July 21, 2000, by and between F.H.
Faulding & Co. Limited and Cumberland Pharmaceuticals
Inc.
|
10.9
|
|
Kristalose Agreement, dated
April 7, 2006, by and among Inalco Biochemicals, Inc.,
Inalco S.p.A., and Cumberland Pharmaceuticals Inc.
|
10.10
|
|
License Agreement, dated
May 28, 1999, by and between Vanderbilt University and
Cumberland Pharmaceuticals Inc.
|
|
|
|
No.
|
|
Description
|
|
|
10.11#
|
|
Employment Agreement effective as
of January 1, 2007 by and between A.J. Kazimi and
Cumberland Pharmaceuticals Inc.
|
10.12#
|
|
Employment Agreement effective as
of January 1, 2007 by and between Jean W. Marstiller and
Cumberland Pharmaceuticals Inc.
|
10.13#
|
|
Employment Agreement effective as
of January 1, 2007 by and between Leo Pavliv and Cumberland
Pharmaceuticals Inc.
|
10.14#
|
|
Employment Agreement effective as
of January 1, 2007 by and between J. William Hix and
Cumberland Pharmaceuticals Inc.
|
10.15#
|
|
Employment Agreement effective as
of January 1, 2007 by and between David L. Lowrance and
Cumberland Pharmaceuticals Inc.
|
10.16*
|
|
Second Amended and Restated Loan
Agreement by and between Cumberland Pharmaceuticals Inc. and
Bank of America, N.A., dated April 6, 2006.
|
10.17#
|
|
1999 Stock Option Plan of
Cumberland Pharmaceuticals Inc.
|
10.18*#
|
|
2007 Long-Term Incentive
Compensation Plan of Cumberland Pharmaceuticals Inc.
|
10.19*#
|
|
2007 Directors
Compensation Plan of Cumberland Pharmaceuticals Inc.
|
10.20
|
|
Form of Indemnification Agreement
between Cumberland Pharmaceuticals Inc. and all members of its
Board of Directors.
|
10.21
|
|
Lease Agreement, dated
September 10, 2005, by and between Nashville Hines
Development, LLC and Cumberland Pharmaceuticals Inc.
|
10.22*
|
|
Sublease Agreement, dated
December 14, 2006, by and between Robert W.
Baird & Co. Incorporated and Cumberland Pharmaceuticals
Inc.
|
10.23
|
|
Amended and Restated Lease
Agreement, dated November 11, 2004, by and between The
Gateway to Nashville LLC and Cumberland Emerging Technologies,
Inc.
|
10.24
|
|
First Amendment to Amended and
Restated Lease Agreement, dated August 23, 2005, by and
between The Gateway to Nashville LLC and Cumberland Emerging
Technologies, Inc.
|
21
|
|
Subsidiaries of Cumberland
Pharmaceuticals Inc.
|
23.1
|
|
Consent of KPMG LLP.
|
23.2*
|
|
Consent of Adams and Reese, LLP
(contained in Exhibit 5).
|
24
|
|
Powers of Attorney (contained on
the signature page hereto).
|
|
|
*
|
To be filed by amendment.
|
|
#
|
Indicates a management contract or compensatory plan.
|
|
|
Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the Registration
Statement and submitted separately to the Securities and
Exchange Commission.
|
EX-3.1
EXHIBIT 3.1
SECOND AMENDED AND RESTATED CHARTER
OF
CUMBERLAND PHARMACEUTICALS INC.
Cumberland Pharmaceuticals Inc. (the Company), a corporation organized and existing under
and by virtue of the Tennessee Business Corporation Act, as amended (the Act), does hereby
certify:
I. That the Company was incorporated upon the filing of its charter (the Original
Charter) with the Secretary of State of the State of Tennessee (the Tennessee Secretary of
State) on January 7, 1999.
II. That the Company filed an Amended and Restated Charter (the Restated Charter) with the
Tennessee Secretary of State on October 12, 2000.
III. That the Company filed a Charter Amendment to the Restated Charter with the Tennessee
Secretary of State on June 5, 2003 that changed the principal office address and registered office
address of the Company.
IV. That the Board of Directors of the Company (the Board of Directors) proposed and
recommended, on January 16, 2007, the amendments (the Amendments) to the shareholders of the
Company (the Shareholders) included in the Second Amended and Restated Charter (the Second
Restated Charter) set forth below as the charter of the Company (the Charter).
V. That the Shareholders adopted, on April 18, 2007, the Amendments included in the Second
Restated Charter as the Companys Charter.
VI. That the Charter has been duly adopted in accordance with Sections 48-20-103 and 48-20-107
of the Act.
The adopted Restated Charter of Cumberland Pharmaceuticals Inc. is as follows:
1. The name of the Company is Cumberland Pharmaceuticals Inc.
2. The Company is for profit.
3. The duration of the Company is perpetual.
4. The street address of the Companys principal office is:
2525 West End Avenue, Suite 950
Nashville, Tennessee 37203
County of Davidson
5. (a) The name of the Companys initial registered agent is A.J. Kazimi.
|
(b) |
|
The street address of the Companys initial
registered office in Tennessee is: |
2525 West End Avenue, Suite 950
Nashville, Tennessee 37203
County of Davidson
6. The name and address of the incorporator is:
Martin S. Brown, Jr.
Adams and Reese LLP
424 Church Street, Suite 2800
Nashville, Tennessee 37219
7. The purpose for which the Company is organized is to engage in any lawful act or activity
for which corporations may be organized under the Act.
8. The maximum number of shares of stock the Company is authorized to issue is (i) One Hundred
Million (100,000,000) shares of common stock, no par value per share (Common Stock), (ii) Twenty
Million (20,000,000) shares of preferred stock, no par value per share (Preferred Stock) and
(iii) Three Million (3,000,000) shares of Series A Preferred Stock, no par value per share (Series
A Preferred Stock and collectively with Common Stock and Preferred Stock, the Capital Stock).
The following is a description of each of the classes of stock of the Company and a statement
of the powers, preferences and rights of such stock, and the qualifications, limitations and
restrictions thereof:
A. Common Stock.
1. Voting Rights. Each holder of Common Stock shall be entitled to one vote per share
of Common Stock on all matters to be voted on by the shareholders of the Company.
2. Dividends and Rights Upon Liquidation. Dividends shall be declared and paid on
Common Stock from funds lawfully available therefore as and when determined by the Board of
Directors and subject to any preferential dividend rights of any then outstanding Preferred Stock.
In the event of a voluntary or involuntary dissolution or liquidation of the Company, after
distribution in full of the preferential amounts, if any, to be distributed to the holders of
Preferred Stock, the holders of Common Stock shall, subject to the additional rights, if any, of
the holders of Preferred Stock fixed in accordance with the provisions of this Charter, be entitled
to receive all of the remaining assets of the Company, tangible and intangible, of whatever kind
available for distribution to shareholders ratably in proportion to the number of shares of Common
Stock held by them respectively.
2
B. Preferred Stock.
1. Authorization and Issuance. Twenty million (20,000,000) shares of Preferred Stock,
no par value per share. Shares of Preferred Stock may be issued from time to time in one or more
classes or series, each such class or series to be so designated as to distinguish the shares
thereof from the shares of all other series and classes. The Board of Directors is hereby vested
with the authority to divide Preferred Stock into classes or series and to fix and determine the
relative rights, preferences, qualifications and limitations of the shares of any class or series
so established.
C. Series A Preferred Stock.
1. Designation. There shall be a series of Preferred Stock designated as
Series A Convertible Preferred Stock (the Series A Preferred Stock). The number of shares
initially constituting the Series A Preferred Stock shall be Three Million (3,000,000), which
number may be decreased by the Board of Directors without a vote of shareholders; provided,
however, that such number may not be decreased below the number of then-outstanding shares of
Series A Preferred Stock.
2. Voting Rights. Except as otherwise provided by law, each holder of issued and
outstanding Series A Preferred Stock shall be entitled to vote on each matter on which the
shareholders of the Company are entitled to vote. Each share of Series A Preferred Stock shall
have the number of votes equal to the number of shares of Common Stock into which such share is
convertible under Section 5 hereof on the applicable record date for the meeting at which a vote is
taken or as of the date on which any written consent of shareholders is being solicited, and such
number of shares of Common Stock shall be included in determining the number of shares voting or
entitled to voted on any such matter. Except as otherwise required by law and except for any
matter on which holders of Series A Preferred Stock have the right to vote separately as a class
either hereunder or under applicable law, holders of Series A Preferred Stock shall vote together
as a single class with holders of Common Stock.
3. Dividends. No dividend may be declared or paid or set aside for payment to, or
other distribution made upon, the Common Stock or on any other stock of the Company ranking junior
to or on parity with the Series A Preferred Stock as to dividends unless the same dividends are
declared and paid (or declared and a sum sufficient for the payment thereof set apart for such
payment) with respect to the Series A Preferred Stock. The amount of such dividends payable to the
holders of the Series A Preferred Stock shall equal the amount that would be payable with respect
to such Series A Preferred Stock had it been converted into Common Stock in accordance with the
terms and provisions of Section 5 hereof as of the date of such dividend.
4. Liquidation. In the event of any liquidation, dissolution, or winding up of the
Company, whether voluntary or involuntary, holders of each share of Series A Preferred Stock shall
be entitled to be paid out of the assets of the Company available for distribution to holders of
the Companys capital stock an amount per share equal to Three Dollars and Twenty-Five Cents
($3.25) (the Preference Amount). The Preference Amount shall be paid to the
3
holders of the Series A Preferred Stock with respect to such liquidation, dissolution, or winding
up before any sums shall be paid or any assets distributed to the holders of shares of Common Stock
or to the holders of any other stock of the Company ranking junior to the Series A Preferred Stock
as to liquidation preferences, but after the payment of liquidation amounts to the holders of any
other stock of the Company ranking senior to the Series A Preferred Stock as to liquidation
preferences. If the assets of the Company shall be insufficient to permit the payment in full of
the Preference Amount to the holders of the Series A Preferred Stock, then the entire assets of the
Company available for such distribution shall be distributed ratably among the holders of the
Series A Preferred Stock and the holders of any other class of stock of the Company ranking on a
parity with the Senior A Preferred Stock as to liquidation preferences. After the Preference
Amount shall have been paid in full to the holders of the Series A Preferred Stock (or funds
necessary for such payment shall have been set aside by the Company in trust for the account of
holders of the Series A Preferred Stock so as to be available for such payment), the holders of the
Series A Preferred Stock shall not be entitled to participate in any further distributions by the
Company and shall have no further rights or claims to any of the assets of the Company. Whenever
the Preference Amount shall be paid in property other than cash, the value of such distribution
shall be the fair value thereof determined in good faith by the Board of Directors of the Company.
In case the outstanding shares of Series A Preferred Stock shall be subdivided into a greater
number of shares of Series A Preferred Stock or, conversely, in case outstanding shares of Series A
Preferred Stock shall be combined into a smaller number of shares of Series A Preferred Stock, the
Preference Amount in effect immediately prior to each such subdivision or combination shall be
adjusted simultaneously with the effectiveness of such subdivision or combination in such a manner
so as to equate the amount to be paid to the holders of the subdivided or combined shares of Series
A Preferred Stock upon liquidation with the amount that would have been paid to the holders of
Series A Preferred Stock upon liquidation absent the subdivision or combination.
5. Conversion of Series A Preferred Stock.
(i) Right to Convert and Conversion Ratio; Anti-Dilution. At any time and from
time to time, any holder of Series A Preferred Stock may convert all or any portion of the
Series A Preferred Stock held by such holder into fully paid and nonassessable shares of
Common Stock. The conversion of Series A Preferred Stock shall be automatic upon completion
of a Public Offering or the approval by the shareholders of the Company of a Qualified Sale
(as defined hereinafter). As used herein, a Public Offering shall be defined as an
underwritten public offering of the Companys equity securities pursuant to an effective
registration statement filed with the United States Securities and Exchange Commission. As
used herein, a Qualified Sale shall be defined as a sale (whether in the form of a merger,
consolidation or sale of substantially all assets) of the Company in
which the holders of shares of Series A Preferred Stock would receive at least Three Dollars and Twenty-Five
Cents ($3.25) for each share of Series A Preferred Stock or for that number of shares of
Common Stock into which each share of Series A Preferred Stock is convertible, as the case
may be. The conversion of any shares of Series A Preferred Stock shall be conditioned upon
the completion of the Public Offering or Qualified Sale, in which case such conversion shall
not be effective
4
until the consummation of the Public Offering or Qualified Sale. Each share of Series A
Preferred Stock shall be converted (the Conversion) into one (1) share of Common Stock
(the Conversion Ratio). Upon the happening of an Extraordinary Capital Stock Event (as
hereinafter defined), the Conversion Ratio, simultaneously with the happening of such
Extraordinary Capital Stock Event, shall be appropriately adjusted such that the
proportionate interest of the holders of the Series A Preferred Stock in the Common Stock
upon Conversion shall be maintained. The Conversion Ratio, as so adjusted, shall be
readjusted upon the happening of any successive Extraordinary Capital Stock Event(s).
Extraordinary Capital Stock Event shall mean (w) the issuance, other than through a Public
Offering or Qualified Sale of additional shares of Capital Stock, or other securities
convertible into shares of Capital Stock, without consideration or for a consideration per
share less than Three Dollars and Twenty-Five Cents ($3.25),
(x) the issuance of additional shares of Capital Stock as a dividend or other distribution on all outstanding shares of
Capital Stock, (y) a stock split or subdivision of outstanding shares of Capital Stock into
a greater number of shares of Capital Stock, or (z) a reverse stock split or combination of
outstanding shares of Capital Stock into a smaller number of shares of Capital Stock. If the
Conversion Ratio is adjusted, the Company shall file at its principal executive offices and
shall mail within thirty (30) days after the date upon which such adjustment shall be made,
by registered or certified mail to each registered holder of shares of Series A Preferred
Stock, a statement signed by a responsible financial officer of the Company specifying the
adjusted Conversion Ratio and setting forth in reasonable detail the method of calculation
of such adjustment and the facts requiring the adjustment and upon which the calculation is
based.
(ii) Procedure for Conversion. The certificate(s) for shares of Series A
Preferred Stock surrendered for Conversion shall be accompanied by proper assignment thereof
to the Company or in blank. As promptly as practicable after delivery of the shares to the
Company, the Company shall issue and deliver to the holder of the shares of Series A
Preferred Stock being converted, or on its written order, such certificate(s) as it may
request of the number of whole shares of Common Stock issuable upon
the Conversion of such shares of Series A Preferred Stock in accordance with the provisions of this Section 5(ii),
and cash, as provided in Section 5(iii) herein, in respect of any fraction of a share of
Common Stock issuable upon such Conversion. Such Conversion shall be deemed to have been
effected immediately prior to the close of business on the date of the Conversion (the
Conversion Date), and at such time the rights of the
holder as holder of the converted shares of Series A Preferred Stock shall cease and the person(s) in whose name(s) any
certificate(s) for shares of Common Stock shall be issuable upon such Conversion shall be
deemed to have become the holder(s) of record of the shares of Common Stock represented
thereby.
(iii) Cash in Lieu of Fractional Shares. No fractional shares of Common Stock
shall be issued upon the Conversion of shares of Series A Preferred Stock. Instead of any
fractional shares of Common Stock that otherwise would be issuable upon Conversion of Series
A Preferred Stock, the Company shall pay to the holder of the shares of Series A Preferred
Stock that were converted a cash adjustment in respect of such fractional shares in an
amount equal to the same fraction of the fair market value price per share of the
5
Common Stock (as determined in a reasonable manner prescribed by the Board of Directors) at
the close of business on the Conversion Date. The determination as to whether any
fractional shares are issuable shall be based upon the total number of shares of Series A
Preferred Stock being converted at any one time by any holder thereof, not upon each share
of Series A Preferred Stock being converted.
(iv) Reservation of Common Stock. The Company shall at all times reserve and
keep available out of its authorized but unissued shares of Common Stock, solely for the
purpose of effecting the Conversion of the shares of the Series A Preferred Stock, such
number of its shares of Common Stock as from time to time shall be sufficient to effect the
Conversion of all outstanding shares of the Series A Preferred Stock, and if at any time the
number of authorized but unissued shares of Common Stock shall not be sufficient to effect
the Conversion of all then outstanding shares of the Series A Preferred Stock, the Company
shall take such corporate action as may be necessary to increase its
authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose.
(v) No Charge for Conversion. The issuance of certificates for shares of
Common Stock upon the Conversion of any shares of the Series A Preferred Stock shall be made
without charge to the converting holder for such certificates or for any tax in respect of
the issuance of such certificates, and such certificates shall be issued in the name of, or
in such names as may be directed by, the holder of the Series A Preferred Stock; provided,
however, that the Company shall not be required to pay any taxes or other governmental
charges which may be payable in respect of any transfer involved in the issuance and
delivery of any such certificate in a name other than that of the holder of the Series A
Preferred Stock, and the Company shall not be required to issue or deliver such certificates
unless or until the person or persons requesting the issuance thereof shall have paid to the
Company the amount of such tax or other governmental charge or shall have established to the
reasonable satisfaction of the Company that such tax or other governmental charge has been
paid or provided for. The Company may also require, as a condition to the issuance and
delivery of any such certificate, an opinion of counsel acceptable to the Company to the
effect that the proposed transfer does not require registration under federal or any state
securities law.
(vi) Notices of Record Date. In the event of any:
a. taking by the Company of a record of the holders of any class of securities
for the purpose of determining the holders thereof who are entitled to receive any
dividend or other distribution, or any right to subscribe for, purchase, or
otherwise acquire any shares of stock of any class or any other securities or
property, or to receive any other right;
b. capital reorganization of the Company, any reclassification or
recapitalization of the capital stock of the Company, a merger, or a sale; or
c. voluntary or involuntary dissolution, liquidation, or winding up the
Company;
6
then and in each such event the Company shall mail or cause to be mailed to each
holder of Series A Preferred Stock a notice specifying (i) the record date for such
dividend, distribution, or right and a description of such dividend, distribution,
or right, (ii) the date on which any such reorganization, reclassification,
recapitalization, merger, or sale is expected to become effective, and (iii) the
time, if any, that is to be fixed, as to when the holders of record of Common Stock
(or other securities) shall be entitled to exchange their shares of Common Stock (or
other securities) for securities or other property deliverable upon such
reorganization, reclassification, recapitalization, merger, sale, dissolution,
liquidation, or winding up. Such notice shall be mailed at least ten (10) days
prior to the date specified in such notice on which such action is to be taken.
(vii) Dividend Payment Upon Conversion. At the date of any Conversion, the
Company shall pay to the holder of record of any Series A Preferred Stock surrendered for or
subject to Conversion any cumulated but unpaid dividends on the shares so converted. This
payment shall be made by the Company in cash or in marketable securities of the Company or
another issuer having a fair market value on the date of payment in an amount equal to the
cumulated dividend so paid. For purposes hereof, marketable securities shall mean equity
securities of an issuer which have been registered under the Securities Exchange Act of
1934, as amended, and which are listed on a national securities exchange or included in an
interdealer quotation system which reports last sale information.
(viii) No Reissuance of Series A Preferred Stock. No share(s) of Series A
Preferred Stock acquired by the Company by reason of Conversion or otherwise shall be
reissued, and, upon Conversion, all such shares shall be canceled, retired, and eliminated
from the shares that the Company shall be authorized to issue. The Company from time to
time may take such appropriate corporate action as may be necessary to reduce the authorized
number of shares of the Series A Preferred Stock accordingly.
(ix) No Impairment. The Company will not, by amendment of its Charter or
through any reorganization, transfer of assets, consolidation, merger, share exchange,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms of the Series A Preferred Stock set
forth herein, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the holders of the Series A Preferred Stock against dilution or other
impairment.
9. The management of the business and the conduct of the affairs of the Company shall be
vested in its Board of Directors. The number of directors which shall constitute the whole Board of
Directors shall be fixed exclusively by one or more resolutions adopted from time to time by the
Board of Directors.
7
The Board of Directors shall be divided into three classes designated as Class I, Class II,
and Class III, respectively. Directors shall be assigned to each class in accordance with one or
more resolutions adopted by the Board of Directors. At the first annual meeting of shareholders
following the date of this Charter (the Effective Date), the term of office of the Class I
directors shall expire and the Class I directors shall be elected for a full term of three years.
At the second annual meeting of shareholders following the Effective Date, the term of office of
the Class II directors shall expire and the Class II directors shall be elected for a full term of
three years. At the third annual meeting of shareholders following the Effective Date, the term of
office of the Class III directors shall expire and the Class III directors shall be elected for a
full term of three years. At each succeeding annual meeting of shareholders, directors shall be
elected for a full term of three years to succeed the directors of the class whose terms expire at
such annual meeting.
Notwithstanding the foregoing provisions of this Paragraph 9, each director shall serve until
his or her successor is duly elected and qualified or until his or her death, resignation or
removal. No decrease in the number of directors constituting the Board of Directors shall shorten
the term of any incumbent director.
Any vacancies on the Board of Directors resulting from death, resignation, disqualification,
removal or other causes shall be filled by the affirmative vote of a majority of the remaining
directors then in office, even though less than a quorum of the Board of Directors. Newly created
directorships resulting from any increase in the number of directors shall, unless the Board of
Directors determines by resolution that any such newly created directorship shall be filled by the
shareholders, be filled only by the affirmative vote of the directors then in office, even though
less than a quorum of the Board of Directors. Any director elected in accordance with the preceding
sentence shall hold office for the remainder of the full term of the class of directors in which
the new directorship was created or the vacancy occurred and until such directors successor shall
have been elected and qualified.
In furtherance and not in limitation of the powers conferred by the Act, the Board of
Directors is expressly authorized to make, alter, amend or repeal the Bylaws of the Corporation.
10. The Company shall indemnify every person who is or was a party or is or was threatened to
be made a party to any action, suit, or proceeding, whether civil, criminal, administrative, or
investigative, by reason of the fact that he or she is or was a director or officer or is or was
serving at the request of the Company as a director or officer, against all expense, liability, and
loss (including counsel fees, judgments, fines, ERISA excise taxes, penalties, and amounts paid in
settlement) actually and reasonably incurred or suffered in connection with such action, suit, or
proceeding, to the fullest extent permitted by applicable law, as in effect on the date hereof and
as hereafter amended. Such indemnification may include advancement of expenses in advance of final
disposition of such action, suit, or proceeding, subject to the provision of any applicable
statute.
The indemnification and advancement of expenses provisions of this Paragraph 10 shall not be
exclusive of any other right that any person (and his or her heirs, executors, and administrators)
may have or hereafter acquire under any statute, this Charter, the Companys
8
Bylaws, resolution adopted by the shareholders, resolution adopted by the Board of Directors,
agreement, or insurance, purchased by the Company or otherwise, both as to action in his or her
official capacity and as to action in another capacity. The Company is hereby authorized to
provide for indemnification and advancement of expenses through its Bylaws, resolution of
shareholders, resolution of the Board of Directors, or agreement, in addition to that provided by
this Charter.
11. To the fullest extent permitted by the Act as in effect on the date hereof and as
hereafter amended from time to time, a director of the Company shall not be liable to the Company
or its shareholders for monetary damages for breach of fiduciary duty as a director. If the Act or
any successor statute is amended after adoption of this provision to authorize corporate action
further eliminating or limiting the personal liability of directors, then the liability of a
director of the Company shall be eliminated or limited to the fullest extent permitted by the Act,
as so amended from time to time. Any repeal or modification of this Paragraph 11 by the
shareholders of the Company shall not adversely affect any right or protection of a director of the
Company existing at the time of such repeal or modification with respect to events occurring prior
to such time.
Dated this 23 day of April, 2007.
|
|
|
|
|
|
|
|
|
/s/ A.J. Kazimi
|
|
|
A.J. Kazimi, Chairman of the Board of |
|
|
Directors and Chief Executive Officer |
|
|
9
EX-3.2
EXHIBIT 3.2
AMENDED AND RESTATED BYLAWS
OF
CUMBERLAND PHARMACEUTICALS INC.
ARTICLE I
NAME
The affairs of the corporation shall be conducted using the name Cumberland Pharmaceuticals
Inc., or such other name or names as the board of directors may from time to time authorize.
ARTICLE II
MEETINGS
Section 1. Annual Meetings. An annual meeting of shareholders for the purposes of
electing directors and transacting such other business as may properly come before the meeting
shall be held at such date and time as shall be designated from time to time by the Board of
Directors, the Chairman of the Board, or the Chief Executive.
Section 2. Special Meetings. A special meeting of shareholders may be called for any
purpose or purposes by the Board of Directors, and shall be called by the Chairman of the Board or
the Chief Executive whenever shareholders owning at least thirty three (33) percent of the votes
entitled to be cast on any issue proposed to be considered at a proposed special meeting sign,
date, and deliver to the Secretary one (1) or more written demands for the meeting describing the
purpose or purposes for which the meeting is to be held, including all statements necessary to make
any statement of such purpose not incomplete, false or misleading, and include any other
information specified in the rules and regulations of the Securities and Exchange Commission and
which written request shall be accompanied by a certified check for fifty thousand dollars
($50,000) payable to the Company to help cover the Companys expenses in connection with such
meeting, including the preparation of proxy materials or information statements and the mailing of
notices and proxy materials to shareholders. Only business within the purpose or purposes
described in the meeting notice may be conducted at a special shareholders meeting.
Section 3. Place of Meetings. Annual and special meetings of shareholders shall be
held at the principal office of the corporation or at such other place, either within or without
the State of Tennessee, as the Board of Directors, the Chairman of the Board, or the Chief
Executive shall designate.
1
Section 4. Notice of Meetings. Notice stating the date, time, and place of the
meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is
being called, shall be provided to each shareholder entitled to vote at such meeting no fewer than
ten (10) days nor more than two (2) months before the date of such meeting. In the case of special
meetings of shareholders, the notice of meeting shall include the purpose or purposes for which the
meeting is being called. Notice may be in writing, or oral if reasonable in the circumstance, and
notice shall be deemed provided when received or, if mailed, when deposited in the United States
mail addressed to the shareholder at his or her address as it appears in the Corporations current
record of shareholders, with first class postage affixed thereon. When a meeting is adjourned to
another date, time, or place, it shall not be necessary to provide any notice of the adjourned
meeting if the new date, time, or place to which the meeting is adjourned is announced at the
meeting at which the adjournment is taken, and at the adjourned meeting any business may be
transacted that might have been transacted at the original meeting. If after the adjournment,
however, the Board of Directors fixes a new record date for the adjourned meeting pursuant to
Section 8 of this Article II, a new notice of the adjourned meeting shall be provided.
Section 5. Waiver of Notice. A shareholder may waive in writing any notice required
by these Bylaws, provided that the waiver must be signed by the shareholder entitled to the notice
and must be delivered to the corporation for inclusion in the minutes or for filing with the
corporate records. A shareholders attendance at a meeting (i) waives objection to lack of notice
or defective notice of the meeting unless the shareholder at the beginning of the meeting (or
promptly upon his or her arrival) objects to holding the meeting or transacting business at the
meeting and (ii) waives objection to consideration of a particular matter at the meeting that is
not within the purpose or purposes described in the meeting notice, unless the shareholder objects
to considering the matter when it is presented.
Section 6. Quorum and Voting. The holders of a majority of shares entitled to vote,
whether present in person or represented by proxy, shall constitute a quorum. Once a share is
represented for any purpose at a meeting, the holder of such share is deemed present for quorum
purposes for the remainder of the meeting and for any adjournment of that meeting, unless a new
record date is or must be set for the adjourned meeting. A meeting may be adjourned despite the
absence of a quorum. If a quorum exists, action on a matter, other than the election of directors,
is approved by the shareholders if the votes cast favoring the action exceeds the votes cast
opposing the action.
Section 7. Proxies. A shareholder may vote his or her shares in person or by proxy
and may appoint a proxy to vote or otherwise act for him or her by signing a proxy or other
appointment form, either personally or by his or her attorney-in-fact. An appointment of a proxy
is effective when received by the Secretary or other officer or agent of the corporation authorized
to tabulate votes. An appointment is valid for eleven (11) months unless another period is
expressly provided in the proxy or other appointment form. An appointment of a proxy is revocable
by the shareholder unless the proxy or other appointment form conspicuously states that it is
irrevocable and the appointment is coupled with an interest, as provided in the Tennessee Business
Corporation Act.
2
Section 8. Action Without a Meeting. Any action required or permitted to be taken at
a meeting of the shareholders may be taken without a meeting. If all shareholders entitled to vote
on the action consent to taking such action without a meeting, the affirmative vote of the number
of shares that would be necessary to authorize or take such action at a meeting is the act of the
shareholders. The action must be evidenced by one (1) or more written consents describing the
action taken, signed by each shareholder entitled to vote on the action in one (1) or more
counterparts, and indicating each shareholders vote or abstention on the action, and such written
consent or consents must be delivered to the corporation for inclusion in the minutes or for filing
with the corporate records. A consent effected as provided in this section shall have the effect
of a meeting vote and may be described as such in any document.
Section 9. Record Date. For the purpose of determining the shareholders entitled to
notice of or entitled to vote at any meeting of shareholders, or for the purpose of determining the
shareholders entitled to receive payment of any dividend, or in order to make a determination of
shareholders for any other purpose, the Board of Directors may fix a future date as the record date
for such purpose, provided that such record date shall not be more than seventy (70) days before
the meeting or action requiring a determination of shareholders. If no record date is fixed by the
Board of Directors: (i) the record date shall be at the close of business on the day next
preceding the day on which notice of the meeting is given, or, if notice is waived, at the close of
business on the eleventh day next preceding the day on which such meeting is held; (ii) the record
date for the determination of shareholders entitled to consent to an action in writing without a
meeting shall be at the close of business on the eleventh day next preceding the date on which the
first shareholder, being entitled so to do, signs such a consent; and (iii) the record date for the
determination of shareholders for any other purpose shall be at the close of business on the date
on which the Board of Directors adopts the resolution or resolutions relating thereto. A
determination of shareholders entitled to notice of or to vote at a shareholders meeting is
effective for any adjournment of the meeting unless the Board of Directors fixes a new record date,
which it shall do if the meeting is adjourned to a date more than four (4) months after the date
fixed for the original meeting.
Section 10. List of Shareholders. After a record date has been fixed for a meeting,
the Secretary shall prepare or cause to be prepared a complete list of the shareholders entitled to
notice of the meeting, arranged in alphabetical order by class of stock and series, if any, and
showing the address of each shareholder and the number of shares registered in the name of the
shareholder. The shareholders list shall be available for inspection by any shareholder,
beginning two (2) business days after notice of the meeting is given for which the list was
prepared and continuing through the meeting, at the Corporations principal office or at the place
identified in the meeting notice in the city where the meeting will be held. If the right to vote
at any meeting is challenged, the person presiding may rely on such list as evidence of the right
of the person challenged to vote at such meeting.
Section 11. Presiding Officer and Secretary. Meetings of the shareholders shall be
presided over by the Chairman, or if the Chairman is not present or if the Corporation shall not
have a Chairman, by the Chief Executive or the President, or if neither the Chairman, Chief
Executive, President is present, by a chairman chosen by the Board of Directors. The Secretary or,
in the Secretarys absence, an Assistant Secretary shall act as secretary of every meeting, but if
neither the
3
Secretary nor an Assistant Secretary is present, a majority of the shareholders entitled to
vote at such meeting shall choose any person present to act as secretary of the meeting.
Section 12. Notice of Nominations. Nominations for the election of directors may be
made by the Board of Directors or a committee appointed by the Board of Directors authorized to
make such nominations or by any shareholder entitled to vote in the election of directors
generally. Any such shareholder nomination may be made, however, only if written notice of such
nomination has been given, either by personal delivery or the United States mail, postage prepaid,
to the Secretary of the Corporation not later than (a) with respect to an election to be held at an
annual meeting of shareholders, one hundred twenty days (120) in advance of the anniversary date of
the proxy statement for the previous years annual meeting, and (b) with respect to an election to
be held at a special meeting of shareholders for the election of directors called other than by
written request of a shareholder, the close of business on the tenth (10th) day
following the date on which notice of such meeting is first given to shareholders, and (c) in the
case of a special meeting of shareholders duly called upon the written request of a shareholder to
fill a vacancy or vacancies (then existing or proposed to be created by removal at such meeting),
within ten business days of such written request. In the case of any nomination by the Board of
Directors or a committee appointed by the Board of Directors authorized to make such nominations,
compliance with the proxy rules of the Securities and Exchange Commission shall constitute
compliance with the notice provisions of the preceding sentence.
In the case of any nomination by a shareholder, each such notice shall set forth: (a) as to
each person whom the shareholder proposes to nominate for election or re-election as a director,
(i) the name, age, business address, and residence address of such person, (ii) the principal
occupation or employment of such person, (iii) the class and number of shares of the Corporation
which are beneficially owned by such person, and (iv) any other information relating to such person
that is required to be disclosed in solicitations of proxies with respect to nominees for election
as directors, pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended
(including without limitation such persons written consent to being named in the proxy statement
as a nominee and to serving as a director, if elected); and (b) as to the shareholder giving the
notice (i) the name and address, as they appear on the Corporations books, of such shareholder,
and (ii) the class and number of shares of the Corporation which are beneficially owned by such
shareholder; and (c) a description of all arrangements or understandings between the shareholder
and each nominee and any other person or persons (naming such person or persons) pursuant to which
the nomination or nominations are to be made by the shareholder. The presiding officer of the
meeting may refuse to acknowledge the nomination of any person not made in compliance with the
foregoing procedure.
Section 13. Notice of New Business. At an annual meeting of the shareholders only such
new business shall be conducted, and only such proposals shall be acted upon, as have been properly
brought before the meeting. To be properly brought before the annual meeting such new business must
be (a) specified in the notice of meeting (or any supplement thereto) given by or at the direction
of the Board of Directors, (b) otherwise properly brought before the meeting by or at the direction
of the Board of Directors, or (c) otherwise properly brought before the meeting by a shareholder.
For a proposal to be properly brought before an annual meeting by a shareholder, the shareholder
must have given timely notice thereof in writing to the Secretary of the Corporation, and the
proposal and
4
the shareholder must comply with Rule 14a-8 under the Securities Exchange Act of 1934. To be
timely, a shareholders notice must be delivered to or mailed and received at the principal
executive offices of the Corporation within the time limits specified by Rule 14a-8.
A shareholders notice to the Secretary shall set forth as to each matter the shareholder
proposes to bring before the annual meeting (a) a brief description of the proposal desired to be
brought before the annual meeting and the reasons for conducting such business at the annual
meeting, (b) the name and address, as they appear on the Corporations books, of the shareholder
proposing such business, (c) the class and number of shares of the Corporation which are
beneficially owned by the shareholder, and (d) any financial interest of the shareholder in such
proposal.
Notwithstanding anything in these Bylaws to the contrary, no business shall be conducted at an
annual meeting except in accordance with the procedures set forth in this Section 13. The presiding
officer of the meeting shall, if the facts warrant, determine and declare to the meeting that new
business or any shareholder proposal was not properly brought before the meeting in accordance with
the provisions of this Section 13, and if he or she should so determine, he or she shall so declare
to the meeting and any such business or proposal not properly brought before the meeting shall not
be acted upon at the meeting. This provision shall not prevent the consideration and approval or
disapproval at the annual meeting of reports of officers, directors and committees, but in
connection with such reports, no new business shall be acted upon at such annual meeting unless
stated and filed as herein provided.
Section 14. Conduct of Meetings. Meetings of the shareholders generally shall follow
accepted rules of parliamentary procedure subject to the following:
(a) The presiding officer of the meeting shall have absolute authority over the matters of
procedure, and there shall be no appeal from the ruling of the presiding officer. If, in his or her
absolute discretion, the presiding officer deems it advisable to dispense with the rules of
parliamentary procedure as to any meeting of shareholders or part thereof, he or she shall so state
and shall state the rules under which the meeting or appropriate part thereof shall be conducted.
(b) If disorder should arise which prevents the continuation of the legitimate business of the
meeting, the presiding officer may quit the chair and announce the adjournment of the meeting, and
upon so doing, the meeting will immediately be adjourned.
(c) The presiding officer may ask or require that anyone not a bona fide shareholder or proxy
leave the meeting.
(d) The resolution or motion shall be considered for vote only if proposed by a shareholder or
a duly authorized proxy and seconded by a shareholder or duly authorized proxy other than the
individual who proposed the resolution or motion.
(e) Except as the President, Chief Executive, or Chairman may permit, no matter shall be
presented to the meeting which has not been submitted for inclusion in the agenda at least thirty
(30) days prior to the meeting.
5
ARTICLE III
DIRECTORS
Section 1. Management. All corporate powers shall be exercised by or under the
authority of, and the business and affairs of the corporation managed under the direction of, the
Board of Directors.
Section 2. Number. The number of directors of the corporation shall be as fixed from
time to time by the Board of Directors.
Section 3. Election and Term of Office. A plurality of all the votes cast at a
meeting of shareholders duly called and at which a quorum is present shall be sufficient to elect a
Director. Each share may be voted for as many individuals as there are Directors to be elected and
for whose election the share is entitled to be voted. Each director, including a director elected
to fill a vacancy, shall hold office until the next annual meeting of shareholders and until his or
her successor is elected and qualified, or until his or her earlier death, resignation, or removal.
Except as prohibited by law or by the Charter, any nominee for election as a Director at a
meeting of shareholders duly called and at which a quorum is present, in an uncontested election,
who receives a greater number of votes cast withheld for his or her election than for such
election (a Majority Withhold Vote) shall tender his or her resignation to the Board of
Directors, or an applicable committee of the Board, for consideration following certification of
such vote.
The Board of Directors shall promptly consider the resignation offer, and a range of possible
responses based on any facts or circumstances it considers relevant. The independent Directors who
did not receive a Majority Withhold Vote shall appoint a committee amongst themselves to consider
the resignation offers and will make a determination on how to proceed within 90 days following
certification of the stockholder vote. The Company will publicly disclose each such resignation and
the related action taken by the Board of Directors.
The Board of Directors expects that any Director whose resignation is under consideration to
abstain from participating in any decision regarding that resignation. However, if the only
Directors who did not receive a Majority Withhold Vote in the same election constitute three or
fewer Directors, all Directors may participate in the action regarding whether to accept the
resignation offers.
An election will be deemed to be uncontested if no stockholder provides notice of an intention
to nominate one or more candidates to compete with the Board of Directors nominees in a Director
election in the manner required by these Bylaws, or if any such shareholders have withdrawn all
such nominations by the day before the mailing of notice of the meeting to shareholders.
6
A majority of the votes cast at a meeting of shareholders duly called and at which a quorum is
present shall be sufficient to approve any other matter which may properly come before the meeting,
unless more than a majority of the votes cast is required by statute or by the Charter.
Notwithstanding the foregoing, unless otherwise provided by statute or by the Charter, each
outstanding share, regardless of class, shall be entitled to one vote on each matter submitted to a
vote at a meeting of shareholders.
Section 4. Resignation. Any director may resign at any time by delivering written
notice to the Board of Directors, the Chairman of the Board, the Chief Executive, or the
corporation. A resignation shall be effective when notice thereof is so delivered, unless the
notice specifies a later effective date.
Section 5. Removal. One or more directors may be removed with or without cause by a
vote of the shareholders or with cause by a vote of a majority of the number of directors then
prescribed. A director may be removed only at a meeting called for the purpose, and the notice of
the meeting must state that the purpose, or one (1) of the purposes, of the meeting is the removal
of a director or directors.
Section 6. Annual and Other Regular Meetings. An annual meeting of the Board of
Directors shall be held on the date of the annual meeting of shareholders, at the place of such
annual meeting of shareholders. The Board of Directors may provide for the holding of other
regular meetings of the Board of Directors, and may fix the dates, times, and places thereof.
Section 7. Special Meetings. A special meeting of the Board of Directors shall be
held whenever called by the Chairman of the Board, the Chief Executive, or any three (3) directors,
at such date, time, and place as may be specified by the person or persons calling the meeting.
Section 8. Notice. Notice of an annual or other regular meeting of the Board of
Directors need not be provided. Notice stating the date, time, and place of any special meeting of
the Board of Directors shall be provided to each director in writing, or it may be provided orally
if reasonable in the circumstances, no fewer than two (2) days before such meeting. Notice shall
be deemed provided when received or, if mailed, five (5) days after it is deposited in the United
States mail addressed to the director at his or her address as it appears in the corporations
current record of directors, with first class postage affixed thereon. Notice of an adjourned
meeting need not be given if the time and place to which such meeting is adjourned are fixed at the
meeting at which the adjournment is taken and if the period of adjournment does not exceed one (1)
month in any one (1) adjournment. At the adjourned meeting, the Board of Directors may transact
any business that might have been transacted at the original meeting.
Section 9. Waiver of Notice. A director may waive in writing any notice required by
these Bylaws, provided that the waiver must be signed by the director entitled to the notice and
must be filed with the minutes or corporate records. A directors attendance at or participation
in a meeting waives any required notice to him of the meeting unless the director at the beginning
of the meeting (or promptly upon his or her arrival) objects to holding the meeting or transacting
business at the meeting and does not thereafter vote for or assent to action taken at the meeting.
7
Section 10. Quorum and Voting. A majority of the number of directors then in office
shall constitute a quorum for the transaction of business, provided that at no time shall a quorum
consist of fewer than one-third (1/3) of the number of directors then prescribed. If a quorum is
present when a vote is taken, the affirmative vote of a majority of directors present is the act of
the Board of Directors. A director who is present at a meeting of the Board of Directors when
corporate action is taken is deemed to have assented to the action taken unless: (i) the director
objects at the beginning of the meeting (or promptly upon his or her arrival) to holding the
meeting or transacting business at the meeting; (ii) the directors dissent or abstention from the
action taken is entered in the minutes of the meeting; or (iii) the director delivers written
notice of his or her dissent or abstention to the presiding officer of the meeting before its
adjournment or to the corporation immediately after adjournment of the meeting. The right of
dissent or abstention is not available to a director who votes in favor of the action taken.
Section 11. Telephone Meetings. Any or all directors may participate in a meeting of
the Board of Directors by use of conference telephone or similar communications equipment by means
of which all persons participating in the meeting may simultaneously hear each other during the
meeting, and participation in such a meeting shall constitute presence in person at such a meeting.
Section 12. Action Without a Meeting. Any action required or permitted to be taken
at a meeting of the Board of Directors may be taken without a meeting. If all directors consent to
taking such action without a meeting, the affirmative vote of the number of directors that would be
necessary to authorize or take such action at a meeting is the act of the Board of Directors. The
action must be evidenced by one (1) or more written consents describing the action taken, signed by
each director in one (1) or more counterparts, and indicating each directors vote or abstention on
the action, and such written consent or consents shall be included in the minutes or filed with the
corporate records reflecting the action taken. Any action taken under this section shall be
effective when the last director signs the consent, unless the consent specifies a different
effective date. A consent effected as provided in this section shall have the effect of a meeting
vote and may be described as such in any document.
Section 13. Committees. Unless the Charter otherwise provides, the Board of
Directors may create one (1) or more committees, each consisting of one (1) or more members. All
members of committees of the Board of Directors which exercise powers of the Board of Directors
must be members of the Board of Directors and serve at the pleasure of the Board of Directors.
The creation of a committee and appointment of a member or members to it must be approved by the
greater of (i) a majority of all directors in office when the action is taken or (ii) the number of
directors required by the Charter or these Bylaws to take action.
Unless otherwise provided in the Act, to the extent specified by the Board of Directors or in the
Charter, each committee may exercise the authority of the Board of Directors. All such committees
and their members shall be governed by the same statutory requirements regarding meetings, action
without meetings, notice and waiver of notice, quorum and voting requirements as are applicable to
the Board of Directors and its members.
8
Section 14. Reliance Upon Information, Opinions, Reports, or Statements. To the full
extent allowed by law, a director shall be, in the performance of his or her duties, protected in
relying in good faith upon information, opinions, reports, or statements, including financial
statements and other financial data, if prepared or presented by (i) one or more officers or
employees of the corporation whom the director reasonably believes to be reliable and competent in
the matters presented; (ii) legal counsel, public accountants, or other persons as to matters the
director reasonably believes are within the persons professional or expert competence; or (iii) a
committee of the Board of Directors of which he or she is not a member if the director reasonably
believes the committee merits confidence.
ARTICLE IV
OFFICERS
Section 1. General. The corporation shall have a President and a Secretary, and may
have a Chairman of the Board, a Chief Executive, one or more Vice Presidents, a Treasurer, and such
other officers as may from time to time be deemed advisable by the Board of Directors, the Chairman
of the Board, or the President. Any two (2) or more offices may be held by the same person, except
the offices of President and Secretary. The Chairman of the Board, the Chief Executive, the
President, any Vice President, the Secretary, and the Treasurer shall be appointed by the Board of
Directors. Each other officer may be appointed by the Board of Directors, the Chairman of the
Board, or the President. Each officer shall hold office until the meeting of the Board of
Directors following the next annual meeting of shareholders and until his or her successor has been
appointed and qualified, or until his or her earlier death, resignation, or removal. The Chairman
of the Board must be a director of the corporation. Any other officer may be, but is not required
to be, a director of the corporation. Each officer shall have the authority and perform the duties
set forth in these Bylaws or, to the extent consistent with these Bylaws, the duties prescribed by
the Board of Directors or prescribed by an officer authorized by the Board of Directors to
prescribe the duties of other officers.
Section 2. Resignation. Any officer may resign at any time by delivering notice to
the corporation. A resignation shall be effective when notice thereof is so delivered, unless the
notice specifies a later effective date.
Section 3. Removal. The Board of Directors may remove any officer at any time with
or without cause, and any officer appointed by another officer may be removed likewise by such
other officer.
Section 4. Vacancies. Any vacancy occurring in any office for any reason may be
filled by the Board of Directors or by an officer having the power of appointment with respect to
the office in question.
Section 5. Reliance Upon Information, Opinions, Reports, or Statements. To the full
extent allowed by law, an officer shall be, in the performance of his or her duties, protected in
relying in
9
good faith upon information, opinions, reports, or statements, including financial statements
and other financial data, if prepared or presented by (i) one or more officers or employees of the
corporation whom the officer reasonably believes to be reliable and competent in the matters
presented; or (ii) legal counsel, public accountants, or other persons as to matters the officer
reasonably believes are within the persons professional or expert competence.
Section 6. Chairman of the Board. The Chairman of the Board, when present, shall
preside at all meetings of the Board of Directors. The Chairman of the Board shall also perform
such other duties and have such other powers as the Board of Directors shall from time to time
prescribe.
Section 7. Chief Executive. The Chief Executive shall exercise general supervision
over the management of the business and affairs of the corporation and shall perform such other
duties and have such other powers as the Board of Directors shall from time to time prescribe. In
the absence of the Chairman of the Board or in the event of his or her inability or refusal to act,
the Chief Executive may perform the duties of the Chairman of the Board, and when so acting shall
have all the powers of and be subject to all the restrictions upon the Chairman of the Board.
Section 8. President and Vice Presidents. The President shall perform such duties
and have such powers as the Board of Directors shall from time to time prescribe. In the absence of
the President or in the event of his or her inability or refusal to act, the Vice President, or in
the event there is more than one Vice President, the Vice Presidents in the order designated, or in
the absence of any designation, then in the order of their appointment, may perform the duties of
the President, and when so acting shall have all the powers of and be subject to all the
restrictions upon the President. Each Vice President shall also perform such other duties and have
such other powers as the Board of Directors or the President may from time to time prescribe.
Section 9. Secretary and Assistant Secretaries. The Secretary shall, when possible,
attend all meetings of the shareholders and all meetings of the Board of Directors, shall prepare
or supervise the preparation of minutes of the proceedings of the shareholders, the Board of
Directors, and the Executive Committee and other committees, and shall keep such minutes, along
with all written consents to action without a meeting, in a book or books devoted to that purpose.
The Secretary shall be the officer primarily responsible for authenticating records of the
corporation. The Secretary shall keep a record of the shareholders of the corporation, arranged
alphabetically for class and series, if any, giving the names and addresses of all shareholders and
the number of shares held by each, and shall cause such a list as of the appropriate record date to
be open for inspection prior to and at any meeting of shareholders, as provided in Section 10 of
Article II. The Secretary shall give, or cause to be given, notice of meetings of the shareholders
and special meetings of the Board of Directors. The Secretary shall also perform such other duties
as are generally performed by a secretary of a corporation and, in addition, shall perform such
other duties and have such other powers as the Board of Directors or the President, or the Chairman
of the Board if he or she is the Chief Executive, may from time to time prescribe. Any Assistant
Secretary may, in the absence of the Secretary or in the event of his or her inability or refusal
to act, perform the duties of the Secretary, and when so acting shall have all the powers of and be
subject to all the restrictions upon the Secretary. Each Assistant Secretary shall also perform
such other duties and have such other
10
powers as the Board of Directors, the Chief Executive, the Secretary, or the Chairman of the
Board if he or she is the Chief Executive, may from time to time prescribe.
Section 10. Treasurer and Assistant Treasurers. The Treasurer shall have custody of
the corporations funds and securities, shall keep or cause to be kept full and accurate accounts
of receipts and disbursements, and shall deposit all monies and other valuable effects in the name
and to the credit of the corporation in such depositories as may be designated by the Board of
Directors. The Treasurer shall disburse the funds of the corporation as ordered by the Board of
Directors or by an officer authorized by the Board of Directors so to order, taking proper vouchers
for such disbursements, and shall render to the Board of Directors, the Chairman of the Board, and
the Chief Executive an account of all his or her transactions as Treasurer and of the financial
condition of the corporation. The Treasurer shall also perform such other duties as are generally
performed by a treasurer of a corporation and, in addition, shall perform such other duties and
have such other powers as the Board of Directors or the Chief Executive, or the Chairman of the
Board if he or she is the chief executive officer, may from time to time prescribe. Any Assistant
Treasurer may, in the absence of the Treasurer or in the event of his or her inability or refusal
to act, perform the duties of the Treasurer, and when so acting shall have all the powers of and be
subject to all the restrictions upon the Treasurer. Each Assistant Treasurer shall also perform
such other duties and have such other powers as the Board of Directors, the Chief Executive, the
Treasurer, or the Chairman of the Board may from time to time prescribe.
ARTICLE V
SHARES OF STOCK
Section 1. Certificates. Unless the Board of Directors authorizes the issuance of
some or all of the shares of the corporation as uncertificated shares, the shares of the
corporation shall be represented by certificates signed on behalf of the corporation by the
Chairman of the Board, the Chief Executive, or the President and by the Treasurer, an Assistant
Treasurer, the Secretary, or an Assistant Secretary. The certificates shall be in such form as
shall be approved by the Board of Directors and shall be numbered and registered in the order
issued. Each certificate shall include, as a minimum, the name of the corporation and that the
corporation is organized under the laws of the State of Tennessee, the name of the person to whom
issued, and the number and class of shares and the designation of the series, if any, the
certificate represents.
Section 2. Lost, Destroyed, or Stolen Certificates. The corporation may issue a new
certificate in the place of any certificate previously issued and alleged to have been lost,
destroyed, or stolen, on production of such evidence of loss, destruction, or theft as the Board of
Directors may require. The Board of Directors may require the owner of such lost, destroyed, or
stolen certificate, or his or her legal representative, to provide to the corporation a bond in
such sum as the Board of Directors may direct, and with such surety or sureties as may be
satisfactory to the Board of Directors, to indemnify the corporation against any claims, loss,
liability, or damage it may suffer on account of issuing a new certificate.
11
Section 3. Transfers of Shares. Transfers of shares of the corporation shall be made
on the stock transfer books of the corporation only as permitted in this section and only by the
holder of record thereof, or by his or her duly authorized attorney, upon surrender for
cancellation of the certificate or certificates representing such shares, with an assignment or
power of transfer endorsed thereon or delivered therewith, duly executed with such proof of the
authenticity of the signature and of authority to transfer as the corporation may require. The
corporation shall be entitled to treat the holder of record of any share or shares as the absolute
owner thereof for all purposes and, accordingly, shall not be bound to recognize any legal,
equitable, or other claim to, or interest in, such share or shares on the part of any other person,
whether or not it shall have express or other notice thereof, except as otherwise expressly
provided by law.
ARTICLE VI
TRANSACTIONS IN WHICH A DIRECTOR OR OFFICER HAS AN INTEREST
No transaction in which a director or officer has a direct or indirect interest shall be
voidable solely for this reason, provided that (i) the material facts of the transaction and of the
directors or officers interest were disclosed or known to the Board of Directors or a committee
of the Board of Directors, and the Board of Directors or such committee authorized, approved, or
ratified the transaction by the affirmative vote of a majority of the directors on the Board of
Directors, or on such committee, who had no direct or indirect interest in the transaction, except
that such a transaction may not be authorized, approved, or ratified by a single director; (ii) the
material facts of the transaction and of the directors or officers interest were disclosed or
known to the shareholders entitled to vote on the transaction, and the shareholders authorized,
approved, or ratified the transaction; or (iii) the transaction was fair to the corporation. If a
majority of the directors who have no direct or indirect interest in the transaction vote to
authorize, approve, or ratify the transaction, a quorum is present for the purpose of taking
action.
ARTICLE VII
INDEMNIFICATION OF OFFICERS, DIRECTORS, EMPLOYEES, AND AGENTS
Section 1. General. The Board of Directors may indemnify any person authorized by
the Tennessee Business Corporation Act, as amended, in the manner and to the extent set forth
therein.
Section 2. Insurance. The corporation shall have the power to purchase and maintain
insurance on behalf of any person who is or was a director, officer, employee, or agent of the
corporation, or who, while a director, officer, employee, or agent of the corporation, is or was
serving at the request of the corporation as a director, officer, partner, trustee, employee, or
agent of another corporation, partnership, joint venture, trust, employee benefit plan, or other
enterprise, against any liability asserted against him or incurred by him in any such capacity or
arising from his status as such, whether or not the corporation would have the power to indemnify
him against such liability under the provisions of this Article VII.
12
ARTICLE VIII
FISCAL YEAR
The fiscal year of the corporation shall be fixed by the Board of Directors from time to time.
ARTICLE IX
CORPORATE SEAL
The corporate seal, if any, shall be in such form as shall be approved from time to time by
the Board of Directors.
ARTICLE X
AMENDMENTS
These Bylaws may be amended or repealed, and new Bylaws may be adopted, by the Board of
Directors or the shareholders, but no such action may be taken at any annual or special meeting of
shareholders unless notice of such action is contained in the notice of such meeting.
13
EX-4.2 WARRANT TO PURCHASE COMMON STOCK
EXHIBIT 4.2
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING
SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.
|
|
|
Warrant No. W 1
|
|
Number of Shares 25,000 |
Date of Issuance: October 21, 2003
|
|
(subject to adjustment) |
WARRANT TO PURCHASE
COMMON STOCK OF
CUMBERLAND PHARMACEUTICALS, INC.
(Void after October 21, 2013)
THIS WARRANT TO PURCHASE COMMON STOCK OF CUMBERLAND PHARMACEUTICALS, INC. (the Warrant) is
issued as of this 21st day of October, 2003, by CUMBERLAND PHARMACEUTICALS, INC., a Tennessee
corporation (the Company), having a place of business at 2525 West End Avenue, Suite 950,
Nashville, Tennessee 37203, to BANK OF AMERICA, N.A., a national banking association (Bank of
America, N.A. and any subsequent assignee or transferee hereof are hereinafter referred to
collectively as the Holder).
AGREEMENT:
For and in consideration of the Holder making available to the Company a revolving credit
facility in the maximum principal amount of Three Million Five Hundred Thousand and No/100ths
Dollars ($3,500,000.00) (the Loan) pursuant to the terms of an Amended and Restated Promissory
Note of even date herewith in the aforesaid amount (together with any and all extensions,
modifications, replacements and renewals thereof, the Note) and an Amended and Restated Loan
Agreement of even date herewith (as amended, supplemented or otherwise modified from time to time,
the Loan Agreement; any capitalized terms used but not otherwise defined herein shall have the
same meanings as in the Loan Agreement), and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company hereby grants to the Holder the right to
purchase from the Company at a per share price equal to $12.00 (the Exercise Price), 25,000
shares of the Companys common stock, $0 par value per share (the Common Stock), at any time or
from time to time, from October 21, 2003 up to and including 5:00 p.m. (Central time) on October
21, 2013 (the Expiration Date), upon surrender to the Company at its principal office (or at such
other location as the Company may advise the Holder in writing) of this Warrant properly endorsed
with the Notice of Exercise attached hereto as Exhibit A, duly completed and signed and, if
applicable, upon payment in cash or by check acceptable to the Company of the aggregate Exercise
Price for the number of shares for which this Warrant is being exercised determined in accordance
with the provisions hereof. The Exercise Price and the number of shares purchasable hereunder are
subject to adjustment as provided in Section 3 of this Warrant.
This Warrant is subject to the following terms and conditions:
1. Exercise; Issuance of Certificates; Payment for Shares.
1.1 General. Subject to the terms of Section 1.3 below, this Warrant is exercisable at the
option of the Holder, at any time or from time to time, from the date of the issuance of this
Warrant up to the Expiration Date, for all or any part of the shares of Common Stock (but not for a
fraction of a share) that may be purchased hereunder. The Company agrees that the shares of Common
Stock purchased under this Warrant shall be and are deemed to be issued to the Holder as the record
owner of such shares as of the close of business on the date on which this Warrant shall have been
surrendered to the Company, properly endorsed, the completed, executed Form of Subscription shall
have been delivered and any required payment made for such shares. Certificates for the shares of
Common Stock so purchased, together with any other securities or property to which the Holder is
entitled upon such exercise, shall be delivered to the Holder by the Company at the Companys
expense within a reasonable time after the rights represented by this Warrant have been so
exercised. In case of a purchase of less than all of the shares that may be purchased under this
Warrant, the Company shall cancel this Warrant and execute and deliver a new Warrant or Warrants of
like tenor for the balance of the shares purchasable under the Warrant surrendered upon such
purchase to the Holder within a reasonable time. Each stock certificate so delivered shall be in
such denominations of Common Stock as may be requested by the Holder and shall be registered in the
name of such Holder.
1.2 Net Issue Exercise. Notwithstanding any provisions herein to the contrary, if the Fair
Market Value of one share of the Companys Common Stock is greater than the Exercise Price (at the
date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder
may elect to receive shares equal to the value (as determined below) of this Warrant (or the
portion thereof being canceled) by surrender of this Warrant at the principal office of the Company
together with the properly endorsed Form of Subscription and notice of such election in which event
the Company shall issue to the Holder a number of shares of Common Stock computed using the
following formula:
X = Y (A-B)
A
Where X = the number of shares of Common Stock to be issued to the Holder
Y = the number of shares of Common Stock purchasable under the Warrant or, if only
a portion of the Warrant is being exercised, the portion of the Warrant being canceled
(at the date of such calculation)
A = the Fair Market Value of one share of the Companys Common Stock (at the date
of such calculation)
B = Exercise Price (as adjusted to the date of such calculation)
The Fair Market Value of a share of Common Stock as of a particular date shall mean: (a) if
there is an active public market for the Companys Common Stock at the time of such exercise, the
fair market value per share shall be the average of the closing prices of the Common Stock of the
Company over the five (5) trading days ending immediately prior to the applicable date of valuation
if traded on a securities exchange or the Nasdaq National Market; or, if actively
traded over-the-counter, the average of the closing bid prices over the 30-day period ending
immediately prior to the applicable date of valuation, whichever is applicable; or (b) if there is
no active public market for the Companys Common Stock at the time of such exercise, the Fair
Market Value shall be the value thereof as determined in good faith by the board of directors of
the Company (the Determination). The board of directors shall provide to the Holder a written
notice of the Determination which notice shall set forth supporting data in respect of such
calculation (the Determination Notice). Holder shall have 10 days following receipt of the
Determination Notice within which to deliver to the Company a written notice of an objection, if
any, to the Determination. The failure by Holder to deliver such notice within such 10-day period
shall constitute the Holders acceptance of the Determination as conclusive. In the event of the
timely delivery by Holder of its objection notice, the Company and the Holder shall attempt in good
faith to arrive at an agreement with respect to the Fair Market Value of a share of Common Stock of
the Company, which agreement shall be set forth in writing within 15 days following delivery of
such objection notice by Holder. If the Company and the Holder are unable to reach an agreement
within such 15-day period, the matter shall be promptly referred for determination to a regionally
or nationally recognized investment banking or valuation firm (the Valuer) reasonably acceptable
to the Company and the Holder. The Company and the Holder will cooperate with each other in good
faith to select such Valuer. The Valuer may select the Determination or may select any other number
or value. The Valuers selection will be furnished to the Company and the Holder in writing and be
conclusive and binding upon the parties and shall not be subject to collateral attack. The fees and
expenses of the Valuer shall be borne by the Company unless the Valuers determination of Fair
Market Value per share of the Companys Common Stock is within 10% of the Determination, in which
case the Valuers fees and expenses shall be borne by the Holder.
Notwithstanding the foregoing, in the event the Warrant is exercised in connection with the
Companys initial public offering of Common Stock, the fair market value per share shall be the per
share offering price to the public of the Companys initial public offering.
1.3 Vesting. Notwithstanding anything to the contrary contained herein, the Holder may
exercise its right to purchase up to 12,500 shares of the Common Stock, or any portion thereof, at
any time or from time to time from the date of the issuance of this Warrant up to the Expiration
Date. With respect to the remaining 12,500 shares of Common Stock, the Holders right to purchase
all or any portion of such shares shall be deemed to vest hereunder in the event that, and at such
time as, the Company fails to achieve a Successful CeraLyte® Launch.
2. Shares to be Fully Paid; Reservation of Shares. The Company covenants and agrees that all
shares of Common Stock that may be issued upon the exercise of the rights represented by this
Warrant will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and
free from all preemptive rights of any stockholder and free of all taxes, liens and charges with
respect to the issuance thereof. The Company further covenants and agrees that during the period
within which the rights represented by this Warrant may be exercised, the Company will at all times
have authorized and reserved, for the purpose of issue or transfer upon exercise of the
subscription rights evidenced by this Warrant, a sufficient number of shares of authorized but
unissued Common Stock, or other securities and property, when and as required to provide for the
exercise of the rights represented by this Warrant. The Company will take all such action as may
be necessary to assure that such shares of Common Stock may
be issued as provided herein without violation of any applicable law or regulation, or of any
requirements of any domestic securities exchange upon which the Common Stock may be listed;
provided, however, that the Company shall not be required to effect a registration under federal or
state securities laws with respect to such exercise. The Company will not take any action which
would result in any adjustment of the Exercise Price (as set forth in Section 3 hereof) if the
total number of shares of Common Stock issuable after such action upon exercise of all outstanding
warrants, together with all shares of Common Stock then outstanding and all shares of Common Stock
then issuable upon exercise of all options and upon the conversion of all convertible securities
then outstanding, would exceed the total number of shares of Common Stock then authorized by the
Companys charter, as amended.
3. Adjustment of Exercise Price and Number of Shares. The Exercise Price and the number of
shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to
time upon the occurrence of certain events described in this Section 3. Upon each adjustment to the
Exercise Price, the Holder shall thereafter be entitled to purchase, at the Exercise Price
resulting from such adjustment, the number of shares obtained by multiplying the Exercise Price in
effect immediately prior to such adjustment by the number of shares purchasable pursuant hereto
immediately prior to such adjustment, and dividing the product thereof by the Exercise Price
resulting from such adjustment.
3.1 Subdivision or Combination of Stock. In case the Company shall at any time subdivide its
outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the
outstanding shares of Common Stock of the Company shall be combined into a smaller number of
shares, the Exercise Price in effect immediately prior to such combination shall be proportionately
increased.
3.2 Dividends in Common Stock, Other Stock, Property, Reclassification. If at any time or
from time to time the holders of Common Stock shall have received or become entitled to receive,
without further payment therefor,
(a) Common Stock or any shares of stock or other securities that are at any time directly or
indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe
for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,
(b) any cash paid or payable otherwise than as a cash dividend, or
(c) Common Stock or additional stock or other securities or property (including cash) by way
of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement
(other than shares of Common Stock issued as a stock split or adjustments in respect of which shall
be covered by the terms of Section 3.1 above), then and in each such case, the Holder shall, upon
the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common
Stock receivable thereupon, and without payment of any additional consideration therefor, the
amount of stock and other securities and property (including cash in the cases referred to in
clause (b) above and this clause (c)) that Holder would hold on the date of such exercise had
Holder been the holder of record of such Common Stock as of the date on which holders of Common
Stock received or became entitled to receive such
shares or all other additional stock and other securities and property.
3.3 Reorganization, Reclassification, Consolidation, Merger or Sale. If any recapitalization,
reclassification or reorganization of the capital stock of the Company, or any consolidation or
merger of the Company with another company, or the sale of all or substantially all of its assets
or other transaction shall be effected in such a way that holders of Common Stock shall be entitled
to receive stock, securities or other assets or property (an Organic Change), then, as a
condition of such Organic Change, lawful and adequate provisions shall be made by the Company
whereby the Holder thereafter shall have the right to purchase and receive (in lieu of the shares
of the Common Stock of the Company immediately theretofore purchasable and receivable upon the
exercise of the rights represented hereby) such shares of stock, securities or other assets as may
be issued or payable with respect to or in exchange for a number of outstanding shares of such
Common Stock equal to the number of shares of such stock immediately theretofore purchasable and
receivable upon the exercise of the rights represented hereby. In the event of any Organic Change,
appropriate provision shall be made by the Company with respect to the rights and interests of the
Holder to the end that the provisions hereof (including, without limitation, provisions for
adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the
exercise of this Warrant) shall thereafter be applicable, in relation to any shares of stock,
securities or assets thereafter deliverable upon the exercise hereof. The Company will not effect
any such Organic Change unless, prior to the consummation thereof, the successor company (if other
than the Company) resulting from such consolidation or the company purchasing such assets shall
assume by written instrument reasonably satisfactory in form and substance to the Holder, executed
and mailed or delivered to the registered Holder at the last address of such Holder appearing on
the books of the Company, the obligation to deliver to such Holder such shares of stock, securities
or assets as, in accordance with the foregoing provisions, such Holder may be entitled to purchase.
3.4 Certain Events. If any change in the outstanding Common Stock of the Company or any other
event occurs as to which the other provisions of this Section 3 are not strictly applicable or if
strictly applicable would not fairly protect the purchase rights of the Holder of the Warrant in
accordance with such provisions, then the Board of Directors of this Company shall make an
adjustment in the number and class of shares available under the Warrant, the Exercise Price or the
application of such provisions, so as to protect such purchase rights as aforesaid. The adjustment
shall be such as will give the Holder, upon exercise for the same aggregate Exercise Price, the
total number, class and kind of shares as the Holder would have owned had the Warrant been
exercised prior to the event and had the Holder continued to hold such Common Stock until after the
event requiring adjustment.
4. Issue Tax. The issuance of certificates for shares of Common Stock upon the exercise of
the Warrant shall be made without charge to the Holder for any issue tax (other than any applicable
income taxes) in respect thereof; provided, however, that the Company shall not be required to pay
any tax that may be payable in respect of any transfer involved in the issuance and delivery of any
certificate in a name other than that of the then Holder of the Warrant being exercised.
5. Closing of Books. The Company will at no time close its transfer books against the
transfer of any warrant or of any shares of Common Stock issued or issuable upon the exercise of
any warrant in any manner which interferes with the timely exercise of this Warrant.
6. No Voting or Dividend Rights; Limitation of Liability. Nothing contained in this Warrant
shall be construed as conferring upon the Holder the right to vote or to consent or to receive
notice as a stockholder of the Company or any other matters or any rights whatsoever as a
stockholder of the Company. Except as set forth in Section 3.2 hereof, no dividends or interest
shall be payable or accrued in respect of this Warrant or the interest represented hereby or the
shares purchasable hereunder until, and only to the extent that, this Warrant shall have been
exercised. No provisions hereof, in the absence of affirmative action by the Holder to purchase
shares of Common Stock, and no mere enumeration herein of the rights or privileges of the Holder,
shall give rise to any liability of such Holder for the Exercise Price or as a stockholder of the
Company, whether such liability is asserted by the Company or by its creditors.
7. Rights and Obligations Survive Exercise of Warrant. The rights and obligations of the
Company, of the Holder and of the holder of shares of Common Stock (or other shares of stock,
securities or assets) issued upon exercise of this Warrant shall survive the exercise of this
Warrant.
8. Amendments.
(a) Any term of this Warrant may be amended with the written consent of the Company and the
Holder. Any amendment effected in accordance with this Section 8 shall be binding upon the existing
and each future holder and the Company.
(b) No waivers of, or exceptions to, any term, condition or provision of this Warrant, in any
one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of
any such term, condition or provision.
9. Notices.
(a) Whenever the Exercise Price or number of shares purchasable hereunder shall be adjusted
pursuant to Section 3 hereof, the Company shall issue a certificate signed by its Chief Financial
Officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the
adjustment, the method by which such adjustment was calculated and the Exercise Price and number of
shares purchasable hereunder after giving effect to such adjustment, and shall cause a copy of such
certificate to be mailed (by first-class mail, postage prepaid) to the Holder.
(b) In case:
(i) the Company shall take a record of the holders of its Common Stock
(or other stock or securities at the time receivable upon the exercise of this
Warrant) for the purpose of entitling them to receive any dividend or other
distribution, or any right to subscribe for or purchase any shares of stock of
any class or any other securities, or to receive any other right, or
(ii) of any capital reorganization of the Company, any reclassification of the
capital stock of the Company, any consolidation or
merger of the Company with or into another company, or any conveyance of all
or substantially all of the assets of the Company to another company, or
(iii) of any voluntary dissolution, liquidation or winding-up of the
Company,
then, and in each such case, the Company will mail or cause to be mailed to the Holder or Holders a
notice specifying, as the case may be, (A) the date on which a record is to be taken for the
purpose of such dividend, distribution or right, and stating the amount and character of such
dividend, distribution or right, or (B) the date on which such reorganization, reclassification,
consolidation, merger, conveyance, dissolution, liquidation or winding-up is to take place, and the
time, if any is to be fixed, as of which the holders of record of Common Stock (or such stock or
securities at the time receivable upon the exercise of this Warrant) shall be entitled to exchange
their shares of Common Stock (or such other stock or securities) for securities or other property
deliverable upon such reorganization, reclassification, consolidation, merger, conveyance,
dissolution, liquidation or winding-up. Such notice shall be mailed at least 15 days prior to the
date therein specified.
(c) Any notice, request or other document required or permitted to be given or delivered to
the Holder or the Company shall be delivered or shall be sent by certified mail, postage prepaid,
to the Holder at its address as shown on the books of the Company or to the Company at the address
indicated therefor in the first paragraph of this Warrant or such other address as either may from
time to time provide to the other. Any notice, request or other document required or permitted to
be given or delivered pursuant to this Warrant shall be deemed effectively given: (i) upon personal
delivery to the party to be notified; (iii) five days after having been sent by registered or
certified mail, return receipt requested, postage prepaid; or (iv) one day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt.
11. Binding Effect on Successors. This Warrant shall be binding upon any company succeeding
the Company by merger, consolidation or acquisition of all or substantially all of the Companys
assets. All of the obligations of the Company relating to the Common Stock issuable upon the
exercise of this Warrant shall survive the exercise and termination of this Warrant. This Warrant
and all rights hereunder may be transferred or assigned, in whole or in part, to any person or
business entity upon surrender of this Warrant at the principal office of the Company, accompanied
by an Assignment Form attached hereto as Exhibit B, duly completed and signed. Upon
surrender of this Warrant and receipt of the Assignment Form, the Company, at its expense, shall
issue to or on the order of the new Holder a new warrant or warrants of like tenor in accordance
with the Assignment Form.
12. Descriptive Headings. The description headings of the several sections and paragraphs of
this Warrant are inserted for convenience only and do not constitute a part of this Warrant.
13. Governing Law. This Warrant shall be construed and enforced in accordance with, and the
rights of the parties shall be governed by, the laws of the State of Tennessee.
14. Replacement Warrants. The Company represents and warrants to the Holder that upon receipt
of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction, upon receipt of an indemnity
reasonably satisfactory to the Company, or in the case of any such mutilation, upon surrender and
cancellation of such Warrant, the Company, at its expense, will execute and deliver a new Warrant,
of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant.
15. Fractional Shares. No fractional shares shall be issued upon exercise of this Warrant.
The Company shall, in lieu of issuing any fractional share, pay the Holder entitled to such
fraction a sum in cash equal to such fraction multiplied by the Fair Market Value of a share of
Common Stock.
16. Equity Participation. This Warrant and the rights of the Holder hereunder are intended to
constitute an equity participation for purposes of Title 47, Chapter 24, Tennessee Code
Annotated, and the consideration or value received by the Holder in respect of this Warrant shall
not be deemed to be interest, loan charges, commitment fees or brokerage commissions for purposes
of Title 47, Chapter 14, Tennessee Code Annotated.
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its officers,
thereunto duly authorized this 21st day of October, 2003.
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ A.J. Kazimi
|
|
|
Name: |
A.J. Kazimi |
|
|
Title: |
Chief Executive & President |
|
EXHIBIT A
NOTICE OF EXERCISE
To: Cumberland Pharmaceuticals, Inc.
? The undersigned hereby elects to exercise the attached Warrant and to purchase
thereunder
shares of Common Stock at a purchase price of Dollars
($ ) per Share or an aggregate purchase price of ___Dollars ($___).
Pursuant to the terms of the Warrant, the undersigned has delivered the purchase price herewith in
full.
? The undersigned hereby elects to convert percent ( %) of the
value of the Warrant pursuant to the provisions of Section 1.2 of the Warrant.
Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below:
Please issue a new Warrant for the unexercised portion of the attached Warrant, if applicable,
in the name of the undersigned or in such other name as is specified below:
|
|
|
|
|
|
|
|
|
|
|
(Name)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Name)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Signature)
|
|
|
EXHIBIT B
ASSIGNMENT FORM
FOR VALUE RECEIVED, the undersigned registered owner of the attached Warrant hereby sells,
assigns and transfers all of the rights of the undersigned under the attached Warrant with respect
to the number of shares of the security covered thereby set forth below, unto:
|
|
|
|
|
Name of Assignee
|
|
Address
|
|
No. of Shares |
EX-4.4 WARRANT TO PURCHASE COMMON STOCK
EXHIBIT 4.4
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING
SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.
|
|
|
Warrant No. W 3
|
|
Number of Shares 1,979 |
Date of Issuance: April 6, 2006
|
|
(subject to adjustment) |
WARRANT TO PURCHASE
COMMON STOCK OF
CUMBERLAND PHARMACEUTICALS, INC.
(Void after April 6, 2016)
THIS WARRANT TO PURCHASE COMMON STOCK OF CUMBERLAND PHARMACEUTICALS, INC. (the
Warrant) is issued as of this 6th day of April, 2006, by CUMBERLAND PHARMACEUTICALS,
INC., a Tennessee corporation, having a place of business at 2525 West End Avenue, Suite 950,
Nashville, Tennessee 37203 (the Company), to BANK OF AMERICA, N.A., a national banking
association (Bank of America, N.A. and any subsequent assignee or transferee hereof are hereinafter
referred to collectively as the Holder).
AGREEMENT:
For and in consideration of the Holder making available to the Company (i) a revolving credit
facility in the maximum principal amount of Four Million and No/100ths Dollars ($4,000,000.00) (the
Line of Credit) and (ii) a term loan facility in the original principal amount of Five
Million Five Hundred Thousand and No/100ths Dollars ($5,500,000) (the Term Loan
and together with the Line of Credit, the Loans) pursuant to the terms of (i) a
Fourth Amended and Restated Promissory Note (Revolving) of even date herewith in the maximum
principal amount of Four Million and No/100ths Dollars ($4,000,000) (together with any and all
extensions, modifications, replacements and renewals thereof, the Line of Credit Note),
(ii) Secured Term Promissory Note of even date herewith in the original principal amount of Five
Million Five Hundred Thousand and No/100ths Dollars ($5,500,000) (together with any and all
extensions, modifications, replacements and renewals thereof, the Term Note; and together
with the Line of Credit Note, the Notes) and (iii) a Second Amended and Restated Loan
Agreement of even date herewith (as amended, supplemented or otherwise modified from time to time,
the Loan Agreement; any capitalized terms used but not otherwise defined herein shall
have the same meanings as in the Loan Agreement), and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company hereby grants to the Holder
the right to purchase from the Company at a per share price equal to $18.00 (the Exercise
Price), 1,979 shares of the Companys common stock, $0 par value per share (the Common
Stock), at any time or from time to time, from April 6, 2006 up to and including 5:00
p.m. (Central time) on April 6, 2016 (the Expiration Date), upon surrender to the
Company at its principal office (or at such other location as the Company may advise the Holder in
writing) of this Warrant properly endorsed with the Notice of Exercise attached hereto as
Exhibit A, duly
completed and signed and, if applicable, upon payment in cash or by check
acceptable to the Company of the aggregate Exercise Price for the number of shares for which this
Warrant is being exercised determined in accordance with the provisions hereof. The Exercise Price
and the number of shares purchasable hereunder are subject to adjustment as provided in Section
3 of this Warrant.
This Warrant is subject to the following terms and conditions:
1. Exercise; Issuance of Certificates; Payment for Shares.
1.1 General. This Warrant is exercisable at the option of the Holder, at any time or from
time to time, from the date of the issuance of this Warrant up to the Expiration Date, for all or
any part of the shares of Common Stock (but not for a fraction of a share) that maybe purchased
hereunder. The Company agrees that the shares of Common Stock purchased under this Warrant shall be
and are deemed to be issued to the Holder as the record owner of such shares as of the close of
business on the date on which this Warrant shall have been surrendered to the Company, properly
endorsed, the completed, executed Form of Subscription shall have been delivered and any required
payment made for such shares. Certificates for the shares of Common Stock so purchased, together
with any other securities or property to which the Holder is entitled upon such exercise, shall be
delivered to the Holder by the Company at the Companys expense within a reasonable time after the
rights represented by this Warrant have been so exercised. In case of a purchase of less than all
of the shares that may be purchased under this Warrant, the Company shall cancel this Warrant and
execute and deliver a new Warrant or Warrants of like tenor for the balance of the shares
purchasable under the Warrant surrendered upon such purchase to the Holder within a reasonable
time. Each stock certificate so delivered shall be in such denominations of Common Stock as may be
requested by the Holder and shall be registered in the name of such Holder.
1.2 Net Issue Exercise. Notwithstanding any provisions herein to the contrary, if the Fair
Market Value of one share of the Companys Common Stock is greater than the Exercise Price (at the
date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder
may elect to receive shares equal to the value (as determined below) of this Warrant (or the
portion thereof being canceled) by surrender of this Warrant at the principal office of the Company
together with the properly endorsed Form of Subscription and notice of such election in which event
the Company shall issue to the Holder a number of shares of Common Stock computed using the
following formula:
X=Y(A-B)
A
Where X = the number of shares of Common Stock to be issued to the Holder
Y = the number of shares of Common Stock purchasable under the Warrant or, if only a
portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the
date of such calculation)
A = the Fair Market Value of one share of the Companys Common Stock (at the date of
such calculation)
B = Exercise Price (as adjusted to the date of such calculation)
The Fair Market Value of a share of Common Stock as of a particular date shall mean: (a) if
there is an active public market for the Companys Common Stock at the time of such exercise, the
fair market value per share shall be the average of the closing prices of the Common Stock of the
Company over the five (5) trading days ending immediately prior to the applicable date of valuation
if traded on a securities exchange or the Nasdaq National Market; or, if actively traded
over-the-counter, the average of the closing bid prices over the 30-day period ending immediately
prior to the applicable date of valuation, whichever is applicable; or (b) if there is no active
public market for the Companys Common Stock at the time of such exercise, the Fair Market Value
shall be the value thereof as determined in good faith by the board of directors of the Company
(the Determination). The board of directors shall provide to the Holder a written notice
of the Determination which notice shall set forth supporting data in respect of such calculation
(the Determination Notice). Holder shall have 10 days following receipt of the
Determination Notice within which to deliver to the Company a written notice of an objection, if
any, to the Determination. The failure by Holder to deliver such notice within such 10-day period
shall constitute the Holders acceptance of the Determination as conclusive. In the event of the
timely delivery by Holder of its objection notice, the Company and the Holder shall attempt in good
faith to arrive at an agreement with respect to the Fair Market Value of a share of Common Stock of
the Company, which agreement shall be set forth in writing within 15 days following delivery of
such objection notice by Holder. If the Company and the Holder are unable to reach an agreement
within such 15-day period, the matter shall be promptly referred for determination to a regionally
or nationally recognized investment banking or valuation firm (the Valuer) reasonably
acceptable to the Company and the Holder. The Company and the Holder will cooperate with each
other in good faith to select such Valuer. The Valuer may select the Determination or may select
any other number or value. The Valuers selection will be furnished to the Company and the Holder
in writing and be conclusive and binding upon the parties and shall not be subject to collateral
attack. The fees and expenses of the Valuer shall be borne by the Company unless the Valuers
determination of Fair Market Value per share of the Companys Common Stock is within 10% of the
Determination, in which case the Valuers fees and expenses shall be borne by the Holder.
Notwithstanding the foregoing, in the event the Warrant is exercised in connection with the
Companys initial public offering of Common Stock, the fair market value per share shall be the per
share offering price to the public of the Companys initial public offering.
2. Shares to be Fully Paid; Reservation of Shares. The Company covenants and
agrees that all shares of Common Stock that may be issued upon the exercise of the rights
represented by this Warrant will, upon issuance, be duly authorized, validly issued, fully paid and
nonassessable and free from all preemptive rights of any stockholder and free of all taxes, liens
and charges with respect to the issuance thereof. The Company further covenants and agrees that
during the period within which the rights represented by this Warrant may be exercised, the Company
will at all times have authorized and reserved, for the purpose of issue or transfer upon exercise
of the subscription rights evidenced by this Warrant, a sufficient number of shares of authorized
but unissued Common Stock, or other securities and property, when and as required to provide for
the exercise of the rights represented by this Warrant. The Company will take all such action as
may be necessary to assure that such shares of Common Stock may be
issued as provided herein without violation of any applicable law or regulation, or of any
requirements of any domestic securities exchange upon which the Common Stock may be listed;
provided, however, that the Company shall not be required to effect a registration under federal or
state securities laws with respect to such exercise. The Company will not take any action which
would result in any adjustment of the Exercise Price (as set forth in Section 3 hereof) if
the total number of shares of Common Stock issuable after such action upon exercise of all
outstanding warrants, together with all shares of Common Stock then outstanding and all shares of
Common Stock then issuable upon exercise of all options and upon the conversion of all convertible
securities then outstanding, would exceed the total number of shares of Common Stock then
authorized by the Companys charter, as amended.
3. Adjustment of Exercise Price and Number of Shares. The Exercise Price and
the number of shares purchasable upon the exercise of this Warrant shall be subject to
adjustment from time to time upon the occurrence of certain events described in this Section
3. Upon each adjustment to the Exercise Price, the Holder shall thereafter be entitled to
purchase, at the Exercise Price resulting from such adjustment, the number of shares obtained by
multiplying the Exercise Price in effect immediately prior to such adjustment by the number of
shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product
thereof by the Exercise Price resulting from such adjustment.
3.1 Subdivision or Combination of Stock. In case the Company shall at any time subdivide its
outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the
outstanding shares of Common Stock of the Company shall be combined into a smaller number of
shares, the Exercise Price in effect immediately prior to such combination shall be proportionately
increased.
3.2 Dividends in Common Stock, Other Stock, Property, Reclassification. If at any time or from
time to time. the holders of Common Stock shall have received or become entitled to receive,
without further payment therefor,
(a) Common Stock or any shares of stock or other securities that are at any time directly or
indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe
for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,
(b) any cash paid or payable otherwise than as a cash dividend, or
(c) Common Stock or additional stock or other securities or property
(including cash) by way of spinoff, split-up, reclassification, combination of shares or
similar corporate rearrangement (other than shares of Common Stock issued as a stock split or
adjustments in respect of which shall be covered by the terms of Section 3.1 above), then
and in
each such case, the Holder shall, upon the exercise of this Warrant, be entitled to receive,
in addition to the number of shares of Common Stock receivable thereupon, and without payment of
any additional consideration therefor, the amount of stock and other securities and property
(including cash in the cases referred to in clause (b) above and this clause (c)) that Holder would
hold on the date of such exercise had Holder been the holder of record of such Common Stock as of
the date on which holders of Common Stock received or became entitled to receive such
shares or all other additional stock and other securities and property.
3.3 Reorganization, Reclassification, Consolidation, Merger or Sale. If
any recapitalization, reclassification or reorganization of the capital stock of the Company,
or any consolidation or merger of the Company with another company, or the sale of all or
substantially all of its assets or other transaction shall be effected in such a way that holders
of Common Stock shall be entitled to receive stock, securities or other assets or property (an
Organic Change), then, as a condition of such Organic Change, lawful and adequate
provisions shall be made by the Company whereby the Holder thereafter shall have the right to
purchase and receive (in lieu of the shares of the Common Stock of the Company immediately
theretofore purchasable and receivable upon the exercise of the rights represented hereby) such
shares of stock, securities or other assets as may be issued or payable with respect to or in
exchange for a number of outstanding shares of such Common Stock equal to the number of shares of
such stock immediately theretofore purchasable and receivable upon the exercise of the rights
represented hereby. In the event of any Organic Change, appropriate provision shall be made by the
Company with respect to the rights and interests of the Holder to the end that the provisions
hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the
number of shares purchasable and receivable upon the exercise of this Warrant) shall thereafter be
applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon
the exercise hereof. The Company will not effect any such Organic Change unless, prior to the
consummation thereof, the successor company (if other than the Company) resulting from such
consolidation or the company purchasing such assets shall assume by written instrument reasonably
satisfactory in form and substance to the Holder, executed and mailed or delivered to the
registered Holder at the last address of such Holder appearing on the books of the Company,
the obligation to deliver to such Holder such shares of stock, securities or assets as, in
accordance with the foregoing provisions, such Holder may be entitled to purchase.
3.4 Certain Events. If any change in the outstanding Common Stock of the
Company or any other event occurs as to which the other provisions of this Section 3
are not strictly applicable or if strictly applicable would not fairly protect the purchase rights
of the Holder of the Warrant in accordance with such provisions, then the Board of Directors of
this Company shall make an adjustment in the number and class of shares available under the
Warrant, the Exercise Price or the application of such provisions, so as to protect such purchase
rights as aforesaid. The adjustment shall be such as will give the Holder, upon exercise for the
same aggregate Exercise Price, the total number, class and kind of shares as the Holder would have
owned had the Warrant been exercised prior to the event and had the Holder continued to hold such
Common Stock until after the event requiring adjustment.
4. Issue Tax. The issuance of certificates for shares of Common Stock upon the exercise of
the Warrant shall be made without charge to the Holder for any issue tax (other than any applicable
income taxes) in respect thereof; provided, however, that the Company shall not be required to pay
any tax that may be payable in respect of any transfer involved in the issuance and delivery of any
certificate in a name other than that of the then Holder of the Warrant being exercised.
5. Closing of Books. The Company will at no time close its transfer books against the
transfer of any warrant or of any shares of Common Stock issued or issuable upon the exercise of
any warrant in any manner which interferes with the timely exercise of this Warrant.
6. No Voting or Dividend Rights; Limitation of Liability. Nothing contained in this Warrant
shall be construed as conferring upon the Holder the right to vote or to consent or to receive
notice as a stockholder of the Company or any other matters or any rights whatsoever as a
stockholder of the Company. Except as set forth in Section 3.2 hereof, no dividends or
interest shall be payable or accrued in respect of this Warrant or the interest represented hereby
or the shares purchasable hereunder until, and only to the extent that, this Warrant shall have
been exercised. No provisions hereof, in the absence of affirmative action by the Holder to
purchase shares of Common Stock, and no mere enumeration herein of the rights or privileges of the
Holder, shall give rise to any liability of such Holder for the Exercise Price or as a stockholder
of the Company, whether such liability is asserted by the Company or by its creditors.
7. Rights and Obligations Survive Exercise of Warrant. The rights and obligations of the
Company, of the Holder and of the holder of shares of Common Stock (or other shares of stock,
securities or assets) issued upon exercise of this Warrant shall survive the exercise of this
Warrant.
8. Amendments.
9. Notices.
(a) Whenever the Exercise Price or number of shares purchasable hereunder shall be adjusted
pursuant to Section 3 hereof, the Company shall issue a certificate signed by its Chief
Financial Officer setting forth, in reasonable detail, the event requiring the adjustment, the
amount of the adjustment, the method by which such adjustment was calculated and the Exercise Price
and number of shares purchasable hereunder after giving effect to such adjustment, and shall cause
a copy of such certificate to be mailed (by first-class mail, postage prepaid) to the Holder.
(b) In case:
(i) the Company shall take a record of the holders of its Common Stock
(or other stock or securities at the time receivable upon the exercise of
this Warrant) for the purpose of entitling them to receive any dividend or
other distribution, or any right to subscribe for or purchase any shares of
stock of any class or any other securities, or to receive any other right,
or
(ii) of any capital reorganization of the Company, any reclassification
of the capital stock of the Company, any consolidation or
merger of the Company with or into another company, or any conveyance of all
or substantially all of the assets of the Company to another company, or
(iii) of any voluntary dissolution, liquidation or winding-up of the
Company,
then, and in each such case, the Company will mail or cause to be mailed to the Holder or Holders a
notice specifying, as the case maybe, (A) the date on which a record is to be taken for the purpose
of such dividend, distribution or right, and stating the amount and character of such dividend,
distribution or right, or (B) the date on which such reorganization, reclassification,
consolidation, merger, conveyance, dissolution, liquidation or winding-up is to take place, and the
time, if any is to be fixed, as of which the holders of record of Common Stock (or such stock or
securities at the time receivable upon the exercise of this Warrant) shall be entitled to exchange
their shares of Common Stock (or such other stock or securities) for securities or other property
deliverable upon such reorganization, reclassification, consolidation, merger, conveyance,
dissolution, liquidation or winding-up. Such notice shall be mailed at least 15 days prior to the
date therein specified.
(c) Any notice, request or other document required or permitted to be
given or delivered to the Holder or the Company shall be delivered or shall be sent by
certified mail, postage prepaid, to the Holder at its address as shown on the books of the Company
or to the Company at the address indicated therefor in the first paragraph of this Warrant or such
other address as either may from time to time provide to the other. Any notice, request or other
document required or permitted to be given or delivered pursuant to this Warrant shall be deemed
effectively given: (i) upon personal delivery to the party to be notified; (iii) five days after
having been sent by registered or certified mail, return receipt requested, postage prepaid;
or (iv) one day after deposit with a nationally recognized overnight courier, specifying next
day delivery, with written verification of receipt.
11. Binding Effect on Successors. This Warrant shall be binding upon any company succeeding
the Company by merger, consolidation or acquisition of all or substantially all of the Companys
assets. All of the obligations of the Company relating to the Common Stock issuable upon the
exercise of this Warrant shall survive the exercise and termination of this Warrant. This Warrant
and all rights hereunder may be transferred or assigned, in whole or in part, to any person or
business entity upon surrender of this Warrant at the principal office of the Company, accompanied
by an Assignment Form attached hereto as Exhibit B, duly completed and signed. Upon
surrender of this Warrant and receipt of the Assignment Form, the Company, at its expense, shall
issue to or on the order of the new Holder a new warrant or warrants of like tenor in accordance
with the Assignment Form.
12. Descriptive Headings. The description headings of the several sections and paragraphs of
this Warrant are inserted for convenience only and do not constitute a part of this Warrant.
13. Governing Law. This Warrant shall be construed and enforced in accordance with, and the
rights of the parties shall be governed by, the laws of the State of Tennessee.
14. Replacement Warrants. The Company represents and warrants to the Holder that upon receipt
of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction, upon receipt of an indemnity
reasonably satisfactory to the Company, or in the case of any such mutilation, upon surrender and
cancellation of such Warrant, the Company, at its expense, will execute and deliver a new Warrant,
of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant.
15. Fractional Shares. No fractional shares shall be issued upon exercise of this Warrant.
The Company shall, in lieu of issuing any fractional share, pay the Holder entitled to such
fraction a sum in cash equal to such fraction multiplied by the Fair Market Value of a share of
Common Stock.
16. Equity Participation. This Warrant and the rights of the Holder hereunder are intended to
constitute an equity participation for purposes of Title 47, Chapter 24, Tennessee Code
Annotated, and the consideration or value received by the Holder in respect of this Warrant shall
not be deemed to be interest, loan charges, commitment fees or brokerage commissions for purposes
of Title 47,.Chapter 14, Tennessee Code Annotated.
17. No Novation. This Warrant does not constitute a discharge or novation of any warrant
existing prior to this Warrant, including, without limitation, that certain Warrant to Purchase
Common Stock of Cumberland Pharmaceuticals, Inc. (W-1) dated as of October 21, 2003, and such
documents shall continue in full force and effect, shall be fully binding upon the Company, and all
rights hereunder shall be cumulative in effect with such documents.
In Witness Whereof, the Company has caused this Warrant to be duly executed by its
officers, thereunto duly authorized this 6th day of April, 2006.
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ A.J. Kazimi
|
|
|
Name: |
A.J. Kazimi |
|
|
Title: |
Chief Executive Officer |
|
|
EXHIBIT A
NOTICE OF EXERCISE
To: Cumberland Pharmaceuticals, Inc.
o The undersigned hereby elects to exercise the attached Warrant and to purchase
thereunder
shares of Common Stock at a purchase price of Dollars
($ ) per Share or an aggregate purchase price of Dollars ($ ).
Pursuant to the terms of the Warrant, the undersigned has delivered the purchase price herewith
in full.
o The undersigned hereby elects to convert percent ( %) of the value
of the Warrant pursuant to the provisions of Section 1.2, of the Warrant.
Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below:
Please issue a new Warrant for the unexercised portion of the attached Warrant, if applicable,
in the name of the undersigned or in such other name as is specified below:
|
|
|
|
|
|
|
|
|
|
|
(Name)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Name)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Signature)
|
|
|
EXHIBIT B
ASSIGNMENT FORM
FOR VALUE RECEIVED, the undersigned registered owner of the attached Warrant hereby sells,
assigns and transfers all of the rights of the undersigned under the attached Warrant with respect
to the number of shares of the security covered thereby set forth below, unto:
|
|
|
|
|
Name of Assignee
|
|
Address
|
|
No. of Shares |
EX-4.5 FORM OF OPTION AGREEMENT
EXHIBIT 4.5
CUMBERLAND PHARMACEUTICALS INC.
STOCK OPTION AGREEMENT
This Option Agreement is entered into and effective on , by
and between Cumberland Pharmaceuticals Inc., a Tennessee corporation (the Company), and
(the Participant).
WHEREAS, the Company has adopted the 1999 Stock Option Plan (the Plan); and
WHEREAS, as an increased incentive to contribute to the Companys future success and
prosperity, the Company will, subject to the Participant continuing to provide services to the
Company, or any of its current or future subsidiaries, provide the Participant an opportunity to
acquire shares of the Companys common stock, no par value (the Stock).
NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
the parties hereto agree as follows:
1. Grant of Option. Subject to the terms of the Plan and the terms of this Option Agreement,
the Company grants to the Participant an option (the Option) to purchase from the Company up to
( ) shares of Stock (the Shares), subject to adjustment as provided in the Plan. This Option is not
intended to qualify as an incentive stock option within the meaning of Section 422 of the Internal
Revenue Code of 1986, as amended.
2. Exercise Price. If the Option is exercised, the purchase price per Share shall be
($ ).
3. Method of Exercise. The Option granted under this Agreement shall be fully vested and
exercisable after , in whole or in part, by written notice in the manner set forth in Section 7 hereof, accompanied by payment of the purchase price in accordance with the terms of
the Plan for the Shares which the Participant elects to purchase. The Company shall make prompt
delivery of such Shares; provided that if any law or regulation which requires the Company to take
any action with respect to the Shares specified in such notice before issuance thereof, then the
date of delivery of such Shares shall be extended for the period necessary to take such action.
4. Termination of Option. Except as otherwise stated in this Agreement, this Option, to the
extent not previously exercised, shall expire on the tenth anniversary (the Expiration Date) of
the date of this Agreement.
5. Provisions of Plan. This Option is subject to the Plan. The terms and provisions of the
Plan as it may be amended from time to time are hereby incorporated herein by reference. In the
event of a conflict between any term or provision contained herein and a term or provision of the
Plan, the applicable terms and provisions of the Plan will govern and prevail.
1
6. Representations and Warranties of Participant. Recognizing that the Company will be relying
on the information and on the representations and warranties set forth herein, the Participant
hereby acknowledges, represents, and warrants to the Company that the Participant has been advised
that neither this Option nor the Shares will be registered under the Securities Act of 1933, as
amended (the Securities Act), or under the securities law of any state, unless the Company in its
sole discretion determines that registration under an applicable state securities law would not
subject it to unreasonable expense, and that the Shares will only be offered and sold in reliance
upon an exemption from the registration requirements of the Securities Act. The Participant further
understands and agrees that the Option and any exercise thereof must comply with all applicable
securities laws, including, but not limited to, the Securities Act and the securities laws of the
several states, as such laws exist on the date of this Agreement and on such future dates that the
Option may be exercised. By executing this Option, the Participant represents that this Option, and
the Shares issuable upon exercise of this Option, is being and will be purchased solely for the
Participants own account as an investment, and not with a view to the resale or distribution, in
whole or in part, thereof. The Participant has such knowledge and experience in financial and
business matters that the Participant is capable of evaluating the merits and risks of the
acquisition of this Option and the Shares issuable upon the exercise of this Option. Further, the
Participant understands and agrees that all certificates representing Shares issued pursuant to an
exercise of this Option shall be inscribed with a legend in substantially the following form:
THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAW AND MAY NOT BE OFFERED, SOLD, OR OTHERWISE TRANSFERRED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED.
7. Notices. Any notice, request, instruction, or other document given under this Option
Agreement shall be in writing and shall be addressed and delivered, in the case of the Company, to
the Secretary of the Company at the principal office of the Company and, in the case of the
Participant, the Participants address as set forth herein or to such other address as the
Participant may provide in a written notice to the Company, a copy of which shall be on file with
the Secretary of the Company.
8. Governing Law. This Option Agreement shall be construed in accordance with and governed by
the law of the State of Tennessee, without giving effect to the conflict of law provisions thereof.
2
IN WITNESS WHEREOF, each of the parties hereto has caused this Option Agreement to be executed
by its duly authorized representative.
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC.: |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
Name:
|
|
|
|
|
|
Title:
|
|
|
|
|
|
|
|
|
|
|
PARTICIPANT: |
|
|
|
|
|
|
|
|
|
|
|
Address: |
|
|
|
|
|
|
|
|
|
|
|
|
|
3
EX-10.1 MANUFACTURING AND SUPPLY AGREEMENT
EXHIBIT 10.1
*Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
MANUFACTURING AND SUPPLY AGREEMENT
for
N-ACETYLCYSTEINE
CUMBERLAND PHARMACEUTICALS INC.
and
BIONICHE LIFE SCIENCES, INC.
January 15, 2002
MANUFACTURING AND SUPPLY
AGREEMENT FOR N-ACETYLCYSTEINE
THIS AGREEMENT is made and entered into as of the 15th day of January, 2002.
BY AND BETWEEN:
CUMBERLAND PHARMACEUTICALS INC., a corporation organized and existing under the laws of Tennessee,
United States, with its principal offices located at 209 Tenth Avenue South, Suite 332, Nashville,
Tennessee, 37203 (hereinafter referred to as CUMBERLAND)
AND:
BIONICHE LIFE SCIENCES INC., a corporation organized and existing under the laws of Ontario,
Canada, with its principal place of business located at 231 Dundas Street, East Belleville,
Ontario, Canada K8N 1E2 (hereinafter referred to as BIONICHE);
WHEREAS, CUMBERLAND is the owner of certain intellectual property rights with respect to a Drug
Product (as hereinafter defined);
WHEREAS, BIONICHE has the expertise and the manufacturing facility suitable for the pharmaceutical
preparation and production of the Drug Product;
WHEREAS, CUMBERLAND wishes to have BIONICHE manufacture the Drug Product on an exclusive basis for
sale in the Territory (as hereinafter defined) and BIONICHE wishes to supply the Drug Product on an
exclusive basis to CUMBERLAND on and subject to the terms and conditions set out herein;
NOW, THEREFORE, in consideration of the premises and the undertakings, terms, conditions and
covenants set forth below, the parties hereto agree as follows:
1. DEFINITIONS
1.1 AFFILIATE shall mean, with respect to any Person, any other Person that controls, is
controlled by or is under common control with, such Person. A Person shall be regarded as in
control of another Person if such Person owns, or directly or indirectly controls, more than fifty
percent (50%) of the voting securities (or comparable equity interests) or other ownership
interests of the other Person, or if such Person directly or indirectly possesses the power to
direct or cause the direction of the management or policies of the other Person, whether
through the ownership of voting securities, by contract or any other means whatsoever.
1.2 BUFFER SOLUTION shall mean the buffer solution used for the manufacture of the Drug
Product.
1.3 BULK DRUG SUBSTANCE shall mean the active ingredients in the Drug Product.
1.4 cGMP or GMP shall have the meaning set forth in Schedule I.
1.5 CONFIDENTIAL INFORMATION shall have the meaning set forth in Article 9.
1.6 DEVELOPMENT shall mean all work necessary to develop a process to manufacture the Drug
Product in full accord with cGMP and to supply the Drug Product conforming to the Specifications.
Development activities shall include, but not be limited to, pilot batches, scale-up batches,
validation of the manufacturing process, and successful completion of the Drug Product manufacture
and delivery as defined in Schedule I attached hereto.
1.7 DRUG PRODUCT shall mean the N-Acetylcysteine pharmaceutical product developed by
CUMBERLAND and marketed under the trade name ACETADOTE or any other trade name selected by
CUMBERLAND.
1.8 EXCIPIENT shall mean any inert substance selected by CUMBERLAND and used to give the Drug
Product proper consistency.
1.9 FACILITY shall mean the manufacturing facility and the real property underlying such
manufacturing facility operated by Bioniche Teoranta, an Affiliate of BIONICHE, located at
Inverin, Co. Galway, Republic of Ireland.
1.10 FDA shall mean the United States Food and Drug Administration (FDA) or any successor
entity thereto.
1.11 IN-PROCESS SOLUTION shall mean all Buffer Solutions and Excipients needed to produce
Drug Product in the finished dosage form set forth in Schedule I.
1.12 INVENTION shall have the meaning set forth in Paragraph 9.4.
1.13 LABELING shall mean all labels and other written, printed, or graphic matter upon: (i)
the Drug Product or any container or wrapper utilized with the Drug Product and (ii) any written
material accompanying the Drug Product, including without limitation, package inserts.
1.14 MANUAL shall mean the Manufacturing Project Manual attached as Schedule II to this
Agreement and reviewed and accepted by CUMBERLAND and BIONICHE, the terms and provisions of which
are incorporated by reference as though fully set forth herein.
1.15 MANUFACTURE shall mean the act of compounding, component preparations, filling,
packaging, testing and any other pharmaceutical manufacturing procedures, or any part thereof,
involved in manufacturing the Drug Product from the Bulk Drug Substance.
1.16 PERSON shall mean an individual, corporation, partnership, limited liability company, or
any other form of entity not specifically listed herein.
1.17 SPECIFICATIONS shall mean those specifications set forth in Attachment I to the Manual.
1.18 TERRITORY shall have the meaning set forth in Schedule III.
2. DEVELOPMENT AND MANUFACTURING
2.1 Initiation: Upon request by CUMBERLAND and subject to the provisions hereof, BIONICHE,
directly or through an Affiliate thereof, shall Manufacture and package at the Facility all of
CUMBERLANDs requirements for Drug Product in the Territory in the batch size set forth in
Schedule I in accordance with the terms hereof, including without limitation, Schedules I and II
hereof, the Specifications, and all applicable laws and regulations. Prior to distributing and
selling the Drug Product, CUMBERLAND shall prepare and file submissions to the FDA in order to
obtain and maintain during the term hereof regulatory approval of the Drug Product, BIONICHE shall
prepare and test the Drug Product in accordance with cGMP.
2.2 Documentation: BIONICHE shall provide CUMBERLAND with required supporting documentation
for the manufacture of the Drug Product in a form suitable for CUMBERLANDs submission to the FDA
or applicable governmental authorities for any country into which the Drug Product will be
distributed. BIONICHE shall provide draft Chemistry, Manufacturing, and Controls sections for
CUMBERLANDs FDA submissions,
2.3 Bulk Drug Substance Supply: BIONICHE shall be responsible for the supply of all Bulk Drug
Substance in accordance with Schedules I and II hereto; provided that the supply of Bulk Drug
Substance shall be exclusively from such suppliers and in such grades as have been approved in
writing by CUMBERLAND as reflected on an approved list to be attached hereto as Schedule IV, and
provided further that such suppliers and
grades may not be changed without CUMBERLANDs prior written consent, which consent shall not
be unreasonably withheld or delayed. BIONICHE shall maintain, at its expense, secure storage areas
for the Bulk Drug Substance at the Facility.
2.4 Supply of Components: BIONICHE shall be responsible for the supply of all Buffer Solution,
Excipients, and all other components of the finished Drug Product in accordance with Schedules I
and II hereto; provided that the supply of these components shall be exclusively from such
suppliers and in such grades as have been approved in writing by CUMBERLAND as reflected on an
approved list to be attached hereto as Schedule IV, and provided further that such suppliers and
grades may not be changed without CUMBERLANDs prior written consent which consent shall not be
unreasonably withheld or delayed. BIONICHE shall maintain, at its expense, secure storage areas for
the Buffer Solution, Excipients, and all other components at the Facility.
2.5 Delivery Terms: All deliveries of Drug Product under this Agreement shall be made by
BIONICHE to CUMBERLAND in the manner set forth in Schedule I. CUMBERLAND shall, within twenty (20)
working days after its receipt of any shipment, notify BIONICHE in writing, of any claim relating
to a Drug Product not conforming to GMP or to the Specifications, and, failing such notification,
notwithstanding Paragraph 5.1 of this Agreement, CUMBERLAND shall be deemed to have accepted the
Drug Product. If BIONICHE disputes CUMBERLANDs claim that the Drug Product is non-conforming, then
such dispute shall be resolved by an independent testing organization of recognized repute within
the pharmaceutical industry mutually agreed upon by BIONICHE and CUMBERLAND, the appointment of
which shall not be unreasonably withheld or delayed by either party. In such event, CUMBERLAND
shall ship the testing organization representative samples of the Drug Product from the disputed
production lot, and the fees and costs of such testing organization and related shipping and supply
costs shall be borne by the party whose position is not sustained by the testing organization.
Should CUMBERLANDs claim of non-conformity be sustained by the testing organization, BIONICHE
shall, at CUMBERLANDS sole option, (a) credit towards future orders, or (b) refund within thirty
(30) days thereof; the payment for such non-conforming goods, plus the cost to CUMBERLAND of
Manufacturing and shipping the related Bulk Drug Substance and components.
2.6 Forecasts: In order to permit BIONICHE to regularly supply CUMBERLAND with Drug Product
hereunder, at least [***] prior to its first requested delivery date, CUMBERLAND shall provide
BIONICHE a non-binding twelve (12) month rolling forecast (the Forecast) of CUMBERLANDs
estimated requirements of Drug Product, itemized for use as commercial product or Regulatory
Samples (as defined below), for the term of this Agreement. The Forecast shall be reviewed and
updated by CUMBERLAND on a monthly basis, with copies delivered to BIONICHE. BIONICHE shall have an
opportunity to confirm its ability to deliver the quantities set out in the Forecast and each
update thereto, or to request amendments thereto to ensure its ability to supply. Once accepted by
BIONICHE, the first three (3) months of each Forecast shall constitue a firm order for Drug
Product. Each such Forecast shall reflect a good faith attempt by CUMBERLAND to estimate quantity
requirements of Drug Product, based on anticipated demand therefore.
2.7 Periodic Orders: A purchase order (the Purchase Order) shall be provided by CUMBERLAND
to BIONICHE with respect to Drug Product to be supplied at least [***] prior to the scheduled
delivery date of such Drug Product. Such Purchase Order shall specify the quantities ordered by
CUMBERLAND for delivery by BIONICHE hereunder and the requested delivery date therefore, and, once
delivered to BIONICHE, and shall be firm and binding on the parties (the Delivery Date). Each
such Purchase Order shall become firm and binding on the parties and, except as specifically
provided for herein, may not be increased or decreased by more than [***] from the quantities shown
in the Forecast accepted by BIONICHE pursuant to Section 2.6 without the prior written approval of
the parties. If CUMBERLAND requires quantities of Drug Product exceeding those mentioned in the
Forecast, as updated, BIONICHE shall deliver the amount indicated in the Forecast on the scheduled
Delivery Date and shall use reasonable efforts to supply the additional amount exceeding such
Forecast on the scheduled Delivery Date, but shall have no liability for failure to deliver the
additional amount. Each Purchase Order shall constitute a separate agreement to purchase Drug
Product but where in conflict with the terms and conditions of this Agreement, this Agreement, and
not the standard terms and conditions set forth in the purchase orders, shall govern the
Manufacturing, purchase and sale of the Drug
Product under this Agreement. Any Purchase Order for Drug Product shall be placed in the minimum
amounts listed below or in integral multiples thereof.
For the 10mL form of Drug Product [***]
For the 30mL form of Drug Product [***]
2.8 Failure to Supply: Subject to the provisions of Article 7, BIONICHE shall supply all of
the Drug Product ordered by CUMBERLAND within [***] of receipt of a written order from CUMBERLAND.
If BIONICHE is unable to meet its supply obligations with respect to any Purchase Order,
CUMBERLAND shall be free to procure from third parties part or all of the quantities of the Drug
Product covered by the relevant Purchase Order. In the event that BIONICHE is unable to supply the
Drug Product to CUMBERLAND for any reason other than for Force Majeure or failure of CUMBERLAND to
fulfill its obligations hereunder, BIONICHE will reimburse CUMBERLAND for any increase in the
price of obtaining the Drug Product from an alternate supplier; provided that such replacement
Drug Product was purchased on reasonable commercial terms, and provided further that such failure
to supply was in respect of Drug Product that was the subject of a Purchase Order provided by
CUMBERLAND and accepted by BIONICHE under Paragraph 2.7. Should BIONICHE reimburse CUMBERLAND as
set out in this paragraph, BIONICHE shall have no further liability to CUMBERLAND for said failure
to supply.
2.9 Payment for the Drug Product: At the time of each shipment, BIONICHE shall invoice
CUMBERLAND for BIONICHEs manufacturing services at the prices set forth in Schedule I. Payment
shall be made in Canadian dollars within [***] of each such shipment of conforming Product in
accordance with the terms hereof.
2.10 Price Variations:
(a) Prices are as set on Schedule I for the term hereof unless changed pursuant to Paragraph
2.10(b).
(b) Subject to Subparagraph 2.10(c), prices are subject to annual adjustment beginning two
(2) years after the date hereof. Price increases or decreases will be commensurate with documented
Manufacturing cost increases or decreases since the date that the then-current prices became
effective. For purposes hereof, Manufacturing cost shall mean, with respect to the Drug Product,
BIONICHEs actual and documented cost of raw materials, direct labor, Manufacturing, packaging,
and overhead amounts directly applicable to such Manufacturing costs (including appropriately
amortized capital equipment costs and excluding non-manufacturing overhead and allocations and
excluding costs representing Manufacturing changes for which CUMBERLAND does not provide prior
written consent pursuant to Article 8), calculated in accordance with generally accepted
accounting principles consistently applied (the allocation of overhead to be consistent with
BIONICHEs allocation of overhead as of the date of this Agreement). CUMBERLAND reserves the right
to audit the records of BIONICHE in order to determine that such increases and/or decreases are
appropriate. Any increase in price shall not exceed the twelve (12) month percent increase in the
Producer Price Index as published by the U.S. government and shall be further subject to a maximum
increase of five percent (5%) per year over the life of the Agreement.
(c) Notwithstanding any of the contrary herein contained, should CUMBERLAND: (i) request a
change in Specifications, or (ii) unreasonably withhold the consent requested under Paragraphs 2.3
or 2.4, which request or refusal results in an increase in Manufacturing Costs, BIONICHE shall be
entitled to pass on such costs to CUMBERLAND immediately in the form of a Drug Product price
increase.
3. TERM AND TERMINATION
3.1 Term: This Agreement shall commence on the date first above written and will continue
until the fifth anniversary of the date on which the FDA grants approval to market and sell the
Drug Product, unless sooner terminated pursuant to Paragraphs 3.2 or 3.3 hereof. Subject to
Paragraphs 3.2 and 3.3, the Agreement shall be automatically renewed for successive three-year
terms unless either party notifies the other party in writing at least twelve (12) months in
advance of the expiration of the then current term that the party is terminating the Agreement.
3.2 Termination: This Agreement may be terminated at any time upon the occurrence of any of
the following events:
(a) Default: Thirty (30) days following written notice, by either party to the other party, in
the event that the other party breaches any provision of this Agreement, and such party fails to
remedy the breach prior to the expiration of the thirty (30) day period; provided that, in the case
of nonpayment of sums due hereunder, the remedy period shall be decreased to ten (10) days.
(b) Insolvency: Written notice by either party to the other upon insolvency or bankruptcy of
the other party, and the failure of any such insolvency or bankruptcy to be dismissed within sixty
(60) days.
(c) Force majeure: If, as a result of causes described in Paragraph 7.1, either party is
unable to fully perform its obligations hereunder for a period of one hundred fifty (150)
consecutive days, the other party shall have the right to terminate this Agreement upon at least
thirty (30) days prior written notice; provided that if the required performance is met during that
thirty-day period, this Agreement shall continue in full force and effect as if the notice had not
been given.
(d) Costs: Immediately upon written notice by BIONICHE to CUMBERLAND if the Manufacturing cost
per unit of Drug Product calculated in the manner set forth in Paragraph 2.10(a) hereof exceeds the
purchase price per unit of Drug Product set forth in Schedule I, as adjusted pursuant to Paragraphs
2.10(b) and/or (c) hereof.
(e) No FDA Approval: Immediately upon written notice by BIONICHE to CUMBERLAND if the FDA does
not grant CUMBERLAND approval to market and sell the Drug Product on or before the second
anniversary of the date of this Agreement.
(f) By mutual agreement of the parties hereto.
Except as otherwise specifically set forth in this Paragraph 3.2, termination, expiration,
cancellation or abandonment of this Agreement, through any means and for any reason, shall not
relieve the parties of any obligation accruing prior thereto and shall be without prejudice to the
rights and remedies of either party with respect to any antecedent breach of any of the provisions
of this Agreement. Without limiting the generality of the foregoing, termination, expiration,
cancellation, or abandonment of this Agreement shall not relieve CUMBERLAND of its obligation to
pay the royalty provided for under Schedule I for Drug Product manufactured by BIONICHE hereunder.
3.3 Minimum Quantities Purchased: If the parties fail to agree on minimum purchase quantities
as provided under Paragraph 5.7, or if following such agreement, CUMBERLAND should fail to meet the
agreed upon minimum purchase requirements, BIONICHE shall have the right (but not the obligation)
to terminate this Agreement in its entirety or with respect to any one or more format of the Drug
Product upon ninety (90) days notice; provided, however, that CUMBERLAND shall have the right (but
not the obligation) within such ninety (90) day period to pay BIONICHE any short-fall and avoid
such termination. Such shortfall shall be calculated by subtracting the purchase price of the
amount of each format of Drug Product actually ordered from the amount calculated by multiplying
the minimum quantity of such format under Schedule V by the purchase price thereof. It is
understood and agreed between the parties that BIONICHE shall not be required to supply Drug
Product for such payment. Should BIONICHE exercise its right to terminate under this Paragraph 3.3,
CUMBERLAND shall have no liability to BIONICHE for failing to purchase any minimum quantity of Drug
Product hereunder.
3.4 Impact of Termination on Outstanding Purchase Orders: Upon termination of the Agreement
for any reason whatsoever (except for termination by either party pursuant to Paragraphs 3.2(a),
(b), or (c), or upon expiration of this Agreement), BIONICHE will, at CUMBERLANDs written request
delivered after termination, continue to supply Drug Product to CUMBERLAND in satisfaction of
Purchase Orders already submitted to BIONICHE, subject to the same terms and conditions as applied
during the term of the Agreement, for a period of sixty (60) days from the date of termination or
expiration.
3.5 Survival: Paragraphs 2.5, 2.8, 3.2, 3.3, and 3.5 and Articles 5, 6, 9, and 10 shall
survive the termination or cancellation of the Agreement for any reason.
4. CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE
4.1 Certificates of Analysis: BIONICHE shall perform, or cause to be performed, certain tests
requested by CUMBERLAND in writing and as indicated in the Specifications on each batch of the Drug
Product manufactured pursuant to this Agreement before delivery to CUMBERLAND. A certificate of
analysis for each batch delivered shall be delivered with each batch and shall set forth the items
tested, specifications, and test results. BIONICHE shall also indicate on the certificate of
analysis that all batch production and control records have been reviewed and approved by the
appropriate quality control unit. Subject to Paragraph 2.5, CUMBERLAND shall test, or cause to be
tested, prior to final release, each batch of the Drug Product as meeting the Specifications. As
required by the FDA (see Paragraph 5.2 below), CUMBERLAND shall assume full responsibility for
final release of each lot of the Drug Product.
4.2 Manufacturing Compliance: BIONICHE shall advise CUMBERLAND immediately if an authorized
agent of any regulatory body visits the Facility and makes an inquiry regarding BIONICHEs method
of manufacture of the Drug Product for CUMBERLAND. Upon receipt of any Form 483 Notice of
Inspectional Observations issued by the FDA or notice of deficit from any other regulatory
inspection after a visit to the Facility, BIONICHE shall immediately send CUMBERLAND a copy
thereof; provided that it may redact any language that is subject to a written confidentiality
agreement between BIONICHE and a third party.
4.3 Regulatory Agency Requirements: BIONICHE shall prepare and test the Drug Product in
conformity with GMP. Subject to the allocation of responsibility for regulatory compliance as set
forth in Paragraph 5.2, each party shall consult with the other party hereto before implementing
additional regulatory agency requirements concerning the control of Drug Product components,
manufacture of the Drug Product, or storage and handling of the Drug Product. The full text of
regulatory agency requests or comments will be provided by the party receiving such requests or
comments to the other party hereto. The parties will mutually agree on how to respond to such
requests and comments and on the allocation of the costs thereof; provided that BIONICHE shall be
entitled to reimbursement from CUMBERLAND for any out-of-pocket expenses or extraordinary costs
previously approved in writing by CUMBERLAND and required in connection with implementing such
regulatory requirements other than the ordinary costs of compliance with GMP.
4.4 Regulatory Documents: Each party will advise the other party hereto of its intention to
change any Drug Product regulatory documents prior to submission of the document to any regulatory
body. If the change affects the rights and obligations of a party hereto under this Agreement, such
party may seek to review or alter any part of the document at any time within ten (10) business
days after receipt of notification thereof; provided that if no alterations are submitted to the
other party within such ten-day period, each party will be deemed to have consented to the
documents, as amended.
5. REPRESENTATIONS AND WARRANTIES
5.1 Conformity with Specifications: BIONICHE represents and warrants that, at the time of
Manufacture, the Drug Product is prepared and tested in accordance with cGMP and meets the
Specifications. In the event that any production lot of a Drug Product is not Manufactured in
accordance with the Specifications or other requirements hereunder, BIONICHE shall, at CUMBERLANDs
request, perform new Manufacturing as necessary to fulfill any then outstanding purchase order of
CUMBERLAND. BIONICHE shall be fully responsible for the costs of any Bulk Drug Substance or
components required for such new Manufacturing. Because BIONICHE has no control of the conditions
under which the Drug Product is used, the diagnosis of the patient before or after treatment with
the Drug Product, the method of use or administration of the Drug Product, and handling of the Drug
Product after delivery to CUMBERLAND, BIONICHE does not warrant either a good effect, or against an
ill effect, following the use of the Drug Product. The foregoing warranty is exclusive and in lieu
of all other warranties either written, oral, or implied. No representative of BIONICHE may change
any of the foregoing warranties and CUMBERLAND accepts the Drug Product subject to all terms
hereof.
EXCEPT AS SPECIFICALLY PROVIDED FOR IN THIS ARTICLE 5 AND PARAGRAPH 11.4, BIOMCHE MAKES NO
REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED (i) OF COMMERCIAL UTILITY; (ii) OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; OR (iii) THAT THE USE OF THE DRUG PRODUCTS BY
CUMBERLAND OR ANY THIRD PARTY WILL NOT INFRINGE ANY PATENT, COPYRIGHT OR TRADEMARK OR OTHER
PROPRIETARY OR PROPERTY
RIGHTS OF OTHERS. EXCEPT AS PROVIDED FOR HEREIN, BIONICHE WILL NOT BE LIABLE TO CUMBERLAND,
CUMBERLANDS SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM ARISING FROM
CUMBERLANDS OR ANY THIRD PARTYS USE OF THE DRUG PRODUCTS.
CUMBERLAND ACCEPTS ALL RISK AND RESPONSIBILITY FOR DETERMINING THE MANNER IN WHICH CUMBERLAND
WILL USE THE DRUG PRODUCTS, AND BIONICHE MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING, AND
ASSUMES NO RESPONSIBILITY FOR, THE PERFORMANCE OF ANY OTHER PRODUCT(S) INTO WHICH THE DRUG
PRODUCTS MAY BE INCORPORATED.
5.2 Compliance: CUMBERLAND represents and warrants that CUMBERLAND assumes responsibility for
coordinating all contact with the FDA and other regulatory bodies, pertaining specifically to the
Drug Product. During the term of this Agreement, BIONICHE authorizes CUMBERLANDs representatives
to inspect the methods used in and facilities used for manufacturing, processing, packaging, and
handling of the Drug Product; provided that each such inspection shall be at CUMBERLANDS own
cost, on reasonable prior notice, and subject to the prior execution of reasonable confidentiality
agreement by each inspector who is not an employee of CUMBERLAND but has been selected by
CUMBERLAND to represent it; and provided further that CUMBERLAND shall have no such obligation
under this Agreement. Except as otherwise required by applicable regulations, CUMBERLANDs
inspections shall be conducted during normal business hours; provided that CUMBERLAND may inspect
such facilities immediately after any regulatory inspection thereof.
5.3 Debarring: BIONICHE represents and warrants that it has not been debarred in the United
States within the meaning of 21 U.S.C. § 335a(a) and 335a(b), nor will it use, knowingly after due
inquiry, in any capacity the services of any person debarred pursuant to subsections 3.06(a) or
3.06(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. Section 335(a) and (b).
5.4 FDA Submission: BIONICHE represents and warrants that it has submitted to the FDA
information about the Facility and the operating procedures, and personnel at such site in the
form required by the FDA. BIONICHE shall keep and maintain the equipment necessary for the
Manufacture of any Drug Product in a manufacture-ready state and in good repair. During the term
hereof and until the fifth anniversary of termination or expiration, BIONICHE shall maintain
written documentation of all use, repair, service, and maintenance of such equipment and shall
provide CUMBERLAND copies of such documentation; provided that in the event that a Person acquires
substantially all of the assets and business of BIONICHE, BIONICHE may send all such documentation
to CUMBERLAND promptly after such acquisition.
5.5 Reimbursement: BIONICHE shall not incur any costs for which it intends to seek
reimbursement from CUMBERLAND unless BIONICHE has the prior written consent of CUMBERLAND.
CUMBERLAND shall reimburse BIONICHE at a rate equal to one hundred fifty percent (150%) of all
such costs actually incurred and documented and directly related to the production of materials or
data for submissions to the FDA (Pre-Approval Costs) hereunder, provided that reimbursement of
such Pre-Approval Costs shall be paid by means of twelve (12) equal installments thereof to be
made on the first day of each of the twelve (12) months following the date on which the FDA issues
final approval to CUMBERLAND to market and sell the Drug Product commercially in the United States
(the Approval Date); and provided further that if the Approval Date has not occurred on or
before one year from the date of signing of the Agreement then CUMBERLAND shall immediately
reimburse BIONICHE at a rate equal to one hundred percent (100%) of all Pre-Approval Costs
incurred prior to such date in complete satisfaction of its obligations to reimburse such
Pre-Approval Costs.
5.6 Exclusivity:
(a) Neither BIONICHE nor any Affiliate thereof will sell, give away, or deliver to any other
person, firm, or corporation any form of the Drug Product in the Territory for indications
currently approved as of the date of signing this Agreement (currently-approved indications),
while this Agreement is effective and for two years after the termination of this Agreement;
provided that such restrictions shall not apply in the event of termination by BIONICHE pursuant to
Subparagraphs 3.2 (a), (b), (e), or Paragraph 3.3 and shall not apply to the sale by BIONICHE of a
product that contains the same active ingredients as the Drug Product for use as a chemoprotectant
(Excluded Products) or Other Products, as defined below, subject to the rights set out in
Subparagraph 5.6 (d).
(b) If, during the term hereof, BIONICHE wishes to market or distribute Excluded Products in
the Territory in association with any third Person, BIONICHE shall give CUMBERLAND written notice
thereof, and CUMBERLAND shall have thirty (30) days to notify BIONICHE of its interest in entering
into an arrangement with BIONICHE, on terms to be negotiated by the parties in good faith during
the period of one hundred twenty (120) days immediately following the receipt by CUMBERLAND of
such notice (the Option Period). If the parties negotiate in good faith but do not conclude an
agreement within the Option Period, BIONICHE agrees not to enter into an agreement covering the
Excluded Products in the Territory with any third Person on terms that are more favorable than the
terms previously offered to CUMBERLAND without first offering to enter into an agreement with
CUMBERLAND, to be negotiated during an additional thirty day period, such offer to be made on
terms no less favorable than the terms being offered to the third Person. If CUMBERLAND does not
enter into negotiations with BIONICHE within thirty (30) days following receipt of such notice,
then BIONICHE shall be free to negotiate with third Persons with no further obligation to
CUMBERLAND.
(c) Notwithstanding the provisions of Subparagraph 5.6 (b) above, BIONICHE shall have no
obligation to make any offer to CUMBERLAND with respect to any development, marketing or sale of
Excluded Products in the Territory if it chooses to so develop, market or sell directly, rather
than in association with any third Person.
(d) With respect to any product that contains the same active ingredient as the Drug Product
for indications other than Excluded Products that BIONICHE may seek to develop (Other Products),
BIONICHE shall provide notice to CUMBERLAND as set out in Subparagraph 5.6 (b) above, and the same
procedures shall apply. Likewise, with respect to any indications other than currently-approved
indications for the Drug Product that CUMBERLAND seeks to develop, CUMBERLAND shall provide notice
to BIONICHE regarding the possibility of supply of said Drug Product to CUMBERLAND and the
procedures described in Subparagraph 5.6 (b) above shall apply.
(e) If CUMBERLAND does not acquire rights to Excluded Products or to Other Products as
described in Subparagraphs 5.6 (c) and (d) above, and CUMBERLAND establishes, through the dispute
resolution process set forth in Paragraph 11.7, that sales by BIONICHE of said products have
detrimentally impacted sales of the Drug Product then BIONICHE shall pay CUMBERLAND an amount
equal to the lost profits so established by CUMBERLAND. CUMBERLAND shall bear the burden of
establishing lost sales.
(f) Except in the event that BIONICHE fails to supply all Drug Product ordered within ninety
(90) days of receipt of a Purchase Order in accordance with Paragraph 2.7, or in the event of
Force Majeure, CUMBERLAND will order its entire requirement of the Drug Product for the Territory
from BIONICHE, If CUMBERLAND notifies BIONICHE that it intends. to distribute the Drug Product in
countries other than the United States and its territories, then the parties shall negotiate in
good faith, for a period not to exceed one hundred twenty (120) days after CUMBERLAND provides
such notice, to amend this agreement to expand the Territory hereunder; provided that if the
parties fail to agree upon the terms of supply for an expanded Territory within such 120-day
period, CUMBERLAND shall have no obligation to purchase requirements of Drug Products for such
other countries from BIONICHE, but its obligations hereunder with respect to the United States and
its territories shall remain in full force and effect.
(g) In the event of breach of this Paragraph 5.6, the parties shall have the right, in
addition to other rights hereunder, to seek injunctive relief, notwithstanding any other provision
of this Agreement.
5.7 Minimum Purchase Quantities: CUMBERLAND shall have no minimum purchase requirements for
the first year following FDA approval of the Drug Product. The parties shall, no later than three
(3) months before the end of the first year following FDA approval, negotiate in good faith to set
on the minimum quantities applicable to the second to fifth years of commercial sale, which shall
be incorporated into Schedule V and shall form part of this Agreement. The parties shall negotiate
in good faith to set additional minimum purchase requirements for any extension of the Term of
this Agreement under Paragraph 3.1. CUMBERLAND shall use its best efforts to achieve the minimum
purchase requirements set forth in Schedule V of this Agreement for each format of Drug Product
being sold in the Territory by CUMBERLAND. In the event CUMBERLAND is required to procure Drug
Product from other sources in accordance with Paragraph 2.7, the minimum annual purchase
obligation set out in Schedule V shall be decreased by the quantity BIONICHE failed to deliver
hereunder.
6. DRUG PRODUCT RECALLS
6.1 Drug Product Recalls: In the event: (a) any government authority issues a request,
directive or order that the Drug Product be recalled, or (b) a court of competent jurisdiction
orders such a recall, (c) CUMBERLAND determines that the Drug Product should be recalled, or (d)
BIONICHE recommends to CUMBERLAND that a recall be initiated, the parties shall take all
appropriate corrective actions; provided that a recall pursuant to Subparagraph 6.1 (c) shall be
without prejudice to the parties rights under Paragraph 2.5. In the event that BIONICHE
recommends a recall of Drug Product by CUMBERLAND, such recommendation must take the form of a
notice as per Paragraph 11.1, and CUMBERLAND shall respond promptly indicating to BIONICHE whether
the Drug Product will be recalled. In no event, however, shall BIONICHE have responsibility for
regulatory compliance in connection with any recall, except to the extent and under the
circumstances set forth in the Manual or any other written agreement between the parties hereto or
as required by law. All costs and expenses incurred in connection with such recall shall be the
responsibility of CUMBERLAND unless caused by the negligence of BIONICHE.
7. FORCE MAJEURE; FAILURE TO SUPPLY
7.1 Force Majeure Events: Failure of either party to perform under this Agreement (except the
obligation to make payments) shall not subject such party to any liability to the other if such
failure is caused by acts such as, but not limited to, acts of God, fire, explosion, flood, war,
riot, sabotage, embargo, or by any cause beyond the reasonable control of the parties, provided
that written notice of such event is promptly given to the other party.
8. MANUFACTURING CHANGES
BIONICHE may implement commercially reasonable changes in the equipment used for
Manufacturing of the Drug Product in the Facility, or the Manufacturing methods, labeling, or
packaging of the Drug Product only as expressly provided in the Specifications unless BIONICHE has
the prior written consent of CUMBERLAND, which consent shall not be unreasonably withheld or
delayed.
9. CONFIDENTIALITY
9.1 Confidential Information: Confidential Information means collectively Confidential
Information of CUMBERLAND (as defined herein) and Confidential Information of BIONICHE (as defined
herein).
9.2 Confidential Information of CUMBERLAND: Except as expressly set forth herein,
Confidential Information of CUMBERLAND means all information obtained or developed by BIONICHE
which relates to CUMBERLANDs business or the Drug Product, regardless of the form in which such
information is transmitted. The following shall not be considered Confidential Information of
CUMBERLAND for purposes hereof:
(a) Information that is already in the possession of BIONICHE at the time it is received from
CUMBERLAND or developed by BIONICHE on CUMBERLANDs behalf, if BIONICHE notifies CUMBERLAND of its
belief that the information is excepted under the terms of this subsection;
(b) Information received by BIONICHE from a person which has the right to disclose the same,
when BIONICHE notifies CUMBERLAND of its belief that the information is excepted under the terms
of this subsection;
(c) Information that is or becomes published, or is or becomes otherwise publicly available
without the fault of BIONICHE;
(d) An Invention as defined in Paragraph 9.4; or
(e) Confidential Information of BIONICHE.
In the event of a dispute regarding the applicability of the above exceptions to the
definition of Confidential Information of CUMBERLAND, BIONICHE shall have the burden of producing
clear and convincing proof that the information should be excepted from the definition of
Confidential Information of CUMBERLAND. BIONICHE shall not use or permit the use of the
Confidential Information of CUMBERLAND other than for the limited purposes expressly permitted by
or consistent with this Agreement. Recipients of Confidential Information of CUMBERLAND shall be
granted access thereto strictly on a need-to-know basis. BIONICHE shall take all reasonable steps
to ensure that recipients comply with the terms of this Agreement, including all restrictions on
use, disclosure and dissemination of Confidential Information of CUMBERLAND. BIONICHE shall notify
CUMBERLAND immediately upon becoming aware of any breach hereof and shall take all reasonable steps
to prevent any further disclosure or unauthorized use.
Upon termination or expiration of this Agreement, BIONICHE shall deliver to CUMBERLAND all
Confidential Information of CUMBERLAND, all copies thereof, and all documents or data storage media
containing such Confidential Information of CUMBERLAND, except that one copy of such information
may be retained by BIONICHE as required by regulation or law for future reference. The Confidential
Information of CUMBERLAND shall remain confidential and not be disclosed by BIONICHE for a period
of ten (10) years following the date of expiration or termination of this Agreement except as
expressly set forth herein or in any other written agreement between the parties.
9.3 Confidential Information of BIONICHE: Except as expressly set forth herein, Confidential
Information of BIONICHE means all information obtained or developed by CUMBERLAND which relates to
the manufacture, sale, and distribution of pharmaceutical products by BIONICHE, regardless of the
form in which such information is transmitted. The following shall not be considered Confidential
Information of BIONICHE for purposes hereof:
(a) Information that is already in the possession of CUMBERLAND at the time it is received
from BIONICHE or developed by CUMBERLAND on BIONICHEs behalf, if CUMBERLAND notifies BIONICHE of
its belief that the information is excepted under the terms of this subsection;
(b) Information received by CUMBERLAND from a person which has the right to disclose the same,
when CUMBERLAND notifies BIONICHE of its belief that the information is excepted under the terms of
this subsection;
(c) Information that is or becomes published, or is or becomes otherwise publicly available
without the fault of CUMBERLAND; or
(d) Confidential Information of CUMBERLAND.
In the event of a dispute regarding the applicability of the above exceptions to the
definition of Confidential Information of BIONICHE, CUMBERLAND shall have the burden of producing
clear and convincing proof that the information should be excepted from the definition of
Confidential Information of BIONICHE. CUMBERLAND shall not use or permit the use of the
Confidential Information of BIONICHE other than for the limited purposes expressly permitted by or
consistent with this Agreement. Recipients of Confidential Information of BIONICHE shall be granted
access thereto strictly on a need-to-know basis. CUMBERLAND shall take all reasonable steps to
ensure that recipients comply with the terms of this Agreement, including all restrictions on use,
disclosure and dissemination of Confidential Information of BIONICHE. CUMBERLAND shall notify
BIONICHE immediately upon becoming aware of any breach hereof and shall take all reasonable steps
to prevent any further disclosure or unauthorized use.
Upon termination or expiration of this Agreement, CUMBERLAND shall deliver to BIONICHE all
Confidential Information of BIONICHE, all copies thereof, and all documents or data storage media
containing such Confidential Information of BIONICHE, except that one copy of such information may
be retained by CUMBERLAND as required by regulation or law for future reference. The Confidential
Information of BIONICHE shall remain confidential and not be disclosed by CUMBERLAND for a period
of ten (10) years following the date of expiration or termination of this Agreement except as
expressly set forth herein or in any other written agreement between the parties.
9.4 Invention: As between the parties, CUMBERLAND owns all intellectual property rights in any
improvement to the Drug Product and, subject to Paragraph 5.6, any existing or further developments
or modifications of the Drug Product in the Territory (Invention). Subject to Article 10,
BIONICHE shall, at CUMBERLANDs request and expense, take such actions and execute such documents
as necessary or desirable, in CUMBERLANDs sole judgment, to create, maintain, enforce or defend
CUMBERLANDs rights in any such Invention.
9.5 Press Release; Other Disclosure: Except pursuant to a press release subject to the prior
written approval of both parties hereto, the parties agree that the contents of this Agreement
shall not be disclosed to any third party except (i) the controlling companies of the parties, (ii)
the companies controlled by the parties, (iii) individuals and entities providing paid services to
either of the parties who are bound by confidentiality obligations, and (iv) governmental
regulatory agencies, including, but not limited to, environmental protection authorities, without
prior written consent of the other party.
9.6 Production of Records: BIONICHE shall prepare, maintain, and submit all documents or
reports required under applicable laws and regulations or as reasonably requested by CUMBERLAND
concerning the Manufacture of the Drug Products, including without limitation, batch production
records for each Drug Product. Notwithstanding the restrictions set forth in this Agreement,
BIONICHE shall retain production records for batches of Drug Product for a period of at least one
year after the respective expiration date for each batch. These records will be stored by
appropriate means, including without limitation, optical disk or microfilm in a secure manner in
compliance with current GMP with duplicate copies submitted to CUMBERLAND promptly after the
creation thereof and shall be made available on request of the FDA or any other authorized
regulatory body.
10. INDEMNIFICATION
10.1 Indemnification by CUMBERLAND: Subject to Paragraph 5.1, CUMBERLAND shall indemnify and
hold BIONICHE (and any Affiliate and their officers, directors, shareholders, agents, and the
employees and insurers of any of them and/or their successors and assigns thereto), free and
harmless from any and all claims, demands, liability, actions or causes of actions, and any and all
expenses associated therewith (including, without limiting the generality of the foregoing, defense
costs and reasonable attorneys fees), arising out of or in connection with, as a result of, or
otherwise related to any third party claims arising from: (i) any negligence or recklessness of
CUMBERLAND, its agents, or employees; (ii) the promotion, distribution, use, misuse or sale or
effects of the Drug Product except to the extent any alleged Drug Product defects were caused by
BIONICHE; (iii) CUMBERLANDs non-compliance with any applicable FDA or other applicable
regulations; or, (iv) any failure of CUMBERLAND to perform, in whole or in part, any of its
obligations hereunder in each case, unless caused by the acts or omissions of BIONICHE. Beginning
prior to delivery of the first order of Drug Products pursuant to this Agreement and continuing
until the third anniversary of termination of this Agreement, CUMBERLAND shall maintain products
liability insurance with limits of liability of not less than Five Million U.S. Dollars
($5,000,000) and shall name BIONICHE as additional insured under said policy.
10.2 Indemnification by BIONICHE: Subject to Paragraph 5.1, BIONICHE will indemnify and hold
CUMBERLAND (and any Affiliate and their officers, directors, shareholders, agents, and the
employees and issuers of any of them and/or their successors and assigns thereto), free and
harmless from any and all claims, demands, liability, actions or causes of action, and any and all
expenses associated therewith (including, without limiting the generality of the foregoing, defense
costs and reasonable attorneys fees), arising out of or in connection with, as a result of, or
otherwise related to any third party claims arising from: (i) any negligence or recklessness of
BIONICHE, its agents or employees; (ii) personal injury (including death) or property damage
arising out of or in connection with BIONICHEs manufacture or handling of the Drug Product
otherwise than in accordance with the Specifications and CUMBERLANDS written directions; (iii)
BIONICHEs non-compliance with any applicable FDA or other applicable regulations; or (iv) any
failure of BIONICHE to perform any of its obligations hereunder, in each case, unless caused by the
acts or omissions of CUMBERLAND. Beginning prior to delivery of the first order for Drug Product
pursuant to this Agreement and continuing until the third anniversary of termination of this
Agreement, BIONICHE shall maintain products liability insurance with limits of liability of not
less than U.S. $5,000,000 and shall name CUMBERLAND as additional insured under said policy.
10.3 Conditions of Indemnification: If either party seeks indemnification from the other
under Paragraphs 10.1 or 10.2, it shall promptly give written notice to the other party of any
such claim or suit threatened, made or filed against it, which forms the basis for such claim of
indemnification and shall cooperate fully with the other party in the defense of all such claims
or suits. No settlement or compromise shall be binding on a party hereto without its prior written
consent.
10.4 Limitation: Except as expressly set forth herein, neither party will be liable to the
other for any claim for loss of profits, for loss or interruption of business or for indirect,
special or consequential damages of any kind under this Agreement.
11. GENERAL PROVISIONS
11.1 Notices: Any notice permitted or required by this Agreement may be sent by facsimile with
the original document being sent by certified (or registered) mail, return receipt requested, or
overnight delivery and shall be effective when received (or refused) via facsimile or mail or
overnight if faxed and sent and addressed as follows (or to such other facsimile number or address
as may be designated by a party in writing):
|
|
|
|
|
|
|
|
|
If to CUMBERLAND: |
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
209 Tenth Avenue South, Suite 332 |
|
|
|
|
|
|
Nashville, Tennessee 37203 |
|
|
|
|
|
|
Attn: Chief Executive Officer |
|
|
|
|
|
|
Telephone: 615-255-0068 |
|
|
|
|
|
|
Facsimile: 615-255-0094 |
|
|
|
|
|
|
|
|
|
If to BIONICHE: |
|
BIONICHE LIFE SCIENCES, INC. |
|
|
|
|
|
|
231 Dundas Street East, |
|
|
|
|
|
|
Belleville, Ontario, Canada K8N 1E2 |
|
|
|
|
|
|
Attn: Chief Executive Officer |
|
|
|
|
|
|
Telephone: 800-265-5464 |
|
|
|
|
|
|
Facsimile: 613-966-4177 |
|
|
|
|
|
|
|
|
|
With a copy to: |
|
BIONICHE PHARMA (CANADA) LIMITED |
|
|
|
|
|
|
151 Dundas Street, Suite 507 |
|
|
|
|
|
|
London, Ontario, Canada N6A 5R7 |
|
|
|
|
|
|
Attn: President |
|
|
|
|
|
|
Telephone: 519-453-0641 |
|
|
|
|
|
|
Facsimile: 519-453-6169 |
|
|
|
|
|
|
|
|
|
And to: |
|
BIONICHE LIFE SCIENCES, INC. |
|
|
|
|
|
|
Attn: Vice President, Corporate Counsel |
|
|
|
|
|
|
Telephone: 800-265-5464 |
|
|
|
|
|
|
Facsimile: 613-966-4177 |
11.2 Master Agreement; Amendment: This Agreement is being entered into pursuant to the
Strategic Alliance Agreement dated January 15, 2002, between CUMBERLAND and BIONICHE (the Master
Agreement), and this Agreement (including any and all exhibits hereto, whether entered into now or
hereafter) constitutes an Addendum (as defined in the Master Agreement). In the event of any
conflict or inconsistency between the terms of this Agreement and the Master Agreement, the terms
of this Agreement shall govern. No modification of any of the terms of this Agreement, or any
amendments thereto, shall be deemed to be valid unless in writing and signed by both parties
hereto. No course of dealing or usage of trade shall be used to modify the terms and conditions
herein.
Without limiting the generality of the foregoing, no provisions of any CUMBERLAND purchase order
that are inconsistent with the terms of this Agreement shall apply.
11.3 Waiver: None of the provisions of the Agreement shall be considered waived by any party
hereto unless such waiver is agreed to, in writing, by both parties. The failure of a party to
insist upon strict conformance to any of the terms and conditions hereof, or failure or delay to
exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any
party hereto.
11.4 Obligations to Third Parties: Each party warrants and represents that this Agreement is
not inconsistent with any contractual obligations, expressed or implied, undertaken with any third
party.
11.5 Assignment: This Agreement shall be binding upon and inure to the benefit of the
successors or permitted assigns of each of the parties and may not be assigned, transferred, or
subcontracted by either party without the prior written consent of the other, which consent will
not be unreasonably withheld or delayed, except that no consent shall be required in the case of a
transfer to an Affiliate of a party hereto or transaction involving the merger, consolidation or
sale of substantially all of the assets of the party seeking such assignment or transfer and such
transaction relates to the business covered by this Agreement and the resulting entity assumes all
the obligations of the assigning party under this Agreement.
11.6 Independent Contractor: BIONICHE shall act as an independent contractor for CUMBERLAND
in providing the services required hereunder and shall not be considered an agent of or joint
venturer with CUMBERLAND. Unless otherwise provided herein to the contrary, BIONICHE shall furnish
all expertise, labor, supervision, machining and equipment necessary for performance hereunder and
shall obtain and maintain all building and other permits and licenses required by public
authorities.
11.7 Governing Law and Dispute Resolution: This Agreement is subject to and shall be governed
by the laws of the State of New York. Any dispute, controversy, or claim arising out of or
relating to this Agreement, any purchase orders between the parties hereto, or the breach,
termination, or invalidity thereof shall be settled under the Rules of the American Arbitration
Association by one or more arbitrators appointed in accordance with said Rules. The place of
arbitration shall be within the State of New York. The parties agree that the award of the
arbitrator(s) shall be the sole and exclusive remedy between them regarding any claims,
counterclaims, issues or accountings presented or pled to the arbitrator(s); that it shall be made
and shall promptly be payable in U.S. dollars free of any tax, deduction, or offset; that any
costs and attorney fees incurred by the prevailing party as determined by the arbitrator(s)
incident to the arbitration, shall be included as part of the arbitration award; and that any
costs. fees, or taxes incident to enforcing the award shall, to the maximum extent permitted by
law, be charged against the party resisting such enforcement. The award shall include interest
from the date of any damages incurred for breach or other violation of the Agreement, and from the
date of the award until paid in full, at a rate to be fixed by the arbitrator(s), but in no event
less than the prime interest rate for Bank of America in Nashville, Tennessee, U.S.A.
11.8 Severability: In the event that any term or provision of this Agreement shall violate
any applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or
otherwise be unenforceable, such provision shall be ineffective to the extent of such violation
without invalidating any other provision hereof.
11.9 Headings, Interpretation: The headings used in this Agreement are for convenience only
and are not part of this Agreement.
11.10 Conflict: In the event of conflict between the terms and provisions of this Agreement
and the terms and provisions of the Manual, the terms of this Agreement shall control.
11.11 Limitation: The parties hereto acknowledge and agree that the International Sale of
Goods Act and the United Nations Convention on Contracts for the International Sale of Goods have
no application to this Agreement.
IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their
duly authorized representatives effective as of the date first above written.
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
BIONICHE LIFE SCIENCES, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/
|
|
A. J. Kazimi |
|
|
|
/s/ |
|
Albert Beraldo |
|
|
|
|
|
|
|
|
|
|
|
|
|
Authorized Signature |
|
|
|
Authorized Signature |
|
|
|
A.J. Kazimi |
|
|
|
Albert Beraldo |
|
|
Chief Executive Officer |
|
|
|
Vice President, Business Development |
|
|
SCHEDULE I
[remainder of the Schedule to be inserted as agreed to by the Parties]
Shipping and Storage
|
1. |
|
Finished Drug Product shall be stored by BIONICHE after completion, at ___degrees C
to ___degrees C. |
|
|
2. |
|
Drug product will be delivered by BIONICHE to CUMBERLAND by air on the basis of FCA
(ex works) ex works BIONICHEs plant in Galway, Ireland with the carrier to be selected
by CUMBERLAND. |
|
|
3. |
|
The terms FCA (ex works) and DDP and the Parties respective obligations
shall be determined in accordance with the INCOTERMS adopted by the International
Chamber of Commerce, effective July 1, 1990, unless otherwise specifically provided in
this Agreement. |
|
|
4. |
|
Additional details regarding packaging shall be incorporated herein upon adoption
thereof by written agreement of BIONICHE and CUMBERLAND. |
Pricing
The prices to be paid by CUMBERLAND to BIONICHE for the Drug Products arc as follows:
N-acetylcysteine 30 mL [***]
N-acetylcysteine 10 mL [***]
[***] currency conversions will be based upon the then current exchange rate listed in the Wall
Street Journal.
The minimum size of any order of the Drug Product shall be one production lot of [***] for the 30
mL Drug Product and [***] for the 10 mL Drug Product.
[***]
[remainder of the Schedule to be inserted as agreed to by the Parties]
SCHEDULE II
[to be inserted as agreed to by the Parties]
SCHEDULE III
Territory
The United States of America and all its possessions and territories
SCHEDULE IV
Approved Suppliers
[to be inserted as agreed to by the Parties]
Schedule V
Minimum Purchase Quantities
[to be inserted as agreed to by the Parties]
EX-10.2 NOVATION AGREEMENT
EXHIBIT 10.2
EXECUTION COPY
NOVATION AGREEMENT
This Novation Agreement (as amended, supplemented, restated or otherwise modified from time to
time, this Novation Agreement) is made as of January 27, 2006 between:
BIONICHE LIFE SCIENCES INC., a corporation organized
under the laws of Canada
(BLSI),
and
CUMBERLAND PHARMACEUTICALS INC., a corporation
organized under the laws of the United States
(the CPI),
and
BIONICHE PHARMA GROUP LIMITED, a corporation
organized under the laws of Ireland
(Pharma).
(hereinafter collectively referred to as the Parties)
RECITALS
A. BLSI and the CPI have entered into a Strategic Alliance Agreement dated January 15, 2002 and a
Manufacturing and Supply Agreement for N-Acetylcysteine dated January 15, 2002 copies of which are
annexed as Schedules A and B attached hereto (such agreements and contracts, together with all
notices, certificates, Agreement, instruments and other documents delivered or entered into in
connection therewith, as amended, supplemented, restated or otherwise modified from time to time,
are collectively referred to herein as the Agreements").
B. BLSI desires to be released and discharged from its obligations to the CPI under the Agreements
and the CPI has agreed to release and discharge BLSI.
C. The Parties have agreed that as and from the date of this Novation Agreement (the Effective
Date), the Agreements shall be novated to Pharma so that from the Effective Date Pharma shall be
bound by the terms of the Agreements in place of BLSI and agrees to acknowledge and expressly
assume in the name, place and stead of BLSI all liabilities and obligations of BLSI under the
Agreements.
- 2 -
NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby
acknowledged by each party, the parties agree as follows:
SECTION
1 NOVATION AND RELEASE
1.1 Novation
As of the Effective Date, Pharma agrees and undertakes to perform the obligations of BLSI
under the Agreements, whether arising prior to, on or subsequent to the Effective Date, and agrees
to be bound by the terms and conditions of the Agreements in every way as if Pharma were named as a
party to the Agreements in place of BLSI. Pharma agrees to perform any and all past, present and
future obligations of BLSI under the Agreements, including without limitation indemnification
obligations of BLSI arising out of any failure of BLSI to perform an obligation under the
Agreements prior to the Effective Date.
1.2 Release of the Obligations of BLSI
As of the Effective Date, the CPI and BLSI mutually release each other from the various
covenants, undertakings, warranties and other obligations contained in the Agreements and from all
claims and demands whatsoever in respect of the Agreements whether arising prior to, on or
subsequent to the Effective Date.
SECTION 2 REPRESENTATIONS AND WARRANTIES OF BLSI AND PHARMA TO THE CPI
BLSI and Pharma represent and warrant to the CPI as follows:
2.1 Status
BLSI and Pharma are corporations duly constituted and validly existing and are in good
standing under the laws of their incorporating jurisdictions and are duly qualified to conduct
their business in each jurisdiction where the nature and extent of their business and property
require the same.
2.2 Authority
BLSI and Pharma possess all requisite authority and power to execute, deliver and comply with
the terms of this Novation Agreement. This Novation Agreement has been duly authorized by all
necessary action, has been duly executed and delivered by BLSI and Pharma and constitutes a valid
and binding obligation of BLSI and Pharma enforceable in accordance with its terms, except as the
enforcement thereof may be limited by applicable bankruptcy, insolvency, moratorium, rearrangement,
reorganization or similar legislation affecting the rights of creditors generally.
- 3 -
2.3 Right to Novate
BLSI has the right to novate its rights and benefits under the Agreements to Pharma, free and
clear of any charge, lien, pledge, security interest or direct or indirect participation interest
in favour of any other person, and as of the Effective Date, the Agreements are free and clear of
all charges, liens, pledges, security interests or direct or indirect participation interests in
favour of any other person.
2.4 Non-Conflict
Neither the execution nor the performance of this Novation Agreement requires the approval of
any governmental or regulatory agency having jurisdiction over BLSI or Pharma, nor is this
Novation Agreement in contravention of or in conflict with the articles, by-laws or resolutions of
the directors or shareholders of BLSI or Pharma, or, of the provisions of any agreement to which
BLSI or Pharma is a party, or by which any of the property of BLSI or Pharma may be bound, or of
any statute, regulation, by-law, ordinance or other law, or of any judgment, decree, award, ruling
or order to which BLSI or Pharma, or any of the property of BLSI or Pharma, may be subject.
2.5 Representations and Warranties Repeated
Pharma hereby makes the same representations and warranties with respect to itself that BLSI
made with respect to itself in the Agreements and Pharma represents and warrants to the CPI that
such representations and warranties are true and correct as of the Effective Date.
SECTION 3 REPRESENTATIONS AND WARRANTIES OF CPI TO PHARMA
The CPI represents and warrants to Pharma that:
|
(a) |
|
the representations and warranties of such CPI made in the Agreements are true
and correct as of the Effective Date, |
|
|
(b) |
|
such CPI possesses all requisite power and authority to execute, deliver and
comply with the terms of this Novation Agreement, and |
|
|
(c) |
|
the novation hereunder has been duly authorized by all necessary action, has
been duly executed and delivered by such CPI and constitutes a valid and binding
obligation of such CPI enforceable in accordance with its terms, except as the
enforcement thereof may be limited by applicable bankruptcy, insolvency, moratorium,
rearrangement, reorganization or similar legislation affecting the rights of creditors
generally. |
- 4 -
SECTION 4 GENERAL
4.1 Severability
If any provision of this Novation Agreement is held to be illegal, invalid or unenforceable
under present or future laws effective during the term of this Novation Agreement, the legality,
validity and enforceability of the remaining provisions of this Novation Agreement shall not be
affected thereby.
4.2 Multiple Counterparts
This Novation Agreement may be executed in a number of identical counterparts, each of which,
for all purposes, is to be deemed to be an original, and all of which constitute, collectively,
one agreement, but in making proof of this Novation Agreement, it shall not be necessary to
produce or account for more than one such counterpart.
4.3 Notices
Any notice given hereunder, under any of the Agreements or pursuant to the provisions hereof
or thereof shall be given in accordance with notice provisions of the Agreements, except that no
notice is required to be delivered to BLSI after the Effective Date.
For the purposes of the notice provisions of the Agreements, address for notices or
communications to Pharma shall be as follows:
Bioniche Pharma Group Limited
Inverin County, Galway
Ireland
Telecopier: 011 353 91 593 228
Attention; Albert Beraldo, Chief Executive Officer
4.4 Governing Law
This Novation Agreement shall be interpreted, construed and governed by and in accordance with
the laws of New York.
4.5 Confirmation
The parties hereby confirm, in all other respects, that the Agreements are in full force and
effect, unchanged and unmodified, except in accordance with this Novation Agreement.
4.6 Further Assurances
The parties shall, with reasonable diligence, do all such things and provide all such
reasonable assurances as may be required to consummate the transactions contemplated by this
Novation Agreement, and each party shall provide such further documents or instruments
- 5 -
required by any other party as may be reasonably necessary or desirable to effect the purpose
of this Novation Agreement and carry out is provisions,
The parties have executed this Novation Agreement and this Novation Agreement shall be
effective as of the Effective Date.
|
|
|
|
|
|
BIONICHE LIFE SCIENCES INC.
|
|
|
By: |
/s/ Graeme McRae
|
|
|
Name: |
Graeme McRae |
|
|
Title: |
President & CEO |
|
|
|
CUMBERLAND PHARMACEUTICALS INC.
|
|
|
By: |
/s/ A.J. Kazimi
|
|
|
Name: |
A.J. Kazimi |
|
|
Title: |
Chief Executive Officer |
|
|
|
BIONICHE PHARMA GROUP LIMITED
|
|
|
By: |
/s/ John [illegible]
|
|
|
Name: |
Dr. John [illegible] |
|
|
Title: |
Director |
|
|
EX-10.3 FIRST AMENDMENT TO MANUFACTURING AGREEMENT
EXHIBIT 10.3
*Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
FIRST AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT
FOR N-ACETYLCYSTEINE
THIS FIRST AMENDMENT (the First Amendment) to that certain Manufacturing and Supply
Agreement for N-Acetylcysteine (the "Agreement), dated as of January 15, 2002,
as modified by that certain Novation Agreement, dated as of January 27, 2006 (to be attached
hereto), is entered into by and between CUMBERLAND PHARMACEUTICALS INC., a corporation organized
and existing under the laws of Tennessee, United States (CUMBERLAND), and BIONICHE
TEORANTA, a corporation organized and existing under the laws of Ireland (BIONICHE), and
is effective as of November 16, 2006. Capitalized terms used but not defined in this First
Amendment shall have the meanings that are set forth in the Agreement.
WITNESSETH:
WHEREAS, BIONICHE is the assignee under the Agreement of BIONICHE PHARMA GROUP LIMITED, an
Affiliate thereof.
WHEREAS, CUMBERLAND and BIONICHE agree that the exceptions to the exclusivity provisions set
forth in Paragraph 5.6 of the Agreement which permit BIONICHE to (i) sell Excluded Products or
Other Products or (ii) market or distribute Excluded Products or Other Products in association with
any third Person other than CUMBERLAND in certain circumstances shall be deleted from the
Agreement.
NOW, THEREFORE, in consideration of the mutual covenants, agreements, representation and
warranties contained herein, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the parties hereto hereby agree as follows:
|
1. |
|
Paragraph 1.7 is amended and restated in its entirety as follows: |
|
|
|
|
DRUG PRODUCT shall mean the N-acetylcysteine pharmaceutical product developed by
CUMBERLAND and marketed for any current or future approved indications under the
trade name ACETADOTE or any other trade name selected by CUMBERLAND. |
|
|
2. |
|
Paragraph 1.9 is hereby amended and restated as follows: |
|
|
|
|
FACILITY shall mean the manufacturing facility and the real property underlying such
manufacturing facility operated by BIONICHE, located at Inverin, Co, Galway,
Republic of Ireland. |
|
|
3. |
|
Paragraph 1.18 defines TERRITORY as having the meaning set forth in Schedule
III. Schedule III of the Agreement, and therefore the TERRITORY, is hereby amended and
restated as follows: |
|
|
|
|
The United States of America and all its possessions and territories, [***]. |
|
4. |
|
Paragraph 3.1 is amended and restated in its entirety as follows: |
|
|
|
|
This Agreement shall commence on the date first above written and will continue until
January 23, 2011, unless sooner terminated pursuant to Paragraphs 3.2 or 3.3 hereof or
extended pursuant to this Paragraph 3.1. CUMBERLAND shall have the option to extend the
duration of this Agreement for five (5) years upon prior written notice provided by
CUMBERLAND to BIONICHE at least 180 days prior to January 23, 2011; otherwise, the
Agreement shall expire on such date in accordance with its terms. If CUMBERLAND
exercises such option, then subject to Paragraphs 3.2 and 3.3, the Agreement shall be
automatically renewed for successive three-year terms after expiration of the initial
extended term, unless either party notifies the other party in writing at least twelve
(12) months in advance of the expiration of the then current term that the party is
terminating the Agreement. |
|
|
5. |
|
Subparagraphs 3.2(d) and (e) are deleted from the Agreement in their entirety and
Subparagraph 3.2(f) is re-lettered as 3.2(d). |
|
|
6. |
|
Paragraph 3.5 is amended by adding a reference to Paragraph 3.4 thereto (such that
Paragraph 3.4 is identified as a surviving provision.) |
|
|
7. |
|
Subparagraph 5.6(a) is amended and restated in its entirety as follows: |
|
|
(a) |
|
Neither BIONICHE nor any Affiliate thereof will sell, give away, or deliver to any
other person, firm, or corporation any form of the Drug Product in the Territory for
any indications, while this Agreement is effective and for two years after the
termination of this Agreement; provided that such restrictions shall not apply in the
event of termination by BIONICHE pursuant to Subparagraphs 3.2(a) or (b), or Paragraph
3.3. |
|
|
8. |
|
Subparagraphs 5.6(b), (c), (d), and (e) are deleted from the Agreement in their entirety;
Subparagraphs 5.6(f) and (g) are re-lettered as 5.6(b) and (c), respectively; and
Subparagraph 5.6(f) (re-lettered 5.6(b)) is amended and restated in its entirety as
follows: |
|
|
(b) |
|
Except in the event that BIONICHE fails to supply all Drug Product ordered within
[***] of receipt of a Purchase Order in accordance with Paragraph 2.7, or in the event
of Force Majeure, CUMBERLAND will order its entire requirement of the Drug Product for
the Territory from BIONICHE. If CUMBERLAND notifies BIONICHE that it intends to
distribute the Drug Product in countries not included in the Territory, then the
parties shall negotiate in good faith, for a period not to exceed [***] after
CUMBERLAND provides such notice, to amend this Agreement to expand the Territory
hereunder (and to add additional minimum purchase quantities for such expanded
Territory, as contemplated under Paragraph 5.7); provided that, if the parties fail to
agree upon the terms of supply for an expanded Territory within such [***], CUMBERLAND
shall have no obligation to purchase requirements of such Drug Products for such other
countries |
2
from BIONICHE, but its obligations hereunder with respect to the Territory shall
remain in full force and effect.
|
9. |
|
Paragraph 5.7 is amended and restated in its entirety as follows: |
|
|
|
|
CUMBERLAND shall use its best efforts to achieve the minimum purchase quantities set forth
in Schedule V to this Agreement for each format of Drug Product sold in the Territory by
CUMBERLAND. In the event CUMBERLAND is required to procure Drug Product from other sources
in accordance with Paragraph 2.7, the minimum annual purchase obligation set out in Schedule
V shall be decreased by the quantity BIONICHE failed to deliver hereunder. |
|
|
|
|
Schedule V of the Agreement is hereby stated as follows: |
|
|
|
|
[***] |
|
10. |
|
Paragraph 11.1 is amended by replacing the address for notice (and relevant copies) for
CUMBERLAND and BIONICHE, as follows: |
|
|
|
|
|
|
|
|
|
If to CUMBERLAND: |
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
2525 West End Avenue, Suite 950 |
|
|
|
|
|
|
Nashville, Tennessee 37203 |
|
|
|
|
|
|
Attn: Chief Executive Officer |
|
|
|
|
|
|
Telephone: 615-255-0068 |
|
|
|
|
|
|
Facsimile: 615-255-0094 |
|
|
|
|
|
|
|
|
|
If to BIONICHE: |
|
BIONICHE TEORANTA |
|
|
|
|
|
|
Inverin,
Co. Galway, |
|
|
|
|
|
|
Ireland |
|
|
|
|
|
|
Attn: Managing Director |
|
|
|
|
|
|
Telephone: +353 91 593202 |
|
|
|
|
|
|
Facsimile: +353 91 593228 |
|
11. |
|
Miscellaneous. |
|
|
|
|
(a) Authorization. Each party to this First Amendment hereby represents and warrants
that the execution, delivery and performance of this First Amendment is within the powers of
such party and has been duly authorized by the party, is in accordance with all applicable
laws and regulations, and this First Amendment constitutes the valid and enforceable
obligation of each party in accordance with its terms. |
|
|
|
|
(b)Effect of First Amendment. Each party acknowledges that this First Amendment
constitutes a written instrument as contemplated by Paragraph 11.2 of the Agreement. Except
as specifically amended above, the Agreement shall remain in full force and effect, and is
hereby ratified and confirmed. |
3
(c) Counterparts. This First Amendment may be executed in any number of
counterparts, each of which may be executed by only one of the parties hereto, and
each of which shall be enforceable against the party actually executing such
counterpart, and all of which shall together constitute one instrument.
(d) Titles and Subtitles. The titles and subtitles used in this First
Amendment are used for convenience only and are not to be considered in construing or
interpreting this First Amendment.
(e) Governing Law and Dispute Resolution. This First Amendment shall be
construed in accordance with the laws of the State of New York without regard to
applicable conflicts of laws provisions and any dispute, controversy, or claim
arising out of or relating to this First Amendment shall be governed by the
provisions of Paragraph 11.7 of the Agreement.
(f) Severability. Should any part of this First Amendment be invalid or
unenforceable, such invalidity or unenforceability shall not affect the validity and
enforceability of the remaining portion.
IN WITNESS WHEREOF, each of the undersigned has caused this First Amendment to be
executed as of the date first above written.
|
|
|
|
|
|
|
|
|
CUMBERLAND: |
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ A.J. Kazimi |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
Date:
|
|
December 13, 2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BIONICHE: |
|
|
|
|
|
|
|
|
|
|
|
BIONICHE TEORANTA |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ John Kavanagh |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Managing Director |
|
|
|
|
|
|
|
|
|
|
|
Date:
|
|
November 16, 2006 |
|
|
|
|
|
|
|
|
|
4
EX-10.4 CARDINAL HEALTH CONTRACT SALES AND SERVICE
EXHIBIT 10.4
* Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
Contract Sales and Services Agreement
Between
Cumberland Pharmaceuticals, Inc.
&
Cardinal Health Contract Sales & Services
For
Cumberland Pharmaceuticals Dedicated Sales Force
May 16, 2006
TABLE OF CONTENTS
|
|
|
|
|
Article I |
|
Definitions and References to Cardinal Health |
|
Page 3 |
Article II |
|
Appointment of Cardinal Health; General Scope of Activities |
|
Page 5 |
Article III |
|
Compensation |
|
Page 8 |
Article IV |
|
Representations, Warranties and Covenants |
|
Page 9 |
Article V |
|
Status of Cardinal Health and the Representatives |
|
Page 10 |
Article VI |
|
Training |
|
Page 11 |
Article VII |
|
Samples |
|
Page 11 |
Article VIII |
|
Trademarks and Intellectual Property Rights |
|
Page 12 |
Article IX |
|
Communications; Monitoring the Program |
|
Page 12 |
Article X |
|
Insurance |
|
Page 13 |
Article XI |
|
Adverse Reaction Reporting and Regulatory Matters |
|
Page 14 |
Article XII |
|
Return/Recall |
|
Page 15 |
Article XIV |
|
Term and Termination |
|
Page 16 |
Article XV |
|
Recordkeeping; Audit Rights |
|
Page 18 |
Article XVI |
|
Indemnification |
|
Page 18 |
Article XVII |
|
Notice |
|
Page 21 |
Article XVIII |
|
Miscellaneous |
|
Page 21 |
Schedule 1.1(k) |
|
List of Products |
|
Page 25 |
Schedule 1.1(0) |
|
Definition of Territory |
|
Page 26 |
Schedule 3.1 |
|
Service Fees and Payment Schedule |
|
Page 27 |
-2-
AGREEMENT
This AGREEMENT (Agreement) is dated as of May 16, 2006 by and between Cardinal Health PTS, LLC
(Cardinal Health) with a place of business at 7000 Cardinal Place, Dublin, Ohio, and Cumberland
Pharmaceuticals, Inc. (Cumberland), having a principal place of business at 2525 West End,
Suite 950, Nashville, Tennessee 37203.
Background Information
Cumberland is a Tennessee-based company which focuses on the acquisition, marketing, and
distribution of a portfolio of niche pharmaceutical products. Cardinal Health provides medical
representatives who Detail (as hereinafter defined) pharmaceutical products for third parties.
Cumberland desires Cardinal Health to provide representatives to Detail certain products as
determined and directed by Cumberland in the geographical territory hereinafter specified,
pursuant to the terms and conditions of this Agreement, and Cardinal Health desires to provide
the Representatives and perform such services pursuant to the terms and conditions set forth in
this Agreement.
The parties hereby agree as follows:
ARTICLE I
DEFINITIONS AND REFERENCES TO CARDINAL HEALTH
1.1. Definitions. The following terms when used in this Agreement shall, except
where the context otherwise requires, have the following meanings:
(a) Act means the Federal Food, Drug and Cosmetic Act, as amended, and the regulations
promulgated thereunder from time to time.
(b) Affiliate means any corporate or non-corporate business entity that controls, is
controlled by, or is under common control with a party to this Agreement. A corporation or
non-corporate business entity shall be regarded as in control of another corporation if it owns
or directly or indirectly controls at least forty percent (40%) of the voting stock of the other
corporation, or (i) in the absence of the ownership of at least forty percent (40%) of the voting
stock of a corporation or (ii) in the case of a non-corporate business entity, if it possesses
directly or indirectly, the power to direct or cause the direction of the management and policies
of such corporation or non-corporate business entity, as applicable.
(c) Agency means any governmental regulatory authority in the Territory responsible for
granting approvals for the sale or maintaining regulatory oversight of the Products, including,
without limitation, the FDA.
(d) Cardinal Health means Cardinal Health PTS, LLC and shall be deemed to include the
Representatives and Managers.
-3-
(e) Detail means an interactive, face-to-face visit by a Representative
with a Target Customer or his or her legally empowered designee in the Territory, during
which the FDA-approved indicated uses, safety, effectiveness, contraindications, side
effects, warnings and other relevant characteristics of one or more of the Products (as
defined herein) are described by the Representative in a fair and balanced manner consistent
with the requirements of the Act, and using, as necessary or desirable, the Product Labeling
(as defined herein) and the Product Promotional Materials (as defined herein). Product
Detail means Detail of a Product between Target Customer and Representative. When used as a
verb, Detail or Detailing shall mean to engage in a Detail as defined in this Section
1.1(f).
(f) FDA means the United States Food and Drug Administration and any successor agency
having substantially the same functions.
(g) Manager means an individual hired by and retained as an employee of Cardinal
Health to oversee activities of Representatives under this Agreement, including a project
manager.
(h) PDMA means the Prescription Drug Marketing Act of 1987, as amended, and the
regulations promulgated thereunder from time to time.
(i) Product Labeling means all labels and other written, printed, or graphic matter
provided by Cumberland including (i) any container or wrapper utilized with a Product, or
(ii) any written material accompanying a Product, including, without limitation, Product
package inserts.
(j) Product Promotional Materials means all written, printed or graphic material
provided by Cumberland, including Product Labeling, intended for use by Representatives
during a Detail, including visual aids, file cards, premium items, clinical studies,
reprints, drug information updates and any other promotional support items that Cumberland
deems necessary or appropriate to conduct the Program. Product Promotional Materials shall
include FDA approved indicated uses, safety, effectiveness, contraindications, side effects,
warnings and other relevant characteristics of each of the Products.
(k) Products means the pharmaceutical products to be detailed by Representatives and
marketed by Cumberland as set forth on attached Schedule 1.1(k) and such other products as
may be added by Cumberland from time to time to Schedule 1.1(k) attached hereto.
(l) Program means the program of Detailing to be conducted by the Representatives
pursuant to this Agreement beginning as of September 5, 2006 and continuing thorugh the
remainder of the Term, as defined in Section 14.1.
(m) Representative and Representatives mean an individual or individuals hired
by and retained as an employee of Cardinal Health to conduct Detailing of Cumberland
Products only in connection with the Program.
-4-
(n) Target or Target Customer means a physician or other specialist identified by
Cumberland.
(o) Territory means the geographical area specified in the attached Schedule 1.1(o).
ARTICLE II
APPOINTMENT OF CARDINAL HEALTH; GENERAL SCOPE OF ACTIVITIES
2.1. Detailing. Cardinal Health shall provide twenty four (24) Representatives to
engage in Product Detail activities in the Territory. Cardinal Health shall assign
Representatives for such Target Customers, in such numbers, and in such Territories as
shall be designated by Cumberland during the term of this Agreement. Each Representative shall
make Product Details to his or her assigned Target Customers based on any reasonable
general direction given by Cumberlands designated management team. The duties of such
Representatives shall be exclusively to Detail the Products and perform other related
activities reasonably agreed upon by Cardinal Health as deemed necessary for the establishment
and maintenance of new and existing customers of the Products in the Territories. Cumberland
shall at all times retain the right to promote the Products by whomever, wherever, and to
whomever it chooses.
2.2 Furnishing Managers. Cardinal Health shall provide two Managers to oversee
the activities of Representatives and to perform this Agreement in such numbers and for such
Territories (when relevant) as mutually agreed upon by Cardinal Health and Cumberland.
2.3. Scope of Activities. The parties shall perform the following activities as
applicable to each in connection with the Program:
(a) Cardinal Health shall have sole and exclusive authority to discipline or terminate the
employment of Representatives. Cumberland may reasonably request that a Representative or
Manager be terminated or reassigned if such Representatives or Managers activities or conduct
are not adequately achieving the performance goals of the Product, or if the Representative or
Manager fails to comply with all applicable laws, regulations, and Cumberland requirements for
Detailing the Product. Cardinal Health shall use its best efforts to comply with such request;
provided that such action complies with applicable laws and is in accordance with Cardinal
Healths policies and procedures, as determined by Cardinal Healths human resources manager. In
the event Cardinal Health determines that its policies and procedures or applicable laws
prohibit the termination or reassignment of any Representative so requested by Cumberland, it
shall notify Cumberland of such determination and submit a corrective action plan for
Cumberlands approval.
(b) Cardinal Health shall cause each Representative to attend and successfully complete the
Training Program (as defined in Section 6.1) conducted by Cumberland for each of the Products
prior to participating in the Program. Any such Representative who shall not successfully
complete all such requirements shall be removed and replaced by another Representative who shall
comply with such requirements.
-5-
(c) Cumberland shall provide the Representatives without cost with sufficient
quantities of the Product Promotional Materials and Product Labeling for the performance of
Detailing. Cumberland shall be solely responsible for the preparation, content, and method
of distribution of the Product Promotional Materials and the Product Labeling. In
connection with the Detailing of the Products, the Representatives shall use only the
Product Labeling and the Product Promotional Materials provided by Cumberland; and under no
circumstances shall Cardinal Health or the Representatives develop, create, or use any
other promotional material or literature for the Detailing of the Products. Cumberland
shall advise Cardinal Health immediately of any inaccuracy or incompleteness of the Product
Promotional Materials or the Product Labeling, and upon such notice Cardinal Health and the
Representatives shall immediately cease the use of any portion or all of the Product
Promotional Materials or Product Labeling so identified by Cumberland.
(d) Cardinal Health shall instruct the Representatives to limit their verbal
statements and claims regarding the Products, including efficacy and safety, to those that
are consistent with the Product Labeling and the Product Promotional Materials. The
Representatives shall not add, delete, or modify claims of efficacy or safety in the
Detailing of the Products, nor make any changes (including underlining or otherwise
highlighting any language or adding any notes thereto) in the Product Promotional
Materials. Representatives shall not make any disparaging, untrue, or misleading statements
about Cumberland or its Affiliates, employees, competitors, or competing products.
Representatives shall Detail the Products in strict adherence to all applicable laws,
regulations, and professional requirements, including, but not limited to, the Act, the
Medicare and Medicaid Anti-Kickback Statute, and the American Medical Association Gifts to
Physicians from Industry Guidelines.
(e) The Representatives shall remain under the direct authority and control of
Cardinal Health, but shall cooperate with the members of Cumberland and shall receive
advice and direction related to Detail activities on the Products from Cumberland and
Cardinal Health mutually. Cumberland shall make all decisions with respect to the overall
strategy in connection with the Detailing of the Products. Any Cumberland personnel
interacting with Cardinal Health Representatives shall not discipline the Representatives
or implement terms or conditions of employment or personnel policies and/or practices with
respect to the Representatives. Cumberland shall provide Cardinal Health with copies of all
reports, memoranda, audits and other data it develops pertaining to (i) the
Representatives, Detailing, and the Program within 30 days of the preparation of such
documents, and (ii) any negligent or wrongful acts or omissions of Representatives as
promptly as practicable.
(f) In the event Cardinal Health supplies Representatives and Managers with fleet
vehicles for their use in performing the Detailing as described in the Schedules of this
Agreement, Cumberland shall reimburse Cardinal Health for all of its out-of-pocket costs
related to using such vehicles for Detailing, including but not limited to costs related to
owning, leasing, maintaining, insuring, and/or operating such vehicles (including fuel
costs). Cumberland shall reimburse Cardinal Health for all reasonable out-of-pocket costs
and expenses (i.e., airline tickets and other travel expenses, hotel, rent-a-car,
business meals, travel meals) of
-6-
Representatives and Managers in connection with performing services pursuant to this
Agreement. Cumberland and Cardinal Health shall establish a mutually acceptable budget for
the costs and expenses referenced in this subparagraph for each Territory.
(g) Cumberland shall provide Cardinal Health with a list of Target Customers in the
Territory and with data on prescriptions and sales in the Territory for Cardinal Healths use
in performing this Agreement. Cumberland shall also provide Cardinal Health with other sales
and marketing information concerning the Products that Cumberland obtains or prepares during
the term of this Agreement and deems useful to Cardinal Health.
2.4. Orders for Products. Cumberland shall be solely responsible for
establishing the terms and conditions of the sale of the Products, including without
limitation, the price at which the Products will be sold, whether sales of the Products will
be subject to any discounts, the method of distribution of the Products, and whether any
credit will be granted or refused in connection with the sale or return of any Product.
Cumberland shall be exclusively responsible for accepting and filling all purchase orders for
the Products, billing and returns for the Products, and all other activities in connection
with the sale and delivery of the Products, other than Detailing. If Cardinal Health or the
Representatives receive an order for the Products, they shall immediately transmit such order
to Cumberland for further handling and communications with the submitter of the order,
including acceptance or rejection, which shall be in Cumberlands sole discretion.
2.5. Representatives Activity
(a) Subject to Cumberlands obligations and representations and warranties in this
Agreement, any negligent or wrongful act or omission on the part of the Representatives (both
individually and as a group) that occur during the term of this Agreement and that arise
during the course and within the scope of their employment with Cardinal Health pursuant to
this Agreement shall be deemed to be negligent or wrongful acts or omissions of Cardinal
Health. Notwithstanding the foregoing, any acts or omissions of the Representatives pursuant
to the exclusive direction, control or supervision of Cumberland or its employees or agents
shall not be deemed to be negligent or wrongful acts or omissions of Cardinal Health.
(b) Each party shall notify the other in writing as promptly as practicable of any such
material alleged negligent or wrongful acts or omissions on the part of the Representatives
of which it becomes aware along with a plan to remedy such acts or omissions, and Cumberland
shall provide Cardinal Health with a reasonable opportunity to remedy such acts or omissions,
and if indicated, to replace the involved Representatives.
2.6 Vacancies/Turnover. In the event of a Representative vacancy due to
resignation, reassignment or termination of a Representative, Cardinal Health shall fill any
such vacancy within a six (6) week period. Cumberland shall be responsible for paying the
Service Fees (as defined in Section 3.1 below) during such vacancy, unless such vacancy
exceeds the six (6) week period, in which event, the associated Service Fees for such vacancy
shall be suspended after the six (6) week period and shall resume once the vacancy is filled
by Cardinal Health. All recruiting and other related expenses for filling a vacancy shall
be borne by Cardinal Health;
-7-
provided, however, that Cumberland shall be responsible for all recruiting and other
related expenses for filling any vacancy occurring pursuant to Cumberlands request for
reassignment or termination other than a request pursuant to Section 2.5(b) or resulting from
the Representatives failure to comply with any one or more of the provisions of Section 2.3.
In addition, if Cumberland desires to interview any candidates, Cumberland shall bear its own
cost of attending any final interview conducted by Cardinal Health or the costs of any
separate interview arranged for by Cumberland.
2.7 Management Reports. Cardinal Health or its third party designee shall provide
Cumberland with monthly reports in the form agreed between Cumberland and Cardinal Health
within fifteen (15) days after the end of each month. At the request of Cumberland, Cardinal
Health shall furnish Cumberland at reasonable times such documentation as Cumberland
reasonably requests for purposes of verifying the accuracy of any monthly report.
2.8 Project Manager. Cardinal Health shall appoint a Project Manager to serve
as a liaison between Cardinal Health, Representatives and Cumberland regarding the performance
by Cardinal Health and Cumberland of their respective obligations under this Agreement.
2.9 Non-compete. During the term hereof and until the first anniversary of the
expiration thereof, the Representatives shall not, directly or indirectly, solicit or
influence or attempt to solicit or influence any Target Customer to acquire pharmaceutical
products manufactured by a competitor of Cumberland for a laxative product, an oral
rehydration solution or other Products added to Schedule 1.1(k) by Cumberland.
ARTICLE III
COMPENSATION
3.1. Amount and Time of Payment. For services hereunder, Cumberland shall pay
to Cardinal Health the fees set forth in Schedule 3.1 attached hereto and incorporated by
reference (the Service Fees), which shall be payable as set forth in the payment schedule
set forth therein.
3.2 Cumberlands Hiring of Representatives. Cumberland shall not solicit,
directly or indirectly, any Representative or other employee of Cardinal Health to terminate
their employment with Cardinal Health and/or hire any such Representative or employee during
the Term of this Agreement without the prior written consent of Cardinal Health, which consent
shall not be unreasonably withheld or delayed. At the expiration or termination of this
Agreement, Cumberland shall have the right to hire as its own employee or as an independent
contractor or agent any one or more of the Representatives or Managers (collectively, the
Targeted Employees). Cumberland shall have the right to negotiate with any Targeted
Employee concerning the terms on which Cumberland might hire that Targeted Employee prior to
the end of the Term only upon the prior written consent of Cardinal Health, which shall not be
unreasonably withheld or delayed. Cardinal agrees not to interfere with or restrict in any
manner Cumberlands solicitation and hiring of the Targeted Employees and Cardinal Health will
assist Cumberland in the transition of Targeted Employees from Cardinal Health to Cumberland.
-8-
3.3. Reimbursement of Expenses. All expenses of Cardinal Health for which
Cumberland is obligated to reimburse Cardinal Health as expressly provided in this
Agreement, including but not limited to travel expenses and vehicle expenses under Section
2.3(e), shall be paid by Cumberland within [***] days after Cardinal Health has submitted a
statement itemizing such expenses. Cardinal Health shall submit such expense statements to
Cumberland monthly.
3.4 Past Due Amounts. All amounts owing by Cumberland to Cardinal Health
pursuant to this Agreement that are not timely paid by Cumberland will bear interest at the
rate of twelve (12%) per annum from the due date. An invoice will be considered late and
begin to accrue interest if unpaid 30 days past its due date.
ARTICLE IV
REPRESENTATIONS, WARRANTIES AND COVENANTS
4.1. By Cardinal Health. Cardinal Health represents, warrants, and covenants to
Cumberland, as of execution of this Agreement and during the term of this Agreement, as
follows:
(a) that Cardinal Health and the Representatives shall perform the Detailing in a
professional and timely manner;
(b) that Cardinal Health and the Representatives shall comply with all laws, rules and
regulations that apply to the performance of services under this Agreement, including but
not limited to the PDMA, the Medicare and Medicaid Anti-Kickback Act (42 U.S.C. §
1320a-7b(a)), the Civil False Claims Act (31 U.S.C. § 3729(a)), Sections 1128A, 1128B, and
1877 of the Social Security Act (42 U.S.C. §§ 1320a-7a, -7b, and 1395nn), the Health Care
Fraud Act (18 U.S.C. § 1347), and the Criminal False Claims Act (18 U.S.C. § 287), as
amended from time to time, as well as similar applicable state laws; and
(c) that Cardinal Health is under no obligation to any third party that would prevent
the execution of this Agreement or interfere with its performance under this Agreement.
4.2. By Cumberland. Cumberland represents, warrants, and covenants to
Cardinal Health, as of execution of this Agreement and during the term of this Agreement,
as follows:
(a) that Cumberland is under no obligation to any third party that would prevent the
execution of this Agreement or interfere with its performance under this Agreement;
(b) that Cumberland shall comply with all laws, rules and regulations that apply to the
Products and their sale, the Program, and this Agreement, including but not limited to the
Act, the PDMA, the Medicare and Medicaid Anti-Kickback Act (42 U.S.C. § 1320a-7b(a)), the
Civil False Claims Act (31 U.S.C. § 3729(a)), Sections 1128A, 1128B, and 1877 of the Social
Security Act (42 U.S.C. §§ 1320a-7a, -7b, and 1395nn), the Health Care Fraud Act (18
-9-
U.S.C. § 1347), and the Criminal False Claims Act (18 U.S.C. § 287), as amended from
time to time, as well as similar applicable state laws;
(c) that the Product Labeling and Product Promotional Materials are accurate,
complete, and in compliance with the Act and all applicable rules and regulations of the
FDA; and
(d) that to the best knowledge of Cumberland, the manufacture, sale, and distribution
of the products do not and will not during the term of this Agreement, infringe any patent
or other proprietary rights of third parties, and the Products have all necessary
governmental approvals and may be lawfully Detailed and sold by Cumberland and the
Representatives.
ARTICLE V
STATUS OF CARDINAL HEALTH AND THE REPRESENTATIVES
5.1. Cardinal Health Independent Contractor. Cardinal Health is being
retained and shall perform hereunder strictly as an independent contractor. Representatives
and Managers of Cardinal Health performing services hereunder shall not be, and shall not
be considered to be, employees of Cumberland for any purpose, and shall at all times remain
employees of Cardinal Health, subject to Section 3.3. Neither party shall have any
responsibility for the hiring, termination, compensation, benefits or other conditions of
employment of the other partys employees, except as otherwise provided in this Agreement.
5.2. No Cumberland Benefits. While employees of Cardinal Health, the
Managers and Representatives are not eligible to participate in any benefits programs or
sales bonuses offered by Cumberland to its employees, or in any pension plans, profit
sharing plans, insurance plans or any other employee benefit plans offered from time to
time by Cumberland to its employees, provided that the Representatives shall be eligible to
participate in Cumberland sales contests and bonus plans if so requested by Cumberland and
approved by Cardinal Health. Cardinal Health acknowledges and agrees that Cumberland does
not, and will not, maintain or procure any workers compensation or unemployment
compensation insurance for or on behalf of the Managers or Representatives while they are
employees of Cardinal Health. Cardinal Health acknowledges and agrees that it shall be
solely responsible for paying all salaries, wages, benefits and other compensation which
its employees (including Representatives and Managers) may be entitled to receive in
connection with the performance of the services hereunder.
5.3 Sales, Use and Excise Taxes. If any state or local government or other
taxing authority determines that sales, use or excise Taxes (Taxes) are applicable to
Cardinal Healths services performed hereunder, Cardinal Health shall promptly accrue and
Cumberland shall pay such Taxes on behalf of Cardinal Health to the appropriate taxing
authorities. In addition, Cumberland shall be responsible for the payment of any applicable
Taxes related to Cumberlands supply to Cardinal Health of Product Promotional Materials
and Product Samples.
5.4. No Joint Venture. Nothing contained in this Agreement shall be
construed as creating a joint venture or, except as otherwise provided herein, as granting
to either party the
-10-
authority to bind or contract any obligations in the name of or on the account of the
other party or to make any guarantees or warranties on behalf of the other party.
ARTICLE VI
TRAINING
6.1. Training Programs.
(a) Cumberland shall conduct a training program for new Representatives and Managers
prior to participating in the Program, which shall include such medical and technical
information about the Products and such sales training as Cumberland, along with Cardinal
Health, deems necessary and appropriate (the Training Program). The Training Program
shall also include instruction on compliance with applicable laws, Company policies and
procedures, and computer training. Cardinal Health shall assist Cumberland with
the Training Program only to the extent requested by Cumberland.
(b) In order to qualify for assignment in a Territory, a Representative must
demonstrate thorough knowledge of the Products by passing Cumberland approved Product
tests at a level of proficiency agreed upon by Cumberland and Cardinal Health.
6.2. Training Materials. Cumberland shall prepare written training
materials for the Training Program and an up-to-date programmed learning unit for the
Products, to be sent to each Representative for at home study a minimum of five (5) days
prior to the commencement of the Training Program.
6.3. Cumberland Assistance. During the term of this Agreement,
Cumberland shall make available to Cardinal Health, free of charge, a reasonable number
of, and for a reasonable amount of time, at locations reasonably agreed by Cumberland and
Cardinal Health, Cumberlands sales training and marketing personnel to assist Cardinal
Healths Representatives and Managers with respect to the Training Program and additional
orientation and ongoing training for the Representatives.
ARTICLE VII
SAMPLES
7.1. Provision of Samples. Cumberland shall provide samples of the Products
to the Representatives at Cumberlands option and at its expense. Cumberland shall
determine the quantity and types of samples to be provided to the Representatives and the
method of distribution of the samples. In the event Cumberland elects to have Cardinal
Health manage the storage and distribution of samples, Cardinal Health shall pass on to
Cumberland the actual invoice costs for storage, distribution and other related costs and
use prudent business sense in costs incurred. All samples shall be stored and handled by
Cumberland and Cardinal Health in compliance with the PDMA and applicable law.
7.2 Sample Accountability. Cardinal Health shall prepare and provide to
Cumberland for approval a sample accountability program applicable to the samples
provided by
-11-
Cumberland. After the parties agree in writing to adopt a sample accountability
program Cardinal Health shall comply with such program.
7.3. Return of Samples. Within 30 days following the termination or
expiration of this Agreement or within 30 days from the termination or removal from the
Program of a Representative (unless such Representative has been hired or retained by
Cumberland), Cardinal Health shall cause the Representatives to return to Cumberland all
unused Product samples provided to Cardinal Health or the Representatives by Cumberland.
Cumberland shall pay or reimburse Cardinal Health for all out-of-pocket costs and expenses
in connection with the storage and shipment of returned samples.
ARTICLE VIII
TRADEMARKS AND INTELLECTUAL PROPERTY RIGHTS
The Products shall be Detailed by Cardinal Healths Representatives under trademarks
owned or licensed by Cumberland or an Affiliate of Cumberland. This Agreement does not
constitute a grant to Cardinal Health of any property right or interest in the Products or
any trademarks which Cumberland or an Affiliate of Cumberland uses with respect to the
Products or to the name or business style of Cumberland. Cardinal Health and the
Representatives shall use the Product Promotional Materials only for the purposes of this
Agreement, and all copyright and other intellectual property rights in the Product
Promotional Materials shall remain with Cumberland.
ARTICLE IX
COMMUNICATIONS; MONITORING THE PROGRAM
9.1. Communications from Third Parties. Cardinal Health and its
Representatives shall advise Cumberland promptly of all comments, statements, requests and
inquiries of the medical profession or any other third parties relating to the Products
that are not addressed by either Product Labeling or the Product Promotional Materials, of
which Cardinal Health becomes aware. All responses to such communications to the medical
profession or such other third parties shall be handled solely by Cumberland. Cardinal
Health shall provide reasonable assistance to Cumberland to the extent requested by
Cumberland, and at Cumberlands cost and expense, to fully respond to such communications.
9.2. Government Agencies. All communications with government agencies,
including the FDA, concerning the Products shall be the sole responsibility of Cumberland.
Cardinal Health shall assist Cumberland with respect to such communications with
government agencies to the extent requested by Cumberland, and at Cumberlands cost
and expense. Cardinal Health shall provide Cumberland with any documents or information
reasonably requested by Cumberland for purposes of responding to any communications with
government agencies within 72 hours of Cumberlands request.
9.3. Cumberland Communications. In addition to Detailing, Cardinal Health shall assist
Cumberland with respect to customer communications (as reasonably requested by Cumberland and at
Cumberlands cost and expense) within the Territory and shall regularly
-12-
advise Cumberland of market, economic, regulatory and other developments of which Cardinal
Health may become aware which may affect the sale of the Products in the Territory.
9.4. Review of Results. The parties shall meet periodically, but at least once per
calendar quarter, to review and discuss the actual results compared to the marketing plans for
Detailing of the Products. Cumberland shall regularly and promptly share with Cardinal Health
all reports, audits and other data it develops relative to the Program.
ARTICLE X
INSURANCE
10.1 Cardinal Health Insurance.
|
(a) |
|
During the Term of this Agreement, Cardinal Health shall
obtain and maintain the following insurance with limits not less than those
specified below: |
|
i. |
|
Commercial General Liability Insurance with a
limit of One Million Dollars ($1,000,000) per occurrence. |
|
|
ii. |
|
Workers Compensation and Employers Liability
Insurance with statutory limits for Workers Compensation and
Employers Liability limits of One Million Dollars ($1,000,000) per
accident. |
|
|
iii. |
|
Automobile Liability Insurance with a combined
single limit of $1,000,000. |
|
|
iv. |
|
Products Liability Insurance with a limit of
Five Million Dollars ($5,000,000) per occurrence. |
(b) Cardinal Health may self-insure any or a portion of the required insurance.
In the event that any of the required policies of insurance are written on a claims
made basis, then such policies shall be maintained during the entire term of this
Agreement and for a period of not less than five (5) years following the
termination or expiration of this Agreement.
(c) Cardinal Health shall waive subrogation rights against Cumberland for
workers compensation benefits and shall obtain a waiver from any insurance
carriers with which Cardinal Health carries workers compensation insurance
releasing their subrogation rights against Cumberland.
(d) Each insurance policy which is required under this Section shall be
obtained from an insurance carrier with an A.M. Best rating of at least A- VII.
10.2 Cumberland Insurance.
|
(a) |
|
During the Term of this Agreement, Cumberland shall obtain and
maintain the following insurance with limits not less than those specified
below. |
-13-
|
i. |
|
Commercial General Liability Insurance with a limit of One
Million Dollars ($1,000,000) per occurrence. |
|
|
ii. |
|
Products Liability Insurance with a
limit of Five Million Dollars ($5,000,000) per occurrence. |
|
|
iii. |
|
Workers Compensation and Employers
Liability Insurance with statutory limits for Workers
Compensation and Employers Liability limits of One Million
Dollars ($1,000,000) per accident. |
(b) Cumberland may self-insure any or a portion of the required insurance. In
the event that any of the required policies of insurance are written on a
claims made basis, then such policy(ies) shall be maintained during the
entire period of this Agreement and for a period of not less than five (5)
years following the termination or expiration of this Agreement.
(c) Cumberland shall waive subrogation rights against Cardinal Health for
workers compensation benefits and shall obtain a waiver from any insurance
carriers with which Cumberland carries workers compensation insurance
releasing their subrogation rights against Cardinal Health.
(d) Each insurance policy which is required under this Section shall be
obtained from an insurance carrier with an A.M. Best rating of at least A-
VII.
ARTICLE XI
ADVERSE REACTION REPORTING AND REGULATORY MATTERS
11.1. Immediate Notification. Cardinal Health and Cumberland agree to notify the
other party as soon as reasonably practicable of any information that each may obtain or
learn concerning any Product or package complaint or any serious unexpected side effect,
injury, toxicity, or sensitivity reaction or any unexpected incidence of severity thereof
associated with the clinical uses, studies, investigations, tests and marketing of the
Products, whether or not determined to be attributable to the Products. Serious as used in
this Section 11.1 refers to an experience which results in death, permanent or substantial
disability, in-patient hospitalization, prolongation of existing in-patient hospitalization,
a congenital anomaly or cancer, or a result of an overdose or life threatening condition.
Unexpected as used in this Section 11.1 refers to (i) conditions or developments not
previously submitted to governmental Agencies or encountered during clinical studies of the
Products and not reflected in the Product Promotional Materials or the Product Labeling, or
(ii) conditions or developments occurring with greater frequency, severity, or specificity
than shown by information previously submitted to governmental Agencies or encountered
during clinical studies of the Products and not reflected in the Product Promotional
Materials or the Product Labeling. Each party shall also notify the other in a timely manner
of any other adverse experience, i.e., any unfavorable and unintended change in the
-14-
structure (signs), function (symptoms) or chemistry (laboratory data) of the body
temporally associated with the use of the Products, whether or not considered related
thereto.
11.2. Threatened Agency Action. Cardinal Health and Cumberland shall each
immediately notify the other party of any information that each may obtain or learn
regarding any threatened or pending action by an Agency which may affect the Products.
Cardinal Health shall, at the request of Cumberland and at the cost and expense of
Cumberland, cooperate with Cumberland in formulating a procedure for taking appropriate
action in response to such information. Unless compelled by law, Cardinal Health shall not
respond to an Agency without the prior written consent of Cumberland.
11.3. Training. Cardinal Health and Cumberland shall develop appropriate
instructions in the Training Program for Representatives as to handling of information
received or obtained subject to Sections 11.1 and 11.2.
ARTICLE XII
RETURN/RECALL
12.1. Returned Products.
(a) Cumberland shall be responsible for handling all returned Products, including
shipment and compensation or credit for the returned Products. Any Products inadvertently
returned to Cardinal Health shall be shipped to Cumberland or at its direction, in
compliance with Cumberlands returned goods policy, and Cardinal Health shall advise the
customer who made the return that the Products have been returned to Cumberland. Cumberland
shall reimburse Cardinal Healths out-of-pocket shipping costs arising from its handling of
such returned Products within 30 days of delivery to Cumberland of Cardinal Healths
statement for such costs. Upon request Cardinal Health shall provide Cumberland with
documentation relating to such costs.
(b) At Cumberlands request, Cardinal Health shall assist Cumberland in obtaining and
receiving any Products that have been recalled, and any costs incurred by Cardinal Health,
agreed upon in advance by Cumberland, with respect to participating in any such recall shall
be reimbursed by Cumberland within 30 days of delivery to Cumberland of Cardinal Healths
statement for such costs.
ARTICLE XIII
CONFIDENTIAL INFORMATION
13.1 Mutual Obligation. Cardinal Health and Cumberland agree that they will not
disclose the other partys Confidential Information (defined below) to any third party
without the prior written consent of the other party except as required by law, regulation or
court or administrative order; provided, however, that prior to making any such legally
required disclosure, the party making such disclosure shall give the other party as much
prior notice of the requirement for and contents of such disclosure as is practicable under
the circumstances. Notwithstanding the foregoing, each party may disclose the other partys
Confidential Information to any of its Affiliates that (A) need to know such
-15-
Confidential Information for the purpose of performing under this Agreement, (B) are
advised of the contents of this Article, and (C) agree to be bound by the terms of this
Article.
13.2 Definition. As used in this Agreement, the term Confidential Information
includes all such information furnished by Cardinal Health or Cumberland, or any of their
respective representatives or Affiliates, to the other or its representatives or Affiliates,
whether furnished before, on or after the date of this Agreement and furnished in any form,
including but not limited to written, verbal, visual, electronic or in any other media or
manner. Confidential Information includes all proprietary technologies, know-how, trade
secrets, discoveries, inventions and any other Intellectual Property (whether or not
patented), analyses, compilations, business or technical information and other materials
prepared by either party, or any of their respective representatives, containing or based in
whole or in part on any such information furnished by the other party or its representatives.
Confidential Information also includes the existence of this Agreement and its terms.
13.3 Exclusions. Notwithstanding Section 13.2, Confidential Information does not
include information that (A) is or becomes generally available to the public or within the
industry to which such information relates other than as a result of a breach of this
Agreement, or (B) is already known by the receiving party at the time of disclosure as
evidenced by the receiving partys written records, or (C) becomes available to the
receiving party on a non-confidential basis from a source that is entitled to disclose it on
a non-confidential basis, or (D) was or is independently developed by or for the receiving
party without reference to the Confidential Information, as evidenced by the receiving
partys written records.
13.4 No Implied License. The receiving party will obtain no right of any kind or
license under any patent application or patent by reason of this Agreement. All Confidential
Information will remain the sole property of the party disclosing such information or data.
13.5 Return of Confidential Information. Upon written request or termination of this
Agreement, the receiving party shall promptly return within thirty (30) days all such
information, including any copies thereof, and cease its use or, at the request of the
disclosing party, shall promptly destroy the same and certify such destruction to the
disclosing party; except for a single copy thereof, which may be retained for the sole
purpose of determining the scope of the obligations incurred under this Agreement.
13.6 Survival. The obligations of this Article 13 will terminate five (5) years from
the expiration of this Agreement.
ARTICLE XIV
TERM AND TERMINATION
14.1. Term. This Agreement shall take effect as of September 5, 2006 and shall
continue in effect until August 30, 2008 (the Initial Term), unless terminated earlier
as set forth herein. Notwithstanding the foregoing, Cumberland may, at its option
upon written notice to Cardinal Health at least ninety (90) days prior to the expiration of
the Initial Term, and with the written consent of Cardinal Health, extend the Initial
Term for one additional year (the Renewal Term). If Cumberland desires to exercise the
Renewal Term, parties shall negotiate in good faith provisions of Section 3.1 regarding
Service Fees. References in this Agreement to the term of this Agreement include both the
Initial Term and the Renewal Term, if applicable.
-16-
14.2. Bankruptcy: Insolvency. Either party may terminate this Agreement
upon notice to the other upon the occurrence of: (a) the entry of a decree or order for
relief by a court of proper jurisdiction in an involuntary case of the other party under the
Federal Bankruptcy Code, as now constituted or hereafter amended, or any other applicable
federal or state insolvency or other similar laws, and the continuance of any such decree or
order in effect for a period of sixty (60) consecutive days; or (b) the filing by the other
party of a petition for relief under the Federal Bankruptcy Code, as now constituted or
hereafter amended, or any other applicable federal or state insolvency or similar laws.
14.3 Termination For Breach. Subject to Section 3.2 and other continuing
obligations, either party may terminate this Agreement (i) in the event of a material breach
of the other partys obligations under this Agreement, provided that such breach has not
been cured within thirty (30) days after written notice thereof from the non-breaching party.
14.4 Termination Due To Regulatory And Other Problems. If the Product is not
being marketed due to regulatory problems, court or administrative proceedings, product
liability claims, recalls, raw materials shortages, or similar factors beyond the control of
Cumberland, then, subject to Section 3.2, either party may terminate this Agreement upon
thirty (30) days written notice to the other.
14.5 Termination Due To Assignment or Change in Control. In the event of a
Change of Control (defined herein), the party that has had a Change In Control (the
Affected Party) shall give written notice to the other party (the Non-Affected Party)
within thirty (30) days of the occurrence of such Change In Control. If the Change In
Control involves a material and direct competitor of the Non-Affected Party, the
Non-Affected Party may terminate this Agreement by written notice to the Affected Party
within 60 days after receipt of the Notice of a Change In Control . If the Change In Control
does not involve a material and direct competitor of the Non-Affected Party, this
Agreement may not be terminated by the Non-Affected Party. For purposes of this Section,
Change In Control includes a purchase, assignment or transfer of a controlling interest
in the Affected Party or substantially all of its business and assets and any merger or
consolidation involving the Affected Party or any Affiliate of the Affected Party that
requires a vote of the stockholders of the Ultimate Parent of the Affected Party. Ultimate
Parent for Cardinal Health is Cardinal Health, Inc. and the Ultimate Parent for Cumberland
is its stockholders.
14.6. Termination: Phase Out. In the event that this Agreement is terminated
pursuant to Sections 14.2 through 14.5, and at Cumberlands request, the parties shall
discuss in good faith an appropriate phase-out of Cardinal Healths Detailing activities.
14.7 Termination: Written Notice. Cumberland may terminate the Agreement, with
or without cause, upon 60 days prior written notice.
14.8. Termination: Continuing Rights. The termination or expiration of this Agreement
shall not affect Cumberlands obligation to reimburse or pay Cardinal Health any amount then
due and owing under this Agreement. Further, the termination or expiration of this
Agreement
-17-
shall not affect any rights or obligations of any party under this Agreement which are
intended by the parties to survive such termination. The Service Fee paid by Cumberland
for the month in which this Agreement is terminated shall be prorated based on the number of
days in that month, and Cardinal Health shall refund any overpayment to Cumberland.
14.9 Termination: Return of Materials. Within sixty (60) days following the
termination or expiration of this Agreement, Cardinal Health shall return to Cumberland all
Confidential Information, Product Promotional Materials, marketing plans, forms, territory
lists, reports and any and all other tangible items provided to Cardinal Health by Cumberland.
ARTICLE XV
RECORDKEEPING; AUDIT RIGHTS
15.1. Cardinal Health Record Keeping: Inspection by Cumberland. Cardinal Health
shall keep accurate records in sufficient detail as to costs and expenses for which Cumberland must reimburse Cardinal Health under this Agreement. Upon Cumberlands reasonable
request made during or within one (1) year after the term of this Agreement, and at
Cumberlands expense, Cardinal Health shall permit Cumberlands designated employees or
agents to have access during ordinary business hours to records of such costs and expenses in
order to verify the accuracy of amounts reimbursed by Cumberland to Cardinal Health. Cumberland
and its designated employees or agents shall maintain in confidence all such cost and expense
records of Cardinal Health.
ARTICLE XVI
INDEMNIFICATION
16.1 Definitions. As used in this Article 16 and this Agreement, Damages shall
mean all liabilities, damages, assessments, levies, losses, fines, penalties, costs,
and expenses, including, without limitation, reasonable attorneys, accountants,
investigators, and experts fees and expenses, sustained or incurred as a result of any
claims, suits, liabilities, or actions by any third party.
16.2. Indemnification by Cardinal Health. Except to the extent that any of the
following Damages arises from the negligence or willful misconduct of Cumberland or breach
of this Agreement by Cumberland, Cardinal Health shall indemnify and hold Cumberland, its
Affiliates, directors, officers, employees and agents harmless from and against any and all
Damages arising directly or indirectly from:
(a) Cardinal Healths breach of or failure to comply with any of its obligations
under this Agreement;
(b) any inaccuracy in or breach or failure of any representation, warranty, or
covenant made by Cardinal Health in this Agreement;
(c) any negligent or wrongful act or omission on the part of Cardinal Health or
its employees or agents;
-18-
(d) Cardinal Healths violation of or failure to comply with all applicable laws
relating to the promotion, distribution and sale of the Products, including but not limited
to the Act, the PDMA, the Medicare and Medicaid Anti-Kickback Act (42 U.S.C. §
1320a-7b(a)), the Civil False Claims Act (31 U.S.C. § 3729(a)), Sections 1128A,
1128B, and 1877 of the Social Security Act (42 U.S.C. §§ 1320a-7a, -7b, and 1395nn),
the Health Care Fraud Act (18 U.S.C. § 1347), and the Criminal False Claims Act
(18 U.S.C. § 287), as amended from time to time, as well as similar applicable
state laws;
(e) Detailing of the Products, except to the extent such Damages arise from a negligent or
wrongful act or omission of Cumberland;
(f) any federal or state claim or assessment for nonpayment or late payment by
Cardinal Health of any tax or contribution based on the status of any Representatives
as employees of Cardinal Health:; or
(g) except as limited by Section 2.3(a) or by Cumberlands indemnification obligations, any
employment actions and/or employment related claims alleging violation of any state or federal
employment laws arising out of any action taken or omission made independently by Cardinal
Health.
16.3. Indemnification by Cumberland. Except to the extent that any of the following
Damages arise from the negligence or willful misconduct of Cardinal Health or breach of this
Agreement by Cardinal Health, Cumberland shall indemnify and hold Cardinal Health and its
Affiliates, directors, officers, employees and agents harmless from and against any and all
Damages arising directly or indirectly from:
(a) Cumberlands breach of or failure to comply with any of its obligations under this
Agreement;
(b) any inaccuracy in or breach or failure of any representation, warranty, or covenant made
by Cumberland in this Agreement;
(c) any negligent or wrongful act or omission on the part of Cumberland or its employees or
agents;
(d) Cumberlands violation of or failure to comply with all applicable laws relating to the
manufacture, sale, distribution, possession and use of the Product, the Program and this
Agreement, including but not limited to the Act, the PDMA, the Medicare and Medicaid
Anti-Kickback Act (42 U.S.C. § 1320a-7b(a)), the Civil.False Claims Act (31 U.S.C. § 3729(a)),
Sections 1128A, 1128B, and 1877 of the Social Security Act (42 U.S.C. §§ 1320a-7a, -7b, and
1395nn), the Health Care Fraud Act (18 U.S.C. § 1347), and the Criminal False Claims Act (18
U.S.C. § 287), as amended from time to time, as well as similar applicable state laws;
-19-
(e) Detailing of the Products, except to the extent such Damages arise from a
negligent or wrongful act or omission of Cardinal Health;
(f) the accuracy or completeness of the Product Labels, Product Promotional
Materials, or the Training Program;
(g) any claims or liabilities for injury to or death of persons, regardless of
when such claim or liability is asserted or incurred, resulting from or arising out
of the manufacture, use, sale, distribution, possession of the Products, or a
manufacturing design or defect of the Products, or any failure to warn or inadequacy
of warning regarding the Products;
(h) Cumberlands failure to pay when due or to reimburse Cardinal Health for
any Taxes (as defined in Section 5.3);
(i) any negligent or wrongful acts or omissions on the part of Cumberland with
respect to Cardinal Healths employees or Representatives or those individuals who
have made application to be Representatives of Cardinal Health;
(j) any federal or state claim or assessment for nonpayment or late payment by
Cumberland of any tax or contribution based on the status of any former
Representatives as employees or agents of Cumberland; or
(k) the use by Cardinal Health, in the performance of its duties hereunder and
as specified or directed by Cumberland, of any trademark, trade name, copyright,
patent or other rights which use actually or allegedly infringes on the rights of
any third party.
16.4. Indemnification Procedures. A party (the Indemnitee) which intends to
claim indemnification under this Article 16 shall promptly notify the other party (the
lndemnitor) in writing of any action, claim or liability in respect of which the
lndemnitee or any of its employees or agents are entitled to indemnification. The
Indemnitee shall permit, and shall cause its employees and agents to permit, the Indemnitor
at its discretion, to settle any such action, claim or liability and agrees to the complete
control of such defense or settlement by the Indemnitor; provided, however, that such
settlement or defense does not adversely affect the lndemnitees rights hereunder or impose
any obligations on the Indemnitee in addition to those set forth in this Agreement. The
Indemnitee, its employees, and agents, shall cooperate fully with the Indemnitor and its
legal representatives in the investigation and defense of any action, claim or liability
subject to indemnification. The Indemnitee shall have the right, but not the obligation, to
be represented by counsel of its own selection and at its own expense: in connection with
any indemnified claim.
16.5. Limitation on Cardinal Health Liability. In no event shall Cardinal
Healths total liability under this Agreement exceed an amount equal to the total fees paid
to Cardinal Health under this Agreement.
-20-
16.6 No Consequential Damages. Notwithstanding any provision of this
Agreement to the contrary, and except with regard to claims by third parties, neither party
shall be liable to the other for any special, indirect, incidental or consequential damages
(other than liability for personal injury as provided in this Article 16), including lost
profits.
ARTICLE 17
NOTICE
All notices and other communications hereunder shall be in writing and shall be deemed
given: (A) when delivered personally; (B) when delivered by facsimile transmission (receipt
verified); (C) when received or refused, if mailed by registered or certified mail (return
receipt requested), postage prepaid; or (D) when delivered if sent by express courier
service,
to the parties at the following addresses (or at such other address for a party as shall be
specified by like notice; provided, that notices of a change of address shall be effective only upon receipt thereof):
|
|
|
|
|
|
|
To Cumberland:
|
|
A.J. Kazimi, CEO |
|
|
|
|
Cumberland Pharmaceuticals Inc. |
|
|
|
|
2525 West End Avenue, Suite 950 |
|
|
|
|
Nashville, Tennessee 37203 |
|
|
|
|
Facsimile (615) 255-0094 |
|
|
|
|
|
|
|
With a copy to:
|
|
Adams and Reese / Stokes Bartholomew LLP |
|
|
|
|
424 Church Street, Suite 2800 |
|
|
|
|
Nashville, Tennessee 37219 |
|
|
|
|
Attn. Martin S. Brown, Jr. |
|
|
|
|
Facsimile (615) 259-1470 |
|
|
|
|
|
|
|
To Cardinal Health:
|
|
Cardinal Health PTS, LLC |
|
|
|
|
7000 Cardinal Place |
|
|
|
|
Dublin, Ohio 43017 |
|
|
|
|
Attn: Thomas Dimke, SVP/GM |
|
|
|
|
Cardinal Health Contract Sales and Services |
|
|
|
|
Facsimile: (614) 757-6117 |
|
|
|
|
|
|
|
With a copy to:
|
|
Cardinal Health, Inc. |
|
|
|
|
7000 Cardinal Place |
|
|
|
|
Dublin, Ohio 43017 |
|
|
|
|
Attn: Associate General Counsel, |
|
|
|
|
Pharmaceutical Technologies and Services |
|
|
|
|
Facsimile: (614) 757-5051 |
ARTICLE 18
MISCELLANEOUS
18.1 Entire Agreement; Amendments. This Agreement, the attachments, and any
amendments thereto constitute the entire understanding between the parties and supersede
any
-21-
contracts, agreements or understanding (oral or written) of the parties with respect
to the subject matter hereof. No term of this Agreement may be amended except upon written
agreement of both parties, unless otherwise provided in this Agreement.
18.2 Captions. The captions in this Agreement are for convenience only and
are not to be interpreted or construed as a substantive part of this Agreement.
18.3 Further Assurances. The parties agree to execute, acknowledge and
deliver such further instruments and to take all such other incidental acts as may be
reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.
18.4 No Waiver. Failure by either party to insist upon strict compliance
with any term of this Agreement in any one or more instances will not be deemed to be a
waiver of its rights to insist upon such strict compliance with respect to any subsequent
failure.
18.5 Severability. If any term of this Agreement is declared invalid or
unenforceable by a court or other body of competent jurisdiction, the remaining terms of
this Agreement will continue in full force and effect.
18.6 Independent Contractors. The relationship of the parties is that of
independent contractors, and neither party will incur any debts or make any commitments for
the other party except to the extent expressly provided in this Agreement. Nothing in this
Agreement is intended to create or will be construed as creating between the parties the
relationship of joint ventures, co-partners, employer/employee or principal and agent.
18.7 Successors and Assigns. This Agreement will be binding upon and inure
to the benefit of the parties, their successors and permitted assigns. Neither party may
assign this Agreement, in whole or in part, without the prior written consent of the other
party, except that either party may, without the other partys consent, assign this
Agreement to an Affiliate or to a successor to substantially all of the business or assets
of the assigning company.
18.8 Governing Law. This Agreement shall be governed by and construed under
the laws of the State of Tennessee, excluding its conflicts of law provisions. The United
Nations Convention on Contracts for the International Sale of Goods shall not apply to this
Agreement.
18.9 Alternative Dispute Resolution. If any Dispute arises between the
parties, such Dispute shall be presented to the respective presidents or senior executives
of Cardinal Health and Cumberland for their consideration and resolution. If such parties
cannot reach a resolution of the Dispute, then such Dispute shall be resolved by binding
alternative dispute resolution in accordance with the then existing commercial arbitration
rules of CPR Institute for Dispute Resolution, 366 Madison Avenue, New York, NY 10017.
Arbitration shall be conducted in the jurisdiction of the defendant party.
18.10 Prevailing Party. In any dispute resolution proceeding between the
parties in connection with this Agreement, the prevailing party will be entitled to its
reasonable attorneys fees and costs in such proceeding.
18.11 Counterparts. This Agreement may be executed in one or more counterparts, each
of which will be deemed an original but all of which together will constitute one and the
same
-22-
instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement
shall constitute an original.
18.12 Publicity. Neither party will make any press release or other public
disclosure regarding this Agreement or the transactions contemplated hereby without the
other partys express prior written consent, except as required under applicable law or by
any governmental agency, in which case the party required to make the press release or
public disclosure shall use commercially reasonable efforts to obtain the approval of the
other party as to the form, nature and extent of the press release or public disclosure
prior to issuing the press release or making the public disclosure.
18.13 Setoff. Without limiting Cardinal Healths rights under law or in
equity, Cardinal Health and its Affiliates, parent or related entities, collectively or
individually, may exercise a right of set-off against any and all amounts due to Cardinal
Health from Cumberland. For purposes of this Article, Cardinal Health, its Affiliates,
parent or related entities shall be deemed to be a single creditor.
18.14 Survival. The rights and obligations of the parties shall continue
under Articles 6 (Confidentiality), 7 (Intellectual Property), 9 (Indemnification), 10
(Limitations of Liability), 11 (Insurance), to the extent expressly stated therein, 13
(Notice), 14 (Miscellaneous) and Section 12.3 (Effect of Termination), notwithstanding
expiration or termination of this Agreement.
18.15 Force Majeure. Except as to payments required under this Agreement,
neither party shall be liable in damages for, nor shall this Agreement be terminable or
cancelable by reason of, any delay or default in such partys performance hereunder if such
default or delay is caused by events beyond such partys reasonable control including, but
not limited to, acts of God, regulation or law or other action or failure to act of any
government or agency thereof, war or insurrection, civil commotion, destruction of
production facilities or materials by earthquake, fire, flood or storm, labor disturbances,
epidemic, or failure of suppliers, public utilities or common carriers; provided however,
that the party seeking relief hereunder shall immediately notify the other party of such
cause(s) beyond such partys reasonable control. The party that may invoke this section
shall use all reasonable endeavors to reinstate its ongoing obligations to the other. If the
cause(s) shall continue unabated for one hundred eighty (180) days, then both parties shall
meet to discuss and negotiate in good faith what modifications to this Agreement should
result from this force majeure.
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized officers.
|
|
|
|
|
|
|
|
|
CARDINAL HEALTH PTS, LLC |
|
|
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Thomas G. Dimke
|
|
|
|
By:
|
|
/s/ AJ Kazimi |
|
|
|
|
|
|
|
|
|
Name:
|
|
Thomas G. Dimke
|
|
|
|
Name:
|
|
AJ Kazimi |
Title:
|
|
SVP/GM HCSS
|
|
|
|
Title:
|
|
C.E.O. |
Date:
|
|
5-18-06
|
|
|
|
Date:
|
|
5-17-06 |
-23-
Schedule 1.1(k)
List of Products
CeraLyte®
Kristalose®
-24-
Schedule 1.1(o)
Definition of Territory
The mutually agreed upon headquarter locations for the twenty four representatives are
as follows:
|
Atlanta, GA |
Birmingham, AL |
Boston, MA |
Charlotte, NC |
Chicago, IL |
Dallas, TX |
Dayton, OH |
Detroit, MI |
Hartford, CT |
Houston, TX |
Knoxville, TN |
Lafayette, LA |
Long Island, NY |
Manhattan, NY |
Miami, FL |
Mobile, AL |
Newark, NJ |
Philadelphia N, PA |
Philadelphia S, PA |
Cleveland, OH |
San Antonio, TX |
Tampa, FL |
Washington, DC |
Yonkers, NY |
Each Territory shall include the Target Customers identified by Cumberland and Cardinal
Health.
-25-
Schedule 3.1
Service Fees and Payment Schedule
With respect to the Program defined herein, the following fees shall apply:
A. As compensation for the satisfactory performance by Cardinal Health of its obligations
under the Agreement, Cumberland agrees to pay Cardinal Health Service Fees at the annual rate of
[***]. The Service Fees shall be billed in monthly installments on the last day of each month
during the term hereof. Each such installment shall be in the amount of [***] or pro rata portion
thereof in the event of early termination. The payment schedule for the term is as follows:
|
|
|
Invoice Date |
|
Payment |
September 30, 2006 |
|
[***] |
October 31, 2006 |
|
[***] |
November 30, 2006 |
|
[***] |
December 31, 2006 |
|
[***] |
January 31, 2006 |
|
[***] |
February 28, 2006 |
|
[***] |
March 31, 2006 |
|
[***] |
April 30, 2007 |
|
[***] |
May 31, 2007 |
|
[***] |
June 30, 2007 |
|
[***] |
July 31, 2007 |
|
[***] |
August 31, 2007 |
|
[***] |
September 30, 2007 |
|
[***] |
October 31, 2007 |
|
[***] |
November 30, 2007 |
|
[***] |
December 31, 2007 |
|
[***] |
January 31, 2008 |
|
[***] |
February 28, 2008 |
|
[***] |
March 31, 2008 |
|
[***] |
April 30, 2008 |
|
[***] |
May 31, 2008 |
|
[***] |
June 30, 2008 |
|
[***] |
July 31, 2008 |
|
[***] |
August 31, 2008 |
|
[***] |
B. In addition to the Service Fees, Cardinal Health will invoice Cumberland for
the following pass through costs:
-26-
|
(i) |
|
bonuses to Representatives in amounts as agreed in writing by Cardinal
Health and Cumberland before payment and based upon well-defined
performance criteria (typically [***] of salaries); and |
|
|
(ii) |
|
actual expenses associated with regular territory
business travel for Detailing, training meetings, and plan of action
meetings including airfare, hotels, meals, meeting rooms, A/V
equipment, materials, parking and tolls, each of which is subject to
the Territory Budget as set forth in the Agreement |
C. The expiration or termination of this Agreement shall not release Cumberland from
any obligation to pay Cardinal Health any amounts accrued under this Agreement in
connection with activities completed, expenses accrued prior to the effective date of
such expiration or termination; provided that the Service Fee paid by Cumberland for the
month in which this Agreement is terminated shall be prorated based on the number of days
in that month, and Cardinal Health shall refund any overpayment to Cumberland.
-27-
D. Performance Incentive. Cardinal Health shall be eligible to receive a
Performance Incentive based upon Cardinal Healths performance resulting in Kristalose sales
during the term hereof in excess of a mutually agreed upon threshold which is based on sales
to targeted physicians, over which Cardinal Health will be paid a maximum of [***] in
Performance Incentives according to the scale below:
[***]
-28-
EX-10.5 FIRST AMENDMENT TO CONTRACT SALES AGRMT
EXHIBIT 10.5
* Certain portions of this exhibit have been omitted pursuant to a request for
confidential treatment which has been filed separately with the SEC.
FIRST AMENDMENT TO
CONTRACT SALES AND SERVICES AGREEMENT
This First Amendment to Contract Sales and Services Agreement (the Amendment),
between Cardinal Health PTS, LLC (Cardinal Health) and Cumberland Pharmaceuticals, Inc.
(Cumberland) is entered into by and between Cardinal Health and Cumberland to modify
the terms of the Contract Sales and Services Agreement between the parties dated May 16,
2006 (Agreement). All capitalized terms used in this Amendment shall have the meaning
ascribed to them in the Agreement.
|
A. |
|
Section 2.1 of the agreement is hereby amended to the add the following
to the end of Section 2.1: |
|
|
|
|
In addition to the twenty-four Representatives dedicated to Detailing Products
for Cumberland under this Section, Cardinal Health shall also provide Cumberland
with access to a syndicated sales force which will provide Details for
Cumberland products as well as products of other Cardinal Health customers
(Syndicated Sales Force). Upon agreement of the parties, the Syndicated Sales
Force shall provide Details in accordance with terms set forth in amendments to
Schedule 3.1 of this Agreement. Such amendment shall set forth the details of
the Details, priority of Details, Products, services and fees to be provided by
Cardinal Health through the Syndicated Sales Force. The provisions of Sections
2.3(a) and 3.2 shall not apply with respect to the Syndicated Sales Force.
Cumberland agrees that it will not recruit, solicit or hire any Representative
which is a member of the Syndicated Sales Force during the Term of this
Agreement and for one year thereafter. |
|
|
B. |
|
Section 2.2 of the Agreement is hereby amended to add the following to
the end of Section 2.2: |
|
|
|
|
The two Managers shall be responsible for oversight of the dedicated sales force
and not the Syndicated Sales Force. The Syndicated Sales Force shall continue to
be managed by individuals appointed by Cardinal Health to manage the Syndicated
Sales Force. |
|
|
C. |
|
Schedule 3.1 is hereby amended to add the
following at the end: |
|
|
|
|
SYNDICATED SALES FORCE |
|
|
|
|
Cardinal Healths Syndicated Sales Force will make Calls on Target Customers
identified by Cumberland within the territory currently served by the
Syndicated Sales Force. The Syndicated Sales Force will Detail up to 3
Cumberland products during calls that are dedicated exclusively to Cumberland.
For purposes of this Agreement, a Call means a visit by a Representative or
Manager to a Target Customer in which multiple Products shall be Detailed to
the Target Customer, with the understanding that a small number (less than
10%) of Calls may not involve the |
1
|
|
|
Detailing of all required Products (i.e., where Target Customers will not listen
to all Details). |
|
|
|
|
The Call schedule shall begin on July 1, 2006 and end on June 30, 2007. Cardinal will
deliver [***] during this period. The service fee schedule will be as follows: |
|
|
|
Month |
|
Invoice Amount |
July, 2006 |
|
[***] |
August |
|
[***] |
September |
|
[***] |
October |
|
[***] |
November |
|
[***] |
December |
|
[***] |
January, 2007 |
|
[***] |
February |
|
[***] |
March |
|
[***] |
April |
|
[***] |
May |
|
[***] |
June, 2007 |
|
[***] |
|
|
|
|
[***] |
|
|
|
|
Cardinal Health will invoice Cumberland the amount set forth in the above table on the
last day of each month for service fees. |
|
|
|
|
Cardinal Health will also have the ability to earn up to [***] in performance incentive
for mutually agreed upon sales achievement levels on the target audience. |
|
|
The following expenses shall be direct pass-through to Cumberland for the syndicated program: |
|
|
|
Actual travel expenses for all required participation in any subsequent POA meetings. |
|
|
|
Actual promotional expenses and percentage of representative sample storage cost. The
parties will agree upon and manage to a budget based upon marketing programs and storage
requirements. |
|
2. |
|
Effective Date. This Amendment shall be effective upon full execution hereof
(Effective Date). Except as otherwise amended herein, the terms and conditions of the
Addendum shall remain in full force and effect.
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS, INC. |
|
|
|
CARDINAL HEALTH PTS, LLC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ James D. Aderhold, Jr
|
|
|
|
By:
|
|
/s/ Thomas G. Dimke |
|
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
James D. Aderhold, Jr
|
|
|
|
Name:
|
|
Thomas G. Dimke |
|
|
Title:
|
|
V-P
|
|
|
|
Title:
|
|
SVP/GM |
|
|
Date:
|
|
7/13/06
|
|
|
|
Date:
|
|
7/19/06 |
3
EX-10.6 CONSENT TO ASSIGNMENT
EXHIBIT 10.6
Cardinal Health
Contract Sales & Services
7000 Cardinal Place
Dublin, OH 43017
614.757.5900 main
www.cardinal.com
November 10, 2006
Mr. A.J. Kazimi
Cumberland Pharmaceuticals, Inc.
2525 West End Avenue, Suite 950
Nashville, Tennessee 37203
|
|
|
Re: |
|
Contract Sales and Services Agreement dated May 16, 2006,
by and between Cardinal Health PTS, LLC (Cardinal
Health) and Cumberland Pharmaceuticals, Inc.
(Cumberland), as amended by First Amendment to Contract
Sales and Services Agreement dated July 19, 2006
(collectively referred to as the Agreement) |
Dear Mr. Kazimi:
As you may already know, Cardinal Health has signed a definitive agreement to sell its
Healthcare Marketing Services division to Platinum Equity. This transaction includes Cardinal
Healths Contract Sales Organization (CSO Business) that is providing detailing and sampling
services under the Agreement. Cardinal Health and Platinum Equity expect the transaction to close
before the end of 2006.
In connection with the sale of the CSO Business, Cardinal Health will need to assign the
Agreement to Platinum Equity. As Section 18.7 of the Agreement requires Cumberland to consent to
an assignment of the Agreement, we are requesting that Cumberland provide its consent by signing
the Consent to Assignment attached.
We look forward to continuing to provide you the same high level of service you expect and
deserve. Please feel free to contact me at Tel: (614) 757-5117 with any questions you may have
about this transition. We would like to receive your consent as soon as possible, but no later
than November 22, 2006.
Thank you for your assistance in this matter.
Very Truly Yours,
/s/ Thomas Dimke
Thomas Dimke
Senior Vice President & General Manager,
Cardinal Health Contract Sales and Service
|
|
|
cc:
|
|
Mr. Martin S. Brown, Jr. |
|
|
Adams and Reese / Stokes Bartholomew LLP |
|
|
424 Church Street, Suite 2800 |
|
|
Nashville, Tennessee 37219 |
CONSENT TO ASSIGNMENT
Cumberland Pharmaceuticals, Inc. hereby consents to and approves the assignment by Cardinal
Health PTS, LLC of all of their rights, title, interests and obligations in and under the Contract
Sales and Services Agreement dated May 16, 2006, by and between Cardinal Health PTS, LLC and
Cumberland Pharmaceuticals, Inc., as amended by First Amendment to the Contract Sales and Services
Agreement dated July 19, 2006 (collectively referred to as the Agreement) to PG Holding
Corporation, a Delaware corporation. This consent and approval is given pursuant to Section 18.7 of
the Agreement.
Dated as of November 21 , 2006
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ A. J. Kazimi |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
A.J. Kazimi |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EX-10.7 DISTRIBUTION SERVICES AGREEMENT
EXHIBIT 10.7
* Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
DISTRIBUTION SERVICES AGREEMENT
This agreement is made as of August 3, 2000, between Cumberland Pharmaceuticals Inc., a
Tennessee corporation (Cumberland), and CORD Logistics, Inc., an Ohio corporation
(CORD).
Background Information
A. Cumberland is a Tennessee-based company formed primarily to acquire and market a
portfolio of niche pharmaceutical products to specific physician segments in the United
States, the District of Columbia and Puerto Rico (the Territory).
B. CORD is in the business of distributing pharmaceutical products to wholesalers,
specialty distributors, physicians, clinics, hospitals, retail pharmacies, and other health
care providers in the Territory, and of providing Information Systems and other services
that support its customers use of its distribution capabilities (collectively, the
Services).
C. Cumberland desires to engage CORD as its exclusive distribution agent (described
below) for the pharmaceutical products described on the exhibits attached hereto (each, a
Product) and, with respect to each Product, to perform certain other services described in
this agreement, all upon the terms and conditions set forth in this agreement. This
agreement is being entered into pursuant to a letter of intent from CORD dated April 5,
2000, which was accepted and executed by Cumberland as of April 10, 2000.
Statement of Agreement
Cumberland and CORD (the Parties) hereby acknowledge the accuracy of the above
Background Information and agree as follows:
§1. Appointment. Upon the terms and conditions described in this agreement,
Cumberland hereby appoints CORD as its exclusive distribution agent in and for the Territory
for distribution of each Product (including samples) to Cumberlands direct customers
(Customers).
The Services for each Product or group of Products identified on the same
Product-specific exhibit to this agreement shall be implemented pursuant to the
Implementation Schedule included in such exhibit (each, an Implementation Schedule), with
distribution of each Product to begin on the date specified in the Implementation Schedule
for such Product (the Commencement Date). In performing the Services, CORD will provide,
at its discretion, the services of either the Vice President and General Manager, Director
of Sales or other such representative as mutually agreed to by Cumberland and CORD. CORDs
designated representative will be the primary liaison with Cumberland, unless otherwise
agreed to by the parties.
§2. Product Supply. Warehousing and Storage. Cumberland shall ship each Product
to CORD at CORDs distribution facility currently located at 15 Ingram Boulevard, Suite 100,
La Vergne, TN 37086 or to such other distribution facility as may be designated by CORD
(individually or collectively, the CORD Facility) and agreed by Cumberland, in sufficient
quantities to meet Cumberlands anticipated Customer orders. CORD shall visually inspect
each shipment of each Product for external damage or loss in transit and, in the event of
any such damage or loss, shall, within a commercially reasonable period of time following
discovery of such damage or loss by CORD, notify Cumberland that such damage or loss has
occurred.
With respect to each Product or group of Products identified on the same Product-specific
exhibit to this agreement: (a) Cumberland shall, during the Product Term set forth on such exhibit,
provide CORD with applicable regulatory storage and handling requirements and projections of such
Products volume requirements not less often than quarterly, at least 30 days in advance of the
quarter and written instructions setting forth the storage and handling requirements applicable to
such Product; and (b) CORD shall store such Product in the CORD Facility and comply with applicable
regulatory storage and handling requirements and the storage and handling requirements applicable
to such Product, as such requirements may be supplemented or amended from time to time in writing
by Cumberland with reasonable prior notice to CORD and its prior approval, which approval shall not
be unreasonably withheld or delayed. If CORD notifies Cumberland in good faith that any such
supplement or amendment will require any material modification to the CORD Facility or CORDs
procedures or requirements which are unique and specific to the Product or the Services resulting
in a material increase to CORDs anticipated costs and expenses, then Cumberland and CORD shall
consult regarding such reasonable costs and expenses (hereinafter, simply unique costs) and
Cumberland shall pay such unique costs resulting from that modification.
Cumberland shall pay all costs and expenses of delivering each Product to the CORD Facility.
CORD will never take title to any Product, even when such Product is located at the CORD Facility.
§3. Standard Product Distribution. With respect to each Product or group of Products
identified on the same Product-specific exhibit to this agreement, and during the Product Term set
forth on such exhibit, all Customer orders shall be taken by CORD as described in the Operating
Guidelines (defined in §6, below). CORD shall confirm the receipt of and process each order and, so
long as the ordered Product is then in stock at the CORD Facility and the orders are received no
later than 2:00 p.m. local time at the CORD Facility, routinely have that order available for
shipment within 24 hours of CORDs receipt of the order (exclusive of holidays and weekends) or
such longer period as may be designated or permitted by Cumberland.
Customer orders will be delivered by a courier mutually chosen by Cumberland and CORD. CORD
will invoice Cumberland for such handling services and freight cost on a monthly basis. CORD will
use best efforts to manage any claims by Cumberland against the courier, provided, however, that
Cumberland shall be responsible for all lost or damaged shipments.
In addition, Cumberland shall reimburse CORD for all documented costs and expenses of
packaging material used for shipping the Product and all business forms unique to Cumberland (e.g.,
packing slips, invoices, etc.); provided that the use of such packaging material and business forms
is authorized in advance by Cumberland.
Each Product shall be shipped on a first expiration date, first out basis or as otherwise
directed by Cumberland. In addition, CORD shall establish (and Cumberland shall approve) procedures
for the processing and shipment of emergency orders on weekends and holidays, provided that
Cumberland shall separately pay all increased costs resulting from such orders.
§4. Product Prices. With respect to each Product or group of Products identified in
the same Product-specific exhibit to this agreement, Cumberland shall, upon execution of such
exhibit, deliver to CORD a price list for Customers who purchase such Product or Products (the
Customer Price List). Cumberland shall notify CORD of any change in the Customer Price List not
less than 10 business days prior to the effective date of any such change. The Parties hereby
acknowledge that Cumberland, and not CORD, is the seller of each Product to Customers.
Page 2 of 14
§5. Financial Support Services.
(a) Subject to Section 5(b), during each Product Term set forth on the Product-specific
exhibits to this agreement, CORD shall perform the customer credit research, billing, cash
application, collections, and reporting services described in the Operating Guidelines in
accordance with the policies and procedures set forth in such Operating Guidelines, as such
policies and procedures may be supplemented or amended from time to time by Cumberland with
reasonable prior notice to CORD and with its prior approval (the Financial Support Services);
provided that if CORD notifies Cumberland in good faith that any such supplement or amendment will
require any material modification to CORDs procedures or requirements for providing the Services,
then Cumberland shall pay all unique costs resulting from that modification.
(b) CORD shall have no obligation to pay for any Product or to reimburse Cumberland for any
losses incurred in connection with the failure of any Customer to pay Cumberland any amount due.
(c) Customers shall be directed to make payments for the Products in accordance with the
Operating Guidelines.
§6. Operating Guidelines. As soon as practicable after the date of this agreement,
CORD and Cumberland shall develop operating guidelines relating to the Products and the Services,
which guidelines (the Operating Guidelines) will be in writing, in a form satisfactory to CORD
and Cumberland, and will define and document the responsibilities of CORD and Cumberland in
support of the relationship described in this agreement. All Operating Guidelines shall be
developed and implemented in good faith and in a commercially reasonable manner, subject to the
qualifications set forth therein; provided that in the event of any inconsistency between the
Operating Guidelines and the other provisions of this agreement (including each Product-specific
exhibit to this agreement), the other provisions of this agreement shall control. The Operating
Guidelines may be amended from time to time upon the mutual agreement of CORD and Cumberland.
§7. Returns and Recalls. Pursuant to this agreement and any applicable Operating
Guidelines, CORD shall assist in the processing of Product returns (excluding recall returns,
which will be dealt with as described below) in coordination with the third party returns company
chosen by Cumberland to facilitate return of Product. No such assistance will involve handling by
CORD of the Product being returned. The fees to be paid to CORD for these return services are
described in Section 8.
CORD shall process Customer Product return authorizations and credits as set forth in the
Operating Guidelines. The fee for such Services by CORD will be included as a part of the Customer
Service Fees described in Section 8.
If Cumberland is required to recall, or on its own initiative recalls, any Product, CORD will
assist Cumberland with that recall as reasonably requested by Cumberland; provided that Cumberland
shall pay to CORD an amount equal to all costs incurred by CORD in connection with any such
recall.
§8. Fees. As compensation for services being provided by CORD in connection with the
development and implementation of the infrastructure for the relationship contemplated by this
agreement, including CORDs information system development (separate from the Information System
Access Fees described below) and implementation for Cumberlands use, Cumberland shall pay CORD a
one-time implementation fee of [***] (the Implementation Fee), one-half of which shall be
payable on the first anniversary of the date of this agreement and one-half of which shall be
payable on the second anniversary of the date of this agreement. Cumberlands obligation to pay
the Implementation
Page 3 of 14
Fee is not contingent upon the acquisition by Cumberland of any Product marketing and distribution
rights and shall survive the termination of this agreement. However, the Implementation Fee shall
not be due and payable if this Agreement is terminated early for any reason other than breach by
Cumberland.
In addition, with respect to each Product or group of Products identified on the same
Product-specific exhibit to this agreement, Cumberland shall pay CORD, as compensation for the
Services related to such Product or Products, the fees described in such exhibit (the Fees). CORD
will use commercially reasonable efforts to keep total fees in line with industry standards. The
Fees shall include:
(a) Storage/Distribution Fees. The Storage and Distribution Fees shall be in the
amounts set forth in each applicable Product Exhibit. This component of the Fees shall cover
storage of Product and distribution services, which fees (the Storage and Distribution Fees),
with respect to each Product or group of Products identified on the same Product-specific exhibit
to this agreement, shall be in the amount specified in such exhibit.
The Storage Fees shall be based upon the average weekly number of pallets in storage. The
Distribution Fees, for each calendar month during the Term of this Agreement, shall be based upon
the aggregate number of units (or cases) shipped by CORD from the warehouse. Cumberland shall be
charged an initial price per unit or case (collectively referred to as pick) on the first pick of
each order placed by Cumberland each month, and then a recurring amount per pick for each
incremental pick shipped from the same order thereafter. For example, for the distribution of
Reglan and Donnatal, on a monthly basis, Cumberland shall be charged the sum of [***] per pick of
each order of product shipped that month and the sum of [***] per pick for each incremental pick
from the same order.
(b) Information System Access Fees. This component of the Fees shall cover
Cumberlands access to CORDs or an affiliate of CORDs standard Information Systems, consisting of
the computer hardware and software and other components described in the attached Schedule 8(c)-1
(the System), and other services relating to Cumberlands access to the System as described in
Schedule 8(c)-1, which fees (the System Access Fees), with respect to each Product or group of
Products identified on the same Product-specific exhibit to this agreement, shall be in the amount
specified in such exhibit. Access to the System shall be provided pursuant to a System Access
Agreement in the form of the attached Schedule 8(c)-2, which agreement (the System Access
Agreement) shall be executed by the Parties concurrently with this agreement. Access to the System
shall be made available to Cumberlands facility for each Product at the prices set forth in the
exhibit for such Product, so long as Cumberland first has in place a local area network sufficient
to support all Cumberland terminals and personal computers which will have access to the System and
a centralized server sufficient for data storage related to Cumberlands access to the System. All
costs and expenses associated with establishing initial hook-up of all communication and electronic
information lines necessary for interface of the System with Cumberlands information systems
located at Cumberlands address set forth at the end of this agreement are included in the
Implementation Fee and are separate from the services and costs and expenses covered by the System
Access Fees. Cumberland shall have sole responsibility for payment of all costs and expenses of
maintaining all such communication and electronic information lines. CORD and Cumberland shall each
assign knowledgeable and qualified employees to facilitate the access to the System as contemplated
by this agreement.
(c) Financial Support Services Fees. This component of the Fees shall be payment for cash
application, collections and chargeback processing services (including chargeback system access)
described in the Operating Guidelines, which fees (the Financial Support Services Fees), with
respect to each Product or group of Products identified on the same Product-specific exhibit to this
agreement, shall be in the amount specified in such exhibit.
Page 4 of 14
(d) Customer Service Fees. This component of the Fees shall be payment for the
customer services performed by CORD pursuant to the Operating Guidelines, which fees (the
Customer Support Fees), with respect to each Product or group of Products identified in the same
Product-specific exhibit to this agreement, shall be in the amount specified in such exhibit.
(e) EDI Set-up, Maintenance, Access Fees. This component of the Fees shall be
payment for services related to the set-up and maintenance of Electronic Data Interchange (EDI)
transaction capabilities between Cumberland and its Customers and access and use of a mutually
agreed upon EDI provider. These fees are included in the System Access Fees described in §8(b)
above.
With respect to each Product or group of Products identified on the same Product-specific
exhibit to this agreement, following the end of each calendar month with respect to Product Term
set forth on such exhibit, CORD shall issue an invoice to Cumberland for the Fees payable with
respect to CORDs performance of the Services for the prior month. The Fees or other amounts owed
to CORD by Cumberland under this agreement shall be payable within 30 days of the date of CORDs
invoice for such Fees or other amounts.
The Fees shall be held firm for the first contract year. Thereafter, CORD shall adjust the
price not more often than once per contract year by not more than the increase in the Producer
Price Index All Commodities published by the United States Department of Labor, Bureau of
Statistics, as amended from time to time.
Notwithstanding the above Price Increase, if CORD can demonstrate that the costs for
providing the Services have materially increased, or are likely to materially increase in the
coming year due to the adoption of any applicable law or regulation, or any material change in the
interpretation or administration thereof, then upon notice from CORD, the Parties agree to meet in
good faith and negotiate a mutually acceptable adjustment to the Fees, which compensates CORD for
the change.
§9. Term and Termination.
(a) The initial term of this agreement shall begin upon the day Cumberland signs a letter of
intent to acquire its first Product and shall continue for a period of three (3) years (the
Initial Term), unless terminated earlier pursuant to this agreement. Thereafter, this agreement
shall automatically renew for additional terms of one (1) year each, unless written notice of
termination is given by either Party at least 90 days prior to the end of the Initial Term, or
such other term, in which case this agreement shall terminate at the end of the relevant term. Any
reference in this agreement to the term of this agreement shall include the Initial Term and any
such renewal terms. Upon termination of this agreement or upon the written request of Client, all
Product shall be expeditiously returned to the Client or a designee of the Client.
(b) Either Party shall have the right to terminate this agreement or any Product-specific exhibit
to this agreement upon the breach by the other Party of a material provision of this agreement or
such exhibit and that Partys failure to cure such breach within 60 days following written notice
thereof from the non-breaching Party or, in the event such failure is not capable of being cured
within such 60-day period, the non-breaching Partys failure to continue to diligently prosecute
such cure thereafter; provided, that, with respect to any failure to make any payment when due under this agreement
or any Product-specific exhibit to this agreement, such period in which to cure shall be reduced
to 30 days.
Page 5 of 14
(c) Either Party shall have the right to terminate this agreement or any Product-specific
exhibit to this agreement immediately upon notice to the other Party following the commencement of
any bankruptcy or insolvency proceeding (whether voluntary or involuntary) with respect to such
other Party or its assets, the general assignment for the benefit of creditors by such other
Party, or the appointment of a receiver, trustee or liquidator by or for such other Party.
(d) Sections 8 and Sections 14 through 17, inclusive, of this agreement shall survive the
termination or expiration of this agreement and each Product-specific exhibit to this agreement,
and except as set forth herein, no termination of this agreement or any Product-specific exhibit
to this agreement shall affect any liabilities arising, or based upon acts or omissions occurring,
prior to the date of such termination.
§ 10. Audits. In connection with any services being provided pursuant to this
Agreement, CORD agrees to maintain written records and data during and after the term of this
Agreement in compliance with all applicable legal and regulatory requirements, including without
limitation applicable requirements of the United States Food and Drug Administration. Further,
CORD shall furnish Cumberland within thirty (30) days following each March 31, June 30, September
30, and December 31 of each calendar year a complete and accurate statement for the immediately
preceding calendar quarterly period of (a) the number of units of Products sold; (b) information
as to returns actually credited; (c) current inventory levels for Products; and (d) such other
information as Cumberland may reasonably request. In order to verify compliance, CORD shall
provide Cumberland with such records and agrees to permit representatives of Cumberland to visit
facilities of CORD at which Services are being performed during normal business hours (i.e., 8:00
a.m. to 5:00 p.m. local time), upon 15 business days prior notice, to: (a) review and audit CORDs
records relating directly to Product received at and shipped from the CORD Facility; and (b)
conduct, together with representatives of CORD, an inventory of the Product at the CORD Facility.
§11. Compliance With Laws. Each Party shall conduct its activities in connection with
this agreement in substantial compliance with all applicable laws, rules, regulations, and orders
of governmental entities.
§ 12. Representations and Warranties.
(a) Mutual Representations and Warranties. Each Party represents and warrants to
the other that: (i) it has full power and authority to enter into this agreement and perform and
observe all obligations and conditions to be performed or observed by it under this agreement
without any restriction by any other agreement or otherwise; (ii) the execution, delivery and
performance of this agreement have been duly authorized by all necessary corporate action of that
Party; and (iii) this agreement constitutes the legal, valid and binding obligation of that Party.
(b) Cumberland Representations and Warranties. Cumberland further represents and
warrants to CORD that (i) each Product is and shall be manufactured in conformity with the Food,
Drug, and Cosmetic Act, as amended, and all other applicable laws, rules, regulations and orders
of governmental entities, and (ii) as of the effective date of any Product-specific exhibit
hereto, Cumberland will have (and will have provided CORD with written documentation in form
reasonably satisfactory to CORD that Cumberland has, as of such effective date) title to such
Product or Products and the right to market and distribute such Product or Products as
contemplated hereby.
Page 6 of 14
(c) CORD Representations and Warranties. CORD hereby represents and warrants that it
has the experience, capability and resources, including without limitation, sufficient personnel
and supervisors, to perform the Services offered hereunder in a commercially reasonable manner in
conformity with applicable regulations of any governmental authority, including the United States
Food and Drug Administration. CORD further represent that it will at all times devote the necessary
personnel and supervisors to perform the Services in such a manner.
CORD shall not make any representations, warranties, or guarantees to Customers with respect
to the Products that are inconsistent with information provided by Cumberland to CORD, including
without limitation, representations, warranties, and guarantees concerning specifications,
features, efficacy, prices, or availability of the Products.
§13. Taxes. Cumberland shall pay when due all sales, use, gross receipts, excise,
personal property taxes associated with each Product (excluding any personal property tax
associated with CORDs equipment used in connection with the Services), and other taxes or similar
charges now or hereafter imposed as a result of the transactions contemplated by this agreement,
none of which have been included in the fees payable to CORD under this agreement; provided that
the amounts payable by Cumberland under this section shall not include taxes based on the net
income of CORD.
§ 14. Trademarks and Proprietary Rights.
14.1 Neither party hereto shall have the right to use the trademarks, service marks, logos, or
other similar marks of the party hereto, or any of its affiliates, in any manner except with the
prior written approval of the party that has rights to such intellectual property.
14.2 All materials, documents, information, inventions, improvements, data, programs and
suggestions of every kind and description, whether or not patentable, and all copyrightable works
supplied to CORD by Cumberland pursuant to this Agreement shall be the property of Cumberland
solely and exclusively (the Cumberland Property); provided that any and all information,
processes, documents, computer software or other proprietary information used, owned, licensed or
developed by CORD shall be the property of CORD.
§15. Master Agreement. This agreement is being entered into pursuant to the Strategic
Alliance Agreement dated June 6, 2000, between Cardinal Health (as defined below) and Cumberland
(the Master Agreement), and this agreement (including any and all exhibits hereto, whether
entered into now or hereafter) constitutes an Addendum, as defined in the Master Agreement. In the
event of any conflict or inconsistency between the terms of this agreement (including any and all
exhibits hereto) and the terms of the Master Agreement, the terms of this agreement shall govern.
For purposes of this agreement, Cardinal Health means the following affiliated operating
companies: Cardinal MarketForce, a division of RedKey, Inc., an Ohio corporation (Dublin, OH); CORD
Logistics, Inc., an Ohio corporation (Dublin, OH); and any other subsidiary of Cardinal Health,
Inc., an Ohio corporation (CHI), as may be designated by CHI and agreed by client in writing.
§ 16. Indemnification. Each Party shall indemnify and hold harmless the other and its
parent and affiliates, and each of their respective directors, officers, employees, agents, and
representatives from and against all claims, liabilities, losses, damages, costs, and expenses
(including without limitation reasonable attorneys fees) arising directly or indirectly out of any
failure of that Party to perform and observe fully all obligations and conditions to be performed
or observed by that Party pursuant to this agreement or any breach of any warranty made by that
Party in this agreement. Cumberland further agrees to indemnify and hold harmless CORD and its parent and affiliates and each of their
respective directors, officers, employees, agents and representatives from and against all claims,
liability, losses, damages, costs, and expenses (including without limitation reasonable attorneys
fees) arising directly or
Page 7 of 14
indirectly out of injury or death to person or property alleged to have
been caused by any defect in any
Product. NOTWITHSTANDING THE FOREGOING, OR ANY OTHER PROVISION OF THIS AGREEMENT TO THE
CONTRARY, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY CONSEQUENTIAL, INCIDENTAL,
INDIRECT, SPECIAL, OR OTHER SIMILAR DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT,
AND IN NO EVENT SHALL CORDS LIABILITY HEREUNDER EXCEED CORDS INSURANCE LIMITS SET FORTH BELOW IN
SECTION 17(b)(i).
§17. Insurance.
(a) Promptly after Cumberland acquires rights to distribute its first Product and for as long
thereafter as necessary to cover claims resulting from this agreement, Cumberland shall obtain and
maintain: (i) product liability and commercial general liability insurance having a limit of not
less than $10 million; and (ii) property damage insurance at replacement value for each Product
located at the CORD Facility or in transit to or from the CORD Facility, pursuant to one or more
insurance policies with reputable insurance carriers. Cardinal Health, Inc. and its subsidiaries
shall be designated as additional insureds under the product liability and commercial general
liability insurance policy(ies), and as loss payees under the property damage insurance
policy(ies). Prior to CORDs receipt of Product, Cumberland shall deliver to CORD certificates
evidencing such insurance. Cumberland shall not cause or permit such insurance to be canceled or
modified to materially reduce its scope or limits of coverage during the term of this agreement or
thereafter as provided above. Except for any losses resulting from the negligence or intentional
misconduct of CORD, Cumberland shall bear all risk of loss or damage with respect to each Product,
whether located at the CORD Facility or otherwise.
(b) Promptly after Cumberland acquires rights to distribute its first Product and for as long
thereafter as necessary to cover claims resulting from this agreement, CORD shall obtain and
maintain: (i) product liability and commercial general liability insurance having a limit of not
less than $1 million; and (ii) property damage insurance at replacement value for each Product
located at the CORD Facility or in transit to or from the CORD Facility, pursuant to one or more
insurance policies with reputable insurance carriers. Cumberland shall be designated as additional
insureds under the product liability and commercial general liability insurance policy(ies), and
as loss payees under the property damage insurance policy(ies). Prior to CORDS receipt of
Product, CORD shall deliver to Cumberland certificates evidencing such insurance. CORD shall not
cause or permit such insurance to be canceled or modified to materially reduce its scope or limits
of coverage during the term of this agreement or thereafter as provided above.
§18. Relationship of the Parties. The relationship among the Parties is and shall be
that of independent contractors. This agreement does not establish or create a partnership or joint
venture among the Parties.
§19. Notices. Any notice or other communication required or desired to be given to any
Party under this agreement shall be delivered in writing to the address or facsimile number set
forth beneath the authorized signatures on this agreement and shall be deemed given: (a) three
business days after such notice is deposited in the United States mail, first-class postage
prepaid, and addressed to that Party at the address for such Party set forth at the end of this
agreement; (b) one business day after delivered to Federal Express, Airborne, or any other similar
express delivery service for delivery to that Party at that address; or (c) when sent by facsimile
transmission, with electronic confirmation, to that Party at its
facsimile number set forth at the end of this agreement. Any notice delivered by facsimile
transmission will be deemed delivered upon electronic confirmation provided the notice is also
deposited in the U.S. mail, first-class postage prepaid. Any Party may change its address or
facsimile number for notices under this agreement by giving the other Parties notice of such
change.
Page 8 of 14
§20. Alternative Dispute Resolution.
The Parties agree to use good faith efforts to resolve all disputes within ninety (60) days of
written notice that such a dispute exists. If dispute under this Agreement cannot be resolved by
the Parties within such sixty (60) day period, the Parties agree to refer the matter to one
executive from each Party not directly involved in the dispute for review and resolution. A copy
of the terms of this Agreement, agreed upon facts and areas of disagreement, and a concise summary
of the basis for each sides contentions will be provided to both executives who shall review the
same, confer, and attempt to reach a mutual resolution of the issue within forty-five (45) days
after receipt of the materials referenced above. If the matter has not been resolved within such
forty-five (45) day period, either or both Parties may pursue resolution of the matter through
litigation or other process available under law or equity.
§21. Remedies. Each Party acknowledges that in the event of any violation by that
Party of any of the provisions of Section 14 of this agreement or Article III., Sections D or E of
the Master Agreement, the other Party would suffer irreparable harm and its remedies at law would
be inadequate. Accordingly, in the event of any violation or attempted violation of any such
provisions by either Party, the other Party shall be entitled to a temporary restraining order,
temporary and permanent injunctions, specific performance, and other equitable relief, without any
showing of irreparable harm or damage or the posting of any bond. The rights and remedies of each
Party under this agreement shall be cumulative and in addition to any other rights or remedies
available to such Party, whether under any other agreement, at law, or in equity.
§22. Governing Law. All questions concerning the validity or meaning of this
agreement or relating to the rights and obligations of the Parties with respect to performance
under this agreement shall be construed and resolved under the laws of the State of Tennessee ,
without regard to principles of conflicts of laws. The parties agree that any claims asserted in
any legal proceeding by one party against the other shall be commenced and maintained in any state
or federal court in Nashville, Tennessee or Columbus, Ohio and the parties submit to the
jurisdiction of these courts.
§23. Severability. The intention of the Parties is to comply fully with all laws and
public policies, and this agreement shall be construed consistently with all laws and public
policies to the extent possible. If and to the extent that any court of competent jurisdiction
determines that it is impossible to construe any provision of this agreement consistently with any
law or public policy and consequently holds that provision to be invalid, such holding shall in no
way affect the validity of the other provisions of this agreement, which shall remain in full
force and effect.
§24. Non-waiver. No failure by either Party to insist upon strict compliance with any
term of this agreement, to exercise any option, to enforce any right, or to seek any remedy upon
any default of the other Party shall affect, or constitute a waiver of, the first Partys right to
insist upon strict compliance, to exercise that option, to enforce that right, or to seek that
remedy with respect to that default or any prior, contemporaneous, or subsequent default. No
custom or practice of the Parties at variance with any provision of this agreement shall affect,
or constitute a waiver of, that Partys right to demand strict compliance with all provisions of
this agreement.
§25. Force Majeure. If the performance of any part of this agreement by either Party shall
be affected for any length of time by fire or other casualty, government restrictions, war, riots,
strikes or labor disputes, lock out, transportation delays, acts of God, or any other causes which
are beyond the control of the Parties, such Party shall not be responsible for delay or failure of
performance of this agreement for such length of time, provided, however, that the obligation of
one Party to pay amounts due to any other Party shall not be subject to the provisions of this
section
Page 9 of 14
§26. Genders and Numbers. Where permitted by the context, each pronoun in this
agreement includes the same pronoun in the other genders or numbers and each noun used in this
agreement includes the same noun in other genders.
§27. Complete Agreement. This agreement (together with the Master Agreement, the
Product-specific exhibits hereto, and the other documents referred to herein, all of which are
hereby incorporated herein by reference) contains the entire agreement between the Parties and
supersedes all prior or contemporaneous discussions, negotiations, representations, warranties, or
agreements relating to the subject matter of this agreement. CORD and Cumberland agree to comply
with the obligations of confidentiality set forth in Article III, Section E of the Master
Agreement. No changes to this agreement shall be made or be binding on either Party unless made in
writing and signed by both Parties.
§28. Successors. This Agreement may not be assigned or transferred by a party without
the prior written consent of the other party hereto, provided, however, that either party may
assign this Agreement to any subsidiary, affiliate or an entity which acquires substantially all of
its assets and business that is not in direct competition with CORD. Any such assignment shall not
materially or adversely affect the rights or obligations of either party to this Agreement.
|
|
|
CUMBERLAND PHARMACEUTICALS, INC.
|
|
CORD LOGISTICS, INC.
|
|
|
|
/s/ A.J. Kazimi
|
|
/s/ Frank C. Wegerson |
|
|
|
A.J. Kazimi
|
|
Frank C. Wegerson |
Chief Executive Officer
|
|
Vice President and General Manager |
Initials: /s/ AJK
|
|
Initials: /s/ FCW |
|
|
|
209 10th Avenue South
|
|
15 Ingram Blvd, #100 |
Nashville, TN 37203
|
|
LaVergne, TN 37086 |
|
|
|
Facsimile No. (615) 255-0094
|
|
Facsimile No. (615) 793-4783 |
Page 10 of 14
Schedule 8 (c) -1
OPERATING SYSTEM BASE PACKAGE
A. System Access
Includes access to CORDs processor and operating system Monday through Friday, excluding
holidays, 12 hours per day (5:30 am to 5:30 p.m., Pacific local time).
B. Software Access and Maintenance
Includes access to CORDs or an affiliate of CORDs standard software. CORD or an affiliate of CORD
shall perform at its own expense any necessary modification to bring the systems in compliance
with the standard functionality described below.
|
|
Reports necessary to perform Medicaid rebate calculations |
|
|
Billing (Customization of invoicing/packing slips) |
|
|
Inventory tracking and reporting |
|
|
Ability to download system data to Cumberlands processors for reporting writing |
|
|
Contracts/Pricing maintenance and chargeback processing |
Systems Development/Additional Services:
Cumberland bears financial responsibility for customization beyond the standard systems
functionality described above. Such customization performed by CORD or its representatives
(exclusive of the base package) in connection with this agreement shall be billed to Cumberland
as follows:
|
|
Systems and software development$120 per hour per person, plus travel. |
|
|
On-site training$120 per hour per person, plus travel. |
|
|
Supplies, equipment and other, to be agreed upon by both parties. |
Page 11 of 14
Schedule 8 (c) -2
SYSTEM ACCESS AGREEMENT
This agreement is made as of July ___, 2000, between CORD Logistics, Inc., an Ohio corporation
(Licensor), and Cumberland Pharmaceuticals Inc., a Tennessee corporation (Licensee), who hereby
agree as follows:
1. System Access; Maintenance Obligations. On the terms and subject to the conditions
described in this agreement and the Distribution Services Agreement having the same date as this
agreement between Licensor and Licensee (the Distribution Agreement), Licensor hereby grants to
Licensee a nonexclusive license (the License) to utilize Licensors Order Entry System,
consisting of the computer hardware, software and other components described in Schedule 8(c)-1 to
the Distribution Agreement (collectively, the System), for the information processing needs of
Licensee in connection with the Services to be provided by Licensor under the Distribution
Agreement. Licensee shall maintain during the term of this agreement the network and local area
network (including without limitation centralized server) requirements for the System described in
the Distribution Agreement.
During the term of this agreement, Licensee shall employ reasonable security measures and
policies designed to safeguard the integrity, accessibility, and confidentiality of all of
Licensees data resident on the System and establish reasonable disaster and emergency recovery
plans designed to minimize disruption from System operation interruptions. Licensee shall have the
right to review the operation of the System from time to time upon reasonable prior notice from
Licensee to Licensor; provided that such reviews shall be conducted in a manner to avoid disruption
of Licensors business operations to the extent possible.
2. Proprietary Rights. Licensee shall have the right to use the System during the term
of this agreement as expressly provided in paragraph 1 of this agreement, but not otherwise.
Licensee shall not assign or otherwise transfer, disclose, copy, modify, or decompile the System or
any part thereof without prior written consent of the Licensor. The System and all parts thereof,
in all of their tangible and intangible manifestations, all existing or new enhancements,
developments, derivative works, and other adaptations or modifications to the System (or any part
thereof), and all related proprietary rights, are and shall remain the exclusive property of
Licensor. Except for the License, Licensee shall have no right, title, or interest in or to the
System or any part thereof. Upon termination of this agreement, Licensee shall promptly return to
Licensor all portions of the System then in Licensees possession or under its control.
3. Warranties. Licensee acknowledges that it has had adequate opportunity to review
the System and its features and operation and Licensee accepts the System AS IS for its use as
contemplated in the Distribution Agreement. EXCEPT AS EXPRESSLY SET FORTH HEREIN OR IN THE
DISTRIBUTION AGREEMENT, LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES, AND HEREBY EXPRESSLY
DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED RELATING DIRECTLY OR INDIRECTLY TO
THE SYSTEM OR ANY PART THEREOF, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF QUALITY,
PERFORMANCE, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE.
4. Limitation On Liability. LICENSOR SHALL NOT BE LIABLE FOR ANY CONSEQUENTIAL,
INDIRECT, SPECIAL, OR OTHER SIMILAR DAMAGES ARISING DIRECTLY OR INDIRECTLY OUT OF THE USE OR
INABILITY TO USE THE SYSTEM OR ANY PART THEREOF, EVEN IF INFORMED OF THE POSSIBILITY OF SUCH
DAMAGES, WHETHER CLAIMED UNDER CONTRACT, TORT, OR ANY OTHER LEGAL THEORY.
IF ANY OF THE LIMITATIONS ON THE LIABILITY OF LICENSOR CONTAINED IN THIS AGREEMENT ARE FOUND
TO BE INVALID OR UNENFORCEABLE FOR ANY REASON THEN LICENSOR AND LICENSEE EXPRESSLY AGREE THAT THE
MAXIMUM AGGREGATE LIABILITY OF LICENSOR FOR ALL CLAIMS RELATING TO THE SYSTEM SHALL NOT EXCEED 100%
OF THE AGGREGATE BASE PACKAGE FEES PAID BY LICENSEE TO LICENSOR FOR LICENSEES USE OF THE SYSTEM
UNDER THE DISTRIBUTION AGREEMENT.
5. Taxes. Licensee shall pay when due all sales, use, gross receipts, excise,
property, and other taxes or similar charges (other than taxes based upon Licensors net income)
now or hereafter imposed as a result of the transactions contemplated by this agreement.
6. Term. The term of this agreement shall begin upon Licensees initial use of the
System as evidenced by the first entry of inventory into the System (which may be a date earlier
than the Commencement Date specified for the Distribution Agreement) and shall end: (a)
automatically upon the termination of the Distribution Agreement (for any reason), or (b) on any
earlier date specified by Licensee in notice to Licensor given not less than 180 days prior to
Page 12 of 14
the specified termination date; provided that: (i) paragraph 2 through 5 inclusive, and
paragraph 8 of this agreement shall survive the termination of this agreement, and (ii)
no termination of this agreement shall affect any liabilities arising, or based upon acts or
omissions occurring, prior to such termination.
Licensee shall continue to have access to the System for a reasonable period of time (not be
exceed 60 days) following termination of this agreement solely for purposes of retrieving and
transferring to a separate system Licensees data relating to its pre-termination operations, and
Licensor shall reasonably cooperate with Licensee to preserve the integrity and accessibility of
Licensees data during such period; provided that, during such period, Licensee shall continue to
pay the full Base Package and other fees payable by Licensee under the Distribution Agreement and
comply with all other requirements imposed upon Licensee under this agreement.
7. Notices. Any notice or other communication required or desired to be given to
either party under this agreement shall be in writing and shall be deemed given: (a) three days
after mailing, if deposited in the United States mail, first-class postage prepaid,
and-addressed to that party at its address set forth at the end of this agreement; (b)
when received if delivered to Federal Express or any other similar overnight, delivery
service for delivery to that party at that address; or (c) when sent by facsimile transmission,
with electronic confirmation, to that party at its facsimile number set forth at the end of this
agreement. Either party may change its address or facsimile number for notices under this agreement
by giving the other party notice of such change.
8. Remedies. Licensee shall indemnify Licensor and its affiliates, directors,
officers, employees, agents, and representatives against all claims, liabilities, losses, damages,
costs and expenses (including without limitation reasonable attorneys fees) arising directly or
indirectly out of any failure of Licensee to perform and observe fully all obligations and
conditions to be performed or observed by Licensee pursuant to this agreement. Licensee
acknowledges that in the event of any violation by it of any of the provisions of paragraph 2 of
this agreement, Licensor would suffer irreparable harm and its remedies at law would be inadequate.
Accordingly, in the event of any violation or attempted violation of any such provisions by
Licensee, Licensor shall be entitled to a temporary restraining order, temporary and permanent
injunctions, specific performance, and other equitable relief, without any showing of irreparable
harm or damage or the posting of any bond, in addition to any other rights or remedies which may be
available to Licensor.
9. Force Majeure. Notwithstanding any other provisions of this agreement or the
Distribution Agreement to the contrary, each partys obligations under this agreement (exclusive of
payment obligations) shall be excused if and to the extent that any delay or failure to perform
such obligations is due to fire or other casualty, material shortages, strikes or labor disputes,
acts of God, or other causes beyond the reasonable control of that party.
10. Successors. Licensee shall not assign or otherwise transfer this agreement or any
of its rights or obligations under this agreement without the prior written consent of Licensor,
which consent shall not be unreasonably withheld. Subject to the preceding sentence, this agreement
shall be binding upon, inure to the benefit of, and be enforceable by and against the respective
successors and assigns of each party.
11. Interpretation. This agreement shall be governed by and construed in accordance
with the laws of the State of Tennessee. If and to the extent that any court of competent
jurisdiction determines that it is impossible to construe any provision of this agreement
consistently with any law or public policy and consequently holds that provision to be invalid,
such holding shall in no way affect the validity or the other provisions of this agreement, which
shall remain in full force and effect.
12. Complete Agreement. This agreement (together with the Distribution Agreement,
which is hereby incorporated herein by reference) constitutes the entire agreement between the
parties with respect to the subject matter of this agreement and supersedes all prior or
contemporaneous discussions, negotiations, representations, warranties, or agreements relating to
the subject matter of this agreement. This agreement may not be amended or otherwise modified
except by a written instrument signed by each party.
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS, INC. |
|
|
|
CORD LOGISTICS, INC. |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ A.J. Kazimi
|
|
|
|
By:
|
|
/s/ Frank C. Wegerson |
|
|
|
|
|
|
|
|
|
|
|
A.J. Kazimi
|
|
|
|
|
|
Frank C. Wegerson |
|
|
Chief Executive Officer
|
|
|
|
|
|
Vice President and General Manager |
|
|
Initials: /s/ AJK
|
|
|
|
|
|
Initials: /s/ FCW |
|
|
|
|
|
|
|
|
|
209 10th Avenue South, Suite 332 |
|
|
|
15 Ingram Blvd., #100 |
Nashville, TN 37203 |
|
|
|
LaVergne, TN 37086 |
|
|
|
|
|
|
|
|
|
Facsimile No. (615) 255-0094 |
|
|
|
Facsimile No. (615) 793-4783 |
Page 13 of 14
Exhibit A
[***]
Page 14 of 14
EX-10.8 STRATEGIC ALLIANCE AGREEMENT
EXHIBIT 10.8
*Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT is made and entered into as of the 21st day of July, 2000.
BY AND BETWEEN:
CUMBERLAND PHARMACEUTICALS INC., a corporation organized and existing under the laws of Tennessee,
with its principal offices located at 209 Tenth Avenue South, Suite 332, Nashville, Tennessee,
37203 (hereinafter referred to as CUMBERLAND)
AND:
F.H. FAULDING & CO. LIMITED (ABN 88 007 870 984), a corporation organized under the laws of South
Australia, with its principal place of business located at 115 Sheriff Street, Underdale, South
Australia 5032 (hereinafter referred to as FAULDING);
WHEREAS, CUMBERLAND is the owner of intellectual property rights, formulations and know- how
related to intravenous formulations of a certain pharmaceutical product set forth in Schedule I;
WHEREAS, FAULDING has the expertise and the manufacturing facility suitable for the pharmaceutical
preparation and production of the Drug Product;
WHEREAS, CUMBERLAND wishes to have FAULDING manufacture the Drug Product and FAULDING wishes to
supply the Drug Product to CUMBERLAND;
WHEREAS, CUMBERLAND will appoint FAULDING as its preferred manufacturer for CUMBERLANDs products;
WHEREAS, FAULDING and CUMBERLAND will explore opportunities to collaborate on the manufacture and
distribution of other pharmaceutical products of CUMBERLAND;
NOW, THEREFORE, in consideration of the premises and the undertakings, terms, conditions and
covenants set forth below, the parties hereto agree as follows:
1. DEFINITIONS
1.1 BUFFER SOLUTION shall mean the buffer solution selected by CUMBERLAND for the manufacture
of the Drug Product.
1.2 BULK DRUG SUBSTANCE shall mean the active ingredients in the Drug Product.
1.3 cGMP or GMP shall have the meaning set forth in Schedule I.
1.4 CONFIDENTIAL INFORMATION shall have the meaning set forth in Paragraph 9.
1.5 DEVELOPMENT shall mean all work necessary to develop a process to manufacture the Drug
Product in full accord with cGMP and to supply the Drug Product conforming to the Specifications.
Development activities shall include, but not be limited to, pilot batches, scale- up batches,
validation of the manufacturing process, and successful completion of the Drug Product manufacture
and delivery as defined in Schedule I attached hereto.
1.6 DRUG PRODUCT shall mean the Ibuprofen for injection pharmaceutical product developed by
Cumberland and marketed under the trade name AMELIOR.
1.7 EXCIPIENT shall mean any inert substance selected by CUMBERLAND and used to give the Drug
Product proper consistency.
1.8 FDA shall mean the United States Food and Drug Administration (FDA).
1.9 IN-PROCESS SOLUTION shall mean all Buffer Solutions and Excipients needed to produce Drug
Product in the finished dosage form set forth in Schedule I.
1.10 INVENTION shall have the meaning set forth in Paragraph 9.4.
1.11 LABELING shall mean all labels and other written, printed, or graphic matter upon: (i)
the Drug Product or any container or wrapper utilized with the Drug Product or (ii) any written
material accompanying the Drug Product, including without limitation, package inserts.
1.12 MANUAL shall mean the Manufacturing Project Manual attached as Schedule II to this
Agreement and reviewed and accepted by CUMBERLAND and FAULDING, the terms and provisions of which
are incorporated by reference as though fully set forth herein.
1.13 SPECIFICATIONS shall mean those specifications set forth in Attachment I to the Manual.
2. DEVELOPMENT AND MANUFACTURING
2.1 Initiation: Upon request by CUMBERLAND, FAULDING shall proceed with the schedule for
completing Development of the Drug Product. Upon request by CUMBERLAND, FAULDING shall manufacture
the Drug Product in the batch size set forth in Schedule I in accordance with the terms hereof, the
Specifications, and all applicable laws and
regulations. Prior to distributing and selling the Drug Product, CUMBERLAND shall prepare and
file submissions to the FDA in order to obtain and maintain during the term hereof regulatory
approval of the Drug Product. FAULDING shall prepare and test the Drug Product in accordance with
cGMP.
2
2.2 Processing and Manufacturing: FAULDING shall manufacture and package the Drug Product in
accordance with Schedules I and II hereto.
2.3 Documentation: Subject to CUMBERLANDs prior consent pursuant to Paragraph 5.5 hereof to
reimburse FAULDING for all out-of-pocket expenses and reasonable internal costs, FAULDING shall
provide CUMBERLAND with required supporting documentation for the Development of the Drug Product
in a form suitable for CUMBERLANDs submission to the FDA or applicable governmental authorities
for any country into which the Drug Product will be distributed with the prior written consent of
FAULDING, which consent shall not be unreasonably withheld or delayed.
2.4 Bulk Drug Substance Supply: FAULDING shall be responsible for the supply of all Bulk Drug
Substance in accordance with Schedules I and II hereto; provided that the supply of Bulk Drug
Substance shall be exclusively from such suppliers and in such grades as have been approved in
writing by CUMBERLAND as reflected on an approved list to be attached hereto as Schedule III, and
provided further that such suppliers and grades may not be changed without CUMBERLANDs prior
written consent.
2.5 Supply of Components: FAULDING shall be responsible for the supply of all components in
accordance with Schedules I and II hereto; provided that the supply of components shall be
exclusively from such suppliers and in such grades as have been approved in writing by CUMBERLAND
as reflected on an approved list to be attached hereto as Schedule III, and provided further that
such suppliers and grades may not be changed without CUMBERLANDs prior written consent.
2.6 Delivery Terms: All deliveries of Drug Product under this Agreement shall be made by
FAULDING to CUMBERLAND in the manner set forth in Schedule I. CUMBERLAND shall, within twenty (20)
working days after its receipt of any shipment, notify FAULDING in writing, of any claim relating
to a Drug Product not conforming to the Specifications, and, failing such notification,
notwithstanding Paragraph 5.1 of this Agreement, CUMBERLAND shall be deemed to have accepted the
Drug Product. If FAULDING disputes CUMBERLANDs claim that the Drug Product is non-conforming, then
such dispute shall be resolved by an independent testing organization of recognized repute within
the pharmaceutical industry mutually agreed upon by FAULDING and CUMBERLAND, the appointment of
which shall not be unreasonably withheld by either party. In such event, CUMBERLAND shall ship the
testing organization representative samples of the Drug Product from the disputed production lot,
and the fees and costs of such testing organization and related shipping and supply costs shall be
borne by the party whose position is not sustained by the testing organization. CUMBERLANDs sole
remedy for non-conforming product (other than indemnification under Paragraph 10.2) is to be
provided with replacement Drug Product free of charge, including compensation for all CUMBERLAND
inputs and all freight charges.
2.7 Payment for the Drug Product: At the time of each shipment, FAULDING shall invoice
CUMBERLAND for FAULDINGs manufacturing services at the cost per batch as set forth in Schedule I.
Payment shall be made in [***] of the latter of the invoice date or
3
CUMBERLANDs acceptance of
shipment of conforming Product at its designated receiving facility.
2.8 [***]
3. TERM AND TERMINATION
3.1 Term: This Agreement shall commence on the date first above written and will continue
until the fifth anniversary of the date on which the FDA grants approval to market and sell the
Drug Product, unless sooner terminated pursuant to Paragraph 3.2 herein. The Agreement shall be
automatically renewed for successive three-year terms unless either party notifies the other party
in writing at least twelve (12) months in advance of the expiration of the then current term that
the party is terminating the Agreement.
3.2 Termination: This Agreement may be terminated at any time upon the occurrence of any of
the following events:
(a) Default: Forty-five (45) days following written notice, by either party to the other
party, in the event that the other party breaches any provision of this Agreement, and such party
fails to remedy the breach prior to the expiration of the forty-five (45) day period.
(b) Insolvency: Written notice by either party to the other upon insolvency or bankruptcy of
the other party, and the failure of any such insolvency or bankruptcy to be dismissed within sixty
(60) days.
(c) If, as a result of causes described in Paragraph 7.1, either party is unable to fully
perform its obligations hereunder for a period of one hundred eighty (180) consecutive days, the
other party shall have the right to terminate this Agreement upon at least thirty (30) days prior
written notice; provided that if the required performance is met during that thirty-day period,
this Agreement shall continue in full force and effect as if the notice had not been given.
Termination, expiration, cancellation or abandonment of this Agreement, through any means and
for any reason, shall not relieve the parties of any obligation accruing prior thereto and shall be
without the prejudice to the rights and remedies of either party with respect to any antecedent
breach of any of the provisions of this Agreement or CUMBERLANDs purchase order issued hereunder.
3.3 Survival: Paragraphs 5, 6, 9, and 10 shall survive the termination or cancellation of the
Agreement for any reason.
4. CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE
4.1 Certificates of Analysis: FAULDING shall perform, or cause to be performed, certain tests
requested by CUMBERLAND as indicated in the Specifications on each batch of the Drug Product
manufactured pursuant to this Agreement before delivery to CUMBERLAND.
4
A certificate of analysis
for each batch delivered shall be delivered with each batch and shall set forth the items tested,
specifications, and test results. FAULDING shall also indicate on the certificate of analysis that
all batch production and control records have been reviewed and approved by the appropriate quality
control unit. FAULDING shall send, or cause to be sent, such certificates to CUMBERLAND prior to
the shipment of the Drug Product. CUMBERLAND shall test, or cause to be tested, prior to final
release, each batch of the Drug Product as meeting the Specifications. As required by the FDA (see
Paragraph 5.2 below), CUMBERLAND shall assume full responsibility for final release of each lot of
the Drug Product.
4.2 Manufacturing Compliance: FAULDING shall advise CUMBERLAND immediately if an authorized
agent of any regulatory body visits FAULDINGs manufacturing facility and makes an inquiry
regarding FAULDINGs method of manufacture of the Drug Product for CUMBERLAND. Upon receipt of any
Form 483 Notice of Inspectional Observations issued by the FDA or notice of deficit from any other
regulatory inspection after a visit to FAULDINGs manufacturing facility, FAULDING shall
immediately send CUMBERLAND a copy thereof; provided that it may redact any language that is
subject to a legally enforceable confidentiality agreement between FAULDING and a third party.
4.3 Regulatory Agency Requirements: FAULDING shall prepare and test the Drug Product in
conformity with GMP. Subject to the allocation of responsibility for regulatory compliance as set
forth in Paragraph 5.2, each party shall consult with the other party hereto before implementing
additional regulatory agency requirements concerning the control of Drug Product components,
manufacture of the Drug Product, or storage and handling of the Drug Product. The full text of
regulatory agency requests or comments will be provided by the party receiving such requests or
comments to the other party hereto. The parties will mutually agree on how to respond to such
requests and comments and on the allocation of the costs thereof; provided that FAULDING shall be
liable only for its reasonable internal costs and not for any out-of-pocket expenses or
extraordinary costs required in connection with implementing such regulatory requirements other
than the ordinary costs of compliance with GMP.
4.4 Regulatory Documents: Each party will advise the other party hereto of its intention to
change any Drug Product regulatory documents prior to submission of the document to any regulatory
body. If the change affects the rights and obligations of a party hereto under this Agreement, such
party may seek to review or alter any part of the document at any time within ten (10) business
days after receipt of notification thereof; provided that if no alterations are submitted to the
other party within such ten-day period, each party will be deemed to have consented to the
alteration. CUMBERLAND shall reimburse FAULDING for all out-of-pocket expenses and reasonable
internal costs of changes to Drug Product regulatory documents, subject to CUMBERLANDs prior
consent pursuant to Paragraph 5.5.
5. REPRESENTATIONS AND WARRANTIES
5.1 Conformity with Specifications: FAULDING warrants that, at the time of manufacture, the
Drug Product is prepared and tested in accordance with cGMP and meets the Specifications. Because
FAULDING has no control of the conditions under which the Drug Product is used, the diagnosis of
the patient before or after treatment with the Drug Product, the
5
method of use or administration of
the Drug Product, and handling of the Drug Product after delivery to CUMBERLAND, FAULDING does not
warrant either a good effect, or against an ill effect, following the use of the Drug Product. The
foregoing warranty is exclusive and in lieu of all other warranties either written, oral, or
implied. THERE ARE NO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. No
representative of FAULDING may change any of the foregoing warranties and CUMBERLAND accepts the
Drug Product subject to all terms hereof.
5.2 Compliance: CUMBERLAND assumes responsibility for coordinating all contact with the FDA
and other regulatory bodies, pertaining specifically to Drug Product. FAULDING authorizes
CUMBERLANDs representatives to supervise and inspect the methods used in and facilities used for
manufacturing, processing, packaging, and handling of the Drug Product, but CUMBERLAND shall have
no such obligation under this Agreement. Except as otherwise required by applicable regulations,
CUMBERLANDs inspections shall be limited to two per year, each to occur upon seven days notice and
to be conducted during normal business hours; provided that CUMBERLAND may also inspect such
facilities promptly after any regulatory inspection thereof.
5.3 Debarring: FAULDING represents and warrants that it has not been debarred in the United
States within the meaning of 21 U.S.C. § 335a(a) and 335a(b), nor will it use in any capacity the
services of any person debarred pursuant to subsections 3.06(a) or 3.06(b) of the Federal Food,
Drug, and Cosmetic Act, 21 U.S.C. Section 335(a) and (b).
5.4 FDA Submission: FAULDING represents and warrants that it has submitted to the FDA
information about the manufacturing site to be used for the Drug Product and the facilities,
operating procedures, and personnel at such site.
5.5 Reimbursement: FAULDING shall not incur any development costs for which it intends to seek
reimbursement from CUMBERLAND for the manufacturing facility, equipment, or manufacturing method
unless FAULDING has the prior written consent of CUMBERLAND.
5.6 Exclusivity: FAULDING will not sell, give away, or deliver to any other person, firm, or
corporation any Drug Product without CUMBERLANDs prior written consent while this Agreement is
effective and for two years after the termination of this Agreement. In the event of breach,
CUMBERLAND shall have the right, in addition to other rights, to seek injunctive relief.
6. DRUG PRODUCT RECALLS
6.1 Drug Product Recalls: In the event: (a) any government authority issues a request,
directive or order that the Drug Product be recalled, or (b) a court of competent jurisdiction
orders such a recall, (c) CUMBERLAND determines that the Drug Product should be recalled because
the Drug Product does not conform to Specifications, or (d) FAULDING
recommends to CUMBERLAND that a recall be initiated, the parties shall take all appropriate
corrective actions. In the event that FAULDING recommends a recall of Drug Product by CUMBERLAND,
such recommendation must take the form of a notice as per Paragraph 14.1, and CUMBERLAND shall
respond promptly indicating to FAULDING whether the Drug
6
Product will be recalled. In no event,
however, shall FAULDING have responsibility for regulatory compliance in connection with any
recall, except to the extent and under the circumstances set forth in the Manual or any other
written agreement between the parties hereto or as required by law. All costs and expenses incurred
in connection with such recall shall be the responsibility of CUMBERLAND unless caused by the
negligence of FAULDING.
7. FORCE MAJEURE; FAILURE TO SUPPLY
7.1 Force Majeure Events: Failure of either party to perform under this Agreement (except the
obligation to make payments) shall not subject such party to any liability to the other if such
failure is caused by acts such as, but not limited to, acts of God, fire, explosion, flood,
drought, war, riot, sabotage, embargo, strikes or other labor trouble, compliance with any order or
regulation of any government entity, or by any cause beyond the reasonable control of the parties,
provided that written notice of such event is promptly given to the other party.
7.2 Failure to Supply; Delivery Dates; Forecasts: FAULDING shall supply all of the Drug
Product ordered by CUMBERLAND within sixty (60) days of receipt of a written order from CUMBERLAND.
On the date that CUMBERLAND makes its first order, CUMBERLAND will supply FAULDING with a
non-binding forecast of its future orders of Drug Product for each of the eleven calendar months
following the month in which the initial order is made. CUMBERLAND will update the forecasts on the
first day of the calendar month and on a monthly basis thereafter throughout the term of this
Agreement. The quantity of any Drug Product ordered pursuant to this Agreement shall not be less
than seventy percent (70%) nor more than one hundred thirty percent (130%) of the quantity
indicated in the most recent monthly forecast provided hereunder for the month in which the order
is placed. If CUMBERLAND fails to provide orders, or forecasts by agreed dates, FAULDING shall not
be required to deliver the quantity ordered by CUMBERLAND within sixty (60) days. The provisions of
this Paragraph 7.2 shall be without prejudice to CUMBERLANDs rights under Paragraph 3.2 and
remedies provided for thereunder.
8. IMPROVEMENTS
8.1 Changes by CUMBERLAND:
When CUMBERLAND seeks to change the Drug Product Specifications, such change shall be
incorporated within the Specifications only with the prior written consent of FAULDING, such
consent not to be unreasonably withheld or delayed. The price of the Drug Product may be adjusted
for such change, and CUMBERLAND shall pay FAULDING the agreed costs associated with such change,
including any development work, if necessary, based upon FAULDINGs then-prevailing development
rates. Such prices and costs shall be set forth in a written amendment to this Agreement. It is the
responsibility of CUMBERLAND to ensure that proper regulatory agencies approve the suggested
changes. CUMBERLAND will notify
FAULDING if it intends to change the process or test specifications related to the preparation
of the Bulk Drug Substance.
8.2 Changes by FAULDING:
7
FAULDING shall inform CUMBERLAND in writing of all proposed changes in the manufacturing
facility, equipment, or manufacturing methods and labeling of the Drug Product, each as approved by
applicable regulatory authorities, including the FDA, in advance of the time such changes are
intended to be made to allow CUMBERLAND sufficient time to provide any notice required by FDA
regulations. FAULDING shall not implement any such changes without prior written authorization by
the FDA or other applicable regulatory authorities and the prior written consent of CUMBERLAND,
which consent shall not be unreasonably withheld or delayed. FAULDING shall be liable only for its
reasonable internal costs and not for extraordinary costs in connection with such manufacturing
changes.
9. CONFIDENTIALITY
9.1 Confidential Information: Confidential Information means collectively Confidential
Information of CUMBERLAND (as defined herein) and Confidential Information of FAULDING (as defined
herein).
9.2 Confidential Information of CUMBERLAND: Confidential Information of CUMBERLAND means all
information obtained or developed by FAULDING or any third party which related to CUMBERLANDs
business or the Drug Product, regardless of the form in which such information is transmitted. The
following shall not be considered Confidential Information of CUMBERLAND for purposes hereof:
(a) Information that is already in the possession of FAULDING at the time it is received from
CUMBERLAND or developed on CUMBERLANDs behalf, if FAULDING notifies CUMBERLAND of its belief that
the information is excepted under the terms of this subsection;
(b) Information received by FAULDING from a person which has the right to disclose the same,
when FAULDING notifies CUMBERLAND of its belief that the information is excepted under the terms of
this subsection;
(c) Information that is or becomes published, or is or becomes otherwise publicly available
without the fault of FAULDING; or
(d) An Invention as defined in Paragraph 9.4.
In the event of a dispute regarding the applicability of the above exceptions to the
definition of Confidential Information of CUMBERLAND, FAULDING shall have the burden of producing
clear and convincing proof that the information should be excepted from the definition of
Confidential Information of CUMBERLAND. FAULDING shall not use or permit the use of the
Confidential Information of CUMBERLAND other than for the limited purposes
expressly permitted by or consistent with this Agreement. Recipients of Confidential
Information of CUMBERLAND shall be granted access thereto strictly on a need-to-know basis.
FAULDING shall take all reasonable steps to ensure that recipients comply with the terms of this
Agreement, including all restrictions on use, disclosure and dissemination of Confidential
8
Information of CUMBERLAND. FAULDING shall notify CUMBERLAND immediately upon becoming aware of any
breach hereof and shall take all reasonable steps to prevent any further disclosure or unauthorized
use.
Upon termination or expiration of this Agreement, FAULDING shall deliver to CUMBERLAND all
Confidential Information of CUMBERLAND, all copies thereof, and all documents or data storage media
containing such Confidential Information of CUMBERLAND, except as expressly set forth herein or in
any other written agreement between the parties.
9.3 Confidential Information of FAULDING: Confidential Information of FAULDING means all
information obtained by CUMBERLAND which relates to FAULDINGs business, regardless of the form in
which such information is transmitted. The following shall not be considered Confidential
Information of FAULDING for purposes hereof:
(a) Information that is already in the possession of CUMBERLAND at the time it is received
from FAULDING, if CUMBERLAND notifies FAULDING of its belief that the information is excepted under
the terms of this subsection; or
(b) Information received by CUMBERLAND from a person which has the right to disclose the same,
when CUMBERLAND notifies FAULDING of its belief that the information is excepted under the terms of
this subsection; or
(c) Information that is or becomes published, or is or becomes otherwise publicly available
without the fault of CUMBERLAND.
In the event of a dispute regarding the applicability of the above exceptions to the
definition of Confidential Information of FAULDING, CUMBERLAND shall have the burden of producing
clear and convincing proof that the information should be excepted from the definition of
Confidential Information of FAULDING. CUMBERLAND shall not use or permit the use of the
Confidential Information of FAULDING other than for the limited purposes expressly permitted by or
consistent with this Agreement. Recipients of Confidential Information of FAULDING shall be
granted access thereto strictly on a need-to-know basis. CUMBERLAND shall take all reasonable
steps to ensure that recipients comply with the terms of this Agreement, including all restrictions
on use, disclosure and dissemination of Confidential Information of FAULDING. CUMBERLAND shall
notify FAULDING immediately upon becoming aware of any breach hereof and shall take all reasonable
steps to prevent any further disclosure or unauthorized use.
Upon termination or expiration of this Agreement, CUMBERLAND shall deliver to FAULDING all
Confidential Information of FAULDING, all copies thereof, and all documents or data storage media
containing such Confidential Information of FAULDING, except as expressly set forth herein or in
any other written agreement between the parties.
9.4 Invention: CUMBERLAND owns all intellectual property rights in any improvement to or
derived from the Drug Product and any existing or further developments or modifications of the Drug
Products (Invention), except to the extent that a manufacturing
9
process used therewith is
developed exclusively by FAULDING, in which case the intellectual property rights for such process
shall be retained by FAULDING.
9.5 Disclosure: The parties agree that the existence of this Agreement may be disclosed to
third parties but that the contents of this Agreement shall not be disclosed to any third party
except (i) the controlling companies of the parties, (ii) the companies controlled by the parties,
(iii) individuals and entities providing paid services to either of the parties, and (iv)
governmental regulatory agencies, including, but not limited to, environmental protection
authorities, without prior written consent of the other party.
9.6 Retention of Records: Notwithstanding the restrictions set forth in this Agreement,
FAULDING shall retain production records (a) for batches of Drug Products manufactured prior to
establishment by CUMBERLAND of an expiry date (CTM and validation batches) for three (3) years
after (i) issuance of regulatory approval of the Drug Product necessary for distribution thereof or
(ii) withdrawal of the IND (Notice of Claimed Investigational Exemption for a New Drug) and (b) for
batches of Drug Product manufactured after establishment by CUMBERLAND of an expiry date for a
period of at least one year after the respective expiry date for each batch. These records will be
stored by appropriate means, including without limitation, optical disk or microfilm in a secure
manner in compliance with current GMP with duplicate copies submitted to CUMBERLAND promptly after
the creation thereof and shall be made available on request of the FDA or any other authorized
regulatory body.
9.7 Confidential Information Upon Termination: Upon termination of this Agreement for whatever
reason, FAULDING shall return to CUMBERLAND originals, copies, and derivative forms of disclosed or
developed information relating to the purpose of this Agreement; except that one copy of such
information may be retained as required by regulation or law for future reference. The Confidential
Information shall remain confidential and not be disclosed by either party for a period of ten (10)
years following the date of expiration or termination of this Agreement.
10. INDEMNIFICATION
10.1 Indemnification by CUMBERLAND: CUMBERLAND shall indemnify and hold FAULDING (and any
parent, subsidiary, or affiliate company or corporation, and their officers, directors,
shareholders, agents, and the employees and insurers of any of them and/or their successors and
assigns thereto), free and harmless from any and all claims, demands, liability, actions or causes
of actions, and any and all expenses associated therewith (including, without limiting the
generality of the foregoing, attorneys fees), arising out of or in connection with, as a result
of, or otherwise related to any third party claims arising from: (i) any negligence or recklessness
of CUMBERLAND, its agents, or employees; (ii) the promotion, distribution, use, misuse or sale or
effects of the Drug Product except to the extent the alleged Drug Product
defects were caused by FAULDING; (iii) CUMBERLANDs non-compliance with any applicable FDA or
other applicable regulations; or, (iv) any failure of CUMBERLAND to perform, in whole or in part,
any of its obligations hereunder in each case, unless caused by the acts or omissions of FAULDING.
Beginning prior to use of the Drug Product in humans and
10
continuing until the third anniversary of
termination of this Agreement, CUMBERLAND shall maintain products liability insurance with limits
of liability of not less than [***] and shall name
FAULDING as additional insured under said policy.
10.2 Indemnification by FAULDING: FAULDING will indemnify and hold CUMBERLAND (and any parent,
subsidiary, or affiliate company or corporation, and their officers, directors, shareholders,
agents, and the employees and issuers of any of them and/or their successors and assigns thereto),
free and harmless against any and all claims, demands, actions or causes of action, and any and all
expenses associated therewith (including, without limiting the generality of the foregoing, defense
costs and attorneys fees), arising out of or in connection with, as a result of, or otherwise
related to any third party claims arising from (i) any negligence or recklessness of FAULDING, its
agents or employees; (ii) personal injury (including death) or property damage arising out of or in
connection with FAULDINGs manufacture or handling of the Drug Product otherwise than in accordance
with the Specifications and CUMBERLANDS written directions; (iii) FAULDINGs non-compliance with
any applicable FDA or other applicable regulations; provided that CUMBERLAND perform its
obligations under Paragraph 2.1, or (iv) any failure of FAULDING to perform any of its obligations
hereunder, unless caused by the acts or omissions of CUMBERLAND. Beginning prior to delivery of the
first order for Drug Product pursuant to this Agreement and continuing until the third anniversary
of termination of this Agreement, FAULDING shall maintain products liability insurance with limits
of liability of not less than [***] and shall name CUMBERLAND as additional insured under
said policy.
10.3 Patent Indemnity: Subject to Paragraph 5.1, CUMBERLAND further warrants that importation,
manufacture (excluding manufacturing not specific to the manufacture of the Drug Product to be
performed by FAULDING for CUMBERLAND), use, supply, and sale of the Drug Product and Bulk Drug
Substance will not infringe any patent rights or any other third-party intellectual property rights
and that CUMBERLAND will indemnify, defend, and hold FAULDING free and harmless from any damage,
judgment, liability, loss, cost or expense, including legal expenses, arising from claims that the
Drug Product and Bulk Drug Substance infringe patent rights of a third party or any third-party
intellectual property rights.
10.4 Conditions of Indemnification: If either party seeks indemnification from the other under
Paragraphs 10.1, 10.2, or 10.3, it shall promptly give written notice to the other party of any
such claim or suit threatened, made or filed against it, which forms the basis for such claim of
indemnification and shall cooperate fully with the other party in the defense of all such claims or
suits. No settlement or compromise shall be binding on a party hereto without its prior written
consent.
10.5 Disclaimer of Warranties; Limited Liability: Under no circumstances shall either party be
liable to the other on account of any claim (whether based upon principles of
contract, warranty, negligence, or other tort, breach of any statutory duty, principles of
indemnity, the failure of any expressly limited remedy to achieve its essential purpose) for any
special, consequential, incidental or exemplary damages, or including but not limited to lost
profits.
11
11. APPOINTMENT AS PREFERRED MANUFACTURER
Until the expiration or earlier termination of this Agreement, CUMBERLAND agrees to provide
FAULDING with the first opportunity to negotiate to manufacture each CUMBERLAND pharmaceutical
product to be sold anywhere in the world in addition to the Drug Product; provided that the
foregoing shall not apply to pharmaceutical products in respect of which CUMBERLAND is unable to
enter into a manufacturing arrangement with FAULDING, due to contractual obligations applicable to
CUMBERLAND or where to enter into such an arrangement with FAULDING would adversely affect any
existing regulatory approval or application for regulatory approval for the product, in either case
as reasonably determined by CUMBERLAND having regard to documented evidence which CUMBERLAND shall
provide to FAULDING or FAULDINGs advisers for review at FAULDINGs request. Except as set forth to
the contrary in the preceding sentence, CUMBERLAND agrees not to manufacture, or to have
manufactured, such a product anywhere in the world unless CUMBERLAND first notifies FAULDING of the
opportunity hereunder and unless CUMBERLAND negotiates in good faith with FAULDING for sixty (60)
days after providing such notice in an attempt to enter into a written agreement on substantially
the same terms as this Agreement with respect to such additional product.
12. LICENSING AND DISTRIBUTION OF CUMBERLAND PRODUCTS
Until the expiration or earlier termination of this Agreement, CUMBERLAND agrees to provide
FAULDING with the first opportunity to negotiate to license and distribute each pharmaceutical
product of CUMBERLAND in Australia, New Zealand, Canada, and mutually agreed Southeast Asian and
Latin American countries; provided that the foregoing shall not apply to pharmaceutical products in
respect of which CUMBERLAND is unable to enter into a license and distribution arrangement with
FAULDING, due to contractual obligations applicable to CUMBERLAND as reasonably determined by
CUMBERLAND having regard to documented evidence which CUMBERLAND shall provide to FAULDING or
FAULDINGs advisers for review at FAULDINGs request, and further provided that CUMBERLAND shall
use good faith efforts to initiate such negotiations with FAULDING as soon as such a product is
reasonably available for license and distribution in such territory. Except as set forth to the
contrary in the preceding sentence, CUMBERLAND agrees not to license or distribute such a product
in such territory unless CUMBERLAND first notifies FAULDING of the opportunity hereunder and unless
CUMBERLAND negotiates in good faith with FAULDING for sixty (60) days after providing such notice
in an attempt to enter into a written agreement with respect to the services that are being
negotiated.
13. REGULATORY SUPPORT
If requested by CUMBERLAND, and at CUMBERLANDS cost at reasonable fees to be agreed
by the parties, FAULDING shall provide CUMBERLAND with reasonable assistance in relation to the
Development of, and applications for regulatory approval for, pharmaceutical products other than
the Drug Product which are identified by CUMBERLAND, including but not limited to the preparation
of development reports, stability reports, manufacturing documentation and
12
instructions for use
necessary to support applications for regulatory approval.
14. GENERAL PROVISIONS
14.1 Notices: Any notice permitted or required by this Agreement may be sent by facsimile with
the original document being sent by certified (or registered) mail, return receipt requested, or
overnight delivery and shall be effective when received (or refused) via facsimile or mail or
overnight if faxed and sent and addressed as follows (or to such other facsimile number or address
as may be designated by a party in writing):
|
|
|
|
|
|
|
|
|
If to CUMBERLAND: |
|
Cumberland Pharmaceuticals Inc. |
|
|
|
|
209 Tenth Avenue South, Suite 332 |
|
|
|
|
Nashville, Tennessee 37203 |
|
|
|
|
Attn: Chief Executive Officer |
|
|
|
|
Telephone:
|
|
615-255-0068 |
|
|
|
|
Facsimile:
|
|
615-255-0094 |
|
|
|
|
|
|
|
|
|
If to FAULDING: |
|
F.H. Faulding & Co. Limited |
|
|
|
|
115 Sherriff Street |
|
|
|
|
Underdale, South Australia 5032 |
|
|
|
|
Attn: Company Secretary |
|
|
|
|
Telephone:
|
|
61-8-8205-6500 |
|
|
|
|
Facsimile:
|
|
61-8-8234-8380 |
14.2 Entire Agreement: Amendment: The parties hereto acknowledge that this Agreement sets
forth the entire agreement and understanding of the parties and supersedes all prior written or
oral agreements or understandings with respect to the subject matter hereof; provided that the
Confidentiality Agreement dated August 1, 1999, between FAULDING and CUMBERLAND shall remain in
effect and that the terms thereof shall supersede any conflicting term of Paragraph 9 hereof. No
modification of any of the terms of this Agreement, or any amendments thereto, shall be deemed to
be valid unless in writing and signed by both parties hereto. No course of dealing or usage of
trade shall be used to modify the terms and conditions herein.
14.3 Waiver: None of the provisions of the Agreement shall be considered waived by any party
hereto unless such waiver is agreed to, in writing, by both parties. The failure of a party to
insist upon strict conformance to any of the terms and conditions hereof, or failure or delay to
exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any
party hereto.
14.4 Obligations to Third Parties: Each party warrants and represents that this Agreement is
not inconsistent with any contractual obligations, expressed or implied, undertaken
with any third party.
14.5 Assignment: This Agreement shall be binding upon and inure to the benefit of the
successors or permitted assigns of each of the parties and may not be assigned, transferred, or
13
subcontracted by either party without the prior written consent of the other, which consent will
not be unreasonably withheld or delayed, except that no consent shall be required in the case of a
transfer to a wholly-owned subsidiary or transaction involving the merger, consolidation or sale of
substantially all of the assets of the party seeking such assignment or transfer and such
transaction relates to the business covered by this Agreement and the resulting entity assumes all
the obligations under this Agreement.
14.6 Independent Contractor: FAULDING shall act as an independent contractor for CUMBERLAND in
providing the services required hereunder and shall not be considered an agent of or joint venturer
with CUMBERLAND. Unless otherwise provided herein to the contrary, FAULDING shall furnish all
expertise, labor, supervision, machining and equipment necessary for performance hereunder and
shall obtain and maintain all building and other permits and licenses required by public
authorities.
14.7 Governing Law: This Agreement is subject to and shall be governed by the laws of the
State of Tennessee. The parties hereby submit to the jurisdiction of the courts of the State of
Tennessee in respect to all disputes arising out of or in connection with this Agreement and waive
any and all objections to such venue.
14.8 Severability: In the event that any term or provision of this Agreement shall violate any
applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or otherwise
be unenforceable, such provision shall be ineffective to the extent of such violation without
invalidating any other provision hereof.
14.9 Headings, Interpretation: The headings used in this Agreement are for convenience only
and are not part of this Agreement.
14.10 Conflict: In the event of conflict between the terms and provisions of this Agreement
and the terms and provisions of the Manual, the terms of this Agreement shall control.
IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their
duly authorized representatives effective as of the date first above written.
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC.
|
|
|
|
F.H. FAULDING & CO. LIMITED |
|
|
|
|
|
|
|
|
|
/s/ A.J. Kazimi
|
|
|
|
/s/ Alex Bell |
|
|
|
|
|
|
Authorized Signature
|
|
|
Printed Name
|
|
|
|
Printed Name |
|
|
|
|
|
|
|
|
|
A.J. Kazimi
|
|
|
|
Alex Bell |
|
|
|
|
|
|
|
|
|
Printed Name
|
|
|
|
Printed Name |
|
|
|
|
|
|
Title |
|
|
|
|
|
|
|
|
|
CEO
|
|
|
|
V.P. Tech Ops. |
|
|
|
|
|
|
|
|
|
Title |
|
|
|
|
|
|
14
SCHEDULE I
DEVELOPMENT ACTIVITIES AND PRICING
Development of the Drug Product for use in Clinical Studies and for sale will consist of the
following:
|
|
|
Product -
|
|
Amelior. Ibuprofen for intravenous injection. |
|
|
|
Timing -
|
|
CUMBERLAND shall provide FAULDING with non-binding
forecasts of its requirements in the manner set forth in
Paragraph 7.2 of this Agreement. FAULDING shall
manufacture the number of batches of Drug Product
corresponding to each purchase order therefor within 60
days of receipt of any such order. |
|
|
|
Special Issues -
|
|
All product contact components must be dedicated or
disposed of after use. CUMBERLAND may be present for
manufacturing. The initial batches are for an FDA
submission, and may subsequently be used in clinical
studies or sold. FAULDING shall provide process
validation (scale-up and three validation batches) in
accordance with this Agreement and the Schedules thereto. |
|
|
|
cGMP or GMP -
|
|
GMP or cGMP shall mean the current good manufacturing
practices as defined from time in regulations promulgated
under the Federal Food, Drug and Cosmetic Act of the
United States or any successor laws or regulations
governing the manufacture of the Drug Product. |
|
|
|
Storage - |
|
|
1. |
|
FAULDING shall store and handle Bulk Drug Substance and finished Drug Product at 20E to 25E
C. |
Composition, Process & Container
[***]
15
|
|
|
Preparation -
|
|
Additional details regarding preparation shall be
incorporated herein upon adoption thereof by written
agreement of FAULDING and
CUMBERLAND. |
|
|
|
[***] |
|
|
|
|
|
Disposal -
|
|
Method of disposal is incineration. Any disposal costs
incurred by FAULDING will be charged back to CUMBERLAND;
provided that CUMBERLAND shall not be required to reimburse
FAULDING for such costs if the Drug Product is disposed of
because of FAULDINGs negligence or breach of this
Agreement. FAULDING shall prepare and provide CUMBERLAND
with complete documentation of disposal throughout the chain
of custody. |
Documentation by FAULDING
1. |
|
Master batch record for review and approval by FAULDING and CUMBERLAND. |
|
2. |
|
Product specific validation summaries. |
|
3. |
|
Executed batch records. |
|
4. |
|
Analytical records. |
|
5. |
|
Inventory records. |
|
6. |
|
Disposal records. |
|
|
|
Compensation -
|
|
The price to be paid by CUMBERLAND to FAULDING for the satisfactory performance of its obligations under this Agreement are as
follows: |
|
|
|
[***] |
|
|
|
|
|
Reimbursement of Development Costs -
|
|
CUMBERLAND shall reimburse FAULDING
for development costs incurred and
approved as agreed by the parties. |
|
|
|
Reimbursement of Regulatory Costs -
|
|
CUMBERLAND shall reimburse FAULDING
for regulatory costs incurred and
approved as agreed by the parties. |
|
|
|
Reimbursement of Inspection and Audit
Costs -
|
|
CUMBERLAND shall reimburse FAULDING
for inspection and audit costs
incurred and approved as agreed by
the parties. |
16
SCHEDULE II
MANUFACTURING PROJECT MANUAL
(To be expanded by mutual written consent of F.H. Faulding & Co., Limited (FHF) and
Cumberland Pharmaceuticals, Inc. (CPI))
|
|
|
|
|
|
|
|
|
|
|
Responsibility |
Documentation/Activity |
|
FHF |
|
CPI |
|
Comments |
GMP certificate and other permits
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Active Pharmaceutical Ingredient
(API) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Supply of API
|
|
/
|
|
|
|
CPI to identify source |
|
|
|
|
|
|
|
Provide specifications
|
|
|
|
/ |
|
|
|
|
|
|
|
|
|
Approval of API specifications
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Provide sampling and testing
methods
|
|
|
|
/ |
|
|
|
|
|
|
|
|
|
Approval of sampling and testing
methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of documents
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Starting Materials (except API) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Supply of starting materials
|
|
/
|
|
|
|
CPI to identify arginine source |
|
|
|
|
|
|
|
Provide specifications of starting
materials
|
|
|
|
/ |
|
|
|
|
|
|
|
|
|
Approval of starting materials
specifications
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Providing sampling and testing
methods
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of sampling and testing
materials
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Manufacturing Formula |
|
|
|
|
|
|
|
|
|
|
|
|
|
Development of manufacturing
formula
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Approval of manufacturing formula
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Processing Instructions |
|
|
|
|
|
|
|
|
|
|
|
|
|
Development of processing
instructions
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of processing instructions
|
|
/
|
|
/ |
|
|
17
|
|
|
|
|
|
|
|
|
FHF |
|
CPI |
|
Comments |
Bulk Product |
|
|
|
|
|
|
|
|
|
|
|
|
|
Supply of Bulk Product
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Provide specifications of Bulk Product
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Approval of Bulk Product specifications
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Providing sampling and testing methods
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Prepare stability data for Bulk Product
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Packaging |
|
|
|
|
|
|
|
|
|
|
|
|
|
Supply of packaging materials
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Provide packaging materials specifications
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of specifications
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Providing sampling and testing methods
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Batch Processing Records |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preparation of batch processing records
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Review of batch processing records
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release of batch processing records
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Storage of batch processing records
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Product |
|
|
|
|
|
|
|
|
|
|
|
|
|
Providing sampling and testing methods
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Prepare stability data for Product
|
|
/ |
|
|
|
|
18
Supply of Materials
|
|
|
|
|
|
|
|
|
|
|
Supplier (check one): |
Documentation/Activity |
|
FHF |
|
CPI |
|
Comments |
Starting Materials |
|
|
|
|
|
|
|
|
|
|
|
|
|
Active Pharmaceutical Ingredient |
|
/ |
|
|
|
CPI will identify source |
|
|
|
|
|
|
|
Other Starting Materials |
|
|
|
|
|
|
|
|
|
|
|
|
|
(Auxiliaries, fluids, gases, etc.): |
|
|
|
|
|
|
|
|
|
|
|
|
|
Excipients |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
WFI |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
N2 |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Packaging Materials |
|
|
|
|
|
|
|
|
|
|
|
|
|
Vials |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Stoppers |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Seals |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Boxes |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Shippers |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Labeling |
|
/ |
|
|
|
|
Quality Control
Distribution of responsibilities:
F.H. Faulding & Co. (FHF) shall ensure that all quality control measures follow the applicable cGMP
guidelines. The responsibilities shall be distributed between FAULDING and CPI as follows:
|
|
|
|
|
|
|
|
|
|
|
Supplier (check one): |
Documentation/Activity |
|
FHF |
|
CPI |
|
Comments |
Active Pharmaceutical Ingredient |
|
|
|
|
|
|
|
|
|
|
|
|
|
Providing sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Approval of sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Starting Materials (except API) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Providing sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Approval of sampling and testing methods
|
|
/
|
|
/ |
|
|
19
|
|
|
|
|
|
|
|
|
|
|
Supplier (check one): |
Documentation/Activity |
|
FHF |
|
CPI |
|
Comments |
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Bulk Product |
|
|
|
|
|
|
|
|
|
|
|
|
|
Providing sampling and testing methods
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Prepare stability data for Bulk Product
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Packaging Materials |
|
|
|
|
|
|
|
|
|
|
|
|
|
Providing sampling and testing methods
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
FHF |
|
CPI |
|
Comments |
Batch Documentation |
|
|
|
|
|
|
|
|
|
|
|
|
|
Assignment of batch numbers
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Preparation of batch processing records
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Review of batch processing records
|
|
|
|
/ |
|
|
|
|
|
|
|
|
|
Release of batch processing records
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of batch processing records
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Product |
|
|
|
|
|
|
|
|
|
|
|
|
|
Providing sampling and testing methods
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Approval of sampling and testing methods
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Sampling and testing
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Release
|
|
/ |
|
|
|
|
|
|
|
|
|
|
|
Storage of samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
Storage of documentation
|
|
/
|
|
/ |
|
|
|
|
|
|
|
|
|
Prepare stability data for Product
|
|
/ |
|
|
|
|
20
ATTACHMENT I
BULK DRUG SUBSTANCE
AND DRUG PRODUCT SPECIFICATIONS
AND PROCEDURES
Bulk Drug Substance -
To be agreed.
Drug Product Specifications and Procedures -
To be decided.
21
SCHEDULE 3
Ibuprofen Injection 100mg/ml
[***]
22
EX-10.9 KRISTALOSE AGREEMENT
EXHIBIT 10.9
*Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
KRISTALOSE AGREEMENT
Between
CUMBERLAND PHARMACEUTICALS INC.
And
INALCO BIOCHEMICALS, INC.
And
INALCO S.P.A.
APRIL 2006
TABLE OF CONTENTS
|
|
|
|
|
1. DEFINITIONS |
|
|
1 |
|
|
|
|
|
|
2. REGULATORY APPROVAL, MARKETING AND DISTRIBUTION |
|
|
6 |
|
|
|
|
|
|
3. TERM AND TERMINATION |
|
|
16 |
|
|
|
|
|
|
4. PAYMENTS |
|
|
18 |
|
|
|
|
|
|
5. CONFIDENTIALITY |
|
|
20 |
|
|
|
|
|
|
6. PROTECTION AND OWNERSHIP OF INTELLECTUAL PROPERTY |
|
|
22 |
|
|
|
|
|
|
7. REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION |
|
|
23 |
|
|
|
|
|
|
8. GENERAL |
|
|
27 |
|
|
|
|
|
|
9. ARBITRATION |
|
|
29 |
|
|
|
|
|
|
EXHIBIT A Minimum Purchases |
|
|
|
|
|
|
|
|
|
EXHIBIT B Patents |
|
|
|
|
|
|
|
|
|
EXHIBIT C Transition Plan |
|
|
|
|
|
|
|
|
|
EXHIBIT D Specifications |
|
|
|
|
|
|
|
|
|
EXHIBIT E Adverse Event Reporting |
|
|
|
|
i
THIS AGREEMENT, by and among CUMBERLAND PHARMACEUTICALS INC. (CUMBERLAND), a corporation
organized and existing under the laws of the State of Tennessee, U.S.A., with its principal place
of business located at 2525 West End Avenue, Suite 950, Nashville, Tennessee, U.S.A., 37203, and
INALCO BIOCHEMICALS, INC., a corporation organized and existing under the laws of California, with
its principal place of business located at 3440 Empresa Drive, Suite A, San Luis Obispo,
California 93401 (INALCO U.S.), and INALCO S.p.A., a corporation organized and existing under
the laws of Italy, with its principal place of business located at Via Calabiana 18, 20139 Milan,
Italy (INALCO ITALY) (INALCO U.S. and INALCO ITALY are hereinafter collectively referred to as
INALCO) is entered into as of the day of April, 2006 (the Execution Date).
RECITALS
WHEREAS, INALCO is negotiating the acquisition of the Kristalose Trademark from Mylan Laboratories
Inc. and this Agreement is conditional upon the successful acquisition of the Kristalose
Trademark;
WHEREAS, INALCO owns or has the right to use all Intellectual Property Rights related to the
Product (each as defined herein);
WHEREAS, CUMBERLAND is a pharmaceutical company with capabilities in the marketing, development,
registration and distribution of various pharmaceutical products in the Territory;
WHEREAS, INALCO has obtained and is willing to seek all necessary regulatory approvals for the
marketing and distribution of the Product in the Territory (as defined herein);
WHEREAS, CUMBERLAND wishes to acquire the exclusive distribution and marketing rights to the
Product in the Territory, in accordance with and subject to the terms and conditions set forth in
this Agreement;
WHEREAS, INALCO is willing to grant an exclusive license to CUMBERLAND to market and distribute
the Product in the Territory;
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, it is
agreed by the parties as follows:
1. DEFINITIONS
1.1 |
|
Affiliate shall mean, with respect to any Person, any other Person that controls, is
controlled by or is under common control with, such Person. A Person shall be regarded as in
control of another Person if such Person owns, or directly or indirectly controls, more than
fifty percent (50%) of the voting securities (or comparable equity interests) or other
ownership interests of the other Person, or if such Person directly or indirectly possesses
the power to direct or cause the direction of the management or policies of the other Person,
whether through the ownership of voting securities, by
contract or any other means whatsoever. |
1
1.2 |
|
Agreement shall mean this Agreement and all instruments supplemental hereto or in
amendment or confirmation hereof; herein, hereof, hereto, hereunder and similar
expressions mean and refer to this Agreement and not to any particular Article, Section,
Subsection or other subdivision; Article, Section, Subsection or other subdivision of
this Agreement means and refers to the specified Article, Section, Subsection or other
subdivision of this Agreement. |
|
1.3 |
|
ANDA shall mean any Abbreviated New Drug Application covering the Product and filed
with the FDA pursuant to the U.S. Federal Food, Drug, and Cosmetic Act, as amended, or any
regulations thereunder. |
|
1.4 |
|
Calendar Quarter shall mean each three (3) month period ending March 31, June 30,
September 30, and December 31. |
|
1.5 |
|
Certificate of Analysis means a document which is signed and dated by a duly
authorized representative of INALCO certifying that the Product conforms with the Product
Specifications. |
|
1.6 |
|
Competent Authority shall mean each and every Governmental Body from which approvals
are required for the manufacture, marketing, distribution or sale of the Product within the
Territory. |
|
1.7 |
|
Confidential Information shall have the meaning set forth in Subsection 5.1(A) hereof. |
|
1.8 |
|
Delivery Date is the date of delivery for Products agreed to by the parties. |
|
1.9 |
|
Effective Date shall mean the date on which an authorized representative of INALCO
certifies in a writing delivered to CUMBERLAND that INALCO has met all requirements in order
to transfer exclusive marketing and distribution rights to the Product in accordance with this
Agreement, including without limitation, obtaining all rights to the Trademarks from Mylan
Pharmaceuticals, Inc.; provided that such certificate must be in a form reasonably
satisfactory to CUMBERLAND. |
|
1.10 |
|
FDA shall mean the U.S. Food and Drug Administration. |
|
1.11 |
|
Governmental Body shall mean (i) any domestic or foreign national, federal,
provincial, state, municipal or other government or body, (ii) any international or
multilateral body, (iii) any subdivision, ministry, department, secretariat, bureau, agency,
commission, board, instrumentality or authority of any of the foregoing governments or
bodies, (iv) any quasi-governmental or private body exercising any regulatory, expropriation
or taxing authority under or for the account of any of the foregoing governments or bodies,
or (v) any domestic, foreign, international, multilateral, or multinational judicial,
quasi-judicial, arbitration or administrative court, grand jury, tribunal, commission, board
or panel. |
|
1.12 |
|
Independent Analyst is an analyst which is acceptable to the parties for the purposes
of
Sections 2.7(C) or 2.10. |
2
1.13 |
|
Intellectual Property Rights shall mean whether or not reduced to writing, all
discoveries, inventions, all rights to inventions, patents, patent applications and issued
patents, data, including patient records, proprietary formulation, non-clinical and clinical
data, FDA registrations, market information and plans, designs, design applications and design
registrations, trade marks, trade mark applications, trade mark registration, trade names,
trade dresses, service marks, logos (whether registered or unregistered), copyright, copyright
applications and registrations, and all other rights and intellectual property relating to the
Product now or hereafter owned, held or used by INALCO or any of its Affiliates or
Subsidiaries; without limiting the generality of the foregoing, Intellectual Property Rights
shall include the Patent Rights, the Trademarks, the Know-How (each as defined herein) and all
other rights and intellectual property now or hereafter owned, held or used by INALCO or any
of its Affiliates or Subsidiaries. |
|
1.14 |
|
Know-How shall mean all know-how, information, data, knowledge, discoveries, trade
secrets, works, data, analytical reference materials and confidential or proprietary processes
relating to the Product or to the manufacturing, distribution or sale of the Product in the
Territory, and other information relating to the Product, owned or developed by, in the
possession of, known to or used by INALCO or its Affiliates or Subsidiaries prior to the
Effective Date. Without limiting the generality of the foregoing, Know-How shall include all
techniques, technology, processes, and know-how related to production and purification of the
Product, including systems for fully processing and purifying the Product; types and
configuration of processing equipment; lists of suppliers, customers and prospective
customers; market research data and reports, customer segmentation reports, detail pieces and
any other marketing information relating to Product; development plans; methods of operation
and management; cost control methods of setting prices; reporting methods; quality assurance
programs; information systems; training manuals; databases; production solutions; financial
information; and all other trade secrets of INALCO. |
|
1.15 |
|
Labels shall mean all labels and packaging and other written, printed, or graphic
matter approved by the Competent Authority upon or containing: (i) the Product or any
packaging, container or wrapper utilized with the Product, and (ii) any written material
accompanying the Product, including without limitation, package inserts, produced by INALCO
with CUMBERLANDs prior written approval. |
|
1.16 |
|
Laws shall mean: |
|
(i) |
|
all constitutions, treaties, laws, statutes, codes, ordinances, orders,
decrees, rules, regulations, and municipal by-laws, whether domestic, foreign or
international; |
|
|
(ii) |
|
all judgments, orders, writs, injunctions, decisions, rulings, decrees, and
awards of any Governmental Body; and |
|
|
(iii) |
|
all policies, practices and guidelines of any Governmental Body; |
|
|
in each case binding on or affecting the party or Person referred to in the context in |
3
|
|
which such word is used; and Law shall mean any one of them. |
1.17 |
|
Listing means obtaining approval from the relevant pricing authority in the
Territory to qualify the Product for price reimbursement and/or (as appropriate) obtaining
formulary listing approval in the Territory. |
|
1.18 |
|
Minimum Purchases shall mean the minimum number of
commercial pouches of the Product that CUMBERLAND must purchase, as set forth in Exhibit A. |
|
1.19 |
|
Mylan shall have the meaning set forth in Section 2.5(A). |
|
1.20 |
|
Net Sales shall mean the aggregate amount billed by CUMBERLAND for the sale of the
Product, less returns, buying group chargebacks, group purchasing organization administrative
fees, managed care organization rebates, sales/purchasing discounts, prompt payment
discounts, federally mandated discounts or rebates, state medical assistance program rebates
and discounts, adjustments for quantities shipped, and other discounts and fees, all as
determined on an accrual basis. |
|
1.21 |
|
Order is defined in Section 2.6(C). |
|
1.22 |
|
Patent Rights shall mean all issued patents and patent applications relating to the
Product in the Territory, whether owned by INALCO or its Affiliates or Subsidiaries and/or
made available in any other way to INALCO or its Affiliates or Subsidiaries, including those
listed in Exhibit B hereto, and every divisional, continuation, continuation-in-part,
substitution and confirmation application based thereon, and any reissue or extension based
on any of the foregoing. |
|
1.23 |
|
Person shall mean an individual, corporation, company, co-operative, partnership,
organization or any similar entity. |
|
1.24 |
|
Product shall mean INALCOs pharmaceutical product lactulose crystals sold under the
Kristalose® trademark or any other trademark agreed by the parties, containing the
Label and packaged for sale in 10-gram and 20-gram pouches and all other strengths and dosage
forms. |
|
1.25 |
|
Product Drug Master File shall mean all confidential reference files submitted to the
FDA or other applicable Competent Authorities in the Territory for use in the review of the
ANDA or in connection with obtaining or maintaining Regulatory Approval for the Product in the
Territory. |
|
1.26 |
|
Product Payments shall have the meaning set forth in Section 4.3. |
|
1.27 |
|
Product Specifications means the specifications contained in Exhibit D or any
later approved specification of the Products by the Competent Authority in the Territory which
may also include specifications for packaging material, labeling and product information. |
|
1.28 |
|
Regulatory Approval(s) shall mean all approvals, licenses, registrations, or
authorizations |
4
|
|
of any Competent Authority necessary for the manufacturing, marketing, distribution and/or
sale of the Product in the Territory. |
|
1.29 |
|
Royalty Payment shall have the meaning set forth in Section 4.2. |
|
1.30 |
|
Subcontractor shall mean a Third Person to whom either party hereto has delegated
responsibilities under this Agreement. |
|
1.31 |
|
Subsidiaries shall mean any and all existing and future subsidiaries of Inalco S.p.A.
and/or Inalco Biochemicals, Inc. and their Affiliates, or of Cumberland Pharmaceuticals Inc.
and its Affiliates. |
|
1.32 |
|
Term shall mean the term of this Agreement, as set forth in Section 3.1. |
|
1.33 |
|
Territory shall mean the U.S., subject to potential modifications pursuant to Section
4.2, Exhibit A, and the following understandings: |
|
(a) |
|
As of the Effective Date of this Agreement, INALCO does not have Regulatory
Approval for the Product in Canada. |
|
|
(b) |
|
INALCO cannot guarantee that Regulatory Approval will be granted for the
Product in Canada. |
|
|
(c) |
|
CUMBERLAND and INALCO agree to cooperate reasonably to determine the
feasibility of and develop a strategy for registering and commercializing the Product
in Canada. Upon mutual agreement between INALCO and CUMBERLAND that commercialization
of the Product in Canada is justified, INALCO will act in good faith in order to obtain
the Regulatory Approvals required to register the Product in Canada, and at such time
as the Regulatory Approvals are obtained, the Territory shall be deemed to include
Canada. |
|
|
(d) |
|
In the event that Regulatory Approval in Canada is granted and CUMBERLAND is
not actively marketing and distributing the Product in Canada (as evidenced by its
distribution of the Product in such country or by entering into an agreement with a
Subcontractor to market and distribute the Product) within two (2) years of the date of
issuance of Regulatory Approval for the Product in Canada, then INALCO has the right to
remove Canada from the defined Territory upon ninety (90) days written notice to
CUMBERLAND. |
1.34 |
|
Third Person shall mean any Person other than one of the parties hereto or an
Affiliate or Subsidiary of one of the parties hereto. |
|
1.35 |
|
Trademarks shall mean all trademarks, trademark applications and registrations, trade
names, trade dresses, service logos and other designations of origin owned by INALCO or its
Affiliates or Subsidiaries pursuant to Section 6 and used on or in connection with the
Product, whether registered or not, including without limitation,
Kristalose®. |
|
1.36 |
|
U.S. shall mean the United States of America and each of its territories and
possessions. |
5
1.37 |
|
Valid Claim shall mean, with respect to the Patent Rights; (i) a claim of an issued
and unexpired patent that has not been revoked or held unenforceable or invalid by a decision
of a court or other Governmental Body of competent jurisdiction, unappealable or unappealed
within the time allowed for appeal, and which has not been disclaimed, denied or admitted to
be invalid or unenforceable through reissue, disclaimer or otherwise; or (ii) a claim included
in a pending patent application that is actively prosecuted and which has not been cancelled,
withdrawn, finally determined to be unallowable by the applicable Governmental Body pursuant
to an unappealable decision and/or abandoned in accordance with the terms hereof. |
|
1.38 |
|
Year shall mean the twelve (12) month period commencing on the first date that INALCO
delivers an order of Product to CUMBERLAND pursuant to this Agreement, and each twelve month
period beginning on the anniversary thereof. |
2. REGULATORY APPROVAL, MARKETING AND DISTRIBUTION
2.1 |
|
Regulatory Approval. INALCO shall, at INALCOs expense, secure with the least
possible delay, and maintain Regulatory Approval for the Product from all relevant Competent
Authorities in the Territory, and fulfill any reasonable additional requirements for approval
from the Competent Authorities in the Territory. All registrations and approvals obtained
shall be the sole and exclusive property of INALCO. INALCO agrees to provide additional
information in its possession or control to support CUMBERLAND in answering or attending to
any queries or requests of the Competent Authorities in relation to the Product. |
|
2.2 |
|
Know-How. INALCO hereby grants to CUMBERLAND, and CUMBERLAND hereby accepts, an
exclusive license to use the Know-How to the extent reasonably required by CUMBERLAND in
order to market, distribute, advertise, promote and sell the Product in the Territory in
accordance with and subject to the terms and conditions set forth herein. |
|
2.3 |
|
Trademarks. INALCO is negotiating the acquisition of the Kristalose Trademark from
Mylan Laboratories Inc. and this Agreement is conditional upon the successful acquisition of
the Kristalose Trademark. INALCO hereby grants to CUMBERLAND, and CUMBERLAND hereby accepts,
an exclusive license to use the Trademarks on the Product and in connection with the
marketing, advertisement, promotion, distribution and sale of the Product in the Territory
during the Term. In order to have authority to grant such license to CUMBERLAND, INALCO
agrees to obtain all rights to the Trademarks from Mylan Pharmaceuticals, Inc., prior to the
Effective Date hereof. |
|
2.4 |
|
Patent Rights. INALCO hereby grants to CUMBERLAND, and CUMBERLAND hereby accepts, an
exclusive license to the Patent Rights for purposes of marketing, distribution, and sale of
the Product in the Territory during the Term. |
|
2.5 |
|
Certain Responsibilities of INALCO. |
6
|
A. |
|
Transition Plan. Prior to the Effective Date, INALCO will submit to
CUMBERLAND for consideration a transition plan for Mylan Pharmaceuticals Inc. (Mylan)
to transfer commercial responsibilities for the Product to CUMBERLAND, which plan will
include accurate and complete customer lists, customer data, customer contracts, and
market, financial and other information relating to the Product, as well as provisions
for transitioning Product inventory, Product returns and chargebacks processing,
government reporting, and regulatory reporting. The transition plan will also include
Mylans commitment to processing and payment of rebates, returns and chargebacks for
Product sold by Mylan. The transition plan shall also include Mylans commitment to
provide information necessary to comply with the CMS Medicaid Drug Rebate Program
Release Number 48, which requires that a termination date be supplied equal to the shelf
life of the last lot sold under the old NDC number, as well as pricing data extending
four (4) Calendar Quarters beyond the shelf life. The transition plan shall be finalized
after INALCO and CUMBERLAND agree to any amendments thereto, and in any event, the
parties hereto agree to finalize the transition plan on or before the thirtieth
(30th) day after the Effective Date. The transition plan shall be attached
hereto as Exhibit C when it is completed and shall be a part of this Agreement
effective as of the date thereof. INALCO shall complete all of its responsibilities
under the transition plan. At all times until such transition plan has been completed,
INALCO shall make best efforts to resolve any outstanding items in the transition plan
as promptly as possible. |
|
|
B. |
|
Exclusive Appointment. INALCO hereby appoints CUMBERLAND as exclusive
(even as to INALCO) distributor, marketer, advertiser, promoter, and seller of the
Product in the Territory during the Term. INALCO will not without
CUMBERLANDs prior written approval, itself promote, sell or distribute, nor
appoint nor allow any third party to promote, sell or distribute in the Territory any
presentation of the Product nor any product which competes with the Product; provided
that INALCO may make sales in the Territory of its liquid lactulose products in
existence as of the date hereof. INALCO will ensure that its Affiliates and licensees do
not supply the Products to any other party which it knows, or has reasonable grounds for
suspecting, will store, promote, sell or distribute the Products in or to the Territory. |
|
|
C. |
|
Maintenance of Patent Rights and Trademark. INALCO shall diligently
prosecute and maintain Patent Rights and the Trademarks at its own expense throughout
the Territory in accordance with Article 6. |
|
|
D. |
|
Supply of the Product. INALCO shall manufacture, package or have
packaged, and supply the Product to CUMBERLAND for resale during the Term. Except as
otherwise set forth in the transition plan pursuant to Section 2.5(A) for the first
one-hundred-twenty (120) days of the Term, INALCO shall manufacture, label, store, and
ship the Product with existing packaging from Mylan. At the end of one hundred twenty
(120) days or sooner pursuant to the written agreement of both parties hereto, INALCO
shall manufacture, label, store, and ship the Product with packaging designed by
CUMBERLAND. INALCO shall deliver the Product to CUMBERLAND in finished packages that
shall include the CUMBERLAND NDC number and logo. |
|
|
E. |
|
Provide Promotional Pouches. INALCO shall provide up to 1,000,000
promotional pouches of Product to CUMBERLAND per Year upon request at a price per pouch
as |
7
|
|
|
set forth in Section 4.3 for Promotional Unit Payments. In the event that CUMBERLAND
identifies the need for additional promotional pouches in any given Year, the parties
agree to negotiate in good faith regarding the price and delivery of such additional
pouches. |
|
|
F. |
|
Product Specifications. INALCO shall manufacture all Product in
compliance with (i) the Product DMF as submitted to the FDA, (ii) the FDAs Good
Manufacturing Practices, as promulgated under the U.S. Food, Drug and Cosmetic Act, as
amended, (iii) the Abbreviated New Drug Application for the Product, (iv) the Patent
Rights, and (v) all other applicable Laws, requirements and regulations of the FDA or
other applicable Competent Authorities. In no event will INALCO implement any alteration
(that requires approval of the Competent Authority) to the materials or processes
described in the Drug Master File in relation to any of the Products supplied to
CUMBERLAND under this Agreement until INALCO has provided reasonable prior written
notice of such alteration to CUMBERLAND and the Competent Authority in the Territory has
approved all requisite amendments to the applicable Regulatory Approval. INALCO will not
change the Product Specifications during the Term without CUMBERLANDs prior written
consent. INALCO shall provide for or arrange on-site inspections of each of the
facilities related to manufacturing or packaging the Product at least one time per year
by authorized representatives of CUMBERLAND at any time during regular business hours
and shall provide all reasonably requested information to confirm that the Product is
manufactured and packaged in accordance with the Specifications. |
|
|
G. |
|
Fulfillment of Regulatory Requirements. INALCO shall maintain all
Regulatory Approvals for the Product required to enable the Product to be sold in the
Territory at its own expense. INALCO shall maintain and fulfill all applicable
regulatory requirements with respect to the Product, including reporting and
pharmacovigilance in the Territory, and shall fully cooperate with CUMBERLAND to fulfill
and meet all requirements imposed by applicable law. INALCO shall inform CUMBERLAND of
any governmental submissions relating to the Product. |
|
|
H. |
|
Adverse Events. INALCO shall promptly notify CUMBERLAND of any event that
materially affects or could materially affect the marketing of the Product. With respect
to adverse events, the parties hereto shall report such events to Competent Authorities
per Exhibit E, Adverse Event Reporting. |
|
|
I. |
|
Additional Markets. At any time during the Term, CUMBERLAND may notify
INALCO of its interest in distributing the Product in a country outside of the Territory
for which INALCO does not, as of the date of such notice, already have a distribution
arrangement in effect or pending, as evidenced by a fully executed letter of intent. For
up to ninety (90) days after providing such notice, the parties hereto shall negotiate
in good faith toward developing an agreement for marketing and distribution rights for
the Product in the relevant country(ies). |
|
|
J. |
|
Delivery of Product. INALCO shall deliver Product to Cumberland in a
timely manner and in compliance with specifications for the Product and its packaging in
accordance with Section 2.11, et seq. |
8
2.6 |
|
Certain Responsibilities of CUMBERLAND. |
|
A. |
|
Marketing Plans. Within sixty (60) days after the Effective Date,
CUMBERLAND shall provide INALCO with a summary of marketing plans for the Product in
the Territory, including five (5) year sales forecasts. CUMBERLAND shall provide
updated marketing plans thereafter on an annual basis. |
|
|
B. |
|
Package Design. Except as otherwise set forth in Section 2.5(D),
CUMBERLAND, at its expense, shall design all labeling and exterior packaging to be
used on the Product. CUMBERLAND shall provide such package designs to INALCO within
thirty (30) days of the Effective Date. In the event of a change in the package design
for the Product, CUMBERLAND shall notify INALCO of the package design at least one
hundred fifty (150) days prior to its required use thereof. All labeling and packaging
designs for the Product must be in compliance with the rules and regulations of all
Competent Authorities. CUMBERLAND shall not implement any changes in labeling and
packaging for the Product unless CUMBERLAND has INALCOs prior written consent, not to
be unreasonably withheld or delayed. INALCO and CUMBERLAND agree to work together to
minimize cost increases related to packaging design changes. |
|
|
C. |
|
Purchase Orders. CUMBERLAND shall submit to INALCO a purchase order
setting forth the quantity of Product ordered, Delivery Date, destination, and any
other delivery instructions at least ninety (90) days in advance of its requested
Delivery Date for such purchase order. INALCO will respond to CUMBERLAND promptly
after receipt of any purchase order, and each such response shall (i) accept the
Delivery Date or (ii) reject the Delivery Date and propose an alternative Delivery
Date. When such a purchase order for Product is accepted in writing or by facsimile,
it shall become binding upon INALCO and CUMBERLAND, and shall not be changed or
cancelled by CUMBERLAND without written approval of INALCO. Such approval shall not be
unreasonably withheld or delayed. |
|
|
D. |
|
Rolling Forecasts. Within thirty (30) days after the Effective Date,
and every thirty (30) days thereafter, CUMBERLAND shall complete and provide INALCO a
twelve (12) month rolling forecast of its projected monthly purchases of the Product
and shall adjust them thereafter on a monthly basis. |
|
|
E. |
|
Minimum Purchases. CUMBERLAND agrees to meet Minimum Purchases
annually in accordance with Exhibit A. |
|
|
F. |
|
Sales Reports. Within thirty (30) days after each month in which
CUMBERLAND sells any Product to a third party, CUMBERLAND shall prepare and provide
INALCO with a monthly sales report for the Product. |
|
|
G. |
|
Compliance. CUMBERLAND shall market, distribute, and sell the Product
in the Territory in accordance with applicable Laws. |
9
|
H. |
|
Adverse Drug Experiences. CUMBERLAND shall provide reasonable
cooperation and assistance to INALCO in the investigation of complaints and adverse
events with respect to the Product (see Exhibit E). Each party will bear its
own expenses associated with its duties set forth in Exhibit E. |
|
|
I. |
|
Interaction with DDMAC. CUMBERLAND shall be responsible for
interacting with the FDA Division of Drug Marketing, Advertising and Communication
regarding the Product. |
|
|
J. |
|
Formulary Listings. CUMBERLAND shall be responsible for filing and
maintaining Listings to obtain formulary listing approval from states or localities in
the Territory. |
|
|
K. |
|
Rebate and Managed Care Programs. CUMBERLAND shall have administrative
responsibility for the Product in any rebate and managed care programs through which
the Product is made available in the Territory. |
|
|
L. |
|
Product Returns. CUMBERLAND shall be responsible for administering
returns, discounts, and chargebacks involving third-party purchasers of the Product
during the Term in the Territory. |
|
|
M. |
|
Non-Compete Obligation. CUMBERLAND will not without INALCOs prior
written approval, itself promote, sell or distribute in the Territory during the Term
hereof, any laxative product which competes with the Product. |
|
|
N. |
|
Inspections. CUMBERLAND shall provide for or arrange on-site
inspections of all facilities related to the storage and distribution of the Product
at least one time per year by authorized representatives of INALCO at any time during
regular business hours and shall provide all reasonably requested information to
confirm that the Product is stored, handled, and distributed in accordance with all
applicable rules and regulations of Competent Authorities. |
2.7 |
|
Certain Responsibilities of Both Parties. |
|
A. |
|
Insurance. Beginning on the Effective Date, both CUMBERLAND and INALCO
shall have in place, and shall maintain during the Term and until the third
anniversary of the expiration or earlier termination of this Agreement, comprehensive
product liability insurance in amounts not less than $5,000,000 U.S. per incident and
$5,000,000 U.S. annual aggregate. The minimum amounts of insurance coverage required
shall not be construed to create or limit CUMBERLANDs or INALCOs liability with
respect to its indemnification under this Agreement. Both INALCO and CUMBERLAND shall
provide evidence of insurance to one another on or within thirty (30) days after the
Effective Date and each anniversary date thereof. |
|
|
B. |
|
Publicity. Either party may issue a press release or other public
announcement relating to the existence or terms of this Agreement, subject to the
prior review and written approval of the other party, which approval shall not be
unreasonably withheld or delayed; except where required by Law, in which event the
parties |
10
|
|
|
will use all reasonable efforts to consult with each other and cooperate with
respect to the wording of any such announcement. The parties shall cooperate in
issuing (an) initial public release(s) with respect to the signing of this
Agreement, either separately or as a joint release. |
|
|
C. |
|
Recalls: |
|
(i) |
|
If either party determines that any quantity of the Product
should be recalled for any reason, that party will give to the other party
written notice of its intention to recall that quantity and specify its
reasons. |
|
|
(ii) |
|
If within three (3) days of the receipt of the notice the
parties are unable to agree upon the need to carry out the recall, the parties
agree to submit a sample of the Product to an Independent Analyst for a
report. |
|
|
(iii) |
|
The costs of the report of the Independent Analyst and of the
recall will be paid by the party against which the report is unfavourable. |
|
|
(iv) |
|
Notwithstanding paragraphs (i) to (iii), CUMBERLAND will
administer any such recall in the Territory. |
|
|
(v) |
|
Any Product recall initiated by a Competent Authority due to
the negligence or breach of warranty by a party hereto shall be the
responsibility of such party at its sole cost. |
|
|
(vi) |
|
Each of CUMBERLAND and INALCO agrees to comply with the
obligations set forth in Exhibit E with respect to any adverse drug
event (as defined therein) or any similar event described in Exhibit E
for the Product. |
|
|
(vii) |
|
If a recall results from a cause other than 2.7C (v), then
INALCO and CUMBERLAND will share equally all out-of-pocket costs to administer
the recall. |
2.8 |
|
Subcontractors. CUMBERLAND may make such arrangements with Subsidiaries, Affiliates
or Third Persons as it, in its reasonable judgment, believes is necessary to assure the
diligent and adequate registration, approval, release testing (if applicable), distribution
and sale of the Product in the Territory. Any such Third Persons or Affiliates or
Subsidiaries engaged by CUMBERLAND shall be referred to as Subcontractors. |
|
2.9 |
|
Delivery: |
|
A. |
|
Prior to shipping, INALCO will submit to CUMBERLAND appropriate shipment
notification documents for signature and approval to ship. These documents shall
include CUMBERLANDs Approval to Ship form, packing slip, Certificate of Analysis, and
any required FDA shipment notification. |
11
|
B. |
|
Following receipt of CUMBERLAND approval to ship, INALCO will deliver the
Products to CUMBERLAND F.O.B. the facility of INALCOs packager, which facility shall
be located in the U.S. or Canada unless otherwise agreed in writing by INALCO and
CUMBERLAND, to such location in the Territory as is designated by CUMBERLAND in the
applicable purchase order. |
|
|
C. |
|
All risk of loss or of damage to, and title to the Product, will pass to
CUMBERLAND upon delivery of the Products to the, freight company specified by
CUMBERLAND in the purchase order in accordance with the terms of Article 2 of this
Agreement. |
|
|
D. |
|
CUMBERLAND shall be responsible for all costs of transportation from the
facility of INALCOs packager to the location in the Territory as designated by
CUMBERLAND in the applicable purchase order, except that INALCO shall be responsible
for any costs associated with Customs Clearance at an international border (including
but not limited to brokers fees, import duties, taxes, permits, and licenses). |
2.10 |
|
Acceptance of the Products: |
|
A. |
|
INALCO will supply a Certificate of Analysis with each delivery of the
Products. |
|
|
B. |
|
If CUMBERLAND does not notify INALCO in accordance with the following
paragraph, then CUMBERLAND will, for the purposes of this Section 2.10 only, be deemed
to have accepted the Products upon the expiration of the thirty (30) day period
referred to in that paragraph. |
|
|
C. |
|
If CUMBERLAND notifies INALCO within thirty (30) days of the receipt of any
shipment of the Product that CUMBERLAND believes any of the Product does not conform
to the warranty set out in Section 2.11 (Defective Product) the parties agree to
consult with each other in order to resolve the issue (during which time INALCO may
conduct its own retention sample testing). If such consultation does not resolve the
discrepancy within a further thirty (30) days from receipt of the notice, the parties
agree to nominate an Independent Analyst within the Territory, acceptable to both
parties, that will carry out tests on representative samples taken from such shipment,
and the results of such tests will be binding on the parties. |
|
|
D. |
|
If the Independent Analyst determines that the Defective Product does not
conform to the warranty set out in Section 2.11: |
|
(i) |
|
INALCO will, at its expense, replace any such Defective Product
and reimburse CUMBERLAND for the costs of the Independent Analyst; and |
|
|
(ii) |
|
all quantities of Defective Product will, at INALCOs election and
expense be either: |
|
a. |
|
returned to INALCO, and packed and shipped
according to |
12
|
|
|
instructions provided by INALCO; or |
|
|
b. |
|
destroyed by CUMBERLAND under INALCOs direction. |
|
E. |
|
If the Independent Analyst determines that the Defective Product does conform
to the warranty set out in Section 2.11, CUMBERLAND will for the purposes of Section
2:10 only, be deemed to have accepted the Product and will reimburse INALCO for the
costs of the Independent Analyst. |
|
|
F. |
|
Replacement of Defective Product is in addition to any other obligations,
indemnities or warranties given by INALCO under this Agreement. |
|
A. |
|
INALCO represents and warrants that: |
|
(i) |
|
any Product supplied under this Agreement will, upon delivery
to CUMBERLAND, have a shelf life of at least two (2) years nine (9) months; |
|
|
(ii) |
|
any Product supplied under this Agreement will upon delivery: |
|
a. |
|
conform in all respects to the Product
Specifications and to any applicable Regulatory Approval in the
Territory; |
|
|
b. |
|
be manufactured, identically labelled and
identically packaged for the Territory and tested in accordance with
applicable laws and regulations in the Territory relating to the
manufacture, labelling, packaging and testing of the Product, subject
to any alterations required by law or applicable regulations; and |
|
|
c. |
|
will not be adulterated or misbranded in
contravention of applicable Law; |
|
(iii) |
|
it will, at its expense, apply for, prosecute, maintain,
defend and enforce the Trademarks, the Patent Rights, and any Intellectual
Property Rights concerning the Product which are owned by or licensed to it to
the maximum extent commercially feasible and will also apply for any
appropriate extension of term for any patents covering the Product in
accordance with the laws and regulations in the Territory. |
|
(i) |
|
Any quantities of the Product that do not conform with Section
2.11(A) or that contravene applicable Law, regulations, or Regulatory approvals
will, for the purposes of this Agreement, be deemed to have a defect. |
|
|
(ii) |
|
If either party becomes aware of any defect in the Product, it
will immediately notify the other party and provide it with a full disclosure
of
that defect. |
13
|
(iii) |
|
Where any defect in the Product arises either partially or
wholly as a result of a defect in raw material supplied to INALCO by a third
party, INALCO will make best efforts to ensure that the third party conforms to
any demands of the Competent Authority concerning the defect. |
|
|
(iv) |
|
Except as otherwise set forth in this Agreement,
INALCOs remedy for breach of warranty pertaining to the Product
provided hereunder shall be limited solely to replacement of such Product. |
|
C. |
|
UNLESS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY SHALL BE
LIABLE FOR INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, IRRESPECTIVE OF WHETHER
ATTRIBUTABLE TO CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE. |
3. TERM AND TERMINATION
|
A. |
|
Condition for Commencement of Term. Notwithstanding any other provision
hereof, the commencement of the Term is subject to the satisfaction as of the Effective
Date of the following conditions: (i) the termination of any letter agreements
currently in effect between Mylan Bertek Pharmaceuticals Inc. (f/k/a Bertek
Pharmaceuticals Inc.) (Mylan Bertek) and CUMBERLAND (the Letter Agreements), and
(ii) the full and final mutual release of Mylan Bertek and Mylan by CUMBERLAND and of
CUMBERLAND by Mylan Bertek and Mylan for any and all obligations and/or liabilities in
connection with the Co-Promotion Agreement between CUMBERLAND and Mylan Bertek dated
January 4, 2002, as amended (the Co-Promotion Agreement), and the Letter Agreements;
provided that the sections listed as surviving provisions in Section 11.6 of the
Co-Promotion Agreement survive the termination and release set forth hereinabove. |
|
|
B. |
|
Duration. This Agreement shall commence on the Effective Date and will
continue until the fifteenth (15h) anniversary thereof. Thereafter, subject
to Section 3.2 hereof, the Agreement will automatically renew for successive terms of
three (3) years unless either party gives written notice of its intention not to renew
this Agreement to the other party at least twelve (12) months prior to the expiration
of the period. |
3.2 |
|
Termination. This Agreement may be terminated prior to expiration of the Term under
the following circumstances: |
|
A. |
|
Material Breach. In the event that one party commits a material breach
of this Agreement, the non-breaching party may, at its option, terminate this Agreement
by giving the breaching party written notice pursuant to Section 8.2 of its election |
14
|
|
|
to terminate as of a stated date, but not less than forty-five (45) days from the
date of the notice. Such notice shall state the nature of the breach claimed by the
non-breaching party. The breaching party, during said forty-five (45) day period or
such longer period as may be indicated by the other, may correct any breach stated
in said notice and if such breach is corrected, this Agreement shall continue in
full force and effect as if such notice had not been given. If the breaching party
does not cure the breach to the reasonable satisfaction of the notifying party
within said forty-five (45) day period, or such longer period indicated by the
non-breaching party, then the notifying party may terminate this Agreement. For
purposes hereof, material breach shall mean failure by CUMBERLAND to comply with
any of its obligations under Sections 2.6(G), 2.6(M), 4.1, 4.2, or 4.3 hereunder or
failure by INALCO to comply with any of its obligations under Section 2.5(B),(C),
(D), (F), and (G). |
|
|
B. |
|
Anniversary. If CUMBERLAND gives INALCO written notice at least ninety
(90) days prior to the fourth anniversary of the Effective Date or any subsequent such
anniversary during the Term, CUMBERLAND may terminate the Agreement on the day
immediately preceding such anniversary date without any further liability except as
expressly set forth herein. Notwithstanding the foregoing, in no event shall
termination under this Section 3.2.B. terminate or modify CUMBERLANDs obligations to
make the payments set forth in Section 4.1. |
3.3 |
|
Effect of Expiration or Termination. Upon expiration or termination of this
Agreement, |
|
A. |
|
CUMBERLAND shall cease the sale of all Product for the Territory; provided,
however, that CUMBERLAND may continue to store, promote, sell and distribute its stock
on hand and fill all orders accepted by it prior to the expiration or termination of
the Agreement. INALCO will fill all orders accepted by INALCO hereunder prior to
expiration or termination of the Agreement. All applicable provisions of this
Agreement shall survive termination for such purpose; and |
|
|
B. |
|
all rights, title and interest in and to the Product and the Intellectual
Property Rights in the Product and the Know-How and the Patent Rights and the
Trademarks that INALCO owned prior to this Agreement shall revert to INALCO. |
3.4 |
|
Remedies Not Limited. Except as otherwise provided herein, the termination of this
Agreement by either party shall not limit remedies that may be otherwise available, including
without limitation, injunctive relief. |
|
3.5 |
|
Survival. Expiration or termination of this Agreement for any reason shall not
relieve either party of its obligations that have accrued prior to the expiration or
termination of this Agreement. Without limiting the generality of the foregoing, Sections
2.11, 5.1, 5.2, and 5.3 and Article 3 of this Agreement shall survive expiration or
termination of this Agreement. |
15
3.6 |
|
Expectation of Profits. Except as otherwise provided herein, both parties
acknowledge and agree that they have no expectations and have received no assurances that any
investment by them in the development, marketing or distribution of the Product will be
recovered or recouped, or that they shall obtain any anticipated amount of profit by virtue
of this Agreement. |
|
3.7 |
|
Option Regarding Transfer. CUMBERLAND shall have the first opportunity to negotiate
to acquire all rights to the Product in the Territory. Each party hereto shall negotiate in
good faith if the parties undertake discussions regarding such option. INALCO agrees not to
transfer any rights to the Product in the Territory unless INALCO first notifies CUMBERLAND
of the opportunity hereunder and unless INALCO negotiates in good faith with CUMBERLAND for
sixty (60) days after providing such notice in an attempt to enter into a written agreement
with respect to the rights that are being negotiated. |
4. PAYMENTS
4.1 |
|
Payments. Subject to the terms and conditions contained in this Agreement, in
consideration for rights granted to CUMBERLAND hereunder, CUMBERLAND shall pay Eleven Million
Dollars to INALCO in the following installments: |
|
A. |
|
First Installment. [***], payable upon the Effective Date of this
Agreement; |
|
|
B. |
|
Second Installment. [***], payable upon the first anniversary of the
Effective Date of this Agreement; and |
|
|
C. |
|
Third Installment. [***], payable upon the third anniversary of the
Effective Date of this Agreement. |
4.2 |
|
Royalty Payment. In further consideration of the rights granted to CUMBERLAND
hereunder, CUMBERLAND shall pay INALCO an amount equal to the following percentage of Net
Sales during the preceding [***] (each such payment shall hereinafter be referred to as a
Royalty Payment), within [***] of the end of each [***]: |
|
A. |
|
[***] during first Year of the Term; |
|
|
B. |
|
[***] during each of the second, third, and fourth Years of the Term; and |
|
|
C. |
|
[***] for each Year thereafter during the Term; |
|
|
provided that the accrual of any obligation to make Royalty Payments shall cease immediately
with respect to Net Sales in a country within the Territory if a generic equivalent to the
Product receives Regulatory Approval, and is commercially available in such country. |
|
4.3 |
|
Payment for Product. Subject to Section 2.10, CUMBERLAND shall pay INALCO, |
16
|
|
within [***] of receipt of Product under Section 2.5(D) during the first year of the Term,
and within [***] of receipt of Product thereafter, (a) an amount equal to [***] 10-gram
pouch and [***] per 20-gram pouch for each unit of Product supplied pursuant to purchase
orders submitted in accordance with Section 2.6(C) (Product Payments), and (b) an amount
equal to [***] per pouch for each 10-gram pouch and [***] per pouch for each 20-gram pouch
of Product pursuant to requests for promotional units submitted in accordance with Section
2.5(E) (Promotional Unit Payments). |
|
|
|
[***] |
|
|
|
Promotional Unit Prices are based upon a packaging configuration and cost that is
equivalent to the existing 30-count Commercial and/or 7-count Sample. If a new Sample
package configuration is required, then INALCO has the right to adjust the per pouch
price to reflect any increased direct costs incurred with such reconfiguration. Promotional
Units will be ordered under a unique Purchase Order Number, and such orders are subject to
the terms of Paragraph 2.6C. |
|
4.4 |
|
Payment Currency. All payments under Article 4 hereof shall be made in [***]. |
|
4.5 |
|
Records. CUMBERLAND shall maintain complete and accurate records sufficient to
enable accurate calculation of Royalty Payments due to INALCO under this Agreement.
CUMBERLAND shall, at INALCOs request and expense, provide certified statements from
CUMBERLANDs auditors, concerning Royalty Payments due pursuant to this Agreement. Once a
calendar year, INALCO shall have the right to request that a certified public accountant, the
selection of whom shall be subject to CUMBERLANDs prior written consent, not to be
unreasonably withheld or delayed, inspect, on reasonable notice and during regular business
hours, the records of CUMBERLAND to verify INALCOs statements and payments of Royalty
Payments due pursuant to this Agreement. The entire cost for such inspection shall be borne
by INALCO, unless there is a discrepancy of greater than 5% in INALCOs favor, in which case
CUMBERLAND shall bear the entire cost of the inspection. Records shall be preserved by
CUMBERLAND for three (3) years after preparation thereof for inspection by INALCO. |
|
4.6 |
|
Acquisition. In the event that INALCO or CUMBERLAND is acquired by a Third Person or
in any other way transfers all of its assets, including this Agreement to a Third Person, all
obligations of this Agreement, including the foregoing Royalty Payment terms, shall be binding
upon the party acquiring this Agreement. |
|
4.7 |
|
Manner of Payment. All payments hereunder shall be made by bank wire transfer of
immediately available funds to the account of INALCO or such other reasonable method as INALCO
may request. Each party hereto shall be responsible for and pay all fees and other charges
imposed by its own bank in connection with any such bank wire transfer. Where required to do
so by Law, CUMBERLAND shall withhold taxes required to be paid to a taxing authority on
account of such income to INALCO, and CUMBERLAND shall furnish INALCO with satisfactory
evidence of such withholding and payment in order to permit INALCO to obtain a tax credit or
other relief as may be available under the Law. |
17
5. CONFIDENTIALITY
5.1 |
|
Protection of Confidential Information. The parties recognize that during the Term,
it may be necessary that one party and/or its Affiliates or Subsidiaries hereto be given
access to certain Confidential Information (as defined herein) of the other party and/or its
Affiliates or Subsidiaries hereto. Each party must ensure that the following Subsections shall
be applicable to such Confidential Information and the words Recipient and Disclosing
Party shall be interchangeable as between each of the parties and/or their Affiliates or
Subsidiaries hereto as appropriate under the circumstances: |
|
A. |
|
Title to Confidential Information and Related Documents. Recipient
hereby acknowledges that the Confidential Information and all, including without
limitation, related documents, drawings, designs, products, or samples disclosed or
furnished hereunder by or on behalf of the Recipient are the sole and exclusive
property of Disclosing Party. Recipient hereby agrees to return all such documents,
drawings, designs, products, or samples furnished to it hereunder, together with all
reproductions and copies thereof and shall delete all references thereto stored
electronically promptly under the request of Disclosing Party or upon termination or
expiration of this Agreement, except that the Recipients legal representative may
retain one copy of such of the Confidential Information as required solely for the
purpose of determining the scope of its obligations under this Agreement. |
|
|
B. |
|
Nondisclosure or Use of Confidential Information. Recipient hereby
agrees that it shall hold all Confidential Information disclosed to it in strict
confidence and in a secure place, that it will use the same only for the purpose of
performing this Agreement and for no other purpose whatsoever, and that it will not
disclose the same to any Third Persons (except to its employees or consultants,
strictly on a need-to-know basis, to the extent such disclosure is permitted by or
consistent with this Agreement and the Third Persons are subject to written obligations
of confidentiality no less onerous than are contained in this Agreement) except to the
extent Disclosing Party agrees to it in writing. |
|
|
C. |
|
Definition of Confidential Information. Confidential Information as
used herein shall include without limitation any and all oral, written, or tangible
proprietary or confidential ideas, inventions, information, data, plans, materials,
trade secrets and know-how and the like owned, controlled or developed by or on behalf
of one party hereto and disclosed to the other party for the purposes of this
Agreement; provided however, that Confidential Information shall not include any
information, discovery, invention, improvement, or innovation which: |
|
(i) |
|
was in the public domain at the time of disclosure to the
Recipient, or which becomes generally available to the public after its
disclosure through no fault of the Recipient or breach of this Agreement; |
18
|
(ii) |
|
is already known to, or in the possession of, the Recipient
prior to disclosure by the Disclosing Party as can be demonstrated by
documentary evidence; |
|
|
(iii) |
|
is lawfully disclosed on a non-confidential basis from a
Third Person having the right to make such a disclosure; or |
|
|
(iv) |
|
is independently developed by the Recipient or its
Subsidiaries as can be demonstrated by documentary evidence. |
5.2 |
|
Unauthorized Use. In case either party becomes aware or has knowledge of any
unauthorized use or disclosure of Confidential Information, it shall promptly notify the
other party of such unauthorized use or disclosure and, thereafter, shall take all reasonable
steps to assist the other party in attempting to minimize any potential or actual damages or
losses resulting from such unauthorized use or disclosure. |
|
5.3 |
|
Permitted Disclosure. Each party may disclose Confidential Information of the other
party to the Competent Authorities or Listing authorities in the Territory where such
disclosure is reasonably necessary in the application, grant, variation, renewal or
maintenance of a Regulatory Approval or Listing. Each party may also disclose Confidential
Information where it is required to do so under any laws or regulations in the Territory,
provided that it gives the other party such notice as is reasonably practicable in the
circumstances and allows the other party, at the other partys cost, a reasonable opportunity
to resist such requirements. |
|
5.4 |
|
Term. The provisions of this Article 5 shall survive the expiration or termination
of the Agreement until all of the Confidential Information has fallen within one of the
exceptions set forth in Sections 5.I(C) (i) through (iv), inclusive. |
6. PROTECTION AND OWNERSHIP OF INTELLECTUAL PROPERTY
6.1 |
|
Registration of Trademarks. INALCO shall be responsible, at its expense, for the
preparation, filing, prosecution and maintenance of the Trademarks in the Territory and for
conducting any interferences, re-examinations, reissues, oppositions, or requests for
extension relating thereto. INALCO shall take all steps necessary to maintain the Trademarks
in the Territory in good standing. INALCO shall not use any alternative trademark in the
Territory on or in connection with the Product. Subject to Section 3.3(A), upon the
termination or expiration of this Agreement or CUMBERLANDs right to use the Trademarks,
CUMBERLAND shall cease using the Trademarks. |
|
6.2 |
|
Patent Filings: Maintenance; Prosecution. INALCO shall be responsible, at its
expense, for the preparation, filing, prosecution and maintenance of the Patent Rights in the
Territory and for conducting any interferences, re-examinations, reissues, oppositions, or
requests for extension relating thereto. INALCO shall take all steps necessary to maintain
the Patent Rights in the Territory in good standing. CUMBERLAND agrees to cooperate
reasonably with INALCO, at INALCOs expense, when requested, on matters relating to the
preparation, filing, prosecution and maintenance of the Patent Rights. |
19
6.3 |
|
Infringement by Third Persons. |
|
A. |
|
In the event that either party determines that a Third Person is making,
using, or selling a product that may infringe the Patent Rights or Trademark, it will
promptly notify the other party in writing. INALCO will, at its own cost and to the
extent commercially feasible, take all legal action it deems necessary or advisable to
eliminate or minimize the consequences of the infringement, but will not without
CUMBERLANDs prior written consent enter into any settlement in relation to such
matters nor take any step in relation to the potential or alleged infringement which
will affect CUMBERLANDs storage, promotion, sale and distribution of the Product in
the Territory or other rights under this Agreement. CUMBERLAND shall take all
reasonable steps to assist INALCO at INALCOs expense. |
|
|
B. |
|
Upon receiving any written request from CUMBERLAND to do so, INALCO will
forthwith disclose to CUMBERLAND all necessary information about the Products, their
formulation, use or process of manufacture, to enable CUMBERLAND to: |
|
(i) |
|
ascertain whether the storage, promotion, sale or other
distribution of the Products in the Territory will infringe any existing
patent or other third party intellectual property rights; and |
|
|
(ii) |
|
determine its conduct in relation to any proceedings alleging
infringement of a patent or other third party intellectual property rights in
the Territory. |
|
C. |
|
INALCO represents and warrants that any information disclosed to CUMBERLAND
under paragraph (B) above will be a full and accurate disclosure and that INALCO will
not withhold any information in its possession which might have a material adverse
impact on CUMBERLAND. |
|
|
D. |
|
If INALCO does not take any action to eliminate or minimize the consequences
of any such infringement within ninety (90) days of becoming aware of that
infringement, CUMBERLAND may take any reasonable action to prosecute such
infringement; provided that CUMBERLAND shall not retain legal counsel to prosecute any
such infringement without INALCOs prior written consent, not to be unreasonably
withheld or delayed. In the event that legal counsel is so retained, INALCO shall
reimburse CUMBERLAND for such counsels reasonable fees and expenses directly related
to the prosecution of such infringement. |
|
|
E. |
|
Each party will cooperate fully and promptly with, and provide all reasonable
assistance to, the other party in respect of any action brought by the other party
under this Agreement in relation to alleged infringement of intellectual property
rights in connection with this Agreement and will be entitled to be promptly
reimbursed for all costs and expenses incurred in connection with such co-
operation and assistance. |
20
7. REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION
7.1 |
|
Representations and Warranties of CUMBERLAND. CUMBERLAND represents and warrants
that: |
|
A. |
|
it is a corporation duly organized and validly existing under the laws of
Tennessee; |
|
|
B. |
|
the execution and delivery by CUMBERLAND of this Agreement, the performance by
CUMBERLAND of all the terms and conditions thereof to be performed by it and the
consummation of the transactions contemplated hereby have been duly authorized by all
necessary action, and no other act or approval of any person or entity is required to
authorize such execution, delivery, and performance; |
|
|
C. |
|
the Agreement constitutes a valid and binding obligation of CUMBERLAND,
enforceable in accordance with its terms; and |
|
|
D. |
|
this Agreement and the execution and delivery thereof by CUMBERLAND, does not,
and the fulfillment and compliance with the terms and conditions hereof and the
consummation of the transactions contemplated hereby will not: |
|
(i) |
|
conflict with any of, or require the consent of any person or
entity under, the terms, conditions, or provisions of the organizational
documents of CUMBERLAND; |
|
|
(ii) |
|
violate any provision of, or require any consent,
authorization, or approval under, any Law applicable to CUMBERLAND; or |
|
|
(iii) |
|
conflict with, result in a breach of, or constitute a default
under, any material agreement or obligation to which CUMBERLAND is a party. |
7.2 |
|
Representations and Warranties of INALCO. INALCO ITALY and INALCO U.S. jointly and
severally represent and warrant that: |
|
A. |
|
INALCO U.S. is a corporation duly organized and validly existing under the
laws of California and INALCO ITALY is a corporation duly organized and validly
existing under the laws of Italy and; |
|
|
B. |
|
the execution and delivery by INALCO of this Agreement, the performance by
INALCO of all the terms and conditions thereof to be performed by it and the
consummation of the transactions contemplated hereby have been duly authorized by all
necessary action, and no other act or approval of any person or entity is required to
authorize such execution, delivery, and performance; |
21
|
C. |
|
the Agreement constitutes a valid and binding obligation by each of INALCO
ITALY and INALCO U.S., enforceable in accordance with its terms; and |
|
|
D. |
|
this Agreement and the execution and delivery thereof by INALCO, does not, and
the fulfillment and compliance with the terms and conditions hereof and the
consummation of the transactions contemplated hereby will not: |
|
(i) |
|
conflict with any of, or require the consent of any person or
entity under, the terms, conditions, or provisions of the organizational
documents of INALCO; |
|
|
(ii) |
|
violate any provision of, or require any consent,
authorization, or approval under, any Law applicable to INALCO; or |
|
|
(iii) |
|
conflict with, result in a breach of, or constitute a default
under, any material agreement or obligation to which INALCO is a party. |
|
E. |
|
the manufacture, storage, promotion, sale or other distribution of the Product
in the Territory will not infringe any patent (whether in relation to the Products,
their formulation, use or process of manufacture) or infringe upon any other rights of
a Third Person; |
|
|
F. |
|
as of the Effective Date, INALCO has not received any notice of opposition,
interference, or refusal to register in connection with the Patent Rights in the
Territory or elsewhere; |
|
|
G. |
|
as of the Effective Date, INALCO holds, and shall continue to hold for the
duration of the Term, valid rights to the Patent Rights and all other Intellectual
Property Rights relating to the Product and has the full right, power and authority to
grant the rights granted to CUMBERLAND hereunder, free and clear of any mortgage, lien,
encumbrance or other Third Person interest of any kind; |
|
|
H. |
|
INALCO has licensed to CUMBERLAND all Intellectual Property Rights necessary
for CUMBERLAND to perform its obligations under this Agreement; |
|
|
I. |
|
INALCO has not granted to any other Person in the Territory the rights it is
granting to CUMBERLAND hereunder in respect of the Product; |
|
|
J. |
|
INALCO has informed CUMBERLAND about all information in its possession or
control concerning the safety and efficacy of the Product, and any side effects,
injury, toxicity or sensitivity reactions and incidents associated with all uses,
studies, investigations or tests involving the Product (animal or human) throughout the
world; |
|
|
K. |
|
as of the Effective Date of this Agreement, INALCO is not aware of any facts
that would reasonably lead it to conclude that the Product will be unable to maintain
Regulatory Approval in the Territory or that would indicate that future |
22
|
|
|
marketing and sales of the Product in the Territory may be adversely affected in any
material respect; and |
|
|
L. |
|
no representations, warranties or covenants made by INALCO in this Agreement or
in any document, certificate, exhibit, or schedule furnished or to be furnished in
connection with the transactions contemplated hereby, contain or will contain, to the
best of INALCOs knowledge, any untrue statement of fact or omit or will omit to state
any material fact necessary to make the statement of facts contained therein not
misleading to the best of INALCOs knowledge. |
7.3 |
|
Indemnification by CUMBERLAND. Without affecting any other remedies and recourses
available under this Agreement, under law and in equity, CUMBERLAND shall indemnify INALCO
and its Affiliates and Subsidiaries, and their respective directors, officers, and employees,
from and against claims, suits or demands for liability, damages, costs and expenses
(including reasonable attorney fees) arising from or relating to (i) the negligence or
willful misconduct of CUMBERLAND or its Affiliates or its Subsidiaries, or their respective
directors, shareholders, officers or employees in connection with this Agreement, or (ii) any
breach by CUMBERLAND of any of its representations and warranties provided for in Section
7.1; except to the extent that such claims, suits or demands are the result of the fault,
negligence or willful misconduct of INALCO and/or its Affiliates and/or its Subsidiaries, or
their respective directors, shareholders, officers or employees. |
|
7.4 |
|
Indemnification by INALCO. Without affecting any other remedies and recourses
available under this Agreement, under law and in equity, INALCO shall indemnify CUMBERLAND
and its Affiliates and Subsidiaries, and their respective directors, officers, and employees
from and against claims, suits or demands for liability, damages, costs and expenses
(including reasonable attorney fees) arising from or relating to (i) the negligence or
willful misconduct of INALCO or its Affiliates or Subsidiaries, or their respective
directors, shareholders, officers or employees in connection with this Agreement; or (ii) any
breach by INALCO of any of its representations and warranties provided for in Sections
2.5(F), 2.11 and 7.2 hereof ; (iii) the export, storage, promotion, sale or other
distribution of the Product in the Territory (including the packaging of the Product and
associated promotional and like material provided by or on behalf of INALCO, if any) will not
infringe any patent (whether in relation to the Products, their formulation, use or process
of manufacture) or infringe upon any other rights of a Third Person; except to the extent
that such claims, suits or demands are the result of the fault, negligence or willful
misconduct of CUMBERLAND or its directors, shareholders, officers or employees. |
|
7.5 |
|
Indemnification Procedures. A party (the Indemnitee) which intends to claim
indemnification under this Article 7 shall promptly notify the other party (the Indemnitor)
in writing of the claim, suit or demand for liability with respect to which the claim of
indemnification relates. If the Indemnitor wishes to assume the defense it must notify the
Indemnitee within sixty (60) days of receipt of such notice. Legal counsel of the Indemnitor
must be reasonably satisfactory to the Indemnitee. The Indemnitee shall permit, and shall
cause its employees and agents to permit the Indemnitor, at its discretion, to settle any
such claim, suit or demand for liability, the |
23
|
|
defense and settlement of which shall be under the complete control of the Indemnitor;
provided, however, that such settlement shall not adversely affect the Indemnitees rights
hereunder or impose any obligations on the Indemnitee in addition to those set forth herein
in order for it to exercise those rights. No such claim, suit or demand for liability shall
be settled without the prior written consent of the Indemnitee and the Indemnitee shall not
be responsible for any legal fees or other costs incurred other than as provided herein.
The Indemnitee, its employees and agents shall co-operate fully with the Indemnitor and its
legal representatives in the investigation and defense of any claim, suit or demand for
liability covered by this indemnification. The Indemnitee shall have the right, but not the
obligation, to be represented by counsel of its own selection and expense. |
8. GENERAL
8.1 |
|
Provisions Contrary to Law. In performing this Agreement, the parties shall comply
with all applicable Laws. In particular, it is understood and acknowledged that the transfer
of certain commodities and technical data is subject to U.S. Laws controlling the export of
such commodities and technical data, including all Export Administration Regulations of the
United States Department of Commerce. These Laws among other things prohibit or require a
license for the export of certain types of technical data to certain specified countries.
CUMBERLAND hereby agrees to do all things reasonably requested of it by INALCO to comply with
all U.S. Laws controlling the export of commodities and technical data. |
|
|
|
Nothing in this Agreement shall be construed so as to require the violation of any Law, and
wherever there is any conflict between any provision of this Agreement and any Law, the Law
shall prevail, but in such event the affected provision of this Agreement shall be affected
only to the extent necessary to bring it within the applicable Law. |
|
8.2 |
|
Notices. Any notice permitted or required by this Agreement may be sent by facsimile
with the original document being sent by certified (or registered) mail, return receipt
requested, or overnight delivery and shall be effective when received (or refused) via
facsimile or mail or overnight if faxed and sent and addressed as follows (or to such other
facsimile number or address as may be designated by a party in writing): |
|
|
|
If to CUMBERLAND:
|
|
If to INALCO U.S.: |
|
|
|
Cumberland Pharmaceuticals Inc.
|
|
Inalco Biochemicals, Inc. |
2525 West End Ave., Suite 950
|
|
3440 Empresa Drive, Suite A |
Nashville, Tennessee 37203
|
|
San Luis Obispo, CA 93401 |
Fax: 615-255-0094
|
|
Fax: 805-782-0719 |
Attn: Chief Executive Officer
|
|
Attn: Eric A. Lowe |
With a copy to:
24
Adams and Reese/Stokes Bartholomew LLP
424 Church Street, 28th Floor
Nashville, Tennessee 37219
Fax: 615-259-1470
Attn: Martin S. Brown, Esq.
If to INALCO ITALY:
Inalco S.p.A.
Via Calabiana, 18
20139 Milan
ITALY
Fax: 011-39-02-55213277
Attn: Giovanni Cipolletti
Such notice shall be effective upon the earlier of (i) actual receipt by the party to whom notice
is sent, (ii) seven (7) days after deposit into the mail, or (iii) receipt of fax-back confirmation
if notice is sent via facsimile.
8.3 |
|
Force Majeure. Neither party to this Agreement shall be liable for delay or failure
in the performance of any of its obligations hereunder if such delay or failure is due to
causes beyond its reasonable control, including, without limitation, acts of God, fires,
earthquakes, strikes and labor disputes, acts of war, civil unrest, or intervention of any
governmental authority, but any such delay or failure shall be notified to the other party,
and remedied by such party, as soon as is reasonably possible. |
|
8.4 |
|
Assignments. Except as otherwise set forth herein or in connection with the sale of
all or substantially all of the assets or business of either party or as expressly set forth
in this Agreement, rights and obligations under this Agreement may not be assigned by either
party hereto without the prior written consent of the other party hereto, which consent shall
not be unreasonably withheld or delayed; provided, however, that nothing in this Agreement
shall limit CUMBERLANDs right to assign its rights or delegate its obligations under this
Agreement to a lender to CUMBERLAND in the event of a default in its agreement with such
lender. |
|
8.5 |
|
Independent Contractors. The parties hereto agree that each is acting as an
independent contractor and not as an agent of the other or as joint venturers. |
|
8.6 |
|
Waivers and Modifications. The failure of any party to insist on the performance of
any obligation hereunder shall not act as a waiver of such obligation. No waiver,
modification, release, or amendment of any obligation under this Agreement shall be valid or
effective unless in writing and signed by both parties hereto. |
|
8.7 |
|
Successors in Interest. This Agreement shall inure to the benefit of and be binding
on the parties permitted assigns or successors in interest. |
|
8.8 |
|
Severability. In the event that any term or provision of this Agreement shall violate
any applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or |
25
|
|
otherwise be unenforceable, such provision shall be ineffective to the extent of such
violation without invalidating any other provision hereof. |
|
8.9 |
|
Exhibits; Headings. All exhibits attached to and incorporated in this Agreement by
reference are deemed to be a part hereof. The headings used in this Agreement are for
convenience only and are not part of this Agreement. |
|
8.10 |
|
Choice of Law. This Agreement is subject to and shall be construed and enforced in
accordance with the laws of the State of Delaware, United States of America. The Parties
hereby submit to the jurisdiction of the courts of the State of Delaware in respect to all
disputes arising out of or in connection with this Agreement and waive any and all objections
to such venue. |
|
8.11 |
|
Entire Agreement. This Agreement, constitutes the entire agreement between the
parties as to the subject matter hereof, and all prior negotiations, representations,
agreements and understandings are merged into, extinguished by and completely expressed by
this Agreement. |
9. ARBITRATION
Any matter or disagreement arising under this Agreement shall be submitted for decision to a
panel of three neutral arbitrators with expertise in the subject matter to be arbitrated. One
arbitrator shall be selected by each party and the two arbitrators so selected shall select the
third arbitrator. The arbitration shall be conducted in accordance with the Rules of the American
Arbitration Association. The decision and award rendered by the arbitrators shall be final and
binding. Judgment upon the award may be entered in any court having jurisdiction thereof. Any
arbitration shall be held in Wilmington, Delaware, or such other place as may be mutually agreed
upon in writing by the parties.
26
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
officers on the date first written above.
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC.
|
|
|
|
INALCO BIOCHEMICALS, INC.
|
|
|
|
By:
|
|
/s/ A.J. Kazimi
|
|
|
|
By:
|
|
/s/ Eric A. Lowe
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A.J. Kazimi
|
|
|
|
|
|
Eric A. Lowe |
|
|
|
|
Title: Chief Executive Officer
|
|
|
|
|
|
Title: President |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INALCO S.p.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Giovanni Cipolletti |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Giovanni Cipolletti |
|
|
|
|
|
|
|
|
|
|
Title: President |
|
|
27
EXHIBIT A
Minimum Purchases
[***]
United States Patent
Bimbi
|
|
|
|
|
US005480491A |
Patent Number:
|
|
5,480,491 |
Date of Patent:
|
|
Jan. 2, 1996 |
PROCESS FOR THE PREPARATION OF
CRYSTALLINE LACTULOS FROMCOMMERCIAL SYRUPS
|
|
|
Inventor:
|
|
Giuseppe Bimbi, Pontedera, Italy |
|
|
|
Assignee:
|
|
Inalco S.p.A., Milan, Italy |
|
|
|
Appl. No.:
|
|
229,559 |
|
|
|
Filed:
|
|
April 18, 1994 |
Foreign Application Priority Data
|
|
|
|
|
Apr. 28, 1993 [IT] Italy |
|
|
MI93A0833 |
|
Int. Cl6 |
|
|
C13F 1/00; C13F 1/02 |
|
U.S. Cl. |
|
|
127/61;127/46.2;127/55; |
|
|
|
|
127/56; 127/58 |
|
Field of Search |
|
|
127/61; 58, 56, |
|
|
|
|
127/55, 46.2 |
|
References Cited
U.S. PATENT DOCUMENTS
|
|
|
|
|
4,555,271 11/1985 Carobbi et al |
|
|
127/46.2 |
|
4,978,397 12/1990 Carobbi et al |
|
|
127/46.2 |
|
5,034,064 7/1991 Deya et al |
|
|
127/46.2 |
|
5,304,251 4/1994 Tomita et al |
|
|
127/42 |
|
FOREIGN PATENT DOCUMENTS
|
|
|
|
|
|
|
0132509
|
|
2/1985
|
|
European Pat. Off
|
|
C13K 13/00 |
0159521
|
|
10/1985
|
|
European Pat. Off
|
|
CO8F 8/42 |
0158148
|
|
6/1988
|
|
European Pat. Off
|
|
C13K 13/00 |
0284959
|
|
1/1992
|
|
European Pat. Off
|
|
CO8F 8/42 |
0284960
|
|
6/1992
|
|
European Pat. Off
|
|
C08F 8/42 |
OTHER PUBLICATIONS
J. Agric. Chem. 1984, 32, 288-292 Jul./Dec. 1983.
Primary
ExaminerPaul Lieberman Assistant
ExaminerPatricia Halley
Attorney, Agent, or FirmHedman, Gibson & Costigan
ABSTRACT
The following description sets forth a new process for the preparation of .gtoreq.98.5% pure
crystalline lactulose from commercially available aqueous syrups having the following composition:
50-70% by weight of lactulose, 3-9% by weight of lactose, 3-14% by weight of galactose, 4-7% by
weight of other carbohydrates, the total content of carbohydrates different from lactulose being of
from 10% to 30%.
8 Claims, No Drawings
PROCESS FOR THE PREPARATION OF
CRYSTALLINE LACTULOSE FROM
COMMERCIAL SYRUPS
FIELD OF THE INVENTION
The present invention relates to a process for the preparation of high-purity crystalline
lactulose by crystallization of commercially available aqueous syrups.
PRIOR ART
Lactulose,
or 4-0-b-D-galactopyranosyl-D-fructofuranose, is a semisynthetic disaccharide, used
in the form of syrup or of crystalline product on account of its laxative action, efficacy in the
treatment of hepatic dysfunctions, in particular of portal systemic encephalopathy, and as a
sweetener.
Lactulose syrups that are now available on the market are generally not pure, but contain more
or less large amounts of other carbohydrates, in particular galactose and lactose, and typically
50% by weight of lactulose; from 5 to 8% by weight of galactose; from 3 to 5% by weight of lactose;
from 5 to 10% by weight of other carbohydrates.
As may be seen, the per cent amount of carbohydrates different from lactulose contained in the
syrups of commerce is relatively high. The use of products containing other carbohydrates in
addition to lactulose for the therapy of disorders requiring administration of lactulose alone,
would be prejudicial and raise problems, e.g. in patients suffering from diabetes or requiring a
diet without galactose.
Therefore, as lactulose becomes ever more important in pharmaceutical practice, there is a
need for an adequate purification of same from contaminating carbohydrates.
As disclosed in U.S. Pat. No. 4,536,221, various processes known for lactulose purification
are based on the crystallization from alcoholic solvents, usually ethanol.
However, the lactulose crystals obtained from alcohols always contain a given amount of
solvent, probably due to the formation of hydrogen bonds between the OH groups of sugar and the OH
groups of the solvent, while the solvent residue cannot be completely removed even by prolonged
dryings.
The disadvantage of the crystallization from ethanol is not only that complex process are
required for solvent residue elimination, but also that high operating costs are generally
involved.
Some process for the direct recovery of lactulose from aqueous solutions based on the
concentration of same by drying under vacuum, lyophilization, and spray-drying are also known.
Some of them are mentioned below:
the process disclosed in JP No. 61,104,800, which comprises concentrating an aqueous solution
containing at least 60% lactulose, adding the concentrate with crystal seeds at from 60° to
110° C., kneading and pulverizing, thus affording a powder containing lactulose crystals;
the process disclosed in European patent application EP-A-333,295, for the preparation of solid
lactulose from an aqueous syrup by high-temperature evaporation to lower the water content to
10% max., followed by cooling, grinding, sieving or crumbling of the resulting solid, whose
purity is the same as that of the starting syrup;
the process disclosed in European patent application EP-A-480,519, consisting of lactulose
solidification from aqueous solutions by evaporating the water contained therein and conversion of
the resulting product into a free-flowing powder. Lactulose solidification may be initiated by
addition of crystal seeds, preferably in amounts of from 1% to 5% by weight (on dry residue
basis);
the process disclosed in patent application JP No. 2,200,693, (Derwent abstract) consisting of
lactulose crystallization from a condensed syrup, followed by condensate drying at a reduced
pressure and pulverization of the dried product.
The aforementioned processes are essentially based on the evaporation and concentration of the
starting syrup and greatly differ from crystallizations in that they simply cause the solute
solidification without eliminatingas crystallizations dothe undesirable secondary components
present in mother liquors.
Therefore, since the processes based on concentration give lactulose of the same purity as
that of the starting syrup, they cannot be utilized for the production of high-purity lactulose
from commercial syrups that, as already mentioned, contain high amounts of other carbohydrates.
Furthermore, the aforementioned processes can give crystalline lactulose only if combined with
crystallization from alcohols.
The only known process which involves a real crystallization from water, with no need of
alcoholic solvents, is disclosed in EP-A-318,630 by the Applicant. It is also the only known
process that yields highly pure (³ 98%) and non-hygroscopic crystalline lactulose. However, this
process cannot be exploited if the lactulose aqueous syrup to be crystallized contains
carbohydrates different from lactulose in amounts exceeding 14% by weight of lactulose.
In case of lactulose syrups containing carbohydrates different from lactulose in amounts
exceeding said limit value, it was always deemed it necessary to lower the content of said
carbohydrates below said limit value and, to this purpose, before crystallization from water, the
aqueous syrup was always purified according to one of the other known methods.
The ever growing importance of lactulose in pharmaceutical practice is a spur to the
development of new processes to be applied to the industrial production of high-purity crystalline
lactulose, without causing the inconveniences of the processes already known.
SUMMARY
The Applicant has now found a new process for lactulose purification that may be exploited on
an industrial scale, yielding high-purity crystalline lactulose, in particular having a content of
carbohydrates different from lactulose lower than 1% and a purity higher than 98.5%. The present
process is based on the crystallization of a commercial lactulose aqueous syrup having a total
content of carbohydrates different from lactulose higher than 10% by weight.
In particular, the process of the present invention can be applied to commercial lactulose
aqueous syrups having the following composition: from 50% to 70% by weight of lactulose; from 3% to
9% by weight of lactose; from 3% to 14% by weight of galactose; from 4% to 7% by weight of other
carbohydrates; the total content of carbohydrate different from lactulose ranging between 10% and
30% by weight.
It has surprisingly been foundand this finding constitutes a fundamental feature of the
present inventionthat by
adding a commercial lactulose aqueous syrup with trihydrated crystalline lactulose in
amounts ranging from 5% to 30% of the total lactulose present, a high-purity lactulose
crystallizes in good yields.
As known, in crystallization processes, once the right solvent and the right crystallization
conditions in respect of concentration and temperature have been found, few seed crystals are
generally enough for initiating the progressive crystallization of the product in solution,
according to laws governed by:
product concentration in the concentrated matrix;
crystallization temperature;
residence time.
As far as sugars are concerned, said conditions are generally reached in such long times that
a random self-initiation of the solutes having lower kps than the product to be
crystallized becomes highly probable: consequently, the crystalline cake recovered is still
contaminated by said solutes.
It is, therefore, surprising that the addition to a lactulose aqueous syrup of a large amount
of trihydrated lactulose in the crystal stateand not of few seed crystalscan initiate a
preferential crystallization of lactulose in respect of the other carbohydrates present in the
syrup, yielding a high-purity crystalline lactulose.
Compared with the process disclosed in European patent application EP-A-318630, the process of
the present invention has the advantage of giving very-high-purity crystalline lactulose starting
from any syrup of commerce.
DETAILED DESCRIPTION OF THE
INVENTION
Lactulose crystallization according to the present invention is characterized by the following
process: the water content of the lactulose aqueous syrup is lowered to a sugar concentration of
from 70° to 80° Brix; the resulting syrup is added at from 5° C. to 20° C. with crystalline
trihydrated lactulose, acting as a crystallization initiator, in amounts ranging from 5% to 30% by
weight of the lactulose present in the starting syrup, which temperature is maintained for a period
of from 20 to 120 hrs. The crystalline solid obtained consisted of trihydrated lactulose having a
content of carbohydrates different from lactulose below 1% by weight and a lactulose content of at
least 98.5% (on anhydrous basis).
In particular, the process for the preparation of crystalline lactulose according to the
present invention comprises the following steps:
a) |
|
commercial lactulose aqueous syrup is evaporated under continuous stirring at a temperature
of from 50° to 60° C. and at a pressure of 2660 to 6650 Pa, up to a sugar concentration of
70°-80° Brix; |
b) |
|
the resulting concentrated syrup is cooled to 5° to 20° C. and added with crystalline
trihydrated lactulose in an amount of from 5 to 30 parts by weight of the lactulose present in
the syrup; |
c) |
|
the suspension obtained is stirred at said temperature for a period of from 20 to 120 hours
and the lactulose present in the syrup is crystallizes in the form of trihydrated lactulose; |
d) |
|
the crystallized trihydrated lactulose obtained is separated by centrifuging or filtering
from mother liquors, washed with cold water, and dried at a pressure of from 6650 to 13300 Pa,
at a temperature of from 30° to 60° C., to yield crystalline lactulose having a water content
below 0.5%. |
The process of the invention gives highly pure (98.5% minimum) crystalline lactulose in yields
per cycle greater than 40% of the lactulose present in the starting syrup.
The mother liquors resulting from the separation of crystalline trihydrated lactulose are
passed once or several times through columns containing anionic or cationic exchange resins, either
individually or in sequence, as illustrated in European patent applications EP-A-132,509,
EP-A-158,148, EP-A-159,521, EP-A-284,959, and EP-A-294,960 by the Applicant, so to lower the
content of carbohydrates different from lactulose below the aforesaid limits and, therefore, to
allow the mixing of same with the commercial starting syrup to be subjected to the process of the
present invention.
This operation allows the recycling of the mother liquors and the almost complete recovery of
the lactulose present in the syrups of commerce.
In a preferred embodiment of the present invention, the concentrated syrup of step b) has a
content of 55% to 62% by weight of lactulose and the crystalline trihydrated lactulose is added in
an amount ranging between 5% and 15% by weight of the lactulose present in the commercial syrup
(the amount of trihydrated lactulose used as a crystallization initiator is expressed as % by
weight of anhydrous lactulose).
A single washing of the crystalline trihydrated lactulose obtained in d) with cold water
(3°-5° C.) is generally enough for a satisfactory removal of the residual mother liquors and for
obtaining a product of the desired purity.
The following examples illustrate some embodiments of the claimed process.
EXAMPLES
Crystallization of Lactulose Starting
From Commercially Available Syrups
Several crystallizations of commercially available lactulose syrups were carried out according
to the standard procedure described below.
Syrups characteristics are shown in Table 1 and the results obtained in Table 2.
STANDARD PROCEDURE
A syrup (1000 kg) of composition as shown in Table 1 was concentrated under vacuum at a
pressure of from 2660 to 6650 Pa, under continuous stirring, at a temperature of from 50° to 60°
C., to a sugar concentration of 70°-80° Brix.
The resulting solution was fed to a crystallizer and cooled to 8° C. under continuous
stirring. Once said conditions have been reached, crystalline trihydrated lactulose was fed in the
amounts shown in Table 2.
The obtained suspension was slowly stirred at 8° C. for the period indicated in Table 2, then
the mother liquors were removed by centrifuging, the crystal cake was squeezed to remove most
mother liquors, washed with cold water, and squeezed again.
The resulting product was dried in an air oven at a temperature not exceeding 60° C. and at a
pressure of from 6650 to 13300 Pa, until obtaining anhydrous lactulose crystals (i.e. having a
maximum water content of 0.5%) of >98.8% purity (on dry basis) (Table 2).
The purity of lactulose crystals was determined on the dried product by HPLC analysis (J.
Agric. Food Chem., 32, 288-292, 1984), by means of comparison with standard lactulose produced and
sold by MERCK.
TABLE 1
Composition (%) of the aqueous solutions used
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item |
|
LTL |
|
LTS |
|
EPI |
|
GLT |
|
ND |
|
H2O |
|
I |
|
|
51.4 |
|
|
|
4.4 |
|
|
|
1.2 |
|
|
|
3.6 |
|
|
|
6.4 |
|
|
|
34.0 |
|
II |
|
|
50.6 |
|
|
|
4.9 |
|
|
|
2.0 |
|
|
|
3.8 |
|
|
|
5.0 |
|
|
|
33.7 |
|
III |
|
|
51.9 |
|
|
|
3.1 |
|
|
|
2.2 |
|
|
|
7.9 |
|
|
|
3.1 |
|
|
|
31.8 |
|
IV |
|
|
51.0 |
|
|
|
8.2 |
|
|
|
1.3 |
|
|
|
3.5 |
|
|
|
4.0 |
|
|
|
32.0 |
|
Remarks: all quantities are by weight percentages of the solution total weight.
Abbreviations
LTL lactulose;
LTS lactose;
EPI epilactose;
GLT galactose;
ND carbohydrates different from LTL, LTS, EPI, and GLT.
TABLE 2
Experimental results
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LTL |
|
Cone. syr. |
|
LTL as initiator |
|
LTL |
|
LTL recovered |
Ex. |
|
Syr a |
|
Brixb |
|
hc |
|
% wd |
|
Xge |
|
%f |
|
Kgg |
|
Kgh |
|
Kgi |
|
% titl |
|
% film |
|
yieldn |
|
1 |
|
|
I |
|
|
|
74 |
|
|
|
72 |
|
|
|
55.2 |
|
|
|
931 |
|
|
|
18.7 |
|
|
|
111.6 |
|
|
|
610 |
|
|
|
309 |
|
|
|
84.2 |
|
|
|
99.0 |
|
|
|
42.2 |
|
2 |
|
|
I |
|
|
|
74 |
|
|
|
96 |
|
|
|
55.3 |
|
|
|
929 |
|
|
|
7.5 |
|
|
|
46.1 |
|
|
|
553 |
|
|
|
254 |
|
|
|
83.8 |
|
|
|
98.9 |
|
|
|
38.5 |
|
3 |
|
|
I |
|
|
|
74 |
|
|
|
72 |
|
|
|
55.3 |
|
|
|
929 |
|
|
|
10.0 |
|
|
|
61.1 |
|
|
|
565 |
|
|
|
260 |
|
|
|
84.6 |
|
|
|
99.2 |
|
|
|
38.9 |
|
4 |
|
II |
|
|
78 |
|
|
|
120 |
|
|
|
57.0 |
|
|
|
888 |
|
|
|
5.0 |
|
|
|
30.3 |
|
|
|
531 |
|
|
|
212 |
|
|
|
83.9 |
|
|
|
99.0 |
|
|
|
33.5 |
|
5 |
|
II |
|
|
74 |
|
|
|
72 |
|
|
|
55.0 |
|
|
|
920 |
|
|
|
7.5 |
|
|
|
45.2 |
|
|
|
544 |
|
|
|
253 |
|
|
|
84.1 |
|
|
|
99.4 |
|
|
|
38.9 |
|
6 |
|
II |
|
|
75 |
|
|
|
88 |
|
|
|
55.6 |
|
|
|
933 |
|
|
|
7.5 |
|
|
|
46.5 |
|
|
|
558 |
|
|
|
310 |
|
|
|
83.4 |
|
|
|
99.0 |
|
|
|
46.3 |
|
7 |
|
II |
|
|
71 |
|
|
|
88 |
|
|
|
54.4 |
|
|
|
954 |
|
|
|
7.5 |
|
|
|
46.7 |
|
|
|
558 |
|
|
|
255 |
|
|
|
84.0 |
|
|
|
98.8 |
|
|
|
38.4 |
|
8 |
|
IV |
|
|
74 |
|
|
|
56 |
|
|
|
55.2 |
|
|
|
924 |
|
|
|
15.0 |
|
|
|
69.8 |
|
|
|
587 |
|
|
|
238 |
|
|
|
83.5 |
|
|
|
99.1 |
|
|
|
33.9 |
|
9 |
|
IV |
|
|
74 |
|
|
|
72 |
|
|
|
55.5 |
|
|
|
919 |
|
|
|
7.5 |
|
|
|
45.8 |
|
|
|
548 |
|
|
|
248 |
|
|
|
84.6 |
|
|
|
98.8 |
|
|
|
38.3 |
|
10 |
|
IV |
|
|
70 |
|
|
|
72 |
|
|
|
53.8 |
|
|
|
948 |
|
|
|
7.5 |
|
|
|
45.9 |
|
|
|
548 |
|
|
|
213 |
|
|
|
84.6 |
|
|
|
98.8 |
|
|
|
32.9 |
|
|
|
|
a |
|
Commercial aqueous syrup used |
|
b |
|
Brix degrees after syrup concentration |
|
c |
|
Residence time in crystallizer at 8° C |
|
d |
|
By weight %, amount of LTL after syrup concentration |
|
e |
|
Amount of concentrated syrup (kg) |
|
f |
|
By weight % amount of trihydrated LTL used as a crystallization initiator |
|
g |
|
Weight of trihydrated LTL used as a crystallization initiator |
|
h |
|
LTL total weight (LTL of the syrup + LTL used as a crystallization initiator) |
|
i |
|
Weight of trihydrated LTL recovered |
|
l |
|
titre of anhydrous LTL in trihydrated crystal before drying |
|
m |
|
titre of anhydrous LTL after drying |
|
n |
|
yield calculated by:
(anhydrous) crystalline LTL recovered (kg)
(anhydrous) total LTL In the system (kg) |
I claim:
1. A process for the preparation of crystalline lactulose having a content of carbohydrates
which are different from lactulose that is lower than 1% and a lactulose content of more than
98.5%, said process comprising the following steps:
(a) |
|
evaporating a part of the water from an aqueous lactulose syrup under continuous stirring
at a temperature of from 50° to 60° C. and at a pressure of from 2660 to 6650 Pa to obtain
a concentrated lactulose syrup with a sugar concentration of 70°-80° Brix, said aqueous
lactulose syrup having a lactulose content of from 50% to about 62% by weight and a content
of carbohydrates which are different from lactulose and include lactose, galactose and
other carbohydrates, the lactose content being from 3% to 9% by weight; the galactose
content being from 3% to 14 % and the other carbohydrate content being from 4% to 7% by
weight; |
(b) |
|
cooling the concentrated syrup obtained in step (a) to a temperature of from 5° to 20° C.
prior to adding from 5% to 30% by weight of crystalline trihydrated lactulose based on the total weight of lactulose which is present in said aqueous lactulose syrup; |
(c) |
|
stirring the product of step (c) for a period of from 20 to 120 hours to crystallize the
lactulose which is present as trihydrated lactulose; |
(d) |
|
separating the crystallized trihydrated lactulose by centrifugation or filtration of the
product of Step (c) to obtain a mother liquor and separated crystallized trihydrated
lactulose; and thereafter washing said separated crystallized trihydrate of lactulose with
cold water prior to drying the separated crystallized trihydrate of lactulose at a temperature
of from 30° to 60° C., to obtain crystalline lactulose having a water content of less that
0.5%. |
2. The process according to claim 1, wherein the crystalline trihydrated lactulose is
added in an amount of between 5% and 15% by weight of the lactulose present in said aqueous
lactulose syrup.
3. The process according to claim 1, wherein the mother liquors obtained in step (d) are
passed one or more times through columns containing ion exchange resins to reduce the content of
carbohydrates which are other than lactulose.
4. The process according to claim 3, wherein the mother liquors which are recovered after the
passage through the ion exchange columns are mixed with the aqueous lactulose syrup of step (a).
5. A process for the preparation of crystalline lactulose having a content of carbohydrates
which are different from lactulose that is lower than 1% and a lactulose content of more than
98.5%, said process consisting essentially of the following steps:
(a) evaporating a part of the water from an aqueous lactulose syrup under continuous stirring at a
temperature of from 50° to 60° C. and at a pressure of from 2660 to 6650 Pa to obtain a
concentrated lactulose
|
|
syrup with a sugar concentration of 70°80° Brix, said aqueous lactulose syrup having a
lactulose content of from 50% to about 62% by weight and a content of carbohydrates which are
different from lactulose and include lactose, galactose and other carbohydrates, the lactose
content being from 3% to 9% by weight; the galactose content being from 3% to 14 % and the other
carbohydrate content being from 4% to 7% by weight; |
(b) |
|
cooling the concentrated syrup obtained in step (a) to a temperature of from 5° to 20° C.
prior to adding from 5% to 30% by weight of crystalline trihydrated lactulose based on the
total weight of lactulose which is present in said aqueous lactulose syrup; |
(c) |
|
stirring the product of step (c) for a period of from 20 to 120 hours to crystallize the
lactulose which is present as trihydrated lactulose; |
(d) |
|
separating the crystallized trihydrated lactulose by centrifugation or filtration of the
product of step (c) to obtain a mother liquor and separated crystallized tri-
hydrated lactulose; and thereafter washing said separated crystallized trihydrate of
lactulose with cold water prior to drying the separated crystallized trihydrate of lactulose at
a temperature of from 30° to 60° C., to obtain crystalline lactulose having a water content of
less that 0.5%. |
6. The process according to claim 5, wherein the crystal-line trihydrated lactulose is added
in an amount of between 5% and 15% by weight of the lactulose present in said aqueous lactulose
syrup.
7. The process according to claim 5, wherein the mother liquors obtained in step (d) are
passed one or more times through columns containing ion exchange resins to reduce the content of
carbohydrates which are other than lactulose.
8. The process according to claim 7, wherein the mother liquors which are recovered after the
passage through the ion exchange columns are mixed with the aqueous lactulose syrup of step (a).
* * * * *
|
|
|
|
|
|
|
United States Patent
|
|
Patent Number:
|
|
|
5,003,061 |
|
Carobbi et al.
|
|
Date of Patent:
|
|
Mar. 26, 1991
|
METHOD FOR PREPARING HIGH-PURITY CRYSTALLINE LACTULOSE
|
|
|
Inventors:
|
|
Renato Carobbi, Pistoia; Franco
Innocenti, Bagno a Ripoli, both of
Italy |
|
|
|
Assignee:
|
|
SIRAC Srl, Milan, Italy |
|
|
|
Appl. No.:
|
|
141,786 |
|
|
|
Filed:
|
|
Jan. 11, 1988 |
Foreign Application Priority Data
|
|
|
Dec. 1, 1987 [IT] Italy
|
|
22848 A/87 |
Int. Cl.5
|
|
C07H 1/06; C13F 1/02 |
U.S. Cl
|
|
536/127; 536/1.1; |
|
|
536/4.1; 127/30; 127/46.1; 127/58 |
Field of Search
|
|
536/1.1, 4.1, 127; |
|
|
127/30, 46.1, 58 |
References Cited
U.S. PATENT DOCUMENTS
|
|
|
|
|
|
|
|
|
|
3,110,600 |
|
|
11/1963
|
|
Bok
|
|
536/1.1 |
|
3,546,206 |
|
|
12/1970
|
|
Guth et al.
|
|
127/30 |
|
3,562,012 |
|
|
2/1971
|
|
Reinicke et al.
|
|
536/1.1 |
|
3,816,174 |
|
|
6/1974
|
|
Nagasawa et al.
|
|
127/30 |
|
3,816,394 |
|
|
6/1974
|
|
Nagasawa et al.
|
|
536/124 |
|
4,142,916 |
|
|
3/1979
|
|
Ogasa et al.
|
|
127/63 |
|
4,264,763 |
|
|
4/1981
|
|
Gasparotti
|
|
536/1.1 |
|
4,273,922 |
|
|
6/1981
|
|
Hicks
|
|
127/46.1 |
|
4.536,221 |
|
|
8/1985
|
|
Carobbi et al.
|
|
536/127 |
|
4,555,271 |
|
|
11/1985
|
|
Carobbi et al. |
|
127/46.2 |
|
4,605,646 |
|
|
8/1986
|
|
Bernardi |
|
514/53 |
|
4,812,444 |
|
|
3/1989
|
|
Mitsuhashi et al. |
|
514/53 |
FOREIGN PATENT DOCUMENTS
57-102200 6/1982 Japan.
61-104800 5/1986 Japan.
1232554 5/1971 United Kingdom.
2031430 4/1980
United Kingdom.
OTHER PUBLICATIONS
Montgomery et al; J.A.C.S. 52:2101-2106, May 1930.
Oosten; Chemical Abstracts 67:73799k (1967).
Nitsch et al; Chemical Abstracts 84:150910v (1976).
Krol et al; Chemical Abstracts 90:40510f (1979).
Takahashi; Chemical Abstracts 105:135841g (1986).
Primary ExaminerRonald W. Griffin
Assistant ExaminerNancy S. Carson
Attorney, Agent, or FirmParkhurst, Wendel & Rossi
ABSTRACT
A method for preparing high-purity crystalline lactulose and the product obtained by the method,
which comprises crystallization from aqueous solutions at a temperature of 5-40 C., the starting
aqueous solution having a lactulose concentration of 50-80% w/w, a lactose concentration of less
than 5% of the lactulose concentration by weight, a galactose concentration of less than 5% of the
lactulose concentration by weight, and a concentration of other sugars of less than 4% of the
lactulose concentration by weight.
4 Claims, No Drawings
METHOD FOR PREPARING HIGH-PURITY
CRYSTALLINE LACTULOSE
FIELD OF THE INVENTION
This invention relates to a new method for preparing high-purity crystalline lactulose by
crystallizing aqueous solutions which contain it and eliminating the secondary components during
the crystallization stage, and to the crystalline lactulose obtained in this manner.
PRIOR ART
Lactulose, or 4-O-b-D-galactopyranosyl-D-fructofuranose, is a semisynthetic disaccharide used
in the form of a syrup or crystalline product for its laxative effects, for its effectiveness in
hepatic disfunctions and particularly in portosystemic encephalopathy, or as a sweetener.
Commercially available lactulose syrup is generally impure, containing variable quantities of
other carbohydrates, particularly lactose and galactose.
A typical composition of currently available syrup is the following:
|
|
|
lactulose
|
|
50%by weight |
galactose
|
|
5-8%by weight |
lactose
|
|
3-3%by weight |
other carbohydrates
|
|
5-10%by weight |
in which relatively large percentages of carbohydrates other than lactulose are present. These
carbohydrates are also present, generally in lesser quantity, in currently commercially available
crystalline lactulose.
Carbohydrates other than lactulose are undesirable in therapeutic applications for which
lactulose is intended, and in particular for patients requiring a galactose-free diet and diabetic
patients.
There is therefore a requirement for crystalline lactulose of higher purity, in particular
with the greatest possible reduction in carbohydrates other than lactulose and with the absence of
undesirable residual alcoholic solvent concentrations, which are present when lactulose is
crystallized from alcoholic solutions.
The main currently known lactulose purification methods involve the use of alcoholic solvents,
generally ethanol, together with complex procedures based on the extreme solubility of lactulose in
an aqueous environment, or on various concentration processes by drying.
Crystalline lactulose obtained from alcoholic solvents is known to always contain a
considerable percentage of solvent retained by the crystal, probably by the formation of hydrogen
bonds between the sugar OH groups and the solvent OH groups, and it is never possible to eliminate
the solvent residue even by prolonged drying.
One example of a process of purification by crystallization from ethanol is described in
Italian patent No. 1,155,429.
The yield of such processes when calculated with respect to the lactulose contained in the
starting syrup is particularly low.
In the present text the term yield indicates the amount of crystalline product obtained in a
single step, as a weight percentage of the starting lactulose.
Thus, processes for obtaining crystalline lactulose from alcoholic solutions have the
drawbacks of greater complication, lower yields and consequent higher cost,
and a product from which the undesirable alcoholic solvent traces cannot be eliminated.
Again, processes involving concentration by direct drying of aqueous lactulose solutions, even
if of high purity and whatever drying method is used (vacuum, lyophilization, spray drying), are
known to lead to a very hygroscopic solid amorphous product or, as described in JP No. 61104800, to
a solid containing crystalline lactulose which has to undergo further mixing and grinding before it
can be used.
Thus none of the previously used methods has provided crystalline lactulose free both of
impurities in the form of other undesirable carbohydrates and of residual concentrations of
alcoholic solvent retained by the lactulose crystal.
Up to the present time it has been impossible in practice to directly obtain from aqueous
solutions high-purity crystalline lactulose having the characteristics of the lactulose claimed in
the present patent.
SUMMARY OF THE INVENTION
In accordance with the present invention we have now discovered a new industrially applicable
lactulose purification process which obviates all these drawbacks and enables crystalline lactulose
to be obtained in a particularly simple and economical manner with a degree of purity exceeding 98%
by weight and practically free of carbohydrates other than lactulose, in particular lactose and
galactose, from aqueous solutions which contain it in an impure state due to the presence of
carbohydrates other than lactulose, and/or alcohols. If the process of the present invention is
applied to lactulose crystallized from alcoholic solutions and then redissolved in water, the
crystalline lactulose finally obtained is practically free of any trace of the alcoholic solvent
used and thus has a degree of purity considerably higher than that obtainable by any process
previously used.
The final yield of the process according to the invention varies according to the
crystallization temperature, the crystallization time, the lactulose purity and the solution
purity, and lies between 10 and 70%.
In its preferred embodiments, the yield varies from 55 to 70% as indicated hereinafter, and is
therefore considerably greater than in all previously used methods, so making this process usable
more economically on an industrial scale than previous processes.
The method of the present invention enables crystalline lactulose to be obtained from aqueous
solutions which are impure because of the presence of carbohydrates other than lactulose and/or
alcohols, and in particular from aqueous solutions having the following characteristics:
(a) lactulose concentration of 50-80% w/w and preferably 65-70% w/w in the aqueous solution;
(b) lactose concentration of less than 5% of the lactulose concentration by weight;
(c) galactose concentration of less than 5% of the lactulose concentration by weight;
(d) concentration of other carbohydrates of less than 4% of the lactulose concentration by
weight;
(e) total concentration of carbohydrates other than lactulose not exceeding 6% of the
lactulose concentration by weight.
The method according to the present invention is characterised by maintaining the
crystallization conditions within precise critical values, and more specifi-
cally by simultaneously maintaining all the indicated parameters within the following
defined critical values:
a. Crystallization temperature between 5° and 40° C., and preferably
between 10° and 15° C.
b. Crystallization time between 10 and 60 hours, and preferably between 24 and 36 hours.
Outside these values an extremely low final process yield is obtained such that the process
cannot be used industrially, it being sufficient for only one of these parameters to lie outside
the range of values defined by the present invention for the final yield to be such as to make the
process unusable industrially.
This process, which is described in detail in the examples, therefore not only enables
crystalline lactulose to be obtained directly from sufficiently pure aqueous solutions, but also
enables the residual solvent to be completely eliminated from crystalline lactulose obtained by
conventional crystallization from alcoholic solvents such as methanol, ethanol and propanol.
The following examples are given as non-limiting illustration of the process according to the
invention for purifying and crystallizing lactulose from aqueous solutions.
EXAMPLE 1
1000 kg of a lactulose solution having the following composition:
|
|
|
lactulose
|
|
50% |
lactose
|
|
0.7% |
galactose
|
|
0.9% |
other sugars
|
|
0.3% |
water
|
|
to make up to 100% |
are concentrated under vacuum to a lactulose concentration of 70%.
The concentrated solution is then cooled to 13° C. and 1 kg of crystalline lactulose
is added.
The mixture is left under agitation for 24 hours maintaining the temperature at 13°
C., after which the solid obtained, consisting of crystalline lactulose, is filtered off.
The solid is dried in an air oven at a temperature not exceeding 35° -40°
C. to obtain 273 kg of crystalline lactulose with a purity exceeding 98% and a yield of 54.5%.
EXAMPLE 2
1000 kg of a lactulose solution having the following composition:
|
|
|
|
|
lactulose |
|
|
50 |
% |
lactose |
|
|
0.7 |
% |
galactose |
|
|
0.9 |
% |
other sugars |
|
|
0.3 |
% |
water to make up to |
|
|
100 |
% |
are concentrated under vacuum to a lactulose concentration of 68%.
The concentrated solution is cooled to 35° C. after which 1 kg of crystalline
lactulose is added.
Over a period of 20 hours the temperature is cooled to 15° C. while maintaining slow
agitation, this temperature then being maintained for a further 16 hours.
By centrifuging, 373 kg of wet product (KF 17%) are obtained, equivalent to 309.5 kg of dry
product, with a yield of 61.7% and a purity of 98.3%.
EXAMPLE 3
500 kg of crystalline lactulose (purity 98.7%) obtained by crystallization from ethanol, with
a residual ethanol concentration of 5000 ppm, are dissolved in 2000 l of water.
The solution obtained is concentrated under vacuum to 68% of lactulose and its temperature
allowed to reach 30° -35° C. spontaneously.
Crystallization is triggered by adding 800g of crystalline lactulose.
The solution is then cooled to about 15° C. and kept at this temperature for 30
hours.
By centrifuging, 430 kg of wet product (KF 18%) are obtained, equivalent to 342.5 kg of dry
product, with a yield of 68.5% and a purity exceeding 99%.
The residual ethanol content is reduced to less than 5 ppm.
We claim:
1. A method for preparing crystalline lactulose having less than 2% of carbohydrate other than
lactulose and a purity exceeding 98% comprising:
|
(a) |
|
adding a crystalline lactulose seed to an aqueous solution of lactulose having a
lactulose concentration of from 50% to 80% w/w, a lactose concentration of less than 5% of
the lactulose concentration by wt., a galactose concentration of less than 5% of the
lactulose concentration by wt. and concentration of other carbohydrates of less than 4% of
the lactulose concentration by wt.; |
|
|
(b) |
|
crystallizing said lactulose solution at a temperature between 5° and
40° C. and in a time between 10 and 60 hours; and |
|
|
(c) |
|
drying the obtained crystalline lactulose. |
2. A method as claimed in claim 1, wherein the lactulose concentration in the aqueous solution
is 65-70% w/w and the total concentration of carbohydrates other than lactulose does not exceed 6%
of the lactulose concentration by weight.
3. The method of claim 1 wherein said lactulose solution crystallizing temperature is between
10° C. and 15° C. and said time is between 24 and 36 hours.
4. The method of claim 1 wherein the aqueous solution of lactulose is obtained by dissolving
lactulose, which was previously crystallized from alcoholic solutions, in water.
* * * * *
UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION
|
|
|
PATENT NO.
|
|
5,003,061 |
|
|
|
DATED
|
|
March 26, 1991 |
|
|
|
INVENTORS) :
|
|
Renato CAROBBI et al. |
It is certified that error appears in the above-identified parent and that said Letters Patent is
hereby corrected as shown below:
Title Page:
[73] Assignee: Please change SIRAC Srl, Milan, Italy to
INALCO S.p.A., Milano, Italy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signed and Sealed this
Fifth Day of January, 1993 |
|
|
|
|
|
|
|
Attest: |
|
|
|
|
|
|
|
|
|
|
|
DOUGLAS B. COMER |
|
|
|
|
|
|
|
Attesting Officer
|
|
Acting Commissioner
of Patents and Trademarks |
REEXAMINATION CERTIFICATE
ISSUED UNDER 35 U.S.C. 307
THE PATENT IS HEREBY AMENDED AS
INDICATED BELOW.
Matter enclosed in heavy brackets [ ] appeared in the patent, but has been deleted and is no
longer a part of the patent; matter printed in italics indicates additions made to the patent.
AS A RESULT OP REEXAMINATION, IT HAS BEEN DETERMINED THAT:
|
|
Claim 1 is determined to be patentable as amended. |
Claims 2, 3 and 4, dependent on an amended claim, are determined to be patentable.
1. A method for preparing crystalline lactulose having less than 2% of carbohydrate
other than lactulose and a purity exceeding 98% comprising;
(a) adding a crystalline lactulose seed to an aqueous solution of lactulose having a
lactulose concentration of from 50% to 80% w/w, a lactose concentration of less than 5% of the
lactulose concentration by wt., a galactose concentration of less than 5% of the lactulose
concentration by wt. and concentration of other carbohydrates of less than 4% of the lactulose
concentration by wt., said aqueous solution containing water as the only solvent;
(b) crystallizing said lactulose solution at a temperature between 5° and 40° C. and in a
time between 10 and 60 hours; and
(c) drying the obtained crystalline lactulose.
* * * * *
EXHIBIT C
Transition Plan
EX-10.10 LICENSE AGREEMENT
EXHIBIT 10.10
*Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
License Agreement
between
Vanderbilt University
and
Cumberland Pharmaceuticals Inc.
May 1999
LICENSE AGREEMENT
between
VANDERBILT UNIVERSITY
and
CUMBERLAND PHARMACEUTICALS INC.
THIS AGREEMENT, by and between VANDERBILT UNIVERSITY, a not-for-profit corporation, organized and
existing under the laws of the state of Tennessee (VANDERBILT), and Cumberland Pharmaceuticals
Inc., a Tennessee corporation, having a principal place of business at Nashville, Tennessee (the
LICENSEE) is effective as of the 28TH day of May , 1999 (the
EFFECTIVE DATE).
RECITALS
WHEREAS, VANDERBILT represents that it holds title, by assignment, to the data, including patient
records, created by Gordon R. Bernard, M.D., Professor of Medicine (the Data) relating to
intravenously administered ibuprofen for treatment of sepsis and that it has all rights to the Data
and VANDERBILT is willing to grant a license to the Data and any intellectual property rights
associated therewith; and
WHEREAS, LICENSEE desires to acquire, and VANDERBILT desires to grant to LICENSEE, an exclusive,
worldwide license to use the Data in connection with the development and production of the
Product, as hereinafter defined, for which LICENSEE intends to seek necessary approvals from
regulatory governmental agencies in order to market and sell such products upon the terms and
conditions hereinafter set forth;
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, it is
agreed by the parties as follows:
1. DEFINITIONS
1.1 Product(s) shall mean a pharmaceutical product, consisting, in whole or part, of
intravenously administered ibuprofen manufactured by or for LICENSEE based on the Data and approved
by a regulatory agency for sale or other distribution in the country in which the agency has
regulatory authority.
1.2 Net Sales. The term Net Sales shall mean the receipts for Products sold by LICENSEE
or a sublicense during the term of this Agreement, computed quarter by quarter, less allowances
for:
(a) cash, trade, or quantity discounts and rebates,
(b) taxes, including sales taxes and duties,
(c) credits, returns and replacements, and
(d) shipping and insurance charges.
Products shall be deemed sold when paid for.
1
1.3 The Inventor. The term Inventor shall mean Gordon R. Bernard, M.D., Professor of
Medicine.
1.4 Affiliate means, when used with reference to LICENSEE, any entity directly or
indirectly controlling, controlled by or under common control with LICENSEE. For purposes of this
Agreement, control means the direct or indirect ownership of over fifty percent (50%) of the
outstanding voting securities of an entity, or the right to receive over fifty percent (50%) of the
profits or earnings of an entity, or the right to control the policy decisions of an entity.
2. GRANT
2.0 Exclusive License. VANDERBILT hereby grants to LICENSEE and LICENSEE hereby accepts
from VANDERBILT, upon the terms and conditions herein specified, an exclusive, royalty bearing,
worldwide license, with the right to sublicense, to use Data for any purpose, including manufacture
and sale of the Product(s) as well as submission to regulatory governmental agencies for approval
to sell Product(s), except as otherwise expressly set forth herein. Upon execution of this
Agreement, VANDERBILT through Gordon Bernard will promptly deliver to LICENSEE all information and
data relating to intravenously administered ibuprofen to which VANDERBILT holds title.
2.1 Federal Government Rights Reserved. Notwithstanding the exclusive license granted
herein, the Federal Government shall receive all the rights, if any, to the Data required by law or
regulation to be reserved to the government. All rights granted in this Agreement are expressly
granted subject to the rights of the Federal Government and such rights are specifically reserved
to the Government by this Agreement.
2.2 Reservation of Right. VANDERBILT reserves the right to make, use and further develop
the Data for its own non-commercial, educational and research purposes.
2.3 Upon receipt of regulatory approval to sell the Product, LICENSEE shall use reasonable efforts
to effect introduction of the Products into the commercial market as soon as practicable,
consistent with sound and reasonable business practices and judgment; thereafter, until the
expiration of this Agreement, LICENSEE shall use commercially reasonable efforts to keep Products
reasonably available to the public.
2.4 Subsidiaries and Distributors. License rights granted hereunder shall enable LICENSEE
to make, use, sell or otherwise distribute Product through any of its subsidiaries and to sell
Product through any of its normal channels including its subsidiaries, distributors, and agents.
2
3. TERMS AND TERMINATION
3.0 Term. Unless previously terminated as herein provided, this Agreement shall become
effective as stated above and shall continue until LICENSEE ceases distribution of Product in all
countries in which it has obtained regulatory approval for manufacture and distribution of such
product based on use of the Data.
3.1 Termination. This Agreement may be terminated by written notice to the other party:
(a) Other than as stated in Article 3.1(b), in the event that one party commits any
substantial breach of this Agreement, the non-breaching party at its option, may terminate this
Agreement by giving the breaching party written notice pursuant to Article 10.2 of its election to
terminate as of a stated date, not less than forty-five (45) days from the date of the notice.
Such notice shall state the nature of the defaults claimed by the non-breaching party. The
breaching party during said forty-five (45) day period, or such longer period as may be indicated
by the other, may correct any default stated in said notice and if such default is corrected, this
Agreement shall continue in full force and effect as if such notice had not been given. Failure by
LICENSEE to pay earned royalties to VANDERBILT in a timely manner shall be deemed a substantial
breach of the Agreement.
(b) In the event LICENSEE shall file a petition for voluntary bankruptcy, has a petition for
involuntary bankruptcy filed against it (which petition is not withdrawn within sixty (60) days of
such filing), is adjudicated to be bankrupt, or shall make an assignment for the benefit of
creditors, or shall apply for or consent to the appointment of a receiver or trustee of a
substantial part of its property, to the extent permitted by law, this Agreement shall
automatically terminate effective as of a date ten (10) days prior to LICENSEEs change of status
hereunder and shall be subject to Article 3.2.
(c) In the event a LICENSEE provides written notice to VANDERBILT and LICENSEE is terminating
pursuing regulatory approval for the Product.
3.2 Effect of Termination. Upon termination of this Agreement, LICENSEE shall cease all
production and sale of Product except for the production and sale of Product on which production
had begun prior to notice of such termination. LICENSEE may continue to sell such Product for up
to one year after such notice upon payment of royalties accruing thereon, and shall render an
accounting to VANDERBILT of any royalties which may be due. Immediately upon termination all
rights of Licensee, except as expressly stated in this article, shall revert to VANDERBILT.
3.3 Sections 3.2, 3.4, 5.1, Article 6, Article 7, Article 8, Article 9, and Section 10.8 of the
agreement shall survive termination.
3
4. CONSULTING AGREEMENTS
4.0 Consulting Agreements. In the event LICENSEE desires to have a Consulting Agreement
with Dr. Bernard, any such Consulting Agreement will be separate and apart from this Agreement, and
in accord with VANDERBILT policy and procedures.
5. ROYALTIES AND [***]
5.0 [***]
5.1 Royalties. Commencing on the effective date of this Agreement, LICENSEE agrees to pay
VANDERBILT at the rate of [***] percent of Net Sales of Products sold to third parties.
5.2 Schedule of Payment. LICENSEE further agrees to pay royalties on a quarterly basis
based on LICENSEEs fiscal quarter and payments shall be due within forty-five (45) days after the
completion of the fiscal quarter. Each such payment shall be accompanied by a statement for the
period covered by such royalties showing total number or volume of Products sold, and total
royalties due, and identified as Net Sales within U.S. or non-U.S. This statement is to be
certified as accurate by a responsible officer of LICENSEE.
5.3 [***]
5.4 Reports. LICENSEE shall provide written annual reports within [***] after December 31
of each calendar year which shall include but not be limited to: reports of progress on research
and development, regulatory approvals, manufacturing, marketing and sales during the preceding
twelve (12) months as well as plans for the coming year. LICENSEE shall promptly notify VANDERBILT
if any changes in the marketplace or in LICENSEEs financial condition or business aims suggest
commercialization will not occur within three (3) years from the date hereof.
5.5 Records. LICENSEE shall maintain complete and accurate records sufficient to enable
accurate calculation of royalties due VANDERBILT under this Agreement. LICENSEE shall, at
VANDERBILTs request and expense, provide certified statements from LICENSEEs auditors, concerning
royalties due pursuant to this Agreement. Once a calendar year, VANDERBILT shall have the right to
select a certified public accountant to inspect, on reasonable notice and during regular business
hours, the records of LICENSEE to verify LICENSEEs statements and royalty payments pursuant to
this Agreement. The entire cost for such inspection shall be borne by VANDERBILT, unless there is
a discrepancy greater than 5% in VANDERBILTs favor, in which case LICENSEE shall bear the entire
cost of the inspection. Records shall be preserved by LICENSEE for three (3) years for inspection
by VANDERBILT.
5.6 If this Agreement is not terminated in accordance with other provisions hereof, LICENSEEs
obligation to pay royalties hereunder shall continue as long as Product is being distributed by
LICENSEE.
4
5.7 The royalty on sales in currencies other than U.S. Dollars shall be calculated using the
appropriate exchange rate for such transactions quoted by CITICORP BANK (NEW YORK) foreign exchange
desk on the last banking day of each calendar quarter. Royalty payments to VANDERBILT shall be in
U.S. Dollars.
5.8 In the event that LICENSEE is acquired by a third party or enters into a joint venture with a
third party, or in any other way transfers all of its assets, including this License to a third
party, all obligations of this License, including the foregoing royalty terms, shall be binding
upon the party acquiring this License.
6. CONFIDENTIALITY
6.0 It may be necessary for one party to disclose to the other party certain confidential or
proprietary information, including business plans and marketing strategies. In such event, the
receiving party agrees to preserve such identified information as confidential. The obligation of
confidentiality shall not apply to information which:
(a) is now in the public domain or which becomes generally available to the public through no
fault of the receiving party; or
(b) is already known to, or in the possession of, the receiving party prior to disclosure by
the disclosing party as can be demonstrated by documentary evidence; or
(c) is disclosed on a non-confidential basis from a third party having the right to make such
a disclosure; or
(d) is independently developed by the receiving party as can be demonstrated by documentary
evidence.
6.1 Term. The confidentiality obligations of this Article shall continue for a period of
five (5) years beyond the termination of this Agreement.
5
7. INFRINGEMENT
7.0 Products Infringing Third Parties. Each party shall promptly notify the other if any
legal proceedings are commenced or threatened against either party or any purchaser of a Product
sold by LICENSEE on the ground that the manufacture, use, sale or possession of the Product is an
infringement of a third partys patent or other intellectual property rights. LICENSEE shall, at
its own expense, conduct all suits brought against it as a result of the exercise of the rights
granted hereunder, and VANDERBILT shall, at the request and expense of LICENSEE, give LICENSEE all
reasonable assistance in any such proceedings. Payment of any amounts which may be recovered by
such third party by way of judgment, award, decree, or settlement that resulted from infringement
of third party patent rights or other rights by a Product, including attorneys fees and other
costs shall be the sole responsibility of LICENSEE. LICENSEE agrees not to settle or compromise any
action, suit or proceeding without the consent of VANDERBILT.
8. WARRANTIES AND INDEMNITIES
8.0 Nothing in this Agreement shall be constructed as:
(a) a warranty or representation by VANDERBILT that anything made, used, sold, or otherwise
disposed of through the license granted herein is or will be free from infringement of patents
rights of third parties;
(b) an obligation by VANDERBILT to bring or prosecute actions or suits against third parties
for infringement;
(c) Granting by implication, estoppel, or otherwise any licenses under patents of VANDERBILT.
8.1 To the best of its knowledge and belief, VANDERBILT hereby represents and warrants that it is
the sole owner of the Data and has the right to grant the license to the Data provided herein and
that to the best of its knowledge and belief after due inquiry, no rights of patients or other
persons are or will be infringed by the license granted to LICENSEE. VANDERBILT further represents
and warrants that the Data is both accurate and complete and includes all information and data
relating to intravenously administered ibuprofen to which VANDERBILT holds title. VANDERBILT also
represents and warrants that it has full right, title, and authority to enter into this Agreement
and that VANDERBILT is not under any obligation resulting from any contract or arrangement, to any
person, firm, or corporation, which is inconsistent or in conflict with this Agreement.
8.2 (a) LICENSEE shall indemnify, defend and hold harmless VANDERBILT and its trustees, officers,
faculty, staff, employees, students, agents and representatives, and their respective successors,
heirs and assigns (the Indemnities), against any liability, damage, loss or expenses (including
reasonable attorneys fees and expense of litigation) incurred by or imposed upon the Indemnities
or any one of them in connection with any claims, suits, actions, demands, or judgments arising out
of any theory of law (including, but not limited
6
to, actions in the form of tort, warranty, or strict liability) arising from LICENSEEs use of the
Data pursuant to any right or license granted under this Agreement. Such indemnity obligation
shall include claims and expenses related to infringement of a third partys rights by the Product.
(b) LICENSEE agrees, at its own expense, to provide attorneys reasonably acceptable to
VANDERBILT to defend against any actions brought or filed against any party indemnified hereunder
with respect to the subject of indemnity contained herein, whether or not such actions are
rightfully brought.
(c) VANDERBILT shall indemnify, defend and hold harmless LICENSEE and its officers, directors,
employees, agents, and shareholders, notwithstanding termination of this Agreement, against any
liability, damage, loss, or expenses (including reasonable attorneys fees) incurred by or imposed
in connection with any claims, suits, actions, demands or judgments arising out of any theory of
law (including, but not limited to, actions in the form of tort, warranty, or strict liability)
arising from default under any provision of this Agreement by VANDERBILT.
8.3 VANDERBILT MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND EXPRESS OR IMPLIED,
OTHER THAN AS EXPRESSLY STATED HEREIN. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT USE OF A PRODUCT WILL NOT INFRINGE ANY
PATENT, COPYRIGHT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.
8.4 Regarding the indemnity and hold harmless provisions, under Paragraph 8.2, VANDERBILT shall
give prompt written notice to LICENSEE of the commencement of any action, suit, or proceeding for
which indemnification may be sought, and LICENSEE, through counsel reasonably satisfactory to
VANDERBILT shall assume the defense thereof; provided, however, that VANDERBILT shall be entitled
to participate in any such action, suit, or proceeding with counsel of its own choice, but at its
own expense. If LICENSEE fails to assume the defense within ninety (90) days of receipt of written
notice of the action, suit, or proceeding, VANDERBILT may assume such defense and the reasonable
fees and expenses of its attorneys will be covered by the indemnity provided for in Paragraph 8.2.
No such action, suit, or proceeding shall be compromised or settled in any manner which might
adversely affect the interests of VANDERBILT without the prior written consent of VANDERBILT.
Notwithstanding anything in this Paragraph to the contrary, LICENSEE shall not, without the written
consent of VANDERBILT, which consent shall not be unreasonably withheld:
(a) Settle or compromise any action, suit, or proceeding or consent to the entry of any
judgment which does not include as an unconditional term thereof the delivery by the claimant or
plaintiff to VANDERBILT of a written release from all liability in respect of such action, suit, or
proceeding; or
(b) Settle or compromise any action, suit, or proceeding in any manner which may adversely
affect VANDERBILT.
7
8.5 Insurance. (a) Beginning at the time as any Product is being commercially distributed
or sold by LICENSEE or agent of LICENSEE, LICENSEE or such other, shall make commercially
reasonable efforts to procure and maintain comprehensive general product liability and tort
liability insurance in amounts not less than $5,000,000 per incident and $5,000,000 annual
aggregate and name the Indemnities as additional insureds. Such comprehensive general liability
insurance shall provide (i) product liability coverage and (ii) broad form contractual liability
coverage for LICENSEEs indemnification under this Agreement. If LICENSEE elects to self-insure or
otherwise finds it necessary to self-insure all or part of the limits described above, such
self-insurance program must be reasonably acceptable to VANDERBILT. LICENSEE agrees that no amount
greater than the sum of $250,000 shall be deductible under LICENSEEs primary coverage for
VANDERBILT and LICENSEE against any claims or suits arising from alleged defects in Products. The
minimum amounts of insurance coverage required shall not be construed to create or limit LICENSEEs
liability with respect to its indemnification under this Agreement.
(b) LICENSEE represents and warrants that it will make commercially reasonable efforts to
acquire its product liability and general tort liability is of the occurrence-based rather than
claims-made type. Within thirty (30) day after the date of the first commercial sale of a Product
hereunder, LICENSEE shall provide VANDERBILT with a certificate or certificates of insurance
evidencing that VANDERBILT has been named as an additional insured party and evidencing the
insurer(s) is required to notify VANDERBILT in writing at least thirty (30) days in advance of any
termination of the policy or certificate, or any modification that would cause LICENSEE no longer
to be in compliance with the provisions of this Article, or would cause the representation and
warranties set forth above in this Article no longer to be true, such written notification to
specify the reason for such termination, the nature of the proposed modification, as the case may
be. It is expressly agreed by the parties that the provisions of this Article regarding insurance
shall in no way limit LICENSEEs indemnity obligations, except to the extent that LICENSEEs
insurer(s) actually pays VANDERBILT amounts for which VANDERBILT is entitled to be indemnified
under this Agreement, nor shall VANDERBILT have any obligation to pursue any insurer as a
precondition to its rights to be indemnified by LICENSEE. As used in this Article, the term
VANDERBILT shall include VANDERBILT, and its officers, directors, agents and employees. If
LICENSEE does not make commercially reasonable efforts to obtain replacement insurance within such
thirty (30) day period specified above, VANDERBILT shall have the right to terminate this Agreement
effective at the end of such thirty (30) day period without notice or any additional waiting
periods.
(c) LICENSEE shall maintain such comprehensive general product liability and tort liability
insurance or self-insurance beyond the expiration or termination of this Agreement during (i) the
period that any product relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold by LICENSEE or agent of LICENSEE and (ii) a period not less than the statute of
limitations for product liability claims in the state in which the product is being used.
8
9. USE OF VANDERBILTS NAME
9.0 LICENSEE agrees not to identify VANDERBILT or to use the name of VANDERBILT, its faculty,
employees, or students, or any trademark, service mark, trade name, or symbol of VANDERBILT, or
that is associated with any of them, in promotional advertising or other similar materials without
VANDERBILTs written consent, except as required by governmental authority. LICENSEE may, without
prior consent, refer to VANDERBILT as LICENSOR of the Data submitted in support of marketing
approval for Product in a business plan, fund raising material or the like. All other uses of
VANDERBILTs name shall be made only after prior approval.
9.1 VANDERBILT agrees not to identify LICENSEE or to use the name of LICENSEEs officers,
employees, or any trademark, service mark, trade name or symbol of LICENSEE without the written
consent of LICENSEE, except as may be required by governmental authority or as necessary in the
normal course of VANDERBILTS business operations.
10. TERMS AND CONDITIONS
10. Manner of Payment. All payments hereunder shall be made by check to VANDERBILT. Where
required to do so by applicable law or treaty, LICENSEE shall withhold taxes required to be paid
to a taxing authority on account of such income to VANDERBILT, and LICENSEE shall furnish
VANDERBILT with satisfactory evidence of such withholding and payment in order to permit
VANDERBILT to obtain a tax credit or other relief as may be available under the applicable law or
treaty.
10.1 Provisions Contrary to Law. In performing this Agreement, the parties shall comply
with all applicable laws and regulations. In particular, it is understood and acknowledged that
the transfer of certain commodities and technical data is subject to United States laws and
regulations controlling the export of such commodities and technical data, including all Export
Administration Regulations of the United States Department of Commerce. These laws and regulations
among other things, prohibit or require a license for the export of certain types of technical
data to certain specified countries. LICENSEE hereby agrees and gives written assurance that it
will comply with all United States laws and regulations controlling the export of commodities and
technical data, that it will be solely responsible for any violation of such by LICENSEE or its
Affiliates, and that it will defend and hold VANDERBILT harmless in the event of any legal action
of any nature occasioned by such violation.
Nothing in this Agreement shall be construed so as to require the violation of any law, and
wherever there is any conflict between any provision of this Agreement and any law the law shall
prevail, but in such event the affected provision of this Agreement shall be affected only to the
extent necessary to bring it within the applicable law.
10.2 Notices. Any notice may be initially given by facsimile with confirmation required or
permitted to be given by this License by postpaid, first class, registered or certified mail
addressed as set forth below unless changed by notice so given:
9
|
|
|
For LICENSEE:
|
|
For VANDERBILT: |
|
|
|
Cumberland Pharmaceuticals Inc.
|
|
Office of Technology Transfer |
209 10th Ave. South, Suite 332
|
|
VANDERBILT University |
Nashville, Tennessee 37203
|
|
1207 17th Avenue, S., Suite 210 |
Fax: 615-259-9085
|
|
Nashville, TN 37212 |
|
|
Fax: 615-343-4419 |
|
|
|
With a copy to: |
|
|
|
|
|
Stokes & Bartholomew, P.A. |
|
|
424 Church Street, 28th Floor |
|
|
Nashville, Tennessee 37214 |
|
|
Attn: Martin S. Brown, Esq. |
|
|
Fax: 615-259-1470 |
|
|
Such notice shall be effective upon receipt by the party to whom notice is sent.
10.3 Dispute Resolution. The parties acknowledge and agree that they have entered into this
agreement with the expectation of a long-term, mutually beneficial relationship. However, should
disagreement arise regarding obligations imposed on the parties be this Agreement, it is agreed
that the parties will, in good faith, promptly attempt to reach an amicable resolution of such
disagreement.
10.4 Force Majeure. Neither party to this License Agreement shall be liable for delay or
failure in the performance of any of its obligations hereunder if such delay or failure is due to
causes beyond its reasonable control, including, without limitation, acts of God, fires,
earthquakes, strikes, and labor disputes, acts of was, civil unrest, or intervention of any
governmental authority, but any such delay or failure shall be remedied by such party as soon as is
reasonably possible. Failure to make timely royalty payments shall not be excused by Force
Majeure.
10.5 Assignments. Except in connection with the sale of all or substantially all of the
assets of either party, this Agreement may not be assigned by either party without the prior
written consent of the other party, which consent shall not be unreasonably withheld. The parties
hereto agree that each is acting as an independent contractor and not as an agent of the other or
as joint ventures.
10.6 Waivers and Modifications. The failure of any party to insist on the performance of
any obligation hereunder shall not act as a waiver of such obligation. No waiver, modification,
release, or amendment of any obligation under this Agreement shall be valid or effective unless in
writing and signed by both parties hereto.
10.7 Successors in Interest. This Agreement shall inure to the benefit of and be binding on
the parties permitted assigns, successors in interest, and subsidiaries.
10
10.8 Choice of Law and Jurisdiction. This Agreement is subject to and shall be construed
and enforced in accordance with the laws of the U.S.A., and Tennessee. Any action on any dispute
arising out of this Agreement shall be tried in Davidson County, and the parties consent to the
jurisdiction of the state and federal courts there.
10.9 Entire Agreement. This Agreement constitutes the entire agreement between the parties
as to the subject matter hereof, and all prior negotiations, representations, agreements and
understandings are merged into, extinguished by and completely expressed by this Agreement.
11
IN WITNESS WHEREOF, the parties have duly executed this Agreement on the date(s) written below.
|
|
|
|
|
|
|
|
|
|
|
LICENSEE |
|
|
|
VANDERBILT UNIVERSITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ A.J. Kazimi
|
|
|
|
By:
|
|
/s/ Larry R. Steranka
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A.J. Kazimi
|
|
|
|
|
|
Larry R. Steranka, Ph.D. |
|
|
Title:
|
|
President
|
|
|
|
Title:
|
|
Director, Office of Technology Transfer |
|
|
Date:
|
|
May 28, 1999
|
|
|
|
Date:
|
|
June 4, 1999 |
|
|
|
|
|
|
|
|
|
|
|
|
|
ACKNOWLEDGED AND AGREED |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Gordon R. Bernard, M.D. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A.J. Kazimi |
|
|
|
|
|
|
|
|
Title:
|
|
Professor of Medicine |
|
|
|
|
|
|
|
|
Date:
|
|
6/2/99 |
|
|
|
|
|
|
|
|
12
EX-10.11 EMPLOYMENT AGREEMENT
EXHIBIT 10.11
January 31, 2007
Mr. A.J. Kazimi
712 Overton Park
Nashville, Tennessee 37215
Re: Employment of A.J. Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc.
Dear A.J.:
Effective January 1st, 2007, this letter agreement (the Agreement) will evidence the
terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the
Company). In consideration of your appointment as Chief Executive Officer of the Company, and
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties agree as follows:
1. Compensation. The Company agrees to compensate you as follows:
(a) The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of three hundred three thousand three hundred ninety dollars ($303,390.00), payable in arrears in
equal monthly installments on the last day of each calendar month during the term of this
Agreement.
(b) You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
(c) You may be eligible for any Company bonus program, based upon performance in meeting your
individual objectives and the Companys overall performance, both as determined and approved by the
Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the
terms of the applicable bonus program, the terms of which program may be modified from year to year
in the sole discretion of the Companys Board of Directors.
(d) You have elected not to receive this year, as part of your 2007 compensation, an option
award to purchase Cumberland common shares.
(e) Except as set forth in Section 2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Companys prior written consent to reimburse you for such
expense.
CUMBERLAND PHARMACEUTICALS INC.
2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 Telephone: (615) 255-0068 Facsimile: (615) 255-0094
www.cumberlandpharma.com
January 31, 2007
A.J. Kazimi
Page 2.
2. Additional Payments. During the term hereof, you shall be entitled to
receive prompt reimbursement for all reasonable and documented expenses incurred in the performance
of services in accordance with the expense reimbursement policy of the Company.
3. Employment at Will. This Agreement is not intended to and shall not be understood
in any manner as affecting or modifying the at-will status of your employment with the Company. As
an at-will employee either you or the Company may terminated the employment relationship at any
time with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12
herein shall survive the termination of the employment relationship or of this Agreement.
4. Confidentiality. All knowledge and information, not already available to the
public, which you acquire, have acquired, or will acquire in the course of your employment with the
Company with respect to the Companys business, work methods, or pending regulatory matters, or
other Company matters that are treated by the Company as confidential, shall be regarded by you as
trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated
by you as strictly confidential. Such knowledge and information shall not either directly or
indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the
ordinary course of the Companys business under circumstances in which you are authorized to use or
disclose such information. No disclosures of such confidential information shall be made outside of
those you are authorized to make in the regular and ordinary course of your duties unless and until
you receive prior written permission of the Board of Directors of the Company to make such
disclosure.
5. Discoveries and Improvements. During the time that you are employed by the Company,
all confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you, alone or with others, that relate in any way to the Companys present or
planned business or products (collectively the Developments), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute Works for Hire (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
6. Publication. All documents and other writings produced by you during the period of
your employment, which relate to work you are doing or have done for the Company or to the business
of the Company or its affiliates, shall belong to the Company. You will not publish outside of the
Company any such writing without the prior written consent of the Board of Directors of the
January 31, 2007
A.J. Kazimi
Page 3.
Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
7. Litigation. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
8. Competition. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activitywhether as owner,
stockholder, partner, officer, consultant, or otherwiseinvolving a trademark, product, or process
that, in the opinion of the Companys President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Companys President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i) listed on a national securities
exchange, or (ii) having at least one hundred (100) stockholders shall not make you a stockholder
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term Affiliate shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
9. Conflicting Contracts. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
January 31, 2007
A.J. Kazimi
Page 4.
10. Solicitation. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
(a) You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting at
the time of your termination, or a firm which you knew or had reason to know that the Company was
going to solicit business at the time you ceased to be employed by the Company. The restriction set
forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all
the known facts relating to such solicitation and have received a release in writing from the Board
of Directors of the Company to engage in such solicitation.
(b) You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the
Company to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
11. Return of Documents. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This
includes, but is not limited to, trade secrets, confidential information, knowledge, data or
know-how, and software containing such information, whether or not the documents are marked
Confidential.
12. Remedies. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Companys remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys fees, to enforce the provisions of
this Agreement.
13. Debarment. You represent and warrant that you have not been debarred and will
notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the
Federal Food, Drug, and Cosmetic Act.
14. Notice. Any notice required or permitted to be given under this Agreement shall
be sufficient if in writing and if sent by registered or certified mail to your residence or to
the Companys principal office in the case of the Company.
15. Waiver. The waiver by either party of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.
January 31, 2007
A.J. Kazimi
Page 5.
16. Entire Agreement. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
17. Governance. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Companys sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
18. Enforceability. In the event that any provision of this Agreement shall be held
by a court to be unenforceable, such provision will be enforced to the maximum extent permissible,
and the remaining portions of this Agreement shall remain in full force and effect.
19. Survival. Notwithstanding any termination of your employment, this Agreement
shall survive and remain in effect in accordance with its terms.
This letter agreement may be signed in one or more counterparts, each of which shall be an
original and all of which will constitute one and the same instrument.
|
|
|
|
|
|
|
|
|
Sincerely yours, |
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Jean W. Marstiller |
|
|
|
|
|
|
|
|
|
By:
|
|
Jean W. Marstiller |
|
|
|
|
|
|
Corporate Secretary |
|
|
|
|
|
|
|
|
|
Accepted as to all terms
and conditions as |
|
|
|
|
|
|
of
the 7th of
February, 2007: |
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ A.J. Kazimi |
|
|
|
|
|
|
|
|
|
|
|
|
|
EX-10.12 EMPLOYMENT AGREEMENT
EXHIBIT 10.12
January 31, 2007
Mrs. Jean Marstiller
6251 Hillsboro Road
Nashville, TN 37215
|
|
|
Re: |
|
Employment of Jean W. Marstiller as Senior Vice President, Administrative Services by
Cumberland Pharmaceuticals Inc. |
Dear Jeanie:
Effective January 1st, 2007, this letter agreement (the Agreement) will
evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals
Inc. (the Company). In consideration of your appointment as Senior Vice President,
Administrative Services of the Company, and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties agree as follows:
1. Compensation. The Company agrees to compensate you as follows:
(a) The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of one hundred seventy thousand dollars ($170,000.00), payable in arrears in equal monthly
installments on the last day of each calendar month during the term of this Agreement.
(b) You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
(c) You may be eligible for any Company bonus program, based upon performance in meeting your
individual objectives and the Companys overall performance, both as determined and approved by the
Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the
terms of the applicable bonus program, the terms of which program may be modified from year to year
in the sole discretion of the Companys Board of Directors.
(d) You will receive a grant of options, as set forth in Exhibit A, to purchase Cumberland
common shares pursuant to an option agreement. Such options will be subject to the option agreement
and the terms set forth in the option plan under which they are awarded.
(e) Except as set forth in Section 2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Companys prior written consent to reimburse you for such
expense.
CUMBERLAND PHARMACEUTICALS INC.
2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 Telephone: (615) 255-0068 Facsimile: (615) 255-0094
www.cumberlandpharma.com
January 31, 2007
Jean W. Marstiller
Page 2.
2. Additional Payments. During the term hereof, you shall be entitled to
receive prompt reimbursement for all reasonable and documented expenses incurred in the performance
of services in accordance with the expense reimbursement policy of the Company.
3. Employment at Will. This Agreement is not intended to and shall not be understood
in any manner as affecting or modifying the at-will status of your employment with the Company. As
an at-will employee either you or the Company may terminated the employment relationship at any
time with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12
herein shall survive the termination of the employment relationship or of this Agreement.
4. Confidentiality. All knowledge and information, not already available to the
public, which you acquire, have acquired, or will acquire in the course of your employment with the
Company with respect to the Companys business, work methods, or pending regulatory matters, or
other Company matters that are treated by the Company as confidential, shall be regarded by you as
trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated
by you as strictly confidential. Such knowledge and information shall not either directly or
indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the
ordinary course of the Companys business under circumstances in which you are authorized to use or
disclose such information. No disclosures of such confidential information shall be made outside of
those you are authorized to make in the regular and ordinary course of your duties unless and until
you receive prior written permission of the Board of Directors of the Company to make such
disclosure.
5. Discoveries and Improvements. During the time that you are employed by the Company,
all confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you , alone or with others, that relate in any way to the Companys present or
planned business or products (collectively the Developments), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute Works for Hire (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
6.
Publication.
All documents and
other writings
produced by you
during the period
of your employment,
which relate to
work you are doing
or have done for
the Company or to
the business of the
Company or its
affiliates, shall
belong to the
Company. You will
not publish outside
of the Company any
such writing
without the prior
written consent of
the Board of
Directors of
the
January 31,
2007
Jean W. Marstiller
Page 3.
Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
7. Litigation. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
8. Competition. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activitywhether as owner,
stockholder, partner, officer, consultant, or otherwiseinvolving a trademark, product, or process
that, in the opinion of the Companys President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Companys President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i) listed on a national securities
exchange, or (ii) having at least one hundred (100) stockholders shall not make you a stockholder
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term Affiliate shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
9. Conflicting Contracts. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
January 31, 2007
Jean W. Marstiller
Page 4.
10. Solicitation. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
(a) You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting
at the time of your termination, or a firm which you knew or had reason to know that the Company
was going to solicit business at the time you ceased to be employed by the Company. The
restriction set forth in the preceding sentence shall not apply if you have disclosed to the
Company in writing all the known facts relating to such solicitation and have received a release
in writing from the Board of Directors of the Company to engage in such solicitation.
(b) You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the
Company to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
11. Return of Documents. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This
includes, but is not limited to, trade secrets, confidential information, knowledge, data or
know-how, and software containing such information, whether or not the documents are marked
Confidential.
12. Remedies. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Companys remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys fees, to enforce the provisions of
this Agreement.
13. Debarment. You represent and warrant that you have not been debarred and will
notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the
Federal Food, Drug, and Cosmetic Act.
14. Notice. Any notice required or permitted to be given under this Agreement shall
be sufficient if in writing and if sent by registered or certified mail to your residence or to
the Companys principal office in the case of the Company.
15. Waiver. The waiver by either party of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.
January 31, 2007
Jean W. Marstiller
Page 5.
16. Entire Agreement. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
17. Governance. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Companys sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
18. Enforceability. In the event that any provision of this Agreement shall be held by
a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and
the remaining portions of this Agreement shall remain in full force and effect.
19. Survival. Notwithstanding any termination of your employment, this Agreement shall
survive and remain in effect in accordance with its terms.
This letter agreement may be signed in one or more counterparts, each of which shall be an original
and all of which will constitute one and the same instrument.
|
|
|
|
|
|
|
Sincerely yours, |
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC.
|
|
|
|
|
|
|
|
|
|
/s/ A.J. Kazimi |
|
|
|
|
|
|
|
|
|
By: A.J. Kazimi |
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
Accepted as to all terms and conditions |
|
|
|
|
as of the 7th of February, 2007; |
|
|
|
|
|
|
|
|
|
/s/ Jean W. Marstiller |
|
|
|
|
|
|
|
|
|
January 31, 2007
Jean W. Marstiller
Page 6.
Exhibit A
Option Agreement
The Companys standard option agreement shall be forthcoming and shall incorporate the
following several terms:
1. |
|
Subject to the terms therein, the Company will provide a grant of options under its 1999
Stock Option Plan upon the Effective Date of the Agreement to purchase up to six thousand
(6,000) of its shares of common stock. |
2. |
|
Based on your individual performance and the overall performance of the Company, and as
determined by the Board of Directors, up to 1,500 options will vest on each 31st
of December over the four-year period from 2007-2010. |
3. |
|
The options awarded will have an Exercise Price of twenty-two dollars ($22.00) per
share. |
4. |
|
The options awarded will have a term of ten years from grant date. |
5. |
|
Upon termination of employment, the employee will vest the number of options that
otherwise would have vested through the date of termination of employment including those
pro-rated to the actual percent of working time during the calendar year. |
It is important that, after you receive your option agreement and other related documents, you read
and understand the terms and conditions of the option agreement. The Company recommends that you
always seek guidance from your personal accountant or tax advisor prior to initiating any exercise
or action involving your option agreement.
EX-10.13 EMPLOYMENT AGREEMENT
EXHIBIT 10.13
January 31, 2007
Mr. Leo Pavliv
707 Walcott Way
Cary, NC 27519
Re: Employment of Leo Pavliv as Vice President, Operations by Cumberland Pharmaceuticals Inc.
Dear Leo:
Effective January 1st, 2007, this letter agreement (the Agreement) will evidence the
terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the
Company). In consideration of your appointment as Vice President, Operations of the Company, and
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties agree as follows:
1. Compensation. The Company agrees to compensate you as follows:
(a) The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of two hundred eleven thousand dollars ($211,000.00), payable in arrears in equal monthly
installments on the last day of each calendar month during the term of this Agreement.
(b) You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
(c) You may be eligible for any Company bonus program, based upon performance in meeting your
individual objectives and the Companys overall performance, both as determined and approved by the
Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the
terms of the applicable bonus program, the terms of which program may be modified from year to year
in the sole discretion of the Companys Board of Directors.
(d) You will receive a grant of options, as set forth in Exhibit A, to purchase Cumberland
common shares pursuant to an option agreement. Such options will be subject to the option agreement
and the terms set forth in the option plan under which they are awarded.
(e) Except as set forth in Section 2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Companys prior written consent to reimburse you for such
expense.
CUMBERLAND PHARMACEUTICALS INC.
2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 Telephone: (615) 255-0068 Facsimile: (615) 255-0094
www.cumberlandpharma.com
January 31, 2007
Leo Pavliv
Page 2.
2. Additional Payments. During the term hereof, you shall be entitled to receive
prompt reimbursement for all reasonable and documented expenses incurred in the performance of
services in accordance with the expense reimbursement policy of the Company.
3. Employment at Will. This Agreement is not intended to and shall not be understood in any
manner as affecting or modifying the at-will status of your employment with the Company. As an
at-will employee either you or the Company may terminated the employment relationship at any time
with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein
shall survive the termination of the employment relationship or of this Agreement.
4. Confidentiality. All knowledge and information, not already available to the public,
which you acquire, have acquired, or will acquire in the course of your employment with the Company
with respect to the Companys business, work methods, or pending regulatory matters, or other
Company matters that are treated by the Company as confidential, shall be regarded by you as trade
secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you
as strictly confidential. Such knowledge and information shall not either directly or indirectly be
used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course
of the Companys business under circumstances in which you are authorized to use or disclose such
information. No disclosures of such confidential information shall be made outside of those you are
authorized to make in the regular and ordinary course of your duties unless and until you receive
prior written permission of the Board of Directors of the Company to make such disclosure.
5. Discoveries and Improvements. During the time that you are employed by the Company, all
confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you , alone or with others, that relate in any way to the Companys present or
planned business or products (collectively the Developments), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute Works for Hire (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
6. Publication.
All documents and
other writings
produced by you
during the period
of your employment,
which relate to
work you are doing
or have done for
the Company or to
the business of the
Company or its
affiliates, shall
belong to the
Company. You will
not publish outside
of the Company any
such writing
without the prior
written consent of
the Board of
Directors of
the
January 31, 2007
Leo Pavliv
Page 3.
Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
7. Litigation. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
8. Competition. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activitywhether as owner,
stockholder, partner, officer, consultant, or otherwiseinvolving a trademark, product, or process
that, in the opinion of the Companys President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Companys President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i) listed on a national securities
exchange, or (ii) having at least one hundred (100) stockholders shall not make you a stockholder
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term Affiliate shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
9. Conflicting Contracts. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
January 31, 2007
Leo Pavliv
Page 4.
10. Solicitation. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
(a) You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting at
the time of your termination, or a firm which you knew or had reason to know that the Company was
going to solicit business at the time you ceased to be employed by the Company. The restriction set
forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all
the known facts relating to such solicitation and have received a release in writing from the Board
of Directors of the Company to engage in such solicitation.
(b) You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company
to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
11. Return of Documents. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This includes,
but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and
software containing such information, whether or not the documents are marked Confidential.
12. Remedies. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Companys remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys fees, to enforce the provisions of
this Agreement.
13. Debarment. You represent and warrant that you have not been debarred and will
notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the
Federal Food, Drug, and Cosmetic Act.
14. Notice. Any notice required or permitted to be given under this Agreement shall be
sufficient if in writing and if sent by registered or certified mail to your residence or to the
Companys principal office in the case of the Company.
15. Waiver. The waiver by either party of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.
January 31, 2007
Leo Pavliv
Page 5.
16. Entire Agreement. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
17. Governance. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Companys sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
18. Enforceability. In the event that any provision of this Agreement shall be held by
a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and
the remaining portions of this Agreement shall remain in full force and effect.
19. Survival. Notwithstanding any termination of your employment, this Agreement shall
survive and remain in effect in accordance with its terms.
This letter agreement may be signed in one or more counterparts, each of which shall be an original
and all of which will constitute one and the same instrument.
|
|
|
|
|
|
|
|
|
Sincerely yours, |
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
|
|
/s/ A.J. Kazimi |
|
|
|
|
|
|
|
|
|
By:
|
|
A.J. Kazimi |
|
|
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
Accepted as to all terms and conditions |
|
|
|
|
|
|
as of the 14th of February, 2007: |
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Leo Pavliv |
|
|
|
|
|
|
|
|
|
|
|
|
|
January 31, 2007
Leo Pavliv
Page 6.
Exhibit A
Option Agreement
The Companys standard option agreement shall be forthcoming and shall incorporate the
following several terms:
1. |
|
Subject to the terms therein, the Company will provide a grant of options under its 1999
Stock Option Plan upon the Effective Date of the Agreement to purchase up to six thousand
(6,000) of its shares of common stock. |
|
2. |
|
Based on your individual performance and the overall performance of the Company, and as
determined by the Board of Directors, up to 1,500 options will vest on each 31st
of December over the four-year period from 2007-2010. |
|
3. |
|
The options awarded will have an Exercise Price of twenty-two dollars ($22.00) per
share. |
|
4. |
|
The options awarded will have a term of ten years from grant date. |
|
5. |
|
Upon termination of employment, the employee will vest the number of options that otherwise
would have vested through the date of termination of employment including those pro-rated to
the actual percent of working time during the calendar year. |
It is important that, after you receive your option agreement and other related documents, you read
and understand the terms and conditions of the option agreement. The Company recommends that you
always seek guidance from your personal accountant or tax advisor prior to initiating any exercise
or action involving your option agreement.
EX-10.14 EMPLOYMENT AGREEMENT
EXHIBIT 10.14
January 23, 2007
Mr. James William Hix
127 Abigail Avenue
Murfreesboro, TN 37129
Re: Employment of Bill Hix as VP, Sales and Marketing by Cumberland Pharmaceuticals Inc.
Dear Bill:
Effective February 1st, 2007, this letter agreement (the Agreement) will evidence the
terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the
Company). In consideration of your appointment as Vice President, Sales and Marketing of the
Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:
1. Compensation. The Company agrees to compensate you as follows:
(a) The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of one hundred eighty thousand dollars ($180,000.00), payable in arrears in equal monthly
installments on the last day of each calendar month during the term of this Agreement.
(b) You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
(c) You may be eligible for any Company bonus program, with a potential annual bonus of up to
$45,000.00, based upon performance in meeting your individual objectives and the Companys overall
performance, both as determined and approved by the Board of Directors of the Company. Any such
bonus will be discretionary and will be subject to the terms of the applicable bonus program, the
terms of which program may be modified from year to year in the sole discretion of the Companys
Board of Directors.
(d) You
will receive a grant of options, as set forth in Exhibit A, to purchase Cumberland common
shares pursuant to an option agreement. Such options will be subject to the option agreement and
the terms set forth in the option plan under which they are awarded.
(e) Except as set forth in Section 2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Companys prior written consent to reimburse you for such
expense.
CUMBERLAND PHARMACEUTICALS INC.
2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 Telephone: (615) 255-0068 Facsimile: (615) 255-0094
www.cumberlandpharma.com
January 23, 2007
James William Hix
Page 2.
2. Additional Payments. During the term hereof, you shall be entitled to
receive prompt reimbursement for all reasonable and documented expenses incurred in the performance
of services in accordance with the expense reimbursement policy of the Company.
3. Employment at Will. This Agreement is not intended to and shall not be understood
in any manner as affecting or modifying the at-will status of your employment with the Company. As
an at-will employee either you or the Company may terminated the employment relationship at any
time with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12
herein shall survive the termination of the employment relationship or of this Agreement.
4. Confidentiality. All knowledge and information, not already available to the
public, which you acquire, have acquired, or will acquire in the course of your employment with the
Company with respect to the Companys business, work methods, or pending regulatory matters, or
other Company matters that are treated by the Company as confidential, shall be regarded by you as
trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated
by you as strictly confidential. Such knowledge and information shall not either directly or
indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the
ordinary course of the Companys business under circumstances in which you are authorized to use or
disclose such information. No disclosures of such confidential information shall be made outside of
those you are authorized to make in the regular and ordinary course of your duties unless and until
you receive prior written permission of the Board of Directors of the Company to make such
disclosure.
5. Discoveries and Improvements. During the time that you are employed by the Company,
all confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you , alone or with others, that relate in any way to the Companys present or
planned business or products (collectively the Developments), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute Works for Hire (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
6. Publication. All documents and other writings produced by you during the period of
your employment, which relate to work you are doing or have done for the Company or to the business
of the Company or its affiliates, shall belong to the Company. You will not publish outside of the
Company any such writing without the prior written consent of the Board of Directors of the
January 23, 2007
James William Hix
Page 3.
Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
7. Litigation. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
8. Competition. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activitywhether as owner,
stockholder, partner, officer, consultant, or otherwiseinvolving a trademark, product, or process
that, in the opinion of the Companys President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Companys President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i) listed on a national securities
exchange, or (ii) having at least one hundred (100) stockholders shall not make you a stockholder
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term Affiliate shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
9. Conflicting Contracts. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
January 23, 2007
James William Hix
Page 4.
10. Solicitation. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
(a) You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting at
the time of your termination, or a firm which you knew or had reason to know that the Company was
going to solicit business at the time you ceased to be employed by the Company. The restriction set
forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all
the known facts relating to such solicitation and have received a release in writing from the Board
of Directors of the Company to engage in such solicitation.
(b) You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company
to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
11. Return of Documents. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This includes,
but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and
software containing such information, whether or not the documents are marked Confidential.
12. Remedies. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Companys remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys fees, to enforce the provisions of
this Agreement.
13. Debarment. You represent and warrant that you have not been debarred and will
notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the
Federal Food, Drug, and Cosmetic Act.
14. Notice. Any notice required or permitted to be given under this Agreement shall be
sufficient if in writing and if sent by registered or certified mail to your residence or to the
Companys principal office in the case of the Company.
15. Waiver. The waiver by either party of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.
January 23, 2007
James William Hix
Page 5.
16. Entire Agreement. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
17. Governance. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Companys sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
18. Enforceability. In the event that any provision of this Agreement shall be held by
a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and
the remaining portions of this Agreement shall remain in full force and effect.
19. Survival. Notwithstanding any termination of your employment, this Agreement
shall survive and remain in effect in accordance with its terms.
This letter agreement may be signed in one or more counterparts, each of which shall be an original
and all of which will constitute one and the same instrument.
|
|
|
|
|
|
|
|
|
Sincerely yours, |
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
|
|
/s/ A.J. Kazimi |
|
|
|
|
|
|
|
|
|
By:
|
|
A.J. Kazimi |
|
|
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
|
Accepted as to all terms and conditions |
|
|
|
|
|
|
as of the 23rd of January, 2007: |
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ James William Hix |
|
|
|
|
|
|
|
|
|
|
|
|
|
January 23, 2007
James William Hix
Page 6.
Exhibit A
Option Agreement
The Companys standard option agreement shall be forthcoming and shall incorporate the
following several terms:
1 |
|
Subject to the terms therein, the Company will provide a grant of options under its 1999
Stock Option Plan upon the Effective Date of the Agreement to purchase up to five thousand
(5,000) of its shares of common stock. |
|
2. |
|
Based on your individual performance and the overall performance of the Company, and as
determined by the Board of Directors, up to 1,250 options will vest on each 31st
of December over the four-year period from 2007-2010. |
|
3. |
|
The options awarded will have an Exercise Price of twenty-two dollars ($22.00) per
share. |
|
4. |
|
The options awarded will have a term of ten years from grant date. |
|
5. |
|
Upon termination of employment, the employee will vest the number of options that
otherwise would have vested through the date of termination of employment including those
pro-rated to the actual percent of working time during the calendar year. |
It is important that, after you receive your option agreement and other related documents, you read
and understand the terms and conditions of the option agreement. The Company recommends that you
always seek guidance from your personal accountant or tax advisor prior to initiating any exercise
or action involving your option agreement.
EX-10.15 EMPLOYMENT AGREEMENT
EXHIBIT 10.15
January 31, 2007
Mr. David L. Lowrance
422 William Wallace Drive
Franklin, TN 37064
|
|
|
Re: |
|
Employment of David L. Lowrance as Vice President, Finance and Accounting by
Cumberland Pharmaceuticals Inc. |
Dear Dave:
Effective January 1st, 2007, this letter agreement (the Agreement) will evidence
the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc.
(the Company). In consideration of your appointment as Vice President, Finance and Accounting
of the Company, and other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the parties agree as follows:
1. Compensation. The Company agrees to compensate you as follows:
(a) The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of one hundred fifty-eight thousand four hundred dollars ($158,400.00), payable in arrears in equal
monthly installments on the last day of each calendar month during the term of this Agreement.
(b) You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
(c) You may be eligible for any Company bonus program, based upon performance in meeting your
individual objectives and the Companys overall performance, both as determined and approved by the
Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the
terms of the applicable bonus program, the terms of which program may be modified from year to year
in the sole discretion of the Companys Board of Directors.
(d) You will receive a grant of options, as set forth in Exhibit A, to purchase Cumberland
common shares pursuant to an option agreement. Such options will be subject to the option agreement
and the terms set forth in the option plan under which they are awarded.
(e) Except as set forth in Section 2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Companys prior written consent to reimburse you for such
expense.
CUMBERLAND PHARMACEUTICALS INC.
2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 Telephone: (615) 255-0068 Facsimile: (615) 255-0094
www.cumberlandpharma.com
January 31, 2007
David L. Lowrance
Page 2.
2. Additional Payments.
(a) During the term hereof, you shall be entitled to receive prompt reimbursement for all
reasonable and documented expenses incurred in the performance of Services in accordance with the
expense reimbursement policy of the Company.
(b) Assuming you maintain an active license, the Company agrees to pay the following expenses
which are professional costs associated with your CPA: Tennessee Department of Revenue Professional
Privilege Tax, Continuing Professional Education (the Company will reimburse 32 hours of the 40
hours required per year), Tennessee Society of CPAs Annual Membership (excludes elective fees), and
the Tennessee State Board of Accounting License Fee.
3. Employment at Will. This Agreement is not intended to and shall not be understood
in any manner as affecting or modifying the at-will status of your employment with the Company. As
an at-will employee either you or the Company may terminated the employment relationship at any
time with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12
herein shall survive the termination of the employment relationship or of this Agreement.
4. Confidentiality. All knowledge and information, not already available to the
public, which you acquire, have acquired, or will acquire in the course of your employment with the
Company with respect to the Companys business, work methods, or pending regulatory matters, or
other Company matters that are treated by the Company as confidential, shall be regarded by you as
trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated
by you as strictly confidential. Such knowledge and information shall not either directly or
indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the
ordinary course of the Companys business under circumstances in which you are authorized to use or
disclose such information. No disclosures of such confidential information shall be made outside of
those you are authorized to make in the regular and ordinary course of your duties unless and until
you receive prior written permission of the Board of Directors of the Company to make such
disclosure.
5. Discoveries and Improvements. During the time that you are employed by the Company,
all confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you , alone or with others, that relate in any way to the Companys present or
planned business or products (collectively the Developments), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute Works for Hire (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
January 31, 2007
David L. Lowrance
Page 3.
6. Publication. All documents and other writings produced by you during the period
of your employment, which relate to work you are doing or have done for the Company or to the
business of the Company or its affiliates, shall belong to the Company. You will not publish
outside of the Company any such writing without the prior written consent of the Board of Directors
of the Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
7. Litigation. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
8. Competition. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activitywhether as owner,
stockholder, partner, officer, consultant, or otherwiseinvolving a trademark, product, or process
that, in the opinion of the Companys President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Companys President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i) listed on a national securities
exchange, or (ii) having at least one hundred (100) stockholders shall not make you a stockholder
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term Affiliate shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
9. Conflicting Contracts. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
January 31, 2007
David L, Lowrance
Page 4.
10. Solicitation. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
(a) You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting at
the time of your termination, or a firm which you knew or had reason to know that the Company was
going to solicit business at the time you ceased to be employed by the Company. The restriction set
forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all
the known facts relating to such solicitation and have received a release in writing from the Board
of Directors of the Company to engage in such solicitation.
(b) You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company
to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
11. Return of Documents. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This includes,
but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and
software containing such information, whether or not the documents are marked Confidential.
12. Remedies. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Companys remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys fees, to enforce the provisions of
this Agreement.
13. Debarment. You represent and warrant that you have not been debarred and will notify
the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal
Food, Drug, and Cosmetic Act.
14. Notice. Any notice required or permitted to be given under this Agreement shall be
sufficient if in writing and if sent by registered or certified mail to your residence or to the
Companys principal office in the case of the Company.
15. Waiver. The waiver by either party of any provision of this Agreement shall not operate
or be construed as a waiver of any subsequent breach.
January 31, 2007
David L. Lowrance
Page 5.
16. Entire Agreement. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
17. Governance. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Companys sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
18. Enforceability. In the event that any provision of this Agreement shall be held by
a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and
the remaining portions of this Agreement shall remain in full force and effect.
19. Survival. Notwithstanding any termination of your employment, this Agreement shall
survive and remain in effect in accordance with its terms.
This letter agreement may be signed in one or more counterparts, each of which shall be an original
and all of which will constitute one and the same instrument.
|
|
|
|
|
|
|
|
|
Sincerely yours, |
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
|
|
/s/ A.J. Kazimi |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
A.J. Kazimi |
|
|
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
|
Accepted as to all terms
and conditions |
|
|
|
|
|
|
as of the 20th of
February, 2007: |
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ David L. Lowrance |
|
|
|
|
|
|
|
|
|
|
|
|
|
January 31, 2007
David L. Lowrance
Page 6.
Exhibit A
Option Agreement
The Companys standard option agreement shall be forthcoming and shall incorporate the
following several terms:
1 |
|
Subject to the terms therein, the Company will provide a grant of options under its 1999
Stock Option Plan upon the Effective Date of the Agreement to purchase up to five thousand
(5,000) of its shares of common stock. |
|
2. |
|
Based on your individual performance and the overall performance of the Company, and as
determined by the Board of Directors, up to 1,250 options will vest on each 31st
of December over the four-year period from 2007-2010. |
|
3. |
|
The options awarded will have an Exercise Price of twenty-two dollars ($22.00) per
share. |
|
4. |
|
The options awarded will have a term of ten years from grant date. |
|
5. |
|
Upon termination of employment, the employee will vest the number of options that otherwise
would have vested through the date of termination of employment including those pro-rated to
the actual percent of working time during the calendar year. |
It is important that, after you receive your option agreement and other related documents, you read
and understand the terms and conditions of the option agreement. The Company recommends that you
always seek guidance from your personal accountant or tax advisor prior to initiating any exercise
or action involving your option agreement.
EX-10.17 1999 STOCK OPTION PLAN
EXHIBIT 10.17
CUMBERLAND PHARMACEUTICALS INC.
1999 STOCK OPTION PLAN
WHEREAS, Cumberland Pharmaceuticals Inc. (the Company) desires to establish a plan through
which the Company may award options to purchase the common stock of the Company, or the right to
receive compensation due to the increase in the value of the common stock of the Company, to
directors, officers, employees, and consultants of the Company and its affiliates;
WHEREAS, the Company desires to grant options that qualify as incentive stock options within
the meaning of section 422 of the Internal Revenue Code of 1986, and options that are not so
qualified; and
WHEREAS, the Company intends that this stock option plan and the methods granted hereunder (i)
qualify as performance-based compensation described in section 162(m)(4)(C) of the Code, and (ii)
conform to the provisions of Rule 16b-3 of the Securities Exchange Act of 1934, as amended;
NOW, THEREFORE, the Company hereby establishes the Cumberland Pharmaceuticals Inc. 1999 Stock
Option Plan (the Plan), effective on the date of its adoption by the Board of Directors of the
Company:
ARTICLE I. DEFINITIONS
1.1 Affiliate. A parent corporation, as defined in section 424(e) of the Code, or
subsidiary corporation, as defined in Section 424(f) of the Code, of the Company.
1.2 Agreement. A written agreement (including any amendment or supplement thereto)
between the Company or Affiliate and a Participant specifying the terms and conditions of an Option
granted to such Participant.
1.3 Board. The Board of Directors of the Company.
1.4 Code. The Internal Revenue Code of 1986, as amended.
1.5 Committee. A committee composed of individuals who are designated by the Board as
the compensation committee or are otherwise designated to administer the Plan.
1.6 Company. Cumberland Pharmaceuticals Inc. and its successors.
1.7 Date of Exercise. The date that the Company accepts tender of the Option exercise
price of an Incentive Option or Nonqualified Option, or accepts an election to exercise rights
under an SAR.
1.8 Exchange Act. The Securities Exchange Act of 1934, as amended.
1
1.9 Fair Market Value. On any given date, Fair Market Value shall be the mean between
the closing bid and the asked price of the Stock on the National Associations of Securities Dealers
Automated Quotations System (NASDAQ), or if no such quotation is listed on NASDAQ, the Fair
Market Value as determined and fixed by the Board; provided that in the case of Incentive Options,
Fair Market Value shall in no event be less than 100% of the fair market value of the stock on the
date of grant of such option.
1.10 Incentive Option. The right that is granted hereunder to a participant to
purchase from the Company a stated number of shares of Stock at the price set forth in an Agreement
and that is subject to certain provisions herein and to incentive stock options that are
described in Section 422 of the Code. An Incentive Option, or a portion thereof, shall not be
invalid for failure to qualify under Section 422 of the Code, but shall be treated as a
Nonqualified Option to the extent that it does not satisfy such conditions.
1.11 Nonqualified Option. The right that is granted hereunder to a Participant to
purchase from the Company a stated number of shares of Stock at the price set forth in an
Agreement, but is not subject to the conditions of an Incentive Option.
1.12 Option. The right that is granted hereunder to a Participant under the terms of
an Incentive Option, a Nonqualified Option or an SAR.
1.13 Participant. A Board member, employee, consultant or advisor of the Company or of
an Affiliate who: either satisfies the requirements of Article IV and is selected by the Committee
to receive an Option, or receives an Option pursuant to a grant specified in this Plan.
1.14 Plan. The Cumberland Pharmaceuticals Inc. 1999 Stock Option Plan.
1.15 SAR. A right to receive compensation hereunder calculated by reference to the
increase in the value of a certain number of shares of Stock from the date of an award, as
described in Section 4.5. An SAR is an unfunded, unsecured promise of the Company to the
Participant. Unless otherwise stated in an Agreement, or unless the Committee in its discretion
honors the exercise of an SAR by issuing Stock, the holder of an SAR has no beneficial rights of
Stock ownership or to receive shares of Stock.
1.16 Stock. The common stock of the Company.
1.17 Ten Percent Shareholder. An individual who owns more than 10% of the total
combined voting power of all classes of stock of the Company or an Affiliate at the time he is
granted an Incentive Option. For the purpose of determining if an individual is a Ten Percent
Shareholder, he shall be deemed to own any voting stock owned (directly or indirectly) by or for
his brothers and sisters (whether by whole or half blood), spouse, ancestors or lineal descendants
and shall be considered to own proportionately any voting stock owned (directly or indirectly) by
or for a corporation, partnership, estate or trust of which such individual is a shareholder,
partner or beneficiary.
ARTICLE II. PURPOSE OF PLAN
The purpose of the Plan is to provide a performance incentive and to encourage stock ownership by
officers, directors, consultants and advisors of the Company and its Affiliates, and to align the
interests of such individuals with those of the Company, its Affiliates and its shareholders. It is
intended that Participants may acquire or increase their proprietary interests in the Company and
be encouraged to remain
2
in the employ or directorship of the Company or of its Affiliates. The proceeds received by the
Company from the sale of Stock pursuant to this Plan may be used for general corporate purposes.
ARTICLE III. ADMINISTRATION
3.1 Administration of Plan. The Plan shall be administered by the Committee. The
express grant in the Plan of any specific power to the Committee shall not be construed as limiting
any power or authority of the Committee. Any decision made or action taken by the Committee to
administer the Plan shall be final and conclusive. No member of the Committee shall be liable for
any act done in good faith with respect to this Plan or any Agreement or Option. The Company shall
bear all expenses of Plan administration. In addition to all other authority vested with the
Committee under the Plan, the Committee shall have complete authority to:
|
(a) |
|
Interpret all provisions of this Plan; |
|
|
(b) |
|
Prescribe the form of any Agreement and notice and manner for executing or
giving the same; |
|
|
(c) |
|
Make amendments to all Agreements; |
|
|
(d) |
|
Adopt, amend, and rescind rules for Plan administration; and |
|
|
(e) |
|
Make all determinations it deems advisable for the administration of this Plan. |
3.2 Authority to Grant Options. The Committee shall have authority to grant Options
upon such terms the Committee deems appropriate and that are not inconsistent with the provisions
of this Plan. Such terms may include conditions on the exercise of all or any part of an Option.
3.3 Persons Subject to Section 16(b). Notwithstanding anything in the Plan to the
contrary, the Committee, in its absolute discretion, may bifurcate the Plan so as to restrict,
limit or condition the use of any provision of the Plan to participants who are officers and
directors subject to Section 16(b) of the Exchange Act, without so restricting, limiting or
conditioning the Plan with respect to other Participants.
ARTICLE IV. ELIGIBILITY AND LIMITATIONS ON GRANTS
4.1 Participation. The Committee may from time to time designate directors, employees,
consultants and advisors to whom Options are to be granted and who are eligible to become
Participants. Such designation shall specify the number of shares of Stock, if any, subject to each
Option. All Options granted under this Plan shall be evidenced by Agreements which shall be subject
to applicable provisions of this Plan or such other provisions as the Committee may adopt that are
not inconsistent with the Plan.
4.2 Grant of Options. An Option shall be deemed to be granted to a Participant at the
time that the Committee designates in a writing that is adopted by the Committee as the grant of an
Option, and that makes reference to the name of the Participant and the number of shares of Stock
that are subject to the Option. Accordingly, an Option may be deemed to be granted prior to the
approval of this Plan by the shareholders of the Company and prior to the time that an Agreement is
executed by the Participant and the Company.
3
4.3 Limitations on Grants. A person who is not an employee of the Company or an
Affiliate is not eligible to receive an Incentive Option.
4.4 Limitation on Incentive Options. To the extent that the aggregate Fair Market
Value of Stock with respect to which Incentive Options are exercisable for the first time by a
Participant during any calendar year (under all incentive stock option plans of the Company and its
Affiliates) exceeds $100,000 (or the amount specified in Section 422 of the Code), determined as of
the date an Incentive Option is granted, such Options shall be treated as Nonqualified Options.
This provision shall be applied by taking Incentive Options into account in the order in which they
were granted.
4.5 Stock Appreciation Rights. The Committee may grant an SAR to a Participant either
in tandem with the grant of an Incentive Option or a Nonqualified Option, or as an award that is
separate from any other Option granted under the Plan. Subject to the terms of an Agreement, a
Participant who receives an SAR shall have the right, upon written request, to surrender any
exercisable Incentive Option or Nonqualified Option, or portion thereof, in exchange for cash,
whole shares of Stock, or a combination thereof, as determined by the Committee, with a value equal
to the excess of the Fair Market Value, as of the date of such request, of one share of Stock over
the Fair Market Value of the Stock on the Date of Grant (or such other value specified in the
Agreement), multiplied by the number of shares covered by the SAR or portion thereof to be
surrendered. In the case of any SAR which is granted in connection with an Incentive Stock Option,
such SAR shall be exercisable only when the Fair Market Value of the Stock exceeds the price
specified therefor in the SAR or portion thereof to be surrendered. In the event of the exercise of
any SAR granted hereunder, the number of shares reserved for issuance under the Plan shall be
reduced only to the extent that shares of Stock are actually issued in connection with the exercise
of such SAR. Additional terms and conditions governing any such SARs may from time to time be
prescribed by the Committee in its sole discretion.
ARTICLE V. STOCK SUBJECT TO PLAN
5.1 Source of Shares. Upon the exercise of an Incentive Option or Nonqualified Option,
the Company shall deliver to the Participant authorized but unissued Stock.
5.2 Maximum Number of Shares. The maximum aggregate number of shares of Stock that may
be issued under the Plan pursuant to the exercise of Incentive Options and Nonqualified Options, or
with respect to which SARs may be exercised, is 5,000,000, subject to increases and adjustments as
provided in this Article V and Article VIII hereof.
5.3 Forfeitures. If any Option granted hereunder expires or terminates for any reason
without having been exercised in full, the unpurchased shares subject thereto shall again be
available for issuance under this Plan.
4
ARTICLE VI. EXERCISE OF OPTIONS
6.1 Exercise Price. The exercise price of an Incentive Option shall be not less than
100% of the Fair Market Value of a share of Stock on the date the Incentive Option is granted. In
the case of a Ten Percent Shareholder, however, the exercise price of an Incentive Option shall not
be less than 110% of the Fair Market Value of a share of Stock on the date the Incentive Option is
granted. The exercise price of a Nonqualified Option or an SAR shall be the price determined by the
Committee at the time the Nonqualified Option or SAR is granted. If the exercise price of an Option
is changed after the date it is granted, such change shall be deemed to be a termination of the
existing Option and the issuance of a new Option.
6.2 Right to Exercise. An Option shall be exercisable on the date of grant or any
other date established by the Committee or provided for in the agreement; provided, however, that
Options granted to officers or directors subject to Section 16 of the Exchange Act must not be
exercisable until at least six months after the Option is granted. A Participant must exercise an
Incentive Option while he is an employee of the Company or an Affiliate or within the periods that
may be specified in the Agreement after termination of employment, death, disability, or a change
of control (as defined in any change of control agreement to which the Company and any such
Participant are parties).
6.3 Maximum Exercise Period. The maximum period in which an Option may be exercised
shall be determined by the Committee on the date of grant except that no Incentive Option shall be
exercisable after the expiration of 10 years (five years in the case of Incentive Options granted
to a Ten Percent Shareholder) from the date it was granted. The terms of any Option may provide
that it is exercisable for a shorter period. All Incentive Options shall terminate on the date that
the Participants employment with the Company terminates, except as otherwise provided in the
Agreement with respect to termination of employment, death, disability or a change of control (as
defined in any change of control agreement to which the Company and any such Participant are
parties).
6.4 Transferability. Any Option granted under this Plan shall not be transferable
except by will or by the laws of descent and distribution, and shall be exercisable during the
lifetime of the Participant only by the Participant; provided, however, that any Nonqualified
Option granted under this Plan may be transferable to the extent provided in an Agreement. No right
or interest of a Participant in any Option shall be liable for, or subject to, any lien, obligation
or liability of such Participant.
6.5 Employee Status. The Committee shall determine the extent to which a leave of
absence for military or government service, illness, temporary disability, or other reasons shall
be treated as a termination or interruption of employment for purposes of determining questions of
forfeiture and exercise of an Option after termination of employment; provided, however, that if
the period treated as employment with respect to an Incentive Plan exceeds 90 days, such Option
shall be deemed a Nonqualified Option.
ARTICLE VII. METHOD OF EXERCISE
7.1 Exercise. An Option granted hereunder shall be deemed to have been exercised on
the Date of Exercise. Subject to the provisions of Articles VI, VIII and IX, an Option may be
exercised in whole or in part at such times and in compliance with such requirements as the
Committee shall determine.
5
7.2 Payment. Unless otherwise provided by the Agreement, payment of the Option price
shall be made in cash or to the extent approved by the Committee, Stock that was acquired prior to
the exercise of the Option, other consideration acceptable to the Committee, or a combination
thereof.
7.3 Federal Withholding Tax Requirements. Upon exercise of a Nonqualified Option or an
SAR by a Participant who is an employee of the Company or an Affiliate, the Participant shall, upon
notification of the amount due and prior to or concurrently with the delivery of the certificates
representing the shares, pay to the Company amounts necessary to satisfy applicable federal, state
and local withholding tax requirements or shall otherwise make arrangements satisfactory to the
Company for such requirements. Such withholding requirements shall not apply to the exercise of an
Incentive Option, or to a disqualifying disposition of Stock that is acquired with an Incentive
Option, unless the Committee gives the Participant notice that withholding described in this
Section is required.
7.4 Shareholder Rights. No Participant shall have any rights as a stockholder with
respect to shares subject to his Option prior to the Date of Exercise of such Option. No
Participant shall acquire rights as a stockholder through the grant or exercise of an SAR, except
to the extent which the Committee, in its sole discretion, issues Stock to the Participant as
payment upon the exercise of the SAR.
7.5 Issuance and Delivery of Shares. Shares of Stock issued pursuant to the exercise
of Options hereunder shall be delivered to Participants by the Company as soon as administratively
feasible after a Participant exercises an Option hereunder and executes any applicable shareholder
agreement or agreement described in Section 9.2 that the Company requires at the time of exercise.
ARTICLE VIII. ADJUSTMENT UPON CORPORATE CHANGES
8.1 Adjustments to Shares. The maximum number of shares of stock with respect to which
Options hereunder may be granted and which are the subject of outstanding Options shall be adjusted
as the Committee determines (in its sole discretion) to be appropriate, in the event that:
|
(a) |
|
the Company or an Affiliate effects one or more stock dividends, stock splits,
reverse stock splits, subdivisions, consolidations, capitalization issue, rights issue
or other similar events; |
|
|
(b) |
|
the Company or an Affiliate engages in a transaction to which section 424 of
the Code applies; or |
|
|
(c) |
|
there occurs any other event which in the judgment of the Committee
necessitates such action; |
provided, however, that if an event described in paragraph (a) or (b) occurs, the Committee shall
make adjustments to the limits on Options specified in Section 4.3 that are proportionate to the
modifications of the Stock that are on account of such corporate changes. Notwithstanding the
foregoing, the Committee may not modify the Plan or the terms of any Options then outstanding or to
be granted hereunder to provide for the issuance under the Plan of a different class of stock or
kind of securities.
8.2 Substitution of Options on Merger or Acquisition. The Committee may grant Options in
substitution for stock awards, stock options, stock appreciation rights or similar awards held by
an individual who becomes an employee of the Company or an Affiliate in connection with a
transaction to which Section
6
424(a) of the Code applies. The terms of such substituted Options shall be determined by the
Committee in its sole discretion, subject only to the limitations of Article V.
8.3 Effect of Certain Transactions. Upon a merger, consolidation, acquisition of
property or stock, separation, reorganization or liquidation of the Company, as a result of which
the shareholders of the Company receive cash, stock or other property in exchange for their shares
of Stock (but not a public offering of Stock by the Company), and the Company is not the surviving
entity, any Option granted hereunder shall terminate, provided that the Participant may have the
right immediately prior to any such merger, consolidation, acquisition of property or stock,
separation, reorganization or liquidation to exercise his Options in whole or in part, pursuant to
the vesting Schedule set forth in the applicable Agreement unless otherwise designated by the
Committee or unless the Committee elects to convert all Options hereunder into options to purchase
stock of an acquiring corporation. Provided, however, that, notwithstanding the foregoing, a
portion of the acceleration of exercisability of Options shall not occur with respect to any holder
to the extent that such portion of acceleration would cause the grantee or holder of such Option to
be liable for the payment of taxes pursuant to Section 4999 of the Code. If the Committee so elects
to convert the Options, the amount and price of such converted options shall be determined by
adjusting the amount and price of the Options granted hereunder in the same proportion as used for
determining the number of shares of stock of the acquiring corporation the holders of the Stock
receive in such merger, consolidation, acquisition of property or stock, separation or
reorganization, and the vesting schedule set forth in the Agreement shall continue to apply to the
converted options.
8.4 No Adjustment Upon Certain Issuances. The issuance by the Company of shares of
stock of any class, or securities convertible into shares of stock of any class, for cash or
property, or for labor or services rendered, either upon direct sale or upon the exercise of rights
or warrants to subscribe therefor, or upon conversion of shares or obligations of the Company
convertible into such shares or other securities, shall not affect, and no adjustment by reason
thereof shall be made with respect to, outstanding Options.
8.5 Fractional Shares. Only whole shares of Stock may be acquired through the exercise
of an Option. Any amounts tendered in the exercise of an Option remaining after the maximum number
of whole shares have been purchased will be returned to the Participant.
ARTICLE IX. COMPLIANCE WITH LAW AND APPROVAL OF
REGULATORY BODIES
9.1 General. No option shall be exercisable, no Stock shall be issued, no certificates
for shares of Stock shall be delivered, and no payment shall be made under this Plan except in
compliance with all federal or state laws and regulations (including, without limitation,
withholding tax requirements), federal and state securities laws and regulations and the rules of
all securities exchanges or self-regulatory organizations on which the Companys shares may be
listed. The Company shall have the right to rely on an opinion of its counsel as to such
compliance. Any certificate issued to evidence shares of Stock for which an Option is exercised may
bear such legends and statements as the Committee upon advice of counsel may deem advisable to
assure compliance with federal or state laws and regulations. No Options shall be exercisable, no
Stock shall be issued, no certificate for shares shall be delivered and no payment shall be made
under this Plan until the Company has obtained such consent or approval as the Committee may deem
advisable from any regulatory bodies having jurisdiction over such matters.
7
9.2 Representations by Participants. As a condition to the exercise of an Option, the
Company may require a Participant to represent and warrant the time of any such exercise that the
shares are being purchased only for investment and without any present intention to sell or
distribute such shares, if, in the opinion of counsel for the Company, such representation is
required by any relevant provision of the laws referred to in Section 9.1. At the option of the
Company, a stop transfer order against any shares of stock may be placed on the official stock
books and records of the Company, and a legend indicating that the stock may not be pledged, sold
or otherwise transferred unless an opinion of counsel was provided (concurred in by counsel for the
Company) and stating that such transfer is not in violation of any applicable law or regulation may
be stamped on the stock certificate in order to assure exemption from registration. The Committee
may also require such other action or agreement by the Participants as may from time to time be
necessary to comply with federal or state securities laws. This provision shall not obligate the
Company or any Affiliate to undertake registration of Options or stock hereunder.
ARTICLE X. GENERAL PROVISIONS
10.1 Effect on Employment. Neither the adoption of this Plan, its operation, nor any
documents describing or referring to this Plan (or any part thereof) shall confer upon any employee
any right to continue in the employ of the Company or an Affiliate or in any way affect any right
and power of the Company or an Affiliate to terminate the employment of any employee at any time
with or without assigning a reason therefor.
10.2 Unfunded Plan. The Plan, insofar as it provides for grants, shall be unfunded,
and the Company shall not be required to segregate any assets that may at any time be represented
by grants under this Plan. Any liability of the Company to any person with respect to any grant
under this Plan shall be based solely upon contractual obligations that may be created hereunder.
No such obligation of the Company shall be deemed to be secured by any pledge of, or other
encumbrance on, any property of the Company.
10.3 Rules of Construction. Headings are given to the articles and sections of this
Plan solely as a convenience to facilitate reference. The masculine gender when used herein refers
to both masculine and feminine. The reference to any statute, regulation or other provision of law
shall be construed to refer to any amendment to or successor of such provision of law.
10.4 Governing Law. The laws of the State of Tennessee shall apply to all matters
arising under this Plan, to the extent that federal law does not apply.
10.5 Compliance With Section 16 of the Exchange Act. With respect to persons subject
to Section 16 of the Exchange Act, transactions under this Plan are intended to comply with all
applicable conditions of Rule 16b-3 or its successors under the Exchange Act. To the extent any
provision of this Plan or action by Committee fails to so comply, it shall be deemed null and void
to the extent permitted by law and deemed advisable by the Committee.
10.6 Amendment. The Board may amend or terminate this Plan at any time; provided,
however, an amendment that would have a material adverse effect on the rights of a Participant
under an outstanding Option is not valid with respect to such Option without the Participants
consent, except as necessary for Incentive Options to maintain qualification under the Code; and
provided, further, that the shareholders of the Company must approve, in general meeting prior to
the effective date of adoption, any amendment that:
8
|
(a) |
|
changes the number of shares in the aggregate which may be issued pursuant to Options
granted under the Plan or the maximum number of shares with respect to which any
individual may receive Options in any calendar year, except pursuant to Article VIII; |
|
|
(b) |
|
changes the Participants (or class or Participants) eligible to receive Options
under the Plan; |
|
|
(c) |
|
increases the period during which Options may be granted or exercised; |
|
|
(d) |
|
reduces the exercise price of outstanding Incentive Options or reduces the
price at which future Incentive Options may be granted; |
|
|
(e) |
|
alters the basis for determining a Participants entitlement to and the terms
of Stock to be provided and for the adjustment thereof upon the occurrence of any event
specified in Section 8.1 hereof; or |
|
|
(f) |
|
alters the Plan so that Options intended to qualify as Incentive Options under
the Code would not do so, or changes the provisions of this Section 10.6. |
Notwithstanding the foregoing, shareholder approval shall not be required for minor amendments
to the Plan pursuant to Section 3.1 hereof intended to benefit the administration of the Plan, for
amendments necessitated by changes in legislation governing the Plan, or for amendments that the
Committee deems necessary to obtain or maintain favorable tax, exchange control or regulatory
treatment of the Plan for future Participants or for Participating Companies (as defined in
Schedule A hereto).
10.7 Duration of Incentive Options. No Incentive Option may be granted under this Plan
more than 10 years after the earlier of the date that the Plan is adopted by the Board or the date
that the Plan is approved by shareholders as provided in Section 10.8. Incentive Options granted
before such date shall remain valid in accordance with their terms.
10.8 Effective Date of Plan. This Plan shall be effective on the date of its adoption
by the Board, and Options may be granted hereunder at any time after such adoption; provided,
however, that the effectiveness of this Plan will be retroactively revoked if it is not approved by
the shareholders of the Company in a manner that satisfies Treasury Regulation Section 1.422-5
within 12 months of the date that the Board took action to adopt the Plan. All Options granted
under the Plan will become void immediately following the 12-month anniversary of the date the
Board adopted the Plan if such approval by shareholders has not yet been obtained.
9
EX-10.20 FORM OF INDEMNIFICATION AGREEMENT
EXHIBIT 10.20
INDEMNIFICATION AND HOLD HARMLESS AGREEMENT
THIS INDEMNIFICATION AND HOLD HARMLESS AGREEMENT (this Agreement) is made as of March
, 2007, by and between Cumberland Pharmaceuticals Inc., a Tennessee corporation (the
Company), and (Indemnitee).
WHEREAS, in order to incentivize Indemnitee to serve, or to continue to serve, as a director
of the Company (in any such case, the Service), the Company has agreed to indemnify Indemnitee as
set forth below;
NOW, THEREFORE, in consideration of the foregoing and certain other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties, intending to be legally
bound, hereby agree as follows:
1. Indemnification. Effective as of the original date of Indemnitees beginning
Service, the Company shall indemnify Indemnitee and hold Indemnitee harmless if Indemnitee is a
party or is threatened to be made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative, arbitrative or investigative, and in any
appeal in such action, suit or proceeding, and in any inquiry or investigation that could lead to
such an action, suit or proceeding, against any and all liabilities, obligations (whether known or
unknown, or due or to become due or otherwise), judgments, fines, fees, penalties, interest
obligations, deficiencies, other actual losses (for example, verifiable lost income related to time
spent defending such claim or action) and reasonable expenses (including, without limitation
amounts paid in settlement, interest, court costs, costs of investigators, reasonable fees and
expenses of attorneys, accountants, financial advisors and other experts) incurred or suffered by
Indemnitee in connection with such action, suit or proceeding arising out of or pertaining to any
actual or alleged action or omission which arises out of or relates to the fact that Indemnitee is
or was serving as a director or officer of the Company or at the request of the Company as a
director, officer, trustee, employee, or agent of or in any other capacity for another corporation,
partnership, joint venture, trust or other enterprise, to the fullest extent permitted by then
applicable law and the Companys Charter and Bylaws, each as amended (but in the case of any such
amendment, only to the extent that such amendment permits the Company to provide the same or
broader indemnification rights than permitted prior thereto) (each such liability, obligation,
judgment, fine, fee, penalty, interest obligation, deficiency, other actual losses, and reasonable
expenses being referred to herein as a Loss, and collectively, as Losses).
2. Payment. Any Loss incurred by Indemnitee shall be paid in full by the Company on
a regular, monthly basis. This indemnity applies even if Indemnitee caused the Loss through his or
her negligence, strict liability or other fault; however, if any Losses for which Indemnitee
received payment from the Company under this Agreement are determined by final judicial decision
from which there is no further right to appeal, to have been caused by Indemnitee under
circumstances with respect to which indemnification is not permitted by applicable law or this
Agreement (any such Loss, a Non-Indemnification Loss), Indemnitee shall repay to the Company such
Losses paid on behalf of Indemnitee hereunder.
Page 1
3. Term. The indemnification rights provided hereby to Indemnitee shall continue
even though he may have ceased to be a director, officer, trustee, employee, or agent of or in any
other capacity for the applicable entity.
4. Notice and Coverage Prior to Notice. Indemnitee shall give notice (the Notice)
to the Company within five days after actual receipt of service or summons related to any action
begun in respect of which indemnity may be sought hereunder or actual notice of assertion of a
claim with respect to which he seeks indemnification; provided, however, that Indemnitees failure
to give such notice to the Company within such time shall not relieve the Company from any of its
obligations under Section 1 of this Agreement except to the extent the Company has been materially
prejudiced by Indemnitees failure to give such notice within such time period. Upon receipt of the
Notice, the Company shall assume the defense of such action, whereupon Indemnitee shall not be
liable for any reasonable fees or expenses of counsel for Indemnitee or any other Losses incurred
thereafter with respect to the matters set forth in the Notice and the Company shall reimburse
Indemnitee for all reasonable expenses related to the action or claim incurred by Indemnitee prior
to Indemnitees giving of the Notice.
5. Non-Exclusivity. The rights of Indemnitee hereunder shall be in addition to any
rights that Indemnitee may have under the Companys governance documents (e.g. Charter, Bylaws,
etc.) (the Governance Documents), applicable law or otherwise and shall survive any termination,
resignation, death or other dismissal of Indemnitee. No amendment or alteration of the Companys
Governance Documents shall adversely affect Indemnitees rights under the Governance Documents or
this Agreement.
6. Insurance. To the extent the Company maintains, at its expense, an insurance
policy or policies providing liability insurance with respect to the acts or omissions covered by
this Agreement, Indemnitee shall be covered by such policy or policies, in accordance with its or
their terms, to the maximum extent of the coverage available thereunder.
7. Payment. The Company shall not be liable to Indemnitee under this Agreement to
make any payment in connection with any claim against Indemnitee to the extent Indemnitee has
otherwise actually received, and is entitled to retain, payment (under any insurance policy or
otherwise) of the amounts otherwise indemnifiable hereunder.
8. Enforceability. The indemnification contained in this Agreement shall be binding
upon and inure to the benefit of and be enforceable by the parties hereto and their respective
successors, assigns (including any direct or indirect successor by purchase, merger, consolidation,
liquidation or otherwise to all or substantially all of the business and/or assets of the Company),
spouses, heirs and personal and legal representatives.
9. Binding Obligation. If this Agreement or any portion hereof shall be found to be
invalid on any ground by any court of competent jurisdiction, then the Company shall nevertheless
indemnify and hold harmless Indemnitee, as to costs, charges and expenses (including court costs
and attorneys fees), judgments, fines, penalties and amounts paid in settlement with respect to
any action, suit or proceeding, whether civil, criminal, administrative, arbitrative or
investigative, and in any appeal in such action, suit or proceeding, and in any inquiry or
investigation that could lead to such an action, suit or proceeding, to the full extent permitted
by any applicable portion of this Agreement that shall not have been invalidated and to the fullest
extent permitted by applicable law.
Page 2
10. Governing Law; Venue. This Agreement shall be construed in accordance with and
governed by the laws of the State of Tennessee, without regard to the principles of conflicts of
laws. The parties agree that any litigation directly or indirectly relating to this Agreement must
be brought before and determined by a court of competent jurisdiction within Davidson County,
Tennessee, and the parties hereby agree to waive any rights to object to, and hereby agree to
submit to, the jurisdiction of such courts.
11. Right to Sue; Attorneys Fees and Costs. If a claim by Indemnitee for payment of
Losses hereunder is not paid in full by the Company within forty-five (45) days after a written
claim has been delivered to the Company, Indemnitee may at any time thereafter bring suit against
the Company to recover the unpaid amount of the claim. If successful in whole or in part in any
such suit, Indemnitee shall be entitled to be paid also the reasonable costs and expenses of
prosecuting such suit. In any suit brought by Indemnitee to enforce any right hereunder (including,
without limitation, the right to indemnification), the burden of proving that Indemnitee is not
entitled to such right shall be borne by the Company. If a claim by the Company for repayment of
any Non-Indemnification Losses previously paid on behalf of Indemnitee hereunder is not repaid in
full to the Company within forty-five (45) days after such ruling has been delivered to Indemnitee,
the Company may at any time thereafter bring suit against Indemnitee to recover the unpaid amount.
12. Amendment. This Agreement may be amended, modified or supplemented only by a
written instrument executed by each of the parties hereto.
13. Facsimile and Counterpart Signature. This Agreement may be executed by facsimile
signature and in one or more counterparts, each of which shall for all purposes be deemed an
original and all of which shall constitute the same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above
written.
|
|
|
|
|
|
|
|
|
COMPANY |
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INDEMNITEE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[Insert Name] |
|
|
Page 3
EX-10.21 LEASE AGREEMENT
EXHIBIT 10.21
*Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
2525 WEST END
OFFICE LEASE AGREEMENT
BY AND BETWEEN
NASHVILLE HINES DEVELOPMENT, LLC
AS LANDLORD
AND
CUMBERLAND PHARMACEUTICALS INC.,
AS TENANT
BASIC LEASE INFORMATION
|
|
|
Lease Date:
|
|
Sept 10, 2005 |
|
|
|
Tenant:
|
|
Cumberland Pharmaceuticals Inc. |
|
|
|
Address of Tenant:
|
|
2525 West End Avenue, Suite 950 |
|
|
Nashville, Tennessee 37203 |
|
|
|
Primary Contact:
|
|
Jean W. Marstiller |
|
|
|
Landlord:
|
|
Nashville Hines Development, LLC |
|
|
|
Address of Landlord:
|
|
Five Greenway Plaza |
|
|
Houston, Texas 77046 |
|
|
Attention: F. Russ Nicholson |
|
|
|
Leased Premises:
|
|
Approximately 6,341 square feet of RSF |
|
|
Located on Floor 9 |
|
|
|
Commencement Date:
|
|
January 1, 2006 |
|
|
|
Lease Term:
|
|
Five (5) years |
|
|
|
Base Rental:
|
|
Per Exhibit G. Initial monthly Base Rental is [***]. |
|
|
|
Initial Allowance:
|
|
[***] per square foot of RSF |
The foregoing Basic Lease Information is hereby incorporated into and made a part of the Lease
identified above. In the event of any conflict between any Basic Lease Information and the Lease,
the Lease shall control.
TABLE OF CONTENTS
|
|
|
|
|
|
|
PAGE |
|
ARTICLE I |
|
|
1 |
|
1.1. Leased Premises |
|
|
1 |
|
1.2. Term |
|
|
3 |
|
1.3. Use |
|
|
3 |
|
1.4. Landlords Relocation Right |
|
|
4 |
|
1.5. Surrender of Premises |
|
|
5 |
|
1.6. Survival |
|
|
5 |
|
|
|
|
|
|
ARTICLE II |
|
|
6 |
|
2.1. Rental Payments |
|
|
6 |
|
2.2. Base Rental |
|
|
6 |
|
2.3. Additional Rental |
|
|
7 |
|
2.4. Operating Expenses |
|
|
8 |
|
2.5. Security Deposit |
|
|
11 |
|
2.6. Landlords Lien |
|
|
11 |
|
|
|
|
|
|
ARTICLE III |
|
|
11 |
|
3.1. Services |
|
|
11 |
|
3.2. Keys and Locks |
|
|
13 |
|
3.3. Graphics, Building Directory and Name |
|
|
13 |
|
3.4. Parking |
|
|
14 |
|
|
|
|
|
|
ARTICLE IV |
|
|
15 |
|
4.1. Care of Leased Premises |
|
|
15 |
|
4.2. Entry for Repairs and Inspection |
|
|
15 |
|
4.3. Nuisance |
|
|
15 |
|
4.4. Laws and Regulations; Encumbrances; Rules of Building |
|
|
15 |
|
4.5. Legal Use and Violations of Insurance Coverage |
|
|
15 |
|
4.6. Hazardous Substances |
|
|
16 |
|
4.7. Tenant Taxes |
|
|
16 |
|
|
|
|
|
|
ARTICLE V |
|
|
16 |
|
5.1. Initial Allowance; Leasehold Improvements |
|
|
16 |
|
5.2. Repairs by Landlord |
|
|
17 |
|
5.3. Repairs by Tenant |
|
|
17 |
|
|
|
|
|
|
ARTICLE VI |
|
|
18 |
|
6.1. Condemnation |
|
|
18 |
|
6.2. Damages from Certain Causes |
|
|
19 |
|
6.3. Casualty Clause |
|
|
19 |
|
6.4. Casualty Insurance |
|
|
20 |
|
6.5. Liability Insurance |
|
|
21 |
|
6.6. Hold Harmless |
|
|
21 |
|
6.7. Waiver of Subrogation Rights |
|
|
21 |
|
|
|
|
|
|
|
|
PAGE |
|
ARTICLE VII |
|
|
22 |
|
7.1. Default and Remedies |
|
|
22 |
|
7.2. Insolvency or Bankruptcy |
|
|
26 |
|
7.3. Late Payments |
|
|
26 |
|
7.4. Attorneys Fees |
|
|
26 |
|
7.5. Waiver of Homestead |
|
|
26 |
|
7.6. No Waiver of Rights |
|
|
27 |
|
7.7. Holding Over |
|
|
27 |
|
7.8. Subordination |
|
|
27 |
|
7.9. Estoppel Certificate |
|
|
29 |
|
|
|
|
|
|
ARTICLE VIII |
|
|
30 |
|
8.1. Sublease or Assignment by Tenant |
|
|
30 |
|
8.2. Assignment by Landlord |
|
|
32 |
|
8.3. Peaceful Enjoyment |
|
|
32 |
|
8.4. Limitation of Landlords Personal Liability |
|
|
32 |
|
8.5. Force Majeure |
|
|
33 |
|
|
|
|
|
|
ARTICLE IX |
|
|
33 |
|
9.1. Notices |
|
|
33 |
|
9.2. Miscellaneous |
|
|
34 |
|
9.3. Option to Renew |
|
|
36 |
|
|
|
|
EXHIBIT A
|
|
SITE PLAN AND LOCATION OF THE BUILDING |
|
|
|
EXHIBIT A-1
|
|
DESCRIPTION OF LAND |
|
|
|
EXHIBIT B
|
|
FLOOR PLAN OF LEASED PREMISES |
|
|
|
EXHIBIT C
|
|
AIR CONDITIONING AND HEATING SERVICES |
|
|
|
EXHIBIT D
|
|
BUILDING RULES AND REGULATIONS |
|
|
|
EXHIBIT F
|
|
[INTENTIONALLY DELETED] |
|
|
|
EXHIBIT G
|
|
BASE RENTAL |
|
|
|
EXHIBIT H
|
|
JANITORIAL SPECIFICATIONS |
ii
2525 WEST END
OFFICE LEASE AGREEMENT
THIS LEASE AGREEMENT (Lease) is made and entered into on this 10th day
of Sept , 2005 (the Date of Lease), by and between NASHVILLE HINES DEVELOPMENT, LLC, a
limited partnership organized under the laws of the State of Delaware, whose address for purposes
hereof is Five Greenway Plaza, Houston, Texas 77046 Attention: F. Russ Nicholson (hereinafter
called Landlord), and CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation, whose address for
purposes hereof is 2525 West End Avenue, Suite 950, Nashville, TN 37203, Attention: Jean W.
Marstiller, (the address of the Leased Premises within the Building) (hereinafter called Tenant).
ARTICLE I.
1.1. Leased Premises.
Landlord has constructed or intends to construct certain improvements on a certain tract or
parcel of land located on West End Avenue in Nashville, Davidson County, Tennessee, and more
particularly described in Exhibit A-1, attached hereto and incorporated herein by this
reference (the Land). The certain improvements including an office building with a retail area
included within it currently known as 2525 West End Avenue (the
Building) and the Parking
Facility (as defined herein). The Building, the Parking Facility, and the Land together with all
common areas not specifically made a part of the Building or the Parking Facility, and all other
improvements from time to time located thereon or related thereto are hereinafter collectively
referred to as the Project. Subject to and upon the terms hereinafter set forth, and in
consideration of the sum of Ten Dollars ($10.00), the premises, and the mutual covenants set
forth herein, the receipt and sufficiency of which are hereby acknowledged, Landlord does hereby
lease and demise to Tenant and Tenant does hereby lease and take from Landlord (subject to all
matters of record in Davidson County, Tennessee, that affect the Project) those certain premises
(hereinafter sometimes called the Leased Premises) located in the Building as shown on
Exhibit A, attached hereto and incorporated herein, such Leased Premises being more
particularly described as follows:
Approximately 6,341 RSF on the ninth (9th) Floor of the Building and as
generally described or depicted on Exhibit B, attached hereto and
incorporated herein.
Tenant accepts the Leased Premises AS-IS. Landlord has not undertaken to perform any alteration
or improvement to the Lease Premises.
The terms Rentable Square Feet and RSF, as used herein, shall refer to (i) in the case
of a floor leased to a single tenant, the total square footage of all floor area measured from
the inside surface of the exterior glass line of the Building to the inside surface of the
opposite exterior glass line, excluding only Service Areas (defined below) and General Common
Areas (defined below), plus an allocation of the square footage of the General Common Areas, and
(ii) in the case of a floor leased to more than one tenant, the total square footage of all floor
areas within the inside surface of the exterior glass line of the Building enclosing the Leased
Premises and measured to the mid-point of demising walls (i.e., walls separating the Leased
Premises from areas leased to or held for lease to other tenants, from On-Floor Common Areas
(defined
1
below), and from General Common Areas), excluding only Service Areas, plus an allocation of
the square footage of the General Common Areas and an allocation of the square footage of the
On-Floor Common Areas. No deductions from Rentable Square Feet shall be made for columns or
projections.
Service Areas shall mean the areas within (and measured from the exterior surface of the
interior walls enclosing, or from the inside surface of the exterior glass or wall enclosing, as
the case may be) Building stairs, elevator shafts, flues, vents, stacks, pipe shafts and vertical
ducts. Areas for the specific use of Tenant or other tenants of the Building or installed at the
request of Tenant such as special stairs or elevators are not included within the definition of
Service Areas.
General Common Areas shall mean those areas within (and measured from the midpoint of the
walls or from the inside surface of the exterior glass enclosing) the Buildings elevator machine
rooms, main mechanical rooms, electrical rooms, and public lobbies, engineering and cleaning
staging areas, and other areas not leased or held for lease within the Building but which are
reasonably necessary for the proper utilization of the Building or to provide customary services
to the Building, plus an allocation of any On-Floor Common Areas to the General Common Areas on
the floor for floors that contain General Common Areas. The allocation of the square footage of
the General Common Areas shall be equal to the total square footage of the General Common Areas
multiplied by a fraction, the numerator of which is the Rentable Square Feet of the Leased
Premises (excluding the total square footage of the General Common Areas) and the denominator of
which is the total of all Rentable Square Feet contained in the Building (excluding the allocation
of the General Common Areas).
On-Floor Common Areas shall mean the total square footage of all areas within (and measured
from the midpoint of the walls enclosing) public corridors, elevator foyers, rest rooms,
mechanical rooms, janitor closets, telephone and equipment rooms, and other similar facilities for
the use of all tenants on the floor on which the Leased Premises are located. The allocation of
the square footage of the On-Floor Common Areas shall be equal to the total On-Floor Common Areas
on said floor multiplied by a fraction, the numerator of which is the Rentable Square Feet of the
portion of the Leased Premises (excluding the allocations of General Common Areas and On-Floor
Common Areas) located on said floor and the denominator of which is the total of all Rentable
Square Feet on said floor (excluding the allocations of General Common Areas and On-Floor Common
Areas on the floor).
Parking Facility shall mean the parking structure that is constructed or intended to be
constructed and located adjacent to the Building (the Adjacent Parking Facility), the surface
parking area adjacent to the Building (the Surface Parking Area), and the existing garage
located across Kensington Place (the Kensington Parking Facility) as shown and labeled on
Exhibit A (which shall only be used by Tenant as parking for Tenants employees and the
employees of other office tenants, not customer parking), together with any connecting walkways,
covered walkways, or other means of access to said building or buildings, the grounds related
thereto and any additional improvements at any time related thereto. The Parking Facility may be
operated by a parking contractor designated from time to time by Landlord.
(a) This Lease does not grant Tenant any rights to light, air or view over or about the Land
or any other real property. Landlord specifically excepts and reserves to itself all
2
rights to and the use of any roofs, the exterior portions of the Leased Premises, the Land,
improvements and air and other rights below the improved floor level of the Leased Premises, the
improvements and air and other rights above the improved ceiling of Leased Premises, the
improvements and air and other rights located outside the demising walls of the Leased Premises and
such areas within the Leased Premises as are required for installation of utility lines and other
installations required to serve the Building or any occupants of the Building, and Landlord
specifically reserves to itself the right to use, maintain and repair same, and no rights with
respect thereto are conferred upon Tenant, unless otherwise specifically provided herein.
(b) Tenant has been in possession of the Leased Premises prior to the Commencement Date
pursuant to a sublease agreement, is aware of the condition of the Leased Premises and represents
and acknowledges that the Leased Premises is, as of the Commencement Date, in good order and
satisfactory condition. Tenant acknowledges that no promise by or on behalf of Landlord, any of
Landlords beneficiaries, the managing agent of the Building, the leasing agent of the Building or
any of their respective agents, partners or employees to alter, remodel, improve, repair, decorate
or clean the Leased Premises has been made to or relied upon by Tenant, and that no representation
respecting the condition of the Leased Premises or the Building by or on behalf of Landlord, any of
Landlords beneficiaries, the managing agent of the Building, the leasing agent of the Building or
any of their respective agents, partners or employees has been made to or relied upon by Tenant,
except to the extent expressly set forth in this Lease.
1.2. Term.
(a) Subject to and upon the terms and conditions set forth herein, or in any exhibit hereto,
the term of this Lease shall commence on the Commencement Date (defined below) and shall expire at
6:00 P.M on December 31, 2010.
(b) As used herein, Commencement Date means January 1, 2006.
1.3. Use. The Leased Premises are to be used and occupied by Tenant (and its permitted
assignees and subtenants) solely for the purpose of office space and for no other purpose. The
Leased Premises shall not be used for any purpose which would create unreasonable elevator loads or
otherwise unreasonably interfere with Building operations, and Tenant shall not engage in any
activity which is not in keeping with the first class standards of the Building. In no event shall
the Leased Premises be used for the purpose of installing, marketing, operating, or providing
electronic telecommunications, information or data processing, storage or transmissions, or other
electronic office services or equipment for tenants or other occupants of the Building on a
shared-usage basis through a central switch or a local area network.
1.4. Landlords Relocation Right. Upon ninety (90) days written notice to Tenant
(Landlords Relocation Notice), Landlord may substitute for the Leased Premises other premises
in the Building (the New Premises), in which event the New Premises shall be deemed to be the
Leased Premises for all purposes hereunder, provided:
(a) The New Premises shall be comparable to the Leased Premises in size, configuration and
market value;
3
(b) Landlord and Tenant shall cooperate in good faith in making any changes to the Tenant
Program, Space Plan, Preliminary Working Drawings, and/or Working Drawings (as defined herein and
as may be applicable depending upon which, if any, of the foregoing has then been prepared at the
time of Landlords election to relocate the Leased Premises) so as to conform the leasehold
improvements in the New Premises as closely as practicable to those planned for the Leased
Premises;
(c) To the extent Tenant shall have incurred any expense in the preparation of the Tenant
Program, Space Plan, Preliminary Working Drawings, Working Drawings and/or leasehold improvements
(as defined herein and as may be applicable depending upon which, if any, of the foregoing has
then been prepared, purchased or installed at the time of Landlords election to relocate the
Leased Premises), Landlord shall, at Landlords expense, cause each of such applicable items to be
reproduced for the New Premises so that Tenant shall not incur expenses in connection therewith by
reason of the exercise by Landlord of the relocation right contained herein. In addition, Landlord
shall reimburse Tenant within thirty (30) days after receipt of genuine, third-party invoices
marked paid for Tenants moving costs and all costs of reprinting stationery, cards and other
printed material bearing tenants address at the Lease Premises if such address changes due to the
relocation (but only the reasonable quantities existing immediately prior to the relocation); and
(d) Upon substitution of the New Premises for the Leased Premises, the Rentable Square Feet
of the New Premises shall control for purposes of this Lease, and Tenant Percentage Share
(hereinafter defined) and the Base Rental shall be recalculated and adjusted based on the Rentable
Square Feet of the New Premises.
Tenant shall not be entitled to any compensation for any inconvenience or interference with
Tenants business, nor to any abatement or reduction in rent or other sums payable by Tenant
hereunder, nor shall Tenants obligations under this Lease be otherwise affected, as a result of
the substitution of the New Premises, except as otherwise expressly provided in this Section.
Tenant agrees to cooperate with Landlord so as to facilitate the prompt completion by Landlord of
its obligations under this Section. Without limiting the generality of the preceding sentence,
Tenant agrees to promptly provide to Landlord such approvals, instructions, plans, specifications
and other information as may be reasonably requested by Landlord in connection with such
obligations. At Landlords request, Tenant shall execute a supplement to this Lease confirming the
substitution of the New Premises for the Leased Premises. Within twenty (20) days after receipt of
Landlords Relocation Notice, Tenant shall either accept such relocation or deliver written notice
to Landlord terminating this Lease effective no later than the ninetieth (90th) day
after Landlords relocation Notice. Tenants failure to deliver such termination notice within
such twenty (20) day period shall be deemed conclusively Tenants election to relocate to the New
Premises.
1.5. Surrender of Premises.
(a) Upon the termination of this Lease by lapse of time or otherwise or upon the earlier
termination of Tenants right of possession, Tenant shall quit and surrender possession of the
Leased Premises to Landlord, broom clean, in the same condition as upon delivery of possession to
Tenant hereunder, normal wear and tear excepted. Before surrendering possession of the Leased
Premises, Tenant shall, without expense to Landlord, remove all signs, furnishings, equipment
(including all communication and other cables),
4
trade fixtures, merchandise and other personal property installed or placed in the Leased
Premises and all debris and rubbish, and Tenant shall repair all damage to the Leased Premises
resulting from such removal; provided if Tenant is then in default under this Lease, Tenant shall
not remove any such item unless Tenant receives written directions from Landlord authorizing or
directing the removal thereof. If Tenant fails to remove any of the signs, furnishings, equipment,
trade fixtures, merchandise and other personal property installed or placed in the Leased Premises
by the expiration or termination of this Lease, then Landlord may, at its sole option, (i) treat
Tenant as a holdover, in which event the provisions of this Lease regarding holding over shall
apply, (ii) deem any or all of such items abandoned and the sole property of Landlord, or (iii)
remove any and all such items and dispose of same in any manner. Tenant shall pay Landlord on
demand any and all expenses incurred by Landlord in the removal of such items, including, without
limitation, the cost of repairing any damage to the Leased Premises or the Building caused by such
removal and storage charges (if Landlord elects to store such property).
(b) All installations, additions, partitions, hardware, cables, wires, fixtures and
improvements, temporary or permanent (including, but not limited to, Tenants Extra Work), except
for Tenants signs, furnishings, equipment, communication cables, telephone switches, trade
fixtures, merchandise and other personal property, in or upon the Leased Premises, whether placed
there by Tenant or Landlord, shall, upon the termination of this lease by lapse of time or
otherwise or upon the earlier termination of Tenants right of possession, become Landlords
property and shall remain upon the Leased Premises, all without compensation, allowance or credit
to Tenant; provided, however, that if at the time Landlord consents to Tenants installation of
any installations, additions, partitions, hardware, cables, wires, fixtures and improvements or at
any time prior to termination of this Lease, Landlord requires removal of the same upon
termination, then Tenant, at Tenants sole cost and expense, upon termination of this Lease by
lapse of time or otherwise or upon the earlier termination of Tenants right of possession, shall
promptly remove such designated items placed in or upon the Leased Premises by or on behalf of
Tenant and, repair any damage to the Leased Premises or the Building caused by such removal,
failing which Landlord may remove the same and repair the Leased Premises or the Building, as the
case may be, and Tenant shall pay the cost thereof to Landlord on written demand.
1.6. Survival. Any claim, cause of action, liability or obligation arising under the
term of this Lease and under the provisions hereof in favor of a party hereto against or
obligating the other party hereto and all of Tenants indemnification obligations hereunder shall
survive the expiration or any earlier termination of this Lease.
ARTICLE II.
2.1. Rental Payments.
(a) Commencing on the Commencement Date and continuing thereafter throughout the full term of
this Lease, Tenant hereby agrees to pay the Base Rental (defined below), and Tenants Forecast
Additional Rental (defined below) and Tenants Additional Rental Adjustment (defined below) in
accordance with this Article. The Base Rental and Tenants Forecast Additional Rental shall be due
and payable in equal monthly installments on the first
5
day of each calendar month during the initial term of this Lease and any extensions or
renewals hereof, and Tenant hereby agrees to so pay such rent to Landlord at Landlords address as
provided herein (or such other address as may be designated by Landlord from time to time) monthly
in advance.
(b) If the Commencement Date is other than the first day of a calendar month, then the
installments of Base Rental and Tenants Forecast Additional Rental for such month shall be
prorated and the installment or installments so prorated shall be paid in advance. Said
installments for such prorated month shall be calculated by multiplying the equal monthly
installment by a fraction, the numerator of which shall be the number of days of the Lease term
occurring during said commencement or expiration month, as the case may be, and the denominator of
which shall be thirty (30). If the term of this Lease commences or expires on other than the first
day of a calendar year, Tenants Forecast Additional Rental and Tenants Additional Rental shall be
prorated for such commencement or expiration year, as the case may be, by multiplying Tenants
Forecast Additional Rental and Tenants Additional Rental by a fraction, the numerator of which
shall be the number of whole and partial months of the Lease term during the commencement or
expiration year, as the case may be, and the denominator of which shall be twelve (12). In such
event the Tenants Additional Rental Adjustment shall be made as soon as reasonably possible after
the termination of this Lease.
(c) For purposes hereof, the term Rental shall mean and collectively refer to the Base
Rental, Tenants Forecast Additional Rental, Tenants Additional Rental Adjustment and other sums
payable by Tenant hereunder. Tenant agrees to pay all Rental at the times and in the manner
provided in this Lease, without abatement, demand, notice, set-off, deduction or counterclaim, and
all sums payable under this Lease by Tenant shall be deemed to be rent due and owing hereunder. All
Rental shall bear interest from the tenth (10th) day after the date due thereof until
paid at the lesser of (i) a per annum rate equal to the prime rate announced by Chase Manhattan
Bank, New York, New York, or its successor, (or if the prime rate is discontinued, the rate
announced as that being charged to the most credit-worthy commercial borrowers) plus two percent
(2%) or (ii) the maximum interest rate per annum allowed by law.
2.2. Base Rental. Throughout the full term of this Lease, Tenant hereby agrees to pay
a base annual rental (the Base Rental) in accordance with the schedule attached hereto as
Exhibit G, as such dollar amount may be adjusted from lease year to lease year pursuant to
the terms of this Lease.
2.3. Additional Rental.
(a) Commencing with the calendar year in which the Commencement Date occurs and continuing
thereafter for each calendar year during the full term of this Lease, Landlord shall present to
Tenant prior to the beginning of said calendar year (or for the calendar year in which the Lease
term commences, on the Commencement Date) a statement of Tenants Forecast Additional Rental.
Landlords failure to deliver such a statement of Tenants Forecast Additional Rental shall not
operate to excuse Tenant from the payment of the monthly installment of Tenants Forecast
Additional Rental due under Section 2.1(a). Rather, Tenant shall continue to pay the monthly
installment of Tenants Forecast Additional Rental based on Landlords most recent calculation
thereof until such a statement is delivered to Tenant, with such statement being applied
retroactively to the beginning of the calendar year and Tenant
6
making up any under payments immediately upon its receipt of such statement. Landlord may,
from time to time, recalculate Tenants Forecast Additional Rental in order to more accurately
reflect Landlords good faith estimate of Tenants Additional Rental, and Tenant shall commence
paying the recalculated Tenants Forecast Additional Rental, in accordance with Section 2.1(a)
hereof, immediately after receiving notice thereof.
(b) As used herein, Tenants Forecast Additional Rental shall mean Landlords reasonable
estimate of Tenants Additional Rental (defined below) for the coming calendar year (or, in the
calendar year in which the lease term commences, for such calendar year).
(c) Landlord shall absorb and be responsible for paying Operating Expenses (defined below)
during any calendar year to the extent such Operating Expenses are less than Nine and 17/100
Dollars ($9.17) per square foot of space in the Building leased to rent paying tenants (the
Expense Stop). As part of Tenants Additional Rental, Tenant shall be responsible for paying its
pro rata share of the Operating Expenses for any calendar year in excess of the Expense Stop. For
purposes hereof, Tenants Additional Rental for any calendar year shall mean Tenants Percentage
Share (defined below) of the Operating Expenses for such calendar year in excess of the Expense
Stop. As used herein, Tenants Percentage Share shall mean a fraction, the numerator of which is
the total number of square feet of Rentable Square Feet within the Leased Premises and the
denominator of which is the greater of (i) ninety-five percent (95%) of the total square footage of
all Rentable Square Feet in the Building (exclusive of any retail space) held for lease, or (ii)
the total square footage of all Rentable Square Feet in the Building (exclusive of any retail
space) actually leased to rent paying tenants.
(d) Landlord shall use reasonable efforts to provide Tenant, within one hundred twenty (120)
days after the end of the calendar year in which the Commencement Date occurs and of each calendar
year thereafter during the term of this Lease, with a statement detailing the Operating Expenses
for each such calendar year (the Annual Operating Expense Statement) and a statement prepared by
Landlord comparing Tenants Forecast Additional Rental with Tenants Additional Rental. In the
event that Tenants Forecast Additional Rental exceeds Tenants Additional Rental for said calendar
year, Landlord shall pay Tenant (in the form of a credit against rentals next due or, upon
expiration of this Lease, in the form of Landlords check) an amount equal to such excess. In the
event that the Tenants Additional Rental exceeds Tenants Forecast Additional Rental for said
calendar year, Tenant hereby agrees to pay Landlord, within thirty (30) days of receipt of the
statement, an amount equal to such difference (Tenants Additional Rental Adjustment).
(e) Tenant, at Tenants sole cost and expense, shall have the right, to be exercised by
written notice given to Landlord within sixty (60) days after receipt of the Annual Operating
Expense Statement for any calendar year, to audit Landlords books and records pertaining only to
the Operating Expenses for such calendar year, provided such audit must commence within thirty (30)
days after Tenants notice to Landlord and thereafter proceed regularly and continuously to
conclusion and, provided, further, that such audit must be conducted by a nationally recognized
independent public accounting firm in a manner that does not unreasonably interfere with the
conduct of Landlords business. Notwithstanding the foregoing, Tenant shall not have the right to
audit Landlords books
7
and records regarding the Operating Expenses for any calendar year if (i) the Annual Operating
Expense Statement for such calendar year was prepared by a nationally recognized independent public
accounting firm, or (ii) Tenant is in default under the terms of this Lease or any circumstance
exists which with the giving of notice, the passage of time, or both, would constituted such a
default. Landlord agrees to cooperate in good faith with Tenant in the conduct of any such audit.
Tenant (and its agents, employees and accountants) shall hold the results of such audits in strict
confidence and not disclose the same to any third party, except as is necessary during any dispute
between Landlord and Tenant related thereto or as required by law. A copy of the results of any
such audit shall be promptly provided to Landlord, and Landlord may conduct an independent review
of the same. If there is any disagreement regarding the results of any such audit, the parties
shall select a third party auditor to resolve the dispute. Tenant shall not employ any person or
entity to audit Landlords books and records whose compensation is based, in whole or in part, on a
contingency fee or the results of the audit.
2.4. Operating Expenses.
(a) Operating Expenses, for each calendar year, shall consist of (i) all Operating Costs
(defined below) for the Building, plus (ii) an amount equal to the sum of the total ownership,
management, maintenance, repair, replacement and operating costs accruing during each such calendar
year for portions of the Project not within the Building that are designated or maintained from
time to time as common areas, including, but not limited to, fifty (50%) percent of the cost of
maintaining the Kensington Place roadway adjoining the Project and those areas which are for the
benefit of the occupants of the Project whether or not so designated or maintained as common areas
(net of any contribution received from time to time from the owners of the other portions of the
Project for such expenses).
(b) For the purposes of this Lease, Operating Costs shall mean all expenses, costs and
accruals (excluding therefrom, however, specific costs billed to or otherwise incurred for the
particular benefit of specific tenants of the Building) of every kind and nature, computed on an
accrual basis, incurred or accrued in connection with, or relating to, the ownership, operation,
management, maintenance, repair and replacement of the Building during each calendar year,
including, but not limited to, the following:
|
(i) |
|
wages and salaries, including taxes, insurance
and benefits, of all on and off-site employees engaged in operations,
management, maintenance, repair, replacement or access control, as
reasonably allocated by Landlord and rent for the Buildings management
office exclusive of that portion of such office used for leasing; |
|
|
(ii) |
|
cost of all supplies, tools, equipment and
materials to the extent used in operations, management, maintenance,
repairs or replacements, as reasonably allocated by Landlord; |
|
|
(iii) |
|
cost of all utilities, including, but not
limited to, the cost of electricity, the cost of water and the cost of
power for heating, lighting, air conditioning and ventilating; |
8
|
(iv) |
|
the cost of trash and garbage removal, cleaning,
vermin extermination, snow, ice and debris removal, and other services; |
|
|
(v) |
|
cost related to and fees payable under all
maintenance, management and service agreements, including, but not
limited to, a management fee contribution equal to three percent (3%)
of the gross revenues; |
|
|
(vi) |
|
costs related to those agreements related to
access control services, garage operations, window cleaning, elevator
maintenance, janitorial service, pest control and landscaping
maintenance; |
|
|
(vii) |
|
cost of inspections, repairs, maintenance and
replacements (except to the extent covered by proceeds of insurance);
provided the cost of capital repairs and replacements shall be
amortized over such reasonable period of time as Landlord shall
determine and only the portion of such costs allocable to any calendar
year (plus interest on the unpaid balance of such costs) may be
included in the Operating Costs for such calendar year; |
|
|
(viii) |
|
the cost of legal and accounting services incurred by Landlord
relating to management and maintenance of the Building but not
including any such expenses related to leasing of space in the
Building; |
|
|
(ix) |
|
amortization of the cost (plus interest on the
unpaid balance of such costs) of any system, apparatus, device, or
equipment which is installed for the principal purpose of (i) reducing
Operating Expenses, (ii) promoting safety or (iii) complying with
governmental requirements; |
|
|
(x) |
|
the cost of all insurance, including, but not
limited to, the cost of casualty, rental loss and liability insurance,
and insurance on Landlords personal property, plus the cost of all
deductible and co-insurance payments made by Landlord in connection
therewith; |
|
|
(xi) |
|
amounts due under easements, operating agreements,
parking operating agreements, declarations, covenants or instruments
encumbering the Land; |
|
|
(xii) |
|
reasonable replacement reserves; |
|
|
(xiii) |
|
cost of maintaining, striping, repairing, replacing, repaving and
lighting grounds, streets, parking areas, sidewalks, curbs, walkways,
landscaping, drainage and lighting facilities; and |
|
|
(xiv) |
|
all taxes, assessments and governmental charges,
whether or not directly paid by Landlord, whether federal, state, county
or municipal |
9
|
|
|
and whether they be by taxing districts or authorities presently
taxing the Building and said common areas or by others subsequently
created or otherwise, and any other taxes, assessments and
governmental charges attributable to the Building and that portion of
the common areas or their operation, excluding, however, taxes and
assessments attributable to the personal property of other tenants,
federal and state taxes on income, death taxes, franchise taxes, and
any taxes imposed or measured on or by the income of Landlord from the
operation of the Building or imposed in connection with any change of
ownership of the Building; provided, however, that if at any time
during the term of this Lease, the present method of taxation or
assessment shall be so changed that the whole or any part of the
taxes, assessments, levies, impositions or charges now levied,
assessed or imposed on real estate and the improvements thereon shall
be discontinued and as a substitute therefor, or in lieu of or in
addition thereto, taxes, assessments, levies, impositions or charges
shall be levied, assessed or imposed, wholly or partially, as a
capital levy or otherwise, on the rents received from the Building or
the rents reserved herein or any part thereof, then such substitute or
additional taxes, assessments, levies, impositions or charges, to the
extent so levied, assessed or imposed with respect to the Building,
shall be deemed to be included within the Operating Costs.
Consultation, legal fees and costs resulting from any challenge of tax
assessments as reasonably allocated by Landlord shall also be included
in Operating Costs. It is agreed that Tenant will be responsible for
ad valorem taxes on its personal property and on the value of the
leasehold improvements in the Leased Premises to the extent that the
same exceed the Tenant Improvement Allowance (and if the taxing
authorities do not separately assess Tenants leasehold improvements,
Landlord may make a reasonable allocation of the ad valorem taxes
allocated to the Building to give effect to this sentence). In the
case of special taxes and assessments which may be payable in
installments, only the amount of each installment accruing during a
calendar year shall be included in the Operating Costs for such year. |
(c) Notwithstanding any language contained herein to the contrary, Tenant hereby agrees that,
during any calendar year in which the entire Building is not provided with Building Standard
Services or is not completely occupied, Landlord shall compute all Variable Operating Costs
(defined below) for such calendar year as though the entire Building were provided with Building
Standard Services and were completely occupied. For purposes of this Lease the term Variable
Operating Costs shall mean any operating cost that is variable with the level of occupancy of the
Building (e.g. utilities and cleaning services). In the event that Landlord excludes from
Operating Costs any specific costs billed to or otherwise incurred for the particular benefit of
specific tenants of the Building or to other buildings or projects on the Land, Landlord shall have
the right to increase Operating Costs by an amount equal to the cost of providing standard
services similar to the services for which such excluded specific costs were billed or incurred. In
no event shall Landlord receive from all tenants of the Building more than one hundred percent
(100%) of any Operating Costs.
10
2.5. Security Deposit. [Intentionally deleted.]
2.6. Landlords Lien. [Intentionally
deleted.]
ARTICLE III.
3.1. Services. Landlord shall furnish the following services to Tenant during the term
of this Lease (Building Standard Services):
(a) Hot and cold domestic water to common use rest rooms and toilets, in such amounts as are
reasonably determined by Landlord
(b) Subject to curtailment as required by governmental laws, rules or mandatory regulations,
central heat and air conditioning in season, at such temperatures and in such amounts as are
reasonably determined by Landlord and on such dates and at such times as are more particularly
described on Exhibit C attached hereto and incorporated herein.
(c) Electric lighting service for all public areas and special service areas of the Building
in such amounts and locations as are reasonably determined by Landlord.
(d) Janitor service in accordance with the Janitorial Specifications attached hereto and
incorporated herein as Exhibit H; however, if Tenants floor coverings or other
improvements are other than building standard commercial grade, Tenant shall pay one hundred and
fifteen percent (115%) of the actual additional cleaning cost, if any, attributable thereto, and if
supplying such additional cleaning service requires active managerial oversight by Landlord,
Landlord shall be entitled to collect an administrative fee equal to fifteen percent (15%) of the
cost of such service.
(e) Access control for the Building shall be provided to the extent and in the manner
reasonably determined by Landlord; provided, however, Landlord shall have no responsibility to
prevent, and shall not be liable to Tenant for, any liability or loss to Tenant, its agents,
employees and visitors arising out of losses due to theft, burglary, or damage or injury to persons
or property caused by persons gaining access to the Leased Premises, and Tenant hereby releases
Landlord from all liability for such losses, damages or injury.
(f) Electrical service to floors with plug-in type bus risers sized to provide 8.0 watts per
useable square foot of electrical connected load capacity for tenant use above and beyond the base
building electrical requirements. Of that, 6.0 watts per useable square foot of electrical
connected load capacity will be available in 480/277V panels for tenant use leaving 2.0 watts per
useable square foot available in the bus riser for future tenant electrical loads. Of the 6.0 watts
per useable square foot, 3.0 watts per useable square foot of electrical connected load capacity
will be available in 208/120V panels for tenant use leaving 3.0 watts per useable square foot of
capacity in the 480/277V panels for future tenant electrical loads. This capacity is part of the
6.0 watts per useable square foot of power for tenants use noted above.
Should Tenants total rated electrical design load exceed the Building Standard rated
electrical design load for either low or high voltage electrical consumption, or if Tenants
electrical design requires low voltage or high voltage circuits in excess of Tenants share of the
Base Building Shell Condition circuits, Landlord will (at Tenants expense) install one (1)
11
additional high voltage panel and/or one (1) additional low voltage panel with associated
transformer, space for which has been provided in the base building electrical closets based on a
maximum of two (2) such additional panels per floor for all tenants on the floor (which additional
panels and transformers shall be hereinafter referred to as the additional electrical equipment).
If the additional electrical equipment is installed because Tenants low or high voltage rated
electrical design load exceeds the applicable Building Standard rated electrical design load, then
a meter shall also be added (at Tenants expense) to measure the electricity used through the
additional electrical equipment.
The design and installation of any additional electrical equipment (or any related meter)
required by Tenant shall be subject to the prior approval of Landlord (which approval shall not be
unreasonably withheld). All expenses incurred by Landlord in connection with the review and
approval of any additional electrical equipment shall also be reimbursed to Landlord by Tenant.
Tenant shall also pay on demand the actual metered cost of electricity consumed through the
additional electrical equipment (if applicable), plus any actual accounting expenses incurred by
Landlord in connection with the metering thereof.
If any of Tenants electrical equipment requires conditioned air in excess of Base Building
Shell Condition air conditioning, the same shall be installed by Landlord (on Tenants behalf), and
Tenant shall pay all design, installation, metering and operating costs relating thereto.
If Tenant requires that certain areas within Tenants demised premises must operate in excess
of the normal Building Operating Hours (as defined in Exhibit C attached hereto), the
electrical service to such areas shall be separately circuited and metered such that Tenant shall
be billed the costs associated with electricity consumed during hours other than Building Operating
Hours.
(g) All Building Standard fluorescent bulb replacement in all areas and all incandescent bulb
replacement in General Common Areas, Service Areas and On-Floor Common Areas.
(h) Non-exclusive multiple cab passenger service to the Leased Premises during Building
Operating Hours and at least one (1) cab passenger service to the Leased Premises twenty-four (24)
hours per day and non-exclusive freight elevator service during Building Operating Hours (all
subject to temporary cessation for ordinary repair and maintenance and during times when life
safety systems override normal building operating systems) with such freight elevator service
available at other times upon reasonable prior notice and the payment by Tenant to Landlord of any
additional expense actually incurred by Landlord in connection therewith.
To the extent the services described in subsection (a), (b), (c), (f) and (h) above require
electricity and water supplied by public utilities, Landlords covenants thereunder shall only
impose on Landlord the obligation to use its good faith, reasonable efforts to cause the applicable
public utilities to furnish the same. Failure by Landlord to furnish the services described in this
Section, or any cessation thereof, shall not render Landlord liable for damages to either person or
property, nor be construed as an eviction of Tenant, nor work an abatement of rent, nor relieve
Tenant from fulfillment of any covenant or agreement
12
hereof. In addition to the foregoing, should any of the equipment or machinery, for any cause,
fail to operate, or function properly, Tenant shall have no claim for rebate of rent or damages on
account of an interruption in service occasioned thereby or resulting therefrom; provided, however,
Landlord agrees to use reasonable efforts to repair said equipment or machinery promptly and to
restore said services.
3.2. Keys and Locks. Landlord shall install a card reader on the elevator servicing
the Leased Premises that restricts after hours access to the Leased Premises. Landlord shall also
supply Tenant with two (2) keys for each Building Standard lockset on code required doors entering
the Leased Premises from public areas. Additional keys will be furnished by Landlord upon an order
signed by Tenant and at Tenants expense. All such keys shall remain the property of Landlord. No
additional locks shall be allowed on any door of the Leased Premises without Landlords permission,
and Tenant shall not make or permit to be made any duplicate keys. Upon termination of this Lease,
Tenant shall surrender to Landlord all keys to any locks on doors entering or within the Leased
Premises, and give to Landlord the explanation of the combination of all locks for safes, safe
cabinets and vault doors, if any, in the Leased Premises.
3.3. Graphics, Building Directory and Name. Landlord shall provide and install all
graphics, letters, and numerals at the entrance to the Leased Premises on multi-tenant floors, if
any (it being understood that Tenant shall be responsible for all graphics on full floors occupied
by Tenant. Landlord shall maintain an electronic directory in such main lobby which shall include
such information relating to Tenant. All such letters and numerals shall be in the Building
standard graphics (font size to be approved by Landlord). Tenant agrees that Landlord shall not be
liable for any inconvenience or damage occurring as a result of any error or omission in any
directory or graphics. No signs, numerals, letters or other graphics shall be used or permitted on
the exterior of, or may be visible from outside, the Leased Premises, unless approved in writing by
Landlord. All on-floor graphics for full-floor tenants shall be removed by Tenant upon lease
expiration.
3.4. Parking.
(a) Subject to the other provisions hereof, Landlord hereby agrees to make available, or to
cause the lessee or operator of the Parking Facility (the Garage Operator), to make available to
Tenant (so long as Tenant shall continue to lease at least 6,341 RSF) up to twenty-five (25)
permits to park in the Kensington Parking Facility upon the terms and conditions set forth below
(the Parking Permits). Landlord shall also provide (or cause the Garage Operator to provide)
visitor parking in a portion of the Parking Facility on a first come-first served pay basis at
such rates and upon such conditions as Landlord or the Garage Operator, as applicable, shall
establish from time to time.
(b) Tenant shall notify Landlord within thirty (30) days following the execution of this Lease
of the number of Parking Permits that it intends to utilize. Neither Landlord nor the Garage
Operator shall be obligated to hold any Parking Permits that Tenant does not elect to utilize.
(c) Tenant shall pay as rental for the Parking Permits at the rate charged from time to time
by Landlord (or the Garage Operator), in its sole and absolute discretion,
13
plus any applicable taxes thereon; provided the rate charged for the Parking Permits shall be
prorated for any partial months during the term of this Lease. The current charge to Tenant for
each Parking Permit is $40.00 per month, plus any applicable taxes thereon. In the event the rate
charged for the Parking Permits is increased, Tenant may elect to relinquish all or a portion of
the Parking Permits by giving written notice to Landlord (or its designee) within thirty (30) days
after receiving notice of such increase, in which event Tenant shall have no further right to or
interest in such Parking Permit and neither Landlord nor the Garage Operator shall have any
obligation to provide replacement parking for Tenant. If the rate charged for the Parking Permits
is increased and Tenant fails to notify Landlord, in writing, of its election to relinquish all or
a portion of the Parking Permits within thirty (30) days after receiving notice of such increase,
then Tenant shall be deemed to have agreed to such increase and shall have no further right to
relinquish its Parking Permits on account thereof. Unless Landlord directs otherwise, Tenant shall
pay the monthly charges established from time to time in accordance with this Lease by the Garage
Operator for parking in the Kensington Parking Facility to Landlord and Landlord shall collect such
payments, on behalf of the Garage Operator, monthly in advance, at the same time and place as
Tenant makes payments of Base Rent under the terms of this Lease.
(d) In the event the parking spaces covered by the Parking Permits are not available to Tenant
due to causes beyond the control of Landlord or the Garage Operator and Landlord is unable to
provide replacement parking to Tenant, neither Landlord nor Garage Operator shall be liable for any
damages that Tenant suffers on account thereof, nor shall such fact be construed as a constructive
eviction of Tenant, entitle Tenant to an abatement of any Rental or an abatement of the charges for
the Parking Permits, or relieve Tenant from fulfillment of any covenant or agreement hereof.
(e) Landlord or the Garage Operator may make, modify and enforce reasonable rules and
regulations relating to the parking of vehicles in the Parking Facility, and Tenant agrees to abide
by such rules and regulations. Except as expressly provided herein, this Lease does not grant
Tenant (or its agents, employees, contractors and visitors) the right to use the Parking Facilities
or any other parking areas located on the Land or serving the Building. So long as Landlord ensures
that there is sufficient parking available in the Parking Facilities to accommodate the holders of
the Parking Permits, Landlord or the Garage Operator may, from time to time, designate specific
portions of the Parking Facilities as reserved areas and Tenant shall have no right to park in such
reserved areas, except Tenant may park in reserved areas made available to tenants of the Building
to the extent Tenant has purchased Parking Permits specifically entitling Tenant to use the same.
Landlord agrees to make (or cause the Garage Operator to make) parking for Tenants guests and
visitors available on a non-exclusive basis in the Parking Facility. Landlord or the Garage
Operator may restrict Tenants right to utilize the Parking Permits on weekends and after 6:00 p.m.
in the evening when athletic events are scheduled in the nearby athletic facilities.
ARTICLE IV.
4.1. Care of Leased Premises. Tenant shall not commit or allow to be committed by
Tenants employees, agents or contractors, any waste or damage to any portion of the Leased
Premises or the Building. Upon the expiration or any earlier termination of this
14
Lease, Landlord shall have the right to re-enter and resume possession of the Leased Premises
immediately.
4.2. Entry for Repairs and Inspection. Tenant shall permit Landlord and its
contractors, agents or representatives to enter into and upon any part of the Leased Premises
during reasonable hours to inspect or clean the same, make repairs, alterations or additions
thereto, and, upon reasonable prior notice to Tenant, for the purpose of showing the same to
prospective tenants or purchasers and Tenant shall not be entitled to any abatement or reduction of
rent by reason thereof. Landlord shall use its reasonable efforts not to interfere materially with
the operation of Tenants business during any such entry.
4.3. Nuisance. Tenant shall conduct its business and control its agents, employees,
invitees, contractors and visitors in such a manner as not to create any nuisance, or interfere
with, annoy or disturb any other tenant or Landlord in its operation of the Building.
4.4. Laws and Regulations; Encumbrances; Rules of Building. Tenant shall comply with,
and Tenant shall cause its employees, contractors and agents to comply with, and shall use its best
efforts to cause its visitors and invitees to comply with, (i) all laws, ordinances, orders, rules
and regulations of all state, federal, municipal and other governmental or judicial agencies or
bodies relating to the use, condition or occupancy of the Leased Premises, (ii) all recorded
easements, operating agreements, parking agreements, declarations, covenants and instruments
encumbering the Leased Premises, and (iii) the rules of the Building reasonably adopted and altered
by Landlord from time to time for the safety, care and cleanliness of the Leased Premises and
Building and for the preservation of good order therein. The initial rules of the Building are
attached hereto and incorporated herein as Exhibit D.
4.5. Legal Use and Violations of Insurance Coverage. Tenant shall not occupy or use
the Leased Premises, or permit any portion of the Leased Premises to be occupied or used, for any
business or purpose which is unlawful, disreputable or deemed to be hazardous in any manner, or
permit anything to be done which would in any way increase the rate of fire, liability, or any
other insurance coverage on the Building or its contents.
4.6. Hazardous Substances. Tenant shall comply, at its sole expense, with all laws,
ordinances, orders, rules and regulations of all state, federal, municipal and other governmental
or judicial agencies or bodies relating to the protection of public health, safety, welfare or the
environment (collectively, Environmental Laws) in the use, occupancy and operation of the Leased
Premises. Tenant agrees that no Hazardous Substances (as hereinafter defined) shall be used,
located, stored or processed on the Leased Premises or be brought onto any other portion of the
Building by Tenant or any of its agents, employees, contractors, assigns, subtenants, guests or
invitees, and no Hazardous Substances will be released or discharged from the Leased Premises
(including, but not limited to, ground water contamination). The term Hazardous Substances shall
mean and include all hazardous and toxic substances, waste or materials, any pollutant or
contaminant, including, without limitation, PCBs, asbestos and raw materials that include
hazardous constituents or any other similar substances or materials that are now or hereafter
included under or regulated by any Environmental Laws or that would pose a health, safety or
environmental hazard. Tenant hereby agrees to indemnify, defend and hold harmless Landlord from and
against any and all losses, liabilities (including, but not limited to, strict
15
liability), damages, injuries, expenses (including, but not limited to, court costs,
litigation expenses, reasonable attorneys fees and costs of settlement or judgment), suits and
claims of any and every kind whatsoever paid, incurred or suffered by, or asserted against,
Landlord by any person, entity or governmental agency for, with respect to, or as a direct or
indirect result of, the presence in or the escape, leakage, spillage, discharge, emission or
release from the Leased Premises of any Hazardous Substances or the presence of any Hazardous
Substances placed on or discharged from the Building by Tenant or any of its agents, employees,
contractors, assigns, subtenants, guests or invitees, including, without limitation, any losses,
liabilities (including, but not limited to, strict liability), damages, injuries, expenses
(including, but not limited to, court costs, litigation expenses, reasonable attorneys fees and
costs of settlement or judgment), suits and claims asserted or arising under the Comprehensive
Environmental Response, Compensation and Liability Act (CERCLA), any so-called federal, state or
local Superfund or Superlien laws or any other Environmental Law.
4.7. Tenant Taxes. Tenant shall pay promptly when due all taxes directly or indirectly
imposed or assessed upon Tenants gross sales, business operations, machinery, equipment, trade
fixtures and other personal property or assets, whether such taxes are assessed against Tenant,
Landlord or the Building. In the event that such taxes are imposed or assessed against Landlord or
the Building, Landlord shall furnish Tenant with all applicable tax bills, public charges and other
assessments or impositions and Tenant shall forthwith pay the same either directly to the taxing
authority or, at Landlords option, to Landlord.
ARTICLE V.
5.1. Initial Allowance; Leasehold Improvements.
(a) Within ten (10) days of the Commencement Date, Landlord shall contribute [***] per RSF in
the Leased Premises (the Initial Allowance) for Tenants use during the initial Lease Term, all
or any portion of which Tenant may apply as a credit towards Base Rental next due and payable.
(b) Tenant shall not make or allow to be made any alterations or physical additions in or to
the Leased Premises, or place safes, vaults or other heavy furniture or equipment within the
Leased Premises, without first obtaining the written consent of Landlord which consent shall not
be unreasonably withheld so long as said alterations do not impact on Building systems or
structure and are not visible from outside the Leased Premises. Tenant shall deliver to Landlord a
copy of the as-built plans and specifications for all alterations or physical additions so made
in or to the Leased Premises. Tenant further specifically agrees that no food, soft drink or other
vending machine will be installed within the Leased Premises without the written consent of
Landlord. Any such machine(s) shall be for the use of Tenant and its employees and invitees only.
(c) Tenant shall indemnify and hold Landlord harmless from and against all costs (including
reasonable attorneys fees and costs of suit), losses, liabilities, or causes of action arising
out of or relating to any alterations, additions or improvements made by Tenant to the Leased
Premises, including, but not limited to, any mechanics or materialmens liens asserted in
connection therewith. No portion of Landlords interest in the Building shall be
16
subject to attachment on account of any work performed by or on account of Tenant, and Tenant
shall provide written notice of same to all of its contractors.
(d) Should any mechanics or other liens be filed against any portion of the Building by
reason of Tenants acts or omissions or because of a claim against Tenant, Tenant shall cause the
same to be canceled or discharged of record by bond or otherwise within thirty (30) days after
notice by Landlord. If Tenant shall fail to cancel or discharge said lien or liens, within said
thirty (30) day period, Landlord may, at its sole option, cancel or discharge the same and upon
Landlords demand, Tenant shall promptly reimburse Landlord for all reasonable costs incurred in
canceling or discharging such liens, and if canceling or discharging such liens requires active
managerial oversight by Landlord, Landlord shall be entitled to collect an administrative fee
equal to fifteen percent (15%) of the cost thereof.
5.2. Repairs by Landlord. All repairs, alterations or additions that affect the
Buildings structural components or the Buildings mechanical, electrical and plumbing systems
shall be made solely by Landlord or its contractor. In the event of any damage to such components
or systems or any other portion of the Building caused by Tenant or Tenants agents, contractors,
employees, visitors or invitees, the cost of repair or restoration of such damage shall be paid
for solely by Tenant in an amount equal to Landlords costs plus fifteen percent (15%) for
administrative cost recovery. Landlord shall make such repairs to Base Building Shell Condition
improvements as may be deemed necessary by Landlord for normal maintenance operations and Landlord
shall not otherwise be obligated to make improvements to, or repairs of, the Leased Premises.
5.3. Repairs by Tenant. Subject to Section 5.2, Tenant shall at its own cost and
expense, keep the Leased Premises and all leasehold improvements in a condition similar to the
condition as of the Commencement Date, normal wear and tear excepted, and Tenant shall perform all
maintenance, repairs and replacements necessary to accomplish the same. In addition, Tenant shall
perform all maintenance, repairs, replacements and improvements required by any governmental law,
ordination, rule or regulation. If Tenant fails to commence any maintenance, repairs, replacements
or improvements which it is required to perform hereunder within ten (10) days after written
notice from Landlord to Tenant and thereafter diligently proceed with such work until completion,
Landlord may, at its option, perform any such maintenance, repairs, replacements or improvements
deemed necessary by Landlord, and Tenant shall pay to Landlord on demand Landlords cost thereof
plus a charge of fifteen percent (15%) for administrative cost recovery.
ARTICLE VI.
6.1. Condemnation. If all or substantially all of the Leased Premises, or such
portion of the Leased Premises or the Building as would render, in Landlords reasonable judgment,
the continuance of Tenants business from the Leased Premises impracticable, shall be permanently
taken or condemned for any public purpose, then this Lease, at the option of Tenant or Landlord
upon the giving of written notice to the other party within ten (10) days from the date of such
condemnation or taking, shall forthwith cease and terminate. If less than all or substantially all
of the Leased Premises or any portion of the Building shall be permanently taken or condemned for
any public purpose, then Landlord shall have the option of terminating this Lease by written
notice to Tenant within ten (10) days from the date of such condemnation or taking. If this Lease
is terminated as provided above, this Lease shall cease and expire as if
17
the date of transfer of possession of the Leased Premises, the Building, or any portion
thereof, was the expiration date of this Lease. In the event that this Lease is not terminated by
either Landlord or Tenant as aforesaid, Tenant shall pay the Rental up to the date of transfer of
possession of such portion of the Leased Premises so taken or condemned and this Lease shall
thereupon cease and terminate with respect to such portion of the Leased Premises so taken or
condemned as if the date of transfer of possession of the Leased Premises was the expiration date
of the term of this Lease relating to such portion of the Leased Premises. Thereafter the Base
Rental, Tenants Forecast Additional Rental and Tenants Additional Rental shall be adjusted on a
pro rata, net rentable square foot basis. In the event of any such condemnation or taking and this
Lease is not so terminated, Landlord shall promptly repair the Leased Premises or the Building, as
the case may be, to Base Building Shell Condition so that the remaining portion of the Leased
Premises or Building, as the case may be, shall constitute an architectural unit, fit for Tenants
occupancy and business; provided, however, that Landlords obligation to repair hereunder shall be
limited to the extent of the net proceeds made available to Landlord for such repair from any such
condemnation or taking. In the event of any temporary taking or condemnation for any public
purpose of the Leased Premises or any portion thereof, then this Lease shall continue in full
force and effect except that Base Rental, Tenants Forecast Additional Rental, and Tenants
Additional Rental shall be adjusted on a pro rata net rentable square foot basis for the period of
time that the Leased Premises are so taken as of the date of transfer of possession of the Leased
Premises and Landlord shall be under no obligation to make any repairs or alterations. In the
event of any condemnation or taking of the Leased Premises, Tenant hereby assigns to Landlord the
value of all or any portion of the unexpired term of the Lease and all leasehold improvements and
Tenant may not assert a claim for a condemnation award therefor; provided, however, Tenant may
pursue a separate attempt to recover an award or compensation against or from the condemning
authority for (i) the value of any fixtures, furniture, furnishings, Tenants Extra Work and other
personal property which were condemned but which under the terms of this Lease, Tenant is
permitted to remove at the end of the term of this Lease, (ii) relocation and moving expenses, and
(iii) compensation for loss to Tenants business.
6.2. Damages from Certain Causes. Landlord shall not be liable or responsible to
Tenant for any loss or damage to any property or person occasioned by theft, fire, act of God,
public enemy, riot, strike, insurrection, war, act or omission of any tenant or occupant of the
Building, any nuisance or interference caused or created by any tenant or occupant of the Building,
requisition or order of governmental body or authority, court order or injunction, or any cause
beyond Landlords control or, except in the case of the gross negligence or intentional misconduct
of Landlord, for any damage or inconvenience which may arise through repair or alteration of any
part of the Building. Tenant shall notify Landlord of any damage to the Leased Premises, regardless
of the cause of such damage.
6.3. Casualty Clause.
(a) In the event any portion of the Leased Premises or any portion of the General Common Areas
is damaged by fire or other casualty, earthquake or flood or by any other cause of any kind or
nature (hereinafter collectively referred to as the damaged property) and the damaged property
can, in the opinion of the Landlords architect, be repaired within ninety (90) calendar days from
the date of notice of Landlords architects
18
opinion, then Landlord shall proceed to rebuild or restore the damaged property to Base
Building Shell Condition, subject to subsection (e) hereof.
(b) In the event the damaged property can not, in the opinion of Landlords architect, be
repaired within ninety (90) days from the date of notice of Landlords architects opinion, but can
be repaired within one hundred eighty (180) days from the date of notice of Landlords architects
opinion, Landlord, at Landlords sole option, shall have the right (i) to terminate this Lease by
notifying Tenant of such termination within twenty (20) days of receipt of Landlords architects
opinion, or (ii) to restore or rebuild the damaged property to Base Building Shell Condition,
subject to subsection (e) hereof.
(c) If, in the opinion of Landlords architect, damage to the damaged property cannot be
repaired within one hundred eighty (180) days from the date of notice of Landlords architects
opinion, then both Landlord and Tenant shall have the right to terminate this Lease by notifying
the other party in writing of such termination within twenty (20) days of receipt of Landlords
architects opinion.
(d) Notwithstanding any language herein to the contrary, if at the time of any such damage,
less than one (1) year remains in the term of this Lease, exclusive of any renewal options, then
Landlord, at Landlords sole option, shall have the right to terminate this Lease.
(e) If at anytime during the term of this Lease the Building is damaged and the cost of
repairing and restoring the same exceeds twenty-five percent (25%) of the replacement cost of the
improvements comprising the Building, then Landlord, at Landlords sole option, shall have the
right to terminate this Lease.
(f) Notwithstanding any language contained herein to the contrary, in the event this Lease is
not terminated as provided hereunder (i) Landlord shall be obligated to rebuild or restore the
damaged property only to the extent of the net insurance proceeds available to Landlord for the
purpose of rebuilding and restoration, (ii) if the damaged property is all or any portion of the
Leased Premises Landlord shall be obligated to rebuild or restore the damaged property only to Base
Building Shell Condition, except that Tenant shall have the right to require Landlord to rebuild or
restore the damaged property substantially to the condition which existed immediately prior to such
damage, provided that Tenant shall bear all costs and expenses, including without limitation,
rentals that are lost due to extended construction time, in excess of the lesser of (A) any net
insurance proceeds available to Landlord for the purpose of rebuilding or restoration, or (B) the
cost to Landlord of rebuilding and restoring the damaged property to Building Standard condition
(with Building Standard tenant allowances); and (iii) to the extent Landlord has rental loss
insurance proceeds available, Tenant shall be entitled to a pro rata abatement of Base Rental,
Tenants Forecast Additional Rental, and Tenants Additional Rental during the period of time the
Leased Premises, or any portion thereof, are untenantable due to such damage. Landlords
architects opinion shall be delivered to both Landlord and Tenant within thirty (30) days from the
date of any such damage. In the event of any termination of this Lease under this Section, this
Lease shall cease and terminate as if the date of such damage was the expiration date of the term
of this Lease. Notwithstanding any contrary language in this Section, if the Leased Premises, the
Building, or any portion thereof shall be damaged through the negligence or willful misconduct of
Tenant and the cost of repairing the same is not covered by Landlords insurance, such damage shall
be repaired by Landlord at the sole expense of Tenant and rent shall continue hereunder unabated.
19
(g) If any portion of Tenants leasehold improvements (including, but not limited to, Tenants
Extra Work), alterations, additions, improvements, fixtures, furnishing, equipment or trade
fixtures are damaged by fire or other casualty, earthquake or flood or by any other cause of any
kind or nature, Tenant shall immediately restore the same to the condition existing immediately
prior to such damage, unless such damage is so extensive as to permit termination of this Lease as
provided herein and the Lease is terminated in accordance with such provisions.
6.4. Casualty Insurance. Landlord shall maintain all-risk property insurance on the
Building and on all Base Building Shell Condition improvements. Said insurance shall be maintained
with an insurance company authorized to do business in Tennessee, at full replacement cost and
payments for losses thereunder shall be made solely to Landlord. Tenant shall maintain at its
expense business interruption insurance and all-risk property insurance on the full replacement
cost of all its personal property, including removable trade fixtures, located in the Leased
Premises and on Tenants Extra Work and all other additions and improvements (including fixtures)
made by Tenant and not required to be insured by Landlord above, regardless of whether such
improvements were made at Landlords or Tenants expense. If the annual premiums to be paid by
Landlord shall exceed the standard rates because of Tenants operations within, or contents of, the
Leased Premises or because the improvements to the Leased Premises are in excess of improvements
contemplated by the Tenant Improvement Allowance, Tenant shall promptly pay the excess amount of
the premium upon request by Landlord (and if necessary, Landlord may allocate the insurance costs
of the Building to give effect to this sentence). Upon the request of Landlord, a duly executed
certificate of insurance, reflecting Tenants maintenance of the insurance required under this
Section 6.4 and Section 6.5, shall be delivered to Landlord.
6.5. Liability Insurance. Landlord and Tenant shall each maintain a policy or
policies of commercial general liability insurance with the premiums thereon fully paid on or
before the due dates, issued by and binding upon a solvent insurance company authorized to
transact business in Tennessee. Such insurance shall be written on an occurrence basis and shall
afford minimum protection (which may be affected by primary and/or excess coverage) of not less
than $1,000,000.00 per occurrence for bodily injury and property damage with umbrella liability in
excess of $1,000,000 of no less than $2,000,000 per occurrence and in the aggregate provided,
however, Tenant shall carry such greater limits of coverage as Landlord may reasonably request
from time to time so long as Landlord maintains similar limits of coverage.
6.6. Hold Harmless. Landlord shall not be liable to Tenant, its agents, servants,
employees, contractors, customers or invitees for any damage to person or property caused by any
act, omission or neglect of Tenant. Without limiting or being limited by any other indemnity in
this Lease, but rather in confirmation and furtherance thereof, Tenant agrees to indemnify, defend
by counsel reasonably acceptable to Landlord and hold Landlord, Landlords beneficiaries (if
Landlord is a land trust), the managing agent of the Building, the leasing agent of the Building
and their respective agents, partners, shareholders, officers, directors and employees of the
Building harmless of, from and against any and all losses, damages, liabilities, claims, liens,
costs and expenses (including, but not limited to, court costs, reasonable attorneys fees and
litigation expenses) in connection with injury to or death of any person or damage to or theft,
loss or loss of the use of any property occurring in or about the Leased Premises or the Building
arising from Tenants occupancy of the Leased Premises, or the
20
conduct of its business or from any activity, work, or thing done, permitted or suffered by
Tenant in or about the Leased Premises or the Building, or from any breach or default on the part
of Tenant in the performance of any covenant or agreement on the part of Tenant to be performed
pursuant to the terms of this Lease, or due to any other act or omission or willful misconduct of
Tenant or any of its agents, employees, contractors, assigns, subtenants, guest or invitees.
6.7. Waiver of Subrogation Rights. Anything in this Lease to the contrary
notwithstanding, Landlord and Tenant each hereby waives any and all rights of recovery, claim,
action or cause of action, against the other, its agents, servants, partners, shareholders,
officers or employees, for personal injury, loss or damage to business, and loss or damage that
may occur to the Leased Premises, the Building or any improvements thereto or thereon or any
personal property of such party therein or thereon by reason of fire, the elements, or any other
cause to the extent such loss or damage is covered by terms of the all-risk property insurance
policies referred to in Section 6.4 hereof or any other insurance policy maintained by Landlord or
Tenant, as applicable, regardless of cause or origin, including negligence of the other party
hereto, its agents, officers, partners, shareholders, servants or employees, and covenants that no
insurer shall hold any right of subrogation against such other party. The foregoing waiver shall
apply regardless of the cause or origin of such claim, including but not limited to the negligence
of a party, or such partys agents, officers, employees or contractors, but shall not apply if it
would have the effect, but only to the extent of such effect, of invalidating any insurance
coverage of Landlord or Tenant. Each party shall obtain any special endorsements, if any, required
by their respective insurers to evidence compliance with the aforementioned waiver.
ARTICLE VII.
7.1. Default and Remedies.
(a) The occurrence of any of the following shall constitute a default under and breach of this
Lease by Tenant (an Event of Default):
|
(i) |
|
Failure by Tenant to pay any Rental within ten
(10) days after the same becomes due hereunder; |
|
|
(ii) |
|
The Leased Premises are deserted, vacated, or not
used for a period exceeding thirty (30) consecutive days, even though
the Tenant continues to pay the stipulated monthly rent; |
|
|
(iii) |
|
Failure by Tenant to observe or perform any of
the covenants in respect of assignment and subletting set forth in
Article VIII; |
|
|
(iv) |
|
Failure by Tenant to cure forthwith, immediately
after receipt of notice from Landlord, any hazardous condition which
Tenant has created or permitted in violation of law or of this Lease; |
|
|
(v) |
|
Failure by Tenant to complete, execute and
deliver any instrument or document required to be completed, executed
and delivered by Tenant pursuant to Section 7.8 or Section 7.9 of |
21
|
|
|
this Lease, within ten (10) days after the initial written demand
therefor to Tenant; |
|
(vi) |
|
Failure by Tenant to observe or perform any other
covenant, agreement, condition or provision of this Lease, if such
failure shall continue for thirty (30) days after written notice thereof
from Landlord to Tenant; provided that such thirty (30) day period shall
be extended for the time reasonably required to complete such cure, if
such failure cannot reasonably be cured within said thirty (30) day
period and Tenant commences to cure such failure within said thirty (30)
day period and thereafter diligently and continuously proceeds to cure
such failure; |
|
|
(vii) |
|
The levy upon execution or the attachment by
legal process of the leasehold interest of Tenant, or the filing or
creation of a lien in respect of such leasehold interest, which lien
shall not be released or discharged within ten (10) days from the date
of such filing; |
|
|
(viii) |
|
Any default under or breach by any guarantor of Tenants obligations
under this Lease of such guarantors obligations under any agreements
with Landlord; |
|
|
(ix) |
|
Tenant or any guarantor of Tenants obligations
under this Lease becomes insolvent or bankrupt or admits in writing its
inability to pay its debts as they mature, or makes an assignment for
the benefit of creditors, or applies for or consents to the appointment
of a trustee or receiver for all or a major part of its property; |
|
|
(x) |
|
A trustee or receiver is appointed for Tenant,
any guarantor of Tenants obligations under this Lease or for a major
part of either partys property and is not discharged within sixty (60)
days after such appointment; |
|
|
(xi) |
|
Any bankruptcy, reorganization, arrangement,
insolvency or liquidation proceeding, or other proceeding for relief
under any bankruptcy law or similar law for the relief of debtors, is
instituted (A) by Tenant or any guarantor of Tenants obligations under
this Lease, or (B) against Tenant or any guarantor of Tenants
obligations under this Lease and is allowed against it or is consented
to by it or is not dismissed within sixty (60) days after such
institution; |
|
|
(xii) |
|
Tenants repeated or continued failure to
timely pay any Rental due Landlord hereunder where such failure shall
continue or be repeated for two (2) consecutive months, or for a total
of four (4) months in any period of twelve (12) consecutive months; or |
22
|
(xiii) |
|
Tenants repeated failure to observe or perform any of the other
covenants, terms or conditions hereof more than six (6) times, in the
aggregate, in any period of twelve (12) consecutive months. |
(b) Upon the occurrence of an Event of Default, Landlord shall have the option to do and
perform any one or more of the following in addition to, and not in limitation of, any other
remedy or right permitted it by law or in equity or by this Lease:
|
(i) |
|
Landlord, with or without terminating this
Lease, may immediately or at any time thereafter re-enter the Leased
Premises and correct or repair any condition which shall constitute a
failure on Tenants part to keep, observe, perform, satisfy, or abide
by any term, condition, covenant, agreement, or obligation of this
Lease or of the Rules and Regulations now in effect or hereafter
adopted or of any notice given Tenant by Landlord pursuant to the terms
of this Lease, and Tenant shall fully reimburse and compensate Landlord
on demand. |
|
|
(ii) |
|
Landlord, with or without terminating this
Lease, may immediately or at any time thereafter demand in writing that
Tenant vacate the Leased Premises and thereupon Tenant shall vacate the
Leased Premises and remove therefrom all property thereon belonging to
or placed on the Leased Premises by, at the direction of, or with
consent of Tenant within ten (10) days of receipt by Tenant of such
notice from Landlord, whereupon Landlord shall have the right to
re-enter and take possession of the Leased Premises. Any such demand,
re-entry and taking possession of the Leased Premises by Landlord shall
not of itself constitute an acceptance by Landlord of a surrender of
this Lease or of the Leased Premises by Tenant and shall not of itself
constitute a termination of this Lease by Landlord. |
|
|
(iii) |
|
Landlord, with or without terminating this Lease,
may immediately or at any time thereafter, re-enter the Leased Premises
and remove therefrom Tenant and all property belonging to or placed on
the Leased Premises by, at the direction of, or with consent of Tenant.
Any such re-entry and removal by Landlord shall not of itself constitute
an acceptance by Landlord of a surrender of this Lease or of the Leased
Premises by Tenant and shall not of itself constitute a termination of
this Lease by Landlord. |
|
|
(iv) |
|
Landlord, with or without terminating this Lease,
may immediately or at any time thereafter relet the Leased Premises or
any part thereof for such time or times, at such rental or rentals and
upon such other terms and conditions as Landlord in its sole discretion
may deem advisable, and Landlord may make any alterations or repairs to
the Leased Premises which it may deem necessary or |
23
|
|
|
proper to facilitate such reletting; and Tenant shall pay all costs
of such reletting including but not limited to the cost of any such
alterations and repairs to the Leased Premises, attorneys fees,
leasing inducements, and brokerage commissions; and if this Lease
shall not have been terminated, Tenant shall continue to pay all rent
and all other charges due under this lease up to and including the
date of beginning of payment of rent by any subsequent tenant of part
or all of the Leased Premises, and thereafter Tenant shall pay
monthly during the remainder of the term of this Lease the
difference, if any, between the rent and other charges collected from
any such subsequent tenant or tenants and the rent and other charges
reserved in this Lease, but Tenant shall not be entitled to receive
any excess of any such rents collected over the rents reserved
herein. |
|
(v) |
|
Landlord may immediately or at any time thereafter
terminate this Lease, and this Lease shall be deemed to have been
terminated upon receipt by Tenant of written notice of such termination;
upon such termination Landlord shall recover from Tenant all damages
Landlord may suffer by reason of such termination including, without
limitation, unamortized sums expended by Landlord for leasing commissions
and construction of tenant improvements, all arrearages in rentals,
costs, charges, additional rentals, and reimbursements, the cost
(including court costs and attorneys fees) of recovering possession of
the Leased Premises, the cost of any alteration of or repair to the
Leased Premises which is necessary or proper to prepare the same for
reletting and, in addition thereto, Landlord at its election shall have
and recover from Tenant either (A) an amount equal to the excess, if any,
of the total amount of all rents and other charges to be paid by Tenant
for the remainder of the term of this Lease over the then reasonable
rental value of the Leased Premises for the remainder of the term of this
Lease, or (B) the rents and other charges which Landlord would be
entitled to receive from Tenant pursuant to the provisions of Section
7.1(b)(iv) if the Lease were not terminated. Such election shall be made
by Landlord by serving written notice upon Tenant of its choice of one of
the two said alternatives within thirty (30) days of the notice of
termination. All future amounts due in accordance with this Section
7.1(b)(v) shall be discounted to present value at the per annum interest
rate publicly announced by a federally insured bank selected by Landlord
in the state in which the Building is located as such banks prime or
base rate. |
(c) If Landlord re-enters the Leased Premises or terminates this Lease pursuant to any of the
provisions of this Lease, Tenant hereby waives all claims for damages which may be caused by such
re-entry or termination by Landlord. Tenant shall and does hereby indemnify and hold Landlord
harmless from any loss, cost (including court costs and
24
attorneys fees), or damages suffered by Landlord by reason of such re-entry or termination.
No such re-entry or termination shall be considered or construed to be a forcible entry.
(d) The exercise by Landlord of any one or more of the rights and remedies provided in this
Lease shall not prevent the subsequent exercise by Landlord of any one or more of the other rights
and remedies herein provided. All remedies provided for in this Lease are cumulative and may, at
the election of Landlord, be exercised alternatively, successively, or in any other manner and are
in addition to any other rights provided for or allowed by law or in equity.
(e) No act by Landlord with respect to the Leased Premises shall terminate this Lease,
including, but not limited to, acceptance of the keys, institution of an action for detainer or
other dispossessory proceedings, it being understood that this Lease may only be terminated by
express written notice from Landlord to Tenant, and any reletting of the Leased Premises shall be
presumed to be for and on behalf of Tenant, and not Landlord, unless Landlord expressly provides
otherwise in writing to Tenant.
(f) Upon termination of Tenants right to possess the Leased Premises, Landlord shall, only to
the extent required by applicable law, use objectively reasonable efforts to mitigate damages by
reletting the Leased Premises. Landlord shall not be deemed to have failed to do so if Landlord
refuses to lease the Leased Premises to a prospective tenant that Landlord deems, in the exercise
of Landlords business judgment, unacceptable for or incompatible with the other tenants of the
Building, or who (1) is an Affiliate (as defined below), parent or subsidiary of Tenant; (2) is not
acceptable to any Mortgagee of Landlord; (3) requires improvements to the Leased Premises to be
made at Landlords expense; or (4) is unwilling to accept lease terms then proposed by Landlord,
including: (a) leasing for a shorter or longer term than remains under this Lease; (b)
re-configuring or combining the Leased Premises with other space, (c) taking all or only a part of
the Leased Premises; and/or (d) changing the use of the Leased Premises. Notwithstanding Landlords
duty to mitigate its damages as provided herein, Landlord shall not be obligated (i) to give any
priority to reletting Tenants space in connection with its leasing of space in the Building or any
complex of which the Building is or becomes a part, or (ii) to accept below market rental rates for
the Leased Premises or any rate that would negatively impact the market rates for the Building. To
the extent that Landlord is required by applicable law to mitigate damages, Tenant must plead and
prove by clear and convincing evidence that Landlord failed to so mitigate in accordance with the
provisions of this Section 7.1(f), and that such failure resulted in an avoidable and quantifiable
detriment to Tenant.
7.2. Insolvency or Bankruptcy. The appointment of a receiver to take possession of all
or substantially all of the assets of Tenant or any guarantor of Tenants obligations under this
Lease, or any general assignment by Tenant or any guarantor of Tenants obligations under this
Lease for the benefit of creditors, or any action taken or suffered by Tenant or any guarantor of
Tenants obligations under this Lease under any insolvency, bankruptcy, or reorganization act,
shall, at Landlords option, constitute a breach of this Lease by Tenant. Upon the happening of any
such event or at any time thereafter, this Lease shall terminate five (5) days after written notice
of termination from Landlord to Tenant. In no event shall this Lease be assigned or assignable by
operation of law or by voluntary or involuntary bankruptcy proceedings or otherwise and in no event
shall this Lease or any
25
rights or privileges hereunder be an asset of Tenant under any bankruptcy, insolvency, or
reorganization proceedings.
7.3. Late Payments. Tenant shall pay, as a one (1) time late charge on each
installment of any Rental owed by Tenant hereunder that is not paid when due, the greater of
$100.00 or an amount equal to five percent (5%) of the amount due for each and every thirty (30)
day period that said amount remains unpaid (but in no event shall the amount of such late charge
exceed an amount based upon the highest legally permissible rate chargeable at any time by Landlord
under the circumstances). Should Tenant make a partial payment of past due amounts, the amount of
such partial payment shall be applied first to reduce all accrued and unpaid late charges, in
inverse order of their maturity, and then to reduce all other past due amounts, in inverse order of
their maturity.
7.4. Attorneys Fees. In any action to enforce a partys rights under this Lease or
the terms hereof, the prevailing party shall be entitled to collect from the other party all court
costs, reasonable attorneys fees and litigation expenses, including, but not limited to, costs of
depositions and expert witnesses, actually incurred by the prevailing party in connection with such
action.
7.5. Waiver of Homestead. Tenant hereby waives and renounces all homestead or
exemption rights which Tenant may have under or by virtue of the Constitutions and Laws of the
United States, the State of Tennessee, and any other State as against any debt or sum Tenant may
owe Landlord under this Lease and hereby transfers, conveys, and assigns to Landlord all homestead
or exemption rights which may be allowed or set apart to Tenant, including such as may be set apart
in any bankruptcy proceeding, to pay any debt or sum owing by Tenant to Landlord hereunder.
7.6. No Waiver of Rights. No failure or delay of Landlord to exercise any right or
power given it herein or to insist upon strict compliance by Tenant of any obligation imposed on
it herein and no custom or practice of either party hereto at variance with any term hereof shall
constitute a waiver or a modification of the terms hereof by Landlord or any right it has herein
to demand strict compliance with the terms hereof by Tenant. No waiver of any right of Landlord or
any default by Tenant on one occasion shall operate as a waiver of any of Landlords other rights
or of any subsequent default by Tenant. No express waiver shall affect any condition, covenant,
rule, or regulation other than the one specified in such waiver and then only for the time and in
the manner specified in such waiver. No person has or shall have any authority to waive any
provision of this Lease unless such waiver is expressly made in writing and signed by an
authorized officer of Landlord.
7.7. Holding Over. In the event of holding over by Tenant after expiration or
termination of this Lease without the written consent of Landlord, Tenant shall pay as liquidated
damages, solely for such holding over, double the Rental that would have been payable if this
Lease had not so terminated or expired) for the entire holdover period. No holding over by Tenant
after the term of this Lease shall be construed to extend this Lease, and Tenant shall be deemed a
tenant at will, terminable on five (5) days notice from Landlord. In the event of any unauthorized
holding over, Tenant shall indemnify Landlord against all claims for damages by any other tenant
to whom Landlord shall have leased all or any part of the Leased Premises effective upon the
termination of this Lease. Any holding over with the
26
express written consent of Landlord shall thereafter constitute this Lease to be a lease from
month to month (terminable by either party on thirty (30) days notice) at a Base Rental, Tenants
Forecast Additional Rental, and all other sums required to be paid by Tenant prior to the
expiration or termination of this Lease as may be determined by Landlord.
7.8. Subordination.
(a) Landlord may have heretofore or may hereafter encumber with a mortgage, deed of trust,
deed to secure debt, financing statement or other security interests (collectively, a Mortgage)
the Land, the Project or any part thereof or any interest therein, may sell and lease back the
Land, the Project or any part thereof, and may encumber the leasehold estate under such a sale and
leaseback arrangement with a Mortgage. (The holder of any Mortgage is herein called a Mortgagee.
A lease creating Landlords interest in the Land, the Project or part thereof is herein called a
Ground Lease and the lessor under any such Ground Lease is herein called a Ground Lessor.)
This Lease and the rights of Tenant hereunder shall be and are hereby expressly made subject to
and subordinate at all times to any Mortgage and to any Ground Lease now or hereafter existing,
and to all amendments, modifications, renewals, extensions, consolidations and replacements
thereof, and to all advances made or hereafter to be made upon the security thereof; provided,
however, that the Mortgagee or Ground Lessor shall not, so long as Tenant shall not be in default
under this Lease, disturb Tenant in its possession of the Leased Premises or terminate Tenants
rights hereunder. Tenant agrees to execute and deliver to Landlord such further instruments
consenting to or confirming the subordination of this Lease to any Mortgage and to any Ground
Lease and containing such other provisions which may be requested in writing by Landlord within
ten (10) days after Tenants receipt of such written request.
(b) Tenant agrees that if Landlord defaults in the performance or observance of any covenant
or condition of this Lease required to be performed or observed by Landlord hereunder, Tenant will
give written notice specifying such default by certified or registered mail, postage prepaid, to
any Mortgagee or Ground Lessor of which Tenant has been notified in writing, and before Tenant
exercises any right or remedy which it may have on account of any such default of Landlord, such
Mortgagee or Ground Lessor shall have a reasonable amount of time to cure such default of Landlord,
if such default can be cured without such Mortgagee or Ground Lessor taking possession of the
mortgaged or leased estate, or to obtain possession of the mortgaged or leased estate and then to
cure such default of Landlord, if such default cannot be cured without such Mortgagee or Ground
Lessor taking possession of the mortgaged or leased estate.
(c) If any Mortgage is foreclosed, or Landlords interest under this Lease is conveyed or
transferred in lieu of foreclosure, or if any Ground Lease is terminated:
|
(i) |
|
No person or entity which as the result of any
of the foregoing has succeeded to the interest of Landlord in this
Lease (any such person or entity being hereafter called a Successor)
shall be liable for any default by Landlord or any other matter which
occurred prior to the date such Successor succeeded to Landlords
interest in this Lease, nor shall such Successor be bound by or |
27
|
|
|
subject to any offsets or defenses which Tenant may have against
Landlord or any other predecessor in interest to such Successor. |
|
|
(ii) |
|
Upon request of any Successor, Tenant will
attorn to such Successor, as Landlord under this Lease, subject to the
provisions of this Section 7.8(c) and Section 7.8(e), and will execute
and deliver such instruments as may be necessary or appropriate to
evidence such attornment within ten (10) days after receipt of a
written request to do so. |
|
|
(iii) |
|
No Successor shall be bound to recognize any
prepayment by more than thirty (30) days of any Rental payable by
Tenant hereunder. |
(d) Notwithstanding anything to the contrary contained herein, any Mortgagee may subordinate,
in whole or in part, its Mortgage to this Lease by sending Tenant notice in writing subordinating
all or any part of such Mortgage to this Lease, and Tenant agrees to execute and deliver to such
Mortgagee such further instruments consenting to or confirming the subordination of all or any
portion of its Mortgage to this Lease and containing such other provisions which may be requested
in writing by such Mortgagee within ten (10) days after Tenants receipt of such written request.
(e) Whether or not any Mortgage is foreclosed or any Ground Lease is terminated, or any
Mortgagee or Ground Lessor succeeds to any interest of Landlord under this Lease, no Mortgagee or
Ground Lessor shall have any liability to Tenant for any security deposit paid to Landlord by
Tenant hereunder, unless such security deposit has actually been received by such Mortgagee or
Ground Lessor.
(f) Should any prospective Mortgagee or Ground Lessor require a modification or modifications
of this Lease, which modification or modifications will not cause an increased cost or expense to
Tenant or in any other way materially and adversely change the rights and obligations of Tenant
hereunder, in the reasonable judgment of Tenant, then and in such event, Tenant agrees that this
Lease may be so modified and agrees to execute whatever documents are required therefor and deliver
the same to Landlord within ten (10) days following written request therefor. Should any
prospective Mortgagee or Ground Lessor require execution of a short form of this Lease for
recording (containing, among other customary provisions, the names of the parties, a description of
the Leased Premises and the term of this Lease), Tenant agrees to execute such short form of lease
and deliver the same to Landlord within ten (10) days following the request therefor.
(g) If Tenant fails within ten (10) days after initial written demand therefor to execute and
deliver any instruments as may be necessary or proper to effectuate any of the covenants of Tenant
set forth above in this Section, Tenant hereby makes, constitutes and irrevocably appoints any one
of Landlord or any of Landlords beneficiaries or partners in such beneficiaries as
attorney-in-fact for Tenant (such power of attorney being coupled with an interest) with full power
and authority to execute and deliver any such instruments for and in the name of Tenant.
28
(h) No Mortgagee or Ground Lessor of which Tenant has been notified, in writing, shall be
bound any amendment or modification of this Lease made without the written consent of such
Mortgagee or Ground Lessor.
7.9. Estoppel Certificate. Tenant agrees that, from time to time upon not less than
ten (10) days prior request by Landlord, or any existing or prospective Mortgagee or Ground
Lessor, Tenant will, and Tenant will cause any subtenant, licensee, concessionaire or other
occupant of the Leased Premises claiming by, through or under Tenant, to complete, execute and
deliver to Landlord or Landlords designee or to any existing or prospective mortgagee or ground
lessor, a written estoppel certificate certifying (i) that this Lease is unmodified and is in full
force and effect (or if there have been modifications, that this Lease, as modified, is in full
force and effect and setting forth the modifications); (ii) the amounts of the monthly installments
of Base Rental, Tenants Forecast Additional Rental, Tenants Additional Rental Adjustment and
other sums then required to be paid under this Lease by Tenant; (iii) the date to which the Base
Rental, Tenants Forecast Additional Rental, Tenants Additional Rental Adjustment and other sums
required to be paid under this Lease by Tenant have been paid; (iv) that Landlord is not in default
under any of the provisions of this Lease, or if in default, the nature thereof in detail and what
is required to cure same; and (v) such other information concerning the status of this Lease or the
parties performance hereunder reasonably requested by Landlord or the party to whom such estoppel
certificate is to be addressed.
ARTICLE VIII.
8.1. Sublease or Assignment by Tenant.
(a) The Tenant shall not, without the Landlords prior written consent, (i) assign, convey,
mortgage, pledge, encumber, or otherwise transfer (whether voluntarily, by operation of law, or
otherwise) this Lease or any interest hereunder; (ii) allow any lien to be placed upon Tenants
interest hereunder; (iii) sublet the Leased Premises or any part thereof; or (iv) permit the use or
occupancy of the Leased Premises or any part thereof by any one other than Tenant. Any attempt to
consummate any of the foregoing without Landlords consent shall be void and of no force or effect.
For purposes hereof, the transfer of the ownership or voting rights in a controlling interest of
the voting stock of Tenant (if Tenant is a corporation) or the transfer of a general partnership
interest or a majority of the limited partnership interest in Tenant (if Tenant is a partnership),
at any time throughout the term of this Lease, shall be deemed to be an assignment of this Lease.
(b) Notwithstanding anything herein to the contrary, if at any time or from time to time
during the term of this Lease, Tenant desires to sublet all or any portion of the Leased Premises
or assign all or any portion of Tenants interest in this Lease, Tenant shall notify Landlord in
writing (hereinafter referred to in this Section as the Notice) of the terms of the proposed
subletting or assignment, the identity of the proposed sublessee or assignee, the area proposed to
be sublet or covered by the assignment (hereinafter referred to as Sublet Space), and such other
information as Landlord may request to evaluate Tenants request to sublet or assign. Landlord
shall then have the option (i) to sublet the Sublet Space from Tenant as provided in subsection (c)
hereof at the same Base Rental and Tenants Additional Rental as Tenant is required to pay to
Landlord under this Lease for the Sublet Space, (ii) to terminate this Lease as to the Sublet Space
as provided in subsection (d)
29
hereof, or (iii) to allow the proposed sublease or assignment subject only to the final review
for approval as provided in subsection (e) hereof. Landlord s option to sublet, to terminate, or to
allow the proposed sublease or assignment subject to final review, as the case may be, shall be
exercisable by Landlord in writing within a period of thirty (30) calendar days after receipt of
the Notice and any failure by Landlord to exercise any of such options within said thirty (30) day
period shall be deemed to constitute the election of option (iii) above.
(c) In the event Landlord exercises the option to sublet the Sublet Space pursuant to
Landlords options set forth above, the term of the subletting from the Tenant to Landlord shall be
the term set forth in the Notice (which shall not be longer than the then current term of this
Lease unless Landlord expressly agrees in writing that any extension or renewal option contained in
this Lease will apply to such Sublet Space) and shall be on such terms and conditions as are
contained in this Lease to the extent applicable, except that the Landlord shall have the right to
further sublet the Sublet Space freely and without any consent or approval from Tenant and upon
such terms and for such rent as Landlord shall agree upon in its sole and absolute discretion.
(d) If Landlord elects to terminate this Lease pursuant to Landlords options set forth above,
then this Lease shall terminate as to the Sublet Space on the date set forth in Landlords notice
to Tenant, which date shall be no less than thirty (30) days and no more than ninety (90) days
after the date of such notice. If the Sublet Space does not constitute the entire Leased Premises
and Landlord exercises its option to terminate this Lease with respect to the Sublet Space, as to
that portion of the Leased Premises which is not part of the Sublet Space, this Lease shall remain
in full force and effect except that Base Rental, Tenants Forecast Additional Rental, and Tenants
Additional Rental shall be calculated on the difference between the Rentable Square Feet prior to
such termination and the Rentable Square Feet of the Sublet Space.
(e) If Landlord elects or is deemed to have elected to allow the proposed sublease or
assignment subject to final review, Tenant shall submit to Landlord, within twenty (20) calendar
days after receipt of Landlords notice of election (or the expiration of said thirty (30)-day
period if no such election is made), a copy of the proposed sublease or assignment, which sublease
or assignment must provide for the assumption of all of Tenants obligations under this Lease, and
such additional information concerning the business, reputation and credit-worthiness of the
proposed sublessee or assignee as shall be sufficient to allow Landlord to form a commercially
reasonable judgment with respect thereto. Landlord agrees not to unreasonably withhold its
approval of any proposed sublease or assignment and, in the event Landlord fails to approve or
disapprove any such sublease or assignment within thirty (30) days after Landlords receipt of
such submission from Tenant, such sublease or assignment shall be deemed to be approved; provided,
however, that if Landlord approves any proposed sublease or assignment, Landlord shall receive
from Tenant as additional rent hereunder seventy-five percent (75%) of any rents or other sums
received by Tenant pursuant to said sublease or assignment in excess of the rentals payable to
Landlord by Tenant under this Lease with respect to the Sublet Space (after deducting all of
Tenants reasonable costs associated therewith, including reasonable brokerage fees and the
reasonable cost of remodeling or otherwise improving the Leased Premises for said sublessee or
assignee), as such rents or other sums are received by Tenant from the approved sublessee or
assignee. Landlord may require that any rent or other sums paid by a sublessee or assignee be paid
directly to Landlord. If Landlord approves in writing the proposed sublessee or assignee and the
terms of the proposed sublease
30
or assignment, but a fully executed counterpart of such sublease or assignment is not
delivered to Landlord within sixty (60) calendar days after the date of Landlords written
approval, then Landlords approval of the proposed sublease or assignment shall be deemed null and
void and Tenant shall again comply with all the conditions of this Section as if the Notice and
options hereinabove referred to had not been given, received or exercised. If Landlord fails to
approve the form of sublease or assignment or the sublessee or assignee, Tenant shall have the
right to submit amended forms or other sublessees or assignees to Landlord to review for approval.
(f) Notwithstanding the giving by Landlord of its consent to any sublease or assignment with
respect to the Leased Premises, no sublessee or assignee may exercise any expansion option, right
of first refusal option, or renewal option under this Lease except in accordance with a separate
written agreement entered into directly between such sublessee or assignee and Landlord, and
Tenant may not exercise any such right with respect to any space that Tenant has sublet or
assigned.
(g) Notwithstanding the giving by Landlord of its consent to any subletting, assignment or
occupancy as provided hereunder or any language contained in such lease, sublease or assignment to
the contrary, unless this Lease is expressly terminated by Landlord, Tenant shall not be relieved
of any of Tenants obligations or covenants under this Lease and Tenant shall remain fully liable
hereunder.
(h) If, with the consent of the Landlord, the Leased Premises or any part thereof is sublet or
occupied by other than Tenant or this Lease is assigned, Landlord may, after default by Tenant,
collect rent from the subtenant, assignee or occupant, and apply the net amount collected to the
Rental herein reserved. No such subletting, assignment, occupancy, or collection shall be deemed
(i) a waiver of any of Tenants covenants contained in this Lease, (ii) a release of Tenant from
further performance by Tenant of its covenants under this Lease, or (iii) a waiver of any of
Landlords other rights hereunder.
(i) In no event shall Tenant assign this Lease or enter into any sublease, license, concession
or other agreement for use, occupancy or utilization of any part of the Leased Premises which
provides for a rental or other payment for such use, occupancy or utilization based in whole or in
part on the income or profits derived by any person from the Leased Premises leased, used, occupied
or utilized (other than an amount based on a fixed percentage or percentages of gross receipts of
sales), and Tenant agrees that all assignments, subleases, licenses, concessions or other
agreements for use, occupancy or utilization of any part of the Leased Premises shall provide that
the person having an interest in the possession, use, occupancy or utilization of the Leased
Premises shall not enter into any lease, sublease, license, concession or other agreement for use,
occupancy or utilization of space in the Leased Premises which provides for a rental or other
payment for such use, occupancy or utilization based in whole or in part on the income or profits
derived by any person from the Leased Premises leased, used, occupied or utilized (other than an
amount based on a fixed percentage or percentages of gross receipts of sales) and any such
purported assignment, sublease, license, concession or other agreement shall be absolutely void and
ineffective as a conveyance of any right or interest in the possession, use, occupancy or
utilization of any part of the Leased Premises.
31
8.2. Assignment by Landlord. Landlord shall have the right to transfer and assign, in
whole or in part, all its rights and obligations hereunder, in the Building, the Land and all other
property referred to herein, and in such event and upon such transfer (any such transferee to have
the benefit of, and be subject to, the provisions of Sections 8.03 and 8.04 hereof) no further
liability or obligation shall thereafter accrue against Landlord hereunder.
8.3. Peaceful Enjoyment. Landlord covenants that Tenant shall and may peacefully have,
hold and enjoy the Leased Premises free from hindrance by Landlord or any person claiming by,
through or under Landlord but subject to the other terms hereof, provided that Tenant pays the
rental and other sums herein recited to be paid by Tenant and performs all of Tenants covenants
and agreements herein contained. It is understood and agreed that this covenant and any and all
other covenants of Landlord contained in this Lease shall be binding upon Landlord and its
successors only with respect to breaches occurring during the ownership of the Landlords interest
hereunder.
8.4. Limitation of Landlords Personal Liability. Tenant specifically agrees to look
solely to Landlords equity interest in the Building for the recovery of any monetary judgment
against Landlord, it being agreed that Landlord (and its partners and shareholders) shall never be
personally liable for any such judgment. The provision contained in the foregoing sentence is not
intended to, and shall not, limit any right that Tenant might otherwise have to obtain injunctive
relief against Landlord or Landlords successors in interest or any suit or action in connection
with enforcement or collection of amounts which may become owing or payable under or on account of
insurance maintained by Landlord.
8.5. Force Majeure. Landlord and Tenant (except with respect to the payment of Rental
or any other monetary obligation under this Lease shall be excused for the period of any delay and
shall not be deemed in default with respect to the performance of any of the terms, covenants and
conditions of this Lease when prevented from so doing by a cause or causes beyond the Landlords or
Tenants (as the case may be) control (excluding financial inability to perform), which shall
include, without limitation, all labor disputes, governmental regulations or controls, fire or
other casualty, inability to obtain any material or services, acts of God, or any other cause not
within the reasonable control of Landlord or Tenant (as the case may be).
ARTICLE IX.
9.1. Notices. Any notice or other communications required or permitted to be given
under this Lease must be in writing and shall be effectively given or delivered if (i) hand
delivered to the addresses for Landlord and Tenant stated below, (ii) sent by certified or
registered United States Mail, return receipt requested, to said addresses, or (iii) sent by
nationally recognized overnight courier (such as Federal Express, UPS Next Day Air or Airborne
Express), with all delivery charges paid by the sender and signature required for delivery, to said
address. Any notice mailed shall be deemed to have been given upon receipt or refusal thereof.
Notice effected by hand delivery shall be deemed to have been given at the time of actual delivery.
Either party shall have the right to change its address to which notices shall thereafter be sent
and the party to whose attention such notice shall be directed by giving the other party notice
thereof in accordance with the provisions of this Section 9.1. The initial addresses of the parties
for purposes of this Lease are:
32
|
|
|
|
|
|
|
To:
|
|
Lionstone Cash Flow Office One, LP |
|
|
|
|
Five Greenway Plaza |
|
|
|
|
Houston, Texas 77046 |
|
|
|
|
Attn: Daniel R. Dubrowski |
|
|
|
|
Telecopy: (713) 285-2911 |
|
|
|
|
|
|
|
With copy to:
|
|
Property Tennessee One Corporation |
|
|
|
|
c/o Lionstone Cash Flow Office One, LP |
|
|
|
|
Five Greenway Plaza |
|
|
|
|
Houston, Texas 77046 |
|
|
|
|
Attn: F. Russ Nicholson |
|
|
|
|
Telecopy: (713) 285-2911 |
|
|
|
|
|
|
|
With copy to:
|
|
Nashville Hines Development, LLC |
|
|
|
|
Property Management Office |
|
|
|
|
2525 West End Avenue |
|
|
|
|
Nashville, TN 37203 |
|
|
|
|
Attn: Project Manager |
|
|
|
|
|
|
|
Tenant:
|
|
Cumberland Pharmaceuticals Inc. |
|
|
|
|
2525 West End Avenue, Suite 950 |
|
|
|
|
Nashville, TN 37203 |
|
|
|
|
Attn: Jean W. Marstiller |
|
|
|
|
Telecopy: (615) 255-0094 |
|
|
|
|
|
|
|
With a copy to:
|
|
Adams and Reese / Stokes Bartholomew LLP |
|
|
|
|
424 Church Street, Suite 2800 |
|
|
|
|
Nashville, TN 37219-2386 |
|
|
|
|
Attn: Martin S. Brown |
|
|
|
|
Telecopy: (615) 259-1470 |
Tenant shall also send a copy of each such notice to each Mortgagee that notifies Tenant in writing
of its interest and the address to which notices are to be sent.
9.2. Miscellaneous.
(a) This Lease shall be binding upon and inure to the benefit of the successors and assigns of
Landlord, and shall be binding upon and inure to the benefit of Tenant, its successors, and, to the
extent assignment may be approved by Landlord hereunder, Tenants assigns. Where appropriate the
pronouns of any gender shall include the other gender, and either the singular or the plural shall
include the other.
(b) All rights and remedies of Landlord and Tenant under this Lease shall be cumulative and
none shall exclude any other rights or remedies allowed by law. This Lease is declared to be a
Tennessee contract, and all of the terms hereof shall be construed according to the laws of the
State of Tennessee.
(c) This Lease may not be altered, changed or amended, except by an instrument in writing
executed by all parties hereto. Further, the terms and provisions of this
33
Lease shall not be construed against or in favor of a party hereto merely because such party
is the Landlord or the Tenant hereunder or such party or its counsel is the draftsman of this
Lease.
(d) If Tenant is a corporation, partnership or other entity, Tenant warrants that all consents
or approvals required of third parties (including but not limited to its Board of Directors or
partners) for the execution, delivery and performance of this Lease have been obtained and that
Tenant has the right and authority to enter into and perform its covenants contained in this Lease.
Likewise, if Landlord is a corporation, partnership or other entity, Landlord warrants that all
consent or approvals required of third parties (including but not limited to its Board of Directors
or partners) for the execution, delivery and performance of this Lease have been obtained and that
Landlord has the right and authority to enter into and perform its covenants contained in this
Lease.
(e) TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE PARTIES HERETO SHALL AND THEY HEREBY DO
WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF THE PARTIES
HERETO AGAINST THE OTHER ON ANY MATTERS WHATSOEVER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS
LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, TENANTS USE OR OCCUPANCY OF THE DEMISED PREMISES
AND/OR ANY CLAIM OF INJURY OR DAMAGE. IN THE EVENT LANDLORD COMMENCES ANY PROCEEDINGS FOR
NONPAYMENT OF RENT OR ANY OTHER AMOUNTS PAYABLE HEREUNDER, TENANT SHALL NOT INTERPOSE ANY
COUNTERCLAIM OF WHATEVER NATURE OR DESCRIPTION IN ANY SUCH PROCEEDING, UNLESS THE FAILURE TO RAISE
THE SAME WOULD CONSTITUTE A WAIVER THEREOF. THIS SHALL NOT, HOWEVER, BE CONSTRUED AS A WAIVER OF
TENANTS RIGHT TO ASSERT SUCH CLAIMS IN ANY SEPARATE ACTION BROUGHT BY TENANT.
(f) Wherever in this Lease there is imposed upon Landlord the obligation to use best or
reasonable efforts or due diligence, Landlord shall be required to do so only to the extent the
same is economically feasible and otherwise will not impose upon Landlord extreme financial or
other burdens.
(g) If any term or provision of this Lease, or the application thereof to any person or
circumstance, shall to any extent be invalid or unenforceable, the remainder of this Lease, or the
application of such provision to persons or circumstances other than those as to which it is
invalid or unenforceable, shall not be affected thereby, and each provision of this Lease shall be
valid and shall be enforceable to the extent permitted by law.
(h) Time is of the essence in this Lease.
(i) This Lease agreement shall not convey any leasehold estate from Landlord to Tenant.
Landlord and Tenant hereby agree that this Lease creates only the interest of a usufruct in Tenant
which may not be levied upon or assigned without Landlords permission.
34
(j) Tenant represents and warrants to Landlord that Tenant did not deal with any broker in
connection with this Lease. Tenant shall indemnify, defend and hold Landlord, Landlords
beneficiaries, the managing agent of the Building, the leasing agent of the Building and their
respective agents, partners and employees and the Building harmless of, from and against any and
all losses, damages, liabilities, claims, liens, costs and expenses (including, without
limitation, court costs, reasonable attorneys fees and litigation expenses) arising from any
claims or demands of any broker or brokers or finders for any commission alleged to be due such
other broker or brokers or finders claiming to have dealt with Tenant in connection with this
Lease or with whom Tenant hereafter deals or whom Tenant employs. The provisions of this
subsection shall survive the expiration or earlier termination of this Lease.
(k) If Tenant comprises more than one person, corporation, partnership, limited liability
company or other entity, the liability hereunder of all such persons, corporations, partnerships
or other entities shall be joint and several.
(1) Landlords receipt of any Rental payable by Tenant hereunder with knowledge of the breach
of a covenant or agreement contained in this Lease shall not be deemed a waiver of the breach. No
acceptance by Landlord of a lesser amount than the installment of Rental which is due shall be
considered, nor shall any endorsement or statement on any check or any letter accompanying any
check or payment be deemed, an accord and satisfaction. Landlord may accept a check or payment
without prejudice to Landlords right to recover the balance due or to pursue any other remedy
provided in this Lease.
(m) Wherever Landlords consent or approval is required pursuant to the terms of this Lease,
Landlord may grant or withhold the same in Landlords sole and absolute discretion, except as
otherwise expressly provided herein.
(n) Tenant covenants and agrees to keep strictly confidential all of the financial terms of
this Lease and not to disseminate any such information to any third parties without the prior
written consent of Landlord. Tenant further covenants and agrees that, at all times after the date
of this Lease and prior to the Commencement Date, unless consented to in writing by Landlord, no
press release or other public disclosure concerning this Lease shall be made by Tenant.
(o) Submission of this instrument for examination shall not constitute a reservation of or
option to lease the Leased Premises or in any manner bind Landlord, and no lease or obligation on
Landlord shall arise until this instrument is signed and delivered by Landlord and Tenant;
provided, however, the execution and delivery by Tenant of this Lease to Landlord, or the managing
agent of the Building or the leasing agent of the Building shall constitute an irrevocable offer by
Tenant to lease the Leased Premises on the terms and conditions herein contained, which offer may
not be revoked for thirty (30) days after such delivery.
(p) Financial Statements. Tenant shall deliver to Landlord, within fifteen (15) days
after Landlords request, Tenants annual financial statement for the immediately previous fiscal
year and Tenants quarterly financial statements, if any, prepared since such annual financial
statement, including balance sheets, income statements and cash flow statements,
35
prepared in accordance with generally accepted accounting principles consistently applied.
Such financial statements shall be certified by the chief financial officer of Tenant as being
true, accurate and complete in all material respects. If Tenants annual financial statement will
not be prepared or complete within such fifteen (15) day period, then Tenants time to deliver its
annual financial statement shall be extended to the day that such statement is completed in the
normal course of Tenants business and in keeping with reasonable business practices. However, if
Tenants time to respond would be extended by more than thirty (30) days, Tenant shall so notify
Landlord in writing upon Tenants receipt of Landlords request for Tenants financial statement,
and shall offer to Landlord (in the interim) a copy of Tenants prior years financial statement
with Tenants chief financial officers estimate of any material differences in Tenants financial
condition since that statement was prepared. Landlord shall only make request for such financial
statements when Landlord determines, in the exercise of Landlords reasonable judgment, that such
information is of immediate value.
9.3. Option to Renew. Subject to the provisions hereinafter set forth and the
expansion and renewal rights of other tenants on the floor containing the Leased Premises, Landlord
hereby grants to Tenant an option to extend the Lease Term for not less than the entire initial
Leased Premises (the Option to Renew) on the same terms, conditions and provisions as contained
in this Lease, as modified in this Section 9.3, for one period of five (5) years (the Renewal
Period) commencing on January 1, 2011 (the Renewal Period Commencement Date) and ending at 6:00
p.m. on December 31, 2015.
(a) The Option to Renew shall be exercisable by written notice from Tenant to Landlord of
Tenants election to exercise said option (Tenants Renewal Notice) given not earlier than
twenty-four (24) months nor later than nine (9) months prior to the Renewal Period Commencement
Date, time being of the essence. If the Option to Renew is not so exercised, said option shall
thereupon expire.
(b) Tenant may only exercise the Option to Renew, and an exercise thereof shall only be
effective, if at the time of Tenants exercise of said option and on the Renewal Period
Commencement Date this Lease is in full force and effect and there is no Event of Default under
this Lease. No sublessee shall be entitled to exercise the renewal option under this Section 9.3.
(c) Rent per Rentable Square Foot payable during the Renewal Period with respect to all space
included in the Leased Premises as of the Renewal Period Commencement Date shall be equal to
Landlords then-quoted Building rental rate for the Leased Premises, which may be a stepped rate,
taking into account other pecuniary concessions such as any rent abatement, tenant improvement
allowances, commissions, lese term, lease rate escalations, operating expenses, and taxes. Landlord
shall give Tenant written notice of the proposed Market Rental Rate within twenty (20) days
following written request by Tenant made not earlier than fourteen (14) months prior to the Renewal
Period Commencement Date; provided, however, Landlord shall not be required to provide its notice
of the proposed Market Rental Rate until Landlord has received Tenants Renewal Notice.
(d) If Tenant has validly exercised the Option to Renew, within thirty (30) days after request
by either party hereto, Landlord and Tenant shall enter into a written
36
amendment to this Lease confirming the terms, conditions and provisions applicable to the
Renewal Period as determined in accordance herewith, with such revisions to the rental provisions
of this Lease as may be necessary to conform such provisions to the Market Rental Rate.
[signatures appear on following page]
37
IN WITNESS WHEREOF, the parties hereto have executed and sealed this Lease as of the date
aforesaid.
|
|
|
|
|
|
|
|
|
|
|
LANDLORD: |
|
|
|
|
|
|
|
|
|
|
|
|
|
NASHVILLE HINES DEVELOPMENT, LLC,
a Delaware limited liability company |
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
Cash Flow Asset Management, L.P., |
|
|
|
|
|
|
a Texas limited partnership, its sole manager |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
CFAM GP, L.L.C., |
|
|
|
|
|
|
|
|
a Texas limited liability company, its sole partner |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ F. Russ Nicholson
F. Russ Nicholson
|
|
|
|
|
|
|
|
|
Vice President |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TENANT: |
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC.,
a Tennessee corporation |
|
|
|
|
|
|
|
|
|
|
|
By:
Name:
|
|
/s/ A.J. Kazimi
A. J. Kazimi
|
|
|
|
|
Title:
|
|
Chief Executive Officer |
|
|
38
EXHIBIT A
SITE PLAN AND LOCATION OF THE
BUILDING
Exhibit A Page 1
EXHIBIT A-1
DESCRIPTION OF LAND
Tract 1 / 3.01 Acres
Being a parcel of land in Nashville, First Civil District, Eighteenth Councilmanic District,
Davidson County, Tennessee, generally located on the southerly side of West End Avenue between
Twenty-Fifth Avenue South and Natchez Trace, being part of Lot 1, Vanderbilt University
Consolidation Plat of record in Plat Book 9700, page 522, R.O.D.C. and being more particularly
described as follows:
Beginning at a mag nail (new) in the westerly right-of-way line of Twenty-Fifth Avenue South
(50-foot right-of-way) at the southerly terminus of a curve return to the southerly right-of-way
line of West End Avenue (right-of-way varies);
THENCE,
along said westerly right-of-way line of Twenty-Fifth Avenue South, S
36° 59' 53" E,
179.61 to an iron pipe (old) at the northeast corner of property conveyed to Vanderbilt University
by deed of record in Book 5157, page 991, R.O.D.C.;
THENCE,
along the northerly line of said property, S 53° 09' 57" W, 150.00 feet to an x in conc.
wall;
THENCE,
along the westerly line of said property, S 36° 59' 53" E, 179.81 feet to an iron pin
(set) in the northerly line of a fifty foot wide ingress and egress easement;
THENCE, along the northerly line of said ingress and egress easement the following
calls;
S 53°
08' 25" W, 90.85 feet to an iron pin (set) at the beginning of a curve to the
left;
Along said curve to the left, 136.18 feet to a railroad spike (new), said curve having a central
angle of
17° 56' 44", a radius of 434.80 feet, a tangent of
68.65 feet and a chord of S 44° 10' 03" W,
135.63 feet;
S 35°
11' 41" W, 8.07 feet to a mag nail (new);
THENCE, leaving the northerly line of said ingress and egress easement and along a severance line
the following calls:
N 36° 59' 13" W, 103.37 feet to a mag nail
(new);
S 53° 00' 47" W, 43.57 feet to a mag nail (new);
N 36° 59' 13" W, 3.57 feet to a mag nail (new);
S 53° 00' 47" W, 12.00 feet to a mag nail (new);
N 36° 59' 13" W, 285.90 feet to a mag nail (new) in the southerly right-of-way line of West End
Avenue;
THENCE, along said right-of-way the following calls;
N 54° 13' 39" E, 33.07 feet to a mag nail (new);
Exhibit A-1 Page 1
N 53°
00' 47" E, 394.99 feet to an x in conc. (new) at the westerly terminus of a curve return to
the right to the westerly right-of-way line of Twenty-Fifth Avenue South; Along said curve to the
right 15.71 feet to the point of beginning, said curve having a
central angle of 89° 59' 19", a
radius of 10.00 feet, a tangent of 10.00 feet and a chord of S
81° 59' 33" E, 14.14 feet;
Containing 3.01 acres, more or less.
Exhibit A-1 Page 2
EXHIBIT B
FLOOR PLAN OF LEASED PREMISES
[to be attached]
Exhibit B Page 1
EXHIBIT C
AIR CONDITIONING AND HEATING SERVICES
Subject to the provisions of Section 3.1(b), Landlord will furnish Building Standard air
conditioning and heating between 8 a.m. and 6 p.m. on weekdays (from Monday through Friday,
inclusive) and between 8 a.m. and 1:00 p.m. on Saturdays, all exclusive of Holidays as defined
below (the Building Operating Hours). Upon request of Tenant made in accordance with the rules
and regulations for the Building, Landlord will furnish air conditioning and heating at other
times (that is, at times other than the times specified above), in which event Tenant shall
reimburse Landlord for Landlords actual cost of furnishing such services, plus an amount equal to
fifteen percent (15%) of such costs to cover Landlords administrative costs.
The Building Standard heating, ventilation and air conditioning system shall meet the
following design conditions, at the stated outside design conditions, based on one person per 100
square feet:
|
1. |
|
Summer Outdoor conditions 92 degrees Fahrenheit dry bulb, 75 degrees
Fahrenheit wet bulb; indoor conditions 75 degrees Fahrenheit dry bulb, 50% relative
humidity at design condition. |
|
|
2. |
|
Winter Outdoor conditions minus 16 degrees Fahrenheit dry bulb; indoor
conditions 72 degrees Fahrenheit dry bulb. |
|
|
|
|
The following dates shall constitute Holidays as said term is used in this Lease: |
|
(a) |
|
New Years Day |
|
|
(b) |
|
Memorial Day |
|
|
(c) |
|
Independence Day |
|
|
(d) |
|
Labor Day |
|
|
(e) |
|
Thanksgiving Day |
|
|
(f) |
|
Friday following Thanksgiving Day |
|
|
(g) |
|
Christmas |
|
|
(h) |
|
Any other holiday generally recognized as such by landlords of
office space in the metropolitan Nashville, Tennessee office market, as
determined by Landlord in good faith. |
If in the case of any holiday described in (a) through (g) above, a different day shall be
observed than the respective day above-described, then that day which constitutes the day observed
by national banks in Nashville, Tennessee on account of such holiday shall constitute the holiday
under this Lease.
Exhibit C Page 1
EXHIBIT D
BUILDING RULES AND REGULATIONS
1. |
|
Sidewalks, doorways, vestibules, halls, stairways, and other similar areas shall not be used
for the disposal of trash, be obstructed by tenants, or be used by tenants for any purpose
other than entrance to and exit from the Leased Premises and for going from one part of the
Building to another part of the Building. |
|
2. |
|
Plumbing fixtures shall be used only for the purposes for which they are designed, and no
sweepings, rubbish, rags or other unsuitable materials shall be disposed into them. Damage
resulting to any such fixtures from misuse by a tenant shall be the liability of said tenant. |
|
3. |
|
Signs, advertisements, or notices visible in or from public corridors or from outside the
Building shall be subject to Landlords prior written approval. |
|
4. |
|
Movement in or out of the Building of furniture, office equipment, or any other bulky or
heavy materials shall be restricted to such hours as Landlord shall reasonably designate.
Landlord will determine the method and routing of said items so as to ensure the safety of all
persons and property concerned. Advance written notice of intent to move such items must be
made to the Building management office. |
|
5. |
|
All routine deliveries to a tenants Leased Premises during 8:00 a.m. to 5:00 p.m. weekdays
shall be made through the freight elevators. Passenger elevators are to be used only for the
movement of persons, unless an exception is approved by the Building management office.
Delivery vehicles shall be permitted only in such areas as are designated by Landlord, from
time to time, for deliveries to the Building. |
|
6. |
|
Building management shall have the authority to prescribe the manner that heavy furniture and
equipment are positioned. |
|
7. |
|
Corridor doors, when not in use, shall be kept closed. |
|
8. |
|
Tenant space that is visible from public areas must be kept neat and clean. |
|
9. |
|
All freight elevator lobbies are to be kept neat and clean. The disposal of trash or storage
of materials in these areas is prohibited. |
|
10. |
|
No animals shall be brought into or kept in, on or about the Building, except for seeing-eye
dogs. |
|
11. |
|
Tenant shall not tamper with or attempt to adjust temperature control thermostats in the
Leased Premises. Landlord shall adjust thermostats as required to maintain the Building
standard temperature. Landlord requests that all window blinds remain down and tilted at a 45
degree angle toward the street to help maintain comfortable room temperatures and conserve
energy. |
Exhibit D Page 1
12. |
|
Tenant will comply with all security procedures during business hours and after hours
and on weekends. |
|
13. |
|
Tenants are requested to lock all office doors leading to corridors and to turn out all
lights at the close of their working day. |
|
14. |
|
All requests for overtime air conditioning or heating must be submitted in writing to the
Building management office by 2:00 p.m. on the day desired for weekday requests, by 2:00 p.m.
Friday for weekend requests and by 2:00 p.m. on the preceding business day for holiday
requests. |
|
15. |
|
No flammable or explosive fluids or materials shall be kept or used within the Building
except in areas approved by Landlord, and Tenant shall comply with all applicable building
and fire codes relating thereto. |
|
16. |
|
Tenant may not place any items on the balconies of the Building that alter the exterior
appearance of the Building without obtaining Landlords prior written consent. |
|
17. |
|
Any motor vehicle exceeding the height restrictions of the Parking Facility shall not be
parked at any location on the Land or Parking Area. |
|
18. |
|
Tenant may not make any modifications, additions or repairs to the Leased Premises and may
not install any furniture, fixtures or equipment in the Leased Premises which is in violation
of any applicable building and/or fire code governing the Leased Premises or the Building. |
|
19. |
|
Except in those areas designated by Landlord. if any, smoking is prohibited in the Building
(including, but not limited to, the Leased Premises, the main building lobby, public
corridors, elevator lobbies, service elevator vestibules, stairwells, restrooms and other
common areas within the Building). |
|
20. |
|
All Tenant contractors shall abide by the contractors rules and regulations promulgated by
Landlord from time to time. |
Landlord reserves the right to rescind any of these rules and regulations and to make such other
and further rules and regulations as in its reasonable judgment shall, from time to time, be
required for the safety, protection, care and cleanliness of the Building, the operation thereof,
the preservation of good order therein and the protection and comfort of the tenants and their
agents, employees and invitees. Such rules and regulations, when made and written notice thereof
is given to a tenant, shall be binding upon it in like manner as if originally herein prescribed.
Exhibit D Page 2
EXHIBIT F
[INTENTIONALLY DELETED]
Exhibit F Page 1
EXHIBIT G
BASE RENTAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANNUAL BASE |
|
RENTABLE SQUARE |
|
MONTHLY |
PERIOD |
|
RENTAL RATE |
|
FOOTAGE |
|
BASE RENTAL |
|
1/1/06-12/31/06 |
|
|
[***] |
|
|
|
6,341 |
|
|
|
[***] |
|
1/1/07-12/31/07 |
|
|
[***] |
|
|
|
6,341 |
|
|
|
[***] |
|
1/1/08-12/31/09 |
|
|
[***] |
|
|
|
6,341 |
|
|
|
[***] |
|
1/1/09-12/31/09 |
|
|
[***] |
|
|
|
6,341 |
|
|
|
[***] |
|
1/1/10-12/31/10 |
|
|
[***] |
|
|
|
6,341 |
|
|
|
[***] |
|
Exhibit G Page 1
EX-10.23 AMENDED AND RESTATED LEASE AGREEMENT
EXHIBIT 10.23
*Certain portions of this exhibit have been omitted pursuant to a request for confidential
treatment which has been filed separately with the SEC.
AMENDED AND RESTATED LEASE AGREEMENT
THIS AMENDED AND RESTATED LEASE AGREEMENT (the Lease) is made and entered into
effective as of the 11th day of November, 2004 (the Effective Date), by and
between THE GATEWAY TO NASHVILLE, L.L.C., a Tennessee limited liability company, with its principal
office and place of business in Nashville, Tennessee (Landlord), and CUMBERLAND EMERGING
TECHNOLOGIES, INC., A Tennessee corporation, with its principal place of business in Nashville,
Tennessee (Tenant).
WITNESSETH:
WHEREAS, pursuant to that certain Lease Agreement made by and between Landlord and Tenant
dated June 1, 2002 (the Original Lease), Landlord leased and demised to Tenant, and
Tenant leased from Landlord, the Premises (as such term is defined in Section 2 of the Original
Lease, and being referred to herein as the Original Premises); and
WHEREAS, Landlord owns certain other premises (the New Premises, as more
particularly described in Section 1(b) hereof) that are adjacent to the Original Premises, and
Landlord desires to lease and demise to Tenant, and Tenant desires to lease from Landlord, the New
Premises; and
WHEREAS, Landlord has agreed to construct and prepare the New Premises for the occupancy of
Tenant in accordance with the terms hereof; and
WHEREAS, Landlord has granted to Tenant a first right to lease the First Floor Option Space
(as such term is defined in Section 36 hereof) and a first right to lease the Second Floor Option
Space (as such term is defined in Section 37 hereof); and
WHEREAS, Landlord and Tenant desire to amend and restate the Original Lease in order to
reflect the foregoing agreements and otherwise, pursuant to the terms and conditions hereof.
NOW, THEREFORE, for and in consideration of the foregoing premises and the mutual covenants,
terms and conditions recited hereinafter, and for such other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, Landlord and Tenant hereby amend and
restate the Original Lease as follows:
1. PREMISES.
(a) Original Premises. Subject to and upon the terms and conditions set forth herein,
Landlord does by these presents hereby lease unto Tenant, and Tenant does by these presents hereby
lease
from Landlord, those certain premises in The Randall G. Sender Pavilion located at 111
10th Avenue, South in Nashville, Davidson County, Tennessee, 37203 (the
Building), containing approximately 1,500 square feet (with no common area percentage
factor) and identified as the Original Premises in Exhibit A, attached hereto and
incorporated herein by this reference (the Original Premises).
(b) New Premises. Pursuant to the provisions of Section 4, below, Landlord has agreed
to construct and prepare those certain premises in the Building containing approximately 5,390
rentable square feet (including a common area factor of twelve percent) and identified as the New
Premises in Exhibit A, attached hereto (the New Premises) for the occupancy of
Tenant. Upon the Acceptance Date (as such term is defined in Section 4(d) below), Landlord shall
lease the New Premises unto Tenant, and Tenant shall lease the New Premises from Landlord, subject
to and upon the terms and conditions set forth herein. Prior to the Acceptance Date, the term
Premises, as used herein, shall refer solely to the Original Premises. Commencing on the
Acceptance Date, and continuing thereafter for the remainder of the Term, the term
Premises, as used herein, shall refer to the Original Premises and the New Premises,
collectively, which shall be deemed to have 6,890 rentable square feet, subject to the provisions
of Section 36 and Section 37 hereof relating to the First Floor Option Space and the Second Floor
Option Space.
2. TERM. Subject to and upon the terms and conditions set forth herein, or in any
exhibit or addendum hereto, the term of this Lease shall commence on the date hereof and shall
terminated on the date that is sixty-six (66) months after the Acceptance Date, unless this Lease
is sooner terminated according to the terms hereof or unless Tenant chooses to extend this Lease
for an Extension Term, as hereinafter defined (as such term may be renewed or extended, the
Term). If Tenant is not in default under this Lease at the time of such notice and extension,
Tenant may extend the Term on two (2) occasions for five (5) years (each an Extension
Term) by providing written notice to Landlord of Tenants election to extend the Term no
later than one hundred eighty (180) days prior to the end of the current Term or Extension Term,
as applicable.
3. RENT.
(a) Tenant shall pay to Landlord as rent at the office of Landlord in Nashville, Tennessee,
or to such other address as Landlord may direct, the amounts set forth in this Section 3
plus any other amounts due hereunder from time to time. The Annual Rent, Monthly Rent and any
other amounts due Landlord from Tenant shall be referred to herein collectively as Rent). Any
Rent not paid when due shall incur a late charge in the amount of five percent (5%) of such amount
and shall additionally bear interest at the rate of ten percent (10%) per annum from the date
payment was due until paid. Such late charge shall not be deemed a penalty, but is paid to
reimburse Landlord for the administrative costs associated with such late payment. Tenant shall
pay to Landlord the amounts set forth herein during the Term without demand, counterclaim,
deduction, or set-off, except as may otherwise be provided herein. In the event the Term commences
on a date other than the first (1St) day of a calendar month, or terminates on a date
other than the last day of a calendar month, then the amount of Monthly Rent due hereunder for
such month shall be prorated.
(b) From the Effective Date until May 31, 2005, Tenant shall pay to Landlord Rent at a
monthly rate equal to [***] for the portion of the Premises described as
2
the Original Premises with a square footage of 1,500 square feet. On June 1, 2005, the Rent
rate per square foot in the Original Premises shall be equal to that hereafter set forth for the
Premises.
(c) On the Acceptance Date, the amount of Annual Rent due hereunder shall be increased based
on an additional 2,800 rentable square feet of space in the New Premises at the then applicable
Rent rate and the amount of Monthly Rent due hereunder shall increase accordingly. On the earlier
to occur of (i) Tenants use of the remainder of the New Space or (ii) the first day of the
seventh calendar month after the month in which the Acceptance Date occurs, the amount of Annual
Rent due hereunder shall be increased for the entirety of the Premises consisting of 6,890
rentable square feet calculated on the Rent rate then applicable.
(d) During the first twelve (12) months after the Acceptance Date, Tenant shall pay to
Landlord Rent calculated at a rate of [***] per rentable square foot (as modified herein, the
Annual Rent), payable in equal monthly installments (as modified herein, the
Monthly Rent), each such installment being due on the first (1) day of each and every
calendar month, in advance. On the first day of the thirteenth calendar month of the Term, and for
the remainder of the Term, the Annual Rent due hereunder shall be calculated based on [***] per
rentable square foot.
(e) During the first Extension Term, if any, the Annual Rent shall be based on [***] per
rentable square foot, or [***], and the Monthly Rent shall be [***], and Rent shall increase by
[***] per year during each subsequent year of the first Extension Term. During the second Extension
Term, if any, the Annual Rent shall be based on [***] per rentable square foot, or [***], and the
Monthly Rent shall be [***], and Rent shall increase by [***] per year during each subsequent year
of the second Extension Term.
(f) Tenant shall each month promptly pay, as Rent hereunder, all utility charges for the gas,
electricity and/or water used by Tenant in the Premises.
4. LANDLORDS IMPROVEMENTS TO PREMISES.
(a) Landlord shall construct and prepare the New Premises for the occupancy of Tenant in
accordance with the plans and specifications the Plans) set forth in Exhibit B
attached hereto and incorporated herein by this reference (Landlords Work) on or before
, 200___(the Completion Deadline), subject to force majeure and any delays caused by
Tenant.
(b) Approval of Tenants plans and specifications by Landlord is for the sole benefit of
Landlord and shall not constitute the assumption of any responsibility by Landlord for their
accuracy or sufficiency or compliance with applicable laws, ordinances or regulations, including
without limitation the Americans with Disabilities Act, and Tenant shall be solely responsible for
such Plans.
3
(c) Landlord shall complete Landlords Work in a good and workmanlike manner in accordance
with the approved plans and specifications therefor, and all applicable statutes, laws, rules,
codes, regulations, ordinances or other requirements of any federal, state, county or local
governmental or quasi-governmental entity having jurisdiction over, or in any way applicable to,
Landlord or Landlords Work. Landlord shall obtain all licenses and permits required for Landlord
to commence and complete Landlords Work.
(d) Landlords Work shall be deemed complete, and Tenant shall be deemed to have accepted the
New Premises, on such date as all applicable permits required for the use of the New Premises have
been validly issued, and copies thereof have been provided to Tenant (such date being referred to
herein as the Acceptance Date), subject to the provision by Tenant of any punch list
items which shall be completed by Landlord within thirty (30) days after the Acceptance Date.
(e) Tenant shall pay to Landlord as additional Rent hereunder all expenses and costs incurred
by Landlord in completing the Work within thirty (30) days after presentation to Tenant of an
invoice therefor, together with any supporting documentation reasonably requested by Tenant.
5. RULES AND REGULATIONS. Tenant will comply with all reasonable rules and
regulations as may be adopted by Landlord for the safety, care and cleanliness of the Premises and
the Building, and for preservation of good order therein, including, without limitation, the Rules
and Regulations set forth in Exhibit C, attached hereto and incorporated herein by this
reference, as the same may be amended from time to time upon notice to Tenant (the Rules and
Regulations).
6. USE. Tenant will use and occupy the Premises for general office and research
laboratories and for no other purpose. Subject to the provisions of Section 26 of this Amendment,
Tenant shall keep the Premises in good repair and tenantable condition and shall quit and surrender
the Premises peaceably upon the expiration of the Term in as good condition as the reasonable use
thereof will permit, reasonable wear and tear excepted. Without limiting the foregoing, Tenant
shall replace at its own expense any and all broken glass in and about the Premises with glass of
the same size and quality, including all signs thereon. If Tenant fails to make proper repairs,
Landlord, at its option, may make such repairs at Tenants expense.
7. CONDITIONS OF PREMISES. No representations, except as are contained herein or
endorsed hereon, have been made to Tenant with respect to the condition of the Premises. The taking
of possession of any portion of the Premises, including without limitation the New Premises, by
Tenant shall be conclusive evidence against Tenant that such portion of the Premises was in good
and satisfactory condition when possession of the same was so taken, and Tenant will, at the
termination of this Lease, by lapse of time or otherwise, return the Premises to Landlord in as
good condition as when received, loss by fire, storm or other casualty and ordinary wear and tear
excepted.
4
8. SUBLETTING AND ASSIGNMENT. Tenant will not assign this Lease nor any interest
hereunder, and will not permit any assignment hereof by operation of law, and will not sublet the
Premises or any part thereof, and will not permit the use of the Premises by any parties other than
Tenant, and the agents and servants of Tenant, without first obtaining the written consent of
Landlord, which shall not be unreasonably withheld, conditioned or delayed. Landlord may assign
this Lease or any part thereof or right thereunder. Notwithstanding the foregoing, Tenant may
license or sublet portions of the Premises to users of the office and laboratory facilities in the
Premises in conjunction with Tenants business purposes.
9. ALTERATIONS AND IMPROVEMENTS. No alterations, additions or improvements to the
Premises, except such as may be provided for in this Lease, shall be made without first obtaining
the consent, in writing, of Landlord, and any improvements, additions or alterations made by Tenant
after such consent shall have been given, including any and all fixtures installed, excepting trade
fixtures, shall at Landlords option remain on the Premises as the property of Landlord, without
compensation to Tenant, or shall be removed therefrom and the Premises restored to their original
condition at cost to Tenant, at the expiration or sooner termination of this Lease. Without
limiting the foregoing, Tenant shall, at the expiration or sooner termination of this Lease,
restore the Premises to their shell condition prior to the commencement of the Lease, remove all
pipes and other equipment pursuant to Section 26 of this Lease and repair any damage or holes to
the walls associated with such ducts, pipes, wiring and other equipment. Tenant shall at its own
cost repair any damage caused by the removal of trade fixtures in order to restore the Premises to
their original condition. Tenant agrees to save Landlord harmless on account of claims for
mechanics, materialmen or other liens in connection with any alterations, additions, or
improvements to which Landlord may give its consent in connection with the Premises, and Tenant
will, if required by Landlord, furnish such waiver or waivers of lien or bond in form and with
surety satisfactory to Landlord, as Landlord may require before starting any work in connection
with alterations, additions or improvements to the Premises.
10. LIMITS OF USE AND PEACEFUL ENJOYMENT. Tenant will not use or permit upon the
Premises anything that will invalidate any policies of insurance now or hereafter carried on the
Building or that will increase the rate of insurance on the Premises or the Building beyond the
standard rates for coverage on office space. Any increase of insurance costs due as a result of
Tenants use of the Premises for laboratory uses shall be paid to Landlord as additional Rent
hereunder. Tenant will not in any manner deface or injure the Building or any part thereof, or
overload the floors of the Premises, it being mutually agreed that in no event shall any weight be
placed upon said floors in excess of seventy-five (75) pounds per square foot of floor space
covered. Tenant will not permit any objectionable noise or odor to escape or be emitted from the
Premises in any way tending to create a nuisance, or tending to disturb any other tenant in the
Building or the occupants of neighboring property, or tending to injure the reputation of the
Building. Tenant will comply with all governmental, health and police requirements and regulations
respecting the Premises and its use thereof.
5
11. PERSONAL OR PROPERTY RISKS. Landlord shall not be held responsible for, and is hereby
expressly relieved from, all liability by reason of any injury, loss or damage to any person or
property in or about the Premises, unless caused by the negligent or willful act or omission of
Landlord, Landlords agents, employees or invitees, whether the loss, injury, or damage be to the
person or property of Tenant or any other person. This provision shall apply especially (but not
exclusively) to damage caused by water, snow, frost, steam, sewage, illuminating gas, sewer gas, or
odors, or by the bursting or leaking of pipes or plumbing works, and shall apply equally whether
such damage be caused by the act or neglect of other tenants, occupants or janitors of the Building
or of any other persons, and whether such damage be caused or occasioned by anything above
mentioned or referred to, or by any other thing or circumstance, whether of a like nature, or of a
wholly different nature. If any such damage shall be caused by the acts of neglect of Tenant,
Landlord may, at its option, repair such damage, whether caused to the Building or tenants thereof,
and Tenant shall thereupon reimburse Landlord the total cost of such damage both to the Building
and to tenants thereof. Tenant
further agrees that all personal property upon the Premises shall be at risk of Tenant only
and that Landlord shall not be liable for any damage thereto or theft thereof. Nor shall Landlord
be liable for the stoppage or interruption of water, light, heat, air conditioning, janitor or
elevator service, caused by riot, strike, accident, or to make needful repairs, or by any other
cause over which Landlord has no control and such failure, delay or default shall not be construed
or considered as an actual or constructive eviction of Tenant nor shall it in any way operate to
release Tenant from the punctual performance of each and every one of the other covenants herein
contained by the Tenant to be performed.
12. RIGHTS OF LANDLORD ON DEFAULT. If default shall at any time be made by Tenant in
the payment of the rent hereby reserved, or any installment thereof; or if default shall be made in
any of the other covenants herein contained, to be kept, observed and performed by Tenant; or if
the leasehold interest shall be levied on under execution; or in the event of the insolvency or
bankruptcy of Tenant, or the filing of any petition under the bankruptcy statute, voluntarily or
involuntarily and whether or not resulting in an adjudication in bankruptcy, provided that
involuntary filings shall be a default only if not dismissed within sixty (60) days of the date of
its filing; or in the event of a partial or general assignment for the benefit of a creditor; then,
and in any of said cases, Landlord may, at its option, at once, without notice to Tenant, terminate
this Lease or terminate Tenants right to occupy the Premises without termination of the Lease; and
upon the termination of said Lease or Tenants right of occupancy at the option of Landlord as
aforesaid, or at the expiration by lapse of time of the Term, Tenant will at once surrender
possession of the Premises to Landlord, and remove all effects therefrom, and if such possession be
not immediately surrendered, Landlord may forthwith re-enter the Premises and repossess itself
thereof as of its former estate and remove all persons and effects therefrom, using such force as
may be necessary, without being deemed guilty of any manner of trespass or forcible entry and
detainer. Tenant expressly waives the service of any notice of intention to terminate this Lease or
Tenants right to occupy the Premises or to re-enter the Premises, and waives the service of any
demand for payment of rent or for possession, and waives the service of any and every other notice
or demand prescribed by
6
any statute or other law, and agrees that the simple breach of any of the said covenants
shall, of itself, without the service of any notice or demand whatever, constitute a forcible
detainer by Tenant of the Premises, within the meaning of the statutes of the State of Tennessee.
No receipt of moneys by Landlord from Tenant, after the termination in any way of this Lease or
Tenants right of possession thereunder, or after giving of any notice, shall reinstate, continue
or extend the term of this Lease or affect any notice given to Tenant prior to the receipt of such
money, it being agreed that after the service of notice of the commencement of a suit, or after
final judgment for possession of the Premises, Landlord may receive and collect any rent due, and
the payment of said rent shall not waive or affect said notice, said suit or said judgment. If
Tenant shall not remove all effects from the Premises as above agreed, Landlord may, at its option,
remove the same in any manner that Landlord shall choose and store or dispose of the same without
liability to Tenant for loss thereof, and Tenant will pay Landlord, on request, any and all expense
incurred in such removal and also storage of said effects for any length of time during which the
same shall be in Landlords possession; or Landlord may at its option, without notice, sell the
said effects or any of the same for such price as Landlord may deem best and apply the proceeds of
such sale upon any amounts due under this Lease from Tenant to Landlord, including the expenses of
the removal and sale.
13. RIGHTS OF LANDLORD ON ABANDONMENT. In the event that Tenant shall vacate the
Premises or abandon the same during the Term, Landlord may, at its option, without terminating this
Lease, but Landlord shall not be under any obligation to do so, enter into the Premises, remove
Tenants signs therefrom, and relet the same for the account of Tenant for such rent and upon terms
as shall be satisfactory to Landlord, without such reentry working a forfeiture of the rents to be
paid and the covenants to be performed by Tenant during the full Term of this Lease; and for the
purpose of such re-letting Landlord is authorized to make any repairs, changes, alterations or
additions in or to the Premises that may be necessary or convenient, and if a sufficient sum shall
not be realized monthly from such re-letting, after paying all of the costs and expenses of such
re-letting the collection of the rent accruing therefrom each month to satisfy the monthly rent
above provided to be paid by Tenant, then Tenant will pay and satisfy such deficiency each month
upon demand therefor.
14. LOSS OR DAMAGE TO PREMISES. Should the Building be totally destroyed by fire or
other cause, or so damaged that rebuilding or repairs cannot be completed within one hundred eighty
(180) days from date of said fire or other cause of damage, this Lease shall terminate and Tenant
shall be allowed an abatement of rent from the date of such damage or destruction. However, if the
damage is such that rebuilding or repairs can be completed within one hundred eighty (180) days,
Landlord covenants and agrees to make such repairs with reasonable promptness and dispatch, and to
allow Tenant an abatement in the rent for such time as the Building is untenantable (in Tenants
reasonable determination), or proportionately for such portion of the Premises as shall be
untenantable (in Tenants reasonable determination), and Tenant covenants and agrees that the terms
of this Lease shall not otherwise be affected.
7
15. CONDEMNATION. If the whole of the Premises shall be taken or condemned by any
competent authority for public or quasi public use or purpose, then, and in that event, the Term
shall expire when the possession of the Premises so taken shall be required for such use or
purpose. If any part, less than the whole, of the Premises shall be so taken or condemned, then,
and in that event, either Landlord or Tenant shall have the option, exercisable by notice in
writing to the other within sixty (60) days from the date of the notice to Landlord of the taking
or condemnation, to terminate this Lease; and in the event said option to so terminate this Lease
is exercised by either Landlord or Tenant, the Lease shall continue in effect with respect to the
portion of the Premises not taken or condemned unless the same is rendered untenantable (in
Tenants reasonable determination) by such taking and condemnation or cannot be made tenantable (in
Tenants reasonable determination) by repairs to be conducted by Landlord at its expense. In the
event this Lease continues with reference to the portion of the Premises not taken, the rental
specified hereunder shall be prorated and adjusted on a square footage basis. In the event that
this Lease terminates by a taking or condemnation of the whole of the Premises or by the election
on the part of Landlord as provided herein, the current rental shall in either case be apportioned
to the date of termination of the Lease. Landlord shall be entitled to any and all awards and/or
settlements that may be awarded on account of such taking or condemnation. Tenant, however, shall
not be prevented from making a claim against the condemning party (but not against Landlord ) for
any moving or relocation expenses, loss of profits, or taking of Tenants personal property (other
than its leasehold estate) to which Tenant may be entitled; provided that any such award shall not
reduce the amount of the award otherwise payable to Landlord for the taking of the Building and
Premises.
16. REDECORATION. If Tenant shall move from the Premises at any time prior to the
termination of this Lease, Landlord shall have the right to enter upon the Premises for the
purpose of decorating the same or making alterations or changes therein, without such entry in any
manner affecting the obligation of Tenant hereunder.
17. MOVING TENANT. Landlord, at its option, may substitute for the Premises other
space (hereafter called Substitute Premises) owned by Landlord in the Building at any
time during the Term or any extension of this Lease. Insofar as reasonably possible, the
Substitute Premises shall be of comparable quality and shall have a comparable square foot area
and a configuration substantially similar to the Premises. If the parties cannot agree on the
adequacy of the replacement space, an independent mediator with experience in the office real
estate market in the Nashville metropolitan area shall be procured, with the costs of such
mediator shared equally by the parties. Landlord shall give Tenant at least sixty (60) days notice
of its intention to relocate Tenant to the Substitute Premises. This notice will be accompanied by
a floor plan of the Substitute Premises. After such notice, Tenant shall have ten (10) days within
which to agree with Landlord on the proposed Substitute Premises and unless such agreement is
reached within such period of time, Landlord may terminate this Lease at the end of the sixty (60)
day period of time following the notice. Landlord agrees to construct or alter, at its own
expense, the Substitute Premises as expeditiously as possible so that they are in substantially
the same condition that the Premises were in immediately prior to the relocation. Landlord shall
have the right
8
to reuse the fixtures, improvements and alterations used in the Premises. Tenant agrees to
occupy the Substitute Premises as soon as Landlords work is substantially completed, Landlord
shall pay Tenants reasonable third-party costs of moving Tenants furnishings, telephone and
computer wiring, and other property to the Substitute Premises, and reasonable printing costs
associated with the change of address. Except as provided herein, Tenant agrees that all of the
obligations of this Lease, including the payment of rent (to be determined on a per rentable
square foot basis and applied to the Substitute Premises), will continue despite Tenants
relocation to the Substitute Premises. Upon substantial completion of the Substitute Premises,
this Lease will apply to the Substitute Premises as if the Substitute Premises had been the space
originally described in this Lease.
18. RIGHTS OF LANDLORD. The right of Landlord to terminate this Lease as herein set
forth is in addition to and not in exhaustion of such other rights that Landlord has, or causes of
action that may accrue to Landlord because of Tenants failure to fulfill, perform or observe the
obligations, agreements or covenants of this Lease, and the exercise or pursuit by Landlord of any
of the rights or causes of action accruing hereunder shall not be an exhaustion of such other
rights or causes of action that Landlord might otherwise have.
19. WAIVERS. No waiver of any condition expressed in this Lease shall be implied by
any neglect of Landlord to declare a forfeiture on account of the violation of such condition if
such violation be repeated or continued subsequently and no express waiver shall affect any
condition other than the one specified in such waiver, and that one only for the time and in the
manner specifically stated.
20. ATTORNEYS. Either party hereto shall be entitled to recover from the other party
hereto all reasonable attorneys fees and other costs and expenses it incurs in enforcing any of
the obligations of the other party hereunder.
21. LIENS. (Intentionally omitted).
22. HOLD OVER. Tenant will pay to Landlord, as liquidated damages, rent in an
amount equal to one hundred fifty percent (150%) of the rent payable hereunder immediately prior
to the end of the Term, for all the time Tenant shall retain possession of the Premises or any
part thereof for the first two (2) months after the termination of this Lease, whether by lapse
of time or otherwise, and two hundred percent (200%) for any period beyond such time; but the
provisions of this clause shall not operate as a waiver by Landlord of any right of re-entry
hereinbefore provided; nor shall any waiver by Landlord of its right to terminate this Lease for
breach of covenant affect its right to terminate this Lease for any later breach of the same or
another covenant.
23. AIR RIGHTS. It is understood and agreed that this Lease does not grant any
rights to light and air over property, except public streets adjoining the land on which the
Building is situated.
24. HOLD HARMLESS. Tenant covenants to save and hold Landlord harmless from
violations by Tenant of the laws of the United States, of the State of Tennessee, and the
9
ordinances and laws of the Metropolitan Government of Nashville and Davidson County,
Tennessee.
25. EXTRA USE OF PREMISES. Tenant shall not use the Premises for any purpose except
that which is above specified, and in particular will not expose nor offer for sale on the
Premises, any alcoholic or other liquors, tobacco, drugs, flowers, candies, confections, nor any
other thing or things whether of a like or of a wholly different nature, without the written
consent of Landlord, the right being hereby reserved to Landlord to grant to any person, firm or
corporation the exclusive right and privilege to conduct any particular business in the Building,
and such exclusive right and privilege so granted shall be binding upon Tenant hereunder the same
as though specifically incorporated in this Lease upon Landlords notification to Tenant of the
granting of such exclusive right and privilege.
26. MAINTENANCE. Landlord shall be responsible for floors (but not floor coverings),
roof and all other structural elements of the Building, and for maintaining all common area
mechanical systems, including but without limitation the heating, ventilation, air-conditioning,
electrical and plumbing systems. Except as otherwise provided in this Lease or in the Plans, and
except for customary equipment used in laboratories, Tenant shall not install or connect any air
conditioning equipment, electric-driven motor or any electrical, gas or water appliance or
equipment, without the prior written consent of Landlord. With respect to air conditioning or any
other electrical, gas or water appliance or equipment installed by or under Tenant, Landlord shall
have the right to retain all ducts, wiring, piping, and other related equipment upon the
termination of this Lease, provided, however, that in the absence of specific direction from
Landlord, Tenant shall be required to remove all such equipment, ducts, wiring, piping and other
related equipment.
27. STORAGE. If Tenant shall fail to remove all effects from the Premises upon
termination of this Lease for any cause whatsoever, Landlord may at its option remove the same in
any manner that Landlord shall choose and store said effects without liability to Landlord for loss
thereof, and Tenant agrees to pay Landlord on demand any and all expenses incurred in such removal,
including court costs and attorneys fees and storage charge on such effects for any length of time
the same shall be in Landlords possession, or Landlord may at its option without notice sell said
effects or any part of the same at private sale and without legal process for such price as
Landlord may obtain and apply the proceeds of such sale upon any amounts due under this Lease from
Tenant to Landlord and upon the expense incident to the removal and sale of said effects.
28. DEFECTS. Tenant shall provide Landlord or its agent prompt written notice of any
accident to or defects in mechanical or other systems for which Landlord is responsible hereunder,
which defects shall be remedied by Landlord with due diligence promptly after its receipt of any
such notice from Tenant.
29. SUBORDINATION. This Lease is subject and subordinate to all present mortgages
affecting the real estate and improvements thereon of which the Premises form a part, and to all
renewals and extension thereof, and to any mortgages which may hereafter be
10
executed affecting the same, and Tenant shall execute a commercially reasonable form of
agreement evidencing such subordination and attornment in favor of any of Landlords lenders from
time to time within three (3) business days after request therefor from Landlord, provided only
that such agreement shall provide commercially reasonable nondisturbance provisions for Tenant.
30. LIQUIDATED DAMAGES. It is agreed between the parties hereto that if the rent
stipulated herein at any time shall not be paid within ten (10) days of the date when due, then all
subsequent installments of rent, remaining unpaid, shall forthwith become due and payable at the
option of Landlord with notice to Tenant, and in case Tenant is declared bankrupt or voluntarily
offers to creditors terms of composition, or in case a receiver is appointed to take charge of and
conduct the affairs of Tenant, such claim for further unpaid installments of rent due under this
Lease shall be considered liquidated damages and shall constitute a debt provable in bankruptcy or
receivership.
31. REMEDIES. No act or thing done by Landlord or its agents during the Term shall be
deemed an acceptance of a surrender of the Premises, and no agreement to accept a surrender of the
Premises shall be valid unless the same be made in writing and subscribed by Landlord. The
provision in this Lease of any particular remedy shall not preclude Landlord from any other remedy
Landlord might have, either in law or in equity, nor shall the waiver of or redress for any
violation of any covenant or condition in this Lease contained or any of the Rules and Regulations,
prevent a subsequent act, which would have originally constituted a violation, from having all the
force and effect of an original violation. In case it should be necessary or proper for Landlord to
bring any action under this Lease or to consult or place said Lease, for any amount payable by
Tenant thereunder, with an attorney concerning or for the enforcement of any of Landlords rights
hereunder, then Tenant agrees in each and any such case to pay to Landlord its reasonable
attorneys fees actually incurred. The receipt by Landlord of rent with knowledge of the breach of
any covenant in this Lease contained, shall not be deemed a waiver of such breach, The failure of
Landlord to enforce any of the Rules and Regulations against Tenant and/or any other tenant in the
Building shall not be deemed a waiver thereof. The receipt by Landlord of rent from any assignee,
subtenant or occupant of the Premises shall not be deemed a waiver of the covenant in this Lease
contained, against assignment, and subletting or an acceptance of the assignee, subtenant or
occupant as Tenant, or a release of Tenant from the further observance or performance by Tenant of
the covenant in this Lease contained, on the part of Tenant to be observed and performed. No
provision of this Lease shall be deemed to have been waived by Landlord unless such waiver be in
writing signed by Landlord. In case of termination of this Lease by Landlord under any option
herein provided for, Landlord may re-enter the Premises without notice or demand, and in that event
rent shall become due and be apportioned and paid up to and including the day of such entry. The
sole remedy for Landlords failure to complete Landlords Work by the date set forth herein shall
be a delay in the Acceptance Date, provided, however, that if the Acceptance Date is delayed more
than ninety (90) days from the date set forth herein and such delay is not attributable to causes
beyond the control of Landlord, Tenant shall have a one-time right to terminate this Lease upon
written notice to Landlord within ten (10) days of the ninetieth (90th) day of delay.
11
32. ACCESS TO PREMISES. The parties hereto agree that for the purpose of completing or
of making repairs or alterations in any portion of the Building, Landlord may use one or
more of the street entrances, halls, passageways and elevators of the Building, provided, however,
that there shall be no unnecessary obstruction of the right of entry to the Premises while the same
are occupied.
33. ESCALATION. The rent payable by Tenant during each lease year shall be adjusted in
accordance with this Article:
(a) Definitions. For the purpose of this Section 33, the following definitions shall
apply:
(i) The term Base Year shall mean the calendar year 2002.
(ii) The term Percentage shall mean ten and ninety-five one hundreths percent
(10.95%).
(iii) The term Real Estate Taxes shall mean all taxes and assessments levied,
assessed or imposed at any time by any governmental authority upon or against the Building or the
land upon which the Premises are located, and also any taxes or assessments levied, assessed or
imposed at any time by any governmental authority in connection with the receipt of income or rents
from said Building and/or land to the extent that same shall be in lieu of all or a portion of any
of the aforesaid taxes or assessments upon or against said Building and/or land.
(b) Real Estate Taxes. In the event that the Real Estate Taxes payable during any
calendar year following the Base Year shall be estimated by Landlord to exceed the amount of the
Real Estate Taxes payable during the Base Year (the Base Year Taxes), Tenant shall pay to
Landlord as additional Rent for such calendar year an amount equal to the Percentage of such
estimated excess (the Estimated Excess Taxes) in equal monthly installments as determined
by Landlord. By or after April 1st of each calendar year, Landlord shall furnish to Tenant a
statement of the actual excess Real Estate Taxes payable during the preceding calendar over the
Base Year Taxes (the Actual Excess Taxes). Landlord shall apply any amount by which the
Percentage of Estimated Excess Taxes exceeds the Percentage of Actual Excess Taxes to the following
years Estimated Excess Taxes payments due hereunder, and Tenant shall pay any shortfall between
the Percentage of Actual Excess Taxes and the Percentage of Estimated Excess Taxes, with such
payments made as additional Rent by Tenant to Landlord within twenty (20) days after receipt of the
aforesaid statement. Such payments shall be prorated for any year in which this Lease terminates.
(c)
Insurance. Landlord shall maintain on the Building, associated personal property,
fixtures and other improvements, such property, hazard, liability and other insurance policies as
Landlord deems reasonably appropriate or as may be required by any party whose interests are
secured by a lien, mortgage or other security interest in the Building (the
Insurance
Coverage). In the event that the premiums and charges for the Insurance Coverage (the
Insurance Costs) payable during any calendar year following the
12
Base Year shall be estimated by Landlord to exceed the amount of the Insurance Costs payable
during the Base Year (the Base Year Insurance), Tenant shall pay to Landlord as
additional Rent for such calendar year an amount equal to the Percentage of such estimated excess
(the Estimated Excess Insurance Costs) in equal monthly installments as determined by
Landlord. By or after April 1st of each calendar year, Landlord shall furnish to Tenant a
statement of the actual excess Insurance Costs payable during the preceding calendar over the Base
Year Insurance Costs (the Actual Excess Insurance Costs). Landlord shall apply any
amount by which the Percentage of Estimated Excess Insurance Costs exceeds the Percentage of
Actual Excess Insurance Costs to the following years Estimated Excess Insurance Costs payments
due hereunder, and Tenant shall pay any shortfall between the Percentage of Actual Excess
Insurance Costs and the Percentage of Estimated Excess Insurance Costs, with such payments made as
additional Rent by Tenant to Landlord within twenty (20) days after receipt of the aforesaid
statement. Such payments shall be prorated for any year in which this Lease terminates.
34. QUIET ENJOYMENT. Landlord covenants that Tenant, upon paying the Rent and
complying with the terms, covenants and conditions set forth herein, shall and may peaceably and
quietly have, hold, and enjoy the Premises during the Term.
35. TENANTS REMEDIES. In addition to and without limiting the other rights and
remedies available to Tenant hereunder, or that may otherwise be available to Tenant at law or in
equity, in the event Landlord fails to perform any of its obligations or duties hereunder, or
otherwise breaches any of its covenants, warranties, representations or other obligations under
this Lease, after not less than thirty (30) days written notice to Landlord, Tenant may, but shall
not be obligated to, remedy such failure or breach if not cured within such time frame by
Landlord. All reasonable amounts expended or obligations reasonably incurred by Tenant in
connection therewith shall be paid by Landlord to Tenant upon demand.
36. RIGHT OF FIRST REFUSAL TO LEASE FIRST FLOOR SPACE. During the Term, Tenant shall
have the first right to lease (the Option) that certain space identified as the First
Floor Option Space on Exhibit A, attached hereto (the First Floor Option
Space), in the event that same becomes available, upon the terms and conditions set forth in
this Lease, except as otherwise provided in this Section 36. In the event that the First Floor
Option Space becomes available during the Term, Landlord shall promptly provide to Tenant notice
of such availability, provided, however, that the First Floor Option Space shall not be deemed to
become available if the current tenant, by negotiation, extension of its current lease or a new
lease, extends its possession of the First Floor Option Space. Upon receipt of such notice from
Landlord, Tenant shall have fifteen (15) days to notify Landlord in writing of its intention to
exercise the Option. Tenants failure to exercise the Option shall not result in a termination of
this Lease. Further, if Tenant does not exercise the Option, the Option shall not terminate and,
should Landlord fail to lease the First Floor Option Space within six (6) months following
Tenants notice of its election not to exercise the Option, Landlord may not thereafter lease the
First Floor Option Space without again offering it to Tenant pursuant to the terms of this Section
36. Notwithstanding anything to the contrary set
13
forth herein, Landlord and Tenant hereby acknowledge and agree that in the event Tenant
exercises the Option at any time during the Term: (i) the amounts of the Annual Rent and Monthly
Rent applicable to the First Floor Option Space shall be on market rate terms based on leases of
similar duration and services within the Building, and (ii) the First Floor Option Space shall be
deemed to be a part of the Premises for the purposes of this Lease.
37. RIGHT OF FIRST REFUSAL TO LEASE SECOND FLOOR SPACE. During the Term, and so long
as Tenant is not in default under this Lease, Tenant shall have the first right to lease (the
Second Option) that certain space identified as the Second Floor Option Space on
Exhibit A, attached hereto (the Second Floor Option Space), in the event that
same becomes available, upon the terms and conditions set forth in this Lease, except as otherwise
provided in this Section 37. Notwithstanding the foregoing, Tenant acknowledges that the Second
Floor Option Space is currently available and Tenant has elected not to rent the Second Floor
Option Space at this time. Accordingly, the Second Option shall not arise until after any lease
for the Second Floor Option Space into which Landlord may subsequently enter. In the event that
the Second Floor Option Space becomes available during the Term, Landlord shall promptly provide
to Tenant notice of such availability, provided, however, that the Second Floor Option Space shall
not be deemed to become available if any future tenant, by negotiation, extension of its current
lease or a new lease, extends its possession of the Second Floor Option Space. Upon receipt of
such notice from Landlord, Tenant shall have fifteen (15) days to notify Landlord in writing of
its intention to exercise the Second Option. Tenants failure to exercise the Second Option shall
not result in a termination of this Lease. Further, if Tenant does not exercise the Second Option,
the Second Option shall not terminate and, should Landlord fail to lease the Second Floor Option
Space within six (6) months following Tenants notice of its election not to exercise the Second
Option, Landlord may not thereafter lease the Second Floor Option Space without again offering it
to Tenant pursuant to the terms of this Section 37. Notwithstanding anything to the contrary set
forth herein, Landlord and Tenant hereby acknowledge and agree that in the event Tenant exercises
the Second Option at any time during the Term: (i) the amounts of the Annual Rent and Monthly Rent
applicable to the Second Floor Option Space shall be on market rate terms based on leases of
similar duration and services within the Building, and (ii) the Second Floor Option Space shall be
deemed to be a part of the Premises for the purposes of this Lease.
38. PARKING. Landlord will provide Tenant, its employees and invitees, twenty-five
(25) spaces in the parking lot known as Gateway to Nashville, throughout the terms of Lease. Such
parking entitlement shall be on a nonexclusive basis with other tenants and parking licensees and
no guarantee is made that parking spaces will be available at all times.
39. MISCELLANEOUS PROVISIONS.
(a) Remedies Cumulative. All rights and remedies of either party hereunder shall be
cumulative, and none shall exclude any other rights and remedies allowed by law.
14
(b) Grammar. The words Landlord and Tenant whenever used herein shall be
construed to mean Landlords and Tenants in all cases where there is more than one Landlord or
Tenant, and the necessary grammatical changes required to make the provisions hereof apply either
to corporations or individuals, men or women, shall in all cases be assumed as though in each case
fully expressed.
(c) Homestead Exemption. Tenant hereby waives and renounces any and all homestead
exemption rights he may have now, or hereafter, under or by virtue of the constitution and laws of
the State of Tennessee, or of any other state, or of the United States, as against the payment of
said rental or any portion thereof, or any other obligation or damage that may accrue under the
terms of this agreement.
(d) Notices. All notices herein required shall be in writing. Whenever any notice,
demand or request is required or permitted hereunder, such notice, demand or request shall be (i)
hand-delivered personally, (ii) sent by express mail or courier service, (iii) sent by United
States mail registered or certified, postage prepaid, or (iv) sent by confirmed facsimile
transmission, addressed as follows:
|
|
|
If to Landlord: |
|
The Gateway To Nashville, L.L.C. |
|
|
Attention: Zach Liff |
|
|
209 10th Avenue South, Suite 432 |
|
|
Nashville, Tennessee 37203 |
|
|
Facsimile: (615) 259-3141 |
|
|
|
If to Tenant: |
|
Cumberland Emerging Technologies, Inc. |
|
|
Attention: A.J. Kazimi, Chief Executive Officer |
|
|
2525 West End Avenue, Suite 950 |
|
|
Nashville, Tennessee 37203 |
|
|
Facsimile: (615) 255-0094 |
Any notice or demand to be given hereunder shall be deemed sufficiently given for all purposes
hereunder (a) at the time such notices or demands are hand-delivered, (b) one (1) day after
depositing any such notice or demand with any express mail or other overnight courier service, (c)
three (3) days after depositing any such notice or demand in the United States mail with the proper
postage affixed thereto, certified, return receipt requested, or (d) if sent by facsimile, upon
receipt by the sender of an acknowledgment or transmission report generated by the machine from
which the facsimile was sent indicating that the facsimile was sent in its entirety to the
recipients facsimile number; provided that if a notice, request or other communication is served
by hand or is received by facsimile on a day which is not a business day, or after 5:00 P.M. on any
business day at the addressees location, such notice or communication shall be deemed to be duly
received by the recipient at 9:00 a.m. on the first business day thereafter. Any party hereto may
change its address by notice in writing to the other parties in the manner herein provided.
15
IN WITNESS WHEREOF, the parties hereto have, on the day and year first above written,
executed this Lease agreement in duplicate, one copy to be retained by each of the parties and
each such copy to be considered as an original for all purposes.
|
|
|
|
|
|
|
|
|
|
|
|
|
LANDLORD: |
|
|
|
|
|
|
|
|
|
|
|
|
|
THE GATEWAY NASHVILLE, L.L.C. |
|
|
|
|
|
|
|
|
|
ATTEST:
|
|
|
|
By:
|
|
/s/
[ ILLEGIBLE ] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Tracy N. Marsh
|
|
|
|
Its:
|
|
Chief Manager |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TENANT: |
|
|
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND EMERGING |
|
|
|
|
TECHNOLOGIES, INC. |
|
|
|
|
|
|
|
|
|
ATTEST:
|
|
|
|
By:
|
|
/s/ A.J. Kazimi |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ [ ILLEGIBLE ]
|
|
|
|
Its:
|
|
C.E.O. |
|
|
|
|
|
|
|
|
|
|
|
16
EXHIBIT A
DESCRIPTION OF THE PREMISES
See attached First Level Floor Plan
Existing space is that marked as Phase I (completed)
New premises is that marked as Phase II, IIa, and III
17
EXHIBIT B
PLANS AND SPECIFICATIONS
FOR LANDLORDS WORK
EXHIBIT C
RULES AND REGULATIONS
|
|
|
Rule 1.
|
|
No sign, picture, advertisement, or notice shall be
displayed, inscribed, painted or affixed, on any part of
the outside or inside of the Building, or on or about the
Premises hereby demised, except on the glass of the doors
and windows of the Premises and on the Directory Board of
the Building, and then only of such color, size, style and
materials as shall be first specified by Landlord in
writing on this Lease, which consent shall not be
unreasonably withheld, conditioned or delayed. Landlord
shall place a sign on a prominent location on the exterior
of the Building with the name and logo of Cumberland
Emerging Technologies, Inc. or any other name as designed
by Tenant. No For Rent signs shall be displayed by
Tenant, and no showcases, or obstructions, signs, flags,
barber poles, statuary, or any advertising device of any
kind whatever shall be placed in front of the Building or
in the passageways, halls, lobbies, or corridors thereof by
Tenant; and Landlord reserves the right to remove all such
showcases, obstructions, signs, flags, barber poles,
statuary or advertising devices and all signs other than
those provided for, without notice to Tenant and at his
expense. |
|
|
|
Rule 2.
|
|
Tenant shall not, without Landlords written consent, put
up or operate any steam engine, boiler, machinery or stove
upon the Premises, or carry on any mechanical business
thereon, or do any cooking thereon, or use or allow to be
used upon the Premises oil, burning fluids, camphene,
kerosene for heating, warming or lighting, or anything
(except gas or incandescent electric lights, and those only
of such company or companies as may be supplying the
Building) for illuminating the Premises. No article deemed
extra hazardous on account of fire and no explosives shall
be brought into the Premises. |
|
|
|
Rule 3.
|
|
No additional locks shall be placed upon any doors of the
Premises. Upon the Termination of the Lease Tenant shall
surrender to Landlord all keys of the Premises. |
|
|
|
Rule 4.
|
|
Safes, furniture, boxes or other bulky articles shall be
carried into the Premises only with written consent of
Landlord first obtained, and then only by means of the
elevators, by the stairways or through the windows of the
Building as Landlord may in writing direct, and at such
times and in such manner and by such persons as Landlord
may direct. Safes and other heavy articles shall be placed
by Tenant in such places only as may be first specified in
writing by Landlord, and any damage done to the Building or
to Tenants or to other persons taking a safe or other heavy
article in or out of the Premises, from overloading a
floor, or in any other manner shall be paid for by Tenant
causing such damage. |
|
|
|
Rule 5.
|
|
Elevator service and/or self-service elevator will be
furnished by Landlord daily whenever said service shall, in
Landlords judgement, be required for the proper occupation
and use of the Premises. |
|
|
|
Rule 6.
|
|
Any person employed by Tenant to do janitor work, shall,
while in the Building and outside of the Premises, be
subject to and under the control and direction of the
Superintendent of the Building (but not as agent or servant
of said Superintendent or of Landlord). |
|
|
|
|
|
Landlord may retain a pass key to the Premises and be allowed admittance thereto at all
times to enable its representatives to examine the Premises from time to time. |
|
|
|
Rule 7.
|
|
Landlord and its agents shall have the right to enter the
Premises at all reasonable hours for the purpose of examining or
exhibiting the same upon advance notice and without interfering
with Tenants operations. |
|
|
|
Rule 8.
|
|
Landlord, and its agents, shall have the right to enter the
Premises at all reasonable hours for the purpose of making any
repairs, alterations, or additions which it or they shall deem
necessary for the safety, preservation, or improvement of the
Premises of the Building, and Landlord shall be allowed to take
all material into and upon the Premises that may be required to
make such repairs, improvements and additions, or any alterations
for the benefit of Tenant without in any way being deemed or held
guilty of an eviction of Tenant; and the Rent reserved shall in
no wise abate while said repairs, alterations, or additions are
being made; and Tenant shall not be entitled to maintain a
set-off or counter-claim for damages against Landlord by reason
of loss or interruption to the business of Tenant because of the
prosecution of any such work except in the event that such
repairs render the Premises untenantable. All such repairs,
decorations, alterations, additions, and improvements shall be
done during ordinary business hours. |
|
|
|
Rule 9.
|
|
If Tenant desires telegraphic or telephonic connections, or the
installation of any other electrical wiring, Landlord will, upon
receiving a written request from Tenant, direct the electricians
as to where and how the wires are to be introduced and run, and
without such directions no boring, cutting or installations of
wires will be permitted. |
|
|
|
Rule 10.
|
|
Tenant shall not allow anything to be placed against or near the
glass in the partitions, between the Premises and the halls or
corridors of the Building, which shall diminish the light in, or
prove unsightly from the halls or corridors. |
|
|
|
Rule 11.
|
|
No electric current, intended for light or power purposes, shall
be used by Tenants, excepting that furnished or approved by
Landlord; nor shall electric or other wires be brought into the
Premises, except upon the written consent and approval of
Landlord. |
|
|
|
Rule 12.
|
|
Tenant, when closing its office for business at any time, shall
see that all windows are closed, thus avoiding possible damage
from fire, storm, rain or freezing. |
|
|
|
Rule 13.
|
|
Tenant shall not allow anything to be placed on the outside
window ledges of the Premises, nor shall anything be thrown by
Tenant, or his employees, out of the windows of the Building; nor
shall they undertake to regulate the thermostats, if any, which
control the heat or air conditioning. |
|
|
|
Rule 14.
|
|
The water and wash closets and other plumbing fixtures shall not
be used for any purposes other than those for which they were
constructed, and no sweepings, rubbish, rags, or other substances
shall be thrown therein. All damages resulting from any misuse of
the fixtures shall be home by Tenant who, or whose servants,
employees, agents, visitors or licensees, shall have caused the
same. |
|
|
|
Rule 15.
|
|
No bicycle or other vehicle, and no animal shall be brought into
the offices, halls, corridors, elevators or any other parts of
the Building, by Tenant, his agents or employees, except as
required by law. |
|
|
|
Rule 16.
|
|
No person shall disturb the occupants of this or any adjoining
building premises by the use of any musical instruments, unseemly
noises, whistling, singing or in any other way. |
|
|
|
Rule 17.
|
|
The Premises shall not be used for lodging or sleeping, nor for
any immoral or illegal purposes or for any purpose that will
damage the Premises. |
|
|
|
Rule 18.
|
|
The entrances, corridors, passages, stairways and elevators shall
be under the exclusive control of Landlord and shall not be
obstructed, or used by Tenant for any other purpose than ingress
and egress to and from the Premises. |
|
|
|
Rule 19.
|
|
Canvassing, soliciting and peddling in the Building is prohibited
and each Tenant shall co-operate to prevent the same. |
|
|
|
Rule 20.
|
|
All office or other equipment of any electrical or mechanical
nature shall be placed by Tenant in Premises in approved settings
to absorb or prevent any vibration, noise or annoyance. |
|
|
|
Rule 21.
|
|
No water cooler, air conditioning unit or system or other
apparatus shall be installed or used by any Tenant without the
written consent of Landlord. |
|
|
|
Rule 22.
|
|
There shall not be used in any space, or in the public halls of
the Building, either by any Tenant or by jobbers or others, in
the delivery or receipt of merchandise, any hand trucks, except
those equipped with rubber tires and side guards. |
|
|
|
Rule 23.
|
|
Landlord reserves the right to make such other and further
reasonable rules and regulations as in its judgment may from time
to time be needful for the safety, care and cleanliness of the
Premises, and for the preservation of good order therein, and any
such other or further rules and regulations shall be binding upon
the parties hereto with the same force and effect as if they had
been inserted herein at the time of the execution hereof. |
EX-10.24 FIRST AMENDMENT TO AMENDED LEASE AGRMT
EXHIBIT 10.24
FIRST AMENDMENT TO
AMENDED AND RESTATED LEASE AGREEMENT
THIS FIRST AMENDMENT TO AMENDED AND RESTATED LEASE AGREEMENT (the Amendment) is made
and entered into effective as of the 23rd day of August, 2005 (the Effective
Date), by and between THE GATEWAY TO NASHVILLE, L.L.C., a Tennessee limited liability company,
with its principal office and place of business in Nashville, Tennessee (Landlord), and
CUMBERLAND EMERGING TECHNOLOGIES, INC., a Tennessee corporation, with its principal office and
place of business in Nashville, Tennessee (Tenant).
WITNESSETH:
WHEREAS, pursuant to that certain Amended and Restated Lease Agreement made by and between
Landlord and Tenant dated November 11, 2004 (the Lease), Landlord leased and demised to
Tenant, and Tenant leased from Landlord, the Premises, consisting of the Original Premises and the
New Premises; and
WHEREAS, Landlord and Tenant desire to set forth the Completion Date for the New Premises; and
WHEREAS, Landlord and Tenant desire to amend the Lease to reflect the foregoing agreements and
otherwise, pursuant to the terms and conditions hereof.
NOW, THEREFORE, for and in consideration of the foregoing premises and the mutual covenants,
terms and conditions recited hereinafter, and for such other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, Landlord and Tenant hereby amend the Lease
as follows:
1. Section 4(a) of the Lease is amended to provide that the Completion Date shall be
January 1, 2006, provided however, that, if in the event the Landlords master electrical panels
have not been installed and certified by October 15, 2005, then the Completion Date will be
redefined to be the date reflecting seventy-five (75) days after completion of the Landlords
master electrical panel installation as certified by Davidson County Codes.
2. Section 4(d) of the Lease is amended to provide that the Acceptance Date shall be the
earlier of (a) the date that Tenant takes beneficial occupancy of the New Premises and (b) the
Completion Date.
3. Except as herein modified and amended, the terms and conditions of the Lease shall remain in
full force and effect.
[SIGNATURES APPEAR ON FOLLOWING PAGE]
IN WITNESS WHEREOF, the parties hereto have, on the day and year first above written,
executed this Amendment.
|
|
|
|
|
|
|
|
|
LANDLORD: |
|
|
|
|
|
|
|
|
|
|
|
THE GATEWAY TO NASHVILLE, L.L.C. |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ [Illegible] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Its:
|
|
Member |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TENANT: |
|
|
|
|
|
|
|
|
|
|
|
CUMBERLAND EMERGING
TECHNOLOGIES, INC. |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ A.J. Kazimi |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Its:
|
|
C.E.O. |
|
|
|
|
|
|
|
|
|
EX-21 SUBSIDIARIES OF CUMBERLAND PHARMACEUTICALS
EXHIBIT 21
SUBSIDIARIES OF CUMBERLAND PHARMACEUTICALS INC.
The subsidiaries of Cumberland Pharmaceuticals Inc. are listed below.
|
|
|
Name |
|
State of Organization |
Cumberland Emerging Technologies, Inc.
|
|
Tennessee |
|
|
|
Cumberland Pharma Sales Corp.
|
|
Tennessee |
Ex-23.1
EXHIBIT 23.1
Consent
of Independent Registered Public Accounting Firm
The Board of Directors
Cumberland Pharmaceuticals, Inc.:
We consent to the use of our report included herein and to the
reference to our firm under the heading Experts in
the prospectus. Our report refers to a change in accounting for
stock-based compensation in 2006.
Nashville, Tennessee
May 1, 2007